

**Grants and Contracts Office** 

# Funding Opportunities Monthly Edition June 2022 Due Dates

#### Introduction

This funding opportunity packet contains information on funding opportunities with deadlines in June 2022. The opportunities are organized in the following order:

- 1. National Institutes of Health (NIH)
- 2. National Science Foundation (NSF)
- 3. Other Federal
- 4. Non Federal

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
109720	International Bioethics Research T Optional)	raining Pr	ogram (D43 Clinical Trial	Fogarty International Center/NIH/DHHS	PAR-22- 116 07-Jun	-2022	1,150,000 USD
	Contact Name	Barbara S	ina, Ph.D.				
	Contact Telephone	301-402-9	9467				
	Contact Email	sinab@m	ail.nih.gov				
	Sponsor Website						
	Program URL	Link to pro	ogram URL				
	Deadline Dates (ALL)	07-Jun-20	22 , 06-Jun-2023 , 06-Jun-202	4			
	Synopsis	and middl conceptua as provide support L incorpora prepare n Funding C investigat experienc	le-income country (LMIC) rese al ethics research that address e research ethics leadership to MIC-U.S. collaborative institut te mentored research, advan- nultiple individuals for positio Opportunity Announcement (F or of an independent clinical e in a clinical trial led by anot	earch intensive institutions with the operation of the search intensive institutions with the operation of the search institutions, governments and tional bioethics doctoral and postdoor ced theoretical didactic courses and sof ethics scholarship and leadersh (OA) allows appointment of Trainees trial; or proposing a separate ancillar her investigator, as part of their reservers.	capabilities to cor inch and research international res ctoral research tra ethics career skill ip in health resea (D43) proposing y clinical trial; or arch and career o	aduct original emp policy in these co earch organizatio aining programs th s training compon rch institutions in to serve as the le proposing to gain levelopment.	onirical or untries as well ns. FIC will nat ents to LMICs. This ad research
107618	Notice of Special Interest (NOSI): F	<u>RNA Modi</u>	fications in Cancer Biology	National Cancer Institute/NIH/DHHS	NOT- CA-22- 22-Api 003	2022	Not Specified
	Contact Name	Stefan Ma	aas, Ph.D.				
	Contact Telephone	240-276-6	5230				
	Contact Email	stefan.ma	as@nih.gov				
	Sponsor Website						
	Program URL	Link to pro	ogram URL				
	Deadline Dates (ALL)	22-Apr-20 2023 , 16-	)22 , 07-May-2022 , 16-Jun-20 Feb-2023 , 07-May-2023	22 , 24-Jun-2022 , 07-Sep-2022 , 22-	Sep-2022 , 16-Oc	t-2022 , 20-Oct-20	022 , 07-Jan-

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount	
	T c Synopsis r R r r	The purpo cancer bio function, f regulation RNA modi reveal the	ose of this Notice of Special Interpology. Despite the recognition t there are a lack of mechanistic or drives cancer formation. A be ification, and the elucidation of e mechanisms of RNA modificat	erest (NOSI) is to stimulate researc hat RNA modifications and editing insights into the dynamic regulation tter understanding of the extent, of the molecular players that read a ions that underly cancer formation	h on the role of Ri exert substantial on of RNA modifica liversity and cross nd interpret the m n and the cancer p	NA modifications i impact on gene ex ations and how th calk between diffe odification code a henotype.	n the area of opression and eir de- erent types of are needed to	
107760	Notice of Special Interest (NOSI): Re Teamwork and Coordination During	esearch o g Cancer	on Interprofessional I Diagnosis and Treatment I	National Cancer nstitute/NIH/DHHS	NOT- CA-22- 26-Apr 014	-2022	Not Specified	
	Contact Name S	Sallie J. W	'eaver, PhD, MHS					
	Contact Telephone 2	240-276-6	5254					
	Contact Email <u>s</u>	allie.wea	ver@nih.gov					
	Sponsor Website							
	Program URL <u>L</u>	ink to pro	ogram URL					
	2 2 Deadline Dates (ALL) 2 F 2	26-Apr-2022, 07-May-2022, 25-May-2022, 26-May-2022, 05-Jun-2022, 07-Jun-2022, 16-Jun-2022, 24-Jun-2022, 26-Aug 2022, 07-Sep-2022, 25-Sep-2022, 27-Sep-2022, 05-Oct-2022, 07-Oct-2022, 16-Oct-2022, 20-Oct-2022, 08-Nov-2022, 27 Dec-2022, 07-Jan-2023, 25-Jan-2023, 26-Jan-2023, 05-Feb-2023, 16-Feb-2023, 07-Mar-2023, 26-Apr-2023, 07-May-202 eadline Dates (ALL), 25-May-2023, 26-May-2023, 05-Jun-2023, 07-Jun-2023, 16-Jun-2023, 07-Sep-2023, 25-Sep-2023, 26-Sep-2023, 05-Oct-2023, 05-Oct-2023, 05-Oct-2023, 05-Nov-2023, 28-Dec-2023, 07-Jan-2024, 25-Sep-2023, 26-Sep-2024, 05-Nov-2023, 28-Dec-2023, 07-Jan-2024, 25-Sep-2024, 16-Jun-2024, 07-Sep-2024, 25-Sep-2024, 25-Sep-2024, 05-Jun-2024, 07-Jun-2024, 16-Jun-2024, 07-Sep-2024, 25-Sep-2024, 25-Sep-2024, 05-Jun-2024, 07-Jun-2024, 16-Jun-2024, 07-Sep-2024, 25-Sep-2024, 25-Sep-2024, 05-Jun-2024, 07-Jun-2024, 07-Sep-2024, 25-Sep-2024, 25-Sep-2024, 05-Jun-2024, 07-Jun-2024, 07-Sep-2024, 25-Sep-2024, 05-Jun-2024, 07-Jun-2024, 07-Sep-2024, 25-Sep-2024, 05-Jun-2024, 07-Jun-2024, 05-Jun-2024, 05-Jun-2024, 05-Jun-2024, 05-Jun-2024, 05-Sep-2024, 25-Sep-2024, 05-Jun-2024, 05-Jun-2024, 05-Jun-2024, 05-Jun-2024, 05-Jun-2024, 05-Sep-2024, 25-Sep-2024, 05-Jun-2024, 05-Jun-2024, 05-Jun-2024, 05-Jun-2024, 05-Sep-2024, 25-Sep-2024, 25-Sep-2024, 05-Jun-2024,						
	This Notice of Special Interest (NOSI) highlights the NCI Healthcare Delivery Research Program's interest in receiving Synopsis applications focused on understanding and improving interprofessional teamwork and coordination during cancer diagnosis and treatment.							
108323	Notice of Special Interest (NOSI): D Utilization and Health Outcomes A	isparities mong Chi	Affecting Healthcare	National Cancer nstitute/NIH/DHHS	NOT- CA-22- 26-Apr	-2022	Not Specified	

Contact Name Veronica Chollette, RN, MS

Contact Telephone 240-276-6969



029

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount		
	Contact Email Sponsor Website	<u>cholletv@mail.nih.gov</u>						
	Program URL	Link to program URL						
	26-Apr-2022, 07-May-2022, 25-May-2022, 26-May-2022, 05-Jun-2022, 07-Jun-2022, 16-Jun-2022, 24-Jun-2022, 26-Au 2022, 07-Sep-2022, 25-Sep-2022, 27-Sep-2022, 05-Oct-2022, 07-Oct-2022, 16-Oct-2022, 22-Oct-2022, 08-Nov-2022, 2 Dec-2022, 07-Jan-2023, 25-Jan-2023, 26-Jan-2023, 05-Feb-2023, 16-Feb-2023, 07-Mar-2023, 26-Apr-2023, 07-May-20 Deadline Dates (ALL), 25-May-2023, 26-May-2023, 05-Jun-2023, 07-Jun-2023, 16-Jun-2023, 26-Aug-2023, 07-Sep-2023, 25-Sep-2023, 26-Se 2023, 05-Oct-2023, 09-Oct-2023, 16-Oct-2023, 05-Nov-2023, 28-Dec-2023, 07-Jan-2024, 25-Jan-2024, 05-Feb-2024, 1 Feb-2024, 07-Mar-2024, 07-May-2024, 25-May-2024, 05-Jun-2024, 07-Jun-2024, 16-Jun-2024, 25-Sep-2024, 08-Oct- 2024							
	Synopsis	The purpose of this Notice is to highlight the interest of the National Cancer Institute (NCI) Division of Cancer Control and Population Sciences (DCCPS) in receiving applications to understand and address the full spectrum of factors that contribute to disparities in survivorship care, healthcare utilization, and health outcomes among childhood cancer survivors. Studies that focus on factors that extend beyond the individual (e.g., survivor, caregiver, clinician) to include an examination or intervention that involves healthcare teams, healthcare system, community, payer, and/or policy-level factors that contribute to disparities in health outcomes and result in inequitable survivorship care are strongly encouraged.						
106733 <u>F</u>	Notice of Special Interest (NOSI): Pathways in Tumor Etiology and F	Dietary Effects on Nutrient Sensing Prevention	National Cancer Institute/NIH/DHHS	NOT- CA-21- 26-Ap 121	r-2022	Not Specified		
	Contact Name	Phillip J. Daschner, MSc						
	Contact Telephone	240-276-6227						
	Contact Email	pd93u@nih.gov						
	Sponsor Website							
	Program URL	Link to program URL						
26-Apr-2022, 07-May-2022, 26-May-2022, 05-Jun-2022, 12-Jun-2022, 21-Jun-2022, 25-Jun-2022, 20-Jul-2022, 26-Au 2022, 07-Sep-2022, 27-Sep-2022, 05-Oct-2022, 12-Oct-2022, 25-Oct-2022, 28-Dec-2022, 07-Jan-2023, 26-Jan-2023, Deadline Dates (ALL) Feb-2023, 12-Feb-2023, 25-Feb-2023, 26-Apr-2023, 07-May-2023, 26-May-2023, 05-Jun-2023, 12-Jun-2023, 25-Jun- 2023, 07-Sep-2023, 26-Sep-2023, 05-Oct-2023, 12-Oct-2023, 25-Oct-2023, 28-Dec-2023, 07-Jan-2024, 05-Feb-2024, Feb-2024, 25-Feb-2024, 07-May-2024, 05-Jun-2024, 12-Jun-2024, 25-Jun-2024, 07-Sep-2024						22 , 26-Aug- Jan-2023 , 05- 3 , 25-Jun- Feb-2024 , 12-		

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount	
	Synopsis	This Notice of Special Interest (NOSI) seeks to support new and ongoing basic research that provides a deeper understanding of the biology and molecular mechanisms that determine the outcome of key diet/nutrient/cell interactions during early tumor development. Specifically, studies that examine the tumor preventive or tumor-promoting effects of dietary modulation of nutrient sensor signaling pathways during early tumor formation (initiation and malignant progression from early lesions) in preclinical cell, organoid, and animal models, with the goal of identifying and testing potential molecular intervention targets.						
101162	Notice of Special Interest (NOSI): Using Risk-Stratified Pathways	Tailoring F	ollow-up Care for Survivors	National Cancer Institute/NIH/DHHS	NOT- CA-21- 07-M 019	ay-2022	Not Specified	
	Contact Name	Michelle	Mollica, PhD, MPH, RN, OCN					
	Contact Telephone	240-276-7	7621					
	Contact Email	michelle.	mollica@nih.gov					
	Sponsor Website							
	Program URL	Link to pr	ogram URL					
	Deadline Dates (ALL)	07-May-2	022 , 05-Jun-2022 , 07-Sep-202	22 , 05-Oct-2022 , 07-Jan-2023 , 05-	Feb-2023			
	Synopsis	The purper application approach care path triaged ou requires.	ose of this Notice is to highlight ons focused on identifying impo es to improve the clinical mana ways. Risk-stratified survivorsh stratified to distinct care path	t the NCI Division of Cancer Control ortant factors for defining risk-strati agement and outcomes for adult ca hip care describes a personalized ap ways based on the complexity of th	and Population fied survivorship ncer survivors us proach to care in heir needs and th	Sciences' interest i care or developing sing risk-stratified s which cancer surv e types of providen	n receiving g and testing urvivorship rivors are rs their care	
102278	Notice of Special Interest (NOSI): ImagingTools and Methods for th	Translatio e Academ	n of Quantitative ic Industrial Partnership	National Cancer Institute/NIH/DHHS	NOT- CA-21- 07-M 032	ay-2022	Not Specified	
	Contact Name	Robert J.	Nordstrom, Ph.D.					
	Contact Telephone	240-276-5	5934					
	Contact Email	<u>nordstrr@</u>	email.nih.gov					
	Sponsor Website							
	Program URL	<u>Link to pr</u>	ogram URL					

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount			
	Deadline Dates (ALL) 07-May-2022 , 05-Jun-2022 , 07-Sep-2022 This NOSI highlights the NCI Cancer Imaging Program's interest in receiving investigator-initiated grant applications focused on the translation of mature well-developed and optimized quantitative imaging (QI) tools and methods for prediction and/or measurement of response to cancer therapies, or for planning and translating radiation therapy treatment strategies in clinical trials and workflow.								
100707	National Cancer Institute's Investigat Trials for Cancer Treatment and Diag	or-Initiated Early Phase Clinical nosis (R01 Clinical Trial Required)	National Cancer Institute/NIH/DHHS	PAR-21- 033	y-2022	2,499,995 USD			
	Contact Name Lor Contact Telephone 240 Contact Email <u>her</u> Sponsor Website Program URL <u>Lin</u> Deadline Dates (ALL) 07- 202	ri A. Henderson, Ph.D. D-276-5930 <u>ndersonlori@mail.nih.gov</u> <u>k to program URL</u> -May-2022 , 05-Jun-2022 , 07-Sep-202 23 , 05-Oct-2023 , 07-Jan-2024	22 , 05-Oct-2022 , 07-Jan-2023 , 05-	Feb-2023 <i>,</i> 07-Ma	y-2023 , 05-Jun-2(	023 , 07-Sep-			
	The (Ph dire (DC Synopsis cor and Ins infe the	e purpose of this Funding Opportunity hase 0, I, and II) investigator-initiated ect relevance to the research mission CTD) and the Office of HIV and AIDS M hsult the NCI DCTD website and/or th d strategies developed to fight cancer titutes of Health (NIH) definition of a pormation as described in this FOA. Th erefore, applications that propose pha	y Announcement (FOA) is to seek re clinical trials focused on cancer-targ of the National Cancer Institute's ( Malignancies (OHAM, Office of the D e OHAM website to learn more abo . Applications submitted to this FOA clinical trial (see NOT-OD-15-015 fo is FOA does not accept phase III clin ase III clinical trials will be deemed n	esearch projects the geted diagnostic a NCI) Division of Ca Director). Applican but the various pro A must include stu or details) and pro nical trials in any a non-responsive ar	nat implement eau and therapeutic inf ancer Treatment a ts are strongly en- ogram goals, resea udies that meet th vide specific clinic area of cancer rese ad will not be revie	rly phase erventions of and Diagnosis couraged to arch priorities, e National al trial earch; ewed.			
100708	Cancer Prevention and Control Clinic Trial Required)	al Trials Grant Program (R01 Clinical	National Cancer Institute/NIH/DHHS	PAR-21- 035 07-Ma	y-2022	Not Specified			
	Contact Name Bra Contact Telephone 240 Contact Email <u>hea</u> Sponsor Website	andy Heckman-Stoddard, Ph.D., M.P.H D-276-7048 ckmanbm@mail.nih.gov	1.						

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount				
	Program URL	Link to program URL								
	Deadline Dates (ALL)	07-May-2022 , 05-Jun-2022 , 07-Sep-202 2023 , 05-Oct-2023 , 07-Jan-2024	2 , 05-Oct-2022 , 07-Jan-2023 , 05-	Feb-2023 <i>,</i> 07-Ma	y-2023 , 05-Jun-2	023 , 07-Sep-				
	Synopsis	Through this Funding Opportunity Annou of investigator-initiated clinical trials rela- the NCI Division of Cancer Control and Po- improvements in early detection, screen survivorship related to cancer; with such practice and/or public health. Application Health (NIH) definition of a clinical trial (s described in this FOA and the application cancer diagnosis and/or oncologic therap	In ough this runding opportunity Announcement (FOA), the National Cancer Institute (RCI) invites applications for support of investigator-initiated clinical trials related to the programmatic interests of the NCI Division of Cancer Prevention and/or he NCI Division of Cancer Control and Population Sciences that have the potential to reduce the burden of cancer through mprovements in early detection, screening, prevention and interception, healthcare delivery, quality of life, and/or survivorship related to cancer; with such attributes, the proposed studies should also have the potential to improve clinical practice and/or public health. Applications submitted to this FOA must include studies that meet the National Institutes of lealth (NIH) definition of a clinical trial (see NOT-OD-15-015 for details) and provide specific clinical trial information as described in this FOA and the application instructions. This FOA does not and will not support clinical trials for studies of cancer diagnosis and/or oncologic therapy in patients.							
092626	RFA-CA-20-031 Strengthening I Cancer Research in Low- and Mid Not Allowed)	nstitutional Capacity to Conduct Global dle-Income Countries (D43 Clinical Trial	National Cancer Institute/NIH/DHHS	RFA-CA- 20-031 07-Ma	y-2022	1,250,000 USD				
	Contact Name	Sudha Sivaram, DrPH, MPH								
	Contact Telephone	240-276-5804								
	Contact Email	nciglobaltraining@nih.gov								
	Sponsor Website									
	Program URL	Link to program URL								
	Deadline Dates (ALL)	07-May-2022 , 05-Jun-2022 , 07-Sep-202	2							
	Synopsis	The purpose of this Funding Opportunity in global cancer research. This program wintensive institutions working in collabor programs will be built upon the US institu- and will leverage these resources to expa- overarching goal of this initiative is to bu- will contribute to the advancement of ba- does not allow appointed trainees to lea a clinical trial led by a mentor or co-men-	Announcement (FOA) is to establi will support research training led by ration with institutions in low and n utions' pre-existing training infrastr and the global cancer research wor ild capacity to conduct innovative a sic, clinical, translational, and pope d an independent clinical trial but o tor.	sh an institutiona y the United State niddle-income cou ructure and resea kforce both in the and collaborative ulation-based can does allow them t	I program for mer es (U.S.)-based car untries (LMICs). Th rch collaborations e US and in LMICs. global research p cer research in LM o obtain research	itored training icer research- nese training s with LMICs . The rojects that /ICs. This FOA experience in				

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
083680	Stimulating Innovations in Behavi Prevention and Control (R21 Clini	oral Interv cal Trial O	vention Research for Cancer ptional)	National Cancer Institute/NIH/DHHS	PAR-19- 309 07-Ma	ay-2022	275,000 USD
	Contact Name	Tanya Ag	urs-Collins, Ph.D				
	Contact Telephone	240-276-0	6956				
	Contact Email	<u>collinsta@</u>	Dmail.nih.gov				
	Sponsor Website						
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	07-May-2	022 , 16-Jun-2022 , 07-Sep-2	022			
	Synopsis	The purpo intervent intended novel stra and 4) uti targeted and/or ac phase of	ose of this Funding Opportun ions that improve cancer-rela to stimulate research aimed ategies to improve cancer-rel ilizing innovative research de are diet, obesity, physical act therence to cancer-related m the translational spectrum.	ity Announcement (FOA) is to provic ated health behaviors across diverse at 1) testing new theories and conce ated health behaviors; 3) investigatir signs, methodologies, and technolog ivity and sedentary behavior, smokir edical regimens. Research can involv	le support for the racial/ethnic popu ptual frameworks ng multi-level and ies. The cancer-re ng, sleep and circa ve several stages c	development of ir ulations. Specifical ;; 2) developing an multi-behavioral a lated health beha dian dysfunction, of the cancer conti	Inovative ly, this FOA is d evaluating approaches; viors to be alcohol use, nuum and any
101459	Notice of Special Interest (NOSI): Registry Data to Study Health Disp	Leveragin parities	g Population-based Cancer	National Cancer Institute/NIH/DHHS	NOT- CA-21- 07-Ma 020	ay-2022	Not Specified
	Contact Name	Kathy Cro	onin, Ph.D.				
	Contact Telephone	240-276-0	5836				
	Contact Email	cronink@	mail.nih.gov				
	Sponsor Website						
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	07-May-2 2023 , 07	022 , 05-Jun-2022 , 16-Jun-2 -May-2023	022 , 07-Sep-2022 , 05-Oct-2022 , 16	-Oct-2022 , 07-Jar	1-2023 , 05-Feb-20	23 , 16-Feb-
The National Cancer Institute (NCI) is issuing this Notice of Special Interest (NOSI) to encourage applications that effici Synopsis use the existing cancer registry infrastructure by augmenting existing data with additional information not routinely collected by registries to study observed health disparities such as those that exist by race, ethnicity, socioeconomic s							

SPIN IDProgram TitleSponsor NameSp	oonsor Number		Deadline Date	Funding Amount
income, insurance status, age, education lev Program and the National Program of Cance disparities in the United States (US) populat geographically defined areas. The goal of the treatment and outcomes persist by identifyi	vel, or geographic area. The Surveillan er Registries (NPCR) are uniquely posit tion because they contain information nese hypothesis-driven studies should ring factors contributing to disparities a	ce, Epidem ioned to su on all case be to unde and their re	iology, and End Re upport research to s diagnosed within rstand why dispari elative importance.	sults (SEER) assess health ties in cancer
105645Integration of Imaging and Fluid-Based Tumor Monitoring in Cancer Therapy (R01 Clinical Trial Optional)Nati Insti	tional Cancer PAR- titute/NIH/DHHS 290	<sup>21-</sup> 07-Ma	ay-2022	499,999 USD
Contact Name Shane Woodward				
Contact Telephone 240-276-6624				
Contact Email <u>woodwars@mail.nih.gov</u>				
Sponsor Website				
Program URL Link to program URL				
07-May-2022 , 05-Jun-2022 , 05-Jul-2022 , 0 Deadline Dates (ALL) 2023 , 07-May-2023 , 05-Jun-2023 , 05-Jul-2 Mar-2024 , 07-May-2024 , 05-Jun-2024 , 05-	)7-Sep-2022 , 05-Oct-2022 , 05-Nov-20 2023 , 07-Sep-2023 , 05-Oct-2023 , 05- -Jul-2024 , 07-Sep-2024	)22 , 07-Jan Nov-2023 ,	-2023 , 05-Feb-202 07-Jan-2024 , 05-F	23 , 05-Mar- eb-2024 , 05-
National Cancer Institute (NCI) invites appli monitoring (liquid biopsy) assays during can characterization of therapy response and/or award mechanism.	lications for research projects that intencer therapy in patients to determine to remergence of resistance. This FOA w	egrate imag the optimal vill use the I	ing and fluid-base use of those mod NIH Research Proje	d tumor alities in the ect (R01)
103489 Notice of Special Interest (NOSI): Telehealth in Cancer Care Nation   Institution Institution	tional Cancer NOT titute/NIH/DHHS 043	- 1- 07-Ma	ay-2022	Not Specified
Contact Name Gurvaneet Randhawa, M.D., M.P.H.				
Contact Telephone 240-276-6940				
Contact Email Gurvaneet.Randhawa@nih.gov				
Sponsor Website				

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount	
	07- Deadline Dates (ALL) 202 Feb The Pop Synopsis can out con	May-2022 , 05-Jun-2022 , 16-Jun-202 23 , 07-May-2023 , 05-Jun-2023 , 16-Ju -2024 e purpose of this Notice of Special Inte pulation Sciences in receiving investig acer-related care. Studies focused on p comes compared to the general popu npanion announcement to the RFA tit	2, 07-Sep-2022, 05-Oct-2022, 16- un-2023, 07-Sep-2023, 05-Oct-202 erest (NOSI) is to highlight the inter ator-initiated applications for cond populations that experience inequi ulation are strongly encouraged. Th tled "Centers on Telehealth Researc	Oct-2022, 07-Jan 23, 16-Oct-2023, rest of the NCI's D ucting research o ties in access to ca is NOSI for R01 ar ch and Cancer-Re	-2023 , 05-Feb-202 07-Jan-2024 , 05-F ivision of Cancer C n the use of telehe are and have wors nd R21 application lated Care" (RFA-C	23 , 16-Feb- eb-2024 , 16- ontrol and alth in e cancer s is a A-21-029).	
107784	Notice of Special Interest (NOSI): Adn Collaborations with the NCI-supporte Network (DRSN)	ninistrative Supplements to Support ed Drug Resistance and Sensitivity	National Cancer Institute/NIH/DHHS	NOT- CA-22- 07-Ma 020	y-2022	Not Specified	
	Contact Name Kim	n Witherspoon					
	Contact Telephone 240	)-276-6141					
	Contact Email <u>kw</u>	265c@nih.gov					
	Sponsor Website						
	Program URL Lin	k to program URL					
	07- Deadline Dates (ALL) 202 Feb	May-2022 , 05-Jun-2022 , 16-Jun-202 23 , 07-May-2023 , 05-Jun-2023 , 16-Ju -2024 , 07-May-2024 , 05-Jun-2024 ,	2 , 07-Sep-2022 , 05-Oct-2022 , 16- un-2023 , 07-Sep-2023 , 05-Oct-202 16-Jun-2024 , 07-Sep-2024	Oct-2022 , 07-Jan 23 , 16-Oct-2023 ,	-2023 , 05-Feb-202 07-Jan-2024 , 05-F	23 , 16-Feb- eb-2024 , 16-	
	With planned use of funds available from the Cancer Moonshot Initiative, and pursuant to NIH's interest in accelerating cancer research, the National Cancer Institute (NCI) invites, through PA-20-272 in conjunction with this Notice of Special Interest (NOSI), the submission of request for administrative supplement to active NCI-funded grants and cooperative agreements for new interdisciplinary collaborations between outside (non-DSRN-supported) investigators and DSRN U54-supported investigators to perform research within the scientific scope(s) of their active parent grant(s) and/or cooperative agreement award(s).						
104859	Notice of Special Interest (NOSI): Nev Care Delivery Models to Improve Dep	v Information Technology-Enabled I pression Care in Cancer	National Cancer Institute/NIH/DHHS	NOT- CA-21- 07-Ma 085	y-2022	Not Specified	

Contact Name Gurvaneet S. Randhawa, M.D., M.P.H.



SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Contact Telephone	240-276-6940				
	Contact Email	Gurvaneet.Randhawa@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-May-2022 , 05-Jun-2022 , 16-Jun-202 2023 , 16-Feb-2023 , 07-Mar-2023 , 07-I 05-Nov-2023 , 07-Jan-2024 , 05-Feb-202	22 , 07-Sep-2022 , 05-Oct-2022 , 16- May-2023 , 05-Jun-2023 , 16-Jun-20 24 , 16-Feb-2024 , 07-Mar-2024	Oct-2022 , 08-No 23 , 07-Sep-2023	v-2022 , 07-Jan-20 , 05-Oct-2023 , 16	23 , 05-Feb- -Oct-2023 ,
	Synopsis	This Notice of Special Interest (NOSI) hig and Population Sciences in receiving inv implementation of new information tec cancer.	ghlights interest of the National Can restigator-initiated applications for o hnology (IT)-enabled care delivery r	cer Institute (NCI conducting resear nodels to improve	)'s Division of Cano ch on the design a e depression-relato	er Control nd ed care in
106036	Notice of Special Interest (NOSI): Site-Activated Small Molecules	Advancing the Development of Tumor	National Cancer Institute/NIH/DHHS	NOT- CA-21- 07-Ma 101	ıy-2022	Not Specified
	Contact Name	Sharad K. Verma, PhD				
	Contact Telephone	202-657-3694				
	Contact Email	sharad.verma@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-May-2022 , 26-May-2022 , 05-Jun-20 2022 , 25-Oct-2022 , 07-Jan-2023 , 26-Ja 25-Jun-2023 , 07-Sep-2023 , 26-Sep-202 2024 , 16-Jun-2024 , 07-Sep-2024	022 , 21-Jun-2022 , 25-Jun-2022 , 20 an-2023 , 05-Feb-2023 , 25-Feb-2023 3 , 05-Oct-2023 , 25-Oct-2023 , 07-J	-Jul-2022 , 07-Sep 3 , 07-May-2023 , an-2024 , 05-Feb	o-2022 , 27-Sep-20 26-May-2023 , 05 -2024 , 25-Feb-202	22 , 05-Oct- -Jun-2023 , 4 , 07-May-
	Synopsis	This Notice of Special Interest (NOSI) see (DCTD) to support investigation of the d and biology disciplines to support the di profiles for eventual translation to the c	eks to highlight the interest of NCI's levelopment of novel therapies for o iscovery and testing of novel therap clinic.	Division of Cance cancer-applied res eutics offering im	er Treatment and I search encompass proved safety and	Diagnosis ing chemistry efficacy
086964	NCI Small Grants Program for Car 2022 (NCI Omnibus R03 Clinical T	ncer Research for Years 2020, 2021, and Trial Optional)	National Cancer Institute/NIH/DHHS	PAR-20- 052 07-Ma	iy-2022	100,000 USD

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Contact Name Contact Telephone					
	Contact Email					
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-May-2022 , 24-Jun-2022 , 07-Sep-20	)22 , 20-Oct-2022 , 07-Jan-2023			
	Synopsis	This funding opportunity announceme period of time with limited resources. feasibility studies; secondary analysis o methodology; and development of new	nt (FOA) supports small research pro The RO3 grant mechanism supports of f existing data; small, self-contained v research technology.	jects on cancer t lifferent types of research project	hat can be carried of projects including s; development of	out in a short pilot and research
109999	RFA-CA-22-024 Sustained Suppo	ort for Informatics Technologies for	National Cancer	RFA-CA- 15-M	ay-2022	Not
	Cancer Research and Managemer	nt (U24 Clinical Trial Optional)	Institute/NIH/DHHS	22-024 [Opti	onal][LOI/Pre-App]	Specified
	Contact Name	Juli Klemm, Ph.D.				
	Contact Telephone	202-853-7889				
	Contact Email	juli.klemm@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	15-May-2022 [Optional][LOI/Pre-App],	14-Jun-2022 , 18-Oct-2022 [Optiona	l][LOI/Pre-App],	17-Nov-2022	
	Synopsis	continued development and sustainme management, analysis, and disseminat biology, cancer treatment and diagnos epidemiology, and/or cancer health dis (ITCR) Program, this FOA focuses on su widely-adopted informatics tools and r generate these tools and resources that research-driven informatics technology order to be successful, the proposed su be maintained and how it has benefitted	ty Announcement (FOA) is to invite the ent of high value informatics research ion of data and knowledge across the is, early cancer detection, risk assess sparities. As a component of the NCI' staining operations and improving the esources. This is in contrast to early- it are supported by companion ITCR is across the development lifecycle to istainment plan must provide clear ju- ed and will continue to benefit the ca	a resources to im e cancer researc ment and prevent s Informatics Ten the user experience stage and advan FOAs. The centra address priority ustification for w	tement (024) applic prove the acquisiti h continuum includ ntion, cancer contro chnology for Cancel ce and availability o ced development e al mission of ITCR is needs in cancer re why the research res	cations for the on, ing cancer ol and r Research f existing, fforts to to promote search. In cource should chanisms for

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	as be	ssessing and maximizing the value of tl etween the resource and the targeted	he resource to researchers and support of the second support of the second s	porting collaborat cribed.	tion and deep enga	gement
109997	RFA-CA-22-023 Advanced Develog for Cancer Research and Manageme	oment of Informatics Technologies ent (U24 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	RFA-CA- 15-Ma 22-023 [Optic	ay-2022 onal][LOI/Pre-App]	3,000,000 USD
	Contact Name Ju	li Klemm, Ph.D.				
	Contact Telephone 20	02-853-7889				
	Contact Email ju	li.klemm@nih.gov				
	Sponsor Website					
	Program URL Li	nk to program URL				
Deadline Dates (ALL) 15-May-2022 [Optional][LOI/Pre-App], 14-Jun-2022 , 18-Oct-2022 [Optional][LOI/Pre-App], 17-Nov-2022						
	Tr fo vi: ar di Synopsis de er m ac in cc	ne purpose of this Funding Opportunit or advanced development and enhance sualization, and interpretation of data and diagnosis, early cancer detection, ri sparities. As a component of the NCI's in emerging informatics technology, de emonstrated potential to have a signif inhancement, and has not been widely just have a clear rationale on why the iddition, mechanisms to solicit feedbac cluded. Potential applicants who are in ponsult the companion FOAs listed abou	y Announcement (FOA) is to invite ( ement of emerging informatics tech across the cancer research continu- sk assessment and prevention, cance Informatics Technology for Cancer fined as one that has passed the ini- icant and broader impact, has comp adopted in the cancer research field proposed technology is needed and k from users and collaborators throu- nterested in early-stage development (e.	Cooperative Agre nologies to impro um including can cer control and ep Research (ITCR) I tial prototyping a pelling reasons fo d. To be successfu how it will benef ughout the devel nt or informatics	ement (U24) applic ove the acquisition, cer biology, cancer bidemiology, and ca Program, this FOA f and pilot developm r further improvem al, proposed develo fit the cancer resea opment process m resource sustainm	ations analysis, treatment ancer health ocuses ent stage, has bent and opment plans rch field. In ust be ent should
109996	RFA-CA-22-022 Early-Stage Develor for Cancer Research and Manageme	opment of Informatics Technologies ent (U01 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	RFA-CA- 15-Ma 22-022 [Optic	ay-2022 onal][LOI/Pre-App]	900,000 USD
	Contact Name Ju Contact Telephone 20 Contact Email ju Sponsor Website Program URL Lin	li Klemm, Ph.D. D2-853-7889 <u>li.klemm@nih.gov</u> nk to program URL				

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount	
	Deadline Dates (ALL) 15 Th de da ca co Synopsis de as to res teu us	5-May-2022 [Optional][LOI/Pre-A te purpose of this Funding Oppor evelopment of enabling informati inta and knowledge across the can ncer detection, risk assessment a supponent of the NCI's Informatics evelopment from prototyping to h initial tool development or the s promote research-driven inform search. In order to be successful, chnology is needed and how it w ers and collaborators throughout	pp], 14-Jun-2022 , 18-Oct-2022 tunity Announcement (FOA) is ics technologies to improve the neer research continuum includ and prevention, cancer control s Technology for Cancer Resear hardening and adaptation. Early ignificant modification of existi natics technology across the dev proposed development plans ill benefit the cancer research for the development process must	e [Optional][LOI/Pre-App to invite Cooperative Ag acquisition, manageme ing cancer biology, canc and epidemiology, and/ rch (ITCR) Program, this y-stage development is ing tools for new applica velopment lifecycle to ac must have a clear ration field. In addition, mecha st be included.	b), 17-Nov-2022 greement (U01) applic ent, analysis, and disse cer treatment and diag for cancer health dispa FOA focuses on early- defined for the purpo ations. The central mis ddress priority needs hale on why the propo	cations for the emination of gnosis, early arities. As a stage se of this FOA ssion of ITCR is in cancer sed ack from	
109889	RFA-CA-22-021 Development of In Algorithms for Cancer Research and Optional)	novative Informatics Methods ar Management (R21 Clinical Trial	nd National Cancer Institute/NIH/DHHS	RFA-CA- 15- 22-021 [Op	-May-2022 otional][LOI/Pre-App]	275,000 USD	
	Contact Name Jul Contact Telephone 20 Contact Email jul Sponsor Website	li Klemm, Ph.D. )2-853-7889 li.klemm@.nih.gov					
Program URL Deadline Dates (ALL) The purpose of this Funding Opportunity Announcement (FOA) is to invite exploratory/developmental research grant applications (R21) for innovative informatics methods and algorithms to improve the acquisition, analysis, visualization, c interpretation of data across the cancer research continuum including cancer biology, cancer treatment and diagnosis, ea cancer detection, risk assessment and prevention, cancer control and epidemiology, and/or cancer health disparities. As							
	synopsis co su po inf da	pporting the development of nov otential to accelerate or enhance formatics method or algorithm is ita generation and/or data analys	vel informatics capabilities that research. To be successful, the novel and how it will benefit th sis will not be considered respo	involve a high degree o re must be a clear ration he cancer research field. onsive to this funding op	of innovation that have nale for how the prop Projects with a signif portunity.	e the osed icant level of	

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
085330	Linking the Provider Recommendation	on to Adolescent HPV Vaccine	National Cancer Institute/NIH/DHHS	PAR-19- 360 05-Jun	-2022	Not Specified
	Contact Name Sa Contact Telephone 24 Contact Email <u>ko</u> Sponsor Website Program URL <u>Lir</u>	irah Kobrin, Ph.D., MPH 40-276-6931 9 <mark>brins@mail.nih.gov</mark> nk to program URL				
	Deadline Dates (ALL) 05 Th inl Synopsis Ch re in	5-Jun-2022 his Funding Opportunity Announcemer hibits the effectiveness of a provider's haracteristics of the provider, parent/p commendation, and whether that reco cancer prevention, adult and childhoo	nt (FOA) encourages research on hor recommendation of the adolescent patient, and clinical setting, can all a commendation results in uptake of th od behavior, immunization promotic	w the healthcare human papillom ffect whether a p ne HPV vaccine. T on, and healthcare	delivery system er avirus (HPV) vaccir rovider makes a his research requir e delivery.	nhances or ne. res expertise
085257	Intervening with Cancer Caregivers t and Optimize Health Care Utilization	to Improve Patient Health Outcomes n (R01 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PAR-19- 352 05-Jun	-2022	Not Specified
	Contact Name M Contact Telephone 24 Contact Email m Sponsor Website Program URL Lir Deadline Dates (ALL) 05 Synopsis of co	ichelle Mollica, PhD, MPH, RN, OCN 40-276-7621 <u>ichelle.mollica@nih.gov</u> <u>nk to program URL</u> 5-Jun-2022 nis Funding Opportunity Announcemer adult cancer patients. Interventions s oping skills, and ultimately help them n ealth care utilization, (2) improve careg	nt (FOA) invites applications for inte upported by this FOA are intended t nanage care. Outcomes of such inte giver well-being, and (3) improve pa	rvention research to provide caregiv rventions are exp tient physical hea	n designed to supp vers with care train vected to (1) optim alth and psychosoc	ort caregivers ing, promote ize patient ial outcomes.
086149	Perception and Cognition Research t Interpretation (R01 Clinical Trial Opt	to Inform Cancer Image tional)	National Cancer Institute/NIH/DHHS	PAR-19- 387 05-Jun	-2022	Not Specified

Contact Name Todd S. Horowitz, Ph.D.

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount	
	Contact Telephone	240-276-6	5963					
	Sponsor Website		<u>witz@min.gov</u>					
	Program URL	Link to pr	ogram URL					
	Deadline Dates (ALL)	05-Jun-20	22 , 05-Oct-2022					
	Synopsis	The purpo processes accuracy	ose of this Funding Opportunity underlying the performance o of cancer detection and diagno	Announcement (FOA) is to facilita f cancer image observers in radiolo sis.	te research on the gy and pathology,	e perceptual and c , in order to impro	ognitive ve the	
097239	Secondary Analysis and Integratic Genetic Architecture of Cancer Ri Trial Not Allowed)	on of Existi isk and Rel	ng Data to Elucidate the ated Outcomes (R01 Clinical	National Cancer Institute/NIH/DHHS	PAR-20- 276 05-Jun	-2022	1,750,000 USD	
	Contact Name	Melissa R	otunno, Ph.D.					
	Contact Telephone	240-276-7	7245					
	Contact Email	rotunnom	n@mail.nih.gov					
	Sponsor Website							
	Program URL	Link to pr	ogram URL					
	Deadline Dates (ALL)	05-Jun-20	22					
	Synopsis Synopsis Synopsis							
087228	Co-infection and Cancer (R01 Clin	nical Trial N	lot Allowed)	National Cancer Institute/NIH/DHHS	PAR-20- 062 05-Jun	-2022	Not Specified	

Contact Name Tram Kim Lam, Ph.D., MPH



SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Contact Talanhana	240 276 6	5067				
	Contact Telephone	lamt@ma	il nih gov				
	Sponsor Website	Iannenia	<u>II.IIII.gov</u>				
	Program LIRI	Link to pro	ogram LIRI				
	Deadline Dates (ALL)	05-lun-20	22 05-0ct-2022				
	Synopsis	The purpo addressing (pathoger by viruses known on opportuni	ose of this Funding Opportunity g the roles of co-infection. Co-i nic or non-pathogenic) agents – , bacteria, parasites, and/or ot cogenic agents (excluding hum ities for prevention and treatme	Announcement (FOA) is to enhance nfection is defined as the occurrence either concurrently or sequentially her microorganisms. Preference wi an immunodeficiency virus [HIV]) a ent	te mechanistic an ce of infections b y – and includes b Il be given to inve and of co-infection	d epidemiologic ir y two or more infe ooth acute and chr estigations of co-in ns that engender r	ovestigations actious onic infections fections with novel
099622	Tobacco Control Policies to Prom	ote Health	Equity (R01 Clinical Trial	National Cancer	PAR-20- 05-Jun	n-2022	Not
	<u>Optional)</u>	1		nstitute/NIH/DHHS	302	-	Specified
	Contact Name	Bob Vollin	iger, DrPH, MSPH				
	Contact Telephone	240-276-6	5919				
	Contact Email	Bob.Vollin	nger@nih.gov				
	Sponsor Website	b.					
	Program URL	Link to pro	ogram URL				
	Deadline Dates (ALL)	05-Jun-20	22 , 05-Oct-2022 , 05-Feb-2023	3 , 05-Jun-2023			
Synopsis Synopsis Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to support observational stimulate scientific inquiry focused on innovative state and local level tobacco prevention a goal of this FOA is to reduce disparities in tobacco-related cancers, and in doing so, to prom populations. Applicants submitting applications related to health economics are encourage ensure that the research projects align with NIH mission priorities in health economics rese							earch focused aims to The long-term mong all D-16-025 to
103024	Academic-Industrial Partnerships Diagnosis and Treatment (R01 - C	for Transla Clinical Trial	ation of Technologies for I Optional)	National Cancer nstitute/NIH/DHHS	PAR-21- 206	n-2022	2,495,000 USD
	Contact Name	Migual	candon MC				

Contact Name Miguel Ossandon MS



SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
Contact Telephone 240-276-5714 Contact Email ossandom@mail.nih.gov Sponsor Website Program URL Link to program URL Deadline Dates (ALL) 05-Jun-2022 , 05-Oct-2022 , 05-Fe The purpose of this Funding Oppo engineering developments into m applied research to assess risk, de capabilities to meet evolving requ care in pre-clinical, clinical and no participating institutes. This FOA s experience by engaging the streng should establish an inter-discipling strategy to develop and translate the solution will be suitable for er organization. Each partnership shi demonstration of possibility to a s validate, and otherwise translate treatment, and/or monitoring of c end users. This FOA will support c is not intended to support straigh phase III clinical trials in any area does not propose to support com				Announcement (FOA) is to stimula or tools that address problems in revent, diagnose, treat, and/or man its for technologies and methods re- al settings, domestic or foreign, for s a partnership structure that is ex- academic, industrial, and other inv- ilti-institutional research team to w ion to their chosen problem. They is s. Each partnership should include an to transition a technology, meth- iseful in the chosen setting. Fundin logies that address problems in bio status. This FOA defines "innovatio rials that test functionality or valid al trials that lack translation as the er research are not sought by and set	ate efforts to tran basic research to nage disease. The elevant to the adv r conditions and c pected to help bri restigators. The pa vork in strategic a are expected to p at least one acade nod, assay, device g may be request ology, pathology, r on" as likelihood t ate performance primary motivatic will not be suppor	slate scientific disc understand diseas rationale is to del vance of research a liseases within the idge gaps in know artners on each ap lliance to impleme lan, design, and va emic and one indu , and/or system fr ed to enhance, ad risk assessment, di co deliver a new ca in the chosen sett on. Applications th rted through this F	coveries and se, or in iver new and delivery of emissions of ledge and plication ent a coherent alidate that strial om a apt, optimize, iagnosis, apability to ing. This FOA at propose FOA. This FOA
106546	Clinical Characterization of Cance and Mechanism-based Intervention Optional)	r Therapy- onal Strate	induced Adverse Sequelae egies (R01 Clinical Trial	National Cancer nstitute/NIH/DHHS	PAR-21- 329 05-Jun	-2022	Not Specified
	Contact Name Contact Telephone Contact Email Sponsor Website	Kelly Filip 240-276-6 <u>Filipskikk(</u>	ski PhD, MPH 5841 @mail.nih.gov				

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount	
	Program URL	Link to pr	ogram URL					
	Deadline Dates (ALL)	05-Jun-20		3 , 05-Jun-2023 , 05-Oct-2023 , 05-F	eb-2024 , 05-Jun	-2024 , 05-Oct-202	24	
	Synopsis	The purpe address a posttreat mechanis understar projects s identify a use in clir	ose of this Funding Opportunity dverse sequelae of cancer ther ment effects. This FOA support ms of therapy-induced adverse nding into therapeutic approact hould focus on 1) mechanistic nd validate clinical endpoints (I nical trials that will evaluate the	Announcement (FOA) is to suppor apies that persist and become chro s basic, translational, and/or clinica sequelae, clinically characterize th nes to prevent or minimize the deve studies with translational endpoints piomarkers, imaging, patient-report efficacy of interventions designed	t collaborative re nic comorbidities I research projec e adverse sequel elopment of long s; and/or 2) longi ed outcomes, or to prevent or rec	esearch projects de s or develop as del ts that seek to ide ae, or translate the -term sequelae. Re tudinal clinical phe combined elemen duce specific adver	esigned to ayed ntify the e mechanistic esearch enotyping to nts) for future rse sequelae.	
090364	Research Projects to Enhance App Translational Research (R01 Clinic	olicability o al Trial No	of Mammalian Models for ot Allowed)	National Cancer Institute/NIH/DHHS	PAR-20- 131	2022-ו	1,350,000 USD	
	Contact Name	Joanna W	/atson, Ph.D.					
	Contact Telephone	240-276-6	5230					
	Contact Email	Joanna.W	/atson@nih.gov					
	Sponsor Website							
	Program URL	<u>Link to pr</u>	ogram URL					
	Deadline Dates (ALL)	05-Jun-20	022 , 05-Oct-2022 , 05-Feb-2023	3				
	Synopsis	The purpose of this Funding Opportunity Announcement (FOA) is to invite applications for projects to expand, improve, or transform the utility of mammalian cancer and tumor models for translational research. With this FOA, the NCI intends to encourage submission of projects devoted to demonstrating that mammalian models or their derivatives used for translational research are robust representations of human biology, are appropriate to test questions of clinical importance, and provide reliable information for patients' benefit. These practical goals contrast with the goals of many mechanistic, NCI-supported R01 projects that use mammals, or develop and use mammalian cancer models, transplantation tumor models, or models derived from mammalian or human tissues or cells for hypothesis-testing, non-clinical research. Among many other possible endeavors, applicants in response to this FOA could propose demonstrations of how to overcome translational deficiencies of mammalian oncology models, define new uses of mammalian models or their genetics for unexplored translational challenges, advance standard practices for use of translational models, test approaches to validate and credential models, or challenge current practices for how models are used translationally.						

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount		
107221	Modulating Human Microbiome F Responses Against Cancer (R01 Cl	unction to	<u>o Enhance Immune</u> I Not Allowed)	National Cancer Institute/NIH/DHHS	PAR-22- 061	-2022	Not Specified		
	Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL)	Phillip J. E 240-276-0 <u>PD93u@r</u> Link to pr 05-Jun-20	Daschner, M.Sc. 5227 <u>hih.gov</u> <u>ogram URL</u> 122 , 05-Oct-2022 , 05-Feb-202	3 , 05-Jun-2023 , 05-Oct-2023 , 05-F	eb-2024 , 05-Jun-	2024 <i>,</i> 05-Oct-202	24		
	Synopsis	which the targets for microbes sporadic effectiver	be of this Funding Opportunit human microbiome inhibits c r cancer prevention strategies (or consortia) or their metabo cumor formation. Concentration hess and thus those parameter	y Announcement (FOA) is to suppor or enhances anti-tumor immune resp . Applications should be focused on lites target immune responses that on, timing, and duration of administer is should be rigorously addressed in	t basic research t bonses, and to ide delineating how enhance or preve ered beneficial m the application.	nat elucidates me entify potential no host interactions v nt inflammation-a icrobes may alter	chanisms by vel molecular with specific associated or its		
108548	Epidemiologic Research on Emerg Susceptibility (R01 Clinical Trial N	ging Risk F ot Allowed	actors and Liver Cancer I)	National Cancer Institute/NIH/DHHS	PAR-22- 083	-2022	Not Specified		
	Contact Name Contact Telephone Contact Email Sponsor Website	Tram Kim 240-276-( <u>Tram.Lan</u>	Lam, Ph.D., MPH 5967 n <u>@nih.gov</u>						
	Program URL Deadline Dates (ALL)	<u>Link to pr</u> 05-Jun-20 2025	ogram URL 122 , 05-Oct-2022 , 05-Feb-202	3 , 05-Jun-2023 , 05-Oct-2023 , 05-F	eb-2024 , 05-Jun-	2024 , 05-Oct-202	24 , 05-Feb-		
	Synopsis Syn								

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
108551	Cancer Tissue Engineering Collaborer Engineered Technologies for Canorer Optional)	orative: Er cer Resear	abling Biomimetic Tissue- ch (R01 Clinical Trial	National Cancer Institute/NIH/DHHS	PAR-22- 099	n-2022	2,000,000 USD
	Contact Name	Steven Be	ecker, Ph.D.				
	Contact Telephone	240-276-	5210				
	Contact Email	steven.be	ecker@nih.gov				
	Sponsor Website						
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	05-Jun-20 2025	022 , 05-Oct-2022 , 05-Feb-202	3 , 05-Jun-2023 , 05-Oct-2023 , 05-F	eb-2024 , 05-Jun	-2024 , 05-Oct-20	24 <i>,</i> 05-Feb-
	Synopsis	This Fund biomimed fields of r generatin hypothes (TEC) Res and ex viv promote	ing Opportunity Announceme tic tissue-engineered technolog egenerative medicine, tissue e og novel experimental models t is. The projects supported by t earch Program. The Cancer TE vo systems available for cancer the exploration of cancer pher	nt (FOA) will support the development gies for cancer research. Collaboration engineering, biomaterials, and bioen that mimic cancer pathophysiology this FOA will collectively participate C Program will (1) catalyze the adva r research, (2) expand the breadth of homena with biomimetic tissue-eng	ent and character ive, multidisciplin ogineering with ca in the context of in the Cancer Tiss ncement of inno- of these systems t ineered systems.	rization of state-of ary projects that e ancer biology will a testable cancer sue Engineering Co vative, well charac to several cancer t	f-the-art engage the be essential for research ollaborative cterized in vitro ypes, and (3)
106282	Mechanisms that Impact Cancer I Trial Optional)	Risk after I	Bariatric Surgery (R01 Clinical	National Cancer Institute/NIH/DHHS	PAR-21- 331	n-2022	2,500,000 USD
	Contact Name	Edward R	. Sauter, M.D., Ph.D.				
	Contact Telephone	240-276-	7657				
	Contact Email	edward.s	auter@nih.gov				
	Sponsor Website						
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	05-Jun-20 2023 <i>,</i> 05	)22 , 05-Jul-2022 , 05-Oct-2022 -Nov-2023 , 05-Feb-2024 , 05-I	2 , 05-Nov-2022 , 05-Feb-2023 , 05-N Mar-2024 , 05-Jun-2024 , 05-Jul-202	Mar-2023 , 05-Jur 4	n-2023 , 05-Jul-202	23 , 05-Oct-
	Synopsis	Through t of investi	this Funding Opportunity Annc gator-initiated studies address	ouncement (FOA), the National Cance ing mechanisms by which bariatric s	cer Institute (NCI) surgery impacts o	invites applicatio ancer risk, and se	ns for support eks to draw in

SPIN ID Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount			
talen as we	ted scientists who study bariatric s ight loss and diabetes.	surgery to investigate its effects on c	ancer, rather tha	n shorter term ou	tcomes such			
106261 Basic Research in Cancer Health Disparie	ties (R01 Clinical Trial Not	National Cancer Institute/NIH/DHHS	PAR-21- 322 05-Jur	n-2022	Not Specified			
Contact Name Anu S	harman, Ph.D.							
Contact Telephone 240-2	76-6250							
Contact Email <u>sharn</u>	nananu@nih.gov							
Sponsor Website								
Program URL <u>Link t</u>	o program URL							
Deadline Dates (ALL) 05-Ju 2023	n-2022 , 05-Jul-2022 , 05-Oct-2023 , 05-Nov-2023 , 05-Feb-2024 , 05-	2 , 05-Nov-2022 , 05-Feb-2023 , 05-N Mar-2024 , 05-Jun-2024 , 05-Jul-202	/lar-2023 , 05-Jun 4	-2023 , 05-Jul-202	3 , 05-Oct-			
Natio into t studio facto Synopsis also c in car mode Resea	National Cancer Institute (NCI) invites applications from investigators interested in conducting basic, mechanistic research into the biological/genetic causes of cancer health disparities. These research project grants (R01) will support innovative studies designed to investigate biological/genetic bases of cancer disparities, such as (1) mechanistic studies of biological factors associated with cancer disparities, including those related to basic research in cancer biology or cancer prevention strategies, (2) the development and testing of new methodologies and models, and (3) secondary data analyses. This FOA i also designed to aid and facilitate the growth of a nationwide cohort of scientists with a high level of basic research experti in cancer health disparities research who can expand available resources and tools, such as biospecimens, patient derived models, and methods that are necessary to conduct basic research in cancer health disparities. This FOA will use the NIH Besearch Project (B01) award mechanism							
086487 <u>Fundamental Mechanisms of Affective</u> Cancer Control (R01 Clinical Trial Option	and Decisional Processes in nal)	National Cancer Institute/NIH/DHHS	PAR-20- 034 05-Jur	n-2022	Not Specified			
Contact Name Rebe	cca A Ferrer, Ph.D.	·/ / -			1			
Contact Telephone 240-2	76-6963							
Contact Email ferre	ra@mail.nih.gov							
Sponsor Website								
Program URL Link t	o program URL							
Deadline Dates (ALL) 05-Ju	n-2022 , 05-Oct-2022							

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Synopsis	The purpe of affectiv multiple ( control co scientific decision s with down	ose of this Funding Opportunit re processes. Basic affective sc e.g., adherence to oral chemo ontinuum. The FOA is expected disciplines not traditionally con cience, consumer science) to e nstream implications for cance	y Announcement (FOA) is to encour ience projects should have key cons therapy regimen) event decisions a I to encourage collaboration among nnected to cancer control application elucidate perplexing and understud er prevention and control.	rage projects to g sequences for sir nd behaviors acr g cancer control r ons (e.g., affectiv ied problems in a	generate fundamer ngle (e.g., cancer sc oss the cancer prev researchers and tho e and cognitive neu affective and decisi	ntal knowledge reening) and vention and ose from uroscience, on sciences
087000	Program to Assess the Rigor and F Derived Analytes for Cancer Detec	Reproducik ction (R01	bility of Extracellular Vesicle- Clinical Trial Not Allowed)	National Cancer Institute/NIH/DHHS	PAR-20- 053	n-2022	Not Specified
	Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) Synopsis	Sudhir Sriv 240-276-7 srivasts@ Link to pro 05-Jun-20 This Fund isolation a assessment both the i	vastava, Ph.D., M.P.H. 2028 <u>mail.nih.gov</u> 22 , 05-Oct-2022 ing Opportunity Announcement and characterization of extract nt, detection, diagnosis and pr solation of EVs as well as the c	nt (FOA) encourages research proje ellular vesicles (EVs) and their cargo ognosis of early cancer. This FOA w computational analysis of the cargo	cts that focus on for discovery of ill promote rigor carried in these	innovative researc predictive biomark and reproducibility vesicles.	h in the ers for risk / research in
109909	Systematic Testing of Radionuclid (R01 Clinical Trial Not Allowed)	<u>es in Precl</u>	inical Experiments (STRIPE)	National Cancer Institute/NIH/DHHS	PAR-22- 139	n-2022	2,500,000 USD
	Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL)	Michael G 240-276-7 <u>SP@nih.g</u> Link to pro 05-Jun-20 2025	iraham Espey, Ph.D. 7619 <u>ov</u> ogram URL 22 , 05-Oct-2022 , 05-Feb-202	3 , 05-Jun-2023 , 05-Oct-2023 , 05-F	- Feb-2024 <i>,</i> 05-Jur	n-2024 , 05-Oct-202	24 , 05-Feb-



SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	<sup>-</sup> unding Amount					
The purpose of this Funding Opportunity Announcement (FOA) is to solicit R01 research projects utilizing state-of-the-art Synopsis cancer biology methods and model systems to study effects of different types of radiation used in radionuclide-based therapeutics (e.g., radiopharmaceutical therapy) on normal tissue, tumor cells and the tumor microenvironment.											
092676	New Informatics Tools and Methods Research (U01 Clinical Trial Optiona	s to Enhance U.S. Cancer Surveillance I)	National Cancer Institute/NIH/DHHS	PAR-20- 170 06-Jur	ו-2022	Not Specified					
	Contact Name A	ngela B. Mariotto, PhD									
	Contact Telephone 24	40-276-6698									
	Contact Email <u>m</u>	ariotta@mail.nih.gov									
	Sponsor Website										
	Program URL <u>Li</u>	nk to program URL									
	Deadline Dates (ALL) 06	5-Jun-2022 , 18-Nov-2022 , 06-Jun-202	23								
The goal of this Funding Opportunity Announcement (FOA) is to advance surveillance science by supporting the development of new and innovative tools and methods for more efficient, detailed, timely, and accurate data collection cancer registries. Specifically, the FOA solicits applications for projects to develop, adapt, apply, scale-up, and validate to and methods to improve the collection and integration of cancer registry data to expand the data items collected. Applications proposed must be based on partnership with at a minimum of two U.S. population-based central cancer registries. Tools and methods proposed for development are expected to enhance the registry core infrastructure and, i FOA includes but is not limited to Development, validation, evaluation of scalable tools/methods to facilitate automatic/unsupervised extraction and cosolidation of specific data from various types of unstructured medical records for example, pathology reports, diagnostic imaging, laboratory, hospital discharge forms and clinical visits; Supplementa of cancer registries with new or more detailed data items, from existing data sources or from linkages with novel data sources, e.g. electronic medical records (EMR) Funds will be made available through the U01 cooperative agreement aw											
109682	RFA-CA-22-015 Cancer Control Re (U54 Clinical Trial Optional)	search in Persistent Poverty Areas	National Cancer Institute/NIH/DHHS	RFA-CA- 06-Jur 22-015 [Optic	n-2022 nal][LOI/Pre-App]	7,500,000 USD					
	Contact Name Sh	nobha Srinivasan, Ph.D.									
	Contact Telephone 24	40-276-6938									
	Contact Email	688k@nih.gov									



SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount			
	Sponsor Website									
	Program URL	Link to pro	ogram URL							
	Deadline Dates (ALL)	06-Jun-20	22 [Optional][LOI/Pre-App], 06	-Jul-2022						
	Synopsis	Through t Control Re time and c cancer pre serves po long-term research a the effect	Control Research in Persistent Poverty Areas (Persistent Poverty Initiative). The goal is to provide resources to support the time and effort of transdisciplinary teams, in collaboration with institutions, clinics, and communities/tribes, to develop a cancer prevention and control research program and provide support to early-career investigators that focuses on and serves populations living in persistent poverty areas. For this purpose, NCI will support several U54 Specialized Centers. The ong-term goal of this initiative is to build capacity in persistent poverty areas to foster cancer prevention and control research of programs and practices in institutions/clinics/communities/tribes to alleviate the effects of persistent poverty.							
106892	Exploratory Grants in Cancer Cont	rol (R21 C	linical Trial Optional)	National Cancer Institute/NIH/DHHS	PAR-21- 341 07-Jur	-2022	275,000 USD			
	Contact Name	Mukesh V	/erma, Ph.D.							
	Contact Telephone	240-276-6	5889							
	Contact Email	<u>vermam@</u>	email.nih.gov							
	Sponsor Website									
	Program URL	Link to pro	ogram URL							
	Deadline Dates (ALL)	07-Jun-20	22 , 07-Oct-2022 , 07-Jun-2023	6 , 09-Oct-2023 , 07-Jun-2024 , 08-C	oct-2024					
	Through this funding opportunity announcement (FOA), the National Cancer Institute (NCI) encourages the submission of exploratory/developmental research grant (R21) applications that focus on different aspects of cancer control by modifying behavior, screening, and understanding etiologic factors contributing to the development of cancer, and developing ways to control cancer. The overarching goal is to provide support to promote the early and conceptual stages of research efforts or novel scientific ideas that have the potential to substantially advance population-based cancer research, such as the development of novel techniques, agents, methodologies, models, or applications that could have a major impact on a field of cancer research (e.g. epidemiologic, biomedical, behavioral, health care delivery or clinical).									
106117	NCI Research Specialist (Clinician S Allowed)	Scientist) /	Award (R50 Clinical Trial Not	National Cancer Institute/NIH/DHHS	PAR-21- 306 07-Jur	-2022	Not Specified			
	Contact Name	Deborah J	laffe, Ph.D.							



SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Contact Telephone	240-276-6169				
	Contact Email	jaffed@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-Jun-2022 , 06-Oct-2022 , 07-Feb-2023	3 , 06-Jun-2023 , 06-Oct-2023			
	Synopsis	Through this Funding Opportunity Annou Research Specialist Award (R50) specifica Research Specialist Award is designed to clinician scientists who want to continue development of national clinical trials, 2) the NCI clinical trials networks through p activities, but not serve as principal inves the NCI-funded clinical trials enterprise. autonomy so that individuals are not solo research career continuity.	uncement (FOA), the National Cancer ally for clinician scientists supporting encourage the development of stab to participate in the NCI clinical trial implementation of NCI clinical trials articipation in the scientific review co stigators of research project grants. T The Research Specialist Award is inte ely dependent on NCI grants held by	r Institute (NCI) NCI-funded clir le research care s networks thro in their institut ommittees, mo These clinician s ended to provide others or other	invites application nical trials research eer opportunities f ough leadership in cions, and 3) nation nitoring committe cientists are vital e salary support an sources of suppo	ns for the or exceptional the 1) nal service to es and other to sustaining nd sufficient rt for cancer
107027	Integrating Biospecimen Science . Development (U01 Clinical Trial N	Approaches into Clinical Assay Iot Allowed)	National Cancer I nstitute/NIH/DHHS (	PAR-22- 07-Jur	า-2022	1,250,000 USD
	Contact Name	Abhi Rao, Ph.D.				
	Contact Telephone	240-276-5715				
	Contact Email	abhi.rao@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-Jun-2022 , 13-Sep-2022 , 11-Jan-2023	, 07-Jun-2023 , 13-Sep-2023 , 11-Jar	n-2024 <i>,</i> 07-Jun-	2024 , 13-Sep-202	4
	Synopsis	This Funding Opportunity Announcement facing clinical assay development and su biopsies, blood biospecimens utilized as research funded under this FOA may incl study of small biopsies (core biopsies, sm secretions, pleural and esophageal aspira designed experiments will explore how c	t (FOA) will support extramural resea bsequent analytical validation due to "liquid biopsies, or other biospecime ude investigations of preanalytical va nall excision samples), blood utilized ates, feces, or bodily fluids like sweat lifferent biospecimen preanalytical co	arch to investig preanalytical v ns as described ariability associa for liquid biopsi , urine, CSF, bre onditions affect	ate and mitigate c variability in tumor I in this FOA. Extra ated with the proc ies, tissue swabs, t east milk and saliv c emerging and clin	hallenges tissue mural urement and issue a. Investigator- nically relevant

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		biomarke understar collection evidence-	rs quantified by a variety of tending of how analytical quanti , processing, and storage proc based standardization of biop	sting platforms. The results from th fication of clinically relevant bioma edures. The overall goal is to expect sy handling practices.	iis research pro rkers is affecte lite biomarker	ogram will improve th ed by variation in biosp clinical assay develop	e becimen bment through
084969	Innovative Approaches to Studyin Information Ecosystem (R21 Clinic	ig Cancer ( cal Trial Oj	Communication in the New otional)	National Cancer Institute/NIH/DHHS	PAR-19- 350	8-Jun-2022	275,000 USD
	Contact Name Contact Telephone Contact Email Sponsor Website Program URL	Kelly D. B 240-281-5 <u>kelly.blak</u>	lake, ScD 5934 <u>e@nih.gov</u> ogram URL				
	Synopsis	Through t supportin applicatio communi cancer co apply con preventio	his Funding Opportunity Anno g meritorious research projec n of new cancer communicati cation interventions using inn mmunication models emphas nmunication science approach n and control. Applications sh	ouncement (FOA), the National Can ts in three distinct domains related on surveillance approaches; 2) the ovative methods and designs; and 3 izing bidirectional influence betwee es to the investigation of behaviora ould utilize one or more innovative	cer Institute (N to cancer com development a b) the develop en levels. For so al targets and h communicatio	NCI) announces its intent munication: 1) the ut and testing of rapid ca ment and testing of m uch projects, applican health outcomes relat on research methodol	erest in ility and incer ultilevel ts should ed to cancer ogies.
084968	Innovative Approaches to Studyin Information Ecosystem (R01 Clinic	ig Cancer ( cal Trial Oj	Communication in the New otional)	National Cancer Institute/NIH/DHHS	PAR-19- 348	9-Jun-2022	Not Specified
	Contact Name	Kelly D. B	lake, ScD				
	Contact Telephone	240-281-5	5934				
	Contact Email	<u>kelly.blak</u>	<u>e@nih.gov</u>				
	Sponsor Website	Link to pr	ogram LIRI				
	FIUGIAIII UKL	LINK tO PI					

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Synopsis	Through t supportin applicatic communi cancer co apply con preventio	this Funding Opportunity Annou og meritorious research projects on of new cancer communication cation interventions using inno mmunication models emphasiz nmunication science approache on and control. Applications sho	uncement (FOA), the National Can s in three distinct domains related on surveillance approaches; 2) the vative methods and designs; and 3 sing bidirectional influence betwee es to the investigation of behaviora ould utilize one or more innovative	cer Institute (NC to cancer comm development ar b) the developm en levels. For suc al targets and he communicatior	cl) announces its int nunication: 1) the ut d testing of rapid ca ent and testing of m ch projects, applicar alth outcomes relat research methodo	erest in tility and ancer nultilevel nts should ted to cancer logies.
084813	Leveraging Cognitive Neuroscience Treatment-Related Cognitive Impa	<u>e to Impro</u> airment (F	ove Assessment of Cancer R21 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PAR-19- 339 08-J	un-2022	275,000 USE
	Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL)	Todd S Ho 240-276-6 <u>todd.horo</u> L <u>ink to pr</u> 08-Jun-20 This FOA chronic co	orowitz, Ph.D 5963 <u>owitz@mail.nih.gov</u> <u>ogram URL</u> 022 encourages the integration of c ognitive changes following canc	cognitive neuroscience approaches cer treatment for non-central nerve	s to improve trad ous system mali	ditional assessment gnancies.	of acute and
084812	Leveraging Cognitive Neuroscience Treatment-Related Cognitive Impa	<u>e to Impro</u> airment (F	ove Assessment of Cancer R01 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PAR-19- 340	un-2022	Not Specified
	Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL)	Todd S Ho 240-276-6 todd.horo Link to pr 08-Jun-20	orowitz, Ph.D 5963 owitz@mail.nih.gov ogram URL 022				
	Synopsis	This FOA chronic co	encourages the integration of c ognitive changes following canc	cognitive neuroscience approaches er treatment for non-central nerve	s to improve trad ous system mali	ditional assessment gnancies.	of acute and

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
106440	Pancreatic Cancer Detection Cons Trial Optional)	sortium: Research Units (U01 Clinical	National Cancer Institute/NIH/DHHS	PAR-21- 334 10-Jun	n-2022	3,000,000 USD
	Contact Name	Sudhir Srivastava, Ph.D., M.P.H.				
	Contact Telephone	240-276-7028				
	Contact Email	<u>srivasts@mail.nih.gov</u>				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	10-Jun-2022 , 11-Oct-2022 , 10-Feb-20	23 , 13-Jun-2023 , 11-Oct-20	23 , 11-Jun-2024		
	Synopsis	Research Units (RUs), one of the two s conduct research on early detection of lesions to identify those patients who four research priorities identified in th PCDC will support research for the dev early and for identifying those patients could be candidates for early intervent to: identify and test biomarkers measu molecular- and/or imaging-based mark develop molecular- and/or imaging-based and computational approaches toward The PCDC-RUs will also collect longitud participate in collaborative activities w The other scientific component of the companion PAR-21-335). The PCDC-M analysis, coordination, harmonization, including biorepository building effort, wide calls, meetings and workshops.	cientific components of the F f pancreatic ductal adenocard are at high risk of progression e NCI's 2014 Scientific Frame velopment and testing of new s at high risk of PDAC (becaus tion. The PCDC-RUs will consi urable in bodily fluids for early kers of pancreatic cysts and d used approaches for screening ds biomarker discovery and/or dinal biospecimens for buildir with other PCDC-RUs and shar PCDC will be the Managemen DCU will provide support tow data management and stewa . The PCDC-MDCU will also su	Pancreatic Cancer Detection in to cancer. The PCDC will work for Pancreatic Ductar molecular and imaging b e of genetic factors or pre- st of multi-disciplinary tea y detection of PDAC and/or etermine which ones are g populations at high risk or validation; and conduct a biorepository. Each P e ideas, biospecimens, and that and Data Coordination ward study design, protoco ardship for the trans-PCD upport the coordination and	on Consortium (P cterization of its p continue to addu al Adenocarcinom iomarkers for de esence of precurs ams and will unde or its precursor le likely to progress of PDAC; use mad biomarker valida CDC-RU is expect d data within the Unit (MDCU; see of development, s C collaborative pr nd organization o	CDC), to precursor ress one of the na (PDAC). The tecting PDAC or lesions) who ertake studies isions; develop a to cancer; chine learning ition studies. ed to e Consortium. tatistical rojects, f Consortium-
106441	Pancreatic Cancer Detection Cons	sortium: Management and Data	National Cancer	PAR-21- 10-Jun	n-2022	2,500,000

Coordination Unit (U24 Clinical Trial Not Allowed)

Institute/NIH/DHHS

10-Jun-2022

335

Contact Name Sudhir Srivastava, Ph.D., M.P.H.



USD

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Contact Telephone	240-276-3	7028				
	Contact Email	srivasts@	mail.nih.gov				
	Sponsor Website		······································				
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	10-Jun-20	)22 , 11-Oct-2022 , 10-Feb-202	3 , 13-Jun-2023 , 11-Oct-2023 , 11-	Jun-2024		
	Synopsis	Through t establishr Pancreati identified research identify th collabora Other PCI logistics s companic imaging b factors ar	this Funding Opportunity Anno- ment of the Management and c Cancer Detection Consortium in the National Cancer Institu- on early detection of pancreat hose patients who are at high in tive efforts such as: study design DC-MDCU activities include: co upport for PCDC activities. The on PAR-21-334). The PCDC-RUS biomarkers for early detection ind/or family history or presence	uncement (FOA), the National Can Data Coordination Unit (MDCU), or n (PCDC). The PCDC will continue to te's 2014 Scientific Framework for I ic ductal adenocarcinoma (PDAC) a risk of progression to cancer. The P gn, protocol development, statistic ordination and support toward bio e other scientific component of the will conduct research for the deve of PDAC and/or for identifying thos e of precursor lesions) who could b	cer Institute (NCI) ne of the two scier address one of the Pancreatic Ductal A nd characterizatio CDC-MDCU will pr al analysis, coordin repository building PCDC will be the F lopment and testing the patients at high the candidates for e	is soliciting applicant ne four research part Adenocarcinoma a n of its precursor ovide support town nation and data m g; and organizatio Research Units (PC ng of new molecu risk of PDAC (beca varly intervention.	ations for the of the riorities and conduct lesions to vard anagement. nal and CDC-Rus; see lar and ause of genetic
106319	Utilizing the PLCO Biospecimens I Etiology and Early Detection Rese	<u>Resource t</u> earch (U01	<u>o Bridge Gaps in Cancer</u> <u>Clinical Trial Not Allowed)</u>	National Cancer Institute/NIH/DHHS	PAR-21- 330 10-Jun	-2022	Not Specified
	Contact Name	Claire Zhu	ı, Ph.D.				
	Contact Telephone	240-276-7	7013				
	Contact Email	<u>zhucla@n</u>	nail.nih.gov				
	Sponsor Website						
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	10-Jun-20	)22 , 11-Oct-2022 , 10-Feb-202	3 , 13-Jun-2023 , 11-Oct-2023 , 13-	Feb-2024 , 11-Jun-	-2024 , 11-Oct-202	24
	Synopsis	Through t applicatic the uniqu Trial. The screened	this Funding Opportunity Anno ons that propose to advance re le biorepository resources of the PLCO Biorepository offers high arm participants, and a onetin	uncement (FOA), the National Can search in cancer etiology and early ne NCI-sponsored Prostate, Lung, C n-quality, prospectively collected, s ne collection of buccal cells from bo	cer Institute (NCI) detection biomar olorectal, and Ova erial pre-diagnosti oth the screened a	encourages the su kers, utilizing the a prian Cancer (PLCC to blood samples f nd the control arr	ubmission of advantages of )) Screening rom the PLCO n participants.

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		Available clinical da analyses o must invo unique ch Alzheime do not inv	data associated with the biosp ita. This FOA supports a wide ra of cancer risk, as well as discove live use of PLCO biospecimens aracteristics of the PLCO biosp r's, depression, hip fracture, os volve the use of PLCO biospecir	ecimens includes demographic, die ange of cancer research including, l ery and validation of early detectio and may include other resources; a ecimens. Research on non-cancer o teoporosis and rheumatoid arthriti nens will not be supported under t	et, lifestyle, smoki out not limited to n biomarkers. The additionally, it sho outcomes, especi s) may also be su his FOA.	ng, screening resu , biochemical and e proposed resear ould also take adva ally those related t pported. Research	Its, and other genetic ch project intage of the to aging (e.g., i projects that
100261	Assay Validation of High Quality N (UH2/UH3 Clinical Trial Not Allow	Markers fo ed)	r Clinical Studies in Cancer	National Cancer Institute/NIH/DHHS	PAR-20- 313 11-Jur	ח-2022	1,025,000 USD
	Contact Name Contact Telephone Contact Email	Tracy G. L 240-276- <u>s</u> <u>livelyt@m</u>	ively, Ph.D. 5944 nail.nih.gov				
	Sponsor Website Program LIBI	Link to pr	ogram LIRI				
	Deadline Dates (ALL)	11-Jun-20	022 , 11-Oct-2022 , 14-Feb-2023	3 , 10-Jul-2023 , 10-Oct-2023			
	Synopsis	Through t the valida detection cancer pr of assays validation and whos are increa multiple r supports before as assays for FOA may studies. E assays aci will requir	this Funding Opportunity Anno ation of molecular/cellular/imag , diagnosis, prognosis, monitor evention and control. This FOA to be used in cancer treatment of pharmacodynamic markers e importance is well justified for asingly combined with immuno markers, including immune mar analytical validation of assays f says may undergo clinical valid up to 3 years using well-annot be used to validate existing ass fforts to harmonize clinical labor coss multiple clinical laboratori re multi-disciplinary interaction	uncement (FOA), the National Cano ging markers (referred to as "marke ing, and prediction of response or a will support investigator-initiated c, control, or prevention trials support and markers of toxicity. Applicants or development into clinical assays therapies to enhance durability of rkers, can be developed and validat or these molecular/cellular/imagin ation. The UH3 phase of this FOA s tated biospecimens from retrospec says for use in other cancer clinical pratory tests, including investigatio es, are also appropriate for this fun- n and collaboration among scientific	cer Institute (NCI) ers" or "biomarke resistance to trea research for both orted by the NCI. s should have assi . As chemotherap anti-cancer respo ted simultaneous g markers, which upports clinical va tive or prospectiv trials, observation in into the perform iding opportunity c investigators, or	invites application rs") and assays for tment, as well as r analytical, and cli This FOA will also ays that work on h ies and/or radiation nses, assays for m ly. The UH2 phase must be achieved alidation of analyti re clinical trials or anal studies, or pop mance and reprod . Projects propose moologists, statistic	ns to support r cancer markers for nical validation support the numan samples on therapies easuring of this FOA within 2 years cally validated studies. This ulation ucibility of d for this FOA cians, and

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		clinical lal clinical tri investigat accomplis	boratory scientists. This FOA is als but is intended for validatio ional assays. Investigators resp shed in the UH2 phase for trans	not intended to support early-stag on of assays to the point where the oonding to this FOA must address b sition to the UH3 phase must be pr	e development of y could be integra oth UH2 and UH3 oposed by the inv	technology or the ited into clinical tr phases. Mileston estigators.	e conduct of ials/studies as es to be
100262	Assay Validation of High Quality N (UH3 Clinical Trials Not Allowed)	<u>1arkers fo</u>	r Clinical Studies in Cancer	National Cancer Institute/NIH/DHHS	PAR-20- 314 11-Jur	ו-2022	750,000 USD
	Contact Name Contact Telephone Contact Email Sponsor Website	Tracy G. L 240-276- <u>s</u> <u>livelyt@m</u>	ively, Ph.D. 5944 nail.nih.gov				
	Program URL	<u>Link to pr</u>	ogram URL				
	Synopsis	The purpor molecular prognosis control. T FOA must clinical us immunot immune r establishe be used to clinical lal laborator interactio FOA is no validation	pice , 11-Oct-2022, 14-reb-202 ose of this Funding Opportunity r/cellular/imaging markers (ref b, monitoring, and prediction of this FOA will also support the va- thave an assay(s) whose perfor- e of the marker(s) and assay(s) herapies to enhance the durab markers, can be developed and ed assays for up to 3 years usin to validate existing assays for us boratory tests, including invest ies, are also appropriate for the mand collaboration among sci- t intended to support early-state of assays to the point where t	y Announcement (FOA) is to accele erred to as "markers" or "biomarke f response or resistance to treatme alidation of pharmacodynamic mar rmance has been analytically valida ). As chemotherapies and/or radiat ility of anti-cancer responses, assay I validated simultaneously. The UHS g specimens from retrospective or se in other trials, observational stud- igation into the performance and r is funding opportunity. Projects pro entific investigators, oncologists, st ge development of technology or t they could be integrated into clinica	rate the adoption ers") and assays for ent, as well as mar kers and markers ated in specimens ion therapies are ys for measuring n 3 mechanism will prospective clinic dies, or population eproducibility of a posed for this FO atisticians, and cli the conduct of clin al trials/studies as	and validation of or cancer detection kers for cancer pro- of toxicity. Applica similar to those for increasingly comb nultiple markers, i support the clinica al trials or studies. In studies. Efforts to assays across mult A will require multion nical laboratory so incal trials but is inti- investigational as	n, diagnosis, evention and ants to this or the intended ined with ncluding al validation of . This FOA may o harmonize iple clinical ti-disciplinary cientists. This tended for says.
106356	NCI Transition Career Developmen Independent Clinical Trial Not Allo	nt Award ( wed)	to Promote Diversity (K22	National Cancer Institute/NIH/DHHS	PAR-21- 301 12-Jur	n-2022	Not Specified

Contact Name Mulualem E. Tilahun, D.V.M., Ph.D

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Contact Telephone	240-276-7360				
	Contact Email	mulualem.tilahun@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	12-Jun-2022 , 12-Oct-2022 , 12-Feb-202	23 , 12-Jun-2023 , 12-Oct-2023 , 12-I	Feb-2024 , 12-Jun-	-2024	
	Synopsis	The purpose of the NCI Transition Care individuals in equivalent positions to tr biomedical career as an independent re the NCI Transition Career Development research workforce by supporting eligit be nationally underrepresented in the time" through salary and research supp position. This Funding Opportunity Ann not involve leading an independent clin to this FOA are permitted to propose re a clinical trial or a separate ancillary cli	er Development Award to Promote ansition to positions of assistant pro esearch scientist. This Funding Oppo : Award to Promote Diversity (K22) to ble individuals from diverse backgrou- biomedical, behavioral, social and cl port for 3 years beginning at the time founcement (FOA) is designed specifi- nical trial, a clinical trial feasibility stu- esearch experience in a clinical trial field inical trial as lead investigator, shoul	Diversity (K22) is t ifessor or equivale intunity Announce to enhance the div unds, including gra- inical sciences. Th e when the candic fically for applican udy, or a separate led by another inv ld apply to the cor	to assist postdocto ent and initiate a s ment (FOA) is a co versity in the NCI-f oups that have be is award will prov date starts a tenur ts proposing resea ancillary clinical t vestigator. Applica npanion FOA (PAF	oral fellows or uccessful ontinuation of unded cancer en shown to ide "protected e-track faculty arch that does rial. Applicants nts proposing R-21-302).
106354	NCI Mentored Clinical Scientist Re Promote Diversity (K08 Clinical Tr	esearch Career Development Award to rial Required)	National Cancer Institute/NIH/DHHS	PAR-21- 299 12-Jun	n-2022	Not Specified
	Contact Name	Mulualem E. Tilahun, D.V.M., Ph.D				
	Contact Telephone	240-276-7360				
	Contact Email	mulualem.tilahun@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	12-Jun-2022 , 12-Oct-2022 , 12-Feb-202	23 , 12-Jun-2023 , 12-Oct-2023 , 12-I	Feb-2024 , 12-Jun-	-2024	
	Synopsis	The purpose of the NCI Mentored Clinic careers that have a significant impact of continuation of a long-standing NIH pro- degree or a health professional doctora fields of biomedical and behavioral reso designed to enhance the diversity in th	cal Scientist Career Development Aw n the health-related research needs ogram that provides support and pro al degree for an intensive, supervise earch, including translational research e NCI-funded cancer research workf	vard (K08) program of the nation. Thi otected time to ind d research career ch. This NCI-spons force by supportin	m is to prepare ind is program repres dividuals with a cli development exp cored K08 award is g eligible clinical s	lividuals for ents the inical doctoral erience in the s specifically scientists from

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		diverse ba and for th research and traini compete designed feasibility planning must app	ackgrounds, including groups th nose who are committed to a ca on cancer health disparities. Th ing, awardees will develop enha for research project grants (e.g specifically for applicants proper study, or a separate ancillary c an independent clinical trial, or ly to companion FOA (PAR-21-3	nat have been shown to be nationa areer in basic biomedical, behavior e expectation is that through this anced research capabilities for can 5. R03, R21, or R01) funding. This F osing to serve as the lead investiga clinical trial, as part of their research proposing to gain research experi 300).	ally underrepresen ral or translational sustained period o icer research caree Funding Opportuni ator of an independ ch and career deve ience in a clinical to	ited in health-rela cancer research, of research career ers and be better p ty Announcement dent clinical trial, elopment. Applicat rial led by another	ted sciences including development orepared to (FOA) is a clinical trial nts not investigator,
106355 <u>[</u>	VCI Mentored Clinical Scientist Re Promote Diversity (K08 - Indepen	esearch Ca dent Clinic	reer Development Award to cal Trial Not Allowed)	National Cancer Institute/NIH/DHHS	PAR-21- 300 12-Jun	-2022	Not Specified
	Contact Name	Mulualen	n E. Tilahun, D.V.M., Ph.D				
	Contact Telephone	240-276-7	7360				
	Contact Email	mulualem	n.tilahun@nih.gov				
	Sponsor Website						
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	12-Jun-20	022 , 12-Oct-2022 , 12-Feb-2023	3 , 12-Jun-2023 , 12-Oct-2023 , 12-	Feb-2024 , 12-Jun-	-2024	
	Synopsis	The purper careers the continuate degree or fields of be designed diverse be and for the research of and training compete designed trial feasi	ose of the NCI Mentored Clinica nat have a significant impact on tion of a long-standing NIH prog r a health professional doctoral biomedical and behavioral resea to enhance the diversity in the ackgrounds, including groups the nose who are committed to a ca on cancer health disparities. The ing, awardees will develop enha for research project grants (e.g specifically for applicants propo- bility study, or a separate ancilla	al Scientist Career Development Av the health-related research needs gram that provides support and pro- degree for an intensive, supervise arch, including translational resear NCI-funded cancer research work hat have been shown to be national areer in basic biomedical, behavior e expectation is that through this anced research capabilities for can c. R03, R21, or R01) funding. This F osing research that does not involv ary clinical trial. Applicants to this	ward (K08) program s of the nation. This otected time to ind ed research career rch. This NCI-spons force by supportin ally underrepresen ral or translational sustained period of force research career Funding Opportuni we leading an indep FOA are permitted	n is to prepare ind is program repres dividuals with a cli development exp ored K08 award is g eligible clinical s ited in health-rela cancer research, i of research career ers and be better p ty Announcement bendent clinical tr d to propose resea	dividuals for ents the inical doctoral erience in the s specifically ccientists from ted sciences including development orepared to c (FOA) is ial, a clinical arch

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		experienc trial as lea	e in a clinical trial led by a me ad investigator, should apply to	ntor or co-mentor. Applicants propo o the companion FOA (PAR-21-299)	osing a clinical tri	al or a separate an	cillary clinical
106228	NCI Mentored Research Scientist Diversity (K01 Independent Clinic	<u>Developm</u> al Trial No	<u>ent Award to Promote</u> <u>t Allowed)</u>	National Cancer Institute/NIH/DHHS	PAR-21- 295 12-Ju	n-2022	Not Specified
	Contact Name	Mulualen	n E. Tilahun, D.V.M., Ph.D				
	Contact Telephone	240-276-7	7360				
	Contact Email	<u>mulualer</u>	n.tilahun@nih.gov				
	Sponsor Website						
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	12-Jun-20	22 , 12-Oct-2022 , 12-Feb-202	3 , 12-Jun-2023 , 12-Oct-2023 , 12-F	eb-2024 , 12-Jur	n-2024 , 12-Oct-202	<u>2</u> 4
	Synopsis	Award to eligible in the biome of "protec designed trial feasi experienc trial as lea	Ing Opportunity Announceme Promote Diversity (K01) to en dividuals from diverse backgro edical, behavioral, social and c cted time" for intensive resear specifically for applicants prop bility study, or a separate ancil te in a clinical trial led by a men ad investigator, should apply to	nt (FOA) is a continuation of the NC hance the diversity in the NCI-funde bunds, including groups that have be linical sciences. This FOA provides si rch career development under the g bosing research that does not involv llary clinical trial. Applicants to this f ntor or co-mentor. Applicants propo o the companion FOA.	I Mentored Rese ed cancer researc een shown to be alary and researc uidance of an ex e leading an inde FOA are permitte osing a clinical tri	arch Scientist Deve h workforce by su nationally underre h support for a sus perienced mentor. pendent clinical tr d to propose resea al or a separate an	oppment porting presented in tained period This FOA is ial, a clinical arch cillary clinical
106230	NCI Mentored Research Scientist Diversity (K01 Clinical Trial Requir	<u>Developm</u> red)	ent Award to Promote	National Cancer Institute/NIH/DHHS	PAR-21- 296 12-Ju	n-2022	Not Specified
	Contact Name	Mulualen	n E. Tilahun, D.V.M., Ph.D				
	Contact Telephone	240-276-7	7360				
	Contact Email	mulualem	n.tilahun@nih.gov				
	Sponsor Website						
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	12-Jun-20	022 , 12-Oct-2022 , 12-Feb-202	3 , 12-Jun-2023 , 12-Oct-2023 , 12-F	eb-2024 , 12-Jur	n-2024 , 12-Oct-202	24
SPIN ID Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount	
--	---	---	--	---	---	---	
T A Synopsis C i c c	This Fund Award to eligible in the biome of "protee Opportun ndepend career de clinical tri	ing Opportunity Announcemen Promote Diversity (K01) to enh dividuals from diverse backgrou edical, behavioral, social and cli cted time" for intensive researc ity Announcement (FOA) is des ent clinical trial, a clinical trial for velopment. Applicants not plan al led by another investigator, r	t (FOA) is a continuation of the Ne ance the diversity in the NCI-fund unds, including groups that have b nical sciences. This FOA provides h career development under the igned specifically for applicants p easibility study, or a separate anci- ning an independent clinical trial, must apply to the companion FOA	CI Mentored Resea ed cancer research been shown to be r salary and research guidance of an exp roposing to serve a illary clinical trial, a or proposing to ga	arch Scientist Deve n workforce by sup nationally underre n support for a sus erienced mentor. as the lead investig as part of their reso ain research experi	lopment oporting presented in tained period This Funding pator of an earch and ience in a	
106358 NCI Transition Career Developmen Clinical Trial Required)	t Award 1	to Promote Diversity (K22	National Cancer nstitute/NIH/DHHS	PAR-21- 302 12-Jur	-2022	Not Specified	
Contact Name r Contact Telephone 2 Contact Email r Sponsor Website Program URL 1 Deadline Dates (ALL) 1 i t t Synopsis t t	Viulualem 240-276-7 mulualem Link to provide 12-Jun-20 The purpo ndividual biomedica che NCI Tr research v coe nation cime" thro position. The position.	A E. Tilanun, D.V.M., Ph.D 7360 <u>a.tilahun@nih.gov</u> 022, 12-Oct-2022, 12-Feb-2023 ose of the NCI Transition Career s in equivalent positions to trar al career as an independent res ransition Career Development A workforce by supporting eligible ally underrepresented in the bi pugh salary and research suppo This Funding Opportunity Anno or of an independent clinical tr	3, 12-Jun-2023, 12-Oct-2023, 12- r Development Award to Promote nsition to positions of assistant pro- earch scientist. This Funding Oppe Award to Promote Diversity (K22) e individuals from diverse backgro omedical, behavioral, social and cort for 3 years beginning at the tim uncement (FOA) is designed spec ial, a clinical trial feasibility study,	Feb-2024 , 12-Jun- Diversity (K22) is t ofessor or equivale ortunity Announce to enhance the div ounds, including gra linical sciences. Th he when the candic ifically for applican or a separate anci	2024 to assist postdocto ent and initiate a sument (FOA) is a co rersity in the NCI-f oups that have be is award will provi late starts a tenury ts proposing to se llary clinical trial, a	ral fellows or uccessful ontinuation of unded cancer en shown to de "protected e-track faculty rve as the lead as part of their	
102792 The NCI Transition Career Develop	experience ment Aw	e in a clinical trial led by anothe ard (K22 Independent Basic	er investigator, must apply to com National Cancer	PAR-21- 318 12-Jun	21-301). h-2022	450,000 USD	



SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) Synopsis	Sonia B. J 240-276-5 jakowles( Link to pr 12-Jun-20 This Fund investigat This goal independ faculty pc in NOT-O definition include st variables) aspects o specific a companic separate	akowlew, Ph.D. 5630 <u>ogram URL</u> 022 , 12-Oct-2022 , 12-Feb-2023 ing Opportunity Announcement cors in mentored, non-independ is achieved by providing protect ent tenure-track faculty position position. This FOA is designed spective basic of a clinical trial and also meet cudies that prospectively assigned and that assess biomedical or f phenomena without specific a pplication toward processes or on FOA (PAR-21-111). Applicant ancillary clinical trial or indeper- tial Not Allowed" companion EC	5, 12-Jun-2023, 12-Oct-2023, 12-F t (FOA) represents the continuatio lent cancer research positions to ir ted time through salary and resear n, or its equivalent, beginning at the crifically for basic science experime science studies involving human participants to conditions ( behavioral outcomes in humans fo pplication towards processes or pr products in mind should submit ur s not planning an independent clin indent basic experimental study wit pa (PAR-21-128)	Eeb-2024 n of an NCI progr ndependent facul rch support for the ental studies invol articipants." Thes ypes of studies th (i.e., experimenta r the purpose of u roducts in mind. A der the "Indepen ical trial, a clinica h humans, must a	am to facilitate the ty cancer research e initial 3 years of candidate starts a ving humans, refe e studies fall withi at should submit u lly manipulate ind understanding the opplicants planning dent Clinical Trial I trial feasibility stra opply to the "Indep	e transition of positions. the first tenure-track rred to in the NIH under this FOA ependent fundamental g studies with Required" udy, or a pendent
102781	The NCI Transition Career Develo Clinical Trial Required)	pment Aw	ard (K22 - Independent I	National Cancer nstitute/NIH/DHHS	PAR-21- 128 12-Jur	n-2022	450,000 USD
	Contact Name	Sonia B. J	akowlew, Ph.D.				
	Contact Telephone	240-276-5	5630				
	Contact Email	jakowles(	@mail.nih.gov				
	Sponsor Website						
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	12-Jun-20	022 , 12-Oct-2022 , 12-Feb-2023	, 12-Jun-2023 , 12-Oct-2023 , 12-F	eb-2024		

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Synopsis	This Fund investigat This goal independ faculty po independ trial, a clin companic	ing Opportunity Announcemer cors in mentored, non-indepen- is achieved by providing protec ent tenure-track faculty positic osition. This FOA is designed spe ent clinical trial, a clinical trial f nical trial feasibility study, or ar on FOAs (PAR-21-111 or PAR-21	et (FOA) represents the continuation dent cancer research positions to in ted time through salary and resear on, or its equivalent, beginning at the cifically for candidates proposing r easibility study, or an ancillary study of ancillary study to an ongoing clinic -318).	n of an NCI progr ndependent facul ch support for th ne time when the research that doe ly to a clinical tria cal trial as lead in	am to facilitate the ty cancer research e initial 3 years of t candidate starts a s not involve leadir Il. Applicants propo vestigator, should a	e transition of positions. the first tenure-track ng an osing a clinical apply to the
109178	RFA-RM-22-008 NIH Faculty Ins Transformation (FIRST) Program: Optional)	stitutional FIRST Coh	Recruitment for Sustainable ort (U54 Clinical Trial	National Cancer Institute/NIH/DHHS	RFA- RM-22- 008	n-2022 pnal][LOI/Pre-App]	10,245,000 USD
	Contact Name	Jessica M	. Calzola, Ph.D.				
	Contact Telephone	240-276-7	7474				
	Contact Email	FIRSTNIH	<u>@nih.gov</u>				
	Sponsor Website						
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	12-Jun-20	022 [Optional][LOI/Pre-App], 12	-Jul-2022			
	Synopsis	The purpo communi cultures c recipient an advert equivalen to promo	ose of the FIRST Cohort is to tra ty of scientists committed to di of inclusive excellence within th institutions and beyond. This c ised research tenure-track or e at) level), meet the criteria for N ting diversity and inclusive exce	Insform culture at NIH-funded extra versity and inclusive excellence (de e program has the potential to be t ommunity will be built through recu quivalent faculty position (position IIH-defined Early Stage Investigator ellence.	amural institution fined below). Im transformational ruitment of indivi s must be at the rs, and have dem	ns by building a self plementing and sus for biomedical rese duals who: are con Assistant Professor onstrated a strong	-reinforcing staining earch at the npetitive for (or commitment
102778	The NCI Transition Career Develo	pment Aw	ard (K22 - Independent	National Cancer	PAR-21- 12-Jui	า-2022	450,000 USD
	<u>Clinical Trial Required)</u>	I		INSTITUTE/NIH/DHHS	111		
	Contact Name	Sonia B. J	akowlew, Ph.D.				
	Contact Telephone	240-276-5	5630				
	Contact Email	jakowles(	@mail.nih.gov				

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Sponsor Website					
	Program URL <u>L</u>	ink to program URL				
	Deadline Dates (ALL) 1	12-Jun-2022 , 12-Oct-2022 , 12-Feb-2023	3 , 12-Jun-2023 , 12-Oct-2023 , 12-F	eb-2024		
	T ii Synopsis f i a z a	This Funding Opportunity Announcement nvestigators in mentored, non-independ This goal is achieved by providing protect ndependent tenure-track faculty positio faculty position. This FOA is designed spe ndependent clinical trial, a clinical trial f career development. Applicants not plan ancillary clinical trial must apply to the "I	It (FOA) represents the continuation dent cancer research positions to in ted time through salary and research on, or its equivalent, beginning at th ecifically for candidates proposing t reasibility study, or a separate ancill nning an independent clinical trial, a Independent Clinical Trial Not Allow	n of an NCI progr dependent facul ch support for the e time when the o serve as the lea ary clinical trial, a clinical trial feas yed companion F	am to facilitate the ty cancer research e initial 3 years of candidate starts a ad investigator of a as part of their res ibility study, or a s OA (PAR-21-128).	e transition of positions. the first tenure-track an earch and separate
102905	Exploratory Grant Award to Promo Research (R21 Clinical Trial Not Allo	te Workforce Diversity in Basic Cancer   owed)	National Cancer Institute/NIH/DHHS	PAR-21- 061 14-Jur	า-2022	275,000 USD
	Contact Name	Vlauricio Rangel-Gomez, Ph.D.				
	Contact Telephone 2	240-620-0534				
	Contact Email <u>N</u>	<u> Mauricio.Rangel-Gomez@nih.gov</u>				
	Sponsor Website					
	Program URL <u>L</u>	ink to program URL				
	Deadline Dates (ALL) 1	L4-Jun-2022 , 17-Nov-2022 , 14-Jun-2023	3,17-Nov-2023			
	۲ Synopsis د ل	This Funding Opportunity Announcemen the cancer research workforce by recruit diverse backgrounds, including from grou behavioral, clinical and social sciences. T	It (FOA) is a continuation of an NCI ting and supporting eligible New Inv ups that have been shown to be na his FOA will fund investigators to de	program to enha vestigators and Ea tionally underrep evelop a larger re	nce the diversity o arly Stage Investig presented in the bi search project gra	f the pool of ators from omedical, int application.
108550	Epidemiologic Research on Emergi Susceptibility (R21 Clinical Trial Not	ng Risk Factors and Liver Cancer t Allowed)	National Cancer Institute/NIH/DHHS	PAR-22- 084 16-Jur	-2022	275,000 USD
	Contact Name T	Fram Kim Lam, Ph.D., MPH				
	Contact Telephone 2	240-276-6967				
	Contact Email 1	<u>Fram.Lam@nih.gov</u>				

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Sponsor Website						
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	16-Jun-20 2025	022 , 16-Oct-2022 , 16-Feb-2023	3 , 16-Jun-2023 , 16-Oct-2023 , 16	Feb-2024 , 16	-Jun-2024 , 16-Oct-20	24 , 16-Feb-
	Synopsis	The purpo innovative risk factor histologic	ose of this Funding Opportunity e hypotheses on emerging risk rs (e.g., viral hepatitis) associate al subtypes) in the United State	Announcement (FOA) is to prom factors (biological, environmental ed with the development of liver open.	ote epidemiol , and social) an cancer (hepato	ogic research investig nd their interplay with ocellular carcinoma an	ating novel and a established ad other
087229 🤇	Co-infection and Cancer (R21 Clir	nical Trial N	lot Allowed)	National Cancer Institute/NIH/DHHS	PAR-20- 061	6-Jun-2022	275,000 USD
	Contact Name	Tram Kim	Lam, Ph.D., MPH				
	Contact Telephone	240-276-6	5967				
	Contact Email	lamt@ma	iil.nih.gov				
	Sponsor Website						
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	16-Jun-20	)22 , 16-Oct-2022				
	Synopsis	The purpe addressin (pathogen by viruses known or opportun	ose of this Funding Opportunity g the roles of co-infection. Co-i nic or non-pathogenic) agents – s, bacteria, parasites, and/or ot ncogenic agents (excluding hum ities for prevention and treatm	Announcement (FOA) is to enhane infection is defined as the occurre either concurrently or sequentia her microorganisms. Preference v an immunodeficiency virus [HIV]) ent.	nce mechanist nce of infectio ly – and incluo vill be given to and of co-infe	ic and epidemiologic i ons by two or more inf des both acute and ch investigations of co-in ections that engender	nvestigations ectious ronic infections nfections with novel
085337 <u>L</u>	inking the Provider Recommend Jptake (R21 Clinical Trial Optiona	ation to Ad al)	dolescent HPV Vaccine	National Cancer Institute/NIH/DHHS	PAR-19- 358	6-Jun-2022	275,000 USD
	Contact Name	Sarah Kok	orin, Ph.D., MPH				
	Contact Telephone	240-276-6	5931				
	Contact Email	<u>kobrins@</u>	<u>mail.nih.gov</u>				
	Sponsor Website						



SPIN ID Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
Progra	m URL Link to p	rogram URL				
Deadline Date	s (ALL) 16-Jun-20	022				
Sy	This Fund inhibits t nopsis Characte recomme in cancer	ding Opportunity Announcemer he effectiveness of a provider's ristics of the provider, parent/p endation, and whether that reco prevention, adult and childhoo	nt (FOA) encourages research recommendation of the adol patient, and clinical setting, ca commendation results in uptal od behavior, immunization pro	on how the healthca lescent human papillo an all affect whether a ke of the HPV vaccine omotion, and healthc	re delivery system e mavirus (HPV) vacc provider makes a . This research requ are delivery.	enhances or ine. ires expertise
085343 Linking the Provider Recon	nmendation to A ptional)	dolescent HPV Vaccine	National Cancer Institute/NIH/DHHS	PAR-19- 359 16-J	un-2022	100,000 USD
Contact	Name Sarah Ko	brin, Ph.D., MPH				
Contact Tele	phone 240-276-	6931				
Contac	Email <u>kobrins@</u>	<u>)mail.nih.gov</u>				
Sponsor W	ebsite					
Progra	m URL <u>Link to p</u>	rogram URL				
Deadline Date	s (ALL) 16-Jun-20	022				
Sy	This Fund inhibits t nopsis Characte recomme in cancer	ding Opportunity Announcemer he effectiveness of a provider's ristics of the provider, parent/p endation and whether that reco prevention, adult and childhoo	nt (FOA) encourages research recommendation of the adol patient, and clinical setting, ca mmendation results in uptak od behavior, immunization pr	on how the healthca lescent human papillo an all affect whether a ce of the HPV vaccine. omotion, and healthc	re delivery system e mavirus (HPV) vacc provider makes a This research requ are delivery.	enhances or ine. res expertise
099631 Tobacco Control Policies to Optional)	Promote Health	n Equity (R21 Clinical Trial	National Cancer Institute/NIH/DHHS	PAR-20- 303 16-J	un-2022	275,000 USD
Contact	Name Bob Volli	nger, DrPH, MSPH				
Contact Tele	phone 240-276-	6919				
Contac	Email <u>Bob.Volli</u>	nger@nih.gov				
Sponsor W	ebsite					
Progra	m URL Link to p	rogram URL				
Deadline Date	s (ALL) 16-Jun-20	022 , 16-Oct-2022 , 16-Feb-2023	3 , 16-Jun-2023			

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	The on r stim goal pop ensu	purpose of this Funding Opportunity educing disparities in tobacco use ar ulate scientific inquiry focused on in of this FOA is to reduce disparities in ulations. Applicants submitting appli ure that the research projects align w	Announcement (FOA) is to suppore of secondhand smoke (SHS) expose novative state and local level tobac n tobacco-related cancers, and in d cations related to health economic vith NIH mission priorities in health	rt observational our are in the U.S. Spector cooprevention ar oing so, to promo s are encouraged economics resea	or intervention rest ecifically, this FOA nd control policies. ote health equity a l to consult NOT-O urch.	earch focused aims to The long-term mong all D-16-025 to
106264	Basic Research in Cancer Health Dispa Allowed)	rities (R21 Clinical Trial Not	National Cancer nstitute/NIH/DHHS	PAR-21- 323 16-Jur	า-2022	400,000 USD
	Contact Name Anu Contact Telephone 240- Contact Email shar Sponsor Website Program URL Link Deadline Dates (ALL) Deadline Dates (ALL) Synopsis Synopsis	Sharman, Ph.D. 276-6250 <u>mananu@nih.gov</u> <u>to program URL</u> un-2022 , 16-Jul-2022 , 16-Oct-2022 3 , 16-Nov-2023 , 16-Feb-2024 , 16-No onal Cancer Institute (NCI) invites ap the biological/genetic causes of can ies designed to investigate biologica ors associated with cancer disparities regies, (2) the development and test designed to aid and facilitate the gro incer health disparities research who lels, and methods that are necessary	, 16-Nov-2022 , 16-Feb-2023 , 16-N Mar-2024 , 16-Jun-2024 , 16-Jul-202 plications from investigators intere cer health disparities. These resear l/genetic bases of cancer disparities s, including those related to basic r ing of new methodologies and mod bowth of a nationwide cohort of scie o can expand available resources ar to conduct basic research in cance	Mar-2023 , 16-Jun 4 ested in conduction ch project grants as, such as (1) mea esearch in cancer dels, and (3) secon entists with a high and tools, such as b er health dispariti	n-2023 , 16-Jul-202 ng basic, mechanis (R01) will support chanistic studies o biology or cancer ndary data analyse n level of basic rese piospecimens, pati es.	3 , 16-Oct- tic research innovative f biological prevention es. This FOA is earch expertise ent derived
106265	Basic Research in Cancer Health Dispa Allowed)	rities (R03 Clinical Trial Not	National Cancer nstitute/NIH/DHHS	PAR-21- 324 16-Jur	า-2022	100,000 USD
	Contact Name Anu Contact Telephone 240- Contact Email <u>shar</u> Sponsor Website	Sharman, Ph.D. 276-6250 <u>mananu@nih.gov</u>				

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Drogram LIPI	Link to pr					
	Program OKL	16 Jun 20		16 Nov 2022 16 Feb 2022 16 N	Mar 2022 1	C lup 2022 16 Jul 20	22 16 Oct
	Deadline Dates (ALL)	2023, 16	-Nov-2023 , 16-Feb-2024 , 16-N	/ 16-1007-2022 , 16-Feb-2023 , 16-F Mar-2024 , 16-Jun-2024 , 16-Jul-202	24	o-jun-2023 , 16-jul-20	23,10-001-
	Synopsis	This Fund basic, me will suppo projects s mechanis cancer bio secondar	ing Opportunity Announcement chanistic research into the bio port projects on cancer health d hould propose innovative stud tic studies of biological factors plogy or cancer prevention strate y data analyses.	nt (FOA) encourages grant applicati ogical/genetic causes of cancer hea isparities that can be carried out in lies designed to investigate biologic associated with cancer disparities, ategies, (2) the development and te	ons from inv alth disparitie a short peric cal/genetic ba including the esting of new	estigators interested es. These small resear od of time with limited ases of cancer disparit ose related to basic re methodologies and n	in conducting ch grants (RO3) d resources. The ties, such as (1) desearch in nodels, and (3)
106283	Mechanisms that Impact Cancer I Trial Not Allowed)	<u>Risk after I</u>	Bariatric Surgery (R21 Clinical	National Cancer Institute/NIH/DHHS	PAR-21- 332	.6-Jun-2022	550,000 USD
	Contact Name	Edward R	. Sauter, M.D., Ph.D.				
	Contact Telephone	240-276-	7657				
	Contact Email	edward.s	auter@nih.gov				
	Sponsor Website						
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	16-Jun-20 2023 , 16	)22 , 16-Jul-2022 , 16-Oct-2022 -Nov-2023 , 16-Feb-2024 , 16-N	, 16-Nov-2022 , 16-Feb-2023 , 16-№ ⁄lar-2024 , 16-Jun-2024 , 16-Jul-202	Mar-2023 , 10 24	6-Jun-2023 , 16-Jul-20	23 , 16-Oct-
	Synopsis	Through to of investig talented so as weight	his Funding Opportunity Anno gator-initiated studies address scientists who study bariatric s loss and diabetes.	uncement (FOA), the National Cano ing mechanisms by which bariatric urgery to investigate its effects on o	cer Institute ( surgery impa cancer, rathe	(NCI) invites application acts cancer risk, and se er than shorter term o	ons for support eeks to draw in utcomes such
085275	Intervening with Cancer Caregive and Optimize Health Care Utilizat	rs to Impro ion (R21 C	ove Patient Health Outcomes linical Trial Optional)	National Cancer Institute/NIH/DHHS	PAR-19- 355	.6-Jun-2022	275,000 USD
	Contact Name	Michelle	Mollica, PhD, MPH, RN, OCN				
	Contact Telephone	240-276-	7621				
	Contact Email	michelle.	mollica@nih.gov				
	Sponsor Website						

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Program LIRI	Link to program LIRI				
	Deadline Dates (ALL)	16-lun-2022				
	Synopsis	This Funding Opportunity Announcement of adult cancer patients. Interventions s coping skills, and ultimately help them r health care utilization, (2) improve care	nt (FOA) invites applications for int supported by this FOA are intended manage care. Outcomes of such in giver well-being, and (3) improve p	tervention researc d to provide caregi terventions are ex patient physical he	h designed to supp vers with care trai pected to (1) optin alth and psychoso	oort caregivers ning, promote nize patient cial outcomes
086150	Perception and Cognition Research Interpretation (R21 Clinical Trial C	ch to Inform Cancer Image Optional)	National Cancer Institute/NIH/DHHS	PAR-19- 389 16-Jui	า-2022	400,000 USD
	Contact Name	Todd S. Horowitz, Ph.D.				
	Contact Telephone	240-276-6963				
	Contact Email	todd.horowitz@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	16-Jun-2022 , 16-Oct-2022				
	Synopsis	The purpose of this Funding Opportunit processes underlying the performance of accuracy of cancer detection and diagno	y Announcement (FOA) is to facilit of cancer image observers in radio osis.	ate research on th logy and patholog	e perceptual and o , in order to impro	cognitive ove the
097241	Secondary Analysis and Integratic Genetic Architecture of Cancer Ri Trials Not Allowed)	on of Existing Data to Elucidate the isk and Related Outcomes (R21 Clinical	National Cancer Institute/NIH/DHHS	PAR-20- 277 16-Ju	า-2022	400,000 USD
	Contact Name	Melissa Rotunno, Ph.D.				
	Contact Telephone	240-276-7245				
	Contact Email	<u>rotunnom@mail.nih.gov</u>				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	16-Jun-2022				
	Synopsis	Through this funding opportunity anno Genome Research Institute (NHGRI) and	ouncement (FOA), the National Car I National Institute of Dental and C	ncer Institute (NCI) Craniofacial Resear	along with the Na ch (NIDCR) encour	tional Human ages

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		submissic resources prediction questions in combin encourag	on of applications proposing to s, with the ultimate aim to eluc n or reduction, survival, or resp s relevant to cancer genomic an nation with other omics and en ed to leverage existing genetic	conduct secondary data analysis idate the genetic architecture of ponse to treatment, etc.). The go nd epidemiology by supporting th wironmental, clinical, behavioral, data and perform innovative and	and integration of cancer risk and rela al of this initiative is ne analysis of existin lifestyle, and molea alyses of the existin	existing datasets a ited outcomes (e.g to address key sci ng genetic or geno cular profiles data. g data.	nd database g., risk entific mic datasets, Applicants are
108359	Exploratory/Developmental Bioe (R21 Clinical Trial Optional)	ngineering	Research Grants (EBRG)	National Cancer Institute/NIH/DHHS	PAR-22- 091	n-2022	275,000 USD
	Contact Name	Miguel R.	Ossandon, Ph.D.				
	Contact Telephone	240-276-5	5714				
	Contact Email	ossandon	n@mail.nih.gov				
	Sponsor Website						
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	16-Jun-20	)22 , 16-Oct-2022 , 16-Feb-202	3 , 16-Jun-2023 , 16-Oct-2023 , 1	6-Feb-2024 , 16-Jun	-2024 , 16-Oct-202	24
	Synopsis	The purpe explorato utility of r problems clinical tri trials in a	ose of this engineering-oriente ory/developmental Bioengineer new capabilities or improveme in basic biomedical, pre-clinica ials that test functionality or va ny area of cancer research are	d funding opportunity announce ring Research Grant (EBRG) appli- nts in quality, speed, efficacy, op al, or clinical research, clinical car alidate performance in the chosen not sought by and will not be sup	ment (FOA) is to en cations to demonstr erability, costs, and re delivery, or acces n setting. Applicatio pported through thi	courage submissio rate feasibility and /or accessibility of sibility. This FOA v ns that propose pl s FOA	ns of potential solutions to vill support nase III clinical
107222	Modulating Human Microbiome Responses Against Cancer (R21 C	Function to linical Tria	<u>o Enhance Immune</u> I Not Allowed)	National Cancer Institute/NIH/DHHS	PAR-22- 062 16-Ju	n-2022	275,000 USD
	Contact Name	Phillip J. [	Daschner, M.Sc.				
	Contact Telephone	240-276-6	6227				
	Contact Email	<u>PD93u@r</u>	<u>nih.gov</u>				
	Sponsor Website						
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	16-Jun-20	)22 , 16-Oct-2022 , 16-Feb-202	3 , 16-Jun-2023 , 16-Oct-2023 , 1	6-Feb-2024 , 16-Jun	-2024 , 16-Oct-202	24

SPIN ID	Program Title		Sponsor Name	Sponsor Number			Deadline Date	Funding Amount
	Synopsis	The purpo which the targets fo microbes sporadic t effectiver	ose of this Funding Opportunit human microbiome inhibits or r cancer prevention strategies (or consortia) or their metabo cumor formation. Concentration ness and thus those parameter	y Announcement (FOA) is to suppo or enhances anti-tumor immune res . Applications should be focused or lites target immune responses that on, timing, and duration of administ rs should be rigorously addressed in	rt basic res ponses, an delineatin enhance o cered benef the applic	earch th d to ide g how h r prever ficial mic ation.	at elucidates mentify potential no ost interactions on it inflammation-a crobes may alter	chanisms by wel molecular with specific associated or their
109910	Systematic Testing of Radionuclid (R21 Clinical Trial Not Allowed)	les in Precl	inical Experiments (STRIPE)	National Cancer Institute/NIH/DHHS	PAR-22- 140	16-Jun-	2022	275,000 USD
	Contact Name Contact Telephone	Michael G	Graham Espey, Ph.D. 7619					
	Contact Email	SP@nih.g	ov					
	Sponsor Website							
	Program URL	Link to pr	ogram URL					
	Deadline Dates (ALL)	16-Jun-20 2025	022 , 16-Oct-2022 , 16-Feb-202	3 , 16-Jun-2023 , 16-Oct-2023 , 16-	Feb-2024 ,	16-Jun-2	2024 , 16-Oct-202	24 , 16-Feb-
	Synopsis	The purpo cancer bio therapeut	ose of this Funding Opportunit ology methods and model syst tics (e.g., radiopharmaceutical	y Announcement (FOA) is to solicit ems to study effects of different ty therapy) on normal tissue, tumor c	R21 resear pes of radia cells and the	ch proje ation use e tumor	ects utilizing state ed in radionuclide microenvironme	e-of-the-art e-based nt.
098641	NCI Clinical and Translational Exp Clinical Trial Optional)	loratory/D	evelopmental Studies (R21	National Cancer Institute/NIH/DHHS	PAR-20- 292	21-Jun-	2022	275,000 USD
	Contact Name	William C	. Timmer, Ph.D					
	Contact Telephone	240-276-6	5130					
	Contact Email	<u>william.ti</u>	<u>mmer@nih.gov</u>					
	Sponsor Website							
	Program URL	Link to pro	ogram URL					
	Deadline Dates (ALL)	21-Jun-20	22 , 21-Jun-2022 , 20-Jul-2022					
	Synopsis	This Fund studies, d	ling Opportunity Announceme irectly related to advancemen	ent (FOA) supports preclinical and e ts in cancer treatment, diagnosis, p	arly phase revention,	clinical r sympto	esearch, as well a management,	as correlative or reduction

SPIN ID     Program Title     Sponsor Name     Sponsor Number     Deadline Date     Funding Amount	ding ount
--	--------------

of cancer health disparities. This includes (but is not limited to) development and testing of the following: new molecular agents or biologics for cancer treatment; management strategies for cancer-related symptoms or treatment-related toxicity; cancer screening or diagnostic tools, such as imaging techniques; cancer preventive agents or approaches; predictive and prognostic biomarkers for patient selection or stratification; clinically relevant in vivo or in vitro tumor models (including genetically engineered mouse models, patient-derived xenograft models, organoids, and cell lines); and strategies to address therapeutic outcome disparities among diverse racial/ethnic populations. In addition to novel agents, new treatment strategies may involve repurposed agents or novel combinations of interventions (including radiation), based on established mechanisms of action. Comparative oncology studies in dogs investigating strategies for treatment and diagnosis of human disease are supported as well. This FOA does not support research that focuses on basic cancer biology (such as studies of cancer-related pathways or molecular mechanisms), late-stage clinical trials, risk assessment studies, epidemiological studies, or studies of behavioral interventions. These applications will be deemed not responsive to this FOA and will not be reviewed (see below for a more detailed description of studies that are not responsive for this FOA). The R21 mechanism is intended to encourage exploratory and developmental research projects by providing support for the early and conceptual stages of these projects. These studies may involve considerable risk but may lead to breakthroughs in particular areas, or to the development of novel techniques, agents, methodologies, models, or applications that could have a major impact on cancer research (preclinical or clinical).

091405	Investigator Initiated Clinical Trial Interventions Delivered Remotely Required)	National Center for Complementary and Integrative Health/NIH/DHHS	PAR-20- 154	07-May-2022	Not Specified	
	Contact Name	Lanay Mudd, Ph.D				
	Contact Telephone	301-594-9346				
	Contact Email	lanay.mudd@mail.nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-May-2022 , 05-Jun-2022 , 07-Sep-20	022 , 05-Oct-2022 , 07-Jan-2023 , 05-	Feb-2023	, 07-May-2023	
	Synopsis	This Funding Opportunity Announceme and conducted clinical trials to assess t NCCIH designated areas of high researd delivered and conducted clinical trial w utilize mHealth tools or technologies. T applications must have sufficient prelim	ent (FOA) encourages applications fo he efficacy or effectiveness of compl ch priority. Applications submitted un vith no in-person contact between re To justify the proposed remotely deliminary data that includes: demonstra	r investiga ementary nder this F search sta vered effic ation of fe	tor-initiated fully remotely and integrative health inte OA are expected to propos off and study participants a cacy or effectiveness clinica asibility of remote recruitm	delivered rventions in e a remotely nd may al trial, nent and

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		accrual of throughou interventio appropria prior to su	participants; demonstration o ut the study; completion of fina on; and evidence that the inte te NCCIH Scientific/Research c Ibmitting to this FOA.	f participant adherence to the inte al data collection from any related rvention has promise of clinical be ontact for the area of science for v	ervention as studies; den nefit. Applica vhich they an	well as retention of panon nonstration of the saf ants are encouraged t re planning to develop	articipants ety of the to contact the to an application
102903	Notice of Special Interest (NOSI): Complementary and Integrative F	Fundamen Health App	tal Science Research on roaches	National Center for Complementary and Integrative Health/NIH/DHHS	NOT- AT-21- ( 006	07-May-2022	Not Specified
	Contact Name	Wen Cher	n, M.M.Sc., Ph.D.				
	Contact Telephone	301-451-3	989				
	Contact Email	<u>chenw@n</u>	nail.nih.gov				
	Sponsor Website	h -					
	Program URL	Link to pro	ogram URL				
	Deadline Dates (ALL)	07-May-20 2023 , 07- Feb-2024	022 , 05-Jun-2022 , 16-Jun-202 May-2023 , 05-Jun-2023 , 16-J , 07-May-2024 , 05-Jun-2024 ,	2 , 07-Sep-2022 , 05-Oct-2022 , 16 un-2023 , 07-Sep-2023 , 05-Oct-20 16-Jun-2024 , 07-Sep-2024	-Oct-2022 , ( 23 , 16-Oct-2	07-Jan-2023 , 05-Feb- 2023 , 07-Jan-2024 , 0	2023 , 16-Feb- 5-Feb-2024 , 16-
	Synopsis	The purpo research c	ose of this Notice of Special Int or technology/method develop	erest (NOSI) is to describe NCCIH p oment research relevant to comple	riorities in ir mentary and	nnovative basic and m d integrative health a	echanistic oproaches.
107999	Notice of Special Interest (NOSI):	NCCIH Hig	h Priority Pain Research	National Center for Complementary and Integrative Health/NIH/DHHS	NOT- AT-22- ( 007	07-May-2022	Not Specified
	Contact Name	Inna Belfe	r, Ph.D.				
	Contact Telephone	301-435-1	573				
	Contact Email	inna.belfe	<u>r@nih.gov</u>				
	Sponsor Website	h.					
	Program URL	Link to pro	ogram URL				
	Deadline Dates (ALL)	07-May-20 2022 , 25-	022 , 05-Jun-2022 , 16-Jun-202 Oct-2022	2 , 20-Jun-2022 , 25-Jun-2022 , 07-	-Sep-2022 , (	)5-Oct-2022 , 16-Oct-	2022 , 19-Oct-

SPIN ID	Program Title	St	ponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Synopsis	The Nationa related rese	al Center for Complementar earch topic areas in response	y and Integrative Health (NCCIH) is i to this NOTICE.	nviting applica	tions to focus on the	following pain
107544	Notice of Special Interest (NOSI): Priority Topic Areas for NCCIH Gr	<u>Administrati</u> ants	ive Supplements on High	National Center for Complementary and Integrative Health/NIH/DHHS	NOT- AT-22- 01- 002	Jun-2022	100,000 USD
	Contact Name						
	Contact Telephone						
	Contact Email						
	Sponsor Website						
	Program URL	Link to prog	gram URL				
	Deadline Dates (ALL)	01-Jun-2022	2				
	Synopsis	Administrat translationa with project no-cost exte	al Center for Complementar tive Supplements to promote al, technological, or clinical s t end dates in FY 2023 or late ension in FY 2022.	y and Integrative Health (NCCIH) an e or support high priority topic area tudies in the context of complemen er are eligible. The award may not b	nounces the av s in NCCIH gra itary and integ be in a termina	vailability of funds fo nts by expanding ong rative approaches. A l no-cost extension o	r one-year ;oing basic, ctive awards r going into a
	Clinical Coordinating Center for N	ICCIH Multi-S	Site Investigator-Initiated	National Center for			Not
094929	Clinical Trials of Natural Products	(Collaborativ	ve UG3/UH3 Clinical Trial	Complementary and Integrative	215 01·	Jun-2022	Specified
	<u>Required)</u>	1		Health/NIH/DHHS			·
	Contact Name	Wendy Web	ber, N.D., Ph.D, M.P.H.				
	Contact Telephone	301-402-127	72				
	Contact Email	<u>weberwj@n</u>	<u>mail.nih.gov</u>				
	Sponsor Website						
	Program URL	Link to prog	gram URL				
	Deadline Dates (ALL)	01-Jun-2022	2 , 07-Sep-2022 , 01-Feb-202	23,07-May-2023	_		
	Synopsis	This Funding multi-site, c research pri	g Opportunity Announceme linical trials (Phase III and be iority. Applicants should des	nt (FOA) encourages cooperative age eyond) to study the effects of natura cribe plans for a Clinical Coordinations and the state of the	greement appli al products in I ng Center to de	cations for investigat NCCIH designated are evelop and implemer	cor-initiated, eas of high It the

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		proposed and a con responsib conduct, phase, mi Coordinat clinical pr (DCC) app	multi-site clinical trial. The ob- nprehensive scientific and ope ole for project management, pa and dissemination of results. C ilestone-driven, cooperative ag ting Center application, submit oject is required. Both a Clinica olication need to be submitted	jective of the Clinical Coordinating rational plan for the clinical trial. Th articipant recruitment and retention Clinical Coordinating Center applica- greement (UG3/UH3) funding mech sted under PAR-20-219, proposing a al Coordinating Center application a simultaneously for consideration b	Center is to provid ne Clinical Coordin n strategies, perfo tions submitted ur nanism. In additior a data analysis and and a correspondi by NCCIH.	de the design scier ating Center is ex rmance milestone nder this FOA will n, an accompanyin d data managemen ng Data Coordinat	ntific rationale pected to be es, scientific utilize a two- ng Data nt plan for the ting Center
094930	NCCIH Natural Product Mid Phase 1001 Clinical Trial Required)	e Clinical T	rial Cooperative Agreement	National Center for Complementary and Integrative Health/NIH/DHHS	PAR-20- 216 01-Jur	n-2022	1,750,000 USD
	Contact Name	Wendy W	/eber, N.D., Ph.D, M.P.H.				
	Contact Telephone	301-402-2	1272				
	Contact Email	<u>weberwj(</u>	@mail.nih.gov				
	Sponsor Website						
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	01-Jun-20	022 , 07-Sep-2022 , 01-Feb-202	3 , 07-May-2023			
	Synopsis	This Fund phase clir prelimina on a biolo measure product's propose a for use in to the nat FOA are e NCCIH. Th natural pu Scientific, to this FO	ding Opportunity Announcemenical trials of natural products. ry data of bioavailability and d ogical signature (i.e., measure of a biological signature in the pa mechanism of action will this a mid-phase clinical trial to do a future multi-site clinical trial tural product to inform inclusion expected to be hypothesis base his FOA will not support single- roducts for the treatment or pa /Research contact for the area A.	ent (FOA) invites cooperative agreed All applications submitted under the ocumentation that the natural pro- of the mechanism of action). Only in tient population of interest or whe preliminary data requirement be we the following: determine the optime by or determine which patient phen- on/exclusion criteria of a future effi- ed, milestone-driven, and directly re- site or multi-site efficacy or effective revention of cancer. Applicants are of science for which they are plann	ment applications his FOA must be su duct produces a re n cases when it is n there is a fundar vaived. Application al dose or formula otypes will be resp cacy study. Clinicate elated to the reseaveness trials, nor w encouraged to co hing to develop an	for investigator-ir ipported by suffici- eplicable and mea- not possible/pract- mental understan- is submitted to the ation of a given na- bonders versus no al trials submitted arch priorities and vill it support trial ntact the appropri- application prior	hitiated mid- ient surable impact tical to ding of the is FOA should itural product n-responders under this mission of s to test iate NCCIH to submitting

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
094934	Natural Product Multi-Site Clinical T (Collaborative U24 Clinical Trial Req	rial Data uired)	a Coordinating Center	National Center for Complementary and Integrative Health/NIH/DHHS	PAR-20- 219	-2022	Not Specified
	Contact Name W	/endy W	eber, N.D., Ph.D, M.P.H.				
	Contact Telephone 30	01-402-1	272				
	Contact Email <u>w</u>	eberwj@	Dmail.nih.gov				
	Sponsor Website						
	Program URL <u>Li</u>	<u>nk to pro</u>	ogram URL				
	Deadline Dates (ALL) 01	1-Jun-20	22 , 07-Sep-2022 , 01-Feb-202	23 , 07-May-2023			
	Cl (P Cl pr Synopsis cl cc cc pr st pl	pllaborat phase III inical Co rovides o inical tri onsidera onsidere riorities rongly e anning t	ting Data Coordinating Center and beyond) application subn pordinating Center (CCC) appli overall project coordination, a al. Both a DCC application and tion by NCCIH. Trials for which d a high priority by the Cente of the NCCIH, applicants are e ncouraged to contact the app to develop an application prio	(CDCC) application that accompanies inited under PAR-20-215 The DCC ap ication. The objective of the DCC ap and administrative, data management d a corresponding CCC application no h this FOA applies must be relevant r. For additional information about the encouraged to consult the NCCIH we propriate Scientific/Research contact r to submitting to this FOA.	s an investigator-in oplication must be plication is to prop nt, and biostatistic eed to be submitt to the research m the mission, strate bsite: (http://www t for the area of so	nitiated multi-site specific to the co cose a compreher cal support for the ed simultaneously ission of the NCCI egic vision, and res w.nccih.nih.gov)	clinical trial pllaborating nsive plan that proposed y for H and search Applicants are hey are
104713	<u>Clinical Coordinating Center for NCC</u> <u>Clinical Trials of Mind and Body Inte</u> <u>Clinical Trial Required</u> )	<u>CIH Mult</u> rventior	i-Site Investigator-Initiated ns (Collaborative UG3/UH3	National Center for Complementary and Integrative Health/NIH/DHHS	PAR-21- 243 20-Jun	-2022	Not Specified
	Contact Name La	anay Mu	dd, Ph.D.				
	Contact Telephone 30	01-594-9	9346				
	Contact Email <u>la</u>	nay.mu	dd@nih.gov				
	Sponsor Website						
	Program URL Li	nk to pro	ogram URL				

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Deadline Dates (ALL)	20-Jun-20 2023 , 14	022 , 22-Jul-2022 , 19-Oct-2022 -Nov-2023 , 20-Feb-2024 , 11-I	ደ , 14-Nov-2022 , 21-Feb-2023 , 10-N Mar-2024	Лаг-2023 , 20-Jun	-2023 , 22-Jul-202	:3 , 20-Oct-
(e.g. efficacy, effectiveness or pragmatic trials) to study the effects of complementary and integrative health a with physical and/or psychological therapeutic inputs (often called mind and body interventions) in NCCIH des of high research priority. Clinical Coordinating Center should develop and implement the proposed fully pow clinical trial. The objective of a Clinical Coordinating Center application is to present the scientific rationale and comprehensive scientific and operational plan for the clinical trial. Clinical Coordinating Center applications submitted under this FOA will phase, milestone-driven cooperative agreement (UG3/UH3) funding mechanism. In addition, an accompanyin Coordinating Center application (U24), submitted under PAR-21-242 proposing a data analysis and data mana for the clinical project is required. Both a Clinical Coordinating Center application and a corresponding Data Co Center (DCC) application need to be submitted simultaneously for consideration by NCCIH. For additional info the mission, strategic vision, and research priorities of the NCCIH, applicants are encouraged to consult the NC (https://nccih.nih.gov/about/plans). Applicants are encouraged to contact the appropriate the Scientific/Rese for the area of science for which they are planning to develop an application prior to submitting to this FOA.							inical trials pproaches ignated areas ered multi-site d a e expected to ones, scientific utilize a two- g Data gement plan oordinating rmation about CCIH website: arch contact
104706	Feasibility Clinical Trials of Mind a Priority Research Topics (R34 Clin	ind Body I ical Trial R	nterventions for NCCIH High Required)	National Center for Complementary and Integrative Health/NIH/DHHS	PAR-21- 240	n-2022	450,000 USD
	Contact Name	Peter Mu	rray, Ph.D.				
	Contact Telephone	301-496-4	4054				
	Contact Email	<u>peter.mu</u>	<u>rray@nih.gov</u>				
	Sponsor Website						
	Program URL	Link to pr	ogram URL				
Deadline Dates (ALL) 20-Jun-2022 , 22-Jul-2022 , 19-Oct-2022 , 14-Nov-2022 , 21-Feb-2023 , 10-Mar-2023 , 20-Jun-2023 , 22-Jul-2023 , 20- 2023 , 14-Nov-2023 , 20-Feb-2024 , 11-Mar-2024							
	Synopsis	The goal approach that have feasibility	of this funding opportunity is t es with physical and/or psycho been identified by NCCIH as h clinical trials, which will provi	o support early phase clinical trials blogical therapeutic inputs (often ca igh priority research topics. This fur de data that are critical for the plan	of complementary lled mind and boo nding opportunity ning and design o	y and integrative I dy interventions) f is intended to sup f a subsequent cli	nealth for conditions pport nical efficacy

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		or effectiv develop a acceptabi interventi data colle acceptabi efficacy o conducter to write a announce potential	veness study, or a pragmatic tri a competitive full-scale clinical t ility of interventions lacking pul- ion to determine the most app ection procedures; refining and ility and adherence of control c or effectiveness; nor will this FO d in the same or similar patient a protocol or manual of operation ement. Applications must proport to make a significant impact or	ial. The data collected should be us trial, including, but not limited to the blished data; adapting an intervent ropriate frequency or duration; det assessing the feasibility of protoco conditions. This FOA will not suppor the support repetition of feasibility of t population with the same or simila- ons or to develop infrastructure for ose to conduct a feasibility clinical to n public health.	ed to fill gaps in some following: example following: examplion to a specific programming feasibility lized multimodal in the randomized clin for acceptability rest ar intervention. A for a clinical trial are strial. The subsequents of the s	cientific knowledg nining feasibility an opulation; refining ty of recruitment, interventions; or e ical trials that test search that has be pplications that pu not appropriate f ent larger trial sho	e necessary to nd g the retention and examining : or determine en previously ropose solely for this puld have the
104712	Data Coordinating Center for NCC Clinical Trials of Mind and Body In Trial Required)	CIH Multi-S nterventio	Site Investigator-Initiated ns (Collaborative U24 Clinical	National Center for Complementary and Integrative Health/NIH/DHHS	PAR-21- 242 20-Jun	-2022	Not Specified
	Contact Name	Lanay Mu	udd, Ph.D.				
	Contact Telephone	301-594-9	9346				
	Contact Email	lanay.mu	dd@nih.gov				
	Sponsor Website						
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	20-Jun-20 2023 , 14	)22 , 22-Jul-2022 , 19-Oct-2022 -Nov-2023 , 20-Feb-2024 , 11-N	, 14-Nov-2022 , 21-Feb-2023 , 10-№ Лаг-2024	/lar-2023 , 20-Jun	-2023 , 22-Jul-202	3 , 20-Oct-
	Synopsis	This Fund collaborat (Phase III Clinical Co provides o clinical tri considera a high prio applicants	ling Opportunity Announcemer ting Data Coordinating Center ( and beyond) application subm oordinating Center (CCC) applic overall project coordination, ar ial. Both a DCC application and ation by NCCIH. Trials for which ority by the Center. For additio s are encouraged to consult NC	nt (FOA), utilizing the U24 grant fun (DCC) application that accompanies itted under PAR-21-243. The DCC a cation. The objective of the DCC app nd administrative, data managemen a corresponding CCC application ne this FOA applies must be relevant nal information about the mission, CCIH website: (http://www.nccih.ni	ding mechanism, s an investigator-in pplication must be plication is to prop nt, and biostatistic eed to be submitte to the research m strategic vision, a h.gov). Applicants	encourages applic nitiated multi-site e specific to the co cose a comprehen cal support for the ed simultaneously ission of NCCIH ar and research prior are encouraged t	cations for a clinical trial ompanion sive plan that proposed for d considered ities of NCCIH, co contact the

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	a p	ppropriate the Scientific/Research cor prior to submitting to this FOA	ntact for the area of science for whic	h they are planni	ng to develop an a	ipplication
104709	NCCIH Multi-Site Feasibility Clinical Interventions (R01 Clinical Trial Reg	Trials of Mind and Body quired)	National Center for Complementary and Integrative Health/NIH/DHHS	PAR-21- 241 20-Jur	n-2022	Not Specified
	Contact Name D	Della White, Ph.D.				
	Contact Telephone 3	01-827-6538				
	Contact Email <u>d</u>	lella.white@nih.gov				
	Sponsor Website					
	Program URL <u>Li</u>	ink to program URL				
	Deadline Dates (ALL)	0-Jun-2022 , 22-Jul-2022 , 19-Oct-2022 023 , 14-Nov-2023 , 20-Feb-2024 , 11-	2 , 14-Nov-2022 , 21-Feb-2023 , 10-N Mar-2024	/lar-2023 , 20-Jun	-2023 , 22-Jul-202	3 , 20-Oct-
	T a ir p d a Synopsis fe n fe o c u si t t	This Funding Opportunity Announcement and integrative health approaches with interventions) in NCCIH-designated are propose a multi-site feasibility clinical t lemonstrate feasibility of recruitment, adherence to the intervention, as well a easibility of data collection across sites need for multi-site feasibility trials is ex- easibility or acceptability trial(s) or the pr effectiveness. The data collected sho competitive fully powered multi-site cli ubmitting to this FOA, applicants are e- he science area of the planned applica	nt (FOA) invites applications for inver- physical and/or psychological thera as of high research priority. Applicat rial to assess whether the interventi accrual, and randomization of parti- as retention of participants through in preparation for a future fully pow- pected to be justified by sufficient p published literature. This FOA will r published literature. This FOA will r published to fill gaps in scientific k nical trial that has the potential to n incouraged to contact the appropria- tion.	estigator-initiated ipeutic inputs (oft ions submitted u on can be deliver cipants across site out the study acro wered, multi-site ireliminary data fin ot support clinica knowledge and be nake a significant te NCCIH Scientif	I clinical trials of co en called mind an nder this FOA are ed with fidelity ac es; demonstrate po oss sites; and/or do efficacy/ effective rom previous single al trials that deterr e necessary to dev impact on public l ic/Research conta	omplementary d body expected to ross sites; articipant emonstrate ness trial. The e site nine efficacy elop a nealth Prior to ct person for
108854	Notice of Special Interest (NOSI): Ac COVID Home-Based Testing for Indi	ddressing Accessibility Inequities with ividuals with Visual Impairment	National Eye Institute/NIH/DHHS	NOT-EY- 22-010 05-Ap	r-2022	Not Specified
	Contact Name S Contact Telephone 3	angeeta Bhargava, Ph.D 01-435-8175				



SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Contact Email	sangeeta.	bhargava@nih.gov				
	Sponsor Website	-					
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	05-Apr-20 2022 , 25- Jun-2023 07-Jan-20	022 , 07-May-2022 , 05-Jun-202 Oct-2022 , 05-Jan-2023 , 07-Ja , 16-Jun-2023 , 25-Jun-2023 , 0 024 , 05-Feb-2024 , 16-Feb-2024	2 , 16-Jun-2022 , 25-Jun-2022 , 05 n-2023 , 05-Feb-2023 , 16-Feb-202 5-Sep-2023 , 07-Sep-2023 , 05-Oct 1 , 25-Feb-2024	-Sep-2022 , 07-Sej 3 , 25-Feb-2023 , -2023 , 16-Oct-20	p-2022 , 05-Oct-20 05-Apr-2023 , 07-I 23 , 25-Oct-2023 ,	)22 , 16-Oct- May-2023 , 05- 05-Jan-2024 ,
	Synopsis	The Natio need to p	nal Eye Institute (NEI) is issuing rovide accessible home-based	this Notice of Special Interest (NC COVID testing to people who are v	OSI) to support res isually impaired.	search addressing	the urgent
101324 <u> </u>	Notice of Special Interest (NOSI): dentification and Development o Methods to Diagnose Dry Eye Dise	<u>NEI Anteri</u> f New Bio ease.	or Segment Initiative (ASI): markers and Effective	National Eye Institute/NIH/DHHS	NOT-EY- 21-007	r-2022	Not Specified
	Contact Name						
	Contact Telephone						
	Contact Email						
	Sponsor Website						
	Program URL	<u>Link to pr</u>	ogram URL				
	Deadline Dates (ALL)	05-Apr-20 2023 , 07-	)22 , 07-May-2022 , 05-Jun-202 Jan-2023 , 05-Feb-2023 , 16-Fe	2 , 16-Jun-2022 , 05-Sep-2022 , 07 b-2023 , 05-Apr-2023 , 07-May-20	-Sep-2022 , 05-Oc 23	t-2022 , 16-Oct-20	)22 , 05-Jan-
	Synopsis	The purpo research t disease (E	ose of this Notice of Special Inte to identify new biomarkers and DED) and its subtypes, prognosi	erest (NOSI) is to inform potential a develop effective methods that ca s of disease progression, and mon	applicants of the s an be used for the itoring of treatme	special interest of the second s	the NEI in <sup>F</sup> dry eye
109824	<u>VEI Research Grant for Vision-Rel</u> Clinical Trial Not Allowed)	ated Seco	ndary Data Analysis (R21	National Eye Institute/NIH/DHHS	PAR-22- 141	ay-2022	275,000 USD
	Contact Name	Donald Ev	verett, M.A.				
	Contact Telephone	301-435-8	3181				
	Contact Email	everettd@	@mail.nih.gov				
	Sponsor Website						

SPIN ID	Program Title	Sponsor Name		Sponsor Number		Deadline Date	Funding Amount		
	Program URL	Link to program URL							
	Deadline Dates (ALL)	07-May-2022 , 16-Jun-2022 , 2023 , 16-Oct-2023 , 07-Jan-2 Feb-2025 , 07-May-2025	07-Sep-202 024 , 16-Fe	2 , 16-Oct-2022 , 07-Jan-2023 , 16- b-2024 , 07-May-2024 , 16-Jun-202	Feb-2023 , 07-Ma 24 , 07-Sep-2024 ,	y-2023 , 16-Jun-2 16-Oct-2024 , 07	023 , 07-Sep- ·Jan-2025 , 16-		
	Synopsis	Synopsis Syn							
100970	NEI Institutional Mentored Physic Optional)	ian Scientist Award (K12 Clinic	cal Trial	National Eye Institute/NIH/DHHS	PAR-21- 073 09-Jun	-2022	Not Specified		
	Contact Name	Neeraj Agarwal, Ph.D.							
	Contact Telephone	301-451-2020							
	Contact Email	<u>agarwalnee@nei.nih.gov</u>							
	Sponsor Website								
	Program URL	Link to program URL							
	Deadline Dates (ALL)	09-Jun-2022 , 09-Jun-2023							
The purpose of this Funding Opportunity Announcement (FOA) is to encourage institutions to propose creative and innovative institutional research career development programs which prepare clinically trained vision scientists for independent research careers. This initiative is intended to expand and strengthen the community of clinician investiga engaged in clinical research. Such an increase in the number of well-trained clinical researchers is necessary to achieve pool of scientists with contemporary, multidisciplinary expertise able to leverage recent advances in ocular genetics, art intelligence, computational modelling, ocular therapeutics, bioengineering, and bio-behavioral research in order to enh patient treatment and to increase scientific momentum in these fields. This Funding Opportunity Announcement (FOA) allows appointment of Scholars proposing a separate ancillary study to an existing trial or proposing to gain research									

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		experience developm must be a mechanis discomfo during the scholars a NEI progr	ce in a clinical trial led by anoth nent program scholars are limit a NIH-defined clinical trial that f stic trial is designed to understa arm of action of an intervention. rt anticipated in the research a e performance of routine physi are limited to clinical trials that ram staff prior to submitting an	er investigator, as part of their rest ed to clinical trials that are mechar fulfills the NIH requirement for eith nd a biological or behavioral proce A minimal risk trial is one in which re not greater in and of themselves cal or psychological examinations are mechanistic and/or minimal ris application with human subjects t	earch and career of histic and/or minin her a mechanistic of ess, the pathophys of the probability ar s than those ordin or tests. For this ca sk. Applicants are o determine the a	development. For nal risk. The exist or minimal risk tri iology of a diseas nd magnitude of h arily encountered areer developmen strongly advised to ppropriate fundir	this career ing clinical trial al. A e, or the narm or I in daily life or nt program, to consult with ng opportunity.
109530 <u>NE</u> <u>No</u>	El Clinical Research Study Plann ot Allowed)	ing Grant I	Program (R34 Clinical Trial	National Eye Institute/NIH/DHHS	PAR-22- 128 16-Jur	n-2022	300,000 USD
	Contact Name	Donald Ev	verett, MA				
	Contact Telephone	301-435-8	8181				
	Contact Email	everettd(	@mail.nih.gov				
	Sponsor Website						
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	16-Jun-20 2023 , 07 May-2025	022 , 07-Sep-2022 , 16-Oct-2022 -Jan-2024 , 16-Feb-2024 , 07-M 5	2 , 07-Jan-2023 , 16-Feb-2023 , 07- ay-2024 , 16-Jun-2024 , 07-Sep-20	May-2023 , 16-Jur 24 , 16-Oct-2024 ,	1-2023 , 07-Sep-20 07-Jan-2025 , 16	023 , 16-Oct- -Feb-2025 , 07-
	Synopsis	The NEI s on eye/vi provide d and envir of Proced planning The grant procedur intervent	upports large-scale clinical vision sion conditions. At the time of letailed information regarding to onment, organizational structur lures (MOP), the development grant funding opportunity supp may be used to support the development po- con document recruitment po- ion. This NEI FOA is applicable to	on research projects, including rand submission, applications requestin the study rationale, design, analytic re, and collaborative arrangement of which represents a costly and the ports applicants in their planning ef evelopment of a MOP, as well as to otential. The grant must not be use to both epidemiologic and clinical t	domized clinical tr g support for thes c techniques, prot s. This information me-consuming act fforts to conduct c o conduct prelimin d to generate data trial research stud	ials and epidemic e activities are ex ocols and procedu n is best conveyed tivity. This clinical collaborative clinic ary studies to ref a on the effects of ies.	logic studies pected to ures, facilities d in a Manual research cal research. ine study f a proposed
109678 <u>NE</u> Tri	El Regenerative Medicine Clinic ials Not Allowed)	al Trial Pla	nning Grant (R34 - Clinical	National Eye Institute/NIH/DHHS	PAR-22- 135 16-Jur	n-2022	300,000 USD



SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount	
	Contact Name	Donald Everett, MA					
	Contact Telephone	301-435-8181					
	Contact Email	everettd@mail.nih.gov					
	Sponsor Website						
	Program URL	Link to program URL					
	Deadline Dates (ALL)	16-Jun-2022 , 07-Sep-2022 , 16-Oct-2022 2023 , 07-Jan-2024 , 16-Feb-2024 , 07-M May-2025	2 , 07-Jan-2023 , 16-Feb-2023 , 07-I ay-2024 , 16-Jun-2024 , 07-Sep-20	May-2023 , 16-Jur 24 , 16-Oct-2024 ,	n-2023 , 07-Sep-202 07-Jan-2025 , 16-F	23 , 16-Oct- eb-2025 , 07-	
The National Eye Institute (NEI) supports regenerative medicine clinical trials. Before a research team undertakes trial, it is critical to have clear delineation and documentation of the trial's rationale, design, analytic techniques, and procedures in a Manual of Procedures (MOP). Additionally, there are other elements essential to the launch trial, such as obtaining regulatory authorizations or approvals and establishing agreements with requisite partner Synopsis cell manufacturing and production facilities, assay or cell analysis centers, and data coordinating centers. These a often costly and time-consuming, and they may involve collection of preliminary data to assess feasibility. The Re Medicine Clinical Trial Planning Grant may be used by applicants to support the preparation of a clinical trial MOP and procedures necessary for implementing a clinical trial to evaluate interventions (or new treatments) th vision in humans through regeneration of cells.							
093741	RFA-HL-21-013 Disease Modify	ing Therapies for Chronic Lung Disease	National Heart, Lung, and Blood	RFA-HL- 02-Ma	iy-2022	1,000,000	
	(R61/R33 Clinical Trial Required)		Institute/NIH/DHHS	21-013 [Optio	nalj[LOI/Pre-App]	USD	
	Contact Name	Antonello Punturieri, MD, PhD					
	Contact Telephone	301-435-0233					
	Contact Email	punturieria@nhlbi.nih.gov					
	Sponsor Website						
	Program URL	Link to program URL					
	Deadline Dates (ALL)	02-May-2022 [Optional][LOI/Pre-App], 0	1-Jun-2022				
	Synopsis	The purpose of this Funding Opportunity will conduct phase II trials within the NH multiple Protocol Leadership Groups (PL	Announcement (FOA) is to support LBI Pulmonary Trials Cooperative ( Gs) and a single Network Managen	rt multiple Protoc PTC) clinical trials nent Core (NEMO	ol Leadership Grou network. The PTC ) and will conduct (	ps (PLGs) that will include multiple	

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		simultaneous phase II clinical trials t companion FOA (RFA-HL-21-012) se	hat test innovative disease modifying eks applications for the Network Mana	therapies (DMT) fo agement Core (NEN	or chronic lung dis MO).	eases. A
108728	Notice of Special Interest (NOSI): of HIV-Associated Comorbidities	Research on Barriers To Care and Ris Among Vulnerable Population Group	<ul> <li><u>k</u> National Heart, Lung, and Blood</li> <li><u>s</u> Institute/NIH/DHHS</li> </ul>	NOT-HL- 22-010	ay-2022	Not Specified
	Contact Name	Sean Altekruse D.V.M., Ph.D.				
	Contact Telephone	301-435-1290				
	Contact Email	altekrusesf@nhlbi.nih.gov				
	Sponsor Website	<u>b</u>				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-May-2022 , 05-Jun-2022 , 07-Sep 2023 , 05-Oct-2023 , 07-Jan-2024 , 0 Feb-2025 , 07-May-2025	-2022 , 05-Oct-2022 , 07-Jan-2023 , 05 5-Feb-2024 , 07-May-2024 , 05-Jun-20	-Feb-2023 , 07-Ma 24 , 07-Sep-2024 ,	ay-2023 , 05-Jun-2 05-Oct-2024 , 07	023 , 07-Sep- -Jan-2025 , 05-
	Synopsis	The purpose of this Notice is to info area of special interest in supporting disproportionally vulnerable and aff	rm potential applicants to the Nationa g analysis of barriers to care and risk of ected population groups of people livi	l Heart, Lung, and f HIV-associated co ng with or at risk fo	Blood Institute (N omorbidities amor or HIV infection.	HLBI) of an าg
108068	Notice of Special Interest (NOSI): Tools for Use in Underserved Pop	Diagnostics and Disease Managemer pulations	<u>it</u> National Heart, Lung, and Blood Institute/NIH/DHHS	NOT-HL- 22-006	ay-2022	Not Specified
	Contact Name	Bishow Adhikari, Ph.D.				
	Contact Telephone	301-594-2791				
	Contact Email	adhikarb@nhlbi.nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-May-2022 , 05-Jun-2022 , 07-Sep 2023 , 05-Oct-2023 , 07-Jan-2024 , 0 Jun-2025	-2022 , 05-Oct-2022 , 07-Jan-2023 , 05 5-Feb-2024 , 07-May-2024 , 05-Jun-20	-Feb-2023 , 07-Ma 24 , 07-Sep-2024 ,	ay-2023 , 05-Jun-2 05-Oct-2024 , 05-	023 , 07-Sep- -Feb-2025 , 05-
	Synopsis	The purpose of this NOSI is to stimu management tools for heart, lung, b populations. Underserved populatio	late research focused on the developn lood, or sleep (HLBS) disorders that ar ns, for the purpose of this NOSI, can ir	nent of transforma e designed to mee nclude racial and e	tive diagnostics a t the needs of the thnic minorities, in	nd disease a underserved mmigrants, the

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		homeless disadvant accessible ensure su	, low-income individuals, the u aged, rural or have few health and feasible in these commu ccessful development and imp	ninsured and people who live in co care resources. Special considerati nities. Working with community pa lementation.	ommunities that a fon will be given to rtners is required	re socioeconomica o technology solut throughout the pr	illy ions that are oject to
100825	Notice of Special Interest (NOSI): TOPMed Data (Parent R01 Clinica	Integrative I Trial Not	e Omics Analysis of NHLBI Allowed)	National Heart, Lung, and Blood Institute/NIH/DHHS	NOT-HL- 20-823	iy-2022	Not Specified
	Contact Name Contact Telephone Contact Email Sponsor Website	Weiniu Ga 301-435-0 ganw2@r	an, Ph.D. )202 <u>nail.nih.gov</u>				
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	07-May-2	022 , 05-Jun-2022 , 07-Sep-202	22 , 05-Oct-2022 , 07-Jan-2023 , 05-	-Feb-2023 , 07-Ma	ay-2023	
Deadline Dates (ALL) 07-May-2022, 05-Jun-2022, 07-Sep-2022, 05-Oct-2022, 07-Jan-2023, 05-Feb-2023, 07-May-2023 The symptom-based diagnosis and treatment of heart, lung, blood, and sleep (HLBS) diseases has vastly improved in rec years, yet an understanding of the molecular mechanisms underlying many of these diseases has remained elusive. Furthermore, in most cases the impact of genetic variation on severity of disease and treatment outcomes remains unknown. Therefore, the NHLBI has recently created the Trans Omics for Precision Medicine (TOPMed) program, which to utilize high throughput omics to characterize a variety of HLBS diseases. TOPMed is well on its way to collecting whol genome sequence from over 130,000 well-phenotyped individuals and is currently generating high-throughput expressi and other "omics" data (e.g. RNA, DNA methylation, metabolites, and proteins) from many of these individuals to complement whole genome sequence information. Having produced an unprecedented volume of high-throughput dat TOPMed now seeks to turn its attention to effectively leveraging this resource through novel systems biology analyses t uncover disease pathobiology. Although lower costs and technological improvements in sequencing technology have vare expanded our ability to generate large volumes of omics data, the ability to analyze such large datasets to extract biologically meaningful insights from them remains challenging. Systems level models incorporating trans-omics analysis be an important step in uncovering the underlying biological networks, gene-gene and gene-environment interactions influencing disease and treatment outcomes. Thus, advanced analyses that incorporate genotype and phenotype datas from thousands to tens of thousands of individuals are required to move TOPMed to the next phase of discovery.							

SPIN ID	Program Title	Sponsor Name		Sponsor Number		C	Deadline Date	Funding Amount
SPIN ID	Program Title		Spon	sor Name	Sponsor Number	Deadl	line Date	Funding Amount
106202	Notice of Special Interest (NOSI): Promoting Cardiovascular and Cardiometabolic Health in Early Stages of the Lifecourse: Pre- adolescence Through Adolescence to Young Adulthood			nal Heart, Lung, and Blood ute/NIH/DHHS	NOT-HL- 21-015	07-Ma	ay-2022	Not Specified
	Contact Name Ali Contact Telephone 30 Contact Email Ali Sponsor Website Program URL Lin Deadline Dates (ALL) 20 Fe Synopsis pa ph int	son G.M. Brown, PhD, MS, RDN 1-435-0583 son.brown@nih.gov hk to program URL -May-2022, 05-Jun-2022, 07-5 23, 05-Oct-2023, 07-Jan-2024 b-2025, 07-May-2025, 05-Jun- is Notice of Special Interest (NG alth during transitionary phase ars) to young adulthood (19-39 thogenesis of cardiometabolic ases from pre-adolescence into erventions (at the individual ar	Sep-202 , 05-Fe -2025, OSI) cal s acros years) health p adole	2 , 05-Oct-2022 , 07-Jan-2023 , 05- b-2024 , 07-May-2024 , 05-Jun-202 07-Sep-2025 , 05-Oct-2025 , 07-Jan ls for research to understand and p s the lifecourse, from pre-adolescer . This initiative would support resea and cardiovascular disease (CVD) ri scence and adolescence into young Jations levels) to address cardiovas	Feb-2023 , 0 24 , 07-Sep-2 -2026 , 05-F romote carc nce (6-10 ye arch to: 1) ur sk in vulnera adulthood, scular and ca	7-May- 024 , 0 eb-202 liovasci ars) thr ndersta able gro and 2) ardiome	-2023,05-Jun-20 5-Oct-2024,07- 6,07-May-2026 ular and cardiom rough adolescen ind the mechanis oups throughout develop precisic etabolic risk acro	023,07-Sep- Jan-2025,05- ,05-Jun-2026 etabolic ce (11-18 sms and the transitionary n prevention ss these
108064	Notice of Special Interest (NOSI): Pro on Mitochondrial Involvement in Lur	insitionary phases. moting Fundamental Research ng Diseases and Sleep Disorders	Natio Instit	nal Heart, Lung, and Blood ute/NIH/DHHS	NOT-HL- 22-003	07-Ma	ay-2022	Not Specified
	Contact Name Jin Contact Telephone 30 Contact Email jin Sponsor Website Program URL Lin	ing Lu 1-827-2807 ing.lu@nih.gov ik to program URL						·

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount		
	0 Deadline Dates (ALL) 2 Fr	17-May-2022 , 05-Jun-2022 , 07-5 1023 , 05-Oct-2023 , 07-Jan-2024 1eb-2025	Sep-2022 , 05-Oct-2022 , 07-Jan-2023 , ( 4 , 05-Feb-2024 , 07-May-2024 , 05-Jun-2	05-Feb-2023 , 07-Ma 2024 , 07-Sep-2024 ,	ay-2023 , 05-Jun-2 05-Oct-2024 , 07	023 , 07-Sep- -Jan-2025 , 05-		
The purpose of this NOSI is to stimulate research focused on cell-type-specific signatures of mitochondrial behavior healthy and diseased lungs. Multidisciplinary collaboration among experts in recently developed technologies, suc Synopsis cell and lung progenitor/organoid culture systems, advanced single cell-and "-omic" technologies, and lung cell bi encouraged. We encourage investigators to Utilization oflung cells from human donors and animal models with re diseases and/or well-defined congenital mitochondrial diseases is also encouraged.								
107093	Notice of Special Interest (NOSI): DI Evaluation and Analysis to Health	EA2Health: Innovative Data	National Heart, Lung, and Blood Institute/NIH/DHHS	NOT-HL- 22-001 07-M	May-2022	Not Specified		
	Contact Name L	ucy L. Hsu, M.P.H.						
	Contact Telephone 3	01-402-3276						
	Contact Email <u>It</u>	ucy.hsu@nih.gov						
	Sponsor Website							
	Program URL 📘	ink to program URL						
	Deadline Dates (ALL) 2	7-May-2022 , 05-Jun-2022 , 07-5 023 , 05-Oct-2023 , 07-Jan-2024	Sep-2022 , 05-Oct-2022 , 07-Jan-2023 , ( , 05-Feb-2024 , 07-May-2024 , 05-Jun-2	05-Feb-2023 , 07-Ma 2024 , 07-Sep-2024 ,	ay-2023 , 05-Jun-2 05-Oct-2024 , 07	023 <i>,</i> 07-Sep- -Jan-2025		
	T Synopsis to	he purpose of this Notice of Spe cience in heart, lung, blood, or s o improve health.	cial Interest (NOSI) is to stimulate resea leep (HLBS) biomedical research, and u	arch and advanceme Itimately translate no	nt of methodolog ew insights into de	ies in data ecision-making		
100447	Notice of Special Interest (NOSI): Us Accelerate Late-Stage Implementat Lung, Blood, and Sleep Disorders	<u>se of Predictive Analytics to</u> ion Research to Address Heart,	National Heart, Lung, and Blood Institute/NIH/DHHS	NOT-HL- 20-815 07-№	May-2022	Not Specified		
	Contact Name R	ebecca A. Roper, MS, MPH						
	Contact Telephone 3	01-496-1051						
	Contact Email <u>R</u>	ebecca.Roper@nih.gov						
	Sponsor Website							
	Program URL	ink to program URL						



SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount				
	Deadline Dates (ALL)	07-May-2 2023 , 05-	022 , 05-Jun-2022 , 07-Sep- Oct-2023 , 07-Jan-2024	-2022 , 05-Oct-2022 , 07-Jan-2023 , C	)5-Feb-2023 , 07-M	ay-2023 , 05-Jun-2	023 , 07-Sep-				
	Synopsis	NHLBI is is Implemer integratio (HLBS) con data repo address H	and is issuing this Notice of Special Interest (NOSI) to leverage existing data resources using Predictive Analytics ementation Research (PAIR) that utilizes complex and innovative methodologies and modeling techniques to re- ration of existing data to inform the designs (and often test) implementation strategies for heart, lung, blood, S) conditions. NHLBI also encourages applications which focus on the development of advance modeling techniques reporting, which would be publicly available and could be used to inform subsequent implementation strategies ess HLBS conditions. National Heart, Lung, and Blood NOT-HL- of May 2022								
105201	Notice of Special Interest (NOSI): NHLBI TOPMed Data (Parent RO1	Integrative Clinical Tri	e Omics Analysis of N al Not Allowed) In	ational Heart, Lung, and Blood stitute/NIH/DHHS	NOT-HL- 21-017 07-	May-2022	Not Specified				
	Contact Name	James Luc	o, Ph.D.								
	Contact Telephone	301-435-0	)533								
Contact Email luoja@nih.gov											
	Sponsor Website										
	Program URL	Link to pro	ogram URL								
	Deadline Dates (ALL)	07-May-2	022 , 05-Jun-2022 , 07-Sep	-2022 , 05-Oct-2022 , 07-Jan-2023 , 0	)5-Feb-2023 <i>,</i> 07-M	ay-2023					
Deadline Dates (ALL) 07-May-2022, 05-Jun-2022, 07-Sep-2022, 05-Oct-2022, 07-Jan-2023, 05-Feb-2023, 07-May-2023 The symptom-based diagnosis and treatment of heart, lung, blood, and sleep (HLBS) diseases has vastly improved in years, yet an understanding of the molecular mechanisms underlying many of these diseases has remained elusive. Furthermore, in most cases the impact of genetic variation on severity of disease and treatment outcomes remains unknown. Therefore, the NHLBI has recently created the Trans Omics for Precision Medicine (TOPMed) program, w to utilize high throughput omics to characterize a variety of HLBS diseases. TOPMed is well on its way to collecting v genome sequence from over 130,000 well-phenotyped individuals and is currently generating high-throughput exp and other "omics" data (e.g. RNA, DNA methylation, metabolites, and proteins) from many of these individuals to Synopsis Complement whole genome sequence information. Having produced an unprecedented volume of high-throughput TOPMed now seeks to turn its attention to effectively leveraging this resource through novel systems biology analy uncover disease pathobiology. Although lower costs and technological improvements in sequencing technology hav expanded our ability to generate large volumes of omics data, the ability to analyze such large datasets to extract biologically meaningful insights from them remains challenging. Systems level models incorporating trans-omics an be an important step in uncovering the underlying biological networks, gene-gene and gene-environment interactive influencing disease and treatment outcomes. Thus, advanced analyses that incorporate genotype and phenotype d											

SPIN ID	Program Title		Sponsor Name		Sponsor Number		Deadline Date	Funding Amount
099803	Notice of Special Interest (NOSI): Blood, and Sleep Diseases	Palliative	Care in Heart, Lung,	Natio Institu	nal Heart, Lung, and Blood ute/NIH/DHHS	NOT-HL- 20-737 07	-May-2022	Not Specified
	Contact Name	Lora Rein	eck, MD, MS					
	Contact Telephone	301-435-0	0222					
	Contact Email	lora.reine	eck@nih.gov					
	Sponsor Website							
	Program URL	Link to pr	ogram URL					
	Deadline Dates (ALL)	07-May-2	2022 , 05-Jun-2022 , 07-S	Sep-202	2,05-Oct-2022,07-Jan-2023,05-F	eb-2023 , 07-N	1ay-2023 , 05-Jun-2	023
	Synopsis	interdisci families. I and treat Palliative serious ill withholdi concorda integratir risks and preference pulmonar aplastic a improven Integratic professio especially potential	plinary patient-centered Palliative care focuses of ment options in the con care is not synonymous ness from diagnosis thro ing or curbing treatment nt care may, in fact, invo- g palliative care into the benefits of treatment ar ces, and values. Many he ry disease (COPD), pulm- nemia are life-limiting, r nent of symptoms and q on of palliative care into nal societies. Additional v burdensome, even in d to greatly improve the o	d approa n severa text of p with ho ough ten olve opt t. Relief olve opt e manag nd inter eart, lun onary fi non-cura juality o cardiolo ly, symp liseases quality o	ach that aims to improve quality of al objectives including relief of symp patients' goals, and coordination of ospice or end-of-life care. Rather, pa rminal stages of diseases. Moreover of symptoms, enhancing quality of simal medical or surgical treatment gement of the patient's disease is a ventions, and medical treatment de g, blood, and sleep (HLBS) diseases brosis, pulmonary hypertension, cy able illnesses. These and other HLBS of life, in addition to care focused on ogy, pulmonary, hematology, and cu otoms of HLBS diseases such as coug that are not life-limiting. Research of life for all patients with HLBS dise	life for persons otoms and suffe care within an alliative care ac r, palliative care life, and many of diseases. Th better quality ecisions that ali , including hea stic fibrosis, my of diseases may a slowing or hal ritical care prace gh, shortness of to improve bur ases, not just t	with advanced illner ering, communicati d across healthcare ldresses the spectru- e does not necessan other specific aspe e expected outcom of life, a realistic un gn with the patient of failure, chronic o velodysplastic syndu benefit from care f ting progression of tice is recommender f breath, and fatigu densome symptom	ess and their on of prognosis settings. um of care for rily entail cts of goal- e of derstanding of 's goals, bstructive romes, and ocused on diseases. ed by multiple e may be s has the ng disease.
106714	Notice of Special Interest (NOSI): following Acute Heart, Lung, Bloo	Resilience d, and Sle	and Vulnerability ep Insults in People with	Natio	nal Heart, Lung, and Blood	NOT-HL- 07	-May-2022	Not Succified

HIV (R01, Clinical Trial Not Allowed)

Institute/NIH/DHHS

22-002

Specified

Contact Name Shimian Zou, PhD

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount	
	Contact Telephone	301-827-8	2301					
	Contact Telephone	shimian 7	ou@nih gov					
	Snonsor Website	511111011.20						
	Program URI	Link to pro	ogram URI					
	Deadline Dates (ALL) 2023 , 05-Oct-2023 , 07-Jan-2024 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 07-May-2023 , 05-Jun-2023							
	This NOSI encourages the submission of research project applications focused on understanding the long-term manifestations of acute HLBS illnesses with an emphasis on host response, viral pathways, and mechanisms that contri to long-term manifestations in the context of HIV. Proposals considered responsive to the NOSI may address questions across the spectrum of basic science to population science.							
107287	Notice of Special Interest (NOSI): Focused Ancillary Studies to Large (Revised)	Heart, Lun e Ongoing (	g, Blood and Sleep Na Clinical Studies In	ational Heart, Lung, and Blood stitute/NIH/DHHS	NOT-HL- 21-030 07-N	Мау-2022	Not Specified	
	Contact Name	Jue Chen,	Ph.D.					
	Contact Telephone	301-435-0	)550					
	Contact Email	jue.chen@	Dnih.gov					
	Sponsor Website							
	Program URL	Link to pro	ogram URL					
	Deadline Dates (ALL)	07-May-2	022 , 05-Jun-2022 , 07-Sep-	2022,05-Oct-2022,07-Jan-2023,05	-Feb-2023 , 07-Ma	iy-2023		
This Notice of Special Interest (NOSI) seeks to expand the breadth of scientific research on the clinical course, prevention and treatment of diseases within the mission of the National Heart, Lung, and Blood Institute (NHLBI) by leveraging ongo clinical research studies through ancillary studies. The purpose of this NOSI is to invite research project applications to conduct focused ancillary studies to large ongoing clinical trials (including late-stage T4 implementation clinical trials), observational studies, and registries. This NOSI also serves as a replacement for NOT-HL-20-755 (expired as of Novembe 2021).								
100811	NHLBI Clinical Trial Pilot Studies (	R34 Clinica	I Trial Optional) Na In	ational Heart, Lung, and Blood stitute/NIH/DHHS	PAR-21- 079 07-N	May-2022	450,000 USD	

Contact Name Patrice Desvigne-Nickens, MD



SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount				
	Contact Telenhone	301-435-0	7504								
	Contact Email	gweinma	nn@nih gov								
	Sponsor Website	Link to sp	ik to sponsor website								
	Program URL	Link to pr	ogram URL								
	Deadline Dates (ALL)	07-May-2 2023 , 16	.022 , 16-Jun-2022 , 07-So -Oct-2023 , 07-Jan-2024	ep-2022 , 16-Oct-2022 , 07-Jan-2023	3 , 16-Feb-2023 , 07-M	ay-2023 , 16-Jun-2	.023 , 07-Sep-				
	Synopsis	This Funding Opportunity Announcement (FOA) supports studies that are both necessary and sufficient to inform the planning of a Phase II-IV clinical trial within NHLBI's mission. The NHLBI expects that applications to this FOA will describe planned clinical trial and in so doing demonstrate that the proposed (R34) research is scientifically necessary to design of plan the subsequent trial. Furthermore, this FOA will support research projects that are designed to provide results that be sufficient to inform the future trial without further studies. The planned Phase II, III, or IV trial must be primarily inter studies to test the efficacy, safety, clinical management, or implementation of intervention(s) in the prevention and/or treatment heart, lung, blood, and sleep disorders. In contrast to the study start up or preparation phase of NHLBI funding opportune for clinical trials (as described at https://www.nhlbi.nih.gov/grants-and-training/funding-opportunities-and-contacts/clir trials-optimization), the R34 mechanism is intended to provide new information that answers a scientific or operational question(s) which may be pragmatic in nature and, therefore, informs the final development of a Phase II-IV clinical trial Regardless of the results of the R24 support of the proposed future clinical trial will require a new application.									
106072	Notice of Special Interest (NOSI): Research for Heart, Lung, Blood a (Reissue)	Bold New and Sleep [	<u>Bioengineering</u> Disorders and Diseases	National Heart, Lung, and Blood Institute/NIH/DHHS	NOT-HL- 21-024 07-	May-2022	Not Specified				
	Contact Name	Narasimh	an Danthi, Ph.D.								
	Contact Telephone	301-435-	5170								
	Contact Email	<u>ndanthi@</u>	)mail.nih.gov								
	Sponsor Website	h .									
	Program URL	Link to pr	ogram URL								
	Deadline Dates (ALL)	07-May-2 2023 , 16	022 , 16-Jun-2022 , 07-S -Oct-2023 , 07-Jan-2024	ep-2022 , 16-Oct-2022 , 07-Jan-2023 , 16-Feb-2024 , 07-May-2024 , 16-Ju	3 , 16-Feb-2023 , 07-Ma Jn-2024 , 07-Sep-2024	ay-2023 , 16-Jun-2 , 16-Oct-2024 , 07	023 , 07-Sep- -Jan-2025				
	Synopsis	This Notic National bioengine	ce of Special Interest is a Heart, Lung and Blood In Pering projects which are	reissue of NOT-HL-20-796. The purp stitute (NHLBI) of an area of special expected to transition their researc	bose of this NOSI is to a interest to support ear ch into future follow-or	advise potential ap rly phases of innov n funding, technol	plicants to the ative ogies, or				

SPIN ID	Program Title		Sponsor Name	Spon	sor Number		Deadline Date	Funding Amount
		commerc their rese not overla Catalyze p	al products. Please note arch into future follow-o ap with the NHLBI Cataly pipeline.	e that this R2 on funding, te vze Program,	1 program does not overlap v echnologies, or commercial p and it does focus on new inve	vith projects w roducts. Pleas estigator-initia	which are expected to e note that this R21 ted ideas that will fe	o transition program does red into the
084638	linical Coordinating Center for N linical Trials (Collaborative UG3/	Iulti-Site Ir UH3 Clinic	<u>vestigator-Initiated</u> al Trial Required)	National He Institute/N	art, Lung, and Blood H/DHHS	PAR-19- 329	.1-May-2022	Not Specified
	Contact Name Contact Telephone Contact Email Sponsor Website	Nancy DiF 301-435-0 <u>difronzon</u>	ronzo, PhD 1065 <u>@nhlbi.nih.gov</u>					
	Program URL	Link to pr	ogram URL					
	Deadline Dates (ALL)	11-May-2	022 , 10-Jun-2022 , 08-Se	ep-2022				
	Synopsis	This Fund Center (Cr implemer preventio NIH defin research p milestone applicatio present th applicatio conduct c submitted	ing Opportunity Announ CC) for investigator-initia atation research clinical t n strategies. Trials for wh tion of a clinical trial (see priorities of the NHLBI, a -driven cooperative agre ns for a collaborating Da he scientific rationale for n should address project f the trial, and dissemina t on the same application	acement (FOA ated multi-sit trials. These t which this FOA e NOT-OD-1 pplicants are eement mech ata Coordinat r the clinical t manageme ation of resu n due date fo	A) supports applications to de re clinical trials including effic trials may include ones that to 5-015) . For additional inform encouraged to consult the N nanism of award and runs in p ting Center (DCC) ( PAR-19-33 trial and a comprehensive scient, subject recruitment and re ts. Both a CCC application an or consideration by NHLBI.	evelop and imp acy, comparat est different th the research r ation about th IHLBI website. parallel with a 30 ). The objec entific and ope etention, perfe d a collaborat	element a Clinical Co ive effectiveness, pro- nerapeutic, behavior mission of the NHLBI e mission, strategic This FOA will utilize companion FOA that tive of the CCC appli- erational plan that do prmance milestones, ing DCC application r	ordinating agmatic and/or al, and/or and meet the vision, and a bi-phasic, t encourages cation is to escribes it. The scientific must be
084646	Data Coordinating Center for Mul Elinical Trials (Collaborative U24 C	<u>ti-Site Inve</u> Clinical Tria	estigator-Initiated al Required)	National He Institute/N	art, Lung, and Blood H/DHHS	PAR-19- 330	.1-May-2022	Not Specified
	Contact Name Contact Telephone Contact Email	Nancy DiF 301-435-0 difronzon	ronzo, PhD 065 @nhlbi.nih.gov					

SPIN ID	Program Title	Sponsor Name	Spo	onsor Number		Deadline Date	Funding Amount			
	Sponsor Website									
	Program URL	Link to program URL								
	Deadline Dates (ALL)	11-May-2022 , 10-Jun-2022 , 08-	Sep-2022							
	Synopsis	investigator-initiated multi-site clinical trials including efficacy, comparative effectiveness, pragmatic and/or implement research clinical trials. These trials may include ones that test different therapeutic, behavioral, and/or prevention strategies. Trials for which this FOA applies must be relevant to the research mission of the NHLBI and meet the NIH definition of a clinical trial (see NOT-OD-15-015). For additional information about the mission, strategic vision, and re priorities of the NHLBI, applicants are encouraged to consult the NHLBI website. This FOA will utilize a cooperative agreement mechanism of award and runs in parallel with a companion FOA (PAR-19-329) that encourages application a collaborating Clinical Coordinating Center (CCC). The objective of the DCC application is to present a comprehensive to provide overall project coordination, administration, data management, and biostatistical support for the clinical tr proposed in the collaborating CCC application. Both a DCC application and a collaborating CCC application must be submitted on the same application due date for consideration by NHLBI.								
084637 <mark>S</mark>	ingle-Site Investigator-Initiated C Tial Required)	<u> 2linical Trials (R61/R33 Clinical</u>	National I Institute/	Heart, Lung, and Blood NIH/DHHS	PAR-19- 328 11-	May-2022	Not Specified			
	Contact Name	Nahed El Kassar, MD								
	Contact Telephone	301-435-0065								
	Contact Email	nahed.elkassar@nih.gov								
	Sponsor Website									
	Program URL	Link to program URL								
	Deadline Dates (ALL)	11-May-2022 , 10-Jun-2022 , 08-	Sep-2022							
This Funding Opportunity Announcement (FOA) supports applications to develop and implement investigator-initiated si site clinical trials including efficacy, comparative effectiveness, pragmatic and/or implementation research clinical trials. These trials may include ones that test different therapeutic, behavioral, and/or prevention strategies. Trials for which the FOA applies must be relevant to the research mission of the NHLBI and meet the NIH definition of a clinical trial (see NOT OD-15-015). For additional information about the mission, strategic vision, and research priorities of the NHLBI, applican are encouraged to consult the NHLBI website. This FOA will utilize a bi-phasic, milestone-driven mechanism of award. The objective of the application is to present the scientific rationale for the clinical trial and a comprehensive scientific and operational plan that describes it. The application should address project management, subject recruitment and retention of the scientific rationale for the clinical trial and a comprehensive scientific and operational plan that describes it. The application should address project management, subject recruitment and retention of the scientific retention and the scientific rational address project management.										

SPIN ID	Program Title		Sponsor Name	s	ponsor Number		Dea	dline Date	Funding Amount
		performa encourag design, ar	nce milestones, scientific ed but not required. App nd coordination.	c conduct olicants a	t of the trial, and dissemination or re encouraged to include a PD/P	of results. Th I with expert	e multiple ise in bios	PD/PI model tatistics, clini	l is strongly cal trial
101704	NHLBI Early Phase Clinical Trials f Diagnostics (R61/R33 Clinical Tria	or Therape I Required	eutics and/or )	Nationa Institute	Il Heart, Lung, and Blood e/NIH/DHHS	PAR-21- 119	04-Jun-2	022	Not Specified
	Contact Name	Traci Hea	th Mondoro, Ph.D.						
	Contact Telephone	301-435-0	0065						
	Contact Email	<u>xxxx@ma</u>	il.nih.gov						
	Sponsor Website								
	Program URL	Link to pr	ogram URL						
	Deadline Dates (ALL)	04-Jun-20	22 , 07-Sep-2022 , 02-Oo	ct-2022,	07-Jan-2023 , 04-Jun-2023 , 07-S	Sep-2023,02	2-Oct-2023	3,07-Jan-202	24
	Synopsis	The object therapeut clinical tri for the im therapeut bi-phasic, such as st	tive of this funding oppo tic interventions for hear al start-up and implement plementation of the pro tic/diagnostic in preparate milestone-driven mecha ability, shipping studies,	ortunity is rt, lung, k ntation a oposed tri tion for t anism of and site	s to support investigator-initiated blood, and sleep (HLBS) disorders ctivities, this FOA will provide su ial. All the activities proposed in he clinical trial. The proposed tri award where the first phase can training.	d, Phase I cli is in adults an pport for fin the R61 pha al can be sin be used to f	nical trials d children al stage pr ise must bo gle or mult inalize req	for diagnosti . In addition t eclinical activ e directly rela tisite. This FC uired pre-tria	c and to supporting vities needed ated to the DA will utilize a al activities
101703	NHLBI Early Phase Clinical Trials f Diagnostics (R33 Clinical Trial Rec	or Therape Juired)	eutics and/or	Nationa Institute	Il Heart, Lung, and Blood e/NIH/DHHS	PAR-21- 118	04-Jun-2	022	4,545,000 USD
	Contact Name	Traci Hea	th Mondoro, Ph.D.						
	Contact Telephone	301-435-0	0050						
	Contact Email	mondoro	t@nhlbi.nih.gov						
	Sponsor Website								
	Program URL	Link to pr	ogram URL						
	Deadline Dates (ALL)	04-Jun-20	22 , 07-Sep-2022 , 02-Oo	ct-2022,	07-Jan-2023 , 04-Jun-2023 , 07-S	Sep-2023 , 02	2-Oct-2023	3,07-Jan-202	24
	Synopsis	The object therapeut	tive of this funding oppo tic interventions for hear	ortunity is rt, lung, b	s to support investigator-initiate blood, and sleep (HLBS) disorders	d, phase I cli in adults an	nical trials d children	for diagnosti . The propose	c and ed trial can be

SPIN ID	Program Title		Sponsor Name	SI	ponsor Number		Deadline Date	Funding Amount
	NULL DI Coroer Transition Award fo	single or r quarter o and estab establishe desired, a	nultisite. Applicants apply f the project period. Discu lishment of drug (and place ed by the time of award. I pplicants should consider	ying for f ussion, s icebo, if If time a r the con	funding under this FOA should be submission, and attainment of ap applicable) supplies, and any nec nd support for these and other p mpanion FOA, PAR-21-119, which	e ready to initia plicable regula essary third-pa re-clinical and/ utilizes an R61	te the clinical trial v tory (FDA, DSMB, IR rty agreements sho or trial readiness ac /R33 phased appro	vithin the first B) approvals, uld be tivities are ach.
106893	and Research Trainees (K22 Indep	endent Cl	inical Trial Not Allowed)	Institute	e/NIH/DHHS	034 12	2-Jun-2022	Specified
	Contact Name Contact Telephone Contact Email Sponsor Website	Shawn Be 301-827-5 <u>direducat</u>	diako, Ph.D. 5163 ion@nhlbi.nih.gov					
	Program URL	Link to pr	ogram URL					
	Deadline Dates (ALL)	12-Jun-20	22 , 12-Oct-2022 , 12-Feb	o-2023 ,	12-Jun-2023 , 12-Oct-2023 , 12-Fe	eb-2024 , 12-Ju	in-2024	
	Synopsis	The purpe other doc transition Career Tra extramura support to research p of a resea specificall feasibility in a clinica should ap Research	bse of the NHLBI Career Tr toral-level researchers cu their research programs to ansition Award will suppo al phase (three years), for to the extramural phase is program during the mento rch plan to be carried out y for candidates proposin study, or an ancillary stud al trial led by a mentor or ply to the companion FOA Trainees (K22- Clinical Tria	ransitior irrently i to extra ort two p a total o not auto ored pha t at the e ng resear dy to a c co-men A, PAR-2 al Requi	n Award (K22) program is to provi in training in the NHLBI Division o mural institutions as junior invest phases of research: a mentored in of five years of combined support omatic. Approval of the transition ase as determined by an NHLBI pr extramural institution. This Fundin rch that does not involve leading clinical trial. Applicants to this FOA tor. Those proposing a clinical tria 22-040 "NHLBI Career Transition ired)".	ide highly qual f Intramural Re tigators. To ach tramural phase t. Transition fro n will be based rogress review an independer A are permitted al or an ancillar Award for Intr	fied postdoctoral fe search with the op ieve these objective (up to two years) a om the intramural p on the success of th which will include a Announcement (FC t clinical trial, a clin t o propose researc y clinical trial as lea amural Postdoctora	ellows and portunity to es, the NHLBI and an hase of the awardee's an evaluation DA) is designed ical trial ch experience d investigator, I Fellows and
106898	NHLBI Career Transition Award for and Research Trainees (K22 Clinica	r Intramui al Trial Re	al Postdoctoral Fellows quired)	Nationa Institute	l Heart, Lung, and Blood e/NIH/DHHS	PAR-22- 040 12	2-Jun-2022	Not Specified
	Contact Name Contact Telephone	Shawn Be 301-827-5	diako, Ph.D. 5163					

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Contact Email Sponsor Website Program URI	direducat	<u>ion@nhlbi.nih.gov</u> ogram URL				
	Deadline Dates (ALL) 12-Jun-2022 , 12-Oct-2022 , 12-Feb-2023 , 12-Jun-2023 , 12-Oct-2023 , 12-Feb-2024 , 12-Jun-2024						
	Synopsis	The purpose of the NHLBI Career Transition Award (K22) program is to provide highly qualified postdoctoral fellows and other doctoral-level researchers currently in training in the NHLBI Division of Intramural Research with the opportunity to transition their research programs to extramural institutions as junior investigators. To achieve these objectives, the NHLBI Career Transition Award will support two phases of research: a mentored intramural phase (up to two years) and an extramural phase (three years), for a total of five years of combined support. Transition from the intramural phase of support to the extramural phase is not automatic. Approval of the transition will be based on the success of the awardee's research program during the mentored phase as determined by an NHLBI progress review, which will include an evaluation of a research plan to be carried out at the extramural institution. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an existing trial, as part of their research and career development. Applicants not proposing to serve as lead investigator of an independent clinical trial phase investigator of an independent clinical trial phase.					
109308	RFA-HL-23-018 Maximizing the Biologic Biospecimen Repository: Exploratory Research (R21)	Scientific Scientific	Value of the NHLBI Na Opportunities for Ins	itional Heart, Lung, and Blood stitute/NIH/DHHS	RFA-HL- 21-J 23-018	un-2022	150,000 USD
Contact Name Margaret Ochocinska, PhD							
	Contact Telephone	301-827-8	3285				
	Contact Email	<u>ochocinm</u>	@mail.nih.gov				
	Sponsor Website						
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL) 21-Jun-2022 , 09-Aug-2022 , 19-Oct-2022 , 07-Dec-2022 , 20-Jun-2023 , 09-Aug-2023 , 19-Oct-2023 , 07-Dec-2023 , 20-Ju 2024 , 09-Aug-2024 , 21-Oct-2024 , 10-Dec-2024						)23 , 20-Jun-
	Synopsis This Funding Opportunity Announcement (FOA) will support meritorious exploratory research relevant to the NHLBI missi (http://www.nhlbi.nih.gov/about/org/mission) using the existing biospecimen collections that are stored in the NHLBI Biologic Specimen Repository (Biorepository), thereby maximizing the scientific value of the stored collections and provid researchers with an opportunity to generate preliminary data for subsequent research proposals.						
SPIN ID	Program Title	Sponsor Name		Sponsor Number		Deadline Date	Funding Amount
---------	--	---	---	---	--	---	--
101174	Notice of Special Interest (NOSI): A Development for Research and Clin	dvancing Genomic Technology	Natio Institu	nal Human Genome Research ute/NIH/DHHS	NOT-HG- 21-018	)5-Apr-2022	Not Specified
	Contact Name	Michael W. Smith, Ph.D.					
	Contact Telephone	301-480-3413					
	Contact Email <u>s</u>	smithmw@mail.nih.gov					
	Sponsor Website						
	Program URL I	<u>ink to program URL</u>					
	Deadline Dates (ALL) 2	05-Apr-2022 , 07-May-2022 , 05-J 2023 , 07-Jan-2023 , 05-Feb-2023 Sep-2023 , 05-Oct-2023 , 16-Oct-2	un-202 , 16-Fe 2023 , 0	2 , 16-Jun-2022 , 05-Sep-2022 , 07-5 b-2023 , 05-Apr-2023 , 07-May-202 )5-Jan-2024 , 07-Jan-2024	Sep-2022 , 05 3 , 05-Jun-20	-Oct-2022 , 16-Oct-2( 23 , 16-Jun-2023 , 05-	022 , 05-Jan- -Sep-2023 , 07-
	٦ Synopsis a i	The National Human Genome Res applications focused on developin nquiry and clinical applications in	earch I ng nove humar	nstitute (NHGRI) is issuing this Notion I laboratory-focused tools and tech ngenomics.	ce of Special I nologies that	nterest (NOSI) to end enable new lines of s	courage scientific
108325	Notice of Special Interest (NOSI): D Implementation of Clinical Informa Use of Genomic Information	Development and Itics Tools to Enhance Patients'	Natio Institu	nal Human Genome Research ute/NIH/DHHS	NOT-HG- 22-011	)5-Apr-2022	Not Specified
	Contact Name I	Ken Wiley, Jr., Ph.D.					
	Contact Telephone	301-435-5540					
	Contact Email	ken.wiley@nih.gov					
	Sponsor Website						
	Program URL I	ink to program URL					
	Deadline Dates (ALL)	05-Apr-2022 , 07-May-2022 , 25-N 2022 , 16-Oct-2022 , 07-Jan-2023 05-Jun-2023 , 16-Jun-2023 , 07-Se 2024 , 16-Feb-2024 , 07-May-2024	Лау-202 , 25-Jar p-2023 4 , 25-N	22 , 05-Jun-2022 , 16-Jun-2022 , 01- n-2023 , 05-Feb-2023 , 16-Feb-2023 ; , 25-Sep-2023 , 05-Oct-2023 , 16-O /Jay-2024 , 05-Jun-2024 , 16-Jun-202	Aug-2022 , 0 , 13-Mar-202 ct-2023 , 07 24 , 07-Sep-2(	7-Sep-2022 , 25-Sep-2 23 , 07-May-2023 , 25 Jan-2024 , 25-Jan-202 024	2022 , 05-Oct- 5-May-2023 , 24 , 05-Feb-
	Synopsis F	The National Human Genome Res applications to develop and imple patient-provider electronic comm provider electronic prescribing, te	earch I ment p unicati est track	nstitute (NHGRI) is issuing a Notice patient-facing genomic-based clinica on, patient tracking and registry fur king, referral tracking, and health ca	of Special Int Il informatics nctions, patie Ire decision-n	erest (NOSI) to encou tools that facilitate o nt self-management a naking.	irage ir enhance and support,

SPIN ID	Program Title		Sponsor Name		Sponsor Number		Deadline Date	Funding Amount
	Notice of Special Interest (NOSI): I	Methods (	Development for	Natio	nal Human Genome Research	NOT-HG-		Not
107786	Genomic Studies of Genetic Variat	tion, Func	tion, and Disease	Institu	ute/NIH/DHHS	22-007 05-	Apr-2022	Specified
	Contact Name	Lisa D. Bro	ooks, Ph.D.					
	Contact Telephone	301-547-2	1387					
	Contact Email	<u>lisa.brook</u>	<u>s@nih.gov</u>					
	Sponsor Website							
	Program URL	<u>Link to pr</u>	ogram URL					
	Deadline Dates (ALL)	05-Apr-20 2023 , 07 Sep-2023 , 05-Jun-2	022 , 07-May-2022 , 05- Jan-2023 , 05-Feb-2023 , 05-Oct-2023 , 16-Oct- 024 , 16-Jun-2024 , 05-	Jun-202 3 , 16-Fe 2023 , 0 Sep-202	2 , 16-Jun-2022 , 05-Sep-2022 , 07-5 b-2023 , 05-Apr-2023 , 07-May-202 5-Jan-2024 , 07-Jan-2024 , 05-Feb-2 4 , 07-Sep-2024 , 05-Oct-2024	5ep-2022 , 05-00 3 , 05-Jun-2023 2024 , 16-Feb-20	ct-2022 , 16-Oct-2( , 16-Jun-2023 , 05- 124 , 05-Apr-2024 ,	022 , 05-Jan- Sep-2023 , 07- 07-May-2024
	Synopsis	The Natio applicatio relate to g	nal Human Genome Re ns that develop novel c genomic function, phen	search I computa otype, a	nstitute (NHGRI) is issuing this Notic tional or experimental approaches and disease.	ce of Special Inte for genomic stu	erest (NOSI) to end dies of how geneti	courage c variants
101030	Notice of Special Interest (NOSI): H Cellular Phenotyping	High-throu	ughput Molecular and	Natio Institu	nal Human Genome Research ite/NIH/DHHS	NOT-HG- 21-004 07-	May-2022	Not Specified
	Contact Name	Colin Flet	cher, Ph.D.					
	Contact Telephone	301-496-7	7531					
	Contact Email	fletcherc2	@mail.nih.gov					
	Sponsor Website							
	Program URL	<u>Link to pr</u>	ogram URL					
	Deadline Dates (ALL)	07-May-2 2023 , 07·	022 , 05-Jun-2022 , 05 ·May-2023 , 05-Jun-202	Jun-202 3 , 05-Jเ	2 , 07-Sep-2022 , 05-Oct-2022 , 05-0 In-2023 , 07-Sep-2023 , 05-Oct-202	Oct-2022 , 07-Jai 3 , 05-Oct-2023	n-2023 , 05-Feb-20 , 07-Jan-2024	23 , 05-Feb-
	Synopsis	The Natio applicatio to elucida	nal Human Genome Re ns focused on developi te the functional conse	search I ng nove quences	nstitute (NHGRI) is issuing this Notion I methods to perform high-through s of DNA variation.	ce of Special Inte put molecular a	erest (NOSI) to end nd cellular phenot	ourage yping in order
108514	RFA-HG-22-004 Genome Resear Talented Undergraduates into Ger (R25 Clinical Trial Not Allowed)	ch Experie nomic Fiel	ences to Attract ds to Enhance Diversity	Natio Institu	nal Human Genome Research ite/NIH/DHHS	RFA-HG- 01- 22-004 [Op	Jun-2022 tional][LOI/Pre-Ap	1,750,000 pp] USD

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Contact Name Tir Contact Telephone 30 Contact Email ga Sponsor Website Program URL Lir Deadline Dates (ALL) 01 Th ov ba stu mi un Synopsis Re Ur pa or an sci	na Gatlin, Ph.D. D1-480-2280 atlincl@nih.gov nk to program URL L-Jun-2022 [Optional][LOI/Pre-Ap] ne NIH Research Education Progra verarching goal of this R25 progra ackgrounds, including those from udies or careers in research The I ission areas of the NIH. The overa ndergraduates from diverse backg ursue further training and careers complish the stated over-arching esearch Experiences Courses for S ndergraduates into the Genomic I artnerships that provide research Institutional Development Award of one or more research-intensive cientific areas of interest to NHGR	p], 01-Jul-2022 , 01-Jun-2023 [Optiona m (R25) supports research education m is to support educational activities groups underrepresented in the biom NIH Research Education Program (R25 arching goal of this NHGRI R25 program grounds, including those from groups in the scientific, medical, ethical, soci goal, this FOA will support creative en- kills Development This Genome Resea Field to Promote Diversity (GREAT) Pro- education programs for undergradua d (IDEA)-eligible institutions. A partne e institutions or organizations with a s I.	al][LOI/Pre-App], 01- activities in the mis- that encourage indiv- nedical and behavior 5) supports research m is to support educ underrepresented ir ial and/or legal area ducational activities arch Experiences to ogram will support of tes enrolled at mino rship will include a N suitable research bas	-Jul-2023 sion areas of the N viduals from divers al sciences, to purs education activities the biomedical we s of genomics resea with a primary foc Attract Talented collaborative institut rity-serving institut ASI or IDeA-eligible se for graduate-leve	IH. The e sue further es in the nat encourage orkforce, to arch. To us on: utional tions (MSIs) e institution, el training in
109305 <u>/</u>	RFA-AI-22-010 Partnerships for Ra Antibacterial Susceptibility Testing for Acquired Pneumonia (R01 Clinical Tr	pid Diagnostics and Phenotypic or Bacteremia or Hospital rial Not Allowed)	National Institute of Allergy and Infectious Diseases/NIH/DHHS	RFA-AI- 02-N 22-010 [Opt	May-2022 tional][LOI/Pre-App	Not o] Specified
	Contact Name M Contact Telephone 24 Contact Email <u>m</u> Sponsor Website Program URL <u>Lir</u> Deadline Dates (ALL) 02	lichael R. Schaefer, Ph.D. 40-627-3364 <u>schaefer@niaid.nih.gov</u> <u>nk to program URL</u> 2-May-2022 [Optional][LOI/Pre-Ap	op], 01-Jun-2022			

SPIN ID	Program Title		Sponsor Name		Sponsor Number		Deadline Date	Funding Amount
	Synopsis	The purpo and/or pr antibacte facilitate	ose of this Funding Oppo oduction of medical diag rial susceptibility profiles antibacterial stewardship	ortunity a gnostics s for bac p, therel	Announcement (FOA) is to support that permit rapid differential spo teremia or hospital acquired pro by reducing selective pressure an	ort research pr ecies identifica eumonia. The nd improving p	ojects focused on devention, and correspondin primary goal of such dipatient outcomes.	elopment ng phenotypic agnostics is to
108053	RFA-AI-21-079 Asthma and Alle Research Centers (U19 Clinical Tr	rgic Diseas ial Optiona	s <u>es Cooperative</u> <u>II)</u>	Nation Infection	al Institute of Allergy and ous Diseases/NIH/DHHS	RFA-AI- 21-079	04-May-2022 [Optional][LOI/Pre-Ap	4,500,000 p] USD
	Contact Name Contact Telephone Contact Email	Gang Don 240-627-3 gdong@n	g, M.D., Ph.D. 3508 nail.nih.gov					
	Sponsor Website Program URL	Link to pr	ogram URL					
	Deadline Dates (ALL) Synopsis	04-May-2 The purpo of institut program underlyin rhinosinu understar and preve	022 [Optional][LOI/Pre-A ose of this Funding Oppo ions to participate in the will support centers that g the onset and progress sitis, atopic dermatitis, fo nding of the pathogenesis ention strategies.	App], 03 ortunity , e Asthma : integra sion of d ood alle is of the	-Jun-2022 Announcement (FOA) is to invite a and Allergic Diseases Cooperat te clinical and translational resea liseases of interest, including ast rgy, and drug allergy. The overar se conditions and to provide a ra	applications f ive Research ( arch to conduc hma, rhinitis ( ching goal of t tional founda	rom single institutions Centers (AADCRC) prog t studies on the mecha allergic and non-allergi he program is to impro tion for new, effective	or consortia ram. The anisms c), chronic ove the treatments
107638	Notice of Special Interest (NOSI): Discovery	<u>Accelerati</u>	ng Malaria Vaccine	Nation Infection	al Institute of Allergy and ous Diseases/NIH/DHHS	NOT-AI- 22-014	07-May-2022	Not Specified
	Contact Name	Annie Mo	, Ph.D.					
	Contact Telephone	240-627-3	3320					
	Contact Email	<u>moa@nia</u>	<u>id.nih.gov</u>					
	Sponsor Website							
	Program URL	Link to pr	ogram URL					
	Deadline Dates (ALL)	07-May-2 2023 , 05·	022 , 05-Jun-2022 , 07-Se ·Oct-2023 , 07-Jan-2024 ,	ep-2022 , 05-Feb	2 , 05-Oct-2022 , 07-Jan-2023 , 05 -2024 , 07-May-2024 , 05-Jun-20	6-Feb-2023 , 0 024 , 07-Sep-20	7-May-2023 , 05-Jun-2 024 , 05-Oct-2024 , 07-	023 , 07-Sep- Jan-2025



SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	- Synopsis I	The purpo NIAID on suitable f discovery human m	ose of this Notice of Special l early phase translational res or further downstream deve of new vaccine candidates t alaria parasites, especially P	nterest (NOSI) is to inform potential a earch that will generate new malaria lopment and clinical evaluation. This I hat prevent infection, ameliorate dise lasmodium falciparum and Plasmodiu	pplicants about a vaccine candidate NOSI encourages ease, and/or inter m vivax.	an area of special i es with desirable f studies that will le rupt transmission	nterest to eatures ad to caused by
094378	NIAID Physician-Scientist Pathway (K99/R00 Clinical Trial Required)	to Indepo	endence Award Na Inf	tional Institute of Allergy and ectious Diseases/NIH/DHHS	PAR-20- 209 07-I	May-2022	Not Specified
	Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) Synopsis	Deborah 301-761- <u>AlTraining</u> Link to pr 07-May-2 The purpe maintain timely tra research research research fields and Announce clinical tri developm by anothe	Philip, Ph.D. 7776 <u>HelpDesk@niaid.nih.gov</u> ogram URL 022 , 12-Jun-2022 , 07-Sep-2 ose of the NIAID Physician-Se a strong cohort of new and t nsition of outstanding poste positions to independent, te support during this transition thereby help to address the ement (FOA) is designed spe al, a clinical trial feasibility s ient. Those not planning an ier investigator, must apply to	2022, 12-Oct-2022, 07-Jan-2023, 12- cientist Pathway to Independence Awa calented independent physician-scient loctoral researchers with a clinical doc nure-track or equivalent faculty positi in to help awardees launch competitive e national physician-scientist workforc cifically for candidates proposing to se tudy, or a separate ancillary clinical tri ndependent clinical trial, or proposing o companion FOA (PAR-20-210).	Feb-2023 , 07-Ma ard (K99/R00) pro ists. This program torate degree fro ons. The program e, independent re e shortage. This f erve as the lead ir al, as part of thei g to gain research	ay-2023 ogram is to increas m is designed to fa om mentored, pos n will provide inde esearch careers in Funding Opportun nvestigator of an ir r research and car n experience in a c	e and icilitate a tdoctoral pendent NIAID biomedical ity ndependent eer linical trial led
094380	NIAID Physician-Scientist Pathway (K99/R00 Independent Clinical Tria	to Indepo al Not Allo	endence Award Na wed) Inf	tional Institute of Allergy and ectious Diseases/NIH/DHHS	PAR-20- 210 07-I	May-2022	Not Specified
	Contact Name S Contact Telephone S Contact Email <u>A</u> Sponsor Website	Shawn Dr 301-761- AlTrainin	ew Gaillard, Ph.D. 7776 <mark>3HelpDesk@niaid.nih.gov</mark>				

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-May-2022 , 12-Jun-2022 , 07-S	Sep-2022 , 12-Oct-2022 , 07-Jan-2023			
	Synopsis	The purpose of the NIAID Physicia maintain a strong cohort of new a timely transition of outstanding p research positions to independen research support during this trans fields and thereby help to addres Announcement (FOA) is designed independent clinical trial, a clinica permitted to propose a research an ancillary study to an ongoing o	an-Scientist Pathway to Independence A and talented independent physician-scie postdoctoral researchers with a clinical o at, tenure-track or equivalent faculty po- sition to help awardees launch competi- s the national physician-scientist workfor I specifically for candidates proposing re al trial feasibility study, or an ancillary st experience in a clinical trial led by a men- clinical trial as lead investigator, should a	ward (K99/R00) pro entists. This program doctorate degree fro sitions. The program tive, independent re prce shortage. This f esearch that does no cudy to a clinical tria ntor or co-mentor. The apply to the compar	ogram is to increas m is designed to fa om mentored, pos n will provide inde esearch careers in Funding Opportun ot involve leading a I. Under this FOA Those proposing a nion FOA (PAR-20-	e and icilitate a tdoctoral pendent NIAID biomedical ity an candidates are clinical trial or 209).
107851	Notice of Special Interest (NOSI): . Develop a Universal Influenza Vac	Advancing Research Needed to ccine	National Institute of Allergy and Infectious Diseases/NIH/DHHS	NOT-AI- 22-013 07-I	May-2022	Not Specified
	Contact Name	Jennifer L. Gordon, Ph.D.				
	Contact Telephone	301-761-6805				
	Contact Email	Jennifer.gordon2@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-May-2022 , 05-Jun-2022 , 16-J 2023 , 07-May-2023 , 05-Jun-202 Feb-2024 , 07-May-2024 , 05-Jun-	un-2022 , 07-Sep-2022 , 05-Oct-2022 , 1 3 , 16-Jun-2023 , 07-Sep-2023 , 05-Oct-2 -2024 , 16-Jun-2024 , 07-Sep-2024 , 05-0	l6-Oct-2022 , 07-Jar 2023 , 16-Oct-2023 , Dct-2024 , 16-Oct-20	n-2023 , 05-Feb-20 07-Jan-2024 , 05- 024 , 07-Jan-2025	23 , 16-Feb- Feb-2024 , 16-
	Synopsis	The purpose of this Notice of Spe in "A Universal Influenza Vaccine:	cial Interest (NOSI) is to support researd : The Strategic Plan for the National Inst	ch that contributes t itute of Allergy and	to the areas of inte Infectious Disease	erest outlined
102961	Notice of Special Interest (NOSI): Immunity/Primary Immunodeficie	Investigations on Inborn Errors of encies	National Institute of Allergy and Infectious Diseases/NIH/DHHS	NOT-AI- 21-032	May-2022	Not Specified
	Contact Name	Frosso Voulgaropoulou, PhD				
	Contact Telephone	240-627-3205				
	Contact Email	fvoulgaropoulou@niaid.nih.gov				

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Sponsor Website Program UBI	Link to program LIBI				
	Deadline Dates (ALL)	07-May-2022 , 05-Jun-2022 , 16-Jun- 2023 , 07-May-2023 , 05-Jun-2023 , 2 Feb-2024 , 07-May-2024	2022 , 07-Sep-2022 , 05-Oct-2022 , 1 16-Jun-2023 , 07-Sep-2023 , 05-Oct-2	.6-Oct-2022 , 07-Jan 2023 , 16-Oct-2023 ,	-2023 , 05-Feb-20 07-Jan-2024 , 05-	23 , 16-Feb- Feb-2024 , 16-
	Synopsis	This Notice of Special Interest (NOSI) referred to as Primary Immunodefici and molecular diagnosis, and to supp	) is to support the discovery and chan encies, to understand the causes and port the development of strategies to	racterization of Inbo d mechanisms of dis o treat and eventua	rn Errors of Immu ease, to enable ea lly cure these diso	inity, also arly detection rders.
105630 <mark> </mark>	Notice of Special Interest (NOSI): L Functions of DEAD/H-box Helicase	<u>Understanding the Immune</u> N <u>es</u> In	ational Institute of Allergy and fectious Diseases/NIH/DHHS	NOT-AI- 21-066 07-M	May-2022	Not Specified
	Contact Name	Qian "Joy" Liu, M.D., M.Sc.				
	Contact Telephone	301-761-6621				
	Contact Email	<u>liujoy@niaid.nih.gov</u>				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-May-2022 , 05-Jun-2022 , 16-Jun- 2023 , 07-May-2023 , 05-Jun-2023 , 2 Feb-2024 , 07-May-2024 , 05-Jun-202	2022 , 07-Sep-2022 , 05-Oct-2022 , 1 16-Jun-2023 , 07-Sep-2023 , 05-Oct-2 24 , 16-Jun-2024 , 07-Sep-2024	.6-Oct-2022 , 07-Jan 2023 , 16-Oct-2023 ,	-2023 , 05-Feb-20 07-Jan-2024 , 05-	23 , 16-Feb- Feb-2024 , 16-
	Synopsis	This Notice of Special Interest (NOSI) function, and regulation of DEAD/H- from such studies may be applied to or treat/prevent immune-mediated	) supports research aimed at gaining box helicases in immune homeostasi the design of improved vaccines and diseases.	a comprehensive un s, activation, and/o d immunotherapies	nderstanding of th r function. Knowl to combat pathog	e expression, edge obtained enic infections
<u>ا</u> 099832 ( ۱	imited Competition: Exploratory Grant Program for NIAID K01/K08, Not Allowed)	and Developmental Research /K23 Recipients (R21 Clinical Trial In	ational Institute of Allergy and fectious Diseases/NIH/DHHS	PAR-20- 291 07-1	May-2022	275,000 USD
	Contact Name	Timothy A. Gondré-Lewis, Ph.D.				
	Contact Telephone	240-627-3566				
	Contact Email	tglewis@mail.nih.gov				

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Sponsor Website						
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	07-May-2 2023	022 , 16-Jun-2022 , 07-Sep-202	22 , 16-Oct-2022 , 07-Jan-2023 , 16-I	Feb-2023 <i>,</i> 07-Ma	y-2023 , 16-Jun-2	023 , 07-Sep-
	Synopsis	The Natio K08, and some poin capability independ pilot and research projects t	nal Institute of Allergy and Infe K23 recipients with the opport nt during the final two years of of its K01, K08, and K23 award ent investigator status (e.g., R0 feasibility studies; secondary a methodology; and developmen hat may provide preliminary da	ectious Diseases (NIAID) announces unity to apply for Exploratory and D their K award. Through the use of t recipients to conduct research as t 21 support). The R21 grant mechani- nalysis of existing data; small, self-c at of new research technology. The ata to support a subsequent R01, or	a program that p evelopmental Re this mechanism, N they complete the sm supports diffe ontained researc R21 is, therefore,	rovides NIAID-sup search Grant (R21 NIAID seeks to enh eir transition to fui rent types of proj h projects; develo intended to supp ication.	ported K01, ) support at ance the lly ects, including pment of ort research
099831	Limited Competition: Small Resea K01/K08/K23 Recipients (R03 Clin	irch Grant ical Trial N	Program for NIAIDNatioNot Allowed)Infect	nal Institute of Allergy and tious Diseases/NIH/DHHS	PAR-20- 290 07-N	Лау-2022	100,000 USD
	Contact Name	Stacy E. F	erguson, Ph.D.				
	Contact Telephone	240-627-3	3504				
	Contact Email	fergusont	:@niaid.nih.gov				
	Sponsor Website						
	Program URL	<u>Link to pr</u>	ogram URL				
	Deadline Dates (ALL)	07-May-2 2023	022 , 16-Jun-2022 , 07-Sep-202	22 , 16-Oct-2022 , 07-Jan-2023 , 16-I	Feb-2023 <i>,</i> 07-Ma	y-2023 , 16-Jun-2	023,07-Sep-
	Synopsis	The Natio K08, and two years K23 awar support). analysis o of new re period of applicatio	onal Institute of Allergy and Infe K23 recipients with the opport of their K award. Through the d recipients to conduct researc The R03 grant mechanism sup of existing data; small, self-cont search technology. The R03 is, time with limited resources an on.	ectious Diseases (NIAID) announces unity to apply for Small Research Gr use of this mechanism, NIAID seeks th as they complete their transition ports different types of projects, inc ained research projects; development therefore, intended to support rese d that may provide preliminary data	a program that p rant (RO3) suppor to enhance the o to fully independ cluding pilot and f ent of research m earch projects that a to support a sub	rovides NIAID-sup t at some point du capability of its KO ent investigator st easibility studies; ethodology; and d at can be carried o psequent R01, or e	ported K01, iring the final 1, K08, and atus (e.g., R01 secondary evelopment ut in a short equivalent,

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
107589	Notice of Special Interest (NOSI): Characterization of Inborn Errors	Molecular and Genetic of Immunity	National Institute of Allergy and Infectious Diseases/NIH/DHHS	NOT-Al- 21-082 07-	May-2022	Not Specified
	Contact Name Contact Telephone Contact Email Sponsor Website Program URL	Frosso Voulgaropoulou, PhD 240-627-3205 fvoulgaropoulou@niaid.nih.gov Link to program URL				
	Deadline Dates (ALL) Synopsis	07-May-2022, 05-Jun-2022, 16-Ju 2023, 07-May-2023, 05-Jun-2023 Feb-2024, 07-May-2024, 05-Jun- The purpose of this Notice of Spec characterization of genetic variant immunity/primary immunodeficie these disorders. Understanding th prognosis, and the development of	un-2022, 07-Sep-2022, 05-Oct-202 3, 16-Jun-2023, 07-Sep-2023, 05-O 2024, 16-Jun-2024, 07-Sep-2024, 0 cial Interest (NOSI) is to advance the ts in coding or non-coding genomic ency diseases and to elucidate the m he genetic basis of primary immunoo of precision therapeutics.	2, 16-Oct-2022, 07-Ja oct-2023, 16-Oct-2023 05-Oct-2024, 16-Oct-2 e experimental validation regions that result in in nolecular, cellular, and deficiency disorders is o	n-2023, 05-Feb-20 , 07-Jan-2024, 05- 024, 07-Jan-2025 on and functional nborn errors of immunological me essential for their o	)23 , 16-Feb- Feb-2024 , 16- echanisms of diagnosis,
108513	NIAID Career Transition Award (Ka Allowed)	22 Independent Clinical Trial Not	National Institute of Allergy and Infectious Diseases/NIH/DHHS	PAR-22- 075	May-2022	Not Specified
	Contact Name Contact Telephone Contact Email Sponsor Website	AITrainingHelpDesk@niaid.nih.go	<u>v</u>			
	Program URL Deadline Dates (ALL)	LINK TO program URL 07-May-2022 , 12-Jun-2022 , 07-S 2023 , 12-Oct-2023 , 07-Jan-2024	ер-2022 , 12-Oct-2022 , 07-Jan-202 , 12-Feb-2024 , 07-May-2024 , 12-Ju	3 , 12-Feb-2023 , 07-M Jn-2024 , 07-Sep-2024	ay-2023 , 12-Jun-2 , 12-Oct-2024 , 07	023 , 07-Sep- -Jan-2025
	Synopsis	The purpose of the NIAID Career T assistant professor or equivalent a Funding Opportunity Announcem leading an independent clinical tri candidates are permitted to prope	Fransition Award program is to assis and initiate a successful biomedical ent (FOA) is designed specifically for al, a clinical trial feasibility study, or ose a research experience in a clinic	t postdoctoral fellows career as an independer candidates proposing an ancillary study to a al trial led by another i	transition to posit ent research scient research that doe clinical trial. Unde nvestigator.	tions of tist. This is not involve er this FOA

SPIN ID	Program Title		Sponsor Name		Sponsor Number		Deadline Date	Funding Amount
102013	Notice of Special Interest (NOSI): (CIBI)	Compleme	ent in Basic Immunology	Natio Infect	nal Institute of Allergy and ious Diseases/NIH/DHHS	NOT-AI- 21-008 07	-May-2022	Not Specified
	Contact Name	Cheryl La	oham, Ph.D.					
	Contact Telephone	240-627-3	3490					
	Contact Email	<u>clapham@</u>	<u>Pniaid.nih.gov</u>					
	Sponsor Website							
	Program URL							
	Deadline Dates (ALL)	07-May-2	022 , 05-Jun-2022 , 16-Ju	un-2022	2 , 07-Sep-2022 , 05-Oct-2022 , 16-0	Oct-2022 , 07-Ja	an-2023	
	Synopsis	The main compone agents, or infection. target cor	objective of this program nts and/or receptors in t r of the roles played by co The results of such studi mplement components.	n is to s he initi ompler ies will	support studies that accelerate our ation, magnitude, maintenance, an ment in the development of immun inform the development of adjuva	understanding d quality of imi e-mediated paints and vaccine	of the roles of com nune responses ag chogenic responses candidates or ther	plement ainst infectious following apeutics that
105735	Notice of Special Interest (NOSI): Mouse Model for Immunoregulat	Using the ory and In	Collaborative Cross (CC) fectious Disease	Natio Infect	nal Institute of Allergy and ious Diseases/NIH/DHHS	NOT-AI- 21-071 07	-May-2022	Not Specified
	<u>Contact Nama</u>	Oiere "Jess						
	Contact Name	Qian Joy	LIU, IVI.D., IVI.SC.					
	Contact Telephone	301-701-t						
	Conditient	<u>iiujoy@iii</u>						
	Program LIRI	Link to pr	ogram LIRI					
	Deadline Dates (ALL)	07-May-2 2023 , 07- Feb-2024	022 , 05-Jun-2022 , 16-Ju May-2023 , 05-Jun-2023 , 07-May-2024 , 05-Jun-2	un-2022 3 , 16-Ju 2024 , 2	2 , 07-Sep-2022 , 05-Oct-2022 , 16-( un-2023 , 07-Sep-2023 , 05-Oct-202 16-Jun-2024 , 07-Sep-2024	Oct-2022 , 07-Ja 3 , 16-Oct-2023	an-2023 , 05-Feb-20 , 07-Jan-2024 , 05-	023 , 16-Feb- Feb-2024 , 16-
	Synopsis	The Natio in receivir recombin understar	nal Institute of Allergy an ng grant applications focu ant inbred intercrosses o nding of the host genetic	nd Imm using o of CC lir s involv	nunology (NIAID) is issuing this Noti n the following area(s): Use mouse nes (CC-RIX) to more faithfully reproved in immune regulation and function	ce of Special In lines from the oduce human ir tion Screen CC i	terest (NOSI) to hig Collaborative Cross nmune responses a nouse lines to iden	hlight interest (CC) and Ind to advance tify and

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		characterize lines suitable for spe immunology, immune-mediated	ecific studies and disease models within t diseases, infectious diseases).	he mission of N	NAID (e.g., fundament	al
106991	Notice of Special Interest (NOSI): Improving Mouse Models of Hum	Leveraging Microbial Exposure for nan Immunity	r National Institute of Allergy and Infectious Diseases/NIH/DHHS	NOT-AI- 21-072	07-May-2022	Not Specified
	Contact Name Contact Telephone Contact Email Sponsor Website	Qian "Joy" Liu, M.D., M.Sc. 301-761-6621 <u>niaidmousemodelnosi@nih.gov</u>				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-May-2022 , 05-Jun-2022 , 16-J 2023 , 07-May-2023 , 05-Jun-202 Feb-2024 , 07-May-2024 , 05-Jun-	Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 1 3 , 16-Jun-2023 , 07-Sep-2023 , 05-Oct-2 -2024 , 16-Jun-2024 , 07-Sep-2024 , 05-C	6-Oct-2022 , 07 023 , 16-Oct-20 0ct-2024 , 16-Oc	'-Jan-2023 , 05-Feb-20 )23 , 07-Jan-2024 , 05- ct-2024 , 07-Jan-2025	23 , 16-Feb- Feb-2024 , 16-
	Synopsis	This Notice of Special Interest (No exposures (commonly referred to of human immune function in ho	OSI) solicits research on immunologic cha o as "dirty mice") to determine their used meostasis and in response to infectious	aracterization o ulness as resea or immune-me	f mice with diverse m rch tools to advance ι diated diseases.	icrobial Inderstanding
109413	RFA-AI-22-012 Immune Drivers (U01 Clinical Trial Not Allowed)	of Autoimmune Disease (IDAD)	National Institute of Allergy and Infectious Diseases/NIH/DHHS	RFA-AI- 22-012	01-Jun-2022 [Optional][LOI/Pre-Ap	3,750,000 p] USD
	Contact Name	Thomas R. Esch, Ph.D.				
	Contact Telephone	240-627-3565				
	Contact Email	tesch@niaid.nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	01-Jun-2022 [Optional][LOI/Pre-A	App], 01-Jul-2022			
	Synopsis	This Funding Opportunity Annour Disease (IDAD) cooperative resea autoimmune disease. The main o events, and changes that underlie	ncement (FOA) invites applications to pa arch program, which will focus on definin objective of this program is to enhance o e the clinical manifestations of autoimm	rticipate in the g the immunolo ur understandir une diseases, in	Immune Drivers of Au ogic states and dynam ng of the immunologic icluding disease flare,	toimmune ics that drive processes, remission, and

SPIN ID	Program Title	Sponsor Na	me	Sponsor Number		Deadline Date	Funding Amount
		progression of establis autoimmune disease.	shed disease, a	as well as the progression from a stat	e of elevated ri	sk to clinical diagnosis c	f
102837	RFA-AI-21-035 Exploratory Data Development in Infectious and In Clinical Trial Not Allowed)	Science Methods and	Algorithm N ses (R21 Ir	National Institute of Allergy and nfectious Diseases/NIH/DHHS	RFA-AI- 21-035	01-Jun-2022 [Optional][LOI/Pre-App	275,000 ] USD
	Contact Name	Steve Tsang, PhD					
	Contact Telephone	240-627-3330					
	Contact Email	AI-DSFOAinquiries@ni	ih.gov				
	Sponsor Website						
	Program URL	Link to program URL					
	Deadline Dates (ALL)	01-Jun-2022 [Optional [Optional][LOI/Pre-Ap	l][LOI/Pre-App p], 06-Jul-2023	ı], 01-Jul-2022 , 18-Jan-2023 [Optiona 3	al][LOI/Pre-App	], 17-Feb-2023 , 06-Jun-	2023
	Synopsis	The purpose of this Fu innovative methods an the infectious or immu infectious diseases, en reactions associated w applications focused of including artificial inte analysis, visualization, (U01) and enhanceme companion FOAs.	Inding Opport and algorithms une-mediated nerging infectivith transplant on the develop Illigence and mand dissemination and dissemination	unity Announcement (FOA) is to support in biomedical computing, informatic disease research continuum aligned ions, or immune-mediated diseases to tation. As a part of the trans-NIAID Da oment of novel computational, mathe machine learning approaches, that ca ation of relevant data and/or knowle nt (U24) efforts to generate these too	bort exploratory s, and data scie with the resear that include alle ata Science pro- ematical, and st n considerably i dge. This contra ols and resource	y research focused on de nce addressing priority in rch mission of NIAID. This rgy, autoimmunity, or in gram, this R21 FOA enco atistical algorithms and improve acquisition, ma asts with early-stage dev es that are supported by	eveloping needs across s includes mmune ourages methods, nagement, velopment v the
102836	RFA-AI-21-020 Early-Stage Deve Technologies for Infectious and In Clinical Trial Not Allowed)	elopment of Data Scien nmune-mediated Disea	<u>ce</u> N ases (U01 Ir	National Institute of Allergy and nfectious Diseases/NIH/DHHS	RFA-AI- 21-020	01-Jun-2022 [Optional][LOI/Pre-App	900,000 ] USD
	Contact Name Contact Telephone Contact Email Sponsor Website	Steve Tsang, PhD 240-627-3330 <u>AI-DSFOAinquiries@ni</u>	i <u>h.gov</u>				



SPIN ID	Program Title		Sponsor Name		Sponsor Number		Dead	dline Date	Funding Amount
	Program URL	Link to pr	ogram URL						
	Deadline Dates (ALL)	01-Jun-20 [Optional	)22 [Optional][LOI/Pre-A ][LOI/Pre-App], 06-Jul-20	.pp], 0: 023	1-Jul-2022 , 18-Jan-2023 [Optional]	[LOI/Pre-App	)], 17-Feb-2	2023 <i>,</i> 06-Jur	n-2023
	Synopsis	The purpe science te knowledg detection continuur mediated trans-NIA adaptatio modificat (U24) effe	ose of this Funding Oppo echnologies to improve t ge for immune-mediated and diagnosis, treatmen m, aligned with the resea diseases that include al ID data science program on. Early-stage developm ion of existing tools for p prts to generate these to	ortunit the acc l and ir nt and arch m lergy, a n, this F nent is new ap pols an	y Announcement (FOA) is to solicit quisition, management, analysis, vis nfectious diseases including disease vaccines across the allergy, immun ission of NIAID. This includes infect autoimmunity, or immune reaction FOA focuses on early-stage develop defined for the purpose of this FOA oplications. This contrasts with expl d resources that are supported by t	applications ualization, a mechanism e-mediated, ious disease s associated ment from p as initial too oratory (R21 he companio	for the dev nd dissemin , risk predic and infecti s, emerging with transp rototyping ol developn ) and enha on FOAs.	velopment o nation of dat ction, epider ious-disease g infections, plantation. A to hardenin nent or the s ncement/su	f enabling data ta and niology, research or immune- s a part of the g and significant stainment
109336	Notice of Special Interest (NOSI): Allograft Survival	ptimizing '	Vascularized Composite	Natio Infec	onal Institute of Allergy and tious Diseases/NIH/DHHS	NOT-AI- 22-023	05-Jun-20	)22	Not Specified
	Contact Name	Patricia K	ehn, Ph.D.						
	Contact Telephone	240-627-3	3547						
	Contact Email	pkehn@N	IIAID.nih.gov						
	Sponsor Website								
	Program URL	Link to pr	ogram URL						
	Deadline Dates (ALL)	05-Jun-20 2023 , 05 May-2024 , 07-May- 2026 , 07	022 , 16-Jun-2022 , 07-Se -Jun-2023 , 16-Jun-2023 4 , 05-Jun-2024 , 16-Jun- 2025 , 05-Jun-2025 , 16- -May-2026	ep-2023 , 07-Se 2024 , Jun-20	2 , 05-Oct-2022 , 16-Oct-2022 , 07-J ep-2023 , 05-Oct-2023 , 16-Oct-202 07-Sep-2024 , 05-Oct-2024 , 16-Oct 025 , 07-Sep-2025 , 05-Oct-2025 , 16	an-2023 , 05 3 , 07-Jan-20 t-2024 , 07-J 5-Oct-2025 ,	-Feb-2023 24 , 05-Fet an-2025 , 0 07-Jan-202	, 16-Feb-202 b-2024 , 16-F 05-Feb-2025 26 , 05-Feb-2	23 , 07-May- Feb-2024 , 07- , 16-Feb-2025 026 , 16-Feb-
	Synopsis	The Natio models of rejection immunos	nal Institute of Allergy a r human tissue specimer and maximize graft surv uppression required for	ind Infe ns that ival aft long-te	ectious Diseases (NIAID) is intereste focus on 1) optimizing treatment a ter vascularized composite allotrans erm VCA acceptance.	ed in support nd graft moi splantation (	ing preclini nitoring to VCA) and 2	ical studies u reduce incid !) minimizing	utilizing animal ence of acute

SPIN ID	Program Title		Sponsor Name		Sponsor Number		Deadline Date	Funding Amount
109533	RFA-AI-22-016 Improved Drug S Tuberculosis (R01 Clinical Trial No	Susceptibil ot Allowed	ity Testing (DST) for )	Natio Infect	nal Institute of Allergy and ious Diseases/NIH/DHHS	RFA-AI- 22-016	08-Jun-2022 [Optional][LOI/Pre-Ap	2,500,000 p] USD
	Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) Synopsis	Karen A. I 240-627-3 lacourcie Link to pr 08-Jun-20 The purpo technolog diagnosti	Lacourciere, Ph.D. 3297 rek@mail.nih.gov ogram URL 022 [Optional][LOI/Pre-A ose of this Funding Oppo gies for tuberculosis (TB) cs for new TB drugs.	opp], 08 ortunity drug s	-Jul-2022 Announcement (FOA) is to support usceptibility testing (DST), including	t the develop point of car	oment of new diagnost e (POC) DST and comp	ic anion
106576	Notice of Special Interest (NOSI): the NIAMS Mission Areas	Promoting	g Pain Research Within	Natio Musc Disea	nal Institute of Arthritis and uloskeletal and Skin ses/NIH/DHHS	NOT-AR- 22-007	12-Apr-2022	Not Specified
	Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) Synopsis	Leslie K. E 301-402-4 leslie.der Link to pr 12-Apr-20 , 25-Oct-2 The purpo Musculos mission a	Derr, Ph.D. 1735 Cogram URL 222, 05-Jun-2022, 16-Ju 2022, 01-Nov-2022, 12- Dose of this announcement keletal and Skin Disease reas.	ın-2022 Nov-20 nt is to s (NIAN	, 01-Jul-2022 , 12-Jul-2022 , 20-Jul- 22 , 18-Nov-2022 , 12-Dec-2022 , 2 notify the research community that 1S) is interested in receiving grant a	2022 , 12-Au 2-Jun-2025 : the Nationa pplications f	ig-2022 , 05-Oct-2022 , Il Institute of Arthritis a ocused on pain within	, 16-Oct-2022 and the NIAMS
107713	Notice of Special Interest (NOSI): Opportunities on HIV/AIDS in NIA	Promoting MS	<u>Research</u>	Natio Musc Disea	nal Institute of Arthritis and uloskeletal and Skin ses/NIH/DHHS	NOT-AR- 20-005	07-May-2022	Not Specified
	Contact Name	Heiyoung	Park, Ph.D.					

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		201 504 5					
		301-594-5					
	Contact Email	parkn1@r	<u>maii.nin.gov</u>				
	Sponsor website	the later and					
	Program URL		ogram URL		Com 2022 OF Oat 2022 46 Oa	- 2022 40 Nov 20	22 07 14 4
	Deadline Dates (ALL)	2023	022,05-Jun-2022,16-Jui	1-2022 , 20-Jul-2022 , 07-5	sep-2022 , 05-Oct-2022 , 16-Oc	t-2022 , 18-NOV-20	22 , U7-Jan-
	Synopsis	The purpo and Skin I mission.	ose of this announcement Diseases (NIAMS) of an ar	is to inform potential app ea of special interest in HI	blicants to the National Institute V/AIDS-associated comorbiditie	e of Arthritis and M es that are within t	lusculoskeletal he NIAMS
	Notice of Special Interest (NOSI):	Promoting	Research on COVID-19	National Institute of Arthr	ritis and		Not
108115	and Rheumatic, Musculoskeletal	and Skin D	iseases	Musculoskeletal and Skin Diseases/NIH/DHHS	22-012 07-	May-2022	Specified
	Contact Name	Marie Ma	ncini, Ph.D.				
	Contact Telephone	301-594-5	5032				
	Contact Email	mancinim	2@mail.nih.gov				
	Sponsor Website						
	Program URL	Link to pro	ogram URL				
	Deadline Dates (ALL)	07-May-2 2022 , 18-	022 , 05-Jun-2022 , 16-Juı ·Nov-2022 , 07-Jan-2023	n-2022 , 01-Jul-2022 , 20-J	lul-2022 , 07-Sep-2022 , 05-Oct	-2022 , 16-Oct-202	2 <i>,</i> 04-Nov-
	Synopsis	The purpo and Skin I the NIAM	ose of this Notice is to anr Diseases (NIAMS) an inter S mission.	nounce to potential applic est in research on the imp	ants to the National Institute o pact of COVID-19 as related to c	f Arthritis and Mus liseases and condit	culoskeletal ions within
109528	Limited Competition: Small Grant K23, and K25 Recipients (R03) (Cl	<u>: Program f</u> inical Trials	for NIAMS K01, K08, S Not Allowed)	National Institute of Arthr Musculoskeletal and Skin Diseases/NIH/DHHS	ritis and PAR-22- 20- 119	Jun-2022	100,000 USD
	Contact Name	Su-Yau M	ao, Ph.D.				
	Contact Telephone	301-594-5	5032				
	Contact Email	maos2@r	nail.nih.gov				



SPIN ID	Program Title	s	ponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Sponsor Website						
	Program URL	Link to prog	gram URL				
	Deadline Dates (ALL)	20-Jun-2022 2025	2 , 19-Oct-2022 , 21-Feb-20	023 , 19-Jun-2023 , 19-Oct-2023 , 20-F	eb-2024 , 19-Jun	-2024 , 21-Oct-2024	4 , 19-Feb-
	Synopsis	The Nationa NIAMS-supp appropriate \$100,000 di scientists to mechanism small, self-o technology. with limiteo equivalent,	al Institute of Arthritis and ported K01, K08, K23, and e point during the second t irect costs for the entire pr o conduct research as they a supports different types of contained research project . The R03 is, therefore, inte d resources and that provid application. Clinical trials of	Musculoskeletal and Skin Diseases (N K25 recipients the opportunity to app o fourth year of their K award. Throug roject period of up to two years, the N complete their transition to fully inde of projects, including pilot and feasibili s; development of research methodol ended to support research projects the de support, in addition to the career d of any phase will not be supported by	IAMS) announces ly for Small Gran gh the use of this IIAMS is seeking to pendent investig ty studies; secon ogy; and develop at can be carried evelopment awa this FOA.	s a program that pro t (R03) support at a mechanism, which to enhance the capa tor status. The R0 dary analysis of exist oment of new resea out in a short perio rd, for a subsequen	ovides n allows up to ability of its 3 grant sting data; rch od of time t R01, or
100387 <u>C</u>	Aechanistic Ancillary Studies to C Clinical Trial Not Allowed)	Ongoing Clini	ical Projects (R21 Mu Dis	tional Institute of Arthritis and usculoskeletal and Skin eases/NIH/DHHS	PAR-21- 20 054 [Op	lun-2022 tional][LOI/Pre-App	400,000 )] USD
	Contact Name	Heiyoung P	ark, Ph.D.				
	Contact Telephone	301-594-50	)32				
	Contact Email	parkh1@ma	<u>ail.nih.gov</u>				
	Sponsor Website						
	Program URL	Link to prog	gram URL				
	Deadline Dates (ALL)	20-Jun-2022	2 [Optional][LOI/Pre-App],	20-Jul-2022 , 18-Oct-2022 [Optional][	[LOI/Pre-App], 18	S-Nov-2022	
	Synopsis	This Fundin ancillary stu ongoing "pa will be activ characterize response to mechanism	ng Opportunity Announcem udies related to the NIAMS arent" clinical project can b vely collecting patient sam ed patients, infrastructure, o this FOA will undergo an a to leverage established re	nent (FOA) solicits applications that pro- mission in conjunction with privately be an interventional clinical trial, or a co ples or clinical data. The "parent" proj data, and biological samples for the a accelerated review and award process isources and maximize the return on e	opose to conduct or publicly funde clinical study sucl ect(s) should pro ancillary study. A s. The objective o existing investme	t time-sensitive me ed, ongoing clinical n as an observation vide a cohort of we oplications submitte f this FOA is to prov nts in parent projec	chanistic projects. The al study that II- ed in vide a flexible cts. Successful

SPIN ID	Program Title		Sponsor Name	Spon	sor Number		Deadline Date	Funding Amount
		ancillary s understar treatment	tudies will enhance the nding of a disease or org t, and prevention of dis	e scientific cor gan system in ease.	itent and value of the parent the NIAMS portfolio, and thu	projects, impr s may identify	ove the research cor novel targets for dia	nmunity's Ignosis,
100388	Mechanistic Ancillary Studies to C Clinical Trial Not Allowed)	Ongoing Cli	nical Projects (R01	National Ins Musculoske Diseases/N	stitute of Arthritis and eletal and Skin IH/DHHS	PAR-21- 2 055 [	20-Jun-2022 Optional][LOI/Pre-Ap	1,200,000 pp] USD
	Contact Name	Heiyoung	Park, Ph.D.					
	Contact Telephone	301-594-5	5032					
	Contact Email	parkh1@r	<u>mail.nih.gov</u>					
	Sponsor Website	Link to our						
	Program URL	20 Jup 20	0gram URL	V [10] 20 [11] 2	022 19 Oct 2022 [Ontional][	IOI/Bro Appl	19 Nov 2022	
	Synopsis	This Fund ancillary s ongoing " will be act character response mechanis ancillary s understar treatment	ing Opportunity Annou itudies related to the N parent" clinical project tively collecting patient ized patients, infrastruc to this FOA will underge m to leverage establish itudies will enhance the nding of a disease or org t, and prevention of dis	ncement (FOA IAMS mission can be an inte samples or cl cture, data, ar o an accelerat ed resources e scientific cor gan system in ease.	A) solicits applications that pro in conjunction with privately erventional clinical trial, or a c inical data. The "parent" proju- d biological samples for the a red review and award process and maximize the return on e itent and value of the parent the NIAMS portfolio, and thu	opose to cond or publicly fur clinical study s ect(s) should p incillary study to The objectiv existing investr projects, impr s may identify	uct time-sensitive m nded, ongoing clinica uch as an observatio provide a cohort of w . Applications submit e of this FOA is to pro ments in parent proje ove the research cor novel targets for dia	echanistic I projects. The nal study that rell- ted in ovide a flexible ects. Successful nmunity's ignosis,
109946	Notice of Special Interest (NOSI): Advancing Clinical SPECT Imaging	<u>Technolog</u>	ical Innovations for	National Ins and Bioeng	stitute of Biomedical Imaging ineering/NIH/DHHS	NOT-EB- 22-006	)5-Jun-2022	Not Specified
	Contact Name	I. George	Zubal, Ph.D.					
	Contact Telephone	301-827-5	5168					
	Contact Email	igeorge.zu	ubal@nih.gov					
	Sponsor Website							
	Program URL	Link to pro	ogram URL					

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Deadline Dates (ALL)	05-Jun-20 2022 , 16 Apr-2023 , 05-Sep-2 2024 , 05	022 , 12-Jun-2022 , 16-Ju -Oct-2022 , 08-Dec-2022 , 08-Apr-2023 , 12-Apr-2 2023 , 07-Sep-2023 , 05-( -Feb-2024 , 12-Feb-2024	n-2022 , 08-Aug-2022 , 12-Aug-2022 , 12-Dec-2022 , 05-Jan-2023 , 07-Jan 2023 , 07-May-2023 , 05-Jun-2023 , 1 Dct-2023 , 12-Oct-2023 , 16-Oct-202 , 16-Feb-2024 , 05-Apr-2024 , 08-Ap	, 05-Sep-2022 , 07-S n-2023 , 05-Feb-2023 l2-Jun-2023 , 16-Jun- 3 , 08-Dec-2023 , 12- pr-2024 , 07-May-202	ep-2022 , 05-Oct-20 , 12-Feb-2023 , 16- 2023 , 08-Aug-2023 Dec-2023 , 05-Jan-2 4	022 , 12-Oct- Feb-2023 , 05- 5 , 12-Aug-2023 2024 , 07-Jan-
	Synopsis	The purpo Bioengine cost-effic	ose of this Notice is to in eering (NIBIB) of an area ient clinical Single-Photo	form potential applicants to the Nat of special interest in developing nuc n Emission Computerized Tomograp	ional Institute of Bior lear medicine imagin hy (SPECT) applicatio	nedical Imaging and g technologies to a ons.	d chieve more
108116	Notice of Special Interest (NOSI):	Clone Pro	gram	National Institute of Child Health a Human Development/NIH/DHHS	nd NOT-HD- 21-053	-Apr-2022	Not Specified
	Contact Name	Monica L	ongo, MD, PhD				
	Contact Telephone	240-204-4	4605				
	Contact Email	monica.lc	ongo@nih.gov				
	Sponsor Website						
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	05-Apr-20 2023 , 07 Sep-2023	)22 , 07-May-2022 , 05-Ji -Jan-2023 , 05-Feb-2023 , 05-Oct-2023 , 16-Oct-2	un-2022 , 16-Jun-2022 , 05-Sep-2022 , 16-Feb-2023 , 05-Apr-2023 , 07-Ma 023 , 05-Jan-2024 , 07-Jan-2024 , 05	2 , 07-Sep-2022 , 05-0 ay-2023 , 05-Jun-2023 5-Feb-2024 , 16-Feb-2	Oct-2022 , 16-Oct-2 3 , 16-Jun-2023 , 05 024 , 05-Apr-2024	022 , 05-Jan- -Sep-2023 , 07- , 07-May-2024
	Synopsis	The purpe use in fet decision r should fo other dire	ose of this Notice of Spec al assessment. The aim c naking and, ultimately, in cus on direct assessment ect measures.	cial Interest (NOSI) is to stimulate ad of the initiative is to improve accurac mproved maternal and fetal outcom t of fetal status through non-invasive	aptation of non-inva cy in fetal assessment les. Research encoura e measurement of fe	sive monitoring tec , leading to improv aged and supportec cal blood pH, oxyge	hnologies for ed clinical l by this NOSI nation, or
105294	Notice of Special Interest (NOSI): Research for Healthy Pregnancies	High Prior	ity Areas in Placental	National Institute of Child Health a Human Development/NIH/DHHS	nd NOT-HD- 21-040 11	-Apr-2022	Not Specified
	Contact Name	John V. Ile	ekis, PhD				
	Contact Telephone	301-435-0	5895				
	Contact Email	<u>ilekisj@n</u> i	h.gov				
	Sponsor Website						

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Program URI	Link to program URI				
	Deadline Dates (ALL)	11-Apr-2022 07-May-2022 05-1	un-2022 16-lun-2022 10-Aug-2022 07	-Sen-2022		
	Synopsis	Although the placenta is a short-li organ for the propagation of our s may result in many common adve restriction, stillbirth, and preterm fetus that can impact the health o such as obesity, cardiovascular dis necessary to help address a numb	ived organ limited to pregnancy, its impor species and future health of our progeny. erse pregnancy outcomes. These include e birth. In addition, a poorly functioning pl of the individual later in adult life. This inc sease, and diabetes. Thus, a more compre- per of major gaps in knowledge.	rtance is often un Perturbations in a early pregnancy lo acenta can lead to ludes an increase ehensive understa	derappreciated in any one of its man ss, preeclampsia, o aberrant prograr d incidence of adu nding of the place	being a crucial y functions fetal growth nming of the It diseases nta is
087240	Archiving and Documenting Child I Data Sets (R03 Clinical Trial Not All	Health and Human Development lowed)	National Institute of Child Health and Human Development/NIH/DHHS	PAR-20- 064 07-I	May-2022	100,000 USD
	Contact Name	Regina Bures, Ph.D.				
	Contact Telephone	301-496-9485				
	Contact Email	regina.bures@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-May-2022 , 16-Jun-2022 , 07-S	ep-2022 , 16-Oct-2022 , 07-Jan-2023			
	Synopsis	The purpose of this funding oppor sets within the scientific mission o (NICHD) in order to enable second original data collected with NICHE	rtunity announcement (FOA) is to suppor of the Eunice Kennedy Shriver National In dary analysis of these data by the scientifi O funding.	t the archiving an stitute of Child He c community. The	d documentation o ealth and Human D e highest priority is	of existing data pevelopment s to archive
104366	Notice of Special Interest (NOSI): R Infant Death and Sudden Infant De	Reduction of Sudden Unexpected eath Syndrome	National Institute of Child Health and Human Development/NIH/DHHS	NOT-HD- 21-032 07-I	May-2022	Not Specified
	Contact Name	Marion Koso-Thomas M.D, MPH				
	Contact Telephone	301-435-6873				
	Contact Email	kosomari@mail.nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				

SPIN ID	Program Title		Sponsor Name		Sponsor Number		Deadline Date	Funding Amount				
	Deadline Dates (ALL)	07-May-2 2023 , 07	022 , 05-Jun-2022 , 16-J May-2023	un-2022	, 07-Sep-2022 , 05-Oct-2022 , 16	-Oct-2022 , 07-Jar	n-2023 , 05-Feb-20	023 , 16-Feb-				
	Synopsis	Eunice Ke researche submit re efforts to	ennedy Shriver National I ers, behavioral scientists search projects that will understand the root cau	Institute and imp identify uses of s	of Child Health and Human Deve plementation science experts eith risk-reduction strategies that ad udden infant death syndrome an	lopment (NICHD) er as individual or dress infant morta d sudden unexpe	invites basic scien r as multi-disciplin ality domestically , cted infant death.	ice, clinical ary teams, to , as well as				
100064	Notice of Special Interest (NOSI): Analyses of Existing Data Sets and	Small Grai d Stored Bi	nts for Secondary ospecimens	Nation Humai	al Institute of Child Health and n Development/NIH/DHHS	NOT-HD- 20-022 07-	May-2022	Not Specified				
	Contact Name	Regina Bu	ires, PhD									
	Contact Telephone	301-496-9	9485									
	Contact Email	<u>regina.bu</u>	<u>res@nih.gov</u>									
	Sponsor Website											
	Program URL	Link to pr	ogram URL									
	Deadline Dates (ALL)	07-May-2	-May-2022 , 16-Jun-2022 , 07-Sep-2022 , 16-Oct-2022 , 07-Jan-2023 , 16-Feb-2023 , 07-May-2023									
	Synopsis	This Notio available effective	ce of Special Interest (NC NICHD-funded data sets research utilizing data ar	OSI) enco or store nd biosp	burages applications that propose ed biospecimens. The goal of this becimens collected with NICHD re	to conduct secor program is to faci sources.	ndary analyses usi litate innovative y	ng publicly et cost-				
101700	Notice of Special Interest (NOSI): Aspects of Embryonic Developme	<u>Biophysica</u> ent (R21)	al and Biomechanical	Nation Humai	al Institute of Child Health and n Development/NIH/DHHS	NOT-HD- 21-004 07-	May-2022	Not Specified				
	Contact Name	Mahua M	lukhopadhyay, PhD									
	Contact Telephone	301-435-0	5886									
	Contact Email	mukhopa	m@mail.nih.gov									
	Sponsor Website											
	Program URL	Link to pr	ogram URL									
	Deadline Dates (ALL)	07-May-2	.022 , 16-Jun-2022 , 07-S	Sep-2022	2 , 16-Oct-2022							
		The Notic	e of Scientific Interest (N	NOSI) is	intended to encourage innovative	and high risk/im	pact research in th	ne area of				
	Synopsis	physics/n	nechanics of embryonic of	develop	ment to be explored in model org	anisms. The resea	arch proposed und	ler this				
		program	can explore approaches	and con	cepts new to the area of develop	mental tissue me	chanics, research a	and				

SPIN ID	Program Title		Sponsor Name		Sponsor Number		Deadline Date	Funding Amount
		developm be built. mechanic	nent of new technologie The focus of this NOSI is as relevant to vertebrate	es, or init to prom e develop	ial research and development of c ote research aimed at generating oment and understanding the basi	data upon whic new and critic is for developr	ch significant future r cal information about nental disorders.	research may t tissue
085590	Small Research Grants for Analys Pediatric Research Data (R03 Clin	<u>es of Gabr</u> ical Trial N	iella Miller Kids First lot Allowed)	Nation Humar	al Institute of Child Health and n Development/NIH/DHHS	PAR-19- 375	)7-May-2022	200,000 USD
	Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL)	James N. 301-451- <u>Coulomb</u> <u>Link to pr</u> 07-May-2 The NIH (	Coulombe, Ph.D. 1390 <u>eJ@mail.nih.gov</u> ogram URL 2022 , 16-Jun-2022 , 07-5 Common Fund has estab	Sep-2022 Dished th	2 , 16-Oct-2022 , 07-Jan-2023 ne Gabriella Miller Kids First Pedia	tric Research F	Program (Kids First) t	o develop a
	Synopsis	pediatric communi Gabriella childhood accessible collabora support n birth defe Developn structura	research data resource ties of investigators who Miller Kids First Pediatr cancer and birth defect to the research comm tion leading to more ref neritorious small resear ects datasets that are pa nent of statistical metho birth defects may also	populate o study t ic Data R cts cohor unity. Ac fined dia ich projec art of the odology a be propo	ed by genome sequence and phen he genetics of childhood cancers a resource is to build a collection of ts and provide a central portal wh cess to these data will promote co gnostic capabilities and ultimately cts focused on the development a Kids First Data Resource or could appropriate for analyzing genome- psed.	otype data that and/or structu curated genor ere data and a comprehensive more targete nd analyses of be included ir -wide data rele	at will be of high value ral birth defects. The nic and phenotypic d analysis tools will be r and cross-cutting res d therapies. This FOA childhood cancer an the Kids First Data F evant to childhood ca	e for the goal of the ata from readily search and is intended to id/or structural Resource. ancer and/or
103657	NICHD Small Research Grant Prog Studies with Humans Required)	gram (RO3	Basic Experimental	Nation Humar	al Institute of Child Health and n Development/NIH/DHHS	PA-21-231 (	)7-May-2022	100,000 USD
	Contact Name Contact Telephone Contact Email Sponsor Website Program URL	NICHDRe Link to pr	ferral@mail.nih.gov ogram URL					

SPIN ID	Program Title	Sp	ponsor Name		Sponsor Number		Deadline Date	Funding Amount
	Deadline Dates (ALL)	7-May-202 023 , 16-O	22 , 16-Jun-2022 , 07-So ect-2023 , 07-Jan-2024	ep-2022 , 16-Feb	2 , 16-Oct-2022 , 07-Jan-2023 , 16-F 9-2024 , 07-May-2024	-eb-2023 , 07-Ma	ay-2023 , 16-Jun-20	023 , 07-Sep-
	Ti m Synopsis in va a: a; a;	ne NICHD S iission. Thi NOT-OD-2 efinition of clude stud ariables) ar spects of p oplications	Small Research Grant I is funding opportunity 18-212 as "prospective f a clinical trial and also dies that prospectively nd that assess biomed ohenomena without sp s toward processes or p	Program announ e basic s o meet t assign h lical or b pecific ap products	(Clinical Trial Required) supports icement is for basic science experin cience studies involving human pa the definition of basic research. Ty numan participants to conditions (i ehavioral outcomes in humans for oplication towards processes or pro- s in mind should submit under the	clinical trials that mental studies in rticipants." Thes pes of studies th i.e., experimenta the purpose of u oducts in mind. S appropriate 'Clin	a fall within the NIC volving humans, re e studies fall within at should submit u Ily manipulate inde understanding the studies conducted nical Trials Require	CHD eferred to in the NIH inder this FOA ependent fundamental with specific d' FOA.
103808	Notice of Special Interest (NOSI): Re and Parenting among Women with	productive Disabilities	<u>e Health, Pregnancy,</u> <u>s</u>	Nation Humar	al Institute of Child Health and Development/NIH/DHHS	NOT-HD- 21-025 07-1	May-2022	Not Specified
	Contact Name R	osalind Kin	ng, Ph.D.					
	Contact Telephone 3	01-435-698	86					
	Contact Email <u>ki</u>	ngros@ma	<u>ail.nih.gov</u>					
	Sponsor Website							
	Program URL <u>Li</u>	<u>nk to prog</u>	gram URL					
	0 Deadline Dates (ALL) 2 Fe	7-May-202 023 , 07-M eb-2024 , 0	22 , 05-Jun-2022 , 16-Ju 1ay-2023 , 05-Jun-2023 07-May-2024	un-2022 3 , 16-Jui	, 07-Sep-2022 , 05-Oct-2022 , 16-( n-2023 , 07-Sep-2023 , 05-Oct-202	Oct-2022 , 07-Jar 3 , 16-Oct-2023 ,	-2023 , 05-Feb-20 07-Jan-2024 , 05-I	23 , 16-Feb- Feb-2024 , 16-
	TI Synopsis v o	ne purpose VWD) in ai omen and r required	e of this Notice of Spec ny of three interconne adolescent girls with that all areas will be a	cial Inter ected are disabiliti ddresse	rest (NOSI) is to encourage and sup eas of high priority to NICHD: Gyne ies Pregnancy in WWD Postpartun d in one application.	oport research st cologic care and n and parenting r	udies in women w preconception he needs of WWD It is	ith disabilities alth for not expected
103656	NICHD Small Research Grant Progra	m (RO3 Cli	inical Trial Required)	Nation Humar	al Institute of Child Health and n Development/NIH/DHHS	PA-21-221 07-1	May-2022	100,000 USD
	Contact Name							
	Contact Telephone							
	Contact Email <u>N</u>	ICHDRefer	rral@mail.nih.gov					

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-May-2022 , 16-Jun-2022 , 07-S 2023 , 16-Oct-2023 , 07-Jan-2024	ep-2022 , 16-Oct-2022 , 07-Jan-2023 , 16 , 16-Feb-2024 , 07-May-2024	-Feb-2023 , 07-Ma	ay-2023 , 16-Jun-2	023 , 07-Sep-
	Synopsis	The NICHD Small Research Grant I mission. The R03 activity code sup resources. The R03 program may analysis of existing data; small, sel of new research technology.	Program (R03 Clinical Trial Required) sup oports small research projects that can be be used for different types of projects in lf-contained research projects; developm	ports clinical trials e carried out in a s cluding pilot and fo nent of research m	that fall within th hort period of tim easibility studies; s hethodology; and c	e NICHD e with limited secondary levelopment
103810	Notice of Special Interest (NOSI): I Covid 19 Pandemic and Risks for A Vulnerable Children and Youth	Research on the Impact of the Abuse and Injury Among	National Institute of Child Health and Human Development/NIH/DHHS	NOT-HD- 21-026 07-I	May-2022	Not Specified
	Contact Name	Valerie Maholmes, Ph.D., CAS				
	Contact Telephone	301-496-1514				
	Contact Email	maholmev@mail.nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-May-2022 , 05-Jun-2022 , 16-Ju 2023 , 07-May-2023 , 05-Jun-2023 Feb-2024 , 07-May-2024	un-2022 , 07-Sep-2022 , 05-Oct-2022 , 16 3 , 16-Jun-2023 , 07-Sep-2023 , 05-Oct-20	-Oct-2022 , 07-Jar 23 , 16-Oct-2023 ,	n-2023 , 05-Feb-20 , 07-Jan-2024 , 05-	23 , 16-Feb- Feb-2024 , 16-
	Synopsis	Pre-existing disparities and appare more data and research resources children and youth during and foll to provide greater recognition of t communication, identification and identification, treatment and care	ent challenges in resources for treatments to identify, substantiate and improve ca lowing the current crisis. It is anticipated the need for better resources and suppo d screening for risks of child trauma, and e in new and emerging disaster related co	t and care of child are and ultimately that research ster rt for vulnerable cl injury will help inf ontexts in the futur	ren experiencing a outcomes for vuln nming from this N hildren. More touc form processes for re.	buse call for lerable OSI will help chpoints for screening,
105045	Notice of Special Interest (NOSI): I Acceptance and Uptake among Ch and Lactating Women, and Persor	Promoting Vaccine Access, nildren, Adolescents, Pregnant ns with Disabilities	National Institute of Child Health and Human Development/NIH/DHHS	NOT-HD- 21-038 07-I	May-2022	Not Specified



SPIN ID	Program Title		Sponsor Name		Sponsor Number		Deadline Date	Funding Amount
	I							
	Contact Name	Regina M	. Bures, Ph.D.					
	Contact Telephone	301-496-9	9485					
	Contact Email	<u>regina.bu</u>	<u>res@nih.gov</u>					
	Sponsor Website							
	Program URL	Link to pr	ogram URL					
	Deadline Dates (ALL)	07-May-2 2023 , 16-	022 , 16-Jun-2022 , 07-S ·Oct-2023 , 07-Jan-2024	ep-202 , 16-Fe	2 , 16-Oct-2022 , 07-Jan-2023 , 16- b-2024 , 07-May-2024 , 16-Jun-202	Feb-2023 , 07-Ma 4 , 07-Sep-2024	ay-2023 , 16-Jun-20	)23 , 07-Sep-
	Synopsis	This NOSI among int populatio	encourages applications fants, children, adolesce ns who are underserved	s that a nts, pre l or exp	ddress dimensions of access, accep egnant and lactating women, and p erience health disparities.	otance and uptak ersons with disal	e of CDC-recomme bilities, especially a	nded vaccines mong
107427	RFA-RM-22-006 Expert-Driven S Gabriella Miller Kids First Discove	Small Proje ry (R03 Cli	ects to Strengthen nical Trial Not Allowed)	Natio Huma	nal Institute of Child Health and n Development/NIH/DHHS	RFA-RM- 10-I 22-006 [Op	May-2022 tional][LOI/Pre-Ap	200,000 p] USD
	Contact Name	James Co	ulombe <i>,</i> Ph.D.					
	Contact Telephone	301- 451-	1390					
	Contact Email	Coulombe	eJ@mail.nih.gov					
	Sponsor Website							
	Program URL	Link to pr	ogram URL					
	Deadline Dates (ALL)	10-May-2	022 [Optional][LOI/Pre-/	App], 10	0-Jun-2022			
	Synopsis	The NIH C of alleviat etiology o and contil childhood to the res childhood phenotyp researche families a Director	common Fund has estable ing suffering from childle of these diseases and sup nues to develop a Data F cancer and structural b earch community. This F cancer and/or structura ic datasets and resource of community with the u ffected by these condition Office of Strategic Coord	lished t nood ca oporting Resourc irth def OA is in al birth es. Thes ltimate ons. Thi lination	he Gabriella Miller Kids First Pediat incer and structural birth defects by g data sharing within the pediatric is including a large collection of cur fects cohorts and a central portal w intended to engage experts in a var defects genomic datasets generate e activities should strengthen futur goal of improving diagnostic capat is FOA is a Common Fund initiative https://dpcpsi.nih.gov/). All NIH I	ric Research Prog y fostering collab research communi- rated genomic an where these data iety of activities t ed by the Kids First re analyses of Kid pilities and therap (Common Fund) nstitutes and Cer	gram (Kids First) wi orative research to nity. Kids First has of phenotypic data and analysis tools a that will enhance th st program and/or ls First datasets by pies for children an through the NIH O oters participate in	th the vision o uncover the established from are accessible ne utility of associated the broader d their ffice of the Common

SPIN ID	Program Title		Sponsor Name		Sponsor Number		Deadline Date	Funding Amount
		Fund initi Child Hea	atives. The FOA will be a lth and Human Develop	administ oment (N	ered by a trans-NIH team led by th IICHD)	ne Eunice Kenned	y Shriver National	Institute of
107317 <mark> </mark>	nnovative Screening Approaches Disorders in Newborns (R01 - Clir	and Thera	apies for Screenable Optional)	Natior Huma	nal Institute of Child Health and n Development/NIH/DHHS	PAR-21- 353 05	lun-2022	Not Specified
	Contact Name	Mollie M	inear, Ph.D.					
	Contact Telephone	301-827-	9442					
	Contact Email	<u>mollie.mi</u>	near@nih.gov					
	Sponsor Website							
	Program URL	Link to pr	ogram URL					
	Deadline Dates (ALL)	05-Jun-20	022 , 05-Oct-2022 , 05-F	eb-2023	, 05-Jun-2023 , 05-Oct-2023 , 05-F	eb-2024 <i>,</i> 05-Jun	-2024 , 05-Oct-202	24
	Synopsis	for poten priority" ( demonsti screening infants w	tially fatal or disabling c genetic conditions wher rating the benefits of ea g panel. This FOA defines ith the condition would	conditior re screer arly inter s a "high significa	is that have been identified throug ning may be possible in the near fu vention or treatment, are importa priority" condition as one where ntly benefit from early identificati	gh newborn scree ture. Having an a nt criteria for incl screening is not c on and treatmen	ning, as well as fo ccurate screening uding a condition urrently recomme t.	r "high test, as well as on a newborn nded, but
099263 <u>t</u>	Notice of Special Interest (NOSI): heir Impact on the Male and Fer	Emerging nale Repro	<u>Viral Infections and</u> oductive Tract	Natior Huma	nal Institute of Child Health and n Development/NIH/DHHS	NOT-HD- 20-021 05	lun-2022	Not Specified
	Contact Name	Stuart B.	Moss, PhD					
	Contact Telephone	301-435-	6979					
	Contact Email	mossstua	@mail.nih.gov					
	Sponsor Website							
	Program URL	Link to pr	ogram URL					
	Deadline Dates (ALL)	05-Jun-20	)22 , 16-Jun-2022 , 05-O	ct-2022	, 16-Oct-2022 , 05-Feb-2023 , 16-F	eb-2023 , 05-Jun	-2023 , 16-Jun-202	23
	Synopsis	The purpe thought t female re likely not	ose of this Notice is to in to primarily impact non- productive tract. The re be the last virus occurre	nvite app reprodu ecent glo ence. To	blications proposing cutting-edge r ctive sites, at least at initial preser bal outbreak of the novel coronav day, infectious diseases are emerg	esearch on emer itation, but may a irus, SARS-CoV-2, ing and reemerg	ging viral infectior also affect the mal , is not an anomaly ing more quickly th	is that are e and/or y and will most han ever

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
_		before. In SARS-CoV morbiditi reproduct effects of sex specif	the last four-five years /-2 (Covid19), have sprea es., or severe birth defe tive systems in addition emerging viruses on rej fic.	alone, two viral infections, one caused b ad world-wide, resulting in death, severe cts to the new-born. Both ZIKV and SARS to other non-reproductive sites. Therefo productive tissues and cells to better und	y the Zika virus (Z disease with yet, -CoV-2 infections re, it becomes ess lerstand potential	IKV) and the other unknown, long-te may affect male a sential to investiga impacts on fertilit	caused by a rm nd/or female te possible y that may be
107319	Innovative Screening Approaches Disorders in Newborns (R21 - Clir	and Thera	apies for Screenable Optional)	National Institute of Child Health and Human Development/NIH/DHHS	PAR-21- 355 16 <sup>.</sup>	-Jun-2022	275,000 USD
	Contact Name	Mollie Mi	near, Ph.D.				
	Contact Telephone	301-827-9	9442				
	Contact Email	mollie.mi	near@nih.gov				
	Sponsor Website						
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	16-Jun-20	022 , 16-Oct-2022 , 16-Fe	eb-2023 , 16-Jun-2023 , 16-Oct-2023 , 16-	-Feb-2024 , 16-Jui	n-2024 , 16-Oct-20	24
	Synopsis	This FOA for poten priority" g demonstr screening infants w	encourages research rel tially fatal or disabling c genetic conditions wher rating the benefits of ea g panel. This FOA defines ith the condition would	evant to the development of novel scree onditions that have been identified throu e screening may be possible in the near f rly intervention or treatment, are import s a "high priority" condition as one where significantly benefit from early identificat	ning approaches ugh newborn scre uture. Having an a ant criteria for inc screening is not tion and treatmer	and/or therapeutic ening, as well as fo accurate screening cluding a condition currently recomment.	c interventions or "high test, as well as on a newborn ended, but
107320	Innovative Screening Approaches Disorders in Newborns (R03 - Clir	and Thera ical Trial C	apies for Screenable Optional)	National Institute of Child Health and Human Development/NIH/DHHS	PAR-21- 16- 354 16-	-Jun-2022	100,000 USD
	Contact Name	Mollie Mi	near, Ph.D.				
	Contact Telephone	301-827-9	9442				
	Contact Email	<u>mollie.mi</u>	near@nih.gov				
	Sponsor Website						
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	16-Jun-20	)22 , 16-Oct-2022 , 16-Fe	eb-2023 , 16-Jun-2023 , 16-Oct-2023 , 16-	-Feb-2024 , 16-Jui	n-2024 , 16-Oct-20	24

SPIN ID	Program Title		Sponsor Name		Sponsor Number		Deadline Date	Funding Amount
	T fc Synopsis d si ir	This FOA e for potent priority" g demonstra screening nfants wit	encourages research rele ially fatal or disabling co enetic conditions where ating the benefits of earl panel. This FOA defines th the condition would s	evant to nditior screer ly inter a "high ignifica	o the development of novel screer ns that have been identified throug ning may be possible in the near fu vention or treatment, are importa n priority" condition as one where antly benefit from early identificati	ing approaches gh newborn scre ture. Having an nt criteria for ind screening is not on and treatme	and/or therapeutic i ening, as well as for accurate screening t luding a condition c currently recommer at.	interventions "high sest, as well as on a newborn nded, but
087243	Small Research Grants for Establish Collaborations to Understand Struc Trial Not Allowed)	ning Basic ctural Birt	<u>Science-Clinical</u> <u>h Defects (R03 Clinical</u>	Natior Huma	nal Institute of Child Health and n Development/NIH/DHHS	PAR-20- 16 065	Jun-2022	150,000 USD
	Contact Name R	Reiko Toya	ama, PhD					
	Contact Telephone 3	301-435-2	723					
	Contact Email <u>t</u>	oyamar@	<u>)mail.nih.gov</u>					
	Sponsor Website							
	Program URL <u>L</u>	<u>ink to pro</u>	ogram URL					
	Deadline Dates (ALL) 1	L6-Jun-20	22 , 16-Oct-2022					
	T c ir g Synopsis a s t t g g	The purpo collaborat nterdiscip genomicis and/or bic pectrum to facilitat expertise genetics, a	ose of this funding oppor ions by providing small g plinary teams may includ ts, physician-scientists ir pinformaticists. Applicati as well as one from the the gathering of prelin and integrate basic, tran	tunity a grants t e but a ncludin ons mu clinical ninary slation asis of s	announcement (FOA) is to promot to teams of basic scientists, physic are not limited to the following: de g individuals with DVM/VMD degr ust include at least one scientist w side. The multiple PD/PI model is data to support future, larger rese al, and/or clinical approaches to u structural birth defects.	e initial establish ian scientists, an velopmental bio ees, clinicians, e ith expertise frou strongly encoura arch grant applio nderstanding the	ment of basic scien d/or clinicians. Thes logists, cell biologist pidemiologists, bios n the basic science s ged but not require ations that will com e developmental bio	ce-clinical se tas, geneticists, tatisticians, side of the ed. The goal is abine plogy,
109646	RFA-HD-23-007 CAPSTONE Center in Child Abuse and Neglect (P50) (C	<u>ers for Mu</u> Clinical Tri	ultidisciplinary Research al Optional)	Natior Huma	nal Institute of Child Health and n Development/NIH/DHHS	RFA-HD- 27 23-007 [O	Jun-2022 ptional][LOI/Pre-App	5,500,000 o] USD
	Contact Name V Contact Telephone 3 Contact Email <u>n</u>	/alerie Ma 801-496-1 maholmev	aholmes, Ph.D., CAS 514 /@mail.nih.gov					

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount		
	Sponsor Website	program LIRI						
	Deadline Dates (ALL) 27-Jun-2	2022 [Ontional][I OI/Pre-App], 2	7-Iul-2022					
This Request for Applications (RFA) is being re-issued to continue to stimulate collaborative research on all forms of c abuse and neglect and to foster dissemination and outreach efforts that bridge research, clinical practice and policy. T funding opportunity announcement (FOA) will use the specialized research center mechanism (P50) to call for multidisciplinary centers to serve as the CAPSTONE for research on child abuse and neglect and to serve as a national resource for the field. The Center(s) will conduct innovative and high quality research including: 1) trials testing the e and effectiveness of clinical interventions; 2) longitudinal prospective studies examining the long term effects of spect understudied types of maltreatment including abusive head trauma, medical child abuse and neglect, chronic sexual a 3) studies examining the neurobiology of abuse and neglect and implications for health outcomes; and 4) studies test development of screening tools and clinical assessment measures for early identification and treatment of specific typ abuse and neglect to decrease morbidity and mortality and to identify potential comorbidities. The Centers are also required to propose a dissemination and outreach core which will provide opportunities for students and faculty at a to be exposed to cutting edge educational tools and technologies, research, and expertise within the field of child maltreatment. A central goal of this core will be to engage the scientific and lay professional communities in participa activities such as technical assistance, evidence-based practice, participation in grand rounds, conferences and semin webinars based on information emanating from the other cores. The format for the community engagement activitie be tailored to the expertise of the Center and the needs of the community								
109857	RFA-HD-23-011 National Centers for Tra Reproduction and Infertility (NCTRI) (P50)	nslational Research in National (Clinical Trial Optional) Hum	onal Institute of Child Health and an Development/NIH/DHHS	RFA-HD- 28-J 23-011 [Op	lun-2022 tional][LOI/Pre-Ap	5,500,000 p] USD		
	Contact Name Ravi Rav	vindranath, DVM, Ph.D.						
	Contact Telephone 301-435	5-6889						
	Contact Email ravindrr	n@mail.nih.gov						
	Sponsor Website							
	Program URL Link to p	program URL						
	Deadline Dates (ALL) 28-Jun-2	2022 [Optional][LOI/Pre-App], 2	8-Jul-2022					
	The Eun Synopsis Infertilit provide	ice Kennedy Shriver National In y (FI) Branch, provides funding f an arena for multidisciplinary ir	stitute of Child Health and Human I for a limited number of research ce Iteractions among basic and clinica	Development (NIC nters in the repro- l scientists interes	HD), through the ductive sciences. <sup>-</sup> ted in establishing	Fertility and These centers thigh quality		

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		translatio National ( the Specia accelerate reproduct	nal research programs ir Centers for Translational alized Research Center (F es bidirectional knowled tive health through resea	a these scientific areas. The purpose of Research in Reproduction and Inferti 250) award mechanism. These center ge transfer between the laboratory a arch excellence and innovation.	of this FOA is to an ility (NCTRI). The N s will form a nation nd clinic with the u	nounce the re-composition NCTRI will be administ nal network that faci Iltimate goal of impr	etition of the stered through litates and oving human
081268	Clinical Research to Improve the Clinical Trial Not Allowed)	Oral Health	n of Older Adults (R01	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-19- 239	)7-May-2022	Not Specified
	Contact Name	Darien W	eatherspoon, DDS, MPH				
	Contact Telephone	301-594-5	5394				
	Contact Email	darien.we	atherspoon@mail.nih.				
	Sponsor Website						
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	07-May-2	022 , 05-Jun-2022 , 07-Se	ep-2022			
	Synopsis	The purpo related to managem "older ad	ose of this Funding Oppo the risk factors, access t ent of dental, oral, and o ults" as those individuals	rtunity Announcement (FOA) is to sti to care barriers, oral health promotio craniofacial (DOC) diseases more com age 65 years and older.	mulate research to n and disease prev imonly experience	o address gaps in our vention strategies, ar d by older adults. Th	knowledge nd clinical is FOA defines
083076	Mechanistic Studies of Gene-Env Craniofacial, and Other Diseases Not Allowed)	ironment I and Condit	nterplay in Dental, Oral, ions (R01 Clinical Trial	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-19- 292	)7-May-2022	Not Specified
	Contact Name	Kathryn S	tein, Ph.D.				
	Contact Telephone	301-827-4	1653				
	Contact Email	kathryn.s	tein@nih.gov				
	Sponsor Website						
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	07-May-2	022 , 05-Jun-2022 , 07-Se	ep-2022			
	Synopsis	This Fund biological	ing Opportunity Announ mechanisms of gene-en	cement (FOA) is intended to foster re vironment interplay in human diseas	esearch towards a es and conditions.	better understanding Through this FOA, th	g of the NIDCR,

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		NIEHS, an investigat other dise	d NICHD solicit applications th ion of the interplay of genes/g eases and conditions.	at use animal models, in vitro system gene networks and environmental fa	ms, or ex vivo app actors in dental, o	proaches to condu pral, craniofacial (E	oct mechanistic DOC), and
102596	NIDCR Clinical Trial Planning and Agreement (UG3/UH3 Clinical Tri	Implement al Require	tation Cooperative Natio	onal Institute of Dental and iofacial Research/NIH/DHHS	PAR-21- 160 07-1	May-2022	Not Specified
	Contact Name Contact Telephone Contact Email Sponsor Website	Dena Fisc 301-594-4 <u>dena.fisc</u> ł	her, DDS, MSD, MS 4876 <u>her@nih.gov</u>				
	Program URL Deadline Dates (ALL)	<u>Link to pr</u> 07-May-2 2023 , 03·	ogram URL 022 , 07-Jun-2022 , 07-Sep-20 Oct-2023 , 07-Jan-2024 , 06-Fo	22 , 04-Oct-2022 , 07-Jan-2023 , 07- eb-2024 , 07-May-2024	Feb-2023 , 07-Ma	ay-2023 , 06-Jun-2	023 , 07-Sep-
	Synopsis	This Fund to plan ar (NIDCR). S biologic, o for a Food milestone years. The phase per finalizing Manual o assess the mode of i and fidelif future tria trial with applicatio	ing Opportunity Announcement and implement clinical trials with Studies appropriate for this FO device, or procedure for denta d and Drug Administration (FD, e-driven UG3 planning phase, w e UH3 phase of the award will rmits both operational and scient the protocol and preparing oth f Procedures, data manageme e feasibility and/or acceptabilit ntervention delivery; feasibilit ty monitoring procedures) and al. The UG3 phase cannot be u an investigational drug, biolog on to the FDA prior to the UH3	ht (FOA) will support UG3/UH3 phase hin the mission of the National Insti- A are those testing diagnostic, preve l, oral, or craniofacial diseases or co A)-regulated product. Awards made with possible transition to a UH3 clin support the conduct of one investig entific planning activities. Operation her documents to implement the cli nt plan). Allowable scientific plannir by of a planned intervention and asso y of proposed data collection proceed assessment of the subject populati sed to test for intervention safety of ic or device, the investigators must phase.	sed, cooperative a tute of Dental and ention or treatme nditions, includin under this FOA v nical trial impleme ator-initiated clin al planning activi nical trial (e.g., da ng activities includ ociated study pro dures; preliminar on to determine r efficacy. If the a have submitted t	agreement researd d Craniofacial Rese ent approaches to g trials for any pha vill initially suppor entation phase of ical trial. The UG3 ties include, at min ata collection instr de small-scale data ocedures (e.g., acco y testing of intervo recruitment poter pplication propose he appropriate inv	ch applications earch test a drug, ase of testing t a one-year up to five planning nimum, ruments, a collection to eptability of ention training ntial for the es a clinical vestigational

SPIN ID	Program Title		Sponsor Name		Sponsor Number		Deadline Date	Funding Amount
108355	NIDCR Dual Degree Dentist Scient Award (K99/R00 Basic Experiment Required)	ist Pathwa tal Studies	ay to Independence Involving Humans	Natio Cranic	nal Institute of Dental and ofacial Research/NIH/DHHS	PAR-22- 043	)7-May-2022	Not Specified
	Contact Name	Leslie A. F	rieden, PhD					
	Contact Telephone	301-496-4	4263					
	Contact Email	leslie.frie	den@nih.gov					
	Sponsor Website							
	Program URL	Link to pr	ogram URL					
	Deadline Dates (ALL)	07-May-2 2023 , 12	022 , 12-Jun-2022 , 07-5 -Oct-2023 , 07-Jan-2024	Sep-202 ↓, 12-Fe	2 , 12-Oct-2022 , 07-Jan-2023 , 12- b-2024 , 07-May-2024 , 12-Oct-202	Feb-2023 , 07 24 , 07-Jan-202	-May-2023 , 12-Jun-2 25	023 , 07-Sep-
	Synopsis	The purpe and main health. Th postdocto years of r support is (25% full- experime participar Types of s condition humans f processes humans, investigat related to scientific	ose of the NIDCR Dual D tain a strong cohort of i his program is designed oral research positions t nentored training and th s available to accommod time professional effort ntal studies involving hu tots." These studies fall w studies that should be su studies that should be su so the purpose of under s or products in mind. Ap or proposing to gain res cor, must apply to the 'Ir o the programmatic inte missions.	egree D ndepen to facilit o indep hree to date clin date clin t) in any umans, i within th ubmitte nanipula rstandin pplicant earch ex ndepend rests of	tentist Scientist Pathway to Independently funded dentist scientists dec dently funded dentist scientists dec tate a timely transition of outstand endent, tenure-track or equivalent five years of independent research ical training in a dental specialty pr year of the R00 phase. This Fundin referred to in NOT-OD-18-212 as "p the NIH definition of a clinical trial ar d under this FOA include studies th te independent variables) and that g the fundamental aspects of phen s not planning an independent clin experience in a clinical trial or basic dent Clinical Trial Not Allowed' com one or more of the participating N	ndence Award dicated to imp ing dual degre faculty positie. An option for ogram at no r g Opportunity orospective bat and also meet that prospective bat at prospective assess biome omena witho ical trial or bat experimental panion FOA. IH Institutes a	I (K99/R00) program proving dental, oral a se dentist scientists f ons by providing supp r five years of indepe more than 3 person-r v Announcement is for sic science studies in he definition of basic ely assign human par dical or behavioral o ut specific application sic experimental stud study with humans le The proposed project nd Centers (ICs) base	is to develop nd craniofacial rom mentored, port for two ndent (R00) nonths effort or basic science volving human cresearch. ticipants to utcomes in n towards dy with ed by another cmust be ed on their
108353	NIDCR Dual Degree Dentist Scient Award (K99/R00 Clinical Trial Not	ist Pathwa Allowed)	ay to Independence	Natio Cranic	nal Institute of Dental and ofacial Research/NIH/DHHS	PAR-22- 041	)7-May-2022	Not Specified

Contact Name Leslie A. Frieden, PhD

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) Synopsis	301-496-4 leslie.fried Link to pr 07-May-2 2023 , 12- The purpo and main health. Th postdocto years of n support is full-time p specificall feasibility in a clinica trial as lead in human the comp	4263 den@nih.gov Ogram URL 022 , 12-Jun-2022 , 07-Sep-20 Oct-2023 , 07-Jan-2024 , 12-F ose of the NIDCR Dual Degree tain a strong cohort of indepentian tain a strong cohort of indepentian program is designed to factor oral research positions to indepention to indepention and three to a vailable to accommodate of professional effort) in any yea by for applicants proposing resisted study, or an ancillary study to al trial led by a mentor or co-read investigator, should apply to s referred to in NOT-OD-18-22 anion Basic Experimental Study	22 , 12-Oct-2022 , 07-Jan-2023 , 12 eb-2024 , 07-May-2024 , 12-Oct-20 Dentist Scientist Pathway to Independently funded dentist scientists de litate a timely transition of outstand pendent, tenure-track or equivalen o five years of independent research inical training in a dental specialty p r of the R00 phase. This Funding Op earch that does not involve leading o a clinical trial. Applicants to this FC nentor. Applicants proposing a clini o the companion FOA (PAR-22-042) L2 as "prospective basic science stud lies with Humans FOA (PAR-22-043)	-Feb-2023 , 07-Ma 24 , 07-Jan-2025 endence Award (K edicated to improv ding dual degree of t faculty positions n. An option for fiv program at no mon portunity Announ ; an independent of DA are permitted to cal trial or an anci ). Applicants prop dies involving hun ).	ay-2023 , 12-Jun-2 99/R00) program i ving dental, oral ar dentist scientists fr by providing supp ve years of indepen re than 3 person-n icement (FOA) is d clinical trial, a clinic to propose researc llary study to an o posing basic experi nan participants" s	023 , 07-Sep- is to develop nd craniofacial rom mentored, port for two ndent (R00) nonths (25% esigned cal trial ch experience ngoing clinical mental studies should apply to
108354	NIDCR Dual Degree Dentist Scient Award (K99/R00 Clinical Trial Req	<u>ist Pathwa uired)</u>	a <u>y to Independence</u> Nati Crar	onal Institute of Dental and iofacial Research/NIH/DHHS	PAR-22- 042	May-2022	Not Specified
	Contact Name Contact Telephone Contact Email Sponsor Website	Leslie A. F 301-496-4 <u>leslie.frie</u>	rieden, PhD 1263 den@nih.gov				
	Program URL Deadline Dates (ALL)	<u>Link to pr</u> 07-May-2 2023 , 12-	ogram URL 022 , 12-Jun-2022 , 07-Sep-20 -Oct-2023 , 07-Jan-2024 , 12-F	22 , 12-Oct-2022 , 07-Jan-2023 , 12 eb-2024 , 07-May-2024 , 12-Oct-20	-Feb-2023 , 07-Ma 24 , 07-Jan-2025	ay-2023 , 12-Jun-2	023 , 07-Sep-
	Synopsis	The purpo and main	ose of the NIDCR Dual Degree tain a strong cohort of indepe	Dentist Scientist Pathway to Independently funded dentist scientists de	endence Award (K edicated to improv	99/R00) program i ving dental, oral ar	s to develop d craniofacial

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		health. Th postdocto years of n support is (25% full- specificall study, or planning a must app	nis program is designed to facili oral research positions to indep nentored training and three to s available to accommodate clin time professional effort) in any ly for applicants proposing to s a separate ancillary study to ar an independent clinical trial, or ly to companion FOA (PAR-22-0	itate a timely transition of outstand bendent, tenure-track or equivalent five years of independent research nical training in a dental specialty p y year of the R00 phase. This Fundir erve as the lead investigator of an i n existing trial, as part of their research proposing to gain research experie 041).	ling dual degree of faculty positions . An option for five rogram at no mo ng Opportunity Au ndependent clini arch and career de ence in a clinical t	dentist scientists fr by providing supp ve years of indepe re than 3 person-n nnouncement (FO, cal trial, a clinical t evelopment. Appli rial led by another	om mentored, oort for two ndent (R00) nonths effort A) is designed trial feasibility cants not r investigator,
096097	Enabling Technologies to Accelera Biodevices (R01 Clinical Trial Not /	ate Develo Allowed)	p <u>ment of Oral</u> Natio Crani	nal Institute of Dental and ofacial Research/NIH/DHHS	PAR-20- 233 07-	May-2022	Not Specified
	Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL)	Orlando L 301-402-4 orlando.ld Link to pr 07-May-2	.opez, PhD 4243 <u>opez@nih.gov</u> <u>ogram URL</u> 2022 . 05-Jun-2022 . 07-Sep-202	22 . 05-Oct-2022 . 07-Jan-2023 . 05-	Feb-2023 . 07-M	av-2023	
	Synopsis	This Fund technical translatio clinical us health con FOA inclu biodevice research and effec biodevice collaborat between	ling Opportunity Announcemer challenges associated with new on of intraoral biodevices. Prope se, including but not limited to: nditions, and measurement of de engineering approaches that as that are safe and effective fo will be functional biodevices ar tive performance in support of as that advance precision medic tions across engineering, multi- academia and industry.	nt (FOA) invites applications that provide technologies are expected to a precision medicine-based detection patient functional status and clinicated allow integration of electronic, plant detection, diagnosis and treatment integrated approaches thorough specific intended clinical application provide technologies and treatment of the provide technologies and the provide technologies and treatment of technologies and treatment of the provide technologies and treatment of technologies and treatment of technologies and treatment of technologies and treatment of technologies and technologies and treatment of technologies and technolog	opose transforma advance develop n, diagnosis and t al outcome assess hysical, and biolo nt of oral and syst ly characterized t ons. To streamline actice, this FOA e chemistry, medic	ative engineering s technologies and o ment of oral biode treatment of oral a sment. Areas of in gical systems into temic disease. Pro to demonstrate pro the development encourages interdis ine, and dentistry,	solutions to clinical vices for and overall terest in this functional ducts of this eclinical safety t of oral sciplinary , as well as

SPIN ID	Program Title		Sponsor Name		Sponsor Number		[	Deadline Date	Funding Amount
108402	NIDCR Dentist Scientist Career Tra Investigators (K22 Clinical Trial No	ansition Av	ward for Intramural )	Natio Cranio	nal Institute of Dental and ofacial Research/NIH/DHHS	PAR-22- 044	07-M	ay-2022	Not Specified
	Contact Name	Leslie A. F	rieden, PhD						
	Contact Telephone	301-496-4	4263						
	Contact Email	leslie.frie	den@nih.gov						
	Sponsor Website								
	Program URL	Link to pr	ogram URL						
	Deadline Dates (ALL)	07-May-2 2023 , 12	022 , 12-Jun-2022 , 07-5 -Oct-2023 , 07-Jan-2024	Sep-202 ↓, 12-Fe	2 , 12-Oct-2022 , 07-Jan-2023 , 12- b-2024 , 07-May-2024 , 12-Oct-202	<sup>-</sup> eb-2023 , 07 4 , 07-Jan-20	-May 25	-2023 , 12-Jun-2	023 , 07-Sep-
	Synopsis	The purport transition track or e postdocto the extrain research clinical tri mentor. A to the con	ose of the NIDCR Dentis of highly qualified dent quivalent faculty position oral research training in mural institution. This F that does not involve le fal. Applicants to this FO Applicants proposing a c mpanion FOA (PAR-22-0	t Scient tists from ons at el the NIH unding en ading an DA are p clinical tr D45).	ist Career Transition Award for Intra m NIH Intramural postdoctoral rese ligible institutions. The award will p I Intramural Research Program, and Opportunity Announcement (FOA) in independent clinical trial, a clinica ermitted to propose research expen- rial or an ancillary study to an ongo	amural Invest arch position rovide suppo I three years is designed sp I trial feasibil rience in a clin ing clinical tri	igato s to e rt for of ind pecific ity stu nical t al as l	rs (K22) program extramural acade two years of me ependent resear cally for applican udy, or an ancilla crial led by a mer lead investigator	n is to facilitate emic tenure- entored rch funding at ts proposing my study to a ntor or co- r, should apply
087123	NIDCR Prospective Observational Cooperative Agreement (U01 Clin	<u>or Biomar</u> ical Trial N	<u>ker Validation Study</u> Iot Allowed)	Natio Cranie	nal Institute of Dental and ofacial Research/NIH/DHHS	PAR-20- 060	07-M	ay-2022	Not Specified
	Contact Name	Dena Fisc	her, DDS, MSD, MS						
	Contact Telephone	301-594-4	4876						
	Contact Email	dena.fiscl	<u>ner@nih.gov</u>						
	Sponsor Website								
	Program URL	Link to pr	ogram URL						
	Deadline Dates (ALL)	07-May-2	.022 , 05-Jun-2022 , 07-9	Sep-202	2 , 05-Oct-2022 , 07-Jan-2023				
	Synopsis	This Fund initiated of continued	ing Opportunity Annou observational studies or d analysis of data/biospo	ncemen <sup>-</sup> biomar ecimens	t (FOA) will support, through the co ker validation studies that require ( s collected as part of a previous NID	ooperative ag prospective c CR award.	reem ollect	ent mechanism, ion of data/bios	investigator- pecimens or

SPIN ID	Program Title	Sponsor Name		Sponsor Number		Deadline Date	Funding Amount
087114	Improving Oral Health and Reduc Clinical Trial Not Allowed)	ing Disparities in Adolescents (R01	L Natio	nal Institute of Dental and ofacial Research/NIH/DHHS	PAR-20- 058 07	'-May-2022	Not Specified
	Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL)	Darien Weatherspoon, DDS, MPH 301-594-5394 <u>darien.weatherspoon@nih.gov</u> <u>Link to program URL</u> 07-May-2022, 05-Jun-2022, 07-S	l Sep-202	2 , 05-Oct-2022 , 07-Jan-2023	te research to	improve the oral be	palth of
	Synopsis	adolescents in the United States, defines "adolescents" as those in	and to dividua	reduce observed oral health dispar ls between the ages of 10 and 19.	ities and inequi	ties in this populati	on. This FOA
100184	National Dental Practice-Based Ro Observational Study Planning and Agreement (UG3/UH3 Clinical Tri	esearch Network Clinical Trial or I Implementation Cooperative al Optional)	Natio Cranic	nal Institute of Dental and ofacial Research/NIH/DHHS	PAR-20- 306	7-May-2022	Not Specified
	Contact Name Contact Telephone Contact Email Sponsor Website Program URL	Dena Fischer, DDS, MSD, MS 301-594-4876 <u>dena.fischer@nih.gov</u> <u>Link to program URL</u>					
	Deadline Dates (ALL) Synopsis	07-May-2022, 09-Jun-2022, 07-J 2023, 07-Sep-2023 The National Institute of Dental a dental Practice-Based Research N National Coordinating Center sup clinical trials. This Funding Oppor observational studies to be condu agreement mechanism. Each UGS infrastructure and resources for s and potential transition to a UH3	ul-2022 Ind Crar Jetwork port the tunity A Jucted in 3/UH3 a study pla implem	2, 07-Sep-2022, 07-Oct-2022, 07-Ja niofacial Research (NIDCR) is contin (PBRN). The National Dental PBRN e infrastructure for and implement (FOA) is soliciting ap the National Dental PBRN through award will support an individual pro anning and implementation. This Fe nentation phase. Progression to the	an-2023 , 09-Fe uing support fo Administrative ation of multip plications for o a milestone-dr ject which will DA supports a l UH3 phase is l	b-2023 , 07-May-20 r research conduct and Resource Cent e observational stu linical trials and lar iven UG3/UH3 coo utilize the National JG3 clinical study p pased on an admini	023 , 09-Jun- ed within a ter and idies and ge clinical perative Dental PBRN lanning phase strative review

SPIN ID	Program Title		Sponsor Name		Sponsor Number		Deadline Date	Funding Amount		
		and is dep conduct o streamlin practition findings in dental PB	pendent on success in me of the research, NIDCR pro- e the implementation of ers and their patients, to nto clinical practice. This RN.	eeting l ogram nationa provid FOA en	JG3 milestones, consideration of priorities, and availability of funds al oral health research studies in o le evidence useful in daily patient acourages applications proposing i	the dental PBRN s. The main goa dental practices care, and to fac research studies	I as an appropriate v ls of the dental PBRI on topics of importa ilitate the translatio s that align with the	venue for Nare to ance to n of research goals of the		
108427	NIDCR Dentist Scientist Career Tr Investigators (K22 Basic Experime Required)	ansition Av ental Studio	ward for Intramural es Involving Humans	Natior Cranio	nal Institute of Dental and ofacial Research/NIH/DHHS	PAR-22- 0 046	7-May-2022	Not Specified		
	Contact Name	Leslie A. F	rieden, PhD							
	Contact Telephone	301-496-4	4263							
	Contact Email	leslie.frie	den@nih.gov							
	Sponsor Website									
	Program URL	Link to program URL								
	Deadline Dates (ALL)	07-May-2 2023 , 12 <sup>.</sup>	022 , 12-Jun-2022 , 07-Se -Oct-2023 , 07-Jan-2024 ,	ep-2022 , 12-Fel	2 , 12-Oct-2022 , 07-Jan-2023 , 12 p-2024 , 07-May-2024 , 12-Oct-20	-Feb-2023 , 07-l 24 , 07-Jan-202	May-2023 , 12-Jun-2 5	023 , 07-Sep-		
	Synopsis	The purper transition track or e postdocto the extrain humans, in fall within submitted manipula understain Applicant experience interests	ose of the NIDCR Dentist of highly qualified dentist quivalent faculty position oral research training in the mural institution. This Fu- referred to in NOT-OD-18 of the NIH definition of a c d under this FOA include te independent variables anding the fundamental as s not planning an indepen- ce in a clinical trial or basi dent Clinical Trial Not Allo of one or more of the par	Scienti sts from ns at eli the NIH unding ( 3-212 at clinical t studies s) and th spects of ic expen- owed' c rticipat	st Career Transition Award for Int n NIH Intramural postdoctoral res igible institutions. The award will Intramural Research Program, an Opportunity Announcement is for s "prospective basic science studie trial and also meet the definition of that prospectively assign human hat assess biomedical or behavior of phenomena without specific ap clinical trial or basic experimental rimental study with humans led b ompanion FOA. The proposed pro- ing NIH Institutes and Centers (ICS	ramural Investig earch positions provide support d three years of basic science e es involving hur of basic research participants to al outcomes in plication towar study with hum y another inves oject must be re s) based on thei	gators (K22) program to extramural acade for two years of me f independent resea xperimental studies nan participants." Th n. Types of studies th conditions (i.e., expe humans for the purp ds processes or proc ans, or proposing to tigator, must apply t lated to the program r scientific missions.	n is to facilitate emic tenure- entored rch funding at involving nese studies hat should be erimentally oose of ducts in mind. o gain research to the nmatic		


SPIN ID	Program Title		Sponsor Name		Sponsor Number		Deadline Date	Funding Amount
108403	NIDCR Dentist Scientist Career Tra Investigators (K22 Clinical Trial Re	ansition Av equired)	vard for Intramural	Natio Cranic	nal Institute of Dental and ofacial Research/NIH/DHHS	May-2022	Not Specified	
	Contact Name	Leslie A. F	rieden, PhD					
	Contact Telephone	301-496-4	263					
	Contact Email	leslie.fried	len@nih.gov					
	Sponsor Website							
	Program URL	Link to pro	ogram URL					
	Deadline Dates (ALL)	07-May-2 2023 , 12-	022 , 12-Jun-2022 , 07-S Oct-2023 , 07-Jan-2024	ep-202 , 12-Fe	2 , 12-Oct-2022 , 07-Jan-2023 , 12-F b-2024 , 07-May-2024 , 12-Oct-202	<sup>-</sup> eb-2023 <i>,</i> 07-Ma 4 , 07-Jan-2025	ay-2023 , 12-Jun-2	023 , 07-Sep-
	Synopsis	highly qua research e research f as the lead an existing proposing 044).	lified dentists in NIH Interpretended in the NIH Interpretences in the Interpretence in t	scienti ramura portun portun search ence in	I postdoctoral fellowship positions ral program to extramural institutio ity Announcement (FOA) is designent clinical trial, a clinical trial feasibi and career development. Applican a clinical trial led by another invest	with opportunit ons as new invest ed specifically for lity study, or a se ts not planning a tigator, must app	y to transition from gigators with indep applicants propo parate ancillary c n independent clin bly to companion F	m mentored pendent sing to serve linical trial to nical trial, or FOA (PAR-22-
083077	Development of Novel and Robus of Gene-Environment Interplay in Other Diseases and Conditions (R	t Systems Dental, O 21 Clinical	for Mechanistic Studies ral, Craniofacial, and Trial Not Allowed)	Natio Cranic	nal Institute of Dental and ofacial Research/NIH/DHHS	PAR-19- 293 07-	May-2022	275,000 USD
	Contact Name	Kathryn S	tein, Ph.D.					
	Contact Telephone	301-827-4	653					
	Contact Email	<u>kathryn.st</u>	ein@nih.gov					
	Sponsor Website							
	Program URL	Link to pro	ogram URL					
	Deadline Dates (ALL)	07-May-2	022 , 16-Jun-2022 , 07-S	ep-202	2			
	Synopsis	This Fundi biological NIEHS , ar	ng Opportunity Announ mechanisms of gene-en Id NICHD solicit applicat	icemen ivironm ions to	t (FOA) is intended to foster resear ent interplay in human diseases an develop novel and robust experime	ch towards a bet d conditions. Th ental systems the	ter understanding rough this FOA, th at offer approache	g of the e NIDCR, es

SPIN ID	Program Title		Sponsor Name		Sponsor Number		Deadline Date	Funding Amount
_		complem interplay	entary to human epidem in dental, oral, craniofac	niologic ial, and	or in vivo studies to facilitate mech other diseases and conditions.	nanistic inves	tigation of gene-envir	onment
081272	Clinical Research to Improve the Clinical Trial Not Allowed)	<u> Oral Health</u>	n of Older Adults (R21	Natio Cranic	nal Institute of Dental and ofacial Research/NIH/DHHS	PAR-19- 240	07-May-2022	275,000 USD
	Contact Name	Darien W	eatherspoon, DDS, MPH					
	Contact Telephone	301-594-5	5394					
	Contact Email	darien.we	atherspoon@mail.nih.					
	Sponsor Website							
	Program URL	Link to pro	ogram URL					
	Deadline Dates (ALL)	07-May-2	022 , 16-Jun-2022 , 07-S	ep-202	2			
	Synopsis	The purpo address ri managem "older adu	ose of this Funding Oppo sk factors, access to care ent of dental, oral, and o ults" as those individuals	ortunity e barrie craniof age 65	Announcement (FOA) is to encour rs, oral health promotion and disea acial (DOC) diseases more common 5 years and older.	age explorato ase preventio Ily experience	ory or developmental n strategies, and clini ed by older adults. Thi	research to cal s FOA defines
087115	Improving Oral Health and Reduc Clinical Trial Not Allowed)	ing Dispari	<u>ties in Adolescents (R21</u>	Natio Cranic	nal Institute of Dental and ofacial Research/NIH/DHHS	PAR-20- 059	07-May-2022	275,000 USD
	Contact Name	Darien W	eatherspoon, DDS, MPH					
	Contact Telephone	301-594-5	5394					
	Contact Email	darien.we	atherspoon@nih.gov					
	Sponsor Website							
	Program URL	Link to pro	ogram URL					
	Deadline Dates (ALL)	07-May-2	022 , 16-Jun-2022 , 07-S	ep-202	2 , 16-Oct-2022 , 07-Jan-2023			
	Synopsis	The purpo improve t this popul	ose of this Funding Oppo he oral health of adolese ation. This FOA defines	ortunity cents ir "adoles	Announcement (FOA) is to encour the United States, and to reduce of cents" as those individuals betwee	age explorate observed oral in the ages of	bry or developmental health disparities and 10 and 19.	research to I inequities in
101831	Notice of Special Interest (NOSI): the Physiological Involvement of 2019 (COVID-19)	NIDCR Sup Oral Cavity	port for Research on in Coronavirus Disease	Natio Cranic	nal Institute of Dental and ofacial Research/NIH/DHHS	NOT-DE- 21-001	07-May-2022	Not Specified

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount		
	Contact Name Contact Telephone	Amanda Melillo, Ph.D. 301-529-7217						
	Contact Email	amanda.melillo@nih.gov						
	Sponsor Website							
	Program URL	Link to program URL						
	Deadline Dates (ALL)	07-May-2022 , 05-Jun-2022 , 16-Jun-202 2023 , 07-May-2023	2 , 07-Sep-2022 , 05-Oct-2022 , 16	-Oct-2022 , 07-Jar	n-2023 , 05-Feb-20	)23 , 16-Feb-		
	Synopsis	The National Institute of Dental and Crar encourage research studies focused on t CoV-2 and/or Coronavirus Disease 2019 CoV-2 has surpassed 1.9 million, and in t of January 2021. Synergizing with a myri- urgency, NIDCR is positioned to address broad and rapid dissemination of research base of COVID-19 disease mechanisms a	niofacial Research (NIDCR) is issuin he physiological involvement of or (COVID-19). Globally, the death to he United States, more than 375,0 ad of initiatives across NIH and res COVID-19 research knowledge gap ch findings. Outcomes from this No nd presentations in the oral cavity	g this Notice of Sp al cavity and oral Il for COVID-19 ca 100 individuals hav ponding to a palp os unique to our m OSI are expected t	becial Interest (NC manifestations re used by the coror ve succumbed to t able sense of pub hission, as well as to strengthen the	ISI) to lated to SARS- avirus SARS- the disease as lic health to facilitate knowledge		
086959	NIDCR Research Grants for Analys Clinical Trial Not Allowed)	ses of Existing Genomics Data (R01 Natio Cranic	nal Institute of Dental and ofacial Research/NIH/DHHS	PAR-20- 045 07-1	May-2022	Not Specified		
	Contact Name	Lu Wang, Ph.D.						
	Contact Telephone	301-594-4846						
	Contact Email	wanglu@nidcr.nih.gov						
	Sponsor Website							
	Program URL	Link to program URL						
	Deadline Dates (ALL)	07-May-2022 , 05-Jun-2022 , 07-Sep-202	2 , 05-Oct-2022 , 07-Jan-2023					
	Synopsis	The purpose of this FOA is to announce support for meritorious research projects that address research questions relevan to human dental, oral, or craniofacial (DOC) conditions or traits through analysis of existing and publicly available genomic opsis data using statistical and computational approaches. Data analysis for each project can be performed using existing and/c novel methods to be developed in the same project, including machine learning-based methods (ML). In addition to analy of existing data, experimental or in silico work is required to validate data analysis results, or to validate a newly develope						

SPIN ID	Program Title		Sponsor Name		Sponsor Number		Deadline Date	Funding Amount
		analytic n candidate	nethod. Work that tackle causal genetic variants	es causa is highl	al mechanisms of action for onset a y encouraged.	nd progressio	n of disease for iden	tified
108981	NIDCR Mentored Career Develop (K01 Independent Basic Experime Required)	<u>ment Awa</u> ental Studio	rd to Promote Diversity es with Humans	Natio Cranic	nal Institute of Dental and ofacial Research/NIH/DHHS	PAR-22- 0 052 0	7-May-2022	Not Specified
	Contact Name	Leslie A. F	rieden, Ph.D.					
	Contact Telephone	301-496-4	4263					
	Contact Email	leslie.fried	den@nih.gov					
	Sponsor Website							
	Program URL	Link to pr	ogram URL					
	Deadline Dates (ALL)	07-May-2 2023 , 12·	022 , 12-Jun-2022 , 07-S -Oct-2023 , 07-Jan-2024	ep-202 , 12-Fe	2 , 12-Oct-2022 , 07-Jan-2023 , 12-l b-2024 , 07-May-2024 , 12-Jun-202	Feb-2023 , 07- 4 , 07-Sep-202	May-2023 , 12-Jun-2 4 , 12-Oct-2024 , 07	023 , 07-Sep- -Jan-2025
	Synopsis	The purpo early care and socia research s of an expo humans, n fall within submitted manipula understan Applicant experience	ose of the NIDCR Menton eer faculty from diverse k I sciences, to ensure a w support for a sustained p erienced mentor. This Fu referred to in NOT-OD-12 in the NIH definition of a c d under this FOA include te independent variables inding the fundamental a s not planning an indepen- ce in a clinical trial or bas dent Clinical Trial Not Alle	red Car packgro ell-train period o unding ( 8-212 a clinical studies s) and t spects o endent sic expe owed' o	eer Development Award to Promot bunds, including those from groups ned dental, oral, and craniofacial re of "protected time" for intensive re Opportunity Announcement is for k is "prospective basic science studie trial and also meet the definition or is that prospectively assign human p hat assess biomedical or behaviora of phenomena without specific app clinical trial or basic experimental s rimental study with humans led by companion FOA.	e Diversity is t underreprese search workfo search career basic science e s involving hur f basic researc participants to l outcomes in blication towar tudy with hun another inves	o support postdocto nted in the biomedia rce. This FOA provid development under xperimental studies nan participants." T h. Types of studies t conditions (i.e., exp humans for the purp ds processes or prov nans, or proposing to tigator, must apply t	iral fellows and al, behavioral, es salary and the guidance involving hese studies hat should be erimentally pose of ducts in mind. o gain research to the
108979	NIDCR Mentored Career Develop (K01 Clinical Trial Required)	<u>ment Awa</u>	rd to Promote Diversity	Natio Cranic	nal Institute of Dental and ofacial Research/NIH/DHHS	PAR-22- 051	7-May-2022	Not Specified
	Contact Name	Leslie A. F	rieden, Ph.D.					
	Contact Telephone	301-496-4	4263					



SPIN ID	Program Title	Sponsor Name		Sponsor Number		Deadline Date	Funding Amount
	Contact Email	leslie.frieden@nih.gov					
	Sponsor Website						
	Program URL	Link to program URL					
	Deadline Dates (ALL)	07-May-2022 , 12-Jun-2022 , 07-5 2023 , 12-Oct-2023 , 07-Jan-2024	Sep-2022 I , 12-Fel	2 , 12-Oct-2022 , 07-Jan-2023 , 12-l b-2024 , 07-May-2024 , 12-Jun-202	Feb-2023 , 07-M 4 , 07-Sep-2024	ay-2023 , 12-Jun-2 , 12-Oct-2024 , 07-	023 , 07-Sep- Jan-2025
	Synopsis	The purpose of the NIDCR Mento early career faculty from diverse and social sciences, to ensure a w research support for a sustained of an experienced mentor. This F to serve as the lead investigator of to an existing trial, as part of thei proposing to gain research exper 050).	bred Care backgro vell-train period o unding C of an ind ir researc ience in	eer Development Award to Promot unds, including those from groups ned dental, oral, and craniofacial re of "protected time" for intensive re Dpportunity Announcement (FOA) lependent clinical trial, a clinical tri ch and career development. Applic a clinical trial led by another invest	te Diversity is to underrepresente search workforc search career de is designed spec al feasibility stuc ants not plannin tigator, must app	support postdocto ed in the biomedic e. This FOA provide velopment under ifically for applican ly, or a separate ar g an independent oly to companion F	ral fellows and al, behavioral, es salary and the guidance its proposing icillary study clinical trial, or OA (PAR-22-
108980	NIDCR Mentored Career Develop (K01 Independent Clinical Trial No	<u>ment Award to Promote Diversity</u> ot Allowed)	Natior Cranio	nal Institute of Dental and ofacial Research/NIH/DHHS	PAR-22- 050 07-	May-2022	Not Specified
	Contact Name	Leslie A. Frieden, Ph.D.					
	Contact Telephone	301-496-4263					
	Contact Email	leslie.frieden@nih.gov					
	Sponsor Website						
	Program URL	Link to program URL					
	Deadline Dates (ALL)	07-May-2022 , 12-Jun-2022 , 07-5 2023 , 12-Oct-2023 , 07-Jan-2024	Sep-2022 I , 12-Fel	2 , 12-Oct-2022 , 07-Jan-2023 , 12-l b-2024 , 07-May-2024 , 12-Jun-202	Feb-2023 , 07-Ma 4 , 07-Sep-2024	ay-2023 , 12-Jun-2 , 12-Oct-2024 , 07-	023 , 07-Sep- Jan-2025
The purpose of the NIDCR Mentored Career Development Award to Promote Diversity is to support postdoctoral fellow early career faculty from diverse backgrounds, including those from groups underrepresented in the biomedical, behav and social sciences, to ensure a well-trained dental, oral, and craniofacial research workforce. This FOA provides salary research support for a sustained period of "protected time" for intensive research career development under the guida of an experienced mentor. This Funding Opportunity Announcement (FOA) is designed specifically for candidates propor research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co							

SPIN ID	Program Title		Sponsor Name		Sponsor Number		Deadline I	Date	Funding Amount		
		mentor. 1 (PAR-22-0	hose proposing a clinica	al trial or	an ancillary clinical trial as lead ir	nvestigator,	should apply to t	he com	panion FOA		
107548	Notice of Special Interest (NOSI): Health Research Related to HIV/A	Basic and AIDS	Translational Oral	Nation Cranio	al Institute of Dental and facial Research/NIH/DHHS	NOT-DE- 21-019	07-May-2022		Not Specified		
	Contact Name	Hiroko lid	la, DDS, MPH								
	Contact Telephone	301-594-7	7404								
	Contact Email	<u>hiroko.iid</u>	<u>a@nih.gov</u>								
	Sponsor Website										
	Program URL	Link to pr	ogram URL								
	Deadline Dates (ALL)	07-May-2 2023 , 07-	022 , 05-Jun-2022 , 16-Ju -May-2023	un-2022	, 07-Sep-2022 , 05-Oct-2022 , 16-	Oct-2022 , (	)7-Jan-2023 , 05-	Feb-202	23 , 16-Feb-		
	The National Institute of Dental and Craniofacial Research (NIDCR) is issuing this Notice of Special Interest (NOSI) t Synopsis encourage basic and translational research into mechanisms of HIV transmission, persistence, and pathogenesis ir cavity and its associated co-morbidities.							61) to s in the oral			
096105	Enabling Technologies to Acceler Biodevices (R21 Clinical Trial Not	ate Develo Allowed)	pment of Oral	Nation Cranio	al Institute of Dental and facial Research/NIH/DHHS	PAR-20- 232	07-May-2022		Not Specified		
	Contact Name	Orlando L	opez, PhD								
	Contact Telephone	301-402-4	1243								
	Contact Email	orlando.lo	opez@nih.gov								
	Sponsor Website										
	Program URL	Link to pr	ogram URL								
	Deadline Dates (ALL)	07-May-2	.022 , 16-Jun-2022 , 07-S	ep-2022	2 , 16-Oct-2022 , 07-Jan-2023 , 16-	Feb-2023 , (	07-May-2023				
	Synopsis	This Fund engineeri technolog oral biode oral and c interest in	7-May-2022, 16-Jun-2022, 07-Sep-2022, 16-Oct-2022, 07-Jan-2023, 16-Feb-2023, 07-May-2023 his Funding Opportunity Announcement (FOA) invites exploratory/developmental applications that propose transformative ngineering solutions to technical challenges associated with meaningful development, substantial optimization of existing echnologies and clinical translation of intraoral biodevices. Proposed technologies are expected to advance development of ral biodevices to clinical use, including but not limited to: precision medicine-based detection, diagnosis and treatment of ral and overall health conditions, and measurement of patient functional status and clinical outcome assessment. Areas of								

SPIN ID	Program Title		Sponsor Name		Sponsor Number		Dead	lline Date	Funding Amount
		essential oral and s associate clinical ap clinical pr pharmace	to the development of fusions systemic disease. Product d core technologies that oplications. To streamline ractice, this FOA encourage ology, chemistry, medicin	unctiona ts of thi enable e the de ges inte ne, and	al biodevices that are safe and effort is research will be proof-of-concept development of safe and effective evelopment of oral biodevices that erdisciplinary collaborations across dentistry, as well as between acac	ective for def ot prototype e intra-oral b advance pre s engineering demia and ind	ection, dia biodevices, iodevices in ecision med g, multifunc dustry.	gnosis and t dedicated ntended for licine-based tional senso	reatment of piosensors and specific approaches in prs,
100931	NIDCR Small Grant Program for N Not Allowed)	ew Investi	igators (R03 Clinical Trial	Natior Cranio	nal Institute of Dental and facial Research/NIH/DHHS	PAR-21- 084	07-May-2	022	200,000 USD
	Contact Name	Preethi C	hander, PhD						
	Contact Telephone	301-827-4	4620						
	Contact Email	preethi.cl	nander@nih.gov						
	Sponsor Website								
	Program URL	Link to pr	ogram URL						
	Deadline Dates (ALL)	07-May-2 2023 , 16	022 , 16-Jun-2022 , 07-Se -Oct-2023 , 07-Jan-2024	ep-2022	2 , 16-Oct-2022 , 07-Jan-2023 , 16-	Feb-2023 , 0	7-May-202	3 , 16-Jun-2	023 , 07-Sep-
This NIDCR Small Grant Program for New Investigators supports basic and clinical research conducted by scientists Synopsis supports pilot or feasibility studies and developmental research projects with the intention of obtaining sufficient preliminary data for a subsequent investigator- initiated Research Project Grant (R01) or equivalent application.							tists who are s R03 program ent n.		
	NIDCR Behavioral and Social Inter	vention C	linical Trial Planning and	Nation	al Institute of Dontal and	DAD 21			Not
106245	Implementation Cooperative Agr	<u>eement (U</u>	G3/UH3 Clinical Trial	Cranio	facial Research/NIH/DHHS	317	07-May-2	022	Specified
	<u>kequired)</u>				· · · ·				
	Contact Name	Melissa V	V. Riddle, PhD						
	Contact Telephone	301-451-3	3888						
	Contact Email	riddleme	<u>@mail.nih.gov</u>						
	Sponsor Website								
	Program URL	Link to pr	ogram URL						



SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Deadline Dates (ALL)	07-May-2022 , 07-Jun-2022 , 07-J 2023 , 07-May-2023 , 06-Jun-2023 Mar-2024 , 07-May-2024	ul-2022 , 07-Sep-2022 , 04-Oct-2022 , 0 3 , 06-Jul-2023 , 07-Sep-2023 , 03-Oct-2	4-Nov-2022 , 07-Ja 023 , 03-Nov-2023	n-2023 , 07-Feb-20 , 07-Jan-2024 , 06-	)23 , 07-Mar- Feb-2024 , 06-
	Synopsis	The purpose of this Funding Opporesearch applications to plan and FOA include clinical trials to devel conditions. Applications for NIDCI NIH Stage Model framework, descunder this FOA will initially suppo UH3 clinical trial implementation clinical trials will permit both sciedata collection to assess the feasi study procedures (e.g., acceptabil preliminary testing of intervention minimum, development of: the finand other tools for data and quali strategies; and other essential do research at all stages, from early rimplementation and health servic with humans that are considered Requirements for Grants and Con	brtunity Announcement (FOA) is to enco- implement behavioral and social interv- lop and test behavior change interventi R support of clinical trials research are e- cribed in detail here and incorporate ar- ort a milestone-driven UG3 planning pha- phase (UH3) of up to five years. The U- ntific and operational planning activitie ibility and/or acceptability of a planned lity of study content or mode of deliver n training and fidelity monitoring proce nal clinical protocol; the intervention m- ity management, safety and operational cuments. The UH3 phase will support the mechanistic research and intervention of ces research (Stages IV/V). This FOA mar- clinical trials based on the NIH's revised attracts for guidance).	burage UG3/UH3 p vention clinical trial ons related to dent expected to identify a experimental med ase for up to 2 year G3 phase for beha s. Scientific plannir behavioral or socia y; feasibility of pro dures). Operationa anual or equivalen I oversight plans; r he conduct of inves development (e.g., y also support basid d clinical trial defini	hased cooperative s. Studies appropri tal, oral, or craniofa y research proposa dicine approach. Av s, with possible tra- vioral and social im- ng activities include al intervention and posed data collecti al planning activitie t; the data manage ecruitment and ret stigator-initiated in Stages 0/ I) throug c behavioral experi ition (please see Cl	agreement ate for this acial ls using the wards made insition to a tervention e small-scale associated on procedures; s include, at a ement system tervention tervention tervention th mental studies inical Trial
086963	NIDCR Small Research Grants for Data (R03 Clinical Trial Not Allow	Analyses of Existing Genomics ed)	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-20- 046 07	-May-2022	200,000 USD
	Contact Name	Lu Wang, Ph.D.				
	Contact Telephone	301-594-4846				
	Contact Email	wanglu@nidcr.nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-May-2022 , 16-Jun-2022 , 07-S	Sep-2022, 16-Oct-2022, 07-Jan-2023			
	Synopsis	The purpose of this FOA is to annot to human dental, oral, or craniofa	ounce support for meritorious research acial (DOC) conditions or traits through	projects that addr analysis of existing	ess research quest and publicly availa	ions relevant ble genomics

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount		
		data using statistical and computa novel methods to be developed in	ational approaches. Data a n the same project, includi	nalysis for each project can be ng machine learning-based met	performed using exi hods (ML).	sting and/or		
109089	RFA-DE-23-005 In utero Treatm Craniofacial Disorders Using Prec Clinical Trial Not Allowed)	ents of Congenital Dental and ision Medicine Approaches (R21	National Institute of Den Craniofacial Research/NI	tal and RFA-DE- 14 H/DHHS 23-005 [O	-May-2022 ptional][LOI/Pre-Ap	275,000 o] USD		
	Contact Name	Lu Wang, PhD						
	Contact Telephone	301-594-4846						
	Contact Email	wanglu@mail.nih.gov						
	Sponsor Website							
	Program URL	Link to program URL						
	Deadline Dates (ALL)	14-May-2022 [Optional][LOI/Pre-	App], 14-Jun-2022					
	Synopsis	This FOA is intended to foster innovative research to directly enable precision medicine approach- and animal model-based development of in utero treatments for congenital dental and craniofacial diseases and conditions. The FOA looks to suppor projects that will demonstrate the feasibilities of treatment targets, treatment modalities, treatment delivery modalities, and gestational treatment time windows, as well as projects that will establish experimental systems and methods for the development of in utero treatments, all designed in the context of specific congenital dental and craniofacial diseases and conditions. The long-term goal is to lay the groundwork for therapies and cures in humans for congenital dental and craniofacial disease etiologies.						
109088	RFA-DE-23-004 In utero Treatm Craniofacial Disorders Using Prec Clinical Trial Not Allowed)	ents of Congenital Dental and ision Medicine Approaches (R01	National Institute of Den Craniofacial Research/NI	tal and RFA-DE- 14 H/DHHS 23-004 [O	-May-2022 ptional][LOI/Pre-Ap	Not o] Specified		
	Contact Name	Lu Wang, PhD						
	Contact Telephone	301-594-4846						
	Contact Email	wanglu@mail.nih.gov						
	Sponsor Website							
	Program URL	Link to program URL						
	Deadline Dates (ALL)	14-May-2022 [Optional][LOI/Pre-	App], 14-Jun-2022					

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Synopsis 8	This FOA is intended to support re diseases and conditions. The FOA models to develop in utero treatr successful treatments can arrest, groundwork for delivery of in ute and conditions as well as other di	esearch to accelerate the development invites applications for projects that w nents for congenital dental and craniof ameliorate, or cure the diseases or cor ro therapies and cures in humans affec seases and conditions that share simila	of treatments for co rill use precision med facial diseases and co nditions of interest. T ted by congenital de or disease etiologies.	ongenital dental an icine approaches onditions. It is anti he long-term goa ntal and craniofac	nd craniofacial in animal cipated that l is to lay the cial diseases
108878 <mark>6</mark>	RFA-DE-23-001 NIDCR Dental Sp Clinical Trial Not Allowed)	ecialty and PhD Program (K12	National Institute of Dental and Craniofacial Research/NIH/DHHS	RFA-DE- 07-J 23-001 [Opt	un-2022 tional][LOI/Pre-Ap	Not pp] Specified
	Contact Name I Contact Telephone 3 Contact Email <u>I</u> Sponsor Website Program URL <u>I</u> Deadline Dates (ALL) ( Synopsis 4 t	Leslie Frieden, Ph.D. 301-496-4263 leslie.frieden@nih.gov Link to program URL 07-Jun-2022 [Optional][LOI/Pre-A The purpose of the NIDCR Dental structured programs that provide activities, and mentored research to accelerate the process of early facilitate their transition to indep craniofacial health.	opp], 07-Jul-2022 Specialty and PhD Program (DSPP) is to advanced clinical training in an approv training leading to a PhD in biomedica career dentist scientists achieving com endent and productive research career	o develop outstandin ved dental specialty, I or behavioral scien opetencies in both cli rs dedicated to impro	g dentist scientist research career d ce. The programs nical and research oving dental, oral,	s through evelopment are expected n areas, and to and
109617 <mark>6</mark>	RFA-DE-23-003 Advancing HIV/A of Oral and Mental Health (R21 Cli	NDS Research at the Intersection nical Trial Not Allowed)	National Institute of Dental and Craniofacial Research/NIH/DHHS	RFA-DE- 25-J 23-003 [Opt	un-2022 ional][LOI/Pre-Ap	275,000 pp] USD
	Contact Name I Contact Telephone 3 Contact Email <u>I</u> Sponsor Website Program URL <u>I</u> Deadline Dates (ALL) 2	Hiroko Iida, DDS, MPH 301-594-7404 <u>hiroko.iida@nih.gov</u> <u>Link to program URL</u> 25-Jun-2022 [Optional][LOI/Pre-A	۰pp], 25-Jul-2022			

Title Sponsor Name Sponsor Number Deadline Date Amount
--

The purpose of this Funding Opportunity Announcement (FOA) is to support interdisciplinary research to better understand Synopsis the underlying mechanisms and interplay of biological, psychosocial, behavioral, and social structural factors contributing to oral health, mental health and co-occurring disorders in people living with HIV.

SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount			
109616	RFA-DE-23-002 Advancing HIV/. and Mental Health (R01 Clinical T	AIDS Research at the Intersection of Oral rial Not Allowed)	National Institute of Dental and Craniofacial Research/NIH/DHHS	RFA-DE- 23-002	25-Jun-2022 [Optional][LOI/Pre- App]	Not Specified			
	Contact Name	Hiroko lida, DDS, MPH	Sponsor Name         t the Intersection of Oral       National Institute of Dental and Craniofacial Research/NIH/DHHS         1       Research/NIH/DHHS         S, MPH       National][LOI/Pre-App], 25-Jul-2022         this Funding Opportunity Announcement (FOA) is to support interchanisms and interplay of biological, psychosocial, behaviora ntal health and co-occurring disorders in people living with HIV.         rds for Collaborative T1D       National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS         nam, Ph.D       il.nih.gov						
	Contact Telephone	301-594-7404							
	Contact Email	<u>hiroko.iida@nih.gov</u>							
	Sponsor Website								
	Program URL	Link to program URL							
	Deadline Dates (ALL)	25-Jun-2022 [Optional][LOI/Pre-App], 25-Ju	I-2022						
	Synopsis	The purpose of this Funding Opportunity Ar the underlying mechanisms and interplay of oral health, mental health and co-occurring	nouncement (FOA) is to support i f biological, psychosocial, behavior disorders in people living with HIV	nterdiscipli ral, and soc /.	nary research to better u ial structural factors con	inderstand tributing to			
107686	RFA-DK-21-030 New Investigato Research (R03 Clinical Trial Not A	or Gateway Awards for Collaborative T1D llowed)	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	RFA-DK- 21-030	01-May-2022 [Optional][LOI/Pre- App]	200,000 USD			
	Contact Name	Kristin M. Abraham, Ph.D							
	Contact Telephone	301-451-8048							
	Contact Email	abrahamk@mail.nih.gov							
	Sponsor Website								
	Program URL	Link to program URL							
	Deadline Dates (ALL)								



SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Synopsis	The New investigat research, pursue th programs opportun and to es the Gatew interested	Investigator Gateway Award in tors will continue to embark on a the Gateway program provides eir studies within the intellectua E. Embedding awardees within a ities for New andEarly Stage Inv tablish unique and potentially lo way award will providethe suppo d in pursuing careersin T1D rese	T1D Research is designed to ensure successful careers in T1D research. an opportunity for new Program D al environment of a select number of n established scientific framework i estigators to increase their underst ong-lasting collaborations that will p ort needed to enhancethe success of arch.	that a robust pi In addition to pr irectors/Principa of large, ongoing n each of these anding of key qu propel their care of futureR01 sub	peline of talented roviding support for al Investigators (PE g collaborative resu consortia will prov uestions in the fiel ers forward. It is a missions from New	new or preliminary D/PIs) to earch vide unique d, to network, nticipated that wInvestigators
101372	NIDDK High Risk Multi-Center Clir Clinical Trial Required)	nical Study	Cooperative Agreement (U01	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	PAR-21- 102 07	-May-2022	Not Specified
	Contact Name	Tracy Rar	ikin, Ph.D., M.P.H.				
	Contact Telephone	301-594-4	4748				
	Contact Email	rankint@	<u>mail.nih.gov</u>				
	Sponsor Website						
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	07-May-2 2023 , 05	2022 , 05-Jun-2022 , 07-Sep-2022 -Oct-2023 , 07-Jan-2024	2 , 05-Oct-2022 , 07-Jan-2023 , 05-F	eb-2023 <i>,</i> 07-Ma	ay-2023 , 05-Jun-2	023 , 07-Sep-
	This FOA invites applications for investigator-initiated, high-risk multi-center clinical trials involving more than one clinical center. Proposed trials should be hypothesis-driven, have the potential to change clinical practice and/or public health, ar focus on a disease relevant to the mission of NIDDK. Planning activities must be completed prior to submission and are no permitted under this FOA. Applicants who require a planning phase may first apply for an implementation planning cooperative agreement (U34; see PAR-21-101).Consultation with NIDDK Scientific/Research staff is strongly encouraged prior to the submission of either a U34 or U01 application.						
101373	NIDDK High Risk Multi-Center Clir Clinical Trial Not Allowed)	nical Study	Cooperative Agreement (U01	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	PAR-21- 103 07	-May-2022	Not Specified
	Contact Name	Tracy Rar	nkin, Ph.D., M.P.H.				
	Contact Telephone	301-594-4	4748				

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount		
	Contact Email	rankint@mail.nih.gov						
	Sponsor Website							
	Program URL	Link to program URL						
	Deadline Dates (ALL)	07-May-2022 , 05-Jun-2022 , 07-Sep-202 2023 , 05-Oct-2023 , 07-Jan-2024	2 , 05-Oct-2022 , 07-Jan-2023 , 05-Fe	eb-2023 , 07-Ma	ay-2023 , 05-Jun-2	023 , 07-Sep-		
	Synopsis	This FOA invites applications for investigated clinical center. Proposed studies should be Planning activities must be completed proplanning phase may first apply for an important with NIDDK Scientific/Research staff is started.	ator-initiated, high-risk multi-center be hypothesis-driven and focus on a ior to submission and are not permi plementation planning cooperative a rongly encouraged prior to the subn	observational s disease relevan tted under this greement (U34 hission of either	tudies involving m t to the mission of FOA. Applicants w ; see PAR-21-101) a U34 or U01 app	ore than one NIDDK. ho require a . Consultation lication.		
105892	Notice of Special Interest (NOSI): Dysfunction in People with Neuro	Advancing Research in Gastrointestinal developmental Disorders	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	NOT-DK- 21-024 07	'-May-2022	Not Specified		
	Contact Name	Terez Shea-Donohue, Ph.D.						
	Contact Telephone	301 825-2314						
	Contact Email	terez.shea-donohue@nih.gov						
	Sponsor Website							
	Program URL	Link to program URL						
	Deadline Dates (ALL)	07-May-2022 , 05-Jun-2022 , 07-Sep-202 2023 , 05-Oct-2023 , 07-Jan-2024 , 05-Fel	2 , 05-Oct-2022 , 07-Jan-2023 , 05-Fe b-2024 , 07-May-2024 , 05-Jun-2024	eb-2023 , 07-Ma , 07-Sep-2024	ay-2023 , 05-Jun-2	023 , 07-Sep-		
	The National Institute of Diabetes and Digestive and Kidney Diseases is issuing this Notice to highlight interest in receiving grant applications focused in the following area(s) to support basic, translational, and/or clinical research on the causes, diagnosis, prevention, or treatment of gastrointestinal dysfunction in people with neurodevelopmental disorders. Interdisciplinary science in this area plays a pivotal role and projects are encouraged to include close collaboration between scientists with expertise in neurodevelopmental disorders and scientists with expertise in neurodevelopmental disorders and scientists with expertise in neurogastroenterology.							
091518	Small R01s for Clinical Trials Targe (R01 Clinical Trial Required)	eting Diseases within the Mission of NIDDI	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	PAS-20- 160 07	'-May-2022	600,000 USD		

Contact Name Susan Mendley, M.D.

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Contact Talanhana	201 027	1961				
	Contact Telephone	501- 627-	1001				
		<u>susan.me</u>	<u>anuley@min.gov</u>				
		Link to pr	ingram LIDI				
			Ogram OKL	2 05 0ct 2022 07 log 2022 05 5	ah 2022 07 Ma		
	Deadline Dates (ALL)	U7-IVIAy-2	ling Opportunity Appounder	2,05-0ct-2022,07-Jan-2023,05-F	eD-2023,07-IVia	ay-2023 aliaiaal triala aarad	
Synopsis Synopsis Synopsis And Study conduct. Applications for clinical trials submitted under this FOA should have clearly described aims a objectives, and have a high likelihood that the trial findings will lead to more definitive, hypothesis-driven trials understanding, diagnosis, prevention or treatment of the diseases studied and have the potential to impact clin and/or public health. Preliminary data regarding intervention efficacy are not required.							
090534	Catalytic Tool and Technology Dev Hematologic Diseases (R21 Clinica	<u>velopment</u> Il Trial Not	<u>t in Kidney, Urologic, and</u> <u>t Allowed)</u>	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	PAR-20- 140 07	-May-2022	275,000 USD
	Contact Name	Daniel Go	ossett, Ph.D.				
	Contact Telephone	301-594-7	7723				
	Contact Email	daniel.go:	<u>ssett@nih.gov</u>				
	Sponsor Website						
	Program URL	<u>Link to pr</u>	ogram URL				
Deadline Dates (ALL) 07-May-2022 , 16-Jun-2022 , 07-Sep-2022 , 16-Oct-2022 , 07-Jan-2023 , 16-Feb-2023 , 07-May-2023							
	Synopsis	The purpo technoloရု	ose of this Funding Opportunity gies in the areas of kidney, urolo	<ul> <li>Announcement is to promote deve ogic, and hematologic diseases.</li> </ul>	lopment of inno	vative, enabling to	ools and
085472	Limited Competition: Small Grant Recipients (R03 Clinical Trial Optio	Program ( onal)	for NIDDK K01/K08/K23/K25	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	PAR-19- 365 07	-May-2022	150,000 USD

Contact Name Lisa M. Spain, Ph.D.

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		204 454 4	2074				
	Contact Telephone	301-451-9	9871 111 - 11 - 1				
		<u>Spaint@n</u>	<u>liddk.nin.gov</u>				
	Sponsor Website		1151				
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	07-May-2	022, 16-Jun-2022, 07-Sep-202				
	Synopsis	K01, K08, years of t K23, and I The R03 g existing d research t time with This progr	K23, and K25 recipients the oppheir K award. Through the use K25 award recipients to conduc grant mechanism supports differ ata; small, self-contained resea technology. The R03 is, therefor limited resources and that may ram will use the NIH Small Rese	portunity to apply for Small Grant (F of this mechanism, the NIDDK is see t research as they complete their tr rent types of projects, including pilo rch projects; development of resear re, intended to support research pro v provide preliminary data to support arch Grant (R03) award mechanism	Res application (03) support at king to enhance ansition to fully and feasibility ch methodolog ojects that can l rt a subsequent	some point during e the capability of i independent invest studies; secondary cy; and development be carried out in a s R01, or equivalent	the final two ts K01, K08, tigator status. analysis of t of new short period of application.
<u>R</u> 109856 <u>S</u> <u>C</u>	FA-DK-22-004 NIDDK Partners cientific Workforce Diversity and Clinical Trial Not Allowed)	hips with I I Promote	Professional Societies to Enhand Scientific Leadership (R25 -	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	RFA-DK- [C 22-004 A	1-May-2022 Optional][LOI/Pre- pp]	675,000 USD
	Contact Name	Katrina Se	errano, Ph.D.				
	Contact Telephone	301-480-7	7855				
	Contact Email	<u>katrina.se</u>	errano@nih.gov				
	Sponsor Website						
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	21-May-2	022 [Optional][LOI/Pre-App], 2	1-Jun-2022			
	Synopsis	The NIH R overarchi backgroun studies or activities profession junior fac	Research Education Program (R2 ng goal of this R25 program is to nds, including those from group careers in research To accomp with a primary focus on: Course nal societies supporting the NID ulty from diverse backgrounds,	25) supports research education act o support educational activities that is underrepresented in the biomedia olish the stated over-arching goal, th es for Skills Development Mentoring DK mission areas to develop education including those from groups underr	ivities in the mis : encourage ind cal and behavio his FOA will sup ; Activities This tional programs represented in l	ssion areas of the N ividuals from diver- ral sciences, to pur port creative educa R25 program encou aimed at recruitin piomedical, behavio	IIH. The se sue further itional urages g talented oral, clinical,

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		and socia recruitme scientific programs	l sciences research. Professiona Int plan that would enhance the workforce, including recruitmer and leadership.	l societies should propose an educa diversity of the the candidate pool of individuals from groups historic	tional progran for available <sub>l</sub> cally underrep	n that includes a div positions in the orga resented in the orga	ersity nization's anization's
101487	RFA-DK-20-032 Pilot and Feasib Self-Management Education and Clinical Trial Required)	ility Studie Support to	es to Facilitate the Use of Diabet Improve Diabetes Care (R34	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	RFA-DK- 20-032	22-May-2022 Optional][LOI/Pre- App]	600,000 USD
	Contact Name	Henry B. I	Burch, M.D				
	Contact Telephone	301-827-0	)827				
	Contact Email	<u>henry.bur</u>	<u>ch@nih.gov</u>				
	Sponsor Website						
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	22-May-2	022 [Optional][LOI/Pre-App], 22	2-Jun-2022 , 22-May-2023 [Optional	][LOI/Pre-App	), 22-Jun-2023	
	Synopsis	The purpo barriers to diabetes i with the p data in su	ose of this funding opportunity a o and facilitate greater use of di mellitus. Research applications s potential for dissemination. The pport of a future, full-scale trial	announcement (FOA) is to test an in abetes self-management education should engage key stakeholders in c pilot trial of the proposed strategy to study broader dissemination and	novative and and support ( ultivating a pr should be des I implementa	pragmatic approach DSMES) by people l actical and sustaina igned to generate p tion to expand the u	to address iving with ble strategy reliminary se of DSMES.
107664	High Impact, Interdisciplinary Scie Trial Optional)	ence in NIE	DDK Research Areas (RC2 Clinica	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	PAR-22- 069	)1-Jun-2022	Not Specified
	Contact Name	Norann Za	aghloul, Ph.D.				
	Contact Telephone	301-435-6	5677				
	Contact Email	norann.za	ighloul@nih.gov				
	Sponsor Website						
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	01-Jun-20	22 , 02-Nov-2022 , 01-Jun-2023	, 02-Nov-2023 , 30-May-2024 , 30-0	Oct-2024		

SPIN ID	ID Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Synopsis	The purpe foundatic FOA is en have a sig specific ke the area i diseases v	ose of the High Impact, Interdison on for new fields of investigation visioned to generate a research gnificant impact on the broader nowledge gaps, scientific opport n significant ways designed to a within the mission of the NIDDK	tiplinary Science grants program is t within the mission of NIDDK. The i resource and/or foster discovery-basic scientific community. This FOA seek cunities, new technologies, data ger ccelerate scientific progress in the u	to support high in interdisciplinary ased or hypothe as novel approac neration, or rese understanding, t	mpact ideas that r approach encoura sis-generating scie hes in areas that a arch methods tha reatment, and pre	may lay the aged by this ence that can address t will advance evention of
108051	<u>Stimulating Hematology Investiga</u> <u>Trial Not Allowed)</u>	ition: New	Endeavors (SHINE) (R01 Clinical	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	PAS-22- 096	-Jun-2022	Not Specified
	Contact Name	Shilpa Ha	ttangadi, M.D.				
	Contact Telephone	301-594-7	7726				
	Contact Email	<u>shilpam.h</u>	attangadi@nih.gov				
	Sponsor Website						
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL) Synopsis	05-Jun-20 The Stimu nonmalig Diseases initiated r invited to that are a and Contu	22 , 05-Oct-2022 , 05-Feb-2023 Ilating Hematology Investigation nant hematology research relev (NIDDK), National Institute of Ag research project grant application this program that supports grow t the leading edge of the field w racts and hyperlinked to this FO.	, 05-Jun-2023 , 05-Oct-2023 , 05-Fe n: New Endeavors (SHINE) program ant to the missions of the National ging (NIA), and the National Heart, L ons (R01s) in specific areas of basic a wth in the nonmalignant hematolog rill change over time and will be upo A.	b-2024, 05-Jun- is intended to p Institute of Diab ung, and Blood and early transla gy research dom dated regularly t	2024 , 05-Oct-202 romote innovativ etes and Digestive Institute (NHLBI). tional hematology ain. Specific emen hrough the NIH G	24 e, high-quality e and Kidney Investigator- research are rging topics uide to Grants
107685	<u>Stimulating Urology Interdisciplin</u> (R01 Clinical Trial Optional)	ary Team	Opportunity Research (SUITOR)	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	PAS-22- 05 <sup>.</sup> 074	-Jun-2022	Not Specified
	Contact Name	Julie Bart	hold, MD				
	Contact Telephone	301-594-9	9655				
	Contact Email	julia.bartl	nold@nih.gov				

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount			
	Sponsor Website									
	Program URL	<u>Link to pr</u>	ogram URL							
	Deadline Dates (ALL)	05-Jun-20 2025	5-Jun-2022 , 05-Oct-2022 , 05-Feb-2023 , 05-Jun-2023 , 05-Oct-2023 , 05-Feb-2024 , 05-Jun-2024 , 05-Oct-2024 , 05-Feb- )25							
The Stimulating Urology Interdisciplinary Team Opportunity Research (SUITOR) program is intended to promote innova high quality, interdisciplinary research relevant to the mission of the National Institute of Diabetes and Digestive and K Diseases (NIDDK). The NIDDK invites investigator-initiated research project grant applications (R01s) in specific areas of Synopsis basic, translational, or clinical research in specific benign urologic conditions and diseases where needs and opportunit progress are particularly timely. As such, research topics of interest will change over time to take advantage of emergin opportunities. The research topic area previously supported by the SUITOR program, urinary incontinence, will now transition to neurourology, as described below.										
084473	NIDDK Central Repositories Non- Not Allowed)	renewable	Sample Access (X01 Clinical Tri	Al National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	PAR-19- 319 28	-Jun-2022	Not Specified			
	Contact Name	Lisa M. Sp	bain, Ph.D							
	Contact Telephone	301-451-9	9871							
	Contact Email	SpainL@r	niddk.nih.gov							
	Sponsor Website									
	Program URL	Link to pr	ogram URL							
	Deadline Dates (ALL)	28-Jun-20	)22							
Synopsis Synopsis Automatic Synopsis Sy										
084593	RFA-ES-19-011 Mechanism for Environmental Health Sciences (F	Time-Sens 21 Clinical	itive Research Opportunities in   Trial Not Allowed)	National Institute of Environmental Health Sciences/NIH/DHHS	RFA-ES- 02 19-011	-May-2022	275,000 USD			
	Contact Name Contact Telephone	Martha I. 919-541-3	Barnes, MS 3335							

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount	
	Contact Email	barnes@r	niehs.nih.gov					
	Sponsor Website							
	Program URL	Link to pro	ogram URL					
	Deadline Dates (ALL)	02-May-2	022 , 01-Jun-2022 , 01-Jul-2022	, 01-Aug-2022 , 01-Sep-2022 , 03-0	)ct-2022			
	Synopsis	This fundi unpredict environm made disa feature of review/av achieved entire cyc	ing opportunity announcement able event or policy change pro- ental exposure data. The prima asters, emerging environmenta f an appropriate study is the ne ward cycle, for the research que by more frequent application d cle, from submission to award, i	(FOA) is intended to support novel ovides a limited window of opportu- iny motivation of the FOA is to under I public health threats, and policy cl ed for rapid review and funding, su estion to be addressed and swiftly in ue dates and expediting peer review s expected to be within 3-4 months	environmental l nity to collect hu rstand the conse nanges in the U. bstantially short mplemented. Th w, council concu	health research in uman biological sar equences of natura S. and abroad. A di er than the typical e shortened timefu urrence and award	which an nples or al and human- stinguishing NIH grant rame will be issuance. The	
108560	RFA-ES-22-002 Revolutionizing Research (RIVER) (R35 Clinical Tria	Innovative al Optional	e, Visionary Environmental Heal I)	National Institute of Environmental Health Sciences/NIH/DHHS	RFA-ES- 10 22-002 Aj	0-May-2022 0ptional][LOI/Pre- op]	6,000,000 USD	
	Contact Name	Jennifer B	8. Collins					
	Contact Telephone	984-287-3	3247					
	Contact Email	collins6@	niehs.nih.gov					
	Sponsor Website							
	Program URL	Link to pro	ogram URL					
	Deadline Dates (ALL)	10-May-2	022 [Optional][LOI/Pre-App], 0	9-Jun-2022				
	Synopsis	The NIEHS Revolutionizing Innovative, Visionary Environmental health Research (RIVER) program is intended to provide support for outstanding investigators in the Environmental Health Sciences, giving them intellectual and administrative freedom, as well as sustained support to pursue their research in novel directions in order to achieve greater impacts. The program seeks to identify individuals with a potential for continued innovative and impactful research and combine their existing investigator-initiated research into a single award to support the majority of their independent environmental health sciences research program.						

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
110095	Notice of Special Interest (NOSI): Training for COVID-19 Essential W	Promoting /orkers an	Health, Safety, and Recovery their Communities	National Institute of Environmental Health Sciences/NIH/DHHS	NOT-ES- 22-005	06-Jun-2022	400,000 USD
	Contact Name	Sharon D	Beard, MS				
	Contact Telephone	984-287-3	3237				
	Contact Email	beard1@	niehs.nih.gov				
	Sponsor Website						
	Program URL	<u>Link to pr</u>	ogram URL				
	Deadline Dates (ALL)	06-Jun-20	22				
	Synopsis	The purpo centers an average C	ose of this supplement is to pro nd community organizations sp OVID-19 transmission rates.	vide support for successful applican ecifically targeting under served and	ts to develop I disadvantage	partnerships with lo ed communities wit	ocal worker h higher than
102788	Transition to Independent Environ Award (K01 Clinical Trial Not Allow	<u>nmental H</u> wed)	ealth Research (TIEHR) Career	National Institute of Environmental Health Sciences/NIH/DHHS	PAR-21- 172	12-Jun-2022	375,000 USD
	Contact Name	Carol Shr	effler, PhD				
	Contact Telephone	984-287-3	3322				
	Contact Email	<u>shreffl1@</u>	niehs.nih.gov				
	Sponsor Website						
	Program URL	<u>Link to pr</u>	ogram URL				
	Deadline Dates (ALL)	12-Jun-20	22 , 12-Oct-2022 , 12-Feb-2023	3 , 12-Jun-2023 , 12-Oct-2023 , 12-Fe	eb-2024		
	Synopsis	The Trans for newly the caree funding ir applicants ancillary s by a ment investigat	ition to Independent Environm independent faculty who inter r development period the cand the environmental health scie s proposing research that does study to a clinical trial. Applicant for or co-mentor. Applicants pr or, should apply to the compar	ental Health (TIEHR) Career Award i ad to pursue research careers in env idates are expected to demonstrate nces. This Funding Opportunity Ann not involve leading an independent ts to this FOA are permitted to prop oposing a clinical trial or an ancillary nion FOA PAR-21-171. Applicants pro	s a 3-year bric ironmental he they can succ ouncement (F clinical trial, a ose a research study to an o oposing basic s	ge scholar develop alth sciences. At the ressfully compete fo OA) is designed spe clinical trial feasibi n experience in a cli ngoing clinical trial science experimenta	ment program e conclusion of or research ecifically for lity study, or an nical trial led as lead al studies

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount			
	invc app	olving humans, referred to in NOT-OD- ly to the companion FOA PAR-21-170)	18-212 as "prospective basic scienc	e studies involv	ving human partici	pants", should			
102785	Transition to Independent Environmen Award (K01 Independent Basic Experin	ntal Health Research (TIEHR) Career mental Studies with Humans Required	National Institute of Environmental Health Sciences/NIH/DHHS	PAR-21- 170 12	-Jun-2022	375,000 USD			
	Contact Name Card	ol Shreffler, PhD							
	Contact Telephone 984	-287-3322							
	Contact Email <u>shre</u>	effl1@niehs.nih.gov							
	Sponsor Website								
	Program URL Link	to program URL							
	Deadline Dates (ALL) 12-J	Jun-2022 , 12-Oct-2022 , 12-Feb-2023 ,	12-Jun-2023 , 12-Oct-2023 , 12-Fel	o-2024					
	The Transition to Independent Environmental Health (TIEHR) Career Award is a 3-year bridge scholar development prog for newly independent faculty who intend to pursue research careers in environmental health sciences. At the conclusion the career development period the candidates are expected to demonstrate they can successfully compete for research funding in the environmental health sciences. Note: This Parent Funding Opportunity Announcement is for basic science experimental studies involving humans, referred to inNOT-OD-18-212 as "prospective basic science studies involving hu synopsis participants." These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should submit under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes i humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Studies conducted with specific applications toward processes or products in mind shou								
102787	Transition to Independent Environmen Award (K01 Clinical Trial Required)	ntal Health Research (TIEHR) Career	National Institute of Environmental Health Sciences/NIH/DHHS	PAR-21- 171 12	-Jun-2022	375,000 USD			
	Contact Name Card	ol Shreffler, PhD							
	Contact Telephone 984	-287-3322							
	Contact Email shre	effl1@niehs.nih.gov							
	Sponsor Website								

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Program URI	Link to pr	ogram URI				
	Deadline Dates (ALL)	12-Jun-20	)22 . 12-Oct-2022 . 12-Feb-2023	. 12-lun-2023 . 12-Oct-2023 . 12-Fe	b-2024		
	Synopsis	The Trans for newly the caree funding ir applicant separate experime participar to gain re	sition to Independent Environm independent faculty who inten r development period the cand n the environmental health scie s proposing to serve as the lead ancillary clinical trial trial, as pa ntal studies involving humans, in nts", must apply to companion I search experience in a clinical t	ental Health (TIEHR) Career Award is id to pursue research careers in envi idates are expected to demonstrate nces. This Funding Opportunity Ann- investigator of an independent clin rt of their research and career devel referred to in NOT-OD-18-212 as "pr FOA, PAR-21-170. Applicants not pla rial led by another investigator, mus	s a 3-year bridge fronmental healt they can succes ouncement (FOA ical trial, a clinica opment. Applica ospective basic nning an indepe st apply to comp	e scholar developr th sciences. At the sfully compete for A) is designed spec al trial feasibility s ants proposing bas science studies in endent clinical tria anion FOA, PAR-2	nent program conclusion of r research cifically for tudy, or a sic science volving human l, or proposing 1-172.
108741	Notice of Special Interest (NOSI): I Outcomes in Infectious Disease M	Inclusion of Inclusion of Inclusion of Inclusion	of Economic Factors and tudies	National Institute of General Medical Sciences/NIH/DHHS	NOT-GM- 22-021 08-	-Apr-2022	Not Specified
	Contact Name	Veerasam	ıy (Ravi) Ravichandran, Ph.D.				
	Contact Telephone						
	Contact Email	<u>Veerasam</u>	ny.ravichandra@nih.gov				
	Sponsor Website						
	Program URL	<u>Link to pr</u>	ogram URL				
	Deadline Dates (ALL)	08-Apr-20 2022 , 03- Feb-2023 , 05-Oct-2 2024 , 07- 07-Jan-20	022 , 07-May-2022 , 17-May-202 -Oct-2022 , 05-Oct-2022 , 12-Oc , 25-Feb-2023 , 08-Apr-2023 , 0 2023 , 12-Oct-2023 , 25-Oct-202 -May-2024 , 05-Jun-2024 , 12-Ju 25	22 , 27-May-2022 , 05-Jun-2022 , 12 ct-2022 , 25-Oct-2022 , 08-Dec-2022 )7-May-2023 , 05-Jun-2023 , 12-Jun- 3 , 08-Dec-2023 , 07-Jan-2024 , 05-F un-2024 , 08-Aug-2024 , 07-Sep-2024	-Jun-2022 , 25-Ju , 07-Jan-2023 , 2 2023 , 25-Jun-20 eb-2024 , 12-Fe 4 , 05-Oct-2024 ,	un-2022 , 08-Aug- 27-Jan-2023 , 05-F 023 , 08-Aug-2023 b-2024 , 25-Feb-2 , 12-Oct-2024 , 08	2022 , 07-Sep- Feb-2023 , 12- , 07-Sep-2023 024 , 08-Apr- -Dec-2024 ,
	Synopsis	The Natio applicatic interested effects of	nal Institute of General Medica ons focused on infectious diseas d in mathematical and computa possible intervention strategie	l Sciences (NIGMS) is issuing this No e modeling research that incorporat tional modeling studies of infectious s, that include consideration of ecor	tice to highlight tes economic fac s disease spread nomic influences	interest in receivi ctors. The Institute and evolution, ar and feedback.	ng grant e is particularly nd of the
107585	NIGMS National and Regional Res	ources (R2	24 - Clinical Trial Not Allowed)	National Institute of General	PAR-22- 14	-Jun-2022	Not

Icahn School of Medicine at Mount Sinai Medical Sciences/NIH/DHHS

065

Specified

SPIN ID Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
Contact I	Name Christina	Liu, Ph.D., PE				
Contact Telep	hone					
Contact	Email <u>christina.</u>	liu@nih.gov				
Sponsor We	bsite					
Program	n URL <u>Link to pr</u>	rogram URL				
Deadline Dates	(ALL) 14-Jun-20	022 , 14-Jun-2023 , 14-Jun-2024				
Syn	This Fund state-of-t regional supporte consolida the speci other NIH best prac activities and stand	ding Opportunity Announcemen the-art equipment, technologies (multi-state) or national user ba d program areas are eligible for ation of existing local or regiona fic biomedical focus of their res H Institutes and Centers (ICs) or ctices, make its capabilities and a , and provide user training and s d-alone data resources and data	t (FOA) encourages applications for s, research tools, materials, organisr se. Only those resources with techn awards. The resources should alrea I facilities. The intent is to provide re earch, while not duplicating or repla host institutions. The resource is ex availability known to the biomedical support. The FOA does not support bases are not eligible.	support of resound ns, software, and ical capabilities f dy be establishe esource access to acing resources s pected to be ma research comm major new resea	urces that will pro d/or services to a that fall within the of or may be form o investigators wit supported by sour- intained or upgrad unity through out arch and developm	vide access to substantial PNIGMS- ed through hout regard to ces such as ded to current reach hent efforts
099764 Modules for Enhancing Bior Trial Not Allowed)	nedical Researc	h Workforce Training (R25 Clinic	cal National Institute of General Medical Sciences/NIH/DHHS	PAR-20- 296 20	-Jun-2022	250,000 USD
Contact I	Name Patrick H	. Brown, Ph.D.				
Contact Telep	hone					
Contact	Email <u>patrick.b</u>	rown@nih.gov				
Sponsor We	ebsite					
Progran	n URL <u>Link to pr</u>	rogram URL				
Deadline Dates	(ALL) 20-Jun-20	022 , 19-Jun-2023				
Syn	The NIH I overarch opsis workforc goal, this Specifica	Research Education Program (R2 ing goal of this R25 program is t te to meet the nation's biomedic FOA will support creative educa Ily, this FOA will support the dev	25) supports research education act o support educational activities that cal, behavioral and clinical research ational activities with a primary focu- velopment of training modules desi	ivities in the mis t complement ar needs. To accom is on: Curriculum gned to be freely	sion areas of the f nd/or enhance the nplish the stated o n or Methods Deve y available, at no o	VIH. The training of a ver-arching elopment cost to the

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount					
		broader community to enhance training Notices of Special Interest (NOSIs) releas	of the biomedical research workfor ed annually by NIGMS.	ce. Responsive t	opics will be indic	ated through					
109436	Notice of Special Interest (NOSI): Wellness, and Structural Racism a Environments	Training Modules to Address Resiliency and Discrimination in Research Training	nd National Institute of General Medical Sciences/NIH/DHHS	NOT-GM- 20 22-016	)-Jun-2022	Not Specified					
	Contact Name	Patrick H. Brown, Ph.D.									
	Contact Telephone										
	Contact Email	patrick.brown@nih.gov									
	Sponsor Website										
	Program URL	Link to program URL									
	Deadline Dates (ALL)	20-Jun-2022									
	Synopsis	The purpose of this Notice is to inform a opportunity announcement (FOA) PAR-2 Clinical Trial Not Allowed)".	oplicants of the topic areas for the J 0-296 "Modules for Enhancing Bion	une 20, 2022 du nedical Research	e date of the NIGI Workforce Traini	vIS funding ng (R25 -					
107450	Notice of Special Interest (NOSI): Psychopathology Data	Secondary Analysis of Posttraumatic	National Institute of Mental Health/NIH/DHHS	NOT-MH- 22-045	8-Apr-2022	Not Specified					
	Contact Name	Susan Borja, Ph.D.									
	Contact Telephone	310-443-1252									
	Contact Email	susan.borja@nih.gov									
	Sponsor Website										
	Program URL	Link to program URL									
	Deadline Dates (ALL)	08-Apr-2022, 15-Apr-2022, 07-May-202 2022, 12-Oct-2022, 16-Oct-2022, 25-Oc Feb-2023, 25-Feb-2023, 08-Apr-2023, 1 , 08-Aug-2023, 07-Sep-2023, 05-Oct-202 2024, 12-Feb-2024, 16-Feb-2024, 25-Fe	IK TO program UKL -Apr-2022, 15-Apr-2022, 07-May-2022, 05-Jun-2022, 12-Jun-2022, 16-Jun-2022, 25-Jun-2022, 07-Sep-2022, 05-Oct- 22, 12-Oct-2022, 16-Oct-2022, 25-Oct-2022, 08-Dec-2022, 15-Dec-2022, 07-Jan-2023, 05-Feb-2023, 12-Feb-2023, 16- b-2023, 25-Feb-2023, 08-Apr-2023, 14-Apr-2023, 07-May-2023, 05-Jun-2023, 12-Jun-2023, 16-Jun-2023, 25-Jun-2023 I8-Aug-2023, 07-Sep-2023, 05-Oct-2023, 12-Oct-2023, 16-Oct-2023, 25-Oct-2023, 15-Dec-2023, 07-Jan-2024, 05-Feb- 124, 12-Feb-2024, 16-Feb-2024, 25-Feb-2024, 07-May-2024, 05-Jun-2024, 12-Jun-2024, 16-Jun-2024, 07-Sep-2024								
	Synopsis	NIMH is issuing this Notice of Special Inte data to aid in refining phenotypes of pos	erest (NOSI) to highlight interest in r ttraumatic psychopathology(ies), m	esearch to analy arkers of onset a	yze existing and ac and change, and r	cumulating isk detection.					

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount			
		NIMH is a advance a therapeu	lso interested in research using and refine measurement and val tics research.	available data to identify potential idation of potential novel targets f	prevention and or future develo	treatment targets	and to ental			
108843	Notice of Special Interest (NOSI): and Violence Against Others	NIMH Pric	rities on Research on Aggressio	n National Institute of Mental Health/NIH/DHHS	NOT-MH- 22-095	3-Apr-2022	Not Specified			
	Contact Name Contact Telephone									
	Contact Emai	NIMHRes	earchOnAggres@mail.nih.gov							
	Sponsor Website	2								
	Program URI	Link to pr	ogram URL							
	Deadline Dates (ALL	08-Apr-2022, 07-May-2022, 24-May-2022, 05-Jun-2022, 12-Jun-2022, 15-Jun-2022, 16-Jun-2022, 22-Jun-2022, 2022, 08-Aug-2022, 07-Sep-2022, 05-Oct-2022, 12-Oct-2022, 14-Oct-2022, 16-Oct-2022, 25-Oct-2022, 15-Nov-2 Dec-2022, 07-Jan-2023, 05-Feb-2023, 12-Feb-2023, 16-Feb-2023, 22-Feb-2023, 25-Feb-2023, 08-Apr-2023, 07-Feb-2023, 07-Feb-2023, 07-Sep-2023, 05-Oct-2023, 16-Jun-2023, 25-Jun-2023, 08-Aug-2023, 07-Sep-2023, 05-Oct-2023, 25-Oct-2023, 25-Oct-2023, 20-Sep-2023, 07-Jan-2024, 05-Feb-2023, 25-Oct-2023, 15-Nov-2023, 15-Oct-2023, 16-Oct-2023, 25-Oct-2023, 15-Nov-2023, 08-Dec-2023, 07-Jan-2024, 05-Feb-2024, 05-Feb-2024, 16-Feb-2024, 08-Apr-2024, 07-May-2024, 05-Jun-2024, 12-Jun-2024, 16-Jun-2024, 08-Apr-2024, 08-Dec-2024, 07-Jan-2025, 07-Sep-2024, 05-Oct-2024, 16-Jun-2024, 08-Dec-2024, 07-Jan-2025, 07-Sep-2024, 05-Oct-2024, 16-Jun-2024, 08-Dec-2024, 07-Jan-2025, 07-Sep-2024, 05-Oct-2024, 08-Dec-2024, 08-Dec-2024, 07-Jan-2025, 07-Sep-2024, 05-Oct-2024, 07-Jan-2025, 07-Sep-2024, 07-Jan								
	Synopsis	preventic	ssuing this Notice of Special Inte on of interpersonal aggression ar	rest (NOSI) to outline priorities for nd violence against others.	research on the	etiology, risks for,	and			
102539	Notice of Special Interest (NOSI): on HIV Prevention, Treatment ar	Advancing	Health Communication Researc	h National Institute of Mental Health/NIH/DHHS	NOT-MH- 21-105	3-Apr-2022	Not Specified			
	Contact Name	Collene L	awhorn, Ph.D.							
	Contact Telephone	301-828-	7186							
	Contact Emai	collene.la	whorn@nih.gov							
	Sponsor Website	2								
	Program URI	Link to pr	ogram URL							
	Deadline Dates (ALL	08-Apr-20 2022 , 25 Feb-2023	022 , 07-May-2022 , 25-May-202 -Sep-2022 , 05-Oct-2022 , 12-Oc , 12-Feb-2023 , 16-Feb-2023 , 2	2 , 05-Jun-2022 , 12-Jun-2022 , 16 t-2022 , 16-Oct-2022 , 25-Oct-2022 5-Feb-2023 , 08-Apr-2023 , 07-May	-Jun-2022 , 25-Ju 2 , 08-Dec-2022 , γ-2023 , 25-May-	ın-2022 , 08-Aug-2 , 07-Jan-2023 , 25- -2023 , 05-Jun-202	022 , 07-Sep- Jan-2023 , 05- 3 , 12-Jun-			

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount					
	2023, 16-Jun-2023, 25-Jun-2023, 08-Aug-2023, 07-Sep-2023, 25-Sep-2023, 05-Oct-2023, 12-Oct-2023, 16-Oct-2023, 25-Oct-2023, 08-Dec-2023, 07-Jan-2024, 25-Jan-2024, 05-Feb-2024, 12-Feb-2024, 16-Feb-2024, 25-Feb-2024, 08-Apr-2024SynopsisThe National Institute of Mental Health is issuing this Notice to highlight interest in research applications to optimize health communication strategies that advance HIV prevention, treatment and cure.											
083168 <u>C</u>	linical Studies of Mental Illness (	Collaborat	vive R01 Clinical Trial Optional)	National Institute of Mental Health/NIH/DHHS	PAR-19- 297 0	7-May-2022	Not Specified					
	Contact Name	Anjené Ao	ddington									
	Contact Telephone	301-443-6	5653									
	Contact Email	anjene.ad	ldington@nih.gov									
	Sponsor Website											
	Program URL	Link to pr	ogram URL									
	Deadline Dates (ALL)	07-May-2	022 , 05-Jun-2022 , 07-Sep-202	2								
	Synopsis Syn											
104058 <u>N</u>	IIMH Exploratory/Developmenta Illowed)	l Research	<u>n Grant (R21 Clinical Trial Not</u>	National Institute of Mental Health/NIH/DHHS	PA-21- 235 0	7-May-2022	275,000 USD					
	Contact Name	Susan Koe	ester, Ph.D.									
	Contact Telephone	301-443-3	3563									
	Contact Email	koesters@	<u>စာmail.nih.gov</u>									
	Sponsor Website											
	Program URL	Link to pr	ogram URL									

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount		
	Deadline Dates (ALL)	07-May-2 2023 , 16-	022 , 16-Jun-2022 , 07-Sep-2022 Oct-2023 , 07-Jan-2024 , 16-Fel	2 , 16-Oct-2022 , 07-Jan-2023 , 16-F p-2024 , 07-May-2024	eb-2023 , 07-M	ay-2023 , 16-Jun-2	023 , 07-Sep-		
	Synopsis	The NIMH the NIMH considera models, o a major in	NIMH Exploratory/Developmental Grant program supports exploratory and high-risk research projects that fail within NIMH mission by providing support for the early and conceptual stages of these projects. These studies may involve isiderable risk but may lead to a breakthrough or to the development of novel techniques, agents, methods, measures, dels, or strategies, or to the generation of pilot or feasibility data. The preliminary work from these studies could lead to ajor impact on biomedical, behavioral, or clinical mental health research, or on the delivery of mental health care.						
102537	Notice of Special Interest (NOSI): F Low- and Middle-Income Countrie	Reducing S is and Low	Suicide Risk in Young People in r-Resource Settings	National Institute of Mental Health/NIH/DHHS	NOT-MH- 21-090 07	7-May-2022	Not Specified		
	Contact Name	Andrea H	orvath Marques, MD, MPH, PhD						
	Contact Telephone	301-646-7	7320						
	Contact Email	andrea.ho	orvathmarques@nih.gov						
	Sponsor Website								
	Program URL	Link to pro	ogram URL						
	Deadline Dates (ALL)	07-May-2 2023 , 07- Feb-2024	022 , 05-Jun-2022 , 16-Jun-2022 May-2023 , 05-Jun-2023 , 16-Ju , 07-May-2024	2 , 07-Sep-2022 , 05-Oct-2022 , 16-C n-2023 , 07-Sep-2023 , 05-Oct-2023	oct-2022 , 07-Jai 3 , 16-Oct-2023	n-2023 , 05-Feb-20 , 07-Jan-2024 , 05-	23 , 16-Feb- Feb-2024 , 16-		
	Synopsis	The Natio implemer and prom resources upper mic	nal Institute of Mental Health is ating prevention strategies to re ote resilience among young peo settings. NIMH welcomes appli ddle-income countries to partne	issuing this Notice of Special Intere duce suicide risk (suicide ideation a ople, age 10-24 years, in low-and m cants from LMICs and strongly enco r with sites in LMICs.	est (NOSI) to hig nd behavior, ind iddle-income co purages applicar	hlight interest in d cluding acts of self- ountries (LMICs)and nts from the United	eveloping and harm/suicide) I low- I States or		
103802	RFA-MH-21-175 BRAIN Initiative Tools to Probe Cell-Specific and Ci Clinical Trial Not Allowed)	:: Develop rcuit-Spec	ment and Validation of Novel ific Processes in the Brain (R01	National Institute of Mental Health/NIH/DHHS	RFA-MH- [C 21-175 Ap	B-May-2022 Optional][LOI/Pre- op]	Not Specified		
	Contact Name	Douglas S	. Kim, Ph.D.						
	Contact Telephone	301-827-6	5463						
	Contact Email	douglas.k	im@nih.gov						
	Sponsor Website								

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount			
	Program URL Link to Deadline Dates (ALL) 08-May The pureseard into ce and/or success to cells greater species approar encour	7-Jun-2022, 08-May-2023 [Optional gh Advancing Innovative Neurotech ovel tools to facilitate the detailed a ain function. The new tools and tech validating the utility of the tool/tech of new genetic and non-genetic too e expected to target specific cell type rently established methods are enco ose restricted to a single species are echnical barriers to substantially imp	][LOI/Pre-App], nologies® (BRAI nalysis of comp nologies should nology will be a ls for delivering es and/or circuit buraged. Tools t highly desired. A prove current ca	07-Jun-2023 N) Initiative is to e lex circuits and pro l inform and/or ex n essential feature genes, proteins ar s in the nervous sy hat can be used in Applications that p apabilities are high	ncourage ovide insights ploit cell-type of a nd chemicals ystem with a number of provide ly				
108512	RFA-MH-22-111 Scalable and Systemat Neurodevelopmental Disorder Risk Gene Centers (RM1 Clinical Trial Not Allowed)	c Neurobiology of Psychiatric and :: Assay and Data Generation	National Institute of Mental Health/NIH/DHHS	RFA-MH- [O 22-111 Ap	-May-2022 ptional][LOI/Pre- p]	Not Specified			
	Contact Name Alexan Contact Telephone 301-82 Contact Email alexan Sponsor Website Program URL Link to Deadline Dates (ALL) 11-May	ler Arguello, Ph.D. 7-3547 ler.arguello@nih.gov program URL ~2022 [Optional][LOI/Pre-App], 10 nding Opportunity Announcemen	0-Jun-2022 t (FOA) is one of two to establish the	e Scalable and S	vstematic Neurobi	ology of			
	This Funding Opportunity Announcement (FOA) is one of two to establish the Scalable and Systematic Neurobiology of Psychiatric and Neurodevelopmental Disorder Risk Genes (SSPsyGene) Consortium. The long-term goal of SSPsyGene is to systematically characterize phenotypes, across biological scales of organization (molecular, cellular, circuit, systems/organismal), for neurodevelopmental and psychiatric disorder (NPDs) risk genes. This resource will be made available for broad use by the biomedical community. The program will leverage scalable technologies to functionally characterize at ~100-250 null alleles from genes with an increased burden of loss-of-function mutations in NPDs. It will also optimize novel assays for cellular and physiological phenotypes, assess the scale limitations of such methods for allelic series of patient variants across large numbers of risk genes, and develop common data formats. This specific FOA seeks applications for Assay and Data Generation Centers (ADGC). The ADGCs will be responsible for developing and carrying out								

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		high-thro in the cer in collabo companio methods character and the D	ughput assays to characterize the ntral nervous system using releve pration with a central Data Reso on funding announcement, RFA and standards to create a harm ize the function of NPD risk gen PRACC to achieve the goals of the	he function of a set of NPD risk generant experimental systems (e.g., cell urce and Administrative Coordinatio -MH-22-110, to form the SSPsyGener onized cross-modality and cross-sp ues. ADGCs selected for funding will be SSPsyGene Consortium.	es, to be selecte lular, ex vivo, m on Center (DRA e Consortium. T ecies phenotyp collaborate clo	ed by the SSPsyGen odel organism). AD CC), as described ir he consortium will ic data set to syster sely with other fun	e Consortium, GCs will work the develop natically ded ADGCs
108509	RFA-MH-22-110 Scalable and S Neurodevelopmental Disorder Ri Coordination Center (U24 Clinica	ystematic sk Genes:     Trial Not /	Neurobiology of Psychiatric and Data Resource and Administrati Allowed)	National Institute of Mental Health/NIH/DHHS	RFA-MH- 1 22-110 A	1-May-2022 Optional][LOI/Pre- .pp]	Not Specified
	Contact Name	Alexande	r Arguello, Ph.D.				
	Contact Telephone	301-827-3	3547				
	Contact Emai	<u>alexande</u>	r.arguello@nih.gov				
	Sponsor Website						
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	11-May-2	022 [Optional][LOI/Pre-App], 1	0-Jun-2022			
	Synopsis	This Fund Psychiatri systemati systems/d available character optimize of patient applicatic a rigorous administr pipeline, Reuse (FA Centers (A SSPsyGen	ling Opportunity Announcemen ic and Neurodevelopmental Dis ically characterize phenotypes, organismal), for neurodevelopm for broad use by the biomedica ize ~100-250 null alleles from g novel assays for cellular and ph t variants across large numbers ons for a Data Resource and Adr s approach to prioritize NPD risl rative and logistical coordination and (4) building and maintainin AIR) principles. The DRACC will v ADGCs), as described in the com ne Consortium.	t (FOA) is one of two to establish th order Risk Genes (SSPsyGene) Cons across biological scales of organizat nental and psychiatric disorder (NPE I community. The program will leve enes with an increased burden of lo ysiological phenotypes, assess the s of risk genes, and develop common ninistrative Coordination Center (D k genes for functional characterization n among all funded groups in the co g a knowledge base that adheres to vork in a hub and spoke model in co npanion funding announcement RFA	e Scalable and ortium. The lon ion (molecular, Ds) risk genes. T grage scalable to oss-of-function cale limitations data formats. RACC) that will ion across the c onsortium, (3) e o Findability, Act ollaboration wit A-MH-22-111 to	Systematic Neurob og-term goal of SSPs cellular, circuit, his resource will be echnologies to func mutations in NPDs. of such methods for this specific FOA se be responsible for onsortium, (2) prov stablishing a data p cessibility, Interope h the Assay and Da o achieve the goals	ology of yGene is to made tionally It will also or allelic series eks (1) establishing riding rocessing rability, and ta Generation of the

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount				
092121	<u>RFA-MH-20-525 NIMH Biobeha</u> <u>Scientists (NIMH BRAINS) (R01 Cli</u>	vioral Reso inical Trial	earch Awards for Innovative Ne Optional)	w National Institute of Mental Health/NIH/DHHS	RFA-MH- 20-525	21-May-2022 [Optional][LOI/Pre- App]	2,500,000 USD				
	Contact Name	Eric R. Mu	urphy, Ph.D.								
	Contact Telephone	301-443-	9230 ?								
	Contact Email	eric.murp	ohy@nih.gov								
	Sponsor Website										
	Program URL	Link to pr	ogram URL								
	Deadline Dates (ALL)	21-May-2	2022 [Optional][LOI/Pre-App], 2	0-Jun-2022							
	Synopsis	and research career advancement of outstanding, exceptionally productive scientists who are in the early, formative star of their careers and who plan to make a long-term career commitment to research in specific mission areas of the NIMH Synopsis This award seeks to assist these individuals in launching an innovative clinical, translational, basic, or services research program that holds the potential to profoundly transform the understanding, diagnosis, treatment, or prevention of mer disorders. The NIMH BRAINS program will focus on the research priorities and gap areas identified in the NIMH Strategic Plan.									
106865	<u>RFA-MH-22-120 Pilot Practice-k</u> <u>Prevention (R34 Clinical Trial Opt</u>	<u>based Rese</u> ional)	earch for Primary Care Suicide	National Institute of Mental Health/NIH/DHHS	RFA-MH- 22-120	22-May-2022 [Optional][LOI/Pre- App]	450,000 USD				
	Contact Name	Stephen (	O'Connor, Ph.D.								
	Contact Telephone	301-480-	8366								
	Contact Email	stephen.c	o'connor2@nih.gov								
	Sponsor Website										
	Program URL	Link to pr	ogram URL								
	Deadline Dates (ALL)	22-May-2	2022 [Optional][LOI/Pre-App], 2	1-Jun-2022 , 22-Jan-2023 [Option	al][LOI/Pre-Ap	p], 21-Feb-2023					
Synopsis Synopsis Chick and the states of the state of th											

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount		
		intercept brief inte follow-up practice, patient h ready. NI [cell phor focused r administr encourag among in minoritie proposed	s in the chain-of-care, including rventions, promoting initial and o, and tracking patient outcome obstetrics/gynecology, internal ealth needs; proposed strategie MH encourages prevention app nes, tablets, etc.]) and other des esearch approaches that take in rators) and system-level factors es studies that examine suicide dividuals who experience ment s, individuals living in rural area strategies can reduce health d	strategies for identifying individual dongoing engagement in indicated s s. For purposes of this FOA, primary medicine, and geriatric practice. Pr es should meet the practice needs to proaches that incorporate the use of sign features that can facilitate scala nto account the perspectives of key such as setting resources, workford prevention strategies that have bro cal health service disparities (e.g., ra is, socioeconomically disadvantaged isparities and promote health equit	s at risk, asse services, cont care is defin imary care pr b be feasible, f mHealth (the ability and sus stakeholders ce capacity, ar bad reach, inc cial/ethnic m persons), an y.	ssing and stratifying ri inued outcome monit ed as pediatric practic actices range in size, r scalable, sustainable, e use of mobile and w stainability, and deplo (e.g., patients, provid nd training needs. This cluding potential for ac inority groups; sexual d studies that explore	sk, providing oring and e, family resources and and practice- ireless devices yment- lers, 5 FOA also ddressing risk and gender e how the		
107426 <u>F</u> 107426 F	RFA-MH-22-150 Using Just-in-7 Established Adolescent Mental H Required)	<u>Fime Adapt</u> lealth Trea	ive Interventions to Optimize tments (R61/R33 Clinical Trial	National Institute of Mental Health/NIH/DHHS	RFA-MH- 22-150	23-May-2022 [Optional][LOI/Pre- App]	Not Specified		
	Contact Name	Mary Roc	oney, Ph.D.						
	Contact Telephone	301-827-	1325						
	Contact Emai	l <u>mary.roo</u>	ney@nih.gov						
	Sponsor Website	2							
	Program URI	Link to pr	ogram URL						
	Deadline Dates (ALL	) 23-May-2	022 [Optional][LOI/Pre-App], 2	2-Jun-2022 , 23-Jan-2023 [Optional]	][LOI/Pre-App	o], 22-Feb-2023			
	NIMH seeks applications for pilot research to develop and test just-in-time adaptive intervention (JITAI) augmentations to enhance the effectiveness and clinical potency of established adolescent mental health treatments. An emphasis is placed on studies that are informed by developmental science and grounded in an empirical model of behavior change. Support wil be provided for up to two years (R61 phase) for milestone-driven testing, refinement, and/or validation of the intervention's impact on empirically supported, measurable target mechanisms and the possibility (contingent on meeting the R61 milestones) of up to 3 additional years of support (R33 phase) to replicate the target engagement findings in a larger sample and examine the relationship between the target mechanisms and clinical outcomes.								

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
082860	Building in vivo Preclinical Assays o Therapeutic Development (R01 Clir	f Circuit Engagement for Application in nical Trial Not Allowed)	National Institute of Mental Health/NIH/DHHS	PAR-19- 289	5-Jun-2022	Not Specified
	Contact Name L	ois Winsky, Ph.D.				
	Contact Telephone 3	801-443-5288				
	Contact Email <u>h</u>	winsky@mail.nih.gov				
	Sponsor Website					
	Program URL L	ink to program URL				
	Deadline Dates (ALL) 0	)5-Jun-2022				
	I b t n a t t t Synopsis ii v t ii v t ii F ii F ii	The overall goal of this Funding Opportu- behavioral measures for use as assays in o optimize and evaluate measures of ne- neural processes of clinical interest base assays thus developed from this FOA are he scientific value of preclinical animal herapeutic targets and treatment candi- objectives of the FOA will be accomplish mproving the efficiency and scientific va- vivophysiological and behavioral measur- herapeutic screening for mental illness in animals as a first step in generating tr animals to evaluation in humans. As suc- n future projects for coherence of assay FOA will support efforts to improve the incorporating measures proximal to neu	Inity Announcement (FOA) is to iden the early screening phase of treatme europhysiological and behavioral pro- ed on available knowledge of the new expected to build upon systems ne data contributing to a therapeutic de dates on neurobiological mechanisme ed by supporting basic and translati- alue of the therapeutic development res reflecting circuit engagement as treatment development. The efforts anslational assay measures that are h, this FOA may be considered a pre- performance between the preclinic tool kit of assays available for early p ral systems that impact mental heal	tify, in animals, nent developme presses that may irobiology of me urobiology and evelopment pip- ns of clinical rele onal neuroscien tools for early p supported by t adaptable across quel to build a s cal species and h obase testing of th.	In vivo neurophys nt. The FOA will su y serve as surrogat ental illnesses. The clinical neuroscier eline by assessing evance to mental i tists who are com vancing the discove hase target validat his initiative focus as early therapeuti suite of assays that healthy humans. In novel therapeutic	iological and apport efforts te markers of e screening the impact of linesses. The mitted to ery of in tion and on measures c screens in the evaluated summary, this agents by
	Utilizing Invasive Recording and Sti	mulating Opportunities in Humans to	National Institute of Mental	PAR-21-		Not

105700	Advance Neural Circuitry Understanding of Mental Health Disorders (R01 Clinical Trial Optional)	National Institute of Mental Health/NIH/DHHS	PAR-21- 289	05-Jun-2022	Not Specified

Contact Name David McMullen, M.D. Contact Telephone 301-451-0180 Contact Email <u>david.mcmullen@nih.gov</u>

Icahn School of Medicine at Mount Sinai

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Sponsor Website						
	Program URL	Link to pr	rogram URL				
	Deadline Dates (ALL)	05-Jun-20		3 , 05-Jun-2023 , 05-Oct-2023 , 05-Fe	b-2024 , 05-Jun	-2024	
Synopsis Synopsis the RO1 grant mechanism, encouraging longer-term projects, whereas its companion R21 FOA, PAR-21-288, se applications encouraging shorter, higher-risk studies.							
107489	Basic Neurodevelopmental Biolog Not Allowed)	y of Circu	its and Behavior (R01 Clinical Tr	ial National Institute of Mental Health/NIH/DHHS	PAR-22- 066	-Jun-2022	2,500,000 USD
	Contact Name	Andrew E	Breeden, Ph.D.				
	Contact Telephone	301-451-	3185				
	Contact Email	<u>neurode</u> v	velopmentpar@mail.nih.gov				
	Sponsor Website						
	Program URL	Link to pr	rogram URL				
	Deadline Dates (ALL)	05-Jun-20	022 , 05-Oct-2022 , 05-Feb-2023	3 , 05-Jun-2023 , 05-Oct-2023 , 05-Fe	b-2024 , 05-Jun	-2024 , 05-Oct-202	25
	Synopsis	This Func between to build a developn focus on animals. grant app	ling Opportunity Announcement the maturation of brain circuits foundation for understanding ment, allowing for the emergence neurodevelopmental trajectorie This FOA uses the R01 grant me plications.	It (FOA) encourages research project and behaviors across development how interactions within and among ce of cognitive, affective and social b es and investigate questions using in chanism, whereas its companion FO	s focused on th in rodents and brain regions ch ehaviors. To thi vivo neural me A, PAR-22-067,	e dynamic and me non-human prima ange over pre- an s end, projects sup asures in awake, b seeks shorter, hig	chanistic links tes. The goal is d post-natal oported will ehaving ner-risk R21
105881	Implementing and Sustaining Evic Resource Settings to Achieve Equi	lence-Bas ity in Outo	ed Mental Health Practices in Lo comes (R34 Clinical Trial Require	ow- National Institute of Mental ed ) Health/NIH/DHHS	PAR-21- 283	-Jun-2022	450,000 USD

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount		
	Contact NameDenise Pintello, Ph.D.Contact Telephone301-451-1481Contact Emaildenise.pintello@nih.govSponsor WebsiteProgram URLDeadline Dates (ALL)05-Jun-2022, 05-Oct-2022, 05-Feb-2023, 05-Jun-2023, 05-Oct-2023, 05-Feb-2024, 05-Jun-2024This Funding Opportunity Announcement (FOA) supports pilot work for subsequent studies testing the effective strategies to deliver evidence-based mental health services, treatment interventions, and/or preventive interve in low-resourced mental health specialty and non-specialty settings within the United States. The FOA targets set EBPs are not currently delivered or delivered with fidelity, such that there are disparities in mental health and re functional outcomes (e.g., employment, educational attainment, stable housing, integration in the community, nonvative approaches to remediate barriers to provision, receipt, and/or benefit from EBPs and generate new i about factors integral to achieving equity in mental health outcomes for underserved populations. Research ger 						veness of entions (EBPs) settings where related , treatment of d use information enerating new the needs of espond to		
108834	Behaviors (R01 Clinical Trial Optio	<u>inal)</u>	a Mechanisms Governing Comp	Health/NIH/DHHS	22-090 05-	-Jun-2022	Specified		
	Contact Name Contact Telephone	Michele F 301-435-0	Ferrante, Ph.D. 5782						
	Snonsor Website	michele.	en ante@hin.gov						
	Program URL	Link to pr	ogram URL						
	Deadline Dates (ALL)	(ALL) (A							

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount				
	Synopsis This Notice of Special Interest (NOSI) encourages projects to experimentally test mechanistic hypotheses on the role of neuro-glia activity coupling in modulating complex behaviors.										
097908	Cellular and Molecular Biology of Not Allowed)	Complex I	Brain Disorders (R01 Clinical Tria	I National Institute of Menta Health/NIH/DHHS	PAR-20- 263	05-Jun-2022	Not Specified				
	Contact Name	David Par	nchision								
	Contact Telephone	301-443-5288									
	Contact Email	panchisio	nd@mail.nih.gov								
	Sponsor Website										
	Program URL	Link to program URL									
	Deadline Dates (ALL)	05-Jun-20	022 , 05-Oct-2022 , 05-Feb-2023	23 , 05-Jun-2023							
This Funding Opportunity Announcement (FOA) encourages research on the biology of high confidence risk factors associated with complex brain disorders, with a focus on the intracellular, transcellular and circuit substrates of neural function. For the purposes of this FOA, the term "complex" can refer to a multifactorial contribution to risk (e.g., polygi and/or environmental) and/or highly distributed functional features of the brain disorder. Studies may be either hypot generating (unbiased discovery) or hypothesis-testing in design and may utilize in vivo, in situ or in vitro experimental paradigms, e.g., model organisms or human cell-based assays. While behavioral paradigms and outcome measures can incorporated into the research design to facilitate the characterization of intracellular, transcellular and circuit mechan Synopsis these are neither required nor expected. Studies should not attempt to "model" disorders but instead should aim to elucidate the neurobiological impact of individual or combined risk factor(s), such as the affected molecular and cellular components and processes. The resulting paradigms, component pathways and biological processes should be disseminated with sufficient detail to enrich common and/or federated data resources (e.g., those contributing to the Ontology, Synaptic Gene Ontology, FAIR Data Informatics) in order to bridge the gap between disease risk factors, biolo mechanism and therapeutic target identification. The present announcement (R01 activity code) can be used for applications to further develop lines of inquiry where feasibility or proof-of-concept has been established.											
105829	Initiation of a Mental Health Fam Access, Engagement and Coordin Children and Adolescents (R01 Cli	ily Navigat ation of No inical Trial	or Model to Promote Early eeded Mental Health Services fo Required)	National Institute of Menta Health/NIH/DHHS	PAR-21- 291	05-Jun-2022	2,500,000 USD				
	Contact Name Contact Telephone	Denise Pi 301-451-:	ntello, Ph.D., M.S.W. 1481								

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount			
	Contact Email	<u>dpintell@</u>	Omail.nih.gov							
	Sponsor Website									
	Program URL	Link to pr	ogram URL							
	Deadline Dates (ALL)	05-Jun-2022 , 05-Oct-2022 , 05-Feb-2023 , 05-Jun-2023 , 05-Oct-2023 , 05-Feb-2024 , 05-Jun-2024								
	Synopsis	effectiveness and implementation of family navigator models designed to promote early access, engagement, coordination and optimization of mental health treatment and services for children and adolescents who are experiencing early symptoms of mental health problems. For the purposes of this FOA, NIMH defines a family navigator model as a health care professional or paraprofessional whose role is to deploy a set of strategies designed to rapidly engage youth and families in needed treatment and services, work closely with the family and other involved treatment and service providers to optimize care, and through the use of technology – to monitor the trajectory of mental health symptoms and outcomes over time. Applicants are required to develop and test the navigator model's ability to promote early access, engagement, coordination and optimization of mental health treatment and services for children and adolescents as soon as symptoms are detected. Applicants are also required to identify and test components of navigator models that drive improvements in mental health care; detect and interrogate tailoring variables that optimize the 'personalized match' between the unique mental health needs of youth to the appropriate level of intensity and frequency of mental health services; and utilize emerging novel technologies to track and monitor the trajectory of clinical, functional and behavioral progress toward achieving intended services outcomes. This FOA is published in parallel to a companion R34 FOA, PAR-21-292 supporting pilot studies in preparation for the larger-scale studies described here.								
105794	Effectiveness of Implementing Sus Practices in Low-Resource Setting Fraditionally Underserved Populat	stainable s to Achie tions (R01	Evidence-Based Mental Health we Mental Health Equity for Clinical Trial Optional)	National Institute of Mental Health/NIH/DHHS	PAR-21- 284 05	-Jun-2022	Not Specified			
	Contact Name	Denise Pi	ntello, Ph.D.							
	Contact Telephone	301-451-	1481							
	Contact Email	<u>denise.pi</u>	<u>ntello@nih.gov</u>							
	Sponsor Website									
	Program URL	<u>Link to pr</u>	ogram URL							
Deadline Dates (ALL) 05-Jun-2022 , 05-Oct-2022 , 05-Feb-2023 , 05-Jun-2023 , 05-Oct-2023 , 05-Feb-2024 , 05-Jun-2024										
	This Funding Opportunity Announcement (FOA) encourages studies that develop and test the effectiveness of strategie implementation and sustainable delivery of evidence-based mental health treatments and services to improve mental									
SPIN ID	Program Title		Sponsor Name	Spc	onsor Number		Deadline Date	Funding Amount		
---------	--	--	--	--	---	---	--	---		
		outcomes innovative generate populatio including R34, PAR-	for underserved populations in e approaches to remediate barr new information about factors ns. Research generating new in due consideration of the needs 21-283, that supports pilot stu	n lov riers inte iforn s of i idies	w-resourced settings in the Unite to provision, receipt, and/or beingral to achieving equity in menta nation about factors causing/red ndividuals across the life span. T	ed States. Studi nefit from evid al health outco lucing disparitio his FOA is publ ale studies desc	es should identify ence-based practic mes for underserve es are strongly enc shed in parallel to ribed here.	and use tes (EBPs) and ed ouraged, a companion		
106066	Innovative Mental Health Services Clinical Trials Not Allowed)	<u>s Research</u>	Not Involving Clinical Trials (R0	<u>)1</u>	National Institute of Mental Health/NIH/DHHS	PAR-21- 316	-Jun-2022	Not Specified		
	Contact Name Contact Telephone Contact Email Sponsor Website Program URL	Michael C 301-443-3 michael.fr	C. Freed, Ph.D., EMT 3747 reed@nih.gov ogram URL							
	Deadline Dates (ALL)	05-Jun-20	22 , 05-Oct-2022 , 05-Feb-2023	3,05	5-Jun-2023 , 05-Oct-2023 , 05-Fe	b-2024 <i>,</i> 05-Jur	-2024			
	Synopsis	The purport support the individual level project described access, conservices, v tools, tech sets to un approache	ose of this Funding Opportunity ne delivery of high-quality, cont s with, or at risk for developing, ects that address NIMH strategi in Goal 4 of the NIMH Strategio ontinuity, utilization, quality, val which may serve as targets in fu nnologies, measures, or methoo derstand factors affecting menti- es; Wherever possible, leverage	y Anr tinuc ;, a n ic pr c Pla lue, uture ds ar tal h e exi	nouncement (FOA) is to encourage ously improving mental health see nental illness. This announcemer forities that strengthen the public an. Proposed research should see and outcomes, including disparit e service delivery intervention de nd statistical approaches to stud- nealth services outcomes using a sting infrastructure and partners	ge innovative r ervices to bene nt invites applic ic health impace ek to: Identify r cies in outcome evelopment; De y these issues; dvanced comp ships to accomp	esearch that will in fit the greatest nur ations for non-clin t of NIMH-support nutable factors tha s, or scalability of evelop and test new Integrate and anal utational and pred plish these goals.	form and mber of ical trial R01- ed research as it impact mental health w research yze large data ictive analytic		
103213	Effectiveness Trials for Post-Acute Longer-term Outcomes (R01 Clinic	e Intervent cal Trial Re	ions and Services to Optimize equired)		National Institute of Mental Health/NIH/DHHS	PAR-21- 210	i-Jun-2022	Not Specified		
	Contact Name Contact Telephone Contact Email	Adam Hai 301-435-3 <u>haima@n</u>	m, Ph.D. 3593 nail.nih.gov							

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount		
	Sponsor Wabrita	I							
	Program LIRI	Link to pr	ogram LIRI						
	Deadline Dates (ALL)	05-lun-20	0 <u>97411 0112</u> 122 05-0ct-2022 05-Feb-2023	8 05-lun-2023 05-Oct-2023 05-E	eh-2024				
	Synopsis	NIMH seeks applications for research projects to evaluate the effectiveness of therapeutic and service delivery interve for the post-acute management of mental health conditions affecting youth, adults, and older adults. This Funding Opportunity Announcement (FOA) encourages clinical trials to establish the effectiveness and test hypotheses regardin moderators, mediators, and mechanisms of action of post-acute phase therapeutic and services interventions that are matched to the stage of illness in terms of both their focus (e.g., consolidating and maintaining gains from initial treatr managing residual symptoms/impairment, preventing relapse, promoting adherence and appropriate service use) and intensity/burden for promoting optimal longer-term outcomes. This FOA is intended to support trials that are statistical powered to provide a definitive answer regarding the effectiveness of the post-acute phase intervention. Support for p effectiveness trials designed to evaluate the initial feasibility, tolerability, acceptability, safety and preliminary indication post-acute phase intervention approaches is provided via the R34, PAR-21-211.							
106895	Neuromodulation/Neurostimulat Applications (R01 Clinical Trial No	ion Device t Allowed	e Development for Mental Healt )	th National Institute of Mental Health/NIH/DHHS	PAR-22- 039	-Jun-2022	Not Specified		
	Contact Name	David Mo	Mullen, M.D.						
	Contact Telephone	301-451-	0180						
	Contact Email	david.mc	<u>mullen@nih.gov</u>						
	Sponsor Website								
	Program URL	Link to pr	ogram URL						
	Deadline Dates (ALL)	05-Jun-20	022 , 05-Oct-2022 , 05-Feb-2023	3 , 05-Jun-2023 , 05-Oct-2023 , 05-F	eb-2024 <i>,</i> 05-Jun	-2024 , 05-Oct-202	24		
	Synopsis	The purp generatic develop r effectiver Novel dev of increas capabiliti device. In Applicatio	ose of this funding opportunity on of brain stimulation devices f novel brain stimulation devices of ness of brain stimulation device vices should move beyond exist sed spatiotemporal precision as es should focus on significant en noremental changes to existing of ons should be submitted by mul	announcement (FOA) is to encoura or treating mental health disorders or 2) significantly enhance, by mear s that are currently U.S. Food and D ing electrical/magnetic stimulation well as multi-focal, closed-loop app nhancement of the spatial resolutio devices (e.g., software updates) are lti-disciplinary teams with diverse e	ge applications s . Applications are ns of hardware/s orug Administrati and develop nev proaches. Applica on, depth of deliv not within the se xpertise includin	eeking to develop e encouraged that oftware improven on (FDA)-approve v stimulation tech ations seeking to d ery, and/or precis cope of this annou g systems neuroso	the next will either 1) nents, the d or cleared. niques capable levelop new ion of the incement. cience,		

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount	
		engineering, clinical, and regulatory affairs. Applications submitting in response to this FOA should promote th development or significant enhancement of novel tools (hardware/software) for brain stimulation in humans. application should focus on the engineering development and bench top testing of the tool, animal and limited testing necessary to demonstrate initial proof of concept is allowable. Applications to this FOA are not expected hypothesis-driven, but should propose design-directed, developmental, or discovery-driven technology resear integrative approaches.						
106926	Neuromodulation/Neurostimulat Applications (R01 Clinical Trial No	<u>ion Device</u> t Allowed)	Development for Mental Health	n National Institute of Mental Health/NIH/DHHS	PAR-22- 039	-Jun-2022	Not Specified	
	Contact Name	David Mc	Mullen, M.D.					
	Contact Fmail	david mcr	mullen@nih.gov					
	Sponsor Website		<u>Indiene Ini.gov</u>					
	Program URL	Link to pro	ogram URL					
	Deadline Dates (ALL)	05-Jun-20	022 , 05-Oct-2022 , 05-Feb-2023	, 05-Jun-2023 , 05-Oct-2023 , 05-F	eb-2024 , 05-Jun	-2024 , 05-Oct-202	24	
The purpose of this funding opportunity announcement (FOA) is to encourage applications seeking to develo generation of brain stimulation devices for treating mental health disorders. Applications are encouraged that develop novel brain stimulation devices or 2) significantly enhance, by means of hardware/software improve effectiveness of brain stimulation devices that are currently U.S. Food and Drug Administration (FDA)-approv Novel devices should move beyond existing electrical/magnetic stimulation and develop new stimulation tec of increased spatiotemporal precision as well as multi-focal, closed-loop approaches. Applications seeking to capabilities should focus on significant enhancement of the spatial resolution, depth of delivery, and/or prec Synopsis device. Incremental changes to existing devices (e.g., software updates) are not within the scope of this anno Applications should be submitted by multi-disciplinary teams with diverse expertise including systems neuros engineering, clinical, and regulatory affairs. Applications submitting in response to this FOA should promote a development or significant enhancement of novel tools (hardware/software) for brain stimulation in humans application should focus on the engineering development and bench top testing of the tool, animal and limit testing necessary to demonstrate initial proof of concept is allowable. Applications to this FOA are not expec hypothesis-driven, but should propose design-directed, developmental, or discovery-driven technology reser- integrative approaches.							the next will either 1) nents, the d or cleared. niques capable levelop new ion of the incement. cience, ne Although the d human ed to be ch using	

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount		
106498	Mood and Psychosis Symptoms d Clinical Trial Optional)	uring the I	Menopause Transition (R01	National Institute of Mental Health/NIH/DHHS	PAR-22- 035	05-Jun-2022	Not Specified		
	Contact Name	Laura M.	Rowland, Ph.D.						
	Contact Telephone	301-480-8	3335						
	Contact Email	laura.row	land@nih.gov						
	Sponsor Website								
	Program URL	Link to pr	ogram URL						
	Deadline Dates (ALL)	05-Jun-20	022 , 05-Oct-2022 , 05-Feb-2023	3 , 05-Jun-2023 , 05-Oct-2023 , 05-Fe	eb-2024 , 05-J	lun-2024 <i>,</i> 05-Oct-20	24		
	Synopsis	The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications that will advance mech and translational research on the onset and worsening of mood and psychotic disorders during the menopausal tra (or perimenopause). In particular, NIMH seeks research that will advance understanding of the underlying neurobic and behavioral mechanisms of mood disruption and psychosis during the menopausal transition and that will ident targets for future mental health interventions or prevention efforts This FOA uses the R01 grant mechanism, while companion FOA (PAR-22-036) uses the R21 mechanism. Investigators proposing high risk/high reward projects, pro lack preliminary data, or studies that utilize existing data may wish to apply using the R21 mechanism.							
102908	Understanding and Modifying Ter Activity (R01 Clinical Trial Optiona	<u>mporal Dy</u> 1 <u>1)</u>	namics of Coordinated Neural	National Institute of Mental Health/NIH/DHHS	PAR-21- 175	05-Jun-2022	Not Specified		
	Contact Name	Andrew R	ossi, Ph.D.						
	Contact Telephone	301-443-2	1576						
	Contact Email	andrew.ro	ossi@nih.gov						
	Sponsor Website								
	Program URL	Link to pr	ogram URL						
	Deadline Dates (ALL)	05-Jun-20	022 , 05-Oct-2022 , 05-Feb-2023	، 05-Jun-2023 , 05-Oct-2023 , 05-Fe	eb-2024				
	Synopsis	A growing body of evidence suggests that optimal cognitive, affective, and social processes are associated with highly coordinated neural activity. These findings indicate that oscillatory rhythms, their co-modulation across frequency bands, spike-phase correlations, spike population dynamics, and other patterns might be useful drivers of therapeutic development for the treatment of cognitive, social, or affective symptoms in neuropsychiatric disorders. This Funding Opportunity Announcement (FOA) supports projects that test whether modifying electrophysiological patterns during behavior can							

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		improve of manipula paramete social pro levels affo systems-l improver systems-l patterns whereas	cognitive, affective, or social pro tions to address at least one, ar ers of neural coordination, wher ocessing; (2) in animals or huma ect the systems-level coordinati level electrophysiological chang nents in healthy persons or clini level aspects to understand the unfold across the brain to impac its companion FOA, PAR-21-176	ocessing. Applications must use exp and ideally more, of the following top a manipulated in isolation, improve ns, determine how particular abnor on of electrophysiological patterns es in behaving animals predict analo cal populations; and (4) use biologic function and mechanisms by which ct cognitive, affective, or social proc s, seeks shorter, higher-risk R21 gran	erimental design particular aspect malities at the g during behavior ogous electroph cally-realistic co oscillatory and essing. This FOA nt applications.	ns that incorporate Is or humans, dete ts of cognitive, aff enomic, molecular ; (3) determine wh ysiological and cog mputational mode other electrophysi uses the R01 grar	e active ermine which ective, or r, or cellular nether in vivo, initive els that include ological nt mechanism,
109334	RFA-RM-22-013 Somatic Mosai Program: Genome Characterizatio	cism acros	ss Human Tissues (SMaHT) s (UM1 Clinical Trial Not Allowed	National Institute of Mental <u>)</u> Health/NIH/DHHS	RFA-RM- 22-013	3-Jun-2022	Not Specified
	Contact Name	Amy C. Lo	ossie, Ph.D.				
	Contact Telephone	301-827-	6092				
	Contact Email	<u>SMaHT@</u>	mail.nih.gov				
	Sponsor Website						
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	08-Jun-2(	022 , 08-Jul-2022				
	Synopsis	This fund the Soma of new bi generatir from 150 compreh- initiative (https://c administe	ing opportunity announcement atic Mosaicism across Human Tis ology and disease mechanisms by state of the art, high through + donors. The GCCs will work clo ensive catalog of variants. This F (http://commonfund.nih.gov/) dpcpsi.nih.gov/). All NIH Institute ered by the National Institute of	invites applications to establish the ssues (SMaHT) Network. The purpo mediated by genomic variation in so put genomic data characterizing sor osely with the SMaHT Data Analysis Funding Opportunity Announcemen through the NIH Office of the NIH D es and Centers participate in Comm	e Genome Chara se of the SMaH <sup>T</sup> omatic tissues. T natic variants in Center to build t (FOA) is develo irector, Office o on Fund initiative e NIH.	cterization Centers T Network is to ena The GCCs will be re a set of 10-15 hur the framework for oped as a Commor f Strategic Coordin yes. The FOA will b	s (GCCs) for able discovery sponsible for nan tissues r a n Fund nation e
109327	RFA-RM-22-012 Somatic Mosai Program: Tissue Procurement Cer	cism acros nter (U24	ss Human Tissues (SMaHT) Clinical Trial Not Allowed)	National Institute of Mental Health/NIH/DHHS	RFA-RM- 22-012 08	3-Jun-2022	Not Specified
	Contact Name	Geetha S	enthil Ph D				

Contact Name Geetha Senthil, Ph.D.

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Contact Tolonhono	201 402 (	0754				
	Contact Telephone	301-402-0					
		SIVIAH I @	<u>maii.nin.gov</u>				
	Sponsor website	1 in the second					
	Program URL	LINK to pr					
	Deadline Dates (ALL)	08-Jun-20	J22 , 08-JUI-2022				
	Synopsis	Somatic N new biolo Center is tissues re Announce NIH Direc Fund initi	Mosaicism across Human Tissue ogy and disease mechanisms me to collect, process, store, and ra covered from a minimum of 15 ement (FOA) is developed as a C stor, Office of Strategic Coordina atives. The FOA will be adminis	s (SMaHT) Network. The purpose of ediated by genomic variation in soma apidly distribute to the Network at le 0 individuals recruited from a diverse Common Fund initiative (http://comr ation (https://dpcpsi.nih.gov/). All NI tered by the National Institute of Me	the SMaHT Network atic tissues. The ast 15 high qua e pool of donors monfund.nih.go H Institutes and ental Health (NIN	work is to enable goal of the Tissue lity, well characte s. This Funding Op v/) through the NI I Centers participa MH) on behalf of t	discovery of Procurement rized, human portunity H Office of the te in Common he NIH.
105330	NIMH Career Transition Award fo	r Tenure-T	Frack Intramural Investigators (H	<u>Antional Institute of Mental</u>	PAR-21-	-lun-2022	Not
105550	No Independent Clinical Trials)	_		Health/NIH/DHHS	239	5411 2022	Specified
	Contact Name	Ashlee Va	an't Veer, PhD				
	Contact Telephone	301-443-3	3107				
	Contact Email	<u>dnbbstrai</u>	iningbranch@mail.nih.gov				
	Sponsor Website						
	Program URL	<u>Link to pr</u>	ogram URL				
	Deadline Dates (ALL)	12-Jun-20	022 , 12-Oct-2022 , 12-Feb-2023	3 , 12-Jun-2023 , 12-Oct-2023 , 12-Fe	b-2024 , 12-Jun-	-2024	
	Synopsis	The prima abbreviat who aim the extrai fields. Thi not involv	ary goal of the NIMH Career Tra ed as the NIMH Career Transition to transition from the Division of mural community. Applicants s is Funding Opportunity Announ ve leading an independent clinic	nsition Award for Tenure-Track Intra on K22 Program) is to provide suppo of Intramural Research Programs (IRF hould have a demonstrated record o cement (FOA) is designed specifically cal trial, a clinical trial feasibility study	imural Investiga rt for career intr ?) to an indepen if meritorious re / for applicants   y, or an ancillary	tors (K22) Program ramural investigat ident research fac esearch in mental proposing researc y clinical trial.	n (hereafter ors at NIMH ulty position in health-related h that does
102818 <mark> </mark>	Mentored Career Transition Awar Required)	d for Intra	amural Fellows (K22 Clinical Tria	ls National Institute of Mental Health/NIH/DHHS	PA-21- 195 12-	-Jun-2022	Not Specified

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount				
	Contact Name Contact Telephone	Ashlee Van't Veer 301-443-3107								
	Contact Email	Inbbstrainingbranch@mail.nih.gov								
	Sponsor Website									
	Program URL	Link to program URL								
	Deadline Dates (ALL)	12-Jun-2022 , 12-Oct-2022 , 12-Feb-2023	, 12-Jun-2023 , 12-Oct-2023 , 12-Fe	b-2024						
	Synopsis	The Mentored Career Transition Award for NIMH Intramural Fellows (K22) is a two-phase, mentored career development award program that is intended to facilitate a timely transition of qualified postdoctoral fellows in the NIMH Division of Intramural Programs (DIRP) from intramural postdoctoral research positions to extramural, academic tenure-track or equivalent faculty positions at eligible U.S. institutions. Both the intramural and extramural phases will be mentored, and the award will provide research support during the extramural phase to help awardees launch competitive, independent research programs. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to ser as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial, a part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion FOA, PA-21-194.								
102817	Mentored Career Transition Awai Not Allowed)	rd for Intramural Fellows (K22 Clinical Trial	s National Institute of Mental Health/NIH/DHHS	PA-21- 194 12-	-Jun-2022	Not Specified				
	Contact Name	Ashlee Van't Veer								
	Contact Telephone	301-443-3107								
	Contact Email	dnbbstrainingbranch@mail.nih.gov								
	Sponsor Website									
	Program URL	Link to program URL								
	Deadline Dates (ALL)	12-Jun-2022 , 12-Oct-2022 , 12-Feb-2023	, 12-Jun-2023 , 12-Oct-2023 , 12-Fe	b-2024						
	Synopsis	The Mentored Career Transition Award for NIMH Intramural Fellows (K22) is a two-phase, mentored career development award program that is intended to facilitate a timely transition of qualified postdoctoral fellows in the NIMH Division of Intramural Programs (DIRP) from intramural postdoctoral research positions to extramural, academic tenure-track or equivalent faculty positions at eligible U.S. institutions. Both the intramural and extramural phases will be mentored, and the award will provide research support during the extramural phase to help awardees launch competitive, independent research programs. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research								

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		that does Applicant Applicant 21-195.	not involve leading an indepen s to this FOA are permitted to p s proposing a clinical trial or an	dent clinical trial, a clinical trial feas ropose research experience in a cli ancillary clinical trial as lead investi	sibility study, or nical trial led by gator should ap	an ancillary clinica a mentor or co-m ply to the compan	ll trial. entor. ion FOA, PA-
100747	RFA-MH-21-110 Service-Ready Treatment of Individuals at Risk fo	Tools for loor for loor suicide	dentification, Prevention, and (R01 Clinical Trial Optional)	National Institute of Mental Health/NIH/DHHS	RFA-MH- 21-110 15	5-Jun-2022	Not Specified
	Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL)	Stephen ( 301-480-8 stephen.c Link to pro	o connor, Pn.D. 3366 <u>ogram URL</u> 122				
	Synopsis	jects to evaluate the effectiveness itoring, and quality improvement er- es. Specifically, this initiative encou- developing and testing the effective ntion, and treatment of individuals ty, and sustained use of these tools eady accessible resources and pro- chnology and other design features focused approach that takes into a tors) and system-level factors, such s. This Funding Opportunity Annou- pols and technologies for suicide pro- study tool's effectiveness. Support y, safety, and preliminary indication wided via the R34 in RFA-MH-21-11 revention is provided via the R43/R	of service-ready fforts and ultima irages research of eness of optimiz at risk for suicid s, guided by an ir ducts that could that make the t ccount the persp n as workforce can ncement (FOA) if evention that art t for pilot effections of effectivene 1. Support for S 244 in RFA-MH-2	tools and technol ately improve the on the effectivene ed, service-ready e; and (2) testing be readily integrat ools scalable and bectives of key sta apacity that influe is intended to sup re statistically pow veness research to ss of service-ready BIR studies focuse 1-112.	logies that can availability of ss- suicide strategies to ence ted into robust against keholders nce potential port ered to o evaluate the y tools and ed on service-		

100751	RFA-MH-21-112 Service-Ready Tools for Identification, Prevention, and	National Institute of Mental	RFA-MH-	15-Jun-2022	Not
	Treatment of Individuals at Risk for Suicide (R43/R44 Clinical Trial Optional)	Health/NIH/DHHS	21-112		Specified

SPIN ID Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) Synopsis	Stephen O'Connor, Ph.D. 301-480-8366 stephen.o'connor2@nih.gov Link to program URL 15-Jun-2022 This SBIR Funding Opportunity Announce ready, commercially viable tools and tec training, quality monitoring, and quality suicide prevention services. Specifically, aimed at (1) developing and testing the oprevention, and treatment of individuals	ement (FOA) is intended to support hnologies for suicide prevention, ind improvement efforts and ultimately this initiative encourages research o effectiveness of optimized, service-r s at risk for suicide; and (2) testing st	small businesses cluding technolo, y improve the ava on the effectiven ready suicide pre trategies to impr	to develop and te gies that can be us ailability of eviden ess-implementatio vention tools for in ove adoption, imp	Amount est service- sed to advance ce-based on continuum dentification, lementation
Synopsis	fidelity, and sustained use of these tools ready accessible resources and products technology and other design features th deployment-focused approach that take administrators) and system-level factors workflows.	, guided by an implementation scier that could be readily integrated int at make the tools scalable and robu s into account the perspectives of k , such as workforce capacity that inf	nce framework. G o practice, NIMH st against impler ey stakeholders ( fluence potential	Given the focus on I encourages the un nentation drift, an (e.g., service users integration of too	practice- ise of d a , providers, ols into clinical
100749 RFA-MH-21-111 Service-Ready Treatment of Individuals at Risk for	Tools for Identification, Prevention, and or Suicide (R34 Clinical Trial Optional)	National Institute of Mental Health/NIH/DHHS	RFA-MH- 21-111 15	-Jun-2022	450,000 USD
Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) Synopsis	Stephen O'Connor, Ph.D. 301-480-8366 <u>stephen.o'connor2@nih.gov</u> <u>Link to program URL</u> 15-Jun-2022 NIMH seeks applications for pilot effective technologies that can be used to advance	veness projects to evaluate the prel e training, quality monitoring, and c	iminary effective	eness of service-rea	ady tools and timately

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		effectiver suicide pr strategies science fr into pract against in stakehold influence effectiver effectiver trials. Sup preventio technolog	ness-implementation continuur revention tools for identification s to improve adoption, impleme ramework. Given the focus on p tice, NIMH encourages the use mplementation drift, and a depl ders (e.g., service users, provide potential integration of tools in ness research to evaluate the fe ness of service-ready tools and oport for fully-powered, definition on is provided via the R01 in RFA gies or suicide prevention is provided	n aimed at (1) developing and testin n, prevention, and treatment of ind entation fidelity, and sustained use practice-ready accessible resources of technology and other design feat oyment-focused approach that take rs, administrators) and system-leven to clinical workflows. This Funding pasibility, tolerability, acceptability, technologies for suicide prevention ve effectiveness studies focused on A-MH-21-110. Support for SBIR stud wided via the R43/R44 in RFA-MH-2	ng the effectivene ividuals at risk fo of these tools, gu and products tha tures that make t es into account th el factors, such as Opportunity Anr safety and prelim and inform the co service-ready to lies focused on se 21-112.	ess of optimized, s r suicide; and (2) f ided by an impler t could be readily he tools scalable a ne perspectives of workforce capaci nouncement (FOA ninary indications design of definitive ols and technolog ervice-ready tools	Service-ready sesting nentation integrated and robust key ty that supports pilot of effectiveness gies or suicide and
102507	Pilot Effectiveness Trials for Treat R34 Clinical Trial Required)	<u>tment, Pre</u>	ventive and Services Intervention	ons National Institute of Mental Health/NIH/DHHS	PAR-21- 131 15	-Jun-2022	450,000 USD
	Contact Name	Joel Sher	rill, Ph.D.				
	Contact Telephone	301-443-	2477				
	Contact Email	jsherril@	<u>mail.nih.gov</u>				
	Sponsor Website	•					
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	15-Jun-2(	022 , 14-Oct-2022 , 15-Feb-2023	3 , 15-Jun-2023 , 17-Oct-2023 , 15-F	eb-2024		
NIMH solicits clinical trial applications through a series of Funding Opportunity Announcements (FOAs) that consistent vertices development pipeline, from first-inhuman, early testing of new interventions, confirmatory efficient through to effectiveness trials. The purpose of this FOA is to encourage pilot research consistent with NIMH's 1) effectiveness research on preventive and therapeutic interventions with previously demonstrated efficacy, broader target populations or for use in community practice settings, and 2) research on the development and testing of innovative services interventions. Consistent with the NIMH experimental therapeutics approach, the intervention engages the target(s)/mechanism(s) presumed to underlie the intervention effects (i.e., the research construction of the target in clinical/functional outcomes, changes in provider behavior, improved access or conservices, etc.). In this pilot effectiveness phase of research, NIMH places highest priority on intervention and services.							

SPIN ID Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount	
	approach FOA supp prelimina service de comparate Separate Effectives effectives (Collabor of the con	tes that can be justified in terms ports pilot studies and provides ary effectiveness of approaches elivery, and for obtaining the pr tive effectiveness study, pragma FOAs that utilize the R01 mecha ness of Treatment, Preventive, a ness trials (PAR-21-129;"Clinical ative R01 Clinical Trial Required mpanion FOAs.	s of their potential to substantially in resources for evaluating the feasibil to improve mental health/functiona reliminary data needed as a pre-requ atic trial). Support for fully-powered anism for single-site effectiveness tr and Services Interventions (R01).") a Trials to Test the Effectiveness of T I)"). Applicants pursuing other stage	mpact practice a lity, tolerability, a al outcomes, to r uisite to a larger d effectiveness si rials (PAR-21-130 and collaborative reatment, Preve s of the clinical t	nd public health. acceptability and modify risk factors -scale effectivenes tudies is provided 0; "Clinical Trials to e R01 mechanism ntion, and Service trial pipeline shou	This safety and s, or to improve ss trial (e.g., through o Test the for multi-site es Interventions Id consider one	
102505 Clinical Trials to Test the Effective Interventions (Collaborative R01	<u>eness of Tr</u> Clinical Tri	eatment, Preventive, and Servio al Required)	ces National Institute of Mental Health/NIH/DHHS	PAR-21- 15 129	-Jun-2022	Not Specified	
Contact Name	Joel Sher	rill, Ph.D.					
Contact Telephone	301-443-	2477					
Contact Emai	l <u>jsherril@</u>	mail.nih.gov					
Sponsor Website	2						
Program URI	Link to pr	ogram URL					
Deadline Dates (ALL	) 15-Jun-2(	022 , 14-Oct-2022 , 15-Feb-2023	3 , 15-Jun-2023 , 17-Oct-2023 , 15-Fe	eb-2024			
Synopsis	NIMH solicits clinical trial applications through a series of Funding Opportunity Announcements (FOAs) that cover the intervention development pipeline, from first-inhuman, early testing of new interventions, confirmatory efficacy trials, through to effectiveness trials. This FOA seeks to support clinical trials to establish the effectiveness of interventions and to test hypotheses regarding moderators, mediators, and mechanisms of action of these interventions. This FOA supports clinical trials designed to test the therapeutic value of treatment and preventive interventions for which there is already evidence of efficacy, for use in community and practice settings. Applications might include research to evaluate the effectiveness or increase the clinical impact of pharmacologic, somatic, psychosocial (e.g., psychotherapeutic, behavioral), device-based, rehabilitative and combination interventions to prevent or treat mental illness. This FOA also supports clinical trials to test patient-, provider-, organizational-, or systems-level services interventions to improve access, continuity, quality, equity, and/or value of services. The intervention research covered under this announcement is explicitly focused on practice-relevant questions. This FOA supports trials that require participation of two or more collaborative sites for completion of the study. Accordingly, the collaborating studies share a specific protocol across the sites and are organized as such in order to increase sample size, accelerate recruitment, or increase sample diversity and representation. Each site has						

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	its qu a s Pr cli pi	own Program Director/Principal Inve ality control, database management, ngle R01 grant is provided through a ventive, and Services Interventions ( ical trials to establish the effectivene eline should consider one of the com	stigator (PD/PI) and the program pro statistical analysis, and reporting. Su separate FOA, PAR-21-130, "Clinical R01)." This FOA is designed for applic ess of interventions. Applicants pursu panion FOAs.	vides a mechani pport for fully-p Trials to Test the cants seeking fur ing other stages	sm for cross-site c owered effectiven e Effectiveness of nding for multi-site of the clinical tria	oordination, ess studies via Treatment, e collaborative I
102506	Clinical Trials to Test the Effectivene Interventions (R01 Clinical Trial Requ	s of Treatment, Preventive, and Serv red)	ces National Institute of Mental Health/NIH/DHHS	PAR-21- 130	-Jun-2022	Not Specified
	Contact Name Jo Contact Telephone 30 Contact Email j <u>st</u> Sponsor Website	l Sherrill, Ph.D. L-443-2477 erril@mail.nih.gov				
	Program URL <u>Lir</u> Deadline Dates (ALL) 15	<u>k to program URL</u> Jun-2022 , 14-Oct-2022 , 15-Feb-202	3 , 15-Jun-2023 , 17-Oct-2023 , 15-Fe	eb-2024		
	NI int th te cli ev ef de Synopsis tri qu pr su re ac 12 FC Ap	AH solicits clinical trial applications the ervention development pipeline, from ough to effectiveness trials. This FOA t hypotheses regarding moderators, inical trials designed to test the therap dence of efficacy, for use in commune ectiveness or increase the clinical implice-based, rehabilitative and combin ls to test patient-, provider-, organized ality, equity, and/or value of services, ctice-relevant questions. This FOA ufficient scope to test effectiveness an unire participation of two or more collelerate recruitment, or increase sam O "Clinical Trials to Test the Effectiver A is designed for applicants seeking for policants pursuing other stages of the	nrough a series of Funding Opportuni n first-inhuman, early testing of new seeks to support clinical trials to est mediators, and mechanisms of action neutic value of treatment and preven ity and practice settings. Applications pact of pharmacologic, somatic, psych ation interventions to prevent or tre ational-, or systems-level services int The intervention research covered un uses the R01 grant mechanism to sup d examine mediators and moderator laborative sites for completion of the ple diversity and representation) is p mess of Treatment, Preventive, and Secunding for single-site clinical trials to clinical trial pipeline should consider	ity Announceme interventions, c ablish the effect of these interv tive interventior s might include r hosocial (e.g., ps at mental illness erventions to im under this annou port trials that a s of response. So e study (e.g., in c rovided through ervices Intervent establish the efformed one of the comp	nts (FOAs) that co onfirmatory effica iveness of interver entions. This FOA as for which there research to evalua cychotherapeutic, a. This FOA also su prove access, con incement is explici- ire adequately pow upport for multi-si order to increase s a separate FOA, F ions (Collaborative fectiveness of inte panion FOAs.	ver the cy trials, ntions and to supports is already te the behavioral), pports clinical tinuity, itly focused on wered and of te trials that ample size, PAR-21- e RO1)." This rventions.

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
102530	Early Stage Testing of Pharmacologic of Treatment of Mental Disorders (R61/	or Device-based Interventions for the R33 Clinical Trial Required)	National Institute of Mental Health/NIH/DHHS	PAR-21- 137 15	-Jun-2022	Not Specified
	Contact Name Mai	garet Grabb, Ph.D.				
	Contact Telephone 301	-443-3563				
	Contact Email mgr	abb@mail.nih.gov				
	Sponsor Website					
	Program URL Link	to program URL				
	Deadline Dates (ALL) 15-J	un-2022 , 14-Oct-2022 , 15-Feb-2023	3 , 15-Jun-2023 , 17-Oct-2023 , 15-Fe	eb-2024		
	inte thro with fund bipo Synopsis stag acti con biph ava one	rvention development pipeline, from bugh to effectiveness trials. The purper in novel mechanisms of action or devi- ctions in individuals with mental illne blar disorder). Early intervention stud ects (a prodromal phase) prior to ful- te testing of pharmacologic or device on of the intervention is adequately to trolled, dose-dependent neurophysic hasic high-risk applications. Support f lable in the companion R33, PAR-21- of the companion FOAs.	a first-in-human, early testing of new ose of this FOA is to support the ear ce-based interventions for the treat ss (e.g., schizophrenia, depression, a lies are also encouraged where symp I diagnostic criteria being met. Ultim -based interventions using a protoco cested, to provide meaningful inform ological/clinical/behavioral effect. T or a single phased award that does 136 . Applicants pursuing other stag	v interventions, ly stage testing of ment of sympto autism, obsessiv otoms of a disor nately, this FOA of design where nation where ta he R61/R33 FOA not need the de ges of the clinica	confirmatory effic of pharmacologic i ms or domains of e compulsive diso der have been ide is intended to sup the presumed me rget modulation yi As are intended to velopmental (R61) I trial pipeline sho	acy trials, interventions altered rder, anxiety, ntified in port early chanism of ields a well- support ) phase is uld consider
102508	Confirmatory Efficacy Clinical Trials of Mental Disorders (R01 Clinical Trial Re	Non-Pharmacological Interventions quired)	for National Institute of Mental Health/NIH/DHHS	PAR-21- 15 132	-Jun-2022	Not Specified
	Contact Name Ada	m Haim, Ph.D.				
	Contact Telephone 301	-435-3593				
	Contact Email <u>hair</u>	na@mail.nih.gov				
	Sponsor Website					
	Program URL Link	to program URL				
	Deadline Dates (ALL) 15-J	un-2022 , 14-Oct-2022 , 15-Feb-2023	3 , 15-Jun-2023 , 17-Oct-2023 , 15-Fe	eb-2024		

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount		
	Synopsis	NIMH sol intervent through t therapeu approach high scier dissemin interpers combinat previous efficacy s efficacy t mechanis efficacy t clinical tr	licits clinical trial applications the cion development pipeline, from to effectiveness trials. The purper tic and preventive interventions in. Under this FOA, trials must be ntific utility and will support "go ation of the intervention. Intervention onal, and device-based (both in tion thereof. Interventions appre- demonstration that the interven- signal, and must address an unmer hat includes measurement of the sm and change in functional or co- rial to determine the intervention ial pipeline should consider one	rough a series of Funding Opportun first-inhuman, early testing of new ose of this FOA is to support confirm a for mental disorders in adults and designed so that results, whether p /no-go" decisions about further der entions to be studied include, but a vasive/surgically implanted as well opriate for efficacy testing must be ntion engages and alters the hypoth bet therapeutic need. Support will b he hypothesized mechanism of action clinical effects. Ultimately, this FOA on's potential for significant clinical of the companion FOAs	ity Announceme natory efficacy to children throug positive or negat velopment, effect re not limited to as noninvasive/to based on a com nesized mechani re provided for a on and the relative is intended to su benefit. Applica	ents (FOAs) that co confirmatory effica esting of non-phar h an experimental cive, will provide in ctiveness testing, co behavioral, cogni cranscranial) appro pelling scientific ra sm of action, a pre trial of the interve onship between ch upport a sufficientl nts pursuing other	ver the cy trials, macological therapeutics formation of r tive, aches, or a tionale, liminary ention's hange in the y-powered stages of the		
102528	Early Stage Testing of Pharmacolo Freatment of Mental Disorders (F	ogic or Dev R33- Clinic	vice-based Interventions for the al Trial Required)	National Institute of Mental Health/NIH/DHHS	PAR-21- 136 15	-Jun-2022	Not Specified		
	Contact Name	Margaret	t Grabb, Ph.D.						
	Contact Telephone	301-443-	3563						
	Contact Email	mgrabb@	omail.nih.gov						
	Sponsor Website								
	Program URL	Link to pr	rogram URL						
	Deadline Dates (ALL)	15-Jun-20	022 , 14-Oct-2022 , 15-Feb-2023	3 , 15-Jun-2023 , 17-Oct-2023 , 15-F	eb-2024				
Deadline Dates (ALL) 15-Jun-2022 , 14-Oct-2022 , 15-Feb-2023 , 15-Jun-2023 , 17-Oct-2023 , 15-Feb-2024 NIMH solicits clinical trial applications through a series of Funding Opportunity Announcements (FOAs) that intervention development pipeline, from first-in human, early testing of new interventions, confirmatory eff through to effectiveness trials. The purpose of this FOA is to support the early stage testing of pharmacologi with novel mechanisms of action or device-based interventions, for the treatment of symptoms or domains functions in individuals with mental illness (e.g., schizophrenia, depression, autism, obsessive compulsive di bipolar disorder). Early intervention studies are also encouraged where symptoms of a disorder have been i subjects (a prodromal phase), prior to full diagnostic criteria being met. Ultimately, this FOA is intended to s stage testing of pharmacologic or device-based interventions using a protocol design where the presumed r									

SPIN ID	Program Title		Sponsor Name	Spo	onsor Number		Deadline Date	Funding Amount
		action of controlled are appro projects a	the intervention is adequately t d, dose-dependent neurophysio ppriate for this FOA. This R33 FO are encouraged to apply to the o	teste ologi OA su com	ed, to provide meaningful inform ical/clinical/behavioral effect. Pe upports single-phased clinical tria ipanion FOA, PAR-21-137or PAR-	nation where ta diatric, adult an al awards. Appl 21-133.	rget modulation y nd geriatric focuse icants proposing h	ields a well- d interventions iigh risk
102511	Development of Psychosocial The Mental Disorders (R33 Clinical Tri	rapeutic a al Require	<u>nd Preventive Interventions for</u> <u>d)</u>	<u>or</u>	National Institute of Mental Health/NIH/DHHS	PAR-21- 134	5-Jun-2022	Not Specified
	Contact Name Contact Telephone Contact Email Sponsor Website	Alexander 301-827-7 <u>alexander</u>	r Talkovsky, Ph.D. 7614 r <u>.talkovsky@nih.gov</u>					
	Program URL	Link to pr	ogram URL					
	Synopsis	NIMH soli interventi through t psychoso experime processes may inclu processes neurobiol delivery, p augmenta correspor to replica benefit. U scientific FOA is des pipeline s	icits clinical trial applications the ion development pipeline, from o effectiveness trials. The purpo cial intervention approaches in ntal therapeutics approach, this is underlying mental disorders in de, but are not limited to, pote is, neural circuits or neural activit logical mechanisms. Novel psych provided the target and/or the ations of efficacious interventio nding target) is expected to subs te previous target engagement litimately, trials must be design utility and will support "go/no-g signed for applicants seeking to hould consider one of the comp	hroug m firs pose of whi is FO nto p entia vity so chose inte ons fo bstan t finc ned s -go" o fun pani	gh a series of Funding Opportuni st-inhuman, early testing of new of this FOA is to encourage pilot ich the target and/or intervention OA is intended to speed the transi- promising novel psychosocial pre- illy modifiable behavioral, cogniti- ubserving specific behaviors or c ocial intervention strategies migler ervention strategy is novel. They no- for which there is an empirical rat- ntially enhance outcomes. Suppo- dings, and to relate change in the so that results, whether positive decisions about further development pilot stages of research. Applica- ion FOAs.	ty Announcemp interventions, of research devel n strategy is no lation of emerg eventative or the ive, affective ar ognitive process ht include in-per may also be stationale by which rt will be provide intervention the or negative, wi ment and/or te cants pursuing	ents (FOAs) that co confirmatory effica oping and testing i vel. Consistent wit gent research on m erapeutic interver nd/or interpersona cses, and/or other erson or technolog undalone intervent h the augmentatic ded for up to 3 yea arget/mechanism Il provide informat sting of the interve other stages of the	over the acy trials, nnovative th NIMH's techanisms and tions. Targets al factors or y-assisted ions or on (and ars for studies to clinical tion of high ention. This e clinical trial

SPIN ID	Program Title		Sponsor Name	Spc	onsor Number		Deadline Date	Funding Amount
102513	Development of Psychosocial Ther Mental Disorders (R61/R33 Clinical	apeutic a I Trial Rec	Ind Preventive Interventions for quired)	<u>or</u>	National Institute of Mental Health/NIH/DHHS	PAR-21- 135	5-Jun-2022	Not Specified
	Contact Name A	Alexande	r Talkovsky, Ph.D. 7614					
	Contact Email <u>a</u>	alexande	r.talkovsky@nih.gov					
	Program URL	<u>ink to pr</u>	ogram URL					
	Synopsis	NIMH sol ntervent chrough t osychoso experime processes may inclu processes may inclu	icits clinical trial applications th ion development pipeline, from o effectiveness trials. The purpe- cial intervention approaches in ntal therapeutics approach, this s underlying mental disorders in ide, but are not limited to, pote s, neural circuits or neural activi- logical mechanisms. Novel psyc is interventions for which there to substantially enhance outco e-driven testing of a novel interven- n, or maintenance (target engag ings that meet the "go/no-go" n n of target engagement and to utcomes. Ultimately, trials must cientific utility and will support '	hroug n firs pose of n which is FO into p ential vity su rchoso r is all omes rvent geme miles t test st be of clinic	gh a series of Funding Opportunit t-inhuman, early testing of new i of this FOA is to encourage pilot r ch the target and/or intervention A is intended to speed the transla promising novel psychosocial prev lly modifiable behavioral, cognitiv ubserving specific behaviors or co ocial interventions may be standa n empirical rationale by which the Support will be provided for up ion's impact on a target process of ent). Up to 3 years of additional su stones embedded in the R61 phas whether engaging the interventi designed so that results, whether no-go" decisions about further de cal trial pipeline should consider of	y Announcement nterventions, a research devel a strategy is no ation of emergy ventative or the ve, affective ar ognitive process alone intervent e augmentation to two years ( or mechanism upport (R33 ph on target/med r positive or ne evelopment ar one of the com	ents (FOAs) that co confirmatory effica oping and testing i vel. Consistent wit ent research on m erapeutic interven nd/or interpersona ses, and/or other cions or augmentat n (and correspond R61 phase) for pre associated mental hase) will be provide ase is intended to hanism mediates of gative, will provide d/or testing of the panion FOAs.	ver the cy trials, nnovative n NIMH's echanisms and tions. Targets l factors or ions to ing target) is iminary disorder risk, led for studies support the changes in e information intervention.
102509	First in Human and Early Stage Clin Devices for Psychiatric Disorders (L	ical Trial J01 Clinio	s of Novel Investigational Drugs cal Trial Required)	<u>s or</u>	National Institute of Mental Health/NIH/DHHS	PAR-21- 133	5-Jun-2022	Not Specified

Contact Name Margaret Grabb, Ph.D.

Contact Telephone 301-443-3563



SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Contact Email Sponsor Website Program URL Deadline Dates (ALL) NI int thi sta of an ex ps Synopsis (fu de of ps ap co ps su	grabb@mail.nih.gov hk to program URL 5-Jun-2022 , 14-Oct-2022 , 15-Feb-2023 MH solicits clinical trial applications thr tervention development pipeline, from rough to effectiveness trials. The purpo age clinical trials of novel mechanism of psychiatric disorders in areas of unmet id adult populations. First in human (FII- sposure), pharmacological effects, safety ychiatric disorders. Phase II/PoC studies unctional measures) and clinical indicato evices to evaluate target engagement, sa data to "de-risk" novel mechanism of a ychiatric disorders, and devices or coml propriate) for further clinical developm illaborative partnerships between the b ychiatric drug or device development. T pporting early stage clinical trials as out proding for clinical recoarch pot involving	, 15-Jun-2023 , 17-Oct-2023 , 15-Fel ough a series of Funding Opportunit first-inhuman, early testing of new i rese of this FOA is to encourage cooper faction investigational drugs or nover medical need. The FOA will support and Phase Ib studies of novel agen y, and tolerability to assess feasibilit s must evaluate the drug's impact of pors of effect. The FOA also supports afety, tolerability, and efficacy. The action investigational drugs, novel dr bination treatments in order to attra- nent as FDA-approved treatments. A iomedical researchers and biotechn This FOA is designed for applicants s tlined above. Applicants pursuing ot	b-2024 ty Announceme interventions, c erative agreeme el neuromodula t milestone-driv nts must assess ty for Phase II/p n clinically relev FIH and early fe overall objectiv rugs for use in p act private or of key aspect of t ology or indust eeking funding ther stages of th	nts (FOAs) that co onfirmatory effica ent applications to itory devices for th ren early stage tria target engagemen roof of concept (P vant physiological easibility studies (E e is to facilitate ra ediatric populatio ther public funding his FOA is the form ry researchers to f for cooperative ag e clinical trial pipe	ver the cy trials, support early the treatment ils in pediatric nt (brain foC) studies in systems EFS) of novel pid collection ns with g (when nation of facilitate greements eline or
105830	Pilot Studies to Test the Initiation of to Promote Early Access, Engagemer Health Services for Children and Ado	a Mental Health Family Navigator Mod nt and Coordination of Needed Mental plescents (R34 Clinical Trial Required)	el National Institute of Mental Health/NIH/DHHS	PAR-21- 292 16	-Jun-2022	450,000 USD
	Contact Name De Contact Telephone 30 Contact Email dp Sponsor Website Program URL Lir Deadline Dates (ALL) 16	enise Pintello, Ph.D., M.S.W. 01-451-1481 <u>pintell@mail.nih.gov</u> <u>nk to program URL</u> 6-Jun-2022 , 16-Oct-2022 , 16-Feb-2023	, 16-Jun-2023 , 16-Oct-2023 , 16-Fe	b-2024 , 16-Jun	-2024	

SPIN ID Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
Synopsis	The purpose of this Funding Opportunity test the effectiveness and implementation engagement, coordination and optimizal experiencing early symptoms of mental model as a health care professional or pryouth and families in needed treatment providers to optimize care, and through outcomes over time. Applicants are requirent engagement, coordination and optimizal symptoms are detected. Applicants are a improvements in mental health care; de between the unique mental health need services; and utilize emerging novel tech progress toward achieving intended services	y Announcement (FOA) is to encoura on of existing family navigator mode tion of mental health treatment and health problems. For the purposes of araprofessional whose role is to dep and services, work closely with the the use of technology – to monitor uired to develop and pilot test the na- tion of mental health treatment and also required to identify and pilot te tect and interrogate tailoring variab ls of youth to the appropriate level of mologies to track and monitor the tr vices outcomes. This FOA is published ism.	age research app els designed to p l services for chi of this FOA, NIMI loy a set of strat family and other the trajectory of avigator model's l services for chi st components of les that optimize of intensity and f rajectory of clinic d in parallel to a	plications to develop romote early acce Idren and adolesce H defines a family regies designed to involved treatme mental health syr ability to promote dren and adolesce of navigator model the 'personalized requency of ment cal, functional and companion R01 F	op and pilot ss, ents who are navigator rapidly engage nt and service nptoms and e early access, ents as soon as s that drive I match' al health behavioral OA, PAR-21-
103214 Pilot Effectiveness Trials for Post- Optimize Longer-term Outcomes	Acute Interventions and Services to (R34 Clinical Trial Required)	National Institute of Mental Health/NIH/DHHS	PAR-21- 211 16	-Jun-2022	450,000 USD
Contact Name	Adam Haim, Ph.D.				
Contact Telephone	301-435-3593				
Contact Email	haima@mail.nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	16-Jun-2022 , 16-Oct-2022 , 16-Feb-2023	3 , 16-Jun-2023 , 16-Oct-2023 , 16-Fe	eb-2024		
Synopsis	NIMH seeks applications for pilot project interventions for the post-acute manage of both their focus (e.g., consolidating an symptoms/impairment, preventing relap pilot phase of effectiveness research, the safety, and potential effectiveness of the target(s)/mechanisms(s) that is/are press a pre-requisite to a larger-scale effective	ts to evaluate the preliminary effect ement of mental health conditions the nd maintaining gains from initial trees ose, promoting adherence and appro- e trial should be designed to evaluate approach; to address whether the sumed to underlie the intervention e eness trial (e.g., comparative effective	iveness of thera nat are matched atment, managir opriate service u the feasibility, intervention eng offects; and to ob reness study, pra	peutic and service to the stage of illr ng residual se) and intensity/I tolerability, accep gages the otain preliminary c actical trial) design	delivery ness in terms ourden. In this otability, lata needed as ed to

SPIN ID	Program Title		Sponsor Name	Spo	onsor Number		Deadlin	e Date	Funding Amount
		definitely evaluate intervent effectiver	test the effectiveness of intervention the feasibility, tolerability, acception approaches and inform the construction studies focused on post-acc	enti ptal des ute	ions to improve post-acute outco bility, safety and preliminary ind ign of definitive effectiveness tri phase interventions is provided	omes. This F ications of e als. Support via the R01,	OA supports ffectiveness for fully-pov PAR-21-210.	pilot res of post-a vered, de	earch to cute phase finitive
108811	Innovative Pilot Mental Health Se (R34 Clinical Trial Not Allowed)	ervices Res	earch Not Involving Clinical Trial	<u>ls</u>	National Institute of Mental Health/NIH/DHHS	PAR-22- 082	16-Jun-202	2	450,000 USD
	Contact Name	Christine	M. Ulbricht, Ph.D.						
	Contact Telephone	301-480-0	6928						
	Contact Email	christine.	ulbricht@nih.gov						
	Sponsor Website								
	Program URL	Link to pr	ogram URL						
	Deadline Dates (ALL)	16-Jun-20 2025	022 , 16-Oct-2022 , 16-Feb-2023	8,1	6-Jun-2023 , 16-Oct-2023 , 16-Fe	eb-2024 , 16	-Jun-2024 , 1	6-Oct-20	24 , 16-Feb-
	Synopsis	The purper support t individual projects t describect access, co services, t tools, tec integratin computat accomplis	ose of this Funding Opportunity he delivery of high-quality, conti ls with, or at risk for developing, that address NIMH strategic prio d in Goal 4 of the NIMH Strategic pontinuity, utilization, quality, value which may serve as targets in fu hnologies, measures, or method and analyzing large data sets to tional and predictive analytic appoints sh these goals.	An cinu , a r oriti c Pla lue, itur ds a to u pro	nouncement (FOA) is to encoura ously improving mental health s mental illness. This announceme es to strengthen the public healt an. Proposed research should se and outcomes, including dispari e service delivery intervention d nd statistical approaches to stud understand factors affecting men paches; Wherever possible, lever	age innovative ervices to be ent invites ap th impact of ek to: Identi ities in outco evelopment dy these issu ntal health so age existing	ve pilot resea enefit the gre plications fo NIMH-suppo fy mutable fa omes, or scala ; Develop an es; Test the f ervices outco infrastructur	rch that patest nu r non-clir orted rese actors the ability of d test ne easibility mes usir e and pa	will inform and mber of nical trial pilot earch as at impact mental health w research v of ng advanced rtnerships to
107491	Basic Neurodevelopmental Biolog Not Allowed)	gy of Circui	its and Behavior (R21 Clinical Tri	ial	National Institute of Mental Health/NIH/DHHS	PAR-22- 067	16-Jun-202	2	275,000 USD
	Contact Name Contact Telephone	Andrew B 301-451-3	Breeden, Ph.D. 3185						

Contact Email neurodevelopmentpar@mail.nih.gov



SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount				
	Sponsor Website									
	Program URL	Link to program URL								
	Deadline Dates (ALL)	16-Jun-2022 , 16-Oct-2022 , 16-Feb-2023	, 16-Jun-2023 , 16-Oct-2023 , 16-Fe	eb-2024 , 16-Jun	-2024 , 16-Oct-20	25				
	Synopsis	etween the maturation of brain circuits and behaviors across development in rodents and non-human primates. The goal is build a foundation for understanding how interactions within and among brain regions change over pre- and post-natal evelopment, allowing for the emergence of cognitive, affective and social behaviors. To this end, projects supported will ocus on neurodevelopmental trajectories and investigate questions using in vivo neural measures in awake, behaving nimals. This FOA seeks shorter, higher-risk R21 grant applications, whereas its companion funding opportunity PAR-22- 66 seeks R01 grant applications.								
097912	Cellular and Molecular Biology of Not Allowed)	Complex Brain Disorders (R21 Clinical Tria	National Institute of Mental Health/NIH/DHHS	PAR-20- 264 16	5-Jun-2022	275,000 USD				
	Contact Name	David Panchision								
	Contact Telephone	301-443-5288								
	Contact Email	panchisiond@mail.nih.gov								
	Sponsor Website									
	Program URL	Link to program URL								
	Deadline Dates (ALL)	16-Jun-2022 , 16-Oct-2022 , 16-Feb-2023	, 16-Jun-2023							
	Synopsis	This Funding Opportunity Announcement associated with complex brain disorders, function. For the purposes of this FOA, the and/or environmental) and/or highly diste generating (unbiased discovery) or hypoth paradigms, e.g., model organisms or hum incorporated into the research design to f these are neither required nor expected. If elucidate the neurobiological impact of in components and their relationships within factors, components and processes. The r disseminated with sufficient detail to enri	(FOA) encourages research on the with a focus on the intracellular, tr e term "complex" can refer to a mu- ributed functional features of the b nesis-testing in design and may util an cell-based assays. While behavior facilitate the characterization of int Studies should not attempt to "mo dividual or combined risk factor(s), n defined biological process(es). Th esulting paradigms, component pa ch common and/or federated data	biology of high anscellular and ultifactorial cont orain disorder. Si ize in vivo, in sit oral paradigms a cracellular, trans del" disorders b , such as the affe is can include th thways and biol oresources (e.g.,	confidence risk fa circuit substrates of tribution to risk (e. tudies may be eith au, or in vitro expe and outcome meas cellular and circuit out instead should ected molecular and he fundamental bi logical processes s , those contributin	ctors of neural .g., polygenic ier hypothesis- rimental sures can be t mechanisms, aim to nd cellular ology of these should be ng to the Gene				

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		Ontology, mechanis applicatic no prelim	Synaptic Gene Ontology, FAIR m and therapeutic target ident ns to develop early stage, high- inary data.	Data Informatics) in order to bridge ification. The present announceme risk, exploratory approaches or est	e the gap betwe nt (R21 activity ablish proof-of-	een disease risk fac code) can be used concept where the	tors, biological for ere is little or
102910	Understanding and Modifying Te Activity (R21 Clinical Trial Option	mporal Dy al)	namics of Coordinated Neural	National Institute of Mental Health/NIH/DHHS	PAR-21- 176 1	6-Jun-2022	275,000 USD
	Contact Name Contact Telephone Contact Email Sponsor Website	Andrew R 301-443-: andrew.re	ossi, Ph.D. 1576 <u>ossi@nih.gov</u>				
	Program URL	<u>Link to pr</u>	ogram URL				
	Deadline Dates (ALL)	16-Jun-20	22 , 16-Oct-2022 , 16-Feb-2023	3 , 16-Jun-2023 , 16-Oct-2023 , 16-F	eb-2024		
	Synopsis	A growing coordinat spike-pha for treatn Announce improve of manipula paramete social pro levels affe systems-l improven systems-l patterns of mechanis an establi	g body of evidence suggests that ed neural activity. These finding se correlations, spike population nent of cognitive, social, or affe ement (FOA) supports projects to cognitive, affective, or social pro- tions to address at least one, ar rs of neural coordination, where cessing; (2) in animals or huma exit the systems-level coordination evel electrophysiological chang nents in healthy persons or clini- evel aspects to understand the unfold across the brain to impa- m, whereas its companion FOA shed premise.	It optimal cognitive, affective, and s gs indicate that oscillatory rhythms on dynamics, and other patterns mi- ctive symptoms in neuropsychiatric that test whether modifying electro ocessing. Applications must use exp nd ideally more, of the following top n manipulated in isolation, improve ns, determine how particular abno- on of electrophysiological patterns es in behaving animals predict anal ical populations; and (4) use biologi function and mechanisms by which ct cognitive, affective, or social pro- , PAR-21-175, seeks R01 grant appl	social processes , their co-modu ght be useful dr c disorders. This ophysiological p perimental desig pics: (1) in anime particular aspe rmalities at the during behavior ogous electroph ically-realistic con cessing. This FO ications for larg	are associated wit lation across frequ ivers of therapeuti Funding Opportur atterns during beh gns that incorporat als or humans, det ects of cognitive, af genomic, molecula or; (3) determine w hysiological and co omputational mode other electrophys A uses the R21 exp ger research applica	h highly ency bands, c development hity avior can e active ermine which fective, or fective, or fectiv

100000	Neuromodulation/Neurostimulation Device Development for Mental Health	National Institute of Mental	PAR-22-	16 100 2022	275,000
106896	Applications (R21 Clinical Trial Not Allowed)	Health/NIH/DHHS	038	16-Jun-2022	USD

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Contact Name Contact Telephone Sponsor Website Program URL Deadline Dates (ALL) Synopsis Synopsis F	David Mcl 301-451-0 david.mcr Link to pro 16-Jun-20 The purpo generatio develop n effectiven Novel dev of increas capabilitie device. In Applicatic engineerin or signific should for necessary driven, bu approach of this FO funding o	Mullen, M.D. D180 <u>mullen@nih.gov</u> <u>ogram URL</u> D22 , 16-Oct-2022 , 16-Feb-2023 D22 , 16-Oct-2022 , 16-Feb-2023 D22 , 16-Oct-2022 , 16-Feb-2023 D22 , 16-Oct-2022 , 16-Feb-2023 D23 D34 D34 D34 D34 D34 D34 D34 D34 D34 D3	, 16-Jun-2023 , 16-Oct-2023 , 16-Fe announcement (FOA) is to encourag or treating mental health disorders. or 2) significantly enhance, by means that are currently U.S. Food and Dr ing electrical/magnetic stimulation a well as multi-focal, closed-loop app nhancement of the spatial resolution levices (e.g., software updates) are r ti-disciplinary teams with diverse ex rs. Applications submitted in respon s (hardware/software) for brain stim ment and bench top testing of the to concept is allowable. Applications t ed, developmental, or discovery-driv idy scientific or clinical hypotheses t mechanism, encouraging shorter, hi R01 grant applications.	b-2024 , 16-Jun- e applications s Applications are s of hardware/se rug Administrati and develop new roaches. Applica n, depth of deliv not within the se pertise including se to this FOA s nulation in huma ool, animals and o this FOA are n ven technology hat simply utiliz gher-risk applica	-2024 , 16-Oct-202 eeking to develop e sought that will e oftware improver on (FDA)-approve v stimulation tech ations seeking to d ery, and/or precis cope of this annou g systems neurosc hould promote the ans. Although the ans. Although the ot expected to be research using inte e devices are outs ations, whereas its	24 the next either 1) nents, the d or cleared. niques capable evelop new ion of the incement. ience, e development application esting hypothesis- egrative ide the scope s companion
106499	Mood and Psychosis Symptoms du Clinical Trial Optional)	iring the M	Menopause Transition (R21	National Institute of Mental Health/NIH/DHHS	PAR-22- 036	-Jun-2022	275,000 USD
	Contact Name L Contact Telephone 3 Contact Email <u>I</u> Sponsor Website Program URL <u>L</u>	Laura M.   301-480-8  aura.row Link to pre	Rowland, Ph.D. 3335 <u>land@nih.gov</u> ogram URL				

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Deadline Dates (ALL) 1 T a (c Synopsis F p p	6-Jun-2022, 16-Oct-2022, 16-Feb-2023 The purpose of this Funding Opportunity nd translational research on the onset a or perimenopause). In particular, NIMH nd behavioral mechanisms of mood dis argets for future mental health interver OA (PAR-22-035) uses the R01 grant me oreliminary data, or studies that utilize e oreliminary data who seek longer-term f	3, 16-Jun-2023, 16-Oct-2023, 16-Fe Announcement (FOA) is to encoura and worsening of mood and psychot seeks research that will advance un ruption and psychosis during the me ntions or prevention efforts. This FOA echanism. Investigators proposing his existing data may wish to apply using funding may wish to apply using the	b-2024 , 16-Jun ge applications ic disorders duri derstanding of t enopausal transi A uses the R21 n gh risk/high rew the R21 mecha R01 mechanism	-2024 , 16-Oct-202 that will advance in ing the menopausa he underlying neu tion and that will in nechanism, while t vard projects, proje nism, while applic	24 mechanistic al transition robiological dentify novel che companior ects that lack ants with
105701	Utilizing Invasive Recording and Stir Advance Neural Circuitry Understar Clinical Trial Optional)	mulating Opportunities in Humans to nding of Mental Health Disorders (R21	National Institute of Mental Health/NIH/DHHS	PAR-21- 288 16	-Jun-2022	275,000 USD
	Contact Name D Contact Telephone 3 Contact Email d Sponsor Website Program URL Li Deadline Dates (ALL) 1 T re ir fu Synopsis ki to th u	David McMullen, M.D. 201-451-0180 201-451-	3, 16-Jun-2023, 16-Oct-2023, 16-Fe y Announcement (FOA) is to encoura alth-relevant questions. Invasive neu ral circuitry and neural dynamics und al and temporal resolution. Additiona by modulating network dynamics. T inted to mental health disorders. Rese ye high translational potential. Devel tools/methods to enable relevant me ging shorter, higher-risk applications	b-2024 , 16-Jun ge applications ral recordings p derlying comple ally, the ability t his FOA aims to earchers should opment of new ental health stud , whereas its co	-2024 to pursue invasive rovide an unparall x moods, emotion o stimulate, via th target a gap in the target specific que therapies is outsic dies is encouraged mpanion funding	e neural eled window s, cognitive e same e scientific estions suited le the scope of . This FOA
106927	Neuromodulation/Neurostimulation	n Device Development for Mental Heal	th National Institute of Mental Health/NIH/DHHS	PAR-22- 038 16	-Jun-2022	275,000 USD



SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) 16 Th ge de eff No of ca de Synopsis Ap en or sh ne of fut	avid McMullen, M.D. 01-451-0180 avid.mcmullen@nih.gov hk to program URL 6-Jun-2022 , 16-Oct-2022 , 16-Feb-2023 the purpose of this funding opportunity a eneration of brain stimulation devices of evelop novel brain stimulation devices of fectiveness of brain stimulation devices ovel devices should move beyond existing increased spatiotemporal precision as of pabilities should focus on significant en evice. Incremental changes to existing d oplications should be submitted by mult agineering, clinical, and regulatory affair significant enhancement of novel tools ould focus on the engineering developre ecessary to demonstrate initial proof of iven, but should propose design-directed proaches. Applications that seek to stu this FOA. This FOA uses the R21 grant r nding opportunity, PAR-22-039, seeks R	, 16-Jun-2023 , 16-Oct-2023 , 16-Fe announcement (FOA) is to encourag or treating mental health disorders. or 2) significantly enhance, by means that are currently U.S. Food and Dr ng electrical/magnetic stimulation a well as multi-focal, closed-loop appr hancement of the spatial resolutior evices (e.g., software updates) are r ci-disciplinary teams with diverse ex rs. Applications submitted in respon 6 (hardware/software) for brain stim ment and bench top testing of the to concept is allowable. Applications t ed, developmental, or discovery-driv dy scientific or clinical hypotheses t mechanism, encouraging shorter, hi R01 grant applications.	b-2024 , 16-Jun- e applications so Applications are s of hardware/so rug Administrati and develop new roaches. Applica not within the so pertise including se to this FOA si pulation in huma bol, animals and o this FOA are n yen technology in hat simply utiliza	2024 , 16-Oct-202 eeking to develop e sought that will e oftware improver on (FDA)-approve v stimulation techn itions seeking to d ery, and/or precis cope of this annou g systems neurosc hould promote the ins. Although the limited human te ot expected to be research using intre e devices are outs ations, whereas its	24 the next either 1) nents, the d or cleared. niques capable levelop new ion of the incement. cience, e development application esting hypothesis- egrative ide the scope s companion
108301	RFA-NS-22-034 HEAL Initiative: Dis for Safe and Effective Pain Treatmen	scovery and Validation of Novel Targets at (R01 Clinical Trial Not Allowed)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	RFA-NS- 22-034 07-	-Apr-2022	Not Specified
	Contact Name Mi Contact Telephone 30 Contact Email <u>mi</u> Sponsor Website	ichael L. Oshinsky, PhD )1-496-9964 ichael.oshinsky@nih.gov				

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	07-Apr-2 2023 <i>,</i> 04	022 , 02-Jun-2022 , 08-Aug-202 -Oct-2023 , 07-Dec-2023 , 02-Fe	2 , 04-Oct-2022 , 07-Dec-2022 , 02-F eb-2024 , 09-Apr-2024 , 04-Jun-2024	eb-2023 , 07-Ap , 07-Aug-2024 ,	r-2023 , 02-Jun-20 02-Oct-2024 , 06-	)23 , 07-Aug- -Dec-2024
	Synopsis	The purp therapeu science d body tha Research pain trea biologics, develop r responsiv for any o headache pain, oro conditior populatic	ose of this Funding Opportunity tic targets to facilitate the deve iscovery of targets in the periph t can be used to develop treatm supported by this FOA must ind tment target. This will lower the natural substances, or devices new medical devices is not the f ve to this FOA and are encourag ne or group of pain conditions. e disorders, osteoarthritis, diabe facial pain, etc. will be consider as or for specific pathological co ons such as women, children, of	Announcement (FOA) is to promote lopment of pain therapeutics. Spec- neral nervous system, central nervous ents that have minimal side effects clude rigorous validation studies to de- erisk of adopting the target in trans- that interact with this target for new focus of this FOA. Basic science studie ed in the context of novel pain thera Projects to identify novel targets for etic neuropathy, chemotherapy-indu- ed. Projects to identify novel targets nditions will be considered. Projects der adults or other underrepresented	e the discovery a ifically, the focus us system, immu and little to no a demonstrate the lational projects w pain treatmen ies of pain and re apeutic target di acute pain, chro uced neuropathy s for a combinati a that seek to ide ed groups will also	and validation of n s of this FOA is on ine system or othe abuse/addiction lia robustness of the to develop small ts. Translational re elated systems in t scovery. This FOA onic pain, migraine v, sickle-cell pain, p on of chronic over entify novel target so be responsive to	iovel the basic er tissues in the ability. e target as a molecules, esearch to the body are is not specific e, other bost stroke rlapping pain s in specific o this FOA.
106266	NINDS Alzheimer's Disease and A (AD/ADRD) Advanced Postdoctor Diversity (K99/R00 Independent (	lzheimer's al Career Clinical Tri	<u>Disease-Related Dementias</u> Transition Award to Promote al Not Allowed)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-22- 022 07	-May-2022	Not Specified
	Contact Name	Amelie G	ubitz, Ph.D.				
	Contact Telephone	301-451-	7966				
	Contact Email	gubitza@	ninds.nih.gov				
	Sponsor Website						
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	07-May-2 2023 , 12	2022 , 12-Jun-2022 , 07-Sep-202 -Oct-2023 , 07-Jan-2024 , 12-Fe	2 , 12-Oct-2022 , 07-Jan-2023 , 12-F b-2024 , 07-May-2024 , 12-Jun-2024	eb-2023 , 07-Ma 1	ay-2023 , 12-Jun-2	023 , 07-Sep-
	Synopsis	The purp Postdoct indepenc	ose of the NINDS Alzheimer's D oral Career Transition Award to lent investigators from diverse I	isease and Alzheimer's Disease-Rela Promote Diversity (K99/R00) progra backgrounds (e.g. see NOT-OD-20-0	ted Dementias ( am is to support 31, Notice of NII	AD/ADRD) Advand a cohort of new a H's Interest in Dive	ced nd talented, ersity)

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		conductir from thei program independ specifical feasibility in a clinica	ng AD/ADRD research. The prog r mentored, postdoctoral resea will provide independent NIH re ent research programs in the A ly for applicants proposing rese r study, or an ancillary study to a al trial led by a mentor or co-me	ram is designed to facilitate a timely rch positions to independent, tenur esearch support during this transitio D/ADRD field. This Funding Opport arch that does not involve leading a a clinical trial. Applicants to this FOA entor.	/ transition of el e-track or equiv n in order to hel unity Announcer n independent c are permitted t	igible postdoctora alent faculty positi p awardees establ ment (FOA) is desi ilinical trial, a clinic o propose researc	l researchers ions. The lish gned cal trial ch experiences
086932	NINDS Postdoctoral Mentored Ca Required)	reer Deve	lopment Award (K01 - Clinical T	rial Neurological Disorders and Stroke/NIH/DHHS	PAR-20- 050	-May-2022	Not Specified
	Contact Name	Stephen H	Korn, PhD				
	Contact Telephone						
	Contact Email	<u>korns@m</u>	ail.nih.gov				
	Sponsor Website						
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	07-May-2	022 , 12-Jun-2022 , 07-Sep-202	2 , 12-Oct-2022 , 07-Jan-2023			
	Synopsis	The purpo mentored developm for suppo research o experience developm the postd an indepe leader in as the lea not plann investigat	ose of the NINDS Postdoctoral N d postdoctoral researchers to de nent plan that will enable them ort from this NINDS K01 any time experience, and may be suppor ce. Because the completion of a nent of an impactful research pr loctoral eligibility window. By the endent research career with a w the field. This Funding Opportu- id investigator of an independen- ing an independent small clinic cor, must apply to companion Fe	Mentored Career Development Awa evelop a potentially impactful resea to launch an independent research e between the second through four- ted by this NINDS K01 within the fir strong, well-planned, thorough car- roject, is a critical aspect of this K01, he end of the proposed K01 award p vell-developed, impactful research p nity Announcement (FOA) is designed at small clinical trial as part of their al trial, or proposing to gain researc DA (PAR-20-049).	rd is to support rch project with program. Candic th year of cumul st 6 years of cum eer developmen applications are eriod, the candi- troject and the e ed specifically fo research and can h experience in a	the ability of outst a comprehensive dates are encourag ative mentored po- nulative postdocto t plan, in addition e strongly encoura date should be poi xpertise required r applicants propo- eer development. a clinical trial led b	anding, career ged to apply ostdoctoral ral research to ged early in ised to begin to become a osing to serve Applicants by another

SPIN ID Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount			
104258 <u>NINDS Efficacy</u>	104258 NINDS Efficacy Clinical Trials (UG3/UH3 Clin		National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-21- 237	07-May-2022	Not Specified			
	Contact Name	Jeremy Brown, MD							
C	Contact Telephone	301-496-9135							
	Contact Email	Jeremy.brown@nih.gov							
	Sponsor Website								
	Program URL	Link to program URL							
De	adline Dates (ALL)	07-May-2022 , 09-Jun-2022 , 07-Sep-20 2023 , 10-Oct-2023 , 07-Jan-2024 , 09-Fe	22 , 11-Oct-2022 , 07-Jan-2023 , 09-F eb-2024 , 07-May-2024	eb-2023 , 07-	May-2023 , 09-Jun-2	:023 , 07-Sep-			
The purpose of this Funding Opportunity Announcement (FOA) is to encourage grant applications for investigator-initia efficacy clinical trials to the National Institute of Neurological Disorders and Stroke (NINDS). The trials must address guestions within the mission and research interests of the NINDS and may evaluate drugs, biologics, and devices, as we surgical, behavioral and rehabilitation therapies. Information about the mission and research interests of the NINDS cation at the NINDS website (https://www.ninds.nih.gov/).									
103393 <u>NINDS Faculty I</u> <u>Research (K01 (</u>	Development Award Clinical Trial Require	d to Promote Diversity in Neuroscience ed)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-21- 153	07-May-2022	Not Specified			
	Contact Name I	Michelle Jones-London, Ph.D.							
C	Contact Telephone	301-451-7966							
	Contact Email	jonesmiche@ninds.nih.gov							
	Sponsor Website								
	Program URL	Link to program URL							
De	adline Dates (ALL)	07-May-2022 , 12-Jun-2022 , 07-Sep-20 2023 , 12-Oct-2023 , 07-Jan-2024 , 12-Fe	22 , 12-Oct-2022 , 07-Jan-2023 , 12-F eb-2024 , 07-May-2024	eb-2023 , 07-	May-2023 , 12-Jun-2	:023 , 07-Sep-			
	- Synopsis I I	The purpose of the NINDS Faculty Deve the pool of independent neuroscience r protected research time and career stag Individuals from diverse backgrounds, in	lopment Award to Promote Diversity research investigators by providing ju ge appropriate professional develop ncluding those from groups underrep	v in Neuroscier Inior faculty w ment mentors presented in b	nce Research (K01) i ith research cost su hip in neuroscience iomedical research a	s to diversify pport, research. are eligible for			

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		support u tenure tra specificall study, or independ to compa	nder this award if they have do ack or equivalent position at the ly for candidates proposing to s a separate ancillary clinical trial ent clinical trial, or proposing to nion FOA (PAR-21-152).	ctoral research degrees (Ph.D. or e e time of application. This Funding e erve as the lead investigator of an i , as part of their research and care o gain research experience in a clini	quivalent) and a Opportunity Ann independent clin er development. ical trial led by ar	re in the first 3 yea ouncement (FOA) ical trial, a clinical Those not plannin nother investigato	ars of a faculty is designed trial feasibility g an r, must apply
103724	NINDS Faculty Development Awa Research (K01 Independent Clinic	<u>rd to Prom</u> cal Trial No	note Diversity in Neuroscience t Allowed)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-21- 234 07	²-May-2022	Not Specified
	Contact Name	Michelle J	lones-London, Ph.D.				
	Contact Telephone	301-451-7	7966				
	Contact Email	jonesmich	ne@ninds.nih.gov				
	Sponsor Website						
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	07-May-2 2023 , 12·	022 , 12-Jun-2022 , 07-Sep-202 ·Oct-2023 , 07-Jan-2024 , 12-Fe	2 , 12-Oct-2022 , 07-Jan-2023 , 12- b-2024 , 07-May-2024	Feb-2023 , 07-Ma	ay-2023 , 12-Jun-2	023 , 07-Sep-
The purpose of the NINDS Faculty Development Award to Promote Diversity in Neuroscience Research (K01) is to divers the pool of independent neuroscience research investigators by providing junior faculty with research cost support, protected research time and career stage appropriate professional development mentorship in neuroscience research. Individuals from diverse backgrounds, including those from groups underrepresented in biomedical research are eligible support under this award if they have doctoral research degrees (Ph.D. or equivalent) and are in the first 3 years of a fa- tenure track or equivalent position at the time of application. This Funding Opportunity Announcement (FOA) is designed specifically for candidates proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Under this FOA candidates are permitted to propose a research experience in a clinical trial led by a mentor or co-mentor. Those proposing a clinical trial or an ancillary study to an ong clinical trial as lead investigator, should apply to the companion EOA (PAP-21-153)							
100306	NINDS Ruth L. Kirschstein Nationa Training of Postdoctoral Fellows	al Research F32 Clinica	n Service Award (NRSA) for al Trial Not Allowed)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-21- 032 07	'-May-2022	Not Specified

Contact Name Stephen Korn, Ph.D.

SPIN ID	Program Title	Spor	onsor Name	Sponsor Number		Deadline Date	Funding Amount
	Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL)	301-496-4188 korns@ninds.r Link to program 07-May-2022, 2023 . 10-Oct-	n <u>ih.gov</u> <u>m URL</u> , 08-Jun-2022 , 07-Sep-202 -2023 , 07-Jan-2024	2 , 11-Oct-2022 , 07-Jan-2023 , 09-F	eb-2023 <i>,</i> 07-Ma	aγ-2023 <i>,</i> 08-Jun-2	023 <i>,</i> 07-Sep-
	Synopsis	The purpose o outstanding m the proposed p F32 seeks to for candidate that seeks innovativ postdoctoral for reasoning and 4 years of a ca planning and t Announcement to propose ress (FOA) does not research expention	of this award is to support of nentors. Candidates are elig postdoctoral position to wi oster early, goal-directed p t have the potential for sign ive research ideas and thou fellow into an outstanding s I the quantitative principles andidate's activity in a speci- timely completion of "ment nt (FOA) does not allow app search experience in a clinio of allow applicants to propo- prience in a clinical trial led	putstanding scientific training of high gible to apply for support from this p ithin 12 months after starting in the lanning and to encourage application inficant impact. Inclusion of prelimin ghtful plans for training and mento scientist. Applications are expected of experimental design and analysis fic laboratory or research environmetored training" within a particular la plicants to propose to lead an indep cal trial led by a sponsor or co-spon- se to lead an independent clinical to by a sponsor or co-sponsor.	hly promising po program from ~1 proposed postd ons for bold and/ nary data is stror orship that will fa to incorporate st is. Support by thi nent, so as to fur- ab or environmer endent clinical tr sor. This Funding rial, but does allo	stdoctoral candid 2 months prior to octoral position. for innovative pro- ngly discouraged; cilitate the develo trong training in q is program is limit ther encourage ea nt. This Funding O rial, but does allow g Opportunity Anr ow applicants to p	ates with the start of This NINDS jects by the rather, this F32 opment of the uantitative ed to the first arly, thoughtful pportunity w applicants nouncement propose
100819	100819 Clinical Validation of a Candidate Biomarke Neuromuscular Disorders (U44 Clinical Tria		Neurological or ional)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-21- 059	-May-2022	Not Specified
	Contact Name	Mary Ann Pelle	leymounter, PhD				
	Contact Telephone	301-496-1779	ountor Onih cou				
	Contact Email Sponsor Website	mary.pelleymo	ounter@nin.gov				
	Program URL	Link to program	<u>m URL</u>				
	Deadline Dates (ALL)	07-May-2022 ,	, 22-Jun-2022 , 07-Sep-202	2 , 22-Feb-2023 , 07-May-2023 , 22-	-Jun-2023 , 07-Se	ep-2023	

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount				
	Synopsis	The purpose of this Program Announcement (PAR) is to enable clinical validation of strong candidate biomarkers for neurological and neuromuscular disorders and conditions. Specifically, the goal of this PAR is to enable the rigorous clinical validation of biomarker measurements within the clinical population of interest to establish the clinical sensitivity and specificity of the biomarker consistent with FDA guidelines. This PAR assumes that 1) a candidate biomarker has already been identified, 2) detection method technology has already been developed and analytically validated, and 3) the research and/or clinical need and potential context of use has been identified.									
100817	Analytical Validation of a Candida Neuromuscular Disorders (U44 Cl	te Biomar inical Trial	<u>ker for Neurological or</u> <u>Optional)</u>	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-21- 057	7-May-2022	Not Specified				
	Contact Name	Mary Anr	n Pelleymounter, PhD								
	Contact Telephone	301-496-3	1779								
	Contact Email	mary.pell	eymounter@nih.gov								
	Sponsor Website										
	Program URL	Link to pr	ogram URL								
	Deadline Dates (ALL)	07-May-2	022 , 22-Jun-2022 , 07-Sep-202	2 , 22-Feb-2023 , 07-May-2023 , 22	-Jun-2023 , 07-S	ep-2023					
	Synopsis	The purper neurologi validatior performa guidelines already b	ose of this Program Announcem ical and neuromuscular disorder n of analytical methods for biom nce characteristics, and the opt s. This PAR assumes that 1) a ca een developed, and 3) the resea	ent (PAR) is to enable analytical va s and conditions. Specifically, the g arker measurements, which should imal conditions that will generate r ndidate biomarker has already bee arch and/or clinical need and poter	lidation of stron goal of this PAR i d include evalua eproducibility a n identified, 2) o ntial context of u	g candidate bioma s to enable the rig tion of the detection nd accuracy consis detection method se has been identi	rkers for orous on method, its tent with FDA technology has fied.				
100818	Clinical Validation of a Candidate Neuromuscular Disorders (U01 Cl	Biomarkei inical Trial	r for Neurological or Optional)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-21- 058	7-May-2022	Not Specified				
	Contact Name	Mary Anr	n Pelleymounter, PhD								
	Contact Telephone	301-496-3	1779								
	Contact Email	mary.pell	eymounter@nih.gov								
	Sponsor Website										
	Program URL	<u>Link to pr</u>	ogram URL								

SPIN ID	Program Title	Sponsor Name	Sponsor Number			Deadline Date	Funding Amount
	Deadline Dates (ALL) Synopsis	07-May-2022, 22-Jun-2022, 07-Sep The purpose of this Program Annou neurological and neuromuscular dis validation of biomarker measureme specificity of the biomarker consiste been identified, 2) detection metho and/or clinical need and potential co	-2022, 22-Feb-2023, ( ncement (PAR) is to en orders and conditions. nts within the clinical p ent with FDA guidelines d technology has alread ontext of use has been	07-May-2023 , 22- able clinical valida Specifically, the go oopulation of inter . This PAR assume dy been developed identified.	Jun-2023 , 07 tion of strong oal of this PAI est to establis s that 1) a can d and analytic	-Sep-2023 g candidate biomark R is to enable the rig sh the clinical sensiti ndidate biomarker h cally validated, and 3	ers for orous clinical vity and as already ) the research
100816	Analytical Validation of a Candidat Neuromuscular Disorders (U01 Cli	te Biomarker for Neurological or inical Trial Optional)	National Insti Neurological Stroke/NIH/D	tute of Disorders and HHS	PAR-21- 056	07-May-2022	Not Specified
	Contact Name	Mary Ann Pelleymounter, PhD					
	Contact Telephone	301-496-1779					
	Contact Email	<u>mary.pelleymounter@nih.gov</u>					
	Sponsor Website						
	Program URL	Link to program URL					
	Deadline Dates (ALL)	07-May-2022, 22-Jun-2022, 07-Sep	-2022 , 22-Feb-2023 , (	07-May-2023 , 22-	Jun-2023 <i>,</i> 07	-Sep-2023	
	Synopsis	The purpose of this Program Annou neurological and neuromuscular dis validation of analytical methods for performance characteristics, and the guidelines. This PAR assumes that 1 already been developed, and 3) the	ncement (PAR) is to en orders and conditions. biomarker measureme e optimal conditions th ) a candidate biomarke research and/or clinica	able analytical vali Specifically, the go ents, which should hat will generate re r has already beer al need and potent	idation of stro pal of this PAI include evalu producibility identified, 2 tial context of	ong candidate bioma R is to enable the rig Jation of the detection and accuracy consis ) detection method F use has been idention	orkers for orous on method, its tent with FDA technology has fied.
106730	Notice of Special Interest (NOSI): I Functional Neurological Disorders	Biomarker Discover and Validation ir	National Insti Neurological Stroke/NIH/D	tute of Disorders and HHS	NOT-NS- 22-010	07-May-2022	Not Specified
	Contact Name	Codrin Lungu, MD					
	Contact Telephone	301-496-9135					
	Contact Email	<u>lunguci@ninds.nih.gov</u>					
	Sponsor Website						

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount				
	Program LIRI	Link to pr	ogram LIRI								
	Deadline Dates (ALL)	$07 May_2$	022 22_lun_2022 22_Eeb_202	3 07-May-2023 22-lup-2023 07-	Sen-2023						
	Deadline Dates (ALL)	NINDS is i	issuing this Notice of Special Int	erest to encourage the submission of	of applications f	ocused on the dev	elonment and				
	Synopsis	validation of biomarkers for functional neurological disorders (FND).									
086929	NINDS Postdoctoral Mentored Ca Independent Clinical Trial Allowed	ireer Devel d)	lopment Award (K01 - No	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-20- 049 07	7-May-2022	Not Specified				
	Contact Name	Stephen k	Korn, PhD								
	Contact Telephone										
	Contact Email	korns@m	ail.nih.gov								
	Sponsor Website										
	Program URL	Link to pr	ogram URL								
	Deadline Dates (ALL)	07-May-2	022 , 12-Jun-2022 , 07-Sep-202	2 , 12-Oct-2022 , 07-Jan-2023							
	Synopsis	The purper mentored developm for supporesearch experience developm the postd an indeper leader in that does experience investigat	ose of the NINDS Postdoctoral N d postdoctoral researchers to de nent plan that will enable them int from this NINDS K01 any time experience, and may be suppor ce. Because the completion of a nent of an impactful research pr octoral eligibility window. By the endent research career with a w the field. This Funding Opportu not involve leading an indepen ce in a clinical trial led by a men cor, should apply to the compan	Mentored Career Development Awa evelop a potentially impactful resear to launch an independent research e between the second through fourt ted by this NINDS K01 within the firs strong, well-planned, thorough care roject, is a critical aspect of this K01, he end of the proposed K01 award po- vell-developed, impactful research po- nity Announcement (FOA) is designed dent small clinical trial. Applicants to tor or co-mentor. Applicants propos- nion FOA (PAR-20-050).	rd is to support rch project with program. Candi ch year of cumu st 6 years of cur eer developmer applications ar eriod, the candi roject and the e ed specifically fo o this FOA are p ing an independ	the ability of outst a comprehensive dates are encourag lative mentored po- nulative postdocto at plan, in addition e strongly encoura idate should be po- expertise required or applicants propo- permitted to propo- dent small clinical to	anding, career ged to apply ostdoctoral ral research to ged early in ised to begin to become a osing research se research trial as lead				
103957	NeuroNEXT Clinical Trials (U01 Cli	inical Trial	<u>Optional)</u>	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-21- 223 05	5-Jun-2022	Not Specified				



SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount		
	Contact Name Contact Telephone Contact Email	Codrin Lu 301-496-9 <u>lunguci@</u>	ngu, MD 9135 <u>ninds.nih.gov</u>						
	Sponsor Website Program URL	Link to pr	ogram URL						
	Deadline Dates (ALL) 05-Jun-2022, 05-Oct-2022, 05-Feb-2023, 05-Jun-2023, 05-Oct-2023, 05-Feb-2024 This FOA encourages applications for exploratory clinical trials of investigational agents (drugs, biologics, surgical ther or devices) that may contribute to the justification for and provide the data required for designing a future trial, for biomarker validation studies, or for proof of mechanism clinical studies. Diseases chosen for study should be based or NINDS' strategic plan and clinical research interests (www.ninds.nih.gov/funding/areas/index.htm). Successful applicat be given access to the NeuroNEXT infrastructure. Following peer review, NINDS will prioritize and order trials that are access to the NeuroNEXT infrastructure. The NeuroNEXT Clinical Coordinating Center (CCC) will work with the success applicant to efficiently implement the proposed study. The NeuroNEXT Data Coordinating Center (DCC) will provide								
107186	Clinical Trial Readiness for Function Trial Optional)	on-site im	pplementation of the clinical problem	otocol. Applicants do not need to be National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-22- 053	ting NeuroNEXT ir	Not Specified		
	Contact Name	Codrin Lu	ngu, MD						
	Contact Telephone	301-496-9	9135						
	Contact Email	lunguci@	<u>ninds.nih.gov</u>						
	Sponsor Website	h -							
	Program URL	Link to pr	ogram URL						
Deadline Dates (ALL) 05-Jun-2022, 05-Oct-2022, 05-Feb-2023, 05-Jun-2023, 05-Oct-2023, 05-Feb-2024, 05-Jun-2024, 05-Oct-2022 Functional Neurological Disorders (FNDs) are characterized by symptoms of altered voluntary motor or sensory with clinical findings providing evidence of incompatibility between the symptoms and recognized neurological conditions. FNDs are highly prevalent and associated with significant morbidity, health care costs, and even mo some respects, this group of conditions sits at the intersection of neurology and psychiatry, but the majority of come to the attention of neurologists. Management is complex and requires interdisciplinary approaches. Give									

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount		
		disability significan FNDs rem based on subtypes and biom of FNDs. T is hamper thus, prec clinical pr validation context o (PAR-19-3 investigat	caused by the symptoms, and t t missed opportunity for therap nain very challenging. Diagnostic positive clinical findings, and ca are more difficult to correctly d arkers can be developed, but si Therapies exist and have been s red by limitations in available of diction of aggregate treatment tojects that address critical need of biomarkers, endpoints and f use for clinical trials. Projects 815, PAR-21-056, PAR-21-057, P cors, industry, and patient group	he high cost in healthcare utilization beutic intervention and therefore, a c criteria have been proposed but th an be supported by laboratory or an liagnose than others. More importa gnificantly more research is needed studied in select populations but gat utcome measures. Differential response response has been difficult. This FO ds for clinical trial readiness in FNDs clinical outcome assessments (COA) involving biomarker discovery or ea PAR-21-058, PAR-21-059). The initiat ps, and will encourage interactions y	n and loss of pro- healthcare crisis ney are not unive cillary investigat ntly, laboratory- in these areas to hering high-leve onses to treatme A invites researc . Projects approp that are fit-for-p rly validation sho tive will promote with the Food an	ductivity, FNDs an a Diagnosis and ma ersally agreed upon ion findings. Certa supported diagnos o advance clinical d evidence through ents have been rec hers to submit pro priate for this FOA purpose and have puld apply to the r e partnerships amo ad Drug Administra	nount to a anagement of n. Diagnosis is in FND sis is possible, management n clinical trials orded, and ospective include the a defined elevant FOAs ong academic ttion (FDA).		
109312	109312 RFA-RM-22-009 Somatic Mosaicism acro Program: Organizational Center (U24 Clini		is Human Tissues (SMaHT) al Trial Not Allowed)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	RFA-RM- 22-009 08	-Jun-2022	Not Specified		
	Contact Name	Jill Morris	s, Ph.D.						
	Contact Telephone	301-496-5	5745						
	Contact Email	<u>SMaHT@</u>	<u>mail.nih.gov</u>						
	Sponsor Website								
	Program URL	Link to pr	ogram URL						
	Deadline Dates (ALL)	08-Jun-20	)22 , 08-Jul-2022						
This Funding Opportunity Announcement (FOA) invites applications to establish the Organizational Center for the Som Mosaicism across Human Tissues (SMaHT) Network. The purpose of the SMaHT Network is to enable discovery of new biology and disease mechanisms mediated by genomic variation in somatic tissues. The Organizational Center will Synopsis coordinate meetings, communication, outreach, and other organizational activities within the Network and be the ma conduit for collaboration with related programs and the wider research community. This Funding Opportunity Announcement (FOA) is developed as a Common Fund initiative (http://commonfund.nih.gov/) through the NIH Office									

NIH Director, Office of Strategic Coordination (https://dpcpsi.nih.gov/). All NIH Institutes and Centers participate in Common

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount				
	Fund initiatives. The FOA will be administered by the National Institute of Neurological Diseases and Stroke (NINDS) on behalf of the NIH.										
109325 <mark>-</mark>	RFA-RM-22-011 Somatic Mosai Program: Tool Development Proje	<u>cism acros</u> ects (UG3/	<u>s Human Tissues (SMaHT)</u> UH3 Clinical Trial Not Allowed)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	RFA-RM- 22-011	08-Jun-2022 [Optional][LOI/Pre- App]	1,700,000 USD				
	Contact Name	Jill Morris	, Ph.D.								
	Contact Telephone	301-496-5	5754								
	Contact Email	<u>SMaHT@</u>	mail.nih.gov								
	Sponsor Website										
	Program URL	Link to pr	ogram URL								
Deadline Dates (ALL) 08-Jun-2022 [Optional][LOI/Pre-App], 08-Jul-2022											
	Synopsis	This Funding Opportunity Announcement (FOA) invites applications for development of tools and technologies to enhance understanding of somatic variants as part of the Somatic Mosaicism across Human Tissues (SMaHT) Network. The purpose of the SMaHT Network is to enable discovery of new biology and disease mechanisms mediated by genomic variation in somatic tissues. Technology and Tool Development Projects will develop the next generation of technologies that will enhance our ability to detect and characterize somatic variants in human tissues. This Funding Opportunity Announcement (FOA) is developed as a Common Fund initiative (http://commonfund.nih.gov/) through the NIH Office of the NIH Director, Office of Strategic Coordination (https://dpcpsi.nih.gov/). All NIH Institutes and Centers participate in Common Fund initiatives. The FOA will be administered by the National Institute of Neurological Diseases and Stroke (NINDS) on behalf of the NIH.									
107322 <mark>1</mark>	107322 Translational Efforts to Advance Gene-based Therapies for Ultra-Rare Neurological and Neuromuscular Disorders (U01 - Clinical Trial Optional)			National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-22- 030	09-Jun-2022	Not Specified				
	Contact Name	Ann-Mari	e Broome, PhD, MBA								
	Contact Telephone	301-496-2	1779								
	Contact Email	ann-marie	e.broome@nih.gov								
	Sponsor Website										
	Program URL	Link to pr	ogram URL								
	Deadline Dates (ALL)	09-Jun-20	022 , 08-Oct-2022 , 09-Feb-2023	, 09-Jun-2023 , 10-Oct-2023 , 08-Fe	eb-2024 , 07-J	un-2024					

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount			
	Synopsis	The Ultra-Rare Gene-Based Therapy (URGenT) network supports Investigational New Drug (IND)-enabling studies and planning activities for First-in-Human (FIH) clinical testing of gene-based or transcript-directed therapeutics, such as oligonucleotides and viral-based gene therapies, for ultra-rare neurological or neuromuscular disorders. The goal of this funding opportunity announcement (FOA) is to accelerate the development of a promising clinical candidate with robust biological rationale and demonstrated proof of concept (POC) data for the intended approach in a model system relevant to a specified patient population towards an IND filing and the initiation of a clinical trial.								
106359	Career Transition Award for NIND Trial Required)	<u>S Intramu</u>	ral Clinician-Scientists (K22 Clini	cal National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-21- 327 12	-Jun-2022	Not Specified			
	Contact Name	Stephen I	Korn, Ph.D.							
	Contact Telephone									
	Contact Email	<u>korns@n</u>	inds.nih.gov							
	Sponsor Website	Link to av								
	Program URL	LINK to pr	Ogram URL	12 Jun 2022 12 Oct 2022 12 F	ah 2024 12 lun	2024				
	This NINDS K22 is specifically designed to facilitate the transition of NINDS intramural neurologist- and neurosurgeon- scientists to independent, academic faculty positions that support clinician-scientists to engage in independently func- scientific research as well as clinical activities. This Funding Opportunity Announcement (FOA) is designed specifically applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, o separate ancillary study to an existing trial, as part of their research and career development. Applicants not planning independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must to companion FOA PAR-21-328.									
106361	<u>Career Transition Award for NIND</u> <u>Trial Not Allowed)</u>	<u>S Intramu</u>	ral Clinician-Scientists (K22 Clini	cal National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-21- 328 12	-Jun-2022	Not Specified			
	Contact Name	Stephen I	Korn, Ph.D.							
	Contact Telephone									
	Contact Email	<u>korns@n</u> i	inds.nih.gov							
	Sponsor Website									


SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount	
	Program URL	Link to pr	ogram URL					
	Deadline Dates (ALL)	12-Jun-20		, 12-Jun-2023 , 12-Oct-2023 , 12-Fe	eb-2024 , 12-Jun	-2024		
	Synopsis	This NINE scientific applicant ancillary s a mentor investigat	DS K22 is specifically designed to to independent, academic facu research as well as clinical activ s proposing research that does study to a clinical trial. Applicant or co-mentor. Applicants propo tor, should apply to the compan	facilitate the transition of NINDS in Ity positions that support clinician-s ities. This Funding Opportunity Ann not involve leading an independent ts to this FOA are permitted to prop osing a clinical trial or an ancillary st ion FOA PAR-21-327.	ntramural neuro scientists to enga ouncement (FO, clinical trial, a c pose research ex udy to an ongoin	logist- and neuros age in independen A) is designed spec linical trial feasibil perience in a clinic ng clinical trial as l	urgeon- tly funded cifically for ity study, or an cal trial led by ead	
109940	Prospective Observational Compa Neurosciences (UG3/UH3 Clinical	arative Effe Trial Not /	ectiveness Research in Clinical Allowed)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-22- 076 17	'-Jun-2022	Not Specified	
	Contact Name	Adam L. H	Hartman, MD					
	Contact Telephone	301-496-9	9135					
	Contact Email	adam.har	rtman@nih.gov					
	Sponsor Website							
	Program URL	Link to pr	ogram URL					
	Deadline Dates (ALL)	17-Jun-20 2023 , 07 May-2025	022 , 07-Sep-2022 , 18-Oct-2022 -Jan-2024 , 20-Feb-2024 , 07-Ma 5	, 07-Jan-2023 , 17-Feb-2023 , 07-M ay-2024 , 16-Jun-2024 , 07-Sep-2024	lay-2023 , 19-Jui 4 , 18-Oct-2024 ,	n-2023 , 07-Sep-20 , 07-Jan-2025 , 19-	123 , 18-Oct- Feb-2025 , 07-	
	The purpose of this Funding Opportunity Announcement (FOA) is to encourage grant applications for investigator-initiated prospective observational comparative effectiveness research (CER) to the National Institute of Neurological Disorders and Stroke (NINDS) (note: only prospective observational studies will be considered). The study must address questions within the mission and research interests of the NINDS and may evaluate preventive strategies, diagnostic approaches, or interventions including drugs, biologics, and devices, or surgical, behavioral, and rehabilitation therapies. NINDS is particularly interested in pragmatic study designs that utilize a cost-effective means of prospectively collecting observational data important to current clinical practice.							
097476	NIH StrokeNet Clinical Trials and I Recovery, and Prevention (UG3/L	<u> Biomarker</u> JH3 Clinica	Studies for Stroke Treatment, al Trial Optional)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-20- 285 20	-Jun-2022	Not Specified	



SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) Synopsis	Claudia Scala Moy, PhD 301-496-9135 moyc@ninds.nih.gov Link to program URL 20-Jun-2022 , 18-Oct-2022 , 14-Feb-2023 This FOA encourages applications for mu interventions; biomarker or outcome me prevention, treatment, and recovery; and within StrokeNet. Successful applicants w review, NINDS will prioritize studies amou StrokeNet National Coordinating Center ( efficiently and the National Data Manage NIH StrokeNet Regional Coordinating Cer support as well as on-site implementatio collaborate with other US and internation for stroke treatment, prevention, and rec recovery, or prevention supported by NIN circumstances will NINDS consider fundir be part of the existing NIH StrokeNet infr UG3/UH3 cooperative agreement mecha driven planning and start-up phase, with Only UG3 projects that meet the scientifi phase. Applications submitted in response	Iti-site exploratory and confirmator asure validation studies that are im d ancillary studies designed to add s vill collaborate and conduct the stud ng the highest scoring to be conduct (NCC) will work with the successful ement Center (NDMC) will provide s nters (RCCs) and their affiliated clini n of the clinical protocol. The NIH S nal consortia necessary to conduct 1 covery. NINDS intends that all multi NDS will be conducted in the NIH St ng multi-site stroke clinical trials out astructure to apply under this FOA. possible transition to an implement ic milestones and award requirement is to this FOA must address both th	y clinical trials for mediately prepa scientific aims to dy within the NIH ted in the NIH St applicant to imp tatistical and dat cal sites will prov trokeNet networ larger, definitive -center clinical tr rokeNet and that side of this prog This FOA uses th will initially sup tation (UH3) pha- nts of the UG3 pl e UG3 and UH3 p	cused on promising ratory to trials in a active studies bei StrokeNet. Follow rokeNet infrastru lement the propo ta management su vide recruitment/fick will also be unice trials of promising rials in stroke trea t only in exception ram. Applicants d he bi-phasic, miles port a one-year m use of up to 6 addi hase may transitice phases and are ex	ng stroke ng conducted wing peer cture. The NIH sed study upport. The retention quely poised to g interventions tment, nal o not need to stone driven ilestone- tional years. on to the UH3 pected to
103821	RFA-NS-21-022 Translational Ne	eural Devices (U44 Clinical Trial Optional)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	RFA-NS- 21-022 20-	-Jun-2022	Not Specified
	Contact Name	Nick Langhals, PhD				
	Contact Telephone	301-496-1779				



SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Contact Email <u>NINDS</u> Sponsor Website Program URL <u>Link to</u> Deadline Dates (ALL) 20-Jur The pu (SRCs)	<u>-Devices@nih.gov</u> <u>program URL</u> -2022 , 18-Oct-2022 , 21-Feb-2023 prose of this Funding Opportunity	3 , 19-Jun-2023 , 18-Oct-2023 , 20-Fo y Announcement (FOA) is to encoura	eb-2024 age applications	from Small Business	s Concerns
	Synopsis Synopsis device impler activit or Inst inform assess driven plan b	s for disorders that affect the nerv nentation of clinical prototype dev es leading to submission of an Inv itutional Review Board (IRB) appli- ation about the device function of ments (e.g., bench top or animal s cooperative agreement program efore award and monitoring of res	vous or neuromuscular systems. Act vices, non-clinical safety and efficacy vestigational Device Exemption (IDE) cation for a Non-Significant Risk (NS r final design that cannot be practic studies) due to the novelty of the de and will involve participation of NIH search progress.	ivities supported y testing, design to the U.S. Food R) study. The clin ally obtained thr vice or its intend program staff ir	d in this program inc verification and vali d and Drug Administ nical study is expect rough additional nor ded use. This FOA is n negotiating the fina	lude dation ration (FDA) ed to provide a-clinical a milestone- al project
SPIN ID	Program Title	s	ponsor Name	Sponsor Number	dline Date	Funding Amount

103817	RFA-NS-21-021 Translational No Optional)	eural Devices (UG3/UH3 - Clinical Trial	National Institute of Neurological Disorders and Stroke/NIH/DHHS	RFA-NS- 21-021	20-Jun-2022	Not Specified
	Contact Name	Nick Langhals, PhD				
	Contact Telephone	301-496-1779				
	Contact Email	NINDS-Devices@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	20-Jun-2022 , 18-Oct-2022 , 21-Feb-20	023 , 19-Jun-2023 , 18-Oct-2023 , 20-F	eb-2024		
	Synopsis	The purpose of this Funding Opportun activities and small clinical studies to a affect the nervous or neuromuscular s prototype devices, non-clinical safety	nity Announcement (FOA) is to encour advance the development of therapeu systems. Activities supported in this pr and efficacy testing, design verificatio	age investig itic, and diag rogram inclu n and valida	ators to pursue translation gnostic devices for disord ade implementation of cli ation activities, obtaining	onal lers that nical an

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		Investigat Significan about the (e.g., ben cooperati before aw	ional Device Exemption (IDE) t Risk (NSR) study, as well as a device function or final design ch top or animal studies) due to ve agreement program and w vard and monitoring of researd	for a Significant Risk (SR) study or In subsequent small clinical study. Th n that cannot be practically obtaine to the novelty of the device or its in ill involve participation of NIH progr ch progress.	estitutional Review e clinical study is d through additio tended use. This I am staff in negot	v Board (IRB) appr expected to provid nal non-clinical as FOA is a milestone ating the final pro	oval for a Non- le information sessments -driven ject plan
102747	Innovation Grants to Nurture Init Neurotherapeutic Agent Characte (R61/R33 Clinical Trial Not Allowe	ial Translat erization ar ed)	tional Efforts (IGNITE): nd In vivo Efficacy Studies	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-21- 122 21-J	un-2022	750,000 USD
	Contact Name	Becky Roo	of, PhD				
	Contact Telephone	301-496-1	1779				
	Contact Email	rebecca.r	oof@nih.gov				
	Sponsor Website						
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	21-Jun-20	22 , 18-Oct-2022 , 21-Feb-202	3 , 20-Jun-2023 , 20-Oct-2023 , 20-I	Feb-2024		
	Synopsis	This fundi efficacy st developm small mol Initial Tra Neurothe	ng opportunity announcement tudies to demonstrate that pro- lent to treat neurological or ne ecules, biologics or biotechno nslational Efforts (IGNITE) to a rapeutics Network or other tra	t (FOA) provides funding to conduc pposed therapeutic agent(s) have su euromuscular disorders that fall und logy-derived products. This FOA is p dvance projects to the point where anslational programs.	t pharmacodynan ufficient biologica der the NINDS mis part of a suite of Ir they can meet th	nic, pharmacokine activity to warrar sion. Therapeutic movation Grants t e entry criteria for	tic, and in vivo at further agents include o Nurture the Blueprint
102739	Innovation Grants to Nurture Init Development and Validation of M Neurotherapeutic Discovery (R61	ial Translat 1odel Syste /R33 Clinic	tional Efforts (IGNITE): ems to Facilitate cal Trial Not Allowed)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-21- 123 21-J	un-2022	750,000 USD
	Contact Name	Becky Boy	of PhD				
	Contact Telephone	301-496-1	1779				
	Contact Email	rebecca.r	oof@nih.gov				
	Sponsor Website						
	Program URL	Link to pr	ogram URL				

Deadline Dates (ALL) 21-Jun-2022, 18-Oct-2022, 21-Feb-2023, 20-Jun-2023, 20-Oct-2023, 20-Feb-2024   This funding opportunity announcement (FOA) encourages the development and validation of animal models and human/animal tissue ex vivo systems that recapitulate the phenotypic and physiologic characteristics of a defined neurological on neuromuscular disorder. The goal of this FOA is to promote a significant improvement in the translational relevance of animal models or ex vivo systems that will be utilized to facilitate future development of neurotherapeutics. Ideally, models proposed for this FOA would have the potential to provide feasible and meaningful assessments of efficacy to disorder. The goal of this fOA is to provide a significant improvement in the translational filterist (IGNITE) Program focused on enabling the exploratory and early stages of drug discovery.   109299 Development of Biomarkers or Biomarker Signatures for Neurological and Neuromuscular Disorders (R51/R33 Clinical Trial Optional) National Institute of Neurological Disorders (R51/R33 Clinical Trial Optional) National Institute of Neurological Disorders and Stroke/NIH/DHHS PAR-22- 22-Jun-2022 Not Specified   Contact Temal contratyon-burds@nih.gov Specified Contact Temal contasylor-burds@nih.gov Specified   Sponsor Website Program URL Link to program URL Link to program URL Zu-un-2022, 07-Sep-2022, 27-Feb-2023, 07-May-2023, 22-Jun-2023, 22-Feb-2024, 07-May-2024, 22-Jun-2024, 07-May-2024, 22-Jun-2024, 07-Sep-2024, 22-Feb-2024, 07-May-2025 </th <th>SPIN ID</th> <th>Program Title</th> <th></th> <th>Sponsor Name</th> <th>Sponsor Number</th> <th></th> <th>Deadline Date</th> <th>Funding Amount</th>	SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
109209   Development of Biomarker Signatures for Neurological and Neuromuscular Disorders (R61/R33 Clinical Trial Optional)   National Institute of Neurological Disorders and Stroke/NIH/DHHS   PAR-22- 089   22-Jun-2022   Not Specified     Contact Name Contact Telephone Sonsor Website Program URL   Carol Taylor-Burds@nih.gov Sponsor Website Program URL   Link to program URL 2-Jun-2022, 07-Sep-2023, 22-Feb-2023, 07-May-2023, 22-Jun-2023, 07-Sep-2023, 22-Feb-2024, 07-May-2024, 22-Jun- 2024, 07-Sep-2022, 21-Feb-2025, 07-May-2025   Specified     Deadline Dates (ALLI)   22-Jun-2022, 07-Sep-2022, 22-Feb-2023, 07-May-2023, 07-Sep-2023, 22-Feb-2024, 07-May-2024, 22-Jun- 2024, 07-Sep-2024, 21-Feb-2025, 07-May-2025   The purpose of this Funding Opportunity Announcement (FOA) is to promote the development of fit-for-purpose candidate biomarkers and biomarker signatures that enable more efficient clinical trials to advance therapeutic development or be used in clinical practice to help guide clinical care decisions. Specifically, the goal of this phased funding mechanism is to fir identify or confirm candidate biomarkers or biomarker signatures using human samples and/or data, followed by an independent retrospective or prospective clinical study to conduct initial clinical validation of the biomarker/signature's clinical utility for a defined Context of Use(s). In the first phase, applicants are expected to demonstrate that the biomarker acceptably identifies or predicts the concept of interest and may include optimization of the detection method using carefully standardized human samples or datasets. The overarching purpose of this initiative is to deliver candidate biomarkers or biomarker signatures that are ready for definitive analytical and clinical validation studies.		Deadline Dates (ALL) Synopsis	21-Jun-202 This fundin human/an neurologic relevance Ideally, mo following to of Innovat	22, 18-Oct-2022, 21-Feb-20 ng opportunity announceme nimal tissue ex vivo systems cal or neuromuscular disord of animal models or ex vivo odels proposed for this FOA therapeutic intervention tha cion Grants to Nurture Initial drug discovery	023, 20-Jun-2023, 20-Oct-2023, 20- ent (FOA) encourages the development that recapitulate the phenotypic and er. The goal of this FOA is to promote systems that will be utilized to facilit would have the potential to provide the would be applicable in both preclin Translational Efforts (IGNITE) Progra	Feb-2024 ent and validation physiologic chara e a significant imp cate future develo feasible and mea nical and clinical se am focused on ena	of animal models acteristics of a defi rovement in the tr pment of neuroth ningful assessmen ettings. This FOA is abling the explorat	and ned ranslational erapeutics. ts of efficacy s part of a suite cory and early
Contact Name Carol Taylor-Burds Ph.D   301-496-1779 301-496-1779   Contact Email carol.taylor-burds@nih.gov   Sponsor Website Program URL   Deadline Dates (ALL) 22-Jun-2022, 07-Sep-2022, 22-Feb-2023, 07-May-2023, 22-Jun-2023, 07-Sep-2023, 22-Feb-2024, 07-May-2024, 22-Jun-2022, 07-Sep-2024, 21-Feb-2025, 07-May-2025   The purpose of this Funding Opportunity Announcement (FOA) is to promote the development of fit-for-purpose candidate biomarkers and biomarker signatures that enable more efficient clinical trials to advance therapeutic development or be used in clinical practice to help guide clinical care decisions. Specifically, the goal of this phased funding mechanism is to firsi identify or confirm candidate biomarkers or biomarker signatures using human samples and/or data, followed by an independent retrospective or prospective clinical study to conduct initial clinical validation of the biomarker/signature's clinicial utility for a defined Context of Use(s). In the first phase, applicants are expected to demonstrate that the biomarker acceptably identifies or predicts the concet of interest and may include optimization of the detection method using carefully standardized human samples or datasets. The overarching purpose of this initiative is to deliver candidate biomarker signatures that are ready for definitive analytical and clinical validation studies.   102700 Notice of Special Interest (NOSI): NINR Priority Areas for Training and Career Development Awards National Institute of Nursing Research/NIH/DHHS NOT-NR- 21-001 08-Apr-2022 Not Specified	109299	ا Development of Biomarkers or Bio and Neuromuscular Disorders (R6	omarker Si 51/R33 Clin	gnatures for Neurological ical Trial Optional)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-22- 089 22-J	un-2022	Not Specified
biomarkers or biomarker signatures that are ready for definitive analytical and clinical validation studies.   102700 Notice of Special Interest (NOSI): NINR Priority Areas for Training and Career Development Awards National Institute of Nursing Research/NIH/DHHS NOT-NR-21-001 08-Apr-2022 Not Specified   Contact Name Contact Name National Institute of Nursing Research/NIH/DHHS Not Specified Not Specified		Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) Synopsis	Carol Taylo 301-496-1 <u>carol.taylo</u> <u>Link to pro</u> 22-Jun-20 2024 , 07-2 The purpo biomarker used in clin identify or independe clinical uti acceptably carefully s	or-Burds Ph.D .779 <u>or-burds@nih.gov</u> <u>ogram URL</u> 22 , 07-Sep-2022 , 22-Feb-20 Sep-2024 , 21-Feb-2025 , 07 ose of this Funding Opportun rs and biomarker signatures nical practice to help guide of r confirm candidate biomark ent retrospective or prospec lity for a defined Context of y identifies or predicts the co standardized human samples	023, 07-May-2023, 22-Jun-2023, 07 -May-2025 hity Announcement (FOA) is to promo that enable more efficient clinical tri clinical care decisions. Specifically, th ers or biomarker signatures using hu tive clinical study to conduct initial c Use(s). In the first phase, applicants oncept of interest and may include o s or datasets. The overarching purpos	2-Sep-2023 , 22-Fe ote the developm als to advance the e goal of this phas man samples and linical validation c are expected to d ptimization of the se of this initiative	b-2024 , 07-May-2 ent of fit-for-purp erapeutic develop sed funding mecha /or data, followed of the biomarker/s emonstrate that t detection method e is to deliver cand	2024 , 22-Jun- ose candidate ment or be anism is to first by an ignature's he biomarker d using idate
Contact Name	102700	Notice of Special Interest (NOSI): I Career Development Awards	NINR Prior	ity Areas for Training and	National Institute of Nursing Research/NIH/DHHS	NOT-NR- 21-001 08-4	Apr-2022	Not Specified
		Contact Name						

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Contact Telephone						
	Contact Email						
	Sponsor Website						
	Program URL	Link to pro	ogram URL				
	Deadline Dates (ALL)	08-Apr-20 2022 , 07- 07-Sep-20	)22 , 07-May-2022 , 25-May-2 -Jan-2023 , 25-Jan-2023 , 12-F )23	022 , 12-Jun-2022 , 08-Aug-2022 , ( eb-2023 , 08-Apr-2023 , 07-May-20	07-Sep-2022 , 25-S 023 , 25-May-2023	ep-2022 , 12-Oct-2 , 12-Jun-2023 , 08	2022 , 08-Dec- -Aug-2023 ,
	Synopsis	The Natio of educat	nal Institute of Nursing Resea ion and encouraging training	rch (NINR) is committed to training in important new areas of nursing i	the next generati research.	on of nurse scient	ists at all levels
084549	Palliative Care in Home and Comn Optional)	<u>munity Set</u>	tings (R01 Clinical Trial	National Institute of Nursing Research/NIH/DHHS	PAR-19- 321 07-1	May-2022	Not Specified
	Contact Name	Karen A. k	Kehl, PhD, RN, FPCN				
	Contact Telephone	301-594-8	3010				
	Contact Email	<u>karen.keh</u>	ıl@mail.nih.gov				
	Sponsor Website						
	Program URL	Link to pro	ogram URL				
	Deadline Dates (ALL)	07-May-2	022 , 05-Jun-2022 , 07-Sep-20	022			
	Synopsis	The purpo integratio an individ illness wh palliative	ose of this funding opportunit on of palliative care into home ual resides or lives. Home- an o do not require hospitalizati care.	y is to stimulate research aimed at and community settings. Home an d community-based palliative care on but are not appropriate for hosp	determining need d community in th programs ensure bice have access to	s and best practice is FOA refer to the those with serious high quality end-	es for the e place where , advanced of-life and
085700	Omics-guided Biobehavioral Inter Outcomes: A Step Forward in Trar	ventions for nslation (R	<u>or Improved Health</u> 01 Clinical Trial Optional)	National Institute of Nursing Research/NIH/DHHS	PAR-19- 377 07-1	May-2022	Not Specified
	Contact Name	Lois A. Tu	lly, PhD				
	Contact Telephone	301-594-5	5968				
	Contact Email	<u>tullyla@m</u>	nail.nih.gov				
	Sponsor Website						

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Program URL Deadline Dates (ALL) Synopsis	Link to program URL 07-May-2022, 05-Jun-2022, 07-Sep-2 The purpose of this funding opportu advances in the fields of genomics an epigenomics, etc.) to incorporate the health outcomes.	2022 , 05-Oct-2022 , 07-Jan-2023 nity announcement (FOA) is to stimu d other omics (e.g., metabolomics, m se advances into translatable, person	late clinical resear icrobiomics, prote alized biobehavior	ch that harnesses eomics, transcriptc ral interventions fo	the wealth of omics, or improved
085882	Patient Activation for Self-Manage Clinical Trial Optional)	ement of Chronic Conditions (R01	National Institute of Nursing Research/NIH/DHHS	PAR-19- 381 07-N	May-2022	Not Specified
	Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) Synopsis	301-594-5970 <u>hussk@mail.nih.gov</u> <u>Link to program URL</u> 07-May-2022 , 05-Jun-2022 , 05-Jul-24 The purpose of this Funding Opportu patient activation on self-management	022 , 07-Sep-2022 , 05-Feb-2023 , 05- unity Announcement is to encourage nt of chronic conditions.	Mar-2023 , 07-Ma grant applications	ay-2023 s that address the i	influence of
085884	Patient Activation for Self-Manage Clinical Trial Optional)	ement of Chronic Conditions (R21	National Institute of Nursing Research/NIH/DHHS	PAR-19- 382 07-N	May-2022	400,000 USD
	Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) Synopsis	Karen Huss, PhD, RN, APRN-BC, FAAN 301-594-5970 <u>hussk@mail.nih.gov</u> <u>Link to program URL</u> 07-May-2022 , 16-Jun-2022 , 16-Jul-20 The purpose of this Funding Opportu patient activation on self-managemen	, FAAAAI 022 , 07-Sep-2022 , 16-Feb-2023 , 16- unity Announcement is to encourage nt of chronic conditions.	Mar-2023 , 07-Ma grant applications	ay-2023 S that address the i	influence of
084550	Palliative Care in Home and Comm Optional)	nunity Settings (R21 Clinical Trial	National Institute of Nursing Research/NIH/DHHS	PAR-19- 320 07-N	Мау-2022	275,000 USD
<u> </u>		NULL Frankling Onne	stunities Dues June 2022			



SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Contact Name Contact Telephone Contact Email Sponsor Website	Karen A. K 301-594-8 <u>karen.keh</u>	Cehl, PhD, RN, FPCN 3010 I@mail.nih.gov				
	Program URL Deadline Dates (ALL) Synopsis	Link to pro 07-May-20 The purpo integration an individu illness who palliative o	ogram URL 022 , 16-Jun-2022 , 07-Sep-2 ose of this funding opportuni n of palliative care into hom- ual resides or lives. Home- a o do not require hospitalizat care.	022 ty is to stimulate research aimed at c e and community settings. Home and nd community-based palliative care p ion but are not appropriate for hospi	determining needs d community in th programs ensure t ice have access to	s and best practice is FOA refer to the hose with serious high quality end-o	es for the place where , advanced of-life and
108054	Notice of Special Interest (NOSI): and Opioids in Aging	<u>Research o</u>	on Pain, Pain Management,	National Institute on Aging/NIH/DHHS	NOT-AG- 22-004 05-A	pr-2022	Not Specified
	Contact Name Contact Telephone Contact Email Sponsor Website	Devon Osl 301-827-5 <u>devon.osk</u>	kvig, Ph.D. 899 svig@nih.gov				
Sponsor Website   Program URL Link to program URL   05-Apr-2022, 12-Apr-2022, 25-Apr-2022, 07-May-2022, 25-May-2022, 05-Jun-2022, 12-Jun-2022, 16-Jun-2022   2022, 08-Aug-2022, 12-Aug-2022, 05-Sep-2022, 07-Sep-2022, 25-Sep-2022, 05-Oct-2022, 12-Oct-2022, 16-Oct   25-Oct-2022, 08-Dec-2022, 12-Dec-2022, 05-Jan-2023, 07-Jan-2023, 25-Jan-2023, 05-Feb-2023, 12-Feb-2023,   2023, 25-Feb-2023, 05-Apr-2023, 08-Apr-2023, 12-Apr-2023, 25-Apr-2023, 07-May-2023, 25-May-2023, 05-Jan   2023, 12-Oct-2023, 16-Jun-2023, 25-Jun-2023, 08-Apr-2023, 12-Apr-2023, 07-May-2023, 25-Sep-2023, 05-Jan   2023, 12-Oct-2023, 16-Jun-2023, 25-Jun-2023, 08-Aug-2023, 12-Aug-2023, 05-Sep-2023, 07-Sep-2023, 25-Sep-2023, 2023, 12-Oct-2023, 16-Oct-2023, 25-Oct-2023, 08-Aug-2023, 12-Dec-2023, 05-Jan-2024, 07-Jan-2024, 25-Jan-   Feb-2024, 12-Feb-2024, 16-Feb-2024, 25-Feb-2024, 05-Apr-2024, 08-Apr-2024, 07-May-2024, 25-May-2024, 024, 12-Oct-   0ct+2024, 05-Ian-2025, 08-Dec-2025							022 , 25-Jun- -Oct-2022 , 23 , 16-Feb- 5-Jun-2023 , 123 , 05-Oct- Ian-2024 , 05- 4 , 05-Jun- Oct-2024 , 25-
	Synopsis	The purpo receiving §	ose of this Notice of Special In grant applications focused of	nterest (NOSI) is to highlight that the n pain, pain management, and opioic	National Institute Is related to aging	e on Aging (NIA) is or older adults ar	interested in nd within NIA's

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		mission a pain expe improving competin pain, pain 005.	reas. This NOSI invites research rience with aging; enhancing a g health equity of aging popula g revisions to existing awards a management, and opioids rela	a applications that focus on improvi ssessment, prevention, and manage tions suffering with pain. New appli are all encouraged through this NOS ated to aging or older adults and wire	ng the underst ement strategi cations, resubi I. For administ thin NIA's miss	anding of mechanisr es for pain in older a nissions, competing rative supplements f ion areas, please see	ns underlying dults; and renewals, and focused on e NOT-AG-22-
108233 <u>S</u> T	FA-AG-23-008 Pharmacokinet tudies of mTOR Inhibitors on Ag rial Required)	ic and Pha ng-Relate	rmacodynamic (PK/PD) d Indications (U01 Clinical A	lational Institute on ging/NIH/DHHS	RFA-AG- 23-008	-Apr-2022 ptional][LOI/Pre- p]	Not Specified
	Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) Synopsis	Irina Sazo 301-435-3 <u>irina.sazo</u> Link to pr 14-Apr-20 This Fund studies of populatio interact a assessme	nova, Ph.D. 3048 nova@nih.gov 022 [Optional][LOI/Pre-App], 15 ing Opportunity Announcemer <sup>5</sup> mTOR inhibitors in population ns at risk for a variety of aging s a network to exchange inform nt of the effects on multiple ag	5-Jun-2022 at (FOA) invites applications for pha is living with different aging-related conditions. The studies will be fund nation, possibly develop harmonize ing-related outcomes and mechanis	rmacokinetic a diseases or in ed by individu d measures, ar sms affected b	nd pharmacodynam relatively healthy old Il awards but will be Id pool data to facili 7 mTOR modulation.	ic (PK/PD) der adult required to tate broader
107099 <mark>R</mark>	FA-RM-22-003 Cellular Senesc Napping Centers (U54 - Clinical T	ence Netv rial Not Al	vork: Murine Tissue N lowed) A	lational Institute on ging/NIH/DHHS	RFA-RM- 22-003	-May-2022	Not Specified
	Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL)	Viviana Po 240-328-7 <u>viviana.po</u> <u>Link to pr</u> 07-May-2 2023 , 05-	erez, Ph.D. 7301 erezmontes@nih.gov ogram URL 022 , 05-Jun-2022 , 07-Sep-202 -Oct-2023 , 07-Jan-2024 , 05-Fe	22 , 05-Oct-2022 , 07-Jan-2023 , 05-I b-2024 , 07-May-2024 , 05-Jun-202	Feb-2023 , 07- 4 , 07-Sep-202	Лау-2023 , 05-Jun-2 4 , 05-Oct-2024 , 07-	023 , 07-Sep- Jan-2025

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Synopsis	The purpose of this Funding Opportur (TMCs) within the Cellular Senescence goal of the SenNet consortium is to id senescent cells across multiple humar to generate data and build maps in hu effort by generating an atlas of cell se blueprint for future translational resea consortium will generate a multimoda will be predominantly dictated by the innovative tools and technologies to id searchable atlas of murine Cellular Sec content, multiscale biomarkers and m companion to the human Senescence murine tissues (modified disease mod commonly used and have demonstrat parts of the data generation pipeline, cell- level using omics, imaging and ot Opportunity Announcement (FOA) is o Office of the NIH Director, Office of St participate in Common Fund initiative (https://www.nia.nih.gov) on behalf o	ity Announcement (FOA) is to estab Network (SenNet) to build an atlast entify and functionally characterize, tissues in health and lifespan. A pre- mans. The purpose of this FOA is to nescence in mice that will help information arch performed in mice. Through col I, multidimensional atlas of senesce corresponding human tissues alread dentify and characterize senescent conscence. The TMCs solicited throug aps of cellular senescence across the atlas. The mouse component of the els are not allowed) derived from bo ed value in pre-clinical research. TM from tissue collection and preservat her approaches, to data integration, leveloped as a Common Fund initiat rategic Coordination (https://dpcpsi s. The FOA will be administered by th f the NIH.	olish state-of-the-ar of cellular senesce at single-cell resol evious FOA (RFA-RM solicit applications of the ongoing effor llaborative efforts, ent cells in various r dy in use within the cells; and aggregate gh this RFA will create e murine lifespan, for SenNet consortiur oth inbred and out ICs will be expected tion through analysis , analysis and interp tive (http://commo i.nih.gov/). All NIH the National Institu	rt Tissue Mapping ince in mice. The o ution, the heterog M-21-008) establis is that complemen ort in humans and the murine comp murine tissues (tisse SenNet consortine e data across the f ate high-resolution to generate a muri- m will initially focu- bred mouse strained d to integrate and ses at organ-, tissu- pretation. This Fu- pretation. This Fu- onfund.nih.gov/) t Institutes and Cen- te on Aging (NIA)	Centers overarching geneity of shed the TMCs t the human serve as a onent of the sue choices um); develop Vetwork into a n, high- ine-specific us on healthy is that are optimize all ue- and single- nding hrough the NIH iters
102443	Notice of Special Interest (NOSI): Sequelae from SARS-CoV-2 Infect Related Neurodegeneration	Neurological and Neurocognitive ion and COVID-19 in Aging and Age-	National Institute on Aging/NIH/DHHS	NOT-AG- 21-016 07-N	May-2022	Not Specified
	Contact Name	Miroslaw Mackiewicz, Ph.D.				
	Contact Telephone	301-496-9350				
	Contact Email	miroslaw.mackiewicz@nih.gov				
	Sponsor Website	Link to program UD				
	Program URL	LINK LO PROGRAM UKL	022 07 Son 2022 05 Oct 2022 16	6 Oct 2022 07 Ion	2022 OF Ech 20	172 16 Eab
	Deadline Dates (ALL)	2023 , 07-May-2023	uzz, u7-sep-zuzz, us-uct-zuzz, 16	o-UCI-ZUZZ , U7-Jar	1-2023 , US-FED-2l	125, 10-FED-

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Synopsis	The purpo interest ir Acute Res age-relate	ose of this Notice of Special Ir n basic and clinical mechanisti spiratory Syndrome Coronavir ed neurodegeneration.	terest (NOSI) is to inform applicat c research on neurological and ne us 2 (SARS-CoV-2) infection and C	nts to the Natio eurocognitive se Coronavirus Dise	nal Institute on Aging equelae originating fro ease 2019 (COVID-19)	(NIA) of NIA's m Severe in aging and
101790	NIA Academic Leadership Career Not Allowed)	<u>Award (K0</u>	7 Independent Clinical Trial	National Institute on Aging/NIH/DHHS	PAR-21- 106	07-May-2022	Not Specified
	Contact Name Contact Telephone Contact Email Sponsor Website	<u>NIAtrainir</u>	ng@nih.gov				
	Program LIRI	Link to pr	ogram LIRI				
	Deadline Dates (ALL)	07-May-2 2023 , 12·	022 , 12-Jun-2022 , 07-Sep-2( ·Oct-2023 , 07-Jan-2024 , 12-I	022 , 12-Oct-2022 , 07-Jan-2023 , eb-2024 , 07-May-2024	12-Feb-2023 , 0	7-May-2023 , 12-Jun-2	2023 , 07-Sep-
	Synopsis	The object the exper Funding C leading an permittect	tive of the NIA Academic Lea tise and leadership skills to en Opportunity Announcement (In independent clinical trial, a to propose research experie	dership Career Award (KO7) is to p hance aging and geriatric researc OA) is designed specifically for ap clinical trial feasibility study, or ar nce in a clinical trial led by anothe	provide support ch capacity with oplicants propose ancillary clinicater investigator.	for senior investigato in their academic insti sing research that doe al trial. Applicants to th	rs who have tution. This s not involve his FOA are
100297	Notice of Special Interest (NOSI): Mechanisms Underlying Fundam	Integrative ental Affec	e Studies of Neural tive Processes in Aging	National Institute on Aging/NIH/DHHS	NOT-AG- 21-012	07-May-2022	Not Specified
	Contact Name	Luci Robe	rts, Ph.D.				
	Contact Telephone						
	Contact Email	<u>roberlu@</u>	mail.nih.gov				
	Sponsor Website						
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	07-May-2 2023 , 07-	022 , 05-Jun-2022 , 16-Jun-20 May-2023 , 05-Jun-2023 , 16-	22 , 07-Sep-2022 , 05-Oct-2022 , Jun-2023 , 07-Sep-2023 , 05-Oct-	16-Oct-2022 , 0 2023 , 16-Oct-2	7-Jan-2023 , 05-Feb-20 023 , 07-Jan-2024	)23 , 16-Feb-

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Synopsis	The purpo mechanis on neural research mechanis working a	ose of this Notice of Special II ms underlying fundamental a mechanisms underlying affe results on affective processes ms. NIA also wishes to encou t different levels of neurobio	nterest (NOSI) is to inform ag affective processes in aging. Active processes into aging m is in aging into model systems arage collaboration among co ological and behavioral analys	oplicants of NIA's interes Grant applications are e odels; and/or 2) seek to s that support elucidatic ognitive and affective ne sis.	st in research on the ncouraged to 1) ext "reverse translate" on of fundamental n euroscientists and/o	e neural end research clinical eural r investigators
086469	Aging Research Dissertation Awar Trial Not Allowed)	ds to Incre	ease Diversity (R36 Clinical	National Institute on Aging/NIH/DHHS	PAR-19- 394 07	′-May-2022	Not Specified
	Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) Synopsis	Shahrooz 301-496-9 <u>shahrooz</u> <u>Link to pr</u> 07-May-2 The purpo within NI/ and aging	Vahedi, Ph.D. 9322 <u>vahedi@nih.gov</u> 0gram URL 022 , 16-Jun-2022 , 07-Sep-2 ose of this Funding Opportun A's strategic priorities to incre -related health conditions.	022 , 16-Oct-2022 , 07-Jan-2 ity Announcement (FOA) is t ease the diversity of the scie	023 to provide dissertation a ntific research workforc	wards in all areas o e engaged in resear	f research ch on aging
108346	Notice of Special Interest (NOSI): A Biospecimens to Elucidate the Bio Psychological Aspects of Sustained	Analyses c logical Eff d Caloric R	of CALERIE Datasets and ects and the Behavioral and estriction in Humans	National Institute on Aging/NIH/DHHS	NOT-AG- 21-028 07	'-May-2022	Not Specified
	Contact Name Contact Telephone Contact Email Sponsor Website Program URL	Chhanda 301-496-4 <u>Chhanda.</u> Link to pr	Dutta, Ph.D. 4161 <u>Dutta@nih.gov</u> ogram URL				



SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount	
	Synopsis	The Natio research of Energy mechanis	nal Institute on Aging (NIA) is resources generated by the C ) trial to improve our underst ms.	s issuing this Notice of Special Interes ALERIE (Comprehensive Assessment canding of the effects of sustained ca	t (NOSI) to en of Long-term loric restriction	courage analyses of t Effects of Reducing In n (CR) in humans and	he unique take its underlying	
108112	RFA-AG-23-009 Lipids in Brain A and its Related Dementias (ADRD	vging and A (R01 Clin	Alzheimer's Disease (AD) ical Trial Not Allowed)	National Institute on Aging/NIH/DHHS	RFA-AG- 23-009 A	5-May-2022 Optional][LOI/Pre- .pp]	2,500,000 USD	
	Contact Name	Amanda [	DiBattista, Ph.D.					
	Contact Telephone	301-827-3	3342					
	Contact Email	<u>amanda.c</u>	libattista@nih.gov					
	Sponsor Website							
	Program URL	<u>Link to pr</u>	ogram URL					
	Deadline Dates (ALL)	15-May-2	022 [Optional][LOI/Pre-App],	. 14-Jun-2022				
	Synopsis	The goal of this Funding Opportunity Announcement (FOA) is to support research addressing critical knowledge gaps in our understanding of how lipids contribute to vulnerability and resilience to brain aging and Alzheimer's disease (AD) and its related dementias (ADRD), including research addressing how: 1) lipid droplets affect brain aging and AD, including whether their accumulation is pathological or protective; (2) the periphery interacts with lipids in the aging brain, including whether these could be targets for future biomarkers; (3) APOE and lipid-mediated signaling influence brain aging and AD/ADRD progression; and (4) myelin lipids and their signaling contribute to brain aging and AD/ADRD.						
109174	RFA-AG-23-005 Health Equity a Alzheimer's Disease and Related Allowed)	nd the Cos Dementias	<u>t of Novel Treatments for</u> (R61/R33 Clinical Trial Not	National Institute on Aging/NIH/DHHS	RFA-AG- 23-005 A	1-Jun-2022 Optional][LOI/Pre- \pp]	Not Specified	
	Contact Name	Priscilla N	ovak, Ph.D., MPH					
	Contact Telephone	301-401-3	3136					
	Contact Email	NIANovel	TreatmentsRFA@nih.gov					
	Sponsor Website							
	Program URL	<u>Link to pr</u>	ogram URL					
	Deadline Dates (ALL)	01-Jun-20	22 [Optional][LOI/Pre-App],	01-Jul-2022				

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Synopsis	This Fundi to new the Successful people livi living with receiving r stakeholde repurpose and health	ing Opportunity Announcement erapeutics or repurposed drug l applications will seek to iden- ing with AD/ADRD, assess whe had AD/ADRD, and quantify expent novel or repurposed drugs for er engagement with racial and ed drugs. If successful, grantee harelated quality of life and dis	nt (FOA) invites R61/R33 application as for Alzheimer's disease (AD) and a tify preferences for pharmacologica ether cost barriers to pharmacologic nditures and health-related quality AD/ADRD. This FOA supports a stud ethnic minority groups to identify, s will transition to an R33 phase for esemination of model findings.	ns to address Alzheimer's d I treatment a cal care exist of life (HRQo dy developme measure, an implementa	health equity, drug cos isease-related dement mong racial and ethnic for racial and ethnic mi L) among people intere ent phase (R61) to conc d assess the demand fo tion of rigorous modeli	sts, and access ias (ADRD). c minority nority people ested in duct rigorous or new and ng of costs
109243	<u>RFA-AG-23-014 Mechanisms of</u> (R01 Clinical Trial Not Allowed)	Brain Hypo	operfusion in AD/ADRD	National Institute on Aging/NIH/DHHS	RFA-AG- 23-014	01-Jun-2022 [Optional][LOI/Pre- App]	Not Specified
	Contact Name	Miroslaw	'Mack' Mackiewicz, Ph.D.				
	Contact Telephone	301-594-7	/636				
	Contact Email	miroslaw.	mackiewicz@nih.gov				
	Sponsor Website						
	Program URL	Link to pro	ogram URL				
	Deadline Dates (ALL)	01-Jun-20	22 [Optional][LOI/Pre-App], 0	1-Jul-2022			
	Synopsis cellular mechanisms underlying cere dementias (ADRD).			nt (FOA) solicits applications for pro I blood flow reduction in Alzheimer	jects designe 's disease (AI	d to understand molec )) and Alzheimer's dise	ular and ase-related
107991	RFA-AG-23-003 Resources to Pr Collaboration across Deeply Phen Social Studies of Aging (U24 Clinic	romote Coo notyped Lor cal Trial Not	ordination and ngitudinal Behavioral and t Allowed)	National Institute on Aging/NIH/DHHS	RFA-AG- 23-003	01-Jun-2022 [Optional][LOI/Pre- App]	1,600,000 USD
	Contact Name	Janine Sim	imons, M.D., Ph.D.				
	Contact Telephone	301-529-7	254				
	Contact Email	janine.sim	imons@nih.gov				
	Sponsor Website						
	Program URL	Link to pro	ogram URL				

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Deadline Dates (ALL) 01-J This on t long FOA and Synopsis rich and tear adu	22 [Optional][LOI/Pre-App], 01 ing Opportunity Announcemen rastructure needed to promote al behavioral and social studies for investigator teams to design ination among studies. Networ that will stimulate innovation a tform that will identify and des ological, behavioral, and biobe ort cross-project co-analysis. M everage existing deeply pheno- pan, including the influence of alizability issues: and provide e	-Jul-2022 t (FOA) invites applications to estable and support coordination, collabo s of aging that are rich in psycholog n an innovative network that will se rk activities are expected to include and collaboration. Creation of a pub cribe existing deeply phenotyped b havioral content; identify studies we ethodological consultation services typed longitudinal studies to answe social and behavioral factors on he	blish a Resource I ration, and innov ical, behavioral, a erve the field at la : Outreach to inv licly available me ehavioral and so vith overlapping r for investigators er new questions althspan and bio	Development Netw vation across deep and biobehavioral arge and advance of vestigators and sup eta-data catalogue cial datasets chara measures or compa- s. Pilot support for of relevance to ag logical aging; addr	vork focused ly phenotyped content. This collaboration oport for on a web- cterized by atible designs; collaborative ing and the ess replication	
082123	Cognitive Systems Analysis of Alzheim Phenotypic Data (U01 Clinical Trial No	ner's Di Dit Allow	isease Genetic and N ved) A	ational Institute on ging/NIH/DHHS	PAR-19- 269 05-J	un-2022	Not Specified
Contact Name Contact Telephone Contact Email Marilyn Miller, Ph.D. Contact Email Millerm@nia.nih.gov Sponsor Website Program URL Deadline Dates (ALL) Deadline Dates (ALL) Synopsis identification of gene mutations/variants that cause or contribute to the risk of or protection against the dev Alzheimer's disease (AD) and Alzheimer's disease related dementias (ADRD) via analysis of a variety of genetic biomarker data that are currently available to the research community.						ntelligence (AI), Ma tive systems," that n against the devel variety of genetic,	achine t lead to the opment of genomic, and
083316	Non-Invasive Neurostimulation in AD/	/ADRD	(R01 Clinical Trial Optional) A	ational Institute on ging/NIH/DHHS	PAR-19- 298 05-J	un-2022	Not Specified

Contact Name Kristina McLinden

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Contact Telephone	301-827-	2563				
	Contact Email	kristina m	uclinden@nih.gov				
	Sponsor Website	<u>in iseniani</u>					
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	05-Jun-20	)22				
	Synopsis	The goal ( neurostin (ADRD). T AD/ADRD provided invasive t	of this Funding Opportunity Annuation/neuromodulation in the nulation/neuromodulation in the begoal of this FOA is to establing or to refine these intervention the focus and innovative compo- echniques are outside the scop	nouncement (FOA) is to encourage ne treatment of Alzheimer's disease sh initial efficacy of neurostimulation is for AD/ADRD patients. Multimoda onent is neurostimulation. Applicat ne of this FOA.	applications for s (AD) or Alzheim on/neuromodula al or combinatior ions that seek to	studies using non-i er's disease-related tion in the treatme n interventions are develop devices, t	nvasive d dementias ent of allowed, cools, or
083523	NIA Multi-site Clinical Trial Impler Required)	<u>mentation</u>	Grant (R01 Clinical Trial A	ational Institute on ging/NIH/DHHS	PAR-19- 302 05-J	un-2022	Not Specified
	Contact Name	Sergei Ro	mashkan, M.D., Ph.D.				
	Contact Telephone	301-435-3	3047				
	Contact Email	<u>romashks</u>	@mail.nih.gov				
	Sponsor Website						
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	05-Jun-20	022				
	Synopsis	This Fund intervent research	ing Opportunity Announcemen ional clinical trials (all phases). <sup>-</sup> mission. Information about NIA	t (FOA) invites applications for imp The trials should be hypothesis-driv 's mission can be found on the NIA	lementation of ir en, milestone-de website.	vestigator-initiate fined, and related	d multi-site to NIA's
084767	Limited Competition: Renewals of the Longitudinal Early-onset Alzhe Cooperative Agreement (U01 Clin	f, and Revi eimer's Dis iical Trial N	isions and Resubmissions to, sease Study (LEADS) A lot Allowed)	ational Institute on ging/NIH/DHHS	PAR-19- 338 05-J	un-2022	Not Specified
	Contact Name	John K. H	siao, M.D.				
	Contact Telephone	301-496-9	9350				

SPIN ID Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	05-Jun-2022				
Synopsis	This FOA invites revision, resubmissio (LEADS) Cooperative Agreement. Revis award.	n, or renewal applications to the Lo sion applications may not request fu	ngitudinal Early-o Inding beyond the	nset Alzheimer's D e project end date o	sease Study of the Parent
100902 Alzheimer's Clinical Trials Consort	ium (ACTC) Clinical Trials (R01 Clinical	National Institute on	PAR-20-	lun-2022	Not
Trial Required)		Aging/NIH/DHHS	309	Juli-2022	Specified
Contact Name	Laurie Ryan, Ph.D.				
Contact Telephone	301-496-9350				
Contact Email	ryanl@mail.nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	05-Jun-2022 , 05-Oct-2022 , 05-Feb-20	023 , 05-Jun-2023 , 05-Oct-2023			
Synopsis	This Funding Opportunity Announcem promising pharmacological and non-p Alzheimer's disease (AD) and other ag trial coordination and management in	ent (FOA) invites applications to dev harmacological interventions that m e-related dementias using the Alzhe frastructure.	velop and implem nay prevent, delay nimer's disease Cli	ent Phase Ib to III o , or treat the symp nical Trials Consort	linical trials of toms of ium (ACTC)
Pragmatic Clinical Trial on Efficacy081010Risk of Clinically Important Eventsand Anemia (U01 Clinical Trial Res	y of Managing Reduced Iron Stores on s in Older Adults with Heart Failure quired)	National Institute on Aging/NIH/DHHS	PA-19- 230 05-	Jun-2022	Not Specified
Contact Name	Sergei Romashkan, MD, Ph.D.				
Contact Telephone	301-435-3047				
Contact Email	<u>romashks@nia.nih.gov</u>				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	05-Jun-2022				



SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount			
	Synopsis	This FOA invites applications for a pra clinically important events in older ad	gmatic clinical trial to establish ults with heart failure and anen	efficacy of manag nia.	ing reduced iron stores	on risk of			
091505	Translational Bioinformatics Appr and Combination Therapy Develo Clinical Trial Optional)	oaches to Advance Drug Repositioning presented by the presence of the presence	National Institute on Aging/NIH/DHHS	PAR-20- 156	05-Jun-2022	Not Specified			
	Contact Name	Jean Yuan, Ph.D.							
	Contact Telephone	301-496-9350							
	Contact Email	yuanx4@mail.nih.gov							
	Sponsor Website								
	Program URL	Link to program URL							
	Deadline Dates (ALL) 05-Jun-2022 , 05-Oct-2022 , 05-Feb-2023								
	Synopsis	This Funding Opportunity Announcement (FOA) enables data-driven drug repositioning and combination therapy for Alzheimer's disease and Alzheimer's disease-related dementias (AD/ADRD) by developing computational methods and data resources and/or integrating computational approaches with proof-of-concept efficacy studies in cell-based models, animal models, and/or humans.							
107419	Alzheimer's Drug-Development P	rogram (U01 Clinical Trial Optional)	National Institute on Aging/NIH/DHHS	PAR-22- 047	05-Jun-2022	5,000,000 USD			
107419	<u>Alzheimer's Drug-Development P</u> Contact Name	rogram (U01 Clinical Trial Optional)	National Institute on Aging/NIH/DHHS	PAR-22- 047	05-Jun-2022	5,000,000 USD			
107419	<u>Alzheimer's Drug-Development P</u> Contact Name Contact Telephone	Lorenzo M. Refolo, Ph.D. 301-594-7576	National Institute on Aging/NIH/DHHS	PAR-22- 047	05-Jun-2022	5,000,000 USD			
107419	<u>Alzheimer's Drug-Development P</u> Contact Name Contact Telephone Contact Email	rogram (U01 Clinical Trial Optional) Lorenzo M. Refolo, Ph.D. 301-594-7576 refolol@nia.nih.gov	National Institute on Aging/NIH/DHHS	PAR-22- 047	05-Jun-2022	5,000,000 USD			
107419	<u>Alzheimer's Drug-Development P</u> Contact Name Contact Telephone Contact Email Sponsor Website	rogram (U01 Clinical Trial Optional) Lorenzo M. Refolo, Ph.D. 301-594-7576 refolol@nia.nih.gov	National Institute on Aging/NIH/DHHS	PAR-22- 047	05-Jun-2022	5,000,000 USD			
107419	<u>Alzheimer's Drug-Development P</u> Contact Name Contact Telephone Contact Email Sponsor Website Program URL	rogram (U01 Clinical Trial Optional) Lorenzo M. Refolo, Ph.D. 301-594-7576 refolol@nia.nih.gov Link to program URL	National Institute on Aging/NIH/DHHS	PAR-22- 047	05-Jun-2022	5,000,000 USD			
107419	<u>Alzheimer's Drug-Development P</u> Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL)	rogram (U01 Clinical Trial Optional) Lorenzo M. Refolo, Ph.D. 301-594-7576 refolol@nia.nih.gov Link to program URL 05-Jun-2022 , 05-Oct-2022 , 05-Feb-20	National Institute on Aging/NIH/DHHS 023 , 05-Jun-2023 , 05-Oct-2023	PAR-22- 047 3 , 05-Feb-2024 , 0	05-Jun-2022 )5-Jun-2024 , 05-Oct-20	5,000,000 USD			

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		Manufact Applicatio developm drugs and alone clin	ouring Practices (GMP); Invest ons not responsive to this FO nent of biomarkers, devices, r I combinations therapies; disc ical trials.	igational New Drug (IND) enabling st A include: research on basic mechani non-pharmacological interventions (e covery activities such as high-through	udies; and initi sms of disease .g., exercise, di nput screening	al Phase I clinical tes or mechanisms of di et, cognitive training and hit optimization	ting. Tug action; g), repurposed ; and stand-
108328	Early and Late Stage Clinical Trials Disease/Alzheimer's Related Dem Decline (R01 Clinical Trial Optiona	s for the Sp nentias and al)	ectrum of Alzheimer's Age-Related Cognitive	National Institute on Aging/NIH/DHHS	PAR-18- 878 0!	5-Jun-2022	Not Specified
	Contact Name	Laurie Ry	an				
	Contact Telephone	301-496-9	9350				
	Contact Email	<u>ryanl@m</u>	ail.nih.gov				
	Sponsor Website						
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	05-Jun-20	022 , 05-Oct-2022 , 05-Feb-20	23 , 05-Jun-2023 , 05-Oct-2023 , 05-F	eb-2024 , 05-J	un-2024 , 05-Oct-202	<u>2</u> 4
	Synopsis	The purpo implemen cognitive Alzheime and 2) sti	ose of this Funding Opportun nt early to late stage clinical to and neuropsychiatric change r's disease-related Dementias mulate studies to enhance tri	ity Announcement (FOA) is to 1) invit rials of promising pharmacological ar s associated with age-related cogniti s (ADRD) across the spectrum from p al design and methods.	e applications nd non-pharma ve decline and re-symptomati	that propose to devo cological interventio Alzheimer's disease c to more severe sta	elop and ns for (AD) and ges of disease,
102978	Limited Competition: Alzheimer's Up Study 2.0 (ADSP FUS 2.0): The Clinical Trial Not Allowed)	Disease S Diverse Po	equencing Project Follow- opulation Initiative (U01	National Institute on Aging/NIH/DHHS	PAR-21- 212 0!	5-Jun-2022	Not Specified
	Contact Name	Marilyn N	1iller, Ph.D.				
	Contact Telephone	301-496-9	9350				
	Contact Email	<u>millerm@</u>	nia.nih.gov				
	Sponsor Website						
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	05-Jun-20	022 , 05-Oct-2022 , 05-Feb-20	23 , 05-Jun-2023 , 05-Oct-2023 , 05-F	eb-2024		

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Synopsis	This Fund studies, w and analy Project Fo	ing Opportunity Announcemer /hole genome sequencing, qua sis that will support the genera ollow-Up Study 2.0: The Diverse	nt (FOA) invites applications specific lity control checking, variant calling ation of data from multi-ethnic coho e Population Initiative (ADSP FUS 2.	to sample ac , data calling, orts for the Al 0).	equisition, genome wic data sharing, data ha zheimer's Disease Seq	le association monization, uencing
109301	<u>RFA-AG-23-007 Screening for Co</u> (U24 Clinical Trial Optional)	ognitive In	npairment: Decision-Making A	lational Institute on ging/NIH/DHHS	RFA-AG- 23-007	11-Jun-2022 [Optional][LOI/Pre- App]	10,720,000 USD
	Contact Name	Jonathan	W. King, Ph.D.				
	Contact Telephone	301-496-3	3136				
	Contact Email	NIAScree	ningDMFOA@nih.gov				
	Sponsor Website						
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	11-Jun-20	22 [Optional][LOI/Pre-App], 11	-Jul-2022			
	Synopsis	This Fund that could outcomes that could targeting partners/ dimension decision-r instrumer as well as normative	ing Opportunity Announcemer d be used to screen for deficits is in older adults. In particular, v d be useful in the context of fut functional outcomes in person caregivers. The goal of this FOA ns of higher cognitive abilities a making; to develop valid and re nt development and validation a set of enduring resources. En e data that will enable other, fu	It (FOA) invites research to develop related to decision-making, plannin we are interested in instruments that sure screening for cognitive impairment a living with cognitive impairment a A is to support a research network we and functional capacities already be cliable measures of those abilities; a in a racially, ethnically, geographica induring resources include the meas sture projects to incorporate the ne	, validate, an ag, and other at can track cl nent and the and/or quality whose goals w lieved to sup and to provide ally, and diagr urement inst	d disseminate measur important higher orden nanges in decision-ma development of interv of life outcomes of the yould be to review and port higher order plan e support for pilot effor nostically diverse set of ruments, documentat ents into studies.	ement tools r functional king capacity entions leir care l assess the ning and rts during the f participants, ion, and
106670	NIA Career Transition Award (K22	Independ	ent Clinical Trial Not	lational Institute on	PAR-21-	12-lun-2022	Not
100070	Allowed)		А	ging/NIH/DHHS	351	LE JUII-EVEE	Specified
	Contact Name	Saroj Reg	mi, Ph.D.				
	Contact Telephone	301-480-8	3964				
	Contact Email	saroj.regr	ni@nih.gov				



SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Sponsor Website Program URL Deadline Dates (ALL) Synopsis	Link to program URL 12-Jun-2022 , 12-Oct-2022 , 12-Feb-20 The purpose of the NIA Career Transition faculty positions conducting research t time through salary and research supp institution/organization to which the ir assistant professor position (or equival candidates proposing research that do an ancillary clinical trial.	23 , 12-Jun-2023 , 12-Oct-2023 , 12-F on Award (CTA) is to facilitate the tra hat advances the mission of NIA. Thi ort to conduct biomedical research a ndividual has been recruited, been of ent). This Funding Opportunity Annc es not involve leading an independer	Feb-2024 , 12-Jun ansition of mento s award will provi at an extramural s ffered, and has ac puncement (FOA) nt clinical trial, a c	-2024 , 12-Oct-202 red researchers to ide three years of ponsoring ccepted a tenure-t is designed specifi clinical trial feasibi	24 tenure-track protected rack full-time ically for lity study, or
104436	NIA Advanced Postdoctoral Career Diversity in Translational Research Not Allowed)	r Transition Awards to Promote n for AD/ADRD (K99/R00 Clinical Trial	National Institute on Aging/NIH/DHHS	PAR-21- 220 12-J	un-2022	Not Specified
	Contact Name	Yuan Luo, Ph.D.				
	Contact Telephone	301-496-9350				
	Contact Email	<u>yuan.luo@nih.gov</u>				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	12-Jun-2022 , 12-Oct-2022 , 12-Feb-20	23 , 12-Jun-2023 , 12-Oct-2023 , 12-F	eb-2024 , 12-Jun	-2024	
	The purpose of this Funding Opportunity Announcement (FOA) is to promote diversity in the translational research workforce for Alzheimer's disease and Alzheimer's disease-related dementias (AD/ADRD). This pathway to independen award will emphasize the development of skills in data science and drug discovery, and their application to various asp of AD/ADRD research (from populations studies to research that can lead to new treatments and diagnostics, including aspects of behavioral and social research). This award will support early career investigators from diverse backgrounds gain critical translational skills in data science and drug discovery and transition to research independence The long-te goal of this program is to develop a diverse translational research workforce that can effectively participate in and/or le team-science, precision medicine approach to studies of AD/ADRD treatment, prevention, early detection, and disease management and care. This Funding Opportunity Announcement (FOA) is designed for candidates proposing research does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial. Under FOA candidates are permitted to propose a research experience in a clinical trial led by a mentor or co-mentor.					

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount		
109431	<u>RFA-AG-23-010 Noncoding RNA</u> Dementias (R01 Clinical Trial Not	As in Alzheimer's Disease and Related Allowed)	National Institute on Aging/NIH/DHHS	RFA-AG- 23-010	15-Jun-2022 [Optional][LOI/Pre- App]	2,500,000 USD		
	Contact Name	Alison Yao, Ph.D.						
	Contact Telephone	301-827-7264						
	Contact Email	<u>yaoal@nia.nih.gov</u>						
	Sponsor Website							
	Program URL	Link to program URL						
	Deadline Dates (ALL)	15-Jun-2022 [Optional][LOI/Pre-App],	15-Jul-2022					
	Synopsis	The goal of this Funding Opportunity A investigate the causality, directionality Alzheimer's disease-related dementias mediated by ncRNAs and to elucidate AD/ADRD.	Announcement (FOA) is to stimulate r y, mechanisms, and therapeutic poter s (AD/ADRD). This FOA supports appli molecular and cellular functions invo	esearch in n ntial of ncRN cations seek lved in the p	oncoding RNAs (ncRNA IAs in Alzheimer's disea king to discover novel n bathogenesis and progr	As) to use and nechanisms ession of		
109432	<u>RFA-AG-23-011 Noncoding RNA</u> Dementias (R21 Clinical Trial Not	As in Alzheimer's Disease and Related Allowed)	National Institute on Aging/NIH/DHHS	RFA-AG- 23-011	15-Jun-2022 [Optional][LOI/Pre- App]	275,000 USD		
	Contact Name	Alison Yao, Ph.D.						
	Contact Telephone	301-827-7264						
	Contact Email	<u>yaoal@nia.nih.gov</u>						
	Sponsor Website							
	Program URL	Link to program URL						
	Deadline Dates (ALL)	15-Jun-2022 [Optional][LOI/Pre-App],	15-Jul-2022					
	Synopsis	he goal of this Funding Opportunity Announcement (FOA) is to stimulate research in noncoding RNAs (ncRNAs) to nvestigate the causality, directionality, mechanisms, and therapeutic potential of ncRNAs implicated in Alzheimer's disease and Alzheimer's disease-related dementias (AD/ADRD). This FOA supports exploratory and developmental grant (R21) applications seeking to discover functional roles of ncRNAs and underlying mechanisms involved in the pathogenesis and progression of AD/ADRD. Proposed studies should focus on functional characterization and mechanistic investigation of previously identified ncRNAs.						

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
083550 E	arly-Stage T1 Translational Aging Re	esearch (Bench to Bedside) for the	National Institute on	PAR-19-	un-2022	1,500,000
<u></u>	evelopment of Novel Therapeutics	(R33 Clinical Trial Optional)	Aging/NIH/DHHS	304	_	USD
	Contact Name Ch	handa Dutta, Ph.D.				
	Contact Telephone 30	1-496-4161				
	Contact Email <u>du</u>	<u>ttac@nia.nih.gov</u>				
	Sponsor Website					
	Program URL <u>Lin</u>	nk to program URL				
	Deadline Dates (ALL) 16	-Jun-2022				
	Th fac the pe me cla pro rep inv Synopsis to ori en stu R2 rel co R3 ph its	is Funding Opportunity Announceme cilitate early-stage T1 translation (be erapeutics for the prevention and tre ople (e.g., sarcopenia, hearth failure etabolic syndrome, chronic kidney di asses of compounds (e.g., senolytics, oducts (or their derivatives, mimics, purposing of Food and Drug Adminis volve novel treatment targets and/or provide milestone-driven support (u iginally initiated under the R21 mech couraged to apply to this FOA to exp udies. Other applicants with sufficien (1) for a novel drug target, new comp lated conditions are also eligible to a nducted under the R33 is expected to a support should advance the exper armacological interventions is conside related dementias are outside the s	ent (FOA) encourages Exploratory/Dench-to-bedside) of discoveries from the eatment of clinical conditions related with preserved ejection fraction (HF sease). This includes the developmer anti-inflammatory agents, modulato and synthetic equivalents), biologics, tration (FDA)-approved drugs. Applice innovative approaches for engaging to 5 years) for innovative explorated and strong preliminary/proof-of-cobound(s), or for a potential new clinice pply to this FOA. The scope of early-so vary with the stage of translation of imental intervention closer to humar dered outside the scope of this FOA.	velopmental Phase basic and applied to aging or multipePF), immunosen it of pharmacolog rs of proteostasis stem/progenitor ations submitted known targets. T ory and developm translational aging indidate pharmaco incept data (equive cal indication for a stage T1 translatic of the candidate the testing (if warran Applications that	se II (R33) grant a research in aging ple chronic condit escence, pulmona gical strategies suc and autophagy), cell-based therap in response to thi he R33 mechanism ental research act g research progra logical intervention valent to that ach in FDA-approved op onal research active nerapeutic. Never- inted). The develop focus on Alzheimo	pplications to into novel ions in older ary fibrosis, ch as new natural ies, and the s FOA may m is intended tivities m are ons from prior evable under a drug for age- /ities to be theless, the pment of non- er's disease or

002551	Early-Stage T1 Translational Aging Research (Bench to Bedside) for the	National Institute on	PAR-19-	16 Jun 2022	Not
002221	Development of Novel Therapeutics (R21/R33 Clinical Trial Optional)	Aging/NIH/DHHS	305	10-Jun-2022	Specified

Contact Name Chhanda Dutta, Ph.D.

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) Synopsis	301-496-4161 duttac@nia.nih.gov Link to program URL 16-Jun-2022 This Funding Opportunity Announceme applications to facilitate early-stage T1 into novel therapeutics for the prevent conditions in older people (e.g., sarcop metabolic syndrome, chronic kidney dis classes of compounds (e.g., senolytics, products (or their derivatives, mimics, a repurposing of Food and Drug Administ milestone-driven exploratory phase) fo support (R33 phase) for further/expand funds for the development of assays ar R21 and/or R33 phases. Funding for the the R21 phase. The development of no Applications that focus on Alzheimer's Applications using only the R21 mechan	nt (FOA) encourages Exploratory/Det translation (bench-to-bedside) of dis ion and treatment of clinical condition enia, heart failure with preserved eje sease). This includes the development anti-inflammatory agents, modulato and synthetic equivalents), biologics, iration (FDA)-approved drugs. This F r preliminary, proof-of-concept stud led preclinical development of the c d other methodologies required for e R33 phase will be contingent on su n-pharmacological interventions is c disease or its related dementias are hism will not be accepted under this	evelopmental Pha scoveries from ba ons related to agi ection fraction (H nt of pharmacolo ors of proteostasis , stem/progenitor OA provides supp lies, which is follo andidate therape translational stur ccessful completi onsidered outside outside the scope FOA.	ased Innovation (R asic and applied re ng and/or multiple FpEF), immunoser gical strategies suc s and autophagy), r cell-based therap port for up to two wed by up to thre eutic. Applicants m dies in the project ion of established e the scope of this e of this announce	21/R33) grant search in aging e chronic tescence, ch as new natural bies, and the years (R21, e years of ay request budget for the milestones in FOA. ment.
086244 i	Small Research Grant Program for n AD/ADRD Research: Area of Foo Data Sets for Analyses (R03 Clinica	the Next Generation of Researchers cus Archiving and Leveraging Existing al Trial Not Allowed)	National Institute on Aging/NIH/DHHS	PAS-19- 391 16-J	un-2022	200,000 USD
	Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL)	Partha Bhattacharyya, Ph.D. 301-496-3136 <u>bhattacharyyap@mail.nih.gov</u> <u>Link to program URL</u> 16-Jun-2022 , 16-Oct-2022				

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Synopsis	This Sma improve t related de projects c generatio and (ii) to developin from unde NIH suppo	II Research Grant (R03) will sup the prevention, diagnosis, treat ementias (AD/ADRD). Specifica covering a wide array of topics of on of U.S. researchers to pursue stimulate established research og new, innovative AD/ADRD re errepresented racial and ethnic ort.	port important and innovative proj ment, and/or care for individuals w lly, this FOA will support archiving a relating to AD/ADRD. The overall go research and academic careers in m ners who are not currently doing AD search programs that leverage and c groups, as well as individuals with	ects to provide r ith Alzheimer's o nd leveraging ex al of this FOA is neuroscience, AI D/ADRD research build upon their disabilities, are a	needed scientific ins disease and Alzhein disting data sets for (i) to encourage the D/ADRD, and health to perform pilot st existing expertise. always encouraged	sight to ner's disease- analyses of e next by brain aging udies Individuals to apply for
086248 <u>i</u>	Small Research Grant Program for n AD/ADRD Research: Area of Foo Not Allowed)	<u>the Next</u> cus Basic S	Generation of Researchers Science (R03 Clinical Trials A	lational Institute on ging/NIH/DHHS	PAS-19- 392 16-	lun-2022	200,000 USD
	Contact Name	Lisa Opan	ashuk, Ph.D.				
	Contact Telephone	301-807-5	5422				
	Contact Email	lisa.opana	ashuk@nih.gov				
	Sponsor Website						
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	16-Jun-20	022 , 16-Oct-2022				
	Synopsis	This Sma elucidate (AD/ADRI individual pursue re researche AD/ADRD and ethni	II Research Grant (R03) will sup neurodegenerative mechanisn D). Proposed projects should ul s with AD/ADRD. The program search and academic careers in ers who are not currently doing research programs that levera c groups, as well as individuals	port important and innovative proj ns/pathways of Alzheimer's disease timately aim to improve the prever seeks (i) to facilitate the next gener n neuroscience, AD/ADRD, and heal AD/ADRD research to perform pilo ge and build upon their existing exp with disabilities, are always encour	ects focused on and Alzheimer's ation, diagnosis, ration of researc thy brain aging a t studies toward pertise. Individua aged to apply fo	basic science appro disease-related de treatment, and/or hers in the United S and (ii) to stimulate developing new, ir als from underrepre r NIH support.	baches to mentias care for States to established novative esented racial
086252 <u>i</u>	Small Research Grant Program for n AD/ADRD Research: Area of Foo Not Allowed)	the Next cus Systen	Generation of Researchers ns Biology (R03 Clinical Trial A	lational Institute on ging/NIH/DHHS	PAS-19- 393 16	lun-2022	200,000 USD

Contact Name Alison Yao, Ph.D.

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		201 100					
	Contact Telephone	301-496-	9350				
	Contact Email	alison.yad	<u>o@nih.gov</u>				
	Sponsor Website						
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	16-Jun-20	)22 , 16-Oct-2022	- · · · · · · · · · · · · · · · · · · ·			
	Synopsis	scientific and Alzhe generatic healthy b pilot stud expertise encourag	insight is needed to improve t eimer's disease-related demen on of researchers in the United rain aging and (ii) to stimulate ies toward developing new, in . Individuals from underrepres ed to apply for NIH support.	he prevention, diagnosis, treatment, tias (AD/ADRD). The overall goal of t States to pursue research and acade established researchers who are no novative AD/ADRD research program sented racial and ethnic groups, as w	and care for ind his R03 program emic careers in n t currently doing ns that leverage ell as individuals	ividuals with Alzhe is (i) to facilitate the euroscience, AD/A AD/ADRD research and build upon the with disabilities, a	imer's disease ne next DRD, and n to perform eir existing re always
108329	Pilot Studies for the Spectrum of A Disease-Related Dementias and A Clinical Trial Optional)	<u>Alzheimer</u> Age-Relate	' <u>s Disease/Alzheimer's</u> d Cognitive Decline (R61	National Institute on Aging/NIH/DHHS	PAR-21- 360 17-J	un-2022	650,000 USD
	Contact Name	Laurie Ry	an				
	Contact Telephone	301-496-9	9350				
	Contact Email	ryanl@m	ail.nih.gov				
	Sponsor Website						
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	17-Jun-20	022 , 18-Oct-2022 , 17-Feb-202	23 , 19-Jun-2023 , 18-Oct-2023 , 20-F	eb-2024 , 18-Jun	-2024 , 18-Oct-202	4
	Synopsis	The purpe collection for cognit Alzheime and 2) sti	ose of this Funding Opportunit of pilot data to support early tive and neuropsychiatric chan r's disease-related dementias mulate studies to enhance tria	ey Announcement (FOA) is to 1) invite stage testing of promising pharmacc ges associated with age-related coge (ADRD) across the spectrum from pr al design and methods.	e research grant blogical and non- nitive decline and e-symptomatic to	applications that e pharmacological ir d Alzheimer's disea o more severe stag	nable the nterventions se (AD) and ges of disease,
101458	Notice of Special Interest (NOSI): Organ System Diseases (R01/R21,	<u>Alcohol-in</u> /R03)	duced Tissue-specific and	National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS	NOT-AA- 20-024 07-N	May-2022	Not Specified

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Contact Name	Li Lin				
	Contact Telephone	Jul-827-7749				
	Sponsor Website					
	Program URI	Link to program URI				
	Deadline Dates (ALL)	07-May-2022 , 05-Jun-2022 , 16-Jun-20 2023 , 07-May-2023 , 05-Jun-2023 , 16- Feb-2024 , 07-May-2024	22 , 07-Sep-2022 , 05-Oct-2022 , 16-( Jun-2023 , 07-Sep-2023 , 05-Oct-202	Oct-2022 , 07-Jan 3 , 16-Oct-2023 ,	-2023 , 05-Feb-20 07-Jan-2024 , 05-	23 , 16-Feb- Feb-2024 , 16-
	Synopsis	The purpose of this Notice is to inform studying the harmful effects of alcohol	potential applicants of the NIAAA's s on the body's tissues, organs, and sy	pecial interest in stems in diverse	research project a populations acros	pplications s the lifespan.
098270	Notice of Special Interest (NOSI):	Alcohol and Aging	National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS	NOT-AA- 20-019 07-N	1ay-2022	Not Specified
	Contact Name	Andras Orosz, Ph.D.				
	Contact Telephone	301-443-2193				
	Contact Email	orosza@mail.nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-May-2022 , 05-Jun-2022 , 16-Jun-20 2023 , 07-May-2023 , 05-Jun-2023 , 16-	22 , 07-Sep-2022 , 05-Oct-2022 , 16-0 Jun-2023 , 07-Sep-2023	Oct-2022 , 07-Jan	-2023 , 05-Feb-20	23 , 16-Feb-
	Synopsis	The purpose of this Notice of Special In alcohol consumption on aging across di organ, organism, and societal levels. Th defining the effects of alcohol consump consumption, drinking pattern, and dur for alcohol use disorder (AUD) among c and 3) Research to extend the health sp diseases associated with alcohol use.	terest (NOSI) is to promote research fferent levels of biological organizati e following broad research areas will otion on lifespan, health span, and ag ration of drinking; 2) Research to info older adults as well as prevention, dia pan of older adults who drink and de	to improve our u on including the r l be encouraged: ge-related disease orm evidence-bas agnosis, and treat crease the health	nderstanding of the molecular, cellular 1) Basic and clinic s depending on le ed guidance for id ment of AUD in the care burden of ag	ne effects of , tissue, al research vel of alcohol entifying risk nis population; ge-related
097916	Notice of Special Interest (NOSI): Research Data	Secondary Analyses of Existing Alcohol	National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS	NOT-AA- 20-018 07-N	1ay-2022	Not Specified

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount	
	Contact Name	Wenxing	Zha, Ph.D.					
		301-443-0						
		<u>znaw@m</u>	<u>all.nin.gov</u>					
		Link to pr	ogram UDI					
	Program UKL			2 16 lun 2022 07 5an 2022 05	Oct 2022 16 Oc	+ 2022 07 100 20		
	Deadline Dates (ALL)	2023, 16	-Feb-2023 , 07-May-2023 , 16-J	un-2023	000-2022 , 16-00	t-2022 , 07-Jan-20	23,05-Feb-	
The purpose of this Notice of Special Interest (NOSI) is to solicit applications to support the secondary analyses of data sets with the goal of enhancing our understanding of the following: 1) the patterns and trajectories of alcoho consumption, 2) the epidemiology and etiology, including genetics, of alcohol-related problems and disorders, and alcohol-related health services and health systems, including access, quality, and efficiency. This Notice encourage applications proposing innovative analyses of existing alcohol research data, answering novel research hypotheses questions, and developing and testing advanced analytical methodologies applicable to alcohol related epidemiology.								
100945	Notice of Special Interest (NOSI): Treatment, Services, and Recover	Advances ry of Alcoh	in Research for the N ol Use Disorder a	lational Institute on Alcohol Abuse nd Alcoholism/NIH/DHHS	NOT-AA- 20-022 07-N	May-2022	Not Specified	
	Contact Name	Brett T. H	agman, Ph.D.					
	Contact Telephone	301-443-0	0638					
	Contact Email	brett.hag	man@nih.gov					
	Sponsor Website							
	Program URL	Link to pr	ogram URL					
	Deadline Dates (ALL)	07-May-2 2023 , 07·	022 , 05-Jun-2022 , 16-Jun-202 -May-2023 , 05-Jun-2023 , 16-J	2 , 07-Sep-2022 , 05-Oct-2022 , 16- un-2023 , 07-Sep-2023	Oct-2022 , 07-Jar	1-2023 , 05-Feb-20	23 , 16-Feb-	
The purpose of this Notice of Special Interest (NOSI) is to advance research on various topics that fall within NIAAA's of Treatment and Recovery Research (DTRR). DTRR's research interests are wide-ranging and encompass broad cate such as health services, behavioral therapies and mechanisms of behavioral change (MOBC), recovery, translational research, and innovative methods and technologies for alcohol use disorder (AUD) treatment and sustaining recover areas of interest include topics focusing on special-emphasis and underserved populations, including NIH-designated health disparity populations, as well as those with co-occurring disorders; and fetal alcohol spectrum disorders (FAS								

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		studies, a populatic	t all levels from FASD to elder on at large.	ly, efforts will be made to include pa	irticipants that re	flect the diversity	of the
105028	Notice of Special Interest (NOSI): Tolerance	<u>Genetics c</u>	of Alcohol Sensitivity and	National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS	NOT-AA- 21-029 07-1	May-2022	Not Specified
	Contact Name	Hemin Ch	nin, PhD				
	Contact Telephone	301-443-	1282				
	Contact Emai	<u>hemin.ch</u>	in@nih.gov				
	Sponsor Website	h.					
	Program URI	Link to pr	ogram URL				
07-May-2022 , 05-Jun-2022 , 16-Jun Deadline Dates (ALL) 2023 , 07-May-2023 , 05-Jun-2023 , Feb-2024 , 07-May-2024 , 05-Jun-20				22 , 07-Sep-2022 , 05-Oct-2022 , 16- Jun-2023 , 07-Sep-2023 , 05-Oct-202	Oct-2022 , 07-Jai 23 , 16-Oct-2023	1-2023 , 05-Feb-20 , 07-Jan-2024 , 05-	23 , 16-Feb- Feb-2024 , 16-
	The purpose of this notice of special interest (NOSI) is to provide enhanced understanding of genetic, genomic, and epigenetic factors contributing to biological processes for individual variation in sensitivity, the development of tole and progression to AUD. NIAAA is interested in projects that will develop innovative strategies integrating both exp and bioinformatics approaches to establish causality for candidate genes from GWAS and linkage studies and to progression to genetic mechanisms of alcohol sensitivity and the development of tolerance through investigation of genetic, or transcriptional variation, and gene network and pathway analyses. Applicants are encouraged to con model systems in which these complex relationships can be better studied under defined genetic backgrounds and controlled environmental conditions.						
107782	Notice of Special Interest (NOSI): Alcohol Misuse in Understudied N Workforce, and Community Colle	Epidemiol Young Adu ege	ogy and Prevention of It Populations; Military,	National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS	NOT-AA- 22-001 05-J	un-2022	Not Specified
	Contact Name	Bradley K	erridge, Ph.D.				
	Contact Telephone	301-827-	7493				
	Contact Emai	bradley.k	erridge@nih.gov				
	Sponsor Website	h.					
	Program URI	Link to pr	ogram URL				



SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Deadline Dates (ALL)	05-Jun-20 2023 , 26- 05-Sep-20 2024 , 05- Jan-2025 07-Sep-20	022 , 16-Jun-2022 , 05-Sep-202 -Jan-2023 , 05-Feb-2023 , 16-F 023 , 07-Sep-2023 , 26-Sep-202 -Apr-2024 , 07-May-2024 , 05- , 07-Jan-2025 , 05-Feb-2025 , 3 025	2 , 07-Sep-2022 , 27-Sep-2022 , 05-0 eb-2023 , 05-Apr-2023 , 07-May-202 23 , 05-Oct-2023 , 16-Oct-2023 , 05-J Jun-2024 , 16-Jun-2024 , 05-Sep-202 16-Feb-2025 , 05-Apr-2025 , 07-May	Oct-2022 , 16-Oct 23 , 26-May-2023 Jan-2024 , 07-Jan- 24 , 07-Sep-2024 , -2025 , 05-Jun-20	-2022 , 05-Jan-202 , 05-Jun-2023 , 16 ·2024 , 05-Feb-202 05-Oct-2024 , 16- ·25 , 16-Jun-2025 ,	23 , 07-Jan- -Jun-2023 , 24 , 16-Feb- Oct-2024 , 05- 05-Sep-2025 ,
	Synopsis	The purpo alcohol m commonl in four-ye all encour	ose of this future grant applica isuse among persons aged 18 y in the military, workforce, or ear colleges. Research on epide raged.	tion solicitation is to balance the NI/ to 29 who are not enrolled in four-y community college populations, wh emiology, prevention, and screening	AAA research por ear colleges or un nich are understur centered on thes	tfolio by supportir niversities. These p died relative to the se understudied po	ng research on persons are eir age peers opulations are
104867	Mechanisms of Alcohol Tolerance	(R21/R33	Clinical Trial Optional)	National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS	PAR-21- 250 16-Ju	un-2022	1,775,000 USD
	Contact Name	Elizabeth	M Powell, PhD				
	Contact Telephone	301-443-0	0786				
	Contact Email	<u>elizabeth.</u>	.powell3@nih.gov				
	Sponsor Website						
	Program URL	<u>Link to pr</u>	ogram URL				
	Deadline Dates (ALL)	16-Jun-20	022 , 16-Oct-2022 , 16-Feb-202	3 , 16-Jun-2023 , 16-Oct-2023 , 16-F	eb-2024 , 16-Jun-	2024	
	Synopsis	This fundi developm network r developm Innovatio the R21 p be determ	ing opportunity announcemen nent of alcohol use disorder. The mechanisms that regulate sens nent of tolerance and the prog n (R21/R33) mechanism, clinic hase, and research testing the nined by NIAAA program staff	t (FOA) focuses on sensitivity and to ne intent of this FOA is to: (1) develo sitivity and tolerance to alcohol, and ression to alcohol use disorder. Thes cal trial optional, in which secondary hypotheses can be expanded in the after evaluation of the achievement	lerance mechanis op hypotheses abo (2) develop quan se objectives will data analysis or p R33 phase. The t of specific milest	sms underlying the out cellular, molec atitative models to be accomplished v pilot studies can o cransition to the R cones set for the R	e cular or predict the vith a Phased ccur during 33 phase will 21 phase.
101159	Prevention and Intervention Appr Disorders (R34 Clinical Trial Option	oaches fo nal)	r Fetal Alcohol Spectrum	National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS	PAR-21- 097 17-Ju	un-2022	450,000 USD

Contact Name William Dunty, PhD



SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Contact Talankar	201 442	7251				
		301-443-	/351				
		<u>auntyw@</u>	<u>mail.nin.gov</u>				
		Link to pr	ogram LIPI				
	Deadline Dates (ALL)	17-lun-20	0 <u>918111 0112</u> 122 18-0ct-2022 17-Feb-202	3 19-lun-2023 17-Oct-2023			
	Synopsis	This Fund strategies that adva for FASD. preparing interested	ing Opportunity Announcements for fetal alcohol spectrum disc nces (1) prevention approache It is expected that research co and submitting subsequent ap d in exploratory phased project	nt (FOA) for R34 planning grant appl orders (FASD) throughout the lifespa s to reduce prenatal alcohol exposu nducted via this mechanism will cor oplications for larger scale FASD pre- ts may consider FOA (PAR-21-098, th	ications focuses of an. The intent of re and incidence nsist of studies th vention or interve ne R61/R33 optio	on prevention and this FOA is to supp of FASD and (2) ir at are a pre-requis ention studies. Ap m).	intervention port research iterventions site for plicants
101160	Prevention and Intervention Appr Disorders (R61/R33 Clinical Trial C	r <u>oaches fo</u> Optional)	<u>r Fetal Alcohol Spectrum</u> N a	lational Institute on Alcohol Abuse nd Alcoholism/NIH/DHHS	PAR-21- 098 17-Ju	un-2022	Not Specified
	Contact Name	William D	unty, PhD				
	Contact Telephone	301-443-7	7351				
	Contact Email	<u>duntyw@</u>	mail.nih.gov				
	Sponsor Website						
	Program URL	<u>Link to pr</u>	ogram URL				
	Deadline Dates (ALL)	17-Jun-20	022 , 18-Oct-2022 , 17-Feb-202	3 , 19-Jun-2023 , 17-Oct-2023			
This Funding Opportunity Announcement (FOA) focuses on prevention and intervention strategies for fetal alcoho disorders (FASD) throughout the lifespan. The intent of this FOA is to support research that advances (1) prevention approaches to reduce prenatal alcohol exposure and the incidence of FASD and (2) interventions for FASD. These will be accomplished with the Exploratory/Developmental Phased Award (R61/R33) mechanism, clinical trial optio Synopsis R61 phase will support pilot studies or secondary data analysis for hypothesis development and feasibility, and res testing the hypotheses can be expanded in the R33 phase. The transition to the R33 phase will be determined by N program staff after evaluation of the achievement of specific milestones set for the R61 phase. Highest priority wil to applications with clinical trials. Applicants interested in planning clinical trials or adding to current projects may consider FOA (PAR-21-097, the R34 option).							ohol spectrum intion ese objectives ptional. The I research by NIAAA y will be given may also

SPIN ID	Program Title	Sponsor I	Name	Sponsor Number		Deadline Date	Funding Amount
102240	Notice of Special Interest (NOSI): Improving Access and Affordabilit	Hearing Healthcare 1 Y	or Adults: C	National Institute on Deafness and Other Communication Disorders/NIH/DHHS	NOT-DC- 21-001 05	5-Apr-2022	Not Specified
	Contact Name	Kelly King, Au.D, Ph	D.				
	Contact Telephone	301-402-3458					
	Contact Email	kingke@nidcd.nih.g	<u>ov</u>				
	Sponsor Website						
	Program URL	Link to program UR	=				
	Deadline Dates (ALL)	05-Apr-2022 , 07-M 2023 , 07-Jan-2023 Sep-2023 , 05-Oct-2 16-Jun-2024 , 07-Se	ay-2022 , 05-Jun-202 , 05-Feb-2023 , 16-Fo 023 , 16-Oct-2023 , p-2024	22 , 16-Jun-2022 , 05-Sep-2022 , 07- eb-2023 , 05-Apr-2023 , 07-May-202 05-Jan-2024 , 07-Jan-2024 , 05-Feb-	Sep-2022 , 05-0 23 , 05-Jun-202 2024 , 16-Feb-2	Oct-2022 , 16-Oct-20 3 , 16-Jun-2023 , 05- 2024 , 07-May-2024	22 , 05-Jan- Sep-2023 , 07- , 05-Jun-2024 ,
	Synopsis	The purpose of this adults in support of goal of delivering be	Notice of Special Int improving access ar etter hearing health	erest (NOSI) is to encourage applicand affordability. Further research is a care outcomes in adults.	itions for resea needed to strei	rch on hearing healt ngthen the evidence	h care in base with a
104661	Notice of Special Interest (NOSI): Inequities Research	NIDCD Health Dispar	i <u>ties and</u> C	National Institute on Deafness and Other Communication Disorders/NIH/DHHS	NOT-DC- 21-003	3-Apr-2022	Not Specified
	Contact Name	Kelly King, Au.D, Ph	D.				
	Contact Telephone	301-402-3458					
	Contact Email	kingke@nidcd.nih.g	<u>ov</u>				
	Sponsor Website						
	Program URL	Link to program UR	=				
	Deadline Dates (ALL)	08-Apr-2022 , 07-M 2022 , 16-Oct-2022 05-Jun-2023 , 12-Ju 2023 , 07-Jan-2024	ay-2022 , 05-Jun-202 , 08-Dec-2022 , 07-Ja n-2023 , 16-Jun-2023 , 05-Feb-2024 , 12-Fe	22 , 12-Jun-2022 , 16-Jun-2022 , 08- an-2023 , 05-Feb-2023 , 12-Feb-202 3 , 08-Aug-2023 , 07-Sep-2023 , 05-0 eb-2024 , 16-Feb-2024 , 08-Apr-202	Aug-2022 , 07-3 3 , 16-Feb-2023 Oct-2023 , 12-C 4 , 07-May-202	Sep-2022 , 05-Oct-20 3 , 08-Apr-2023 , 07- 0ct-2023 , 16-Oct-202 4	022 , 12-Oct- May-2023 , 23 , 08-Dec-
	Synopsis	This Notice of Speci health disparities ar	al Interest (NOSI) en nd inequities in comr	courages applications that advance munication disorders among racial/	the understane ethnic minority	ding or reduce the in and other underrep	npact of resented

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		populatio disparities hearing, b	ns. Applications that address s and inequities are also enco palance, taste, smell, voice, sp	the influence or reduction of racism uraged. The research must address o eech, and language.	or discrimination one or more of th	in causing or sust e NIDCD mission a	aining health areas of
101155	NIDCD Low Risk Clinical Trials in C Trial Required)	Communica	ation Disorders (R01 Clinical	National Institute on Deafness and Other Communication Disorders/NIH/DHHS	PAR-21- 063	/lay-2022	2,499,995 USD
	Contact Name	Trinh T. Ly	γ, M.D.				
	Contact Telephone	301-435-4	1085				
	Contact Email	<u>trinh.ly@</u>	<u>nih.gov</u>				
	Sponsor Website						
	Program URL Deadline Dates (ALL)	07-May-2 2023 , 05-	ogram URL 022 , 05-Jun-2022 , 07-Sep-20 ·Oct-2023 , 07-Jan-2024	22 , 05-Oct-2022 , 07-Jan-2023 , 05-	Feb-2023 , 07-Ma	ıy-2023 , 05-Jun-2	023 , 07-Sep-
	Synopsis	The NIDC disorders supports must mee formally e risk trials definition proposed the criteri Communi	D is committed to identifying by supporting well-designed a investigator initiated low risk et ALL the following criteria: m establish efficacy and have low determined to be Basic Science of a clinical trial and also mee in each NIDCD Clinical Trials i a above are referred compan cation Disorders.	effective interventions for the diagn and well-executed clinical trials. This clinical trials addressing the mission neet the budget limits of this FOA, no v risks to potentially cause physical of the experimental Studies involving Hu et the definition of basic research. It n Communication Disorders R01 app ion U01 FOA PAR-21-064, NIDCD Co	osis, prevention, funding opportu and research inte of require FDA ov or psychological h imans (BESH). The is advisable that olication. High rish operative Agreen	or treatment of co nity announcement erests of NIDCD. C ersight, are not in arm. This FOA also ese studies fall wit only one clinical tri conical trials not ment for Clinical Tr	ommunication nt (FOA) linical trials tended to o supports low thin the NIH rial be meeting all ials in
101085	NIDCD Mentored Career Develop Au.D./Ph.D. Audiologists (K01 Ind with Humans Required)	<u>ment Awa</u> ependent	rd for Postdoctorate Basic Experimental Studies	National Institute on Deafness and Other Communication Disorders/NIH/DHHS	PAR-21- 087 07-N	/lay-2022	315,000 USD
	Contact Name Contact Telephone Contact Email	Alberto L. 301-496-2 <u>riverara@</u>	Rivera-Rentas, Ph.D. 1804 Pnidcd.nih.gov				

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount				
	Sponsor Website Program URL	Link to pr	ogram URL								
	Deadline Dates (ALL)	07-May-2 2023 , 13	7-May-2022 , 14-Jun-2022 , 07-Sep-2022 , 13-Oct-2022 , 07-Jan-2023 , 14-Feb-2023 , 07-May-2023 , 13-Jun-2023 , 07-Sep- J23 , 13-Oct-2023 , 07-Jan-2024								
The purpose of the NIDCD Mentored Career Development Award for Postdoctorate Au.D./Ph.D. Audiologists (K0 support comprehensive and rigorous postdoctoral research and career development experiences in the biomedi behavioral, or clinical sciences of promising Au.D./Ph.D. audiologists who have the potential to become producti independent investigators in scientific health-related research fields relevant to NIDCD's mission. This Mentored Development Award for Postdoctorate Au.D./Ph.D. Audiologists Funding Opportunity Announcement is for basic experimental studies involving humans, referred to in NOT-OD-18-212 as "prospective basic science studies invo participants." These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should submit under this FOA include studies that prospectively assign human pa conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral out humans for the purpose of understanding the fundamental aspects of phenomena without specific application t processes or products in mind. Studies conducted with specific applications toward processes or products in min submit under the appropriate 'Independent Clinical Trial Required' (PAR-21-085). Applicants not planning an inc clinical trial, or proposing to gain research in a clinical trial led by another investigator must apply to the compan 'Independent Clinical Trial Not Allowed' (PAR-21-086) FOA.							K01) is to edical, ctive, ed Career sic science volving human c participants to utcomes in n towards nind should independent anion				
101080	NIDCD Mentored Career Develop Au.D./Ph.D. Audiologists (K01 No	oment Awa Independo	rd for Postdoctorate C ent Clinical Trials)	Vational Institute on Deafness and Other Communication Disorders/NIH/DHHS	PAR-21- 086	May-2022	315,000 USD				
	Contact Name	Alberto L	Rivera-Rentas, Ph.D.								
	Contact Telephone	301-496-2	1804								
	Contact Email	<u>riverara@</u>	nidcd.nih.gov								
	Sponsor Website										
	Program URL	Link to pr	ogram URL								
	Deadline Dates (ALL)	07-May-2 2023 , 13	07-May-2022 , 14-Jun-2022 , 07-Sep-2022 , 13-Oct-2022 , 07-Jan-2023 , 14-Feb-2023 , 07-May-2023 , 13-Jun-2023 , 07-Sep- 2023 , 13-Oct-2023 , 07-Jan-2024								
	Synopsis	The purp support c	ose of the NIDCD Mentored Ca omprehensive and rigorous po	areer Development Award for Posto stdoctoral research and career dev	loctorate Au.D./P elopment experie	h.D. Audiologists ences in the biome	(K01) is to edical,				

SPIN ID	ID Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount		
		behavioral, or clinical sciences of promising Au.D./Ph.D. audiologists who have the potential to become productive, independent investigators in scientific health-related research fields relevant to NIDCD's mission. This Funding Opportunity Announcement (FOA) is designed specifically for candidates proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Under this FOA candidates are permitted to propose a research experience in a clinical trial led by a mentor or co-mentor. Those proposing a clinical trial or an ancillary study to an ongoing clinical trial as lead investigator, should apply to the companion FOA PAR-21-085 for Clinical Trial Required or for PAR-21-087 for Independent Basic Experimental Studies with Humans Required							
101078 <u>A</u>	IIDCD Mentored Career Develop .u.D./Ph.D. Audiologists (K01 Clir	<u>ment Awa</u> nical Trial F	rd for Postdoctorate C Required) C	National Institute on Deafness and Other Communication Disorders/NIH/DHHS	PAR-21- 085	Лау-2022	315,000 USD		
	Contact Name Alberto L. Rivera-Rentas, Ph.D.								
	Contact Telephone	301-496-2	1804						
	Contact Email	riverara@	<u> Pnidcd.nih.gov</u>						
	Sponsor Website								
	Program URL	Link to pr	ogram URL						
	Deadline Dates (ALL) 07-May-2022 , 14-Jun-2022 , 07-Sep-2022 , 13-Oct-2022 , 07-Jan-2023 , 14-Feb-2023 , 07-May-2023 , 13-Jun-2023 , 07- 2023 , 13-Oct-2023 , 07-Jan-2024								
	Synopsis	The purpose of the NIDCD Mentored Career Development Award for Postdoctorate Au.D./Ph.D. Audiologists (K01) is to support comprehensive and rigorous postdoctoral research and career development experiences in the biomedical, behavioral, or clinical sciences of promising Au.D./Ph.D. audiologists who have the potential to become productive, independent investigators in scientific health-related research fields relevant to NIDCD's mission. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an existing trial, as part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion FOA (PAR-21-086). Observational Studies involving humans should submit under PAR-21-087 - NIDCD Mentored Career Development Award for Postdoctorate Au.D./Ph.D. Audiologists (K01 Independent Basic Experimental Studies with Humans Required).							
NIDCD Research Career Enhancement Award for Established101736Investigators (K18 Independent Basic Experimental Studies with Humans Required)				National Institute on Deafness and Other Communication Disorders/NIH/DHHS	PAR-21- 096	Лау-2022	Not Specified		



SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount			
Contact Name Alberto L.			erto L. Rivera-Rentas, Ph.D.							
	Contact Telephone 301-496-		496-1804							
	Contact Email	riverara@	onidcd.nih.gov							
	Sponsor Website									
	Program URL	Link to pr								
	Deadline Dates (ALL)	07-May-2022 , 07-Jun-2022 , 07-Sep-2022 , 07-Oct-2022 , 07-Jan-2023 , 06-Feb-2023 , 07-May-2023 , 08-Jun-2023 , 2023 , 10-Oct-2023 , 07-Jan-2024								
The purpose of the NIDCD Research Career Enhancement Award for Established Investigators (K18) program is established, proven investigators to augment or redirect their research programs through the acquisition of ne skills to answer questions relevant to the hearing, balance, smell, taste, voice, speech and language sciences. T Opportunity Announcement is for basic science experimental studies involving humans, referred to in NOT-OD "prospective basic science studies involving human participants." These studies fall within the NIH definition or and also meet the definition of basic research. Types of studies that should submit under this FOA include stud prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspect phenomena without specific application towards processes or products in mind. Studies conducted with specif toward processes or products in mind should submit under PAR-21-094 "NIDCD Research Career Enhancemer Established Investigators (K18 Clinical Trial Required)" Applicants not planning an independent clinical trial or experimental study with humans, or proposing to gain research experience in a clinical trial or basic experimer humans led by another investigator, must apply to companion FOA PAR-21-095 "NIDCD Research Career Enhancemer humans led by another investigator, full dependent Clinical Trial Not Allowerd)"										
101734 <u> </u>	NIDCD Research Career Enhancer nvestigators (K18 Independent C	<u>ment Awar</u> linical Tria	r <u>d for Established</u> I Not Allowed)	National Institute on Deafness and Other Communication Disorders/NIH/DHHS	PAR-21- 095	Лау-2022	Not Specified			
Contact Name Alberto L		. Rivera-Rentas, Ph.D.								
	Contact Telephone	301-496-3	1804							
	Contact Email	riverara@	onidcd.nih.gov							
	Sponsor Website									
	Program URL	<u>Link to pr</u>	ogram URL							


SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount	
	Deadline Dates (ALL)	07-May-2 2023 , 10-	022 , 07-Jun-2022 , 07-Sep-202 Oct-2023 , 07-Jan-2024	2 , 07-Oct-2022 , 07-Jan-2023 , 06-	Feb-2023 <i>,</i> 07-Ma	y-2023 , 08-Jun-20	023 , 07-Sep-	
Synopsis Syn							to enable w research his Funding live leading an ve as the lead an r, must apply equired.	
101733	NIDCD Research Career Enhancer nvestigators (K18 Clinical Trial Re	<u>ment Awar</u> equired)	rd for Established O D	lational Institute on Deafness and other Communication visorders/NIH/DHHS	PAR-21- 094 07-N	1ay-2022	Not Specified	
	Contact Name	Alberto L.	Rivera-Rentas, Ph.D.					
	Contact Telephone	301-496-1	1804					
	Contact Email	riverara@nidcd.nih.gov						
	Sponsor Website							
	Program URL	Link to pr	ogram URL					
	Deadline Dates (ALL)	07-May-2 2023 , 10-	022 , 07-Jun-2022 , 07-Sep-202 -Oct-2023 , 07-Jan-2024	2 , 07-Oct-2022 , 07-Jan-2023 , 06-	Feb-2023 <i>,</i> 07-Ma	y-2023 , 08-Jun-20	023 , 07-Sep-	
	Synopsis	The purpo establishe skills to an Opportun independ career de trial led b clinical tri Research Humans F	ose of the NIDCD Research Care ed, proven investigators to augr nswer questions relevant to the ity Announcement (FOA) is des ent clinical trial, a clinical trial f velopment. Those not planning y another investigator, must ap al, but planning a basic experim Career Enhancement Award fo Required)	eer Enhancement Award for Establi ment or redirect their research prog e hearing, balance, smell, taste, void signed specifically for candidates pr easibility study, or a separate ancill g an independent clinical trial, or pro oply to companion FOA (PAR-21-099 mental study with humans, must ap r Established Investigators (K18 Ind	shed Investigator grams through th ce, speech and lan oposing to serve ary clinical trial, a oposing to gain re 5). Applicants not ply to companion lependent Basic E	s (K18) program is e acquisition of ne nguage sciences. T as the lead investi is part of their resp esearch experience planning an indep FOA PAR-21-096 xperimental Studi	to enable w research his Funding gator of an earch and e in a clinical bendent - NIDCD es with	

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount			
105011	RFA-DC-22-001 NIDCD Research into Clinical Tools (R01 Clinical Tri	n Grants for Translating Basic Research al Optional)	National Institute on Deafness and Other Communication Disorders/NIH/DHHS	RFA-DC- 22-001	21-May-2022 [Optional][LOI/Pre- App]	Not Specified			
	Contact Name	Roger L. Miller, Ph.D.							
	Contact Telephone	301-402-3458							
	Contact Email	millerr@nidcd.nih.gov							
	Sponsor Website								
	Program URL	Link to program URL							
	Deadline Dates (ALL)	21-May-2022 [Optional][LOI/Pre-App], [Optional][LOI/Pre-App], 18-Oct-2023	, 20-Jun-2022 , 23-Jan-2023 [Optional , 21-May-2024 [Optional][LOI/Pre-Ap	][LOI/Pre-Ap p], 20-Jun-20	op], 22-Feb-2023 , 18-S 024	ep-2023			
	Synopsis	This Funding Opportunity Announcem scientists to jointly initiate and conduc tools for better human health. The sco findings which will impact the diagnosi condition must be clearly established a	ent (FOA) is intended to provide an a at translational research projects whic ope of this FOA includes a range of act is, treatment and prevention of comm and the outcomes of the grant must h	venue for ba th translate t tivities to en- nunication d nave practica	sic scientists, clinicians basic research findings courage translation of isorders. Connection t Il clinical impact.	and clinical into clinical basic research to the clinical			
106846	NIDCD Clinical Research Center G	rant (P50 Clinical Trial Optional)	National Institute on Deafness and Other Communication Disorders/NIH/DHHS	PAR-22- 025	07-Jun-2022	7,500,000 USD			
	Contact Name	Lana Shekim, Ph.D.							
	Contact Telephone	301-496-5061							
	Contact Email	shekiml@nidcd.nih.gov							
	Sponsor Website								
	Program URL	Link to program URL							
	Deadline Dates (ALL)	07-Jun-2022 , 06-Oct-2022 , 07-Feb-20	23 , 06-Jun-2023 , 06-Oct-2023 , 06-F	eb-2024 , 06	5-Jun-2024 , 09-Oct-202	24			
	Deadline Dates (ALL) Deadline Dates (ALL) O7-Jun-2022, 06-Oct-2022, 07-Feb-2023, 06-Jun-2023, 06-Feb-2024, 06-Jun-2024, 09-Oct-2024 The National Institute on Deafness and Other Communication Disorders (NIDCD) invites applications for Clinical Research Center Grants designed to advance the diagnosis, prevention, treatment, and amelioration of human communication disorders. For this announcement, Clinical Research is defined as research involving individuals with communication disorders or data/tissues from individuals with a communication disorder. Examples of such research include but are not limited to, studies of the prevention, pathogenesis, pathophysiology, diagnosis, treatment, management or epidemiology								

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		a disease risk clinica	or disorder of hearing, balan al trial but are not required to	ce, smell, taste, voice, speech, or lan o (optional).	guage. Applic	ations may propose a	low
101157	NIDCD Cooperative Agreement for Disorders (U01 - Clinical Trial Requ	<u>r Clinical 1</u> uired)	rials in Communication	National Institute on Deafness and Other Communication Disorders/NIH/DHHS	PAR-21- 064	10-Jun-2022	Not Specified
	Contact Name	Trinh T. Ly	γ, M.D.				
	Contact Telephone	301-435-4	1085				
	Contact Email	<u>trinh.ly@</u>	nih.gov				
	Sponsor Website						
	Program URL	<u>Link to pr</u>	ogram URL				
	Deadline Dates (ALL)	10-Jun-20	22 , 11-Oct-2022 , 10-Feb-20	023 , 09-Jun-2023 , 10-Oct-2023			
<ul> <li>The NIDCD is committed to identifying effective interventions for the treatment or prevention of communication di by supporting well- designed and well- executed clinical trials. This funding opportunity announcement (FOA) supportion cooperative agreement between an NIDCD Project Scientist and an investigator to support a clinical trial that meets the following criteria: requires FDA oversight, is intended to formally establish efficacy, or has a higher risk to poter cause physical or psychological harm. Clinical trial applications exceeding the annual direct costs of \$700,000 or more certain cases, may also be a criterion for this FOA. These investigator-initiated clinical trials are perceived to benefit close interaction, oversight, and guidance resulting from a cooperative agreement. Only one clinical trial may be preach NIDCD Clinical Trials in Communication Disorders U01 application. Low risk clinical trials not meeting any of th above are referred to the companion NIDCD Low Risk Clinical Trials in Communication Disorders (R01-Clinical Trial Required) PAR-21-063.</li> </ul>							
101297	NIDCD Early Career Research(ECR)	) Award (F	21 Clinical Trial Optional)	National Institute on Deafness and Other Communication Disorders/NIH/DHHS	PAR-21- 107	23-Jun-2022	375,000 USD
	Contact Name	Bracie Wa	atson, Jr.				
	Contact Telephone	301-402-3	3458				
	Contact Email	watsonb@	Dnidcd.nih.gov				
	Sponsor Website						
	Program URL	<u>Link to pr</u>	ogram URL				

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Deadline Dates (ALL)	23-Jun-20	022 , 27-Oct-2022 , 23-Feb-20	23 , 29-Jun-2023 , 26-Oct-2023			
	Synopsis	The NIDC who are to research to hearing, to types of po research to Irrespecti Investigat	D Early Career Research (ECR beginning to establish an inde must be focused on one or m balance, smell, taste, voice, sp projects including secondary a methodology; translational re ve of the type of project, the tor(s) (PD(s)/PI(s)) to obtain s	) Award (R21) is intended to suppor pendent research career. It cannot ore of the areas within the biomedi- peech, or language. The NIDCD ECR A analysis of existing data; small, self-or esearch; outcomes research; and de intent of the NIDCD ECR Award R21 ufficient preliminary data for a subs	t both basic and c be used for thesis cal and behaviora Award R21 grant r contained research velopment of new is for the Prograr equent R01 applic	linical research fro or dissertation res l scientific mission nechanism suppor n projects; develop v research technolo n Director(s)/Princ ation.	m scientists earch. The of the NIDCD: ts different ment of ogy. pal
106339	Notice of Special Interest (NOSI): Associated Comorbidities in the C	Evaluation	n of Sex Differences on HIV- Stimulant Use	National Institute on Drug Abuse/NIH/DHHS	NOT-DA- 21-020 07-I	May-2022	Not Specified
	Contact Name	Da-Yu Wu	ı, PhD				
	Contact Telephone	301-435-4	4649				
	Contact Email	<u>wudy@ni</u>	da.nih.gov				
	Sponsor Website						
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	07-May-2 2023 , 05·	022 , 05-Jun-2022 , 07-Sep-2 -Oct-2023 , 07-Jan-2024 , 05-	022 , 05-Oct-2022 , 07-Jan-2023 , 05 Feb-2024 , 07-May-2024	-Feb-2023 , 07-M	ay-2023 , 05-Jun-2	023 , 07-Sep-
	Synopsis	The goal o HIV neuro cocaine, a	of this Notice is to encourage opathogenesis and the comor and nicotine. Studies at single	applications focusing on the unders bidity of HIV with misuse of stimula cell and CNS circuits levels and in live	tanding of the bio nts, including amp ve behaving anima	ological basis of sex ohetamine, methar als are encouraged	differences in nphetamine,
101989	Notice of Special Interest (NOSI): Consequences of COVID-19 in Ind Use Disorders	Long-Term ividuals Liv	<u>n Neurocognitive</u> ving with HIV and Substance	National Institute on Drug Abuse/NIH/DHHS	NOT-DA- 21-018 07-I	May-2022	Not Specified
	Contact Name	Raul Man	dler, MD				
	Contact Telephone	301-480-2	2541				
	Contact Email	mandlerr	@nih.gov				
	Sponsor Website						
	Program URL	Link to pr	ogram URL				

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Deadline Dates (ALL)	07-May-20 2023 , 05-	022 , 05-Jun-2022 , 07-Sep-20 Oct-2023 , 07-Jan-2024 , 05-F	22 , 05-Oct-2022 , 07-Jan-2023 , 05- eb-2024 , 07-May-2024 , 05-Jun-202	Feb-2023 , 07-N 24 , 07-Sep-2024	Лау-2023 , 05-Jun-2 1	023 , 07-Sep-
	Synopsis	NIDA is int COVID-19	terested in receiving research /HIV/SUDs syndemic.	applications focusing on studying t	he long-term ne	urocognitive conse	quences of the
102988	Notice of Special Interest (NOSI): Synthetic Fentanyl Analogs: Signa	Basic Resea ling, Neurc	arch on Fentanyl and bbiology, and Pharmacology	National Institute on Drug Abuse/NIH/DHHS	NOT-DA- 21-033 07	-May-2022	Not Specified
	Contact Name	Pamela G.	Fleming				
	Contact Telephone	301-480-1	.159				
	Contact Email	pfleming@	<u>Pnih.gov</u>				
	Sponsor Website						
	Program URL	Link to pro	ogram URL				
	Deadline Dates (ALL)	07-May-20 2023 , 05-	022 , 05-Jun-2022 , 07-Sep-20 Oct-2023 , 07-Jan-2024 , 05-F	22 , 05-Oct-2022 , 07-Jan-2023 , 05 eb-2024 , 07-May-2024 , 05-Jun-20	Feb-2023 , 07-N 24 , 07-Sep-2024	/lay-2023 , 05-Jun-2 1	023 , 07-Sep-
	Synopsis	This Notice research c chemical, liability an	e informs potential applicants on fentanyl and synthetic fent cellular, signaling, and neurol nd deaths due to overdose of	s to the National Institute on Drug A anyl analogs. Of particular interest i piological mechanisms underlying al fentanyl and fentanyl analogs.	buse (NIDA) abo s research that ouse potential, j	out a special interes is focused on elucid physical dependenc	t in basic ating e, addiction
103015	Notice of Special Interest (NOSI): Strategic Approaches to Countera	<u>Synthetic F</u> act Their De	Psychoactive Drugs and eleterious Effects	National Institute on Drug Abuse/NIH/DHHS	NOT-DA- 21-028 07	-May-2022	Not Specified
	Contact Name	Pamela G.	Fleming				
	Contact Telephone	301-480-1	.159				
	Contact Email	pfleming@	Dnih.gov				
	Sponsor Website						
	Program URL	Link to pro	ogram URL				
	Deadline Dates (ALL)	07-May-20 2023 , 05-	022 , 05-Jun-2022 , 07-Sep-20 Oct-2023 , 07-Jan-2024 , 05-F	22 , 05-Oct-2022 , 07-Jan-2023 , 05- eb-2024 , 07-May-2024 , 05-Jun-202	Feb-2023 , 07-N 24 , 07-Sep-2024	Лау-2023 , 05-Jun-2 1	023 , 07-Sep-



SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	T Synopsis o p	his Notice informs potential applicant on chemistry, pharmacology, biological osychoactive substances.	s to the National Institute on Drug A targets and biochemical mechanism	buse (NIDA) abou ns that contribute	t a special interes to the effects of s	t in research synthetic
101618	Pilot and Feasibility Studies in Preparentian Trial Prevention Trials (R34 Clinical Trial	aration for Substance Use Optional)	National Institute on Drug Abuse/NIH/DHHS	PA-21- 110 07-N	/lay-2022	450,000 USD
	Contact Name A Contact Telephone 3 Contact Email <u>a</u> Sponsor Website	amy B. Goldstein, PhD 301-827-4124 3my.goldstein@nih.gov				
	Program URL <u>L</u> 0 22 Deadline Dates (ALL)	ink to program URL 17-May-2022 , 16-Jun-2022 , 07-Sep-20 2023 , 16-Oct-2023 , 07-Jan-2024	22 , 16-Oct-2022 , 07-Jan-2023 , 16-	Feb-2023 , 07-Ma	ıy-2023 , 16-Jun-2	023 , 07-Sep-
	T rd tl Synopsis ir e rd si v	The purpose of this Funding Opportuni esearch in the following areas: 1) the of he initiation of substance use and/or to puestions specific to the prevention of intervention, and/or other service syste engagement. In addition to the prevent esearch supported through this FOA in uicidal behavior (e.g., nonfatal and fat riral hepatitis among diverse populatio	ty Announcement (FOA) is to encour development and pilot testing of new he progression from use to misuse of substance use. The latter may include em-based research to address areas tion of substance use, misuse and dis include a reduction in negative sequa al attempts), and substance-related ns and settings.	rage theoretically v or adapted inte or disorder and 2) le pilot studies of such as economic sorder, other out lae such as death acquisition or tra	-driven pilot and/o rventions to preve services research strategies or appr cs, funding, service comes of interest s related to impain nsmission of HIV i	or feasibility ent or delay examining roaches to e quality and for the red driving, nfection and
104182	Notice of Special Interest (NOSI): A to Elucidate Disease Pathology and Addiction	dvanced Computational Approaches Identify Novel Therapeutics for	National Institute on Drug Abuse/NIH/DHHS	NOT-DA- 21-004 07-N	/lay-2022	Not Specified
	Contact Name S Contact Telephone 3 Contact Email <u>S</u> Sponsor Website Program URL <u>L</u>	usan Wright, Ph.D. 01-402-6683 <u>usan.wright@nih.gov</u> <u>ink to program URL</u>				

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount		
	Deadline Dates (ALL)	07-May-2 2023 , 07- Feb-2024	022 , 05-Jun-2022 , 16-Jun-202 May-2023 , 05-Jun-2023 , 16-J , 07-May-2024 , 05-Jun-2024 ,	22 , 07-Sep-2022 , 05-Oct-2022 , 16- un-2023 , 07-Sep-2023 , 05-Oct-202 16-Jun-2024 , 07-Sep-2024 , 05-Oct	Oct-2022 , 07-Jan 23 , 16-Oct-2023 , t-2024 , 16-Oct-20	-2023 , 05-Feb-20 07-Jan-2024 , 05- 024 , 07-Jan-2025 Abuse (NIDA) of N	23 , 16-Feb- Feb-2024 , 16-		
	Synopsis	Synopsis in grant applications that will develop or utilize advanced computational approaches to describe complex drug-disease relationships in ways that will rapidly advance the development of new treatments, allow for targeted funding of substance use disorder (SUD) drug discovery and improve health care. NIDA has a particular interest in applications that include approaches in one or more of the following categories: 1) artificial intelligence, including machine learning and deep learning, 2) supercomputing/parallel computing, and/or 3) quantum computing.							
102446	Notice of Special Interest (NOSI): I Knowledge and Program Planning	Using Data	a to Advance HIV Epidemic A	National Institute on Drug Abuse/NIH/DHHS	NOT-DA- 21-007 07-N	/lay-2022	Not Specified		
	Contact Name	Richard A	. Jenkins PhD						
	Contact Telephone	301-443-1	1923						
	Contact Email	<u>jenkinsri@</u>	email.nih.gov						
	Sponsor Website								
	Program URL	Link to pro	ogram URL						
	Deadline Dates (ALL)	07-May-2 2023 , 07- Feb-2024	022 , 05-Jun-2022 , 16-Jun-202 May-2023 , 05-Jun-2023 , 16-J , 07-May-2024 , 05-Jun-2024 ,	22 , 07-Sep-2022 , 05-Oct-2022 , 16- un-2023 , 07-Sep-2023 , 05-Oct-202 16-Jun-2024 , 07-Sep-2024	Oct-2022 , 07-Jan 23 , 16-Oct-2023 ,	-2023 , 05-Feb-20 07-Jan-2024 , 05-	23 , 16-Feb- Feb-2024 , 16-		
	SynopsisSy								

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
107619	Notice of Special Interest (NOSI): Pharmacology of Addictive Drugs	Research in the Chemistry and	National Institute on Drug Abuse/NIH/DHHS	NOT-DA- 23-002 07-N	Лау-2022	Not Specified
	Contact Name	Kiran Vemuri, Ph.D.				
	Contact Telephone	301-435-4446				
	Contact Email	kiran.vemuri@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-May-2022, 05-Jun-2022, 12-Jun- 2022, 07-Jan-2023, 05-Feb-2023, 1 10-Aug-2023, 07-Sep-2023, 05-Oct- 2024, 05-Jun-2024, 16-Jun-2024, 0	-2022 , 16-Jun-2022 , 10-Aug-2022 , 07 .2-Feb-2023 , 16-Feb-2023 , 08-Mar-20 -2023 , 16-Oct-2023 , 07-Jan-2024 , 05- .7-Sep-2024 , 12-Feb-2025	-Sep-2022 , 05-Oc 23 , 07-May-2023 Feb-2024 , 16-Fet	t-2022 , 12-Oct-20 , 05-Jun-2023 , 16 -2024 , 08-Mar-2	)22 , 16-Oct- 5-Jun-2023 , 024 , 07-May-
	Synopsis	The mission of the Division of Neuro animal and human research aimed a guide treatment strategies. As a com all aspects of the chemistry and phan encompassing research on substance synthetic and biosynthetic methodo determination of 3D structures of lig agents, and 3) discover and advance overdose, emphasizing the pre-clinic	escience and Behavior of NIDA is to disc at identifying the causes and consequent ponent of the Division, the Chemistry rmacology of addictive drugs. The Bran e use disorders (SUD) and overdose de logies, structure-activity relationships, gands bound to biological targets, 2) de the pre-clinical development of new p cal stages of target identification throu	over, facilitate an nces of drug addic and Pharmacolog ich develops and o signed to: 1) eluci pharmacology an velop new recept harmacotherapie gh hit-to-lead.	d promote outsta tion across the lif y Branch supports oversees a broad date mechanisms d toxicity of addic or type and subty s for the treatmen	nding basic espan and to research on portfolio of action, tive drugs, and pe specific nt of SUD and
101829	Notice of Special Interest (NOSI): Risk and Outcome of COVID-19 In	Effects of Smoking and Vaping on the fection	National Institute on Drug Abuse/NIH/DHHS	NOT-DA- 21-011 07-N	/lay-2022	Not Specified
	Contact Name	Raul Mandler, MD; FAAN; FANA				
	Contact Telephone	301-480-2541				
	Contact Email	mandlerr@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Deadline Dates (ALL)	07-May-2 2023 , 07 Feb-2024	022 , 05-Jun-2022 , 16-Jun-2 -May-2023 , 05-Jun-2023 , 16 , 07-May-2024 , 05-Jun-2024	022 , 07-Sep-2022 , 05-Oct-2022 5-Jun-2023 , 07-Sep-2023 , 05-Oc 4 , 16-Jun-2024 , 07-Sep-2024	, 16-Oct-2022 , 07 t-2023 , 16-Oct-20	7-Jan-2023 , 05-Feb-20 123 , 07-Jan-2024 , 05	023 , 16-Feb- -Feb-2024 , 16-
	Synopsis	The purpo tobacco c of NOT-D	ose of this notice is to comm or marijuana on the risk of ac A-20-084.	unicate NIDA's interest in suppor quiring COVID-19 and the clinical	ting research on t course of the infe	he effects of smoking ection. This Notice is a	gor vaping a reissuance
102120	Notice of Special Interest (NOSI): with HIV and Substance Use Diso	<u>Telehealth</u> rders	<u>Strategies for Individuals</u>	National Institute on Drug Abuse/NIH/DHHS	NOT-DA- 21-019	07-May-2022	Not Specified
	Contact Name	Raul Man	dler, MD				
	Contact Telephone	301-480-2	2541				
	Contact Email	mandlerr	@nih.gov				
	Sponsor Website						
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	07-May-2 2023 , 07 Feb-2024	022 , 05-Jun-2022 , 16-Jun-2 -May-2023 , 05-Jun-2023 , 16 , 07-May-2024 , 05-Jun-2024	022 , 07-Sep-2022 , 05-Oct-2022 5-Jun-2023 , 07-Sep-2023 , 05-Oc 1 , 16-Jun-2024 , 07-Sep-2024	, 16-Oct-2022 , 07 t-2023 , 16-Oct-20	'-Jan-2023 , 05-Feb-20 123 , 07-Jan-2024 , 05	023 , 16-Feb- -Feb-2024 , 16-
	Synopsis	The Natio explore a individual	nal Institute on Drug Abuse nd develop telehealth metho s living with HIV and Substar	(NIDA) is issuing this Notice of Sp ods and strategies for diagnosis, p nce Use Disorder (SUD).	ecial Interest (NO prevention, treatm	SI) inviting research a nent, and population	pplications to analysis in
094123	Substance Use/Substance Use Dis (R36 - Clinical Trials Optional)	sorder Diss	sertation Research Award	National Institute on Drug Abuse/NIH/DHHS	PA-20- 208	07-May-2022	100,000 USD
	Contact Name	Aria Crum	np, Sc.D.				
	Contact Telephone	301-435-0	0881				
	Contact Email	acrump@	nida.nih.gov				
	Sponsor Website						
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	07-May-2	.022 , 16-Jun-2022 , 07-Sep-2	022 , 16-Oct-2022 , 07-Jan-2023	, 16-Feb-2023 , 07	'-May-2023	

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Synopsis	The goal of completion here (http: (https://w new invest talented s research	of this FOA is to support docto on of the doctoral dissertation os://www.drugabuse.gov/func www.drugabuse.gov/about-nic stigators into the field of subst SU(D) researchers. Application workforce as described in the	ral candidates from a variety of aca research project. Research project ling/funding-priorities) or within th la/2016-2020-nida-strategic-plan). ance use/substance use disorder (S s are particularly encouraged from Notice of NIH's Interest in Diversity	ademic disciplines s should align with e NIDA Strategic F This award will fac SU(D) research, en those who can co (NOT-OD-20-031	for up to two year NIDA funding pri Plan cilitate the entry o hancing the pool ntribute to diversi ).	rs for the orities detailed f promising of highly fying the
090993 <u>N</u>	IIDA Small Research Grant Progr	am (R03 C	linical Trial Required)	National Institute on Drug Abuse/NIH/DHHS	PA-20- 146 07-1	May-2022	100,000 USD
	Contact Name	Katrina L	Foster, PhD				
	Contact Telephone	301-827-5	5815				
	Contact Email	fosterkl@	nih.gov				
	Sponsor Website						
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	07-May-2	022 , 16-Jun-2022 , 07-Sep-20	22 , 16-Oct-2022 , 07-Jan-2023 , 16	-Feb-2023 , 07-Ma	ay-2023	
	Synopsis	The NIDA limited re medicatic services, Announce interests	Small Research Grant Program sources. This program support ons, behavioral interventions, prevention interventions, bior ement requires that a clinical to of NIDA.	n supports small clinical trials that o ts different types of projects includ mmunotherapies, therapeutic devi narkers, and development of resea rial be proposed. The proposed pro	can be carried out ing pilot, feasibilit ces, therapeutic c rch methodology. bject must be relat	in a short period o y, or small clinical ligital applications This Funding Opp ted to the program	of time with trials with , health ortunity nmatic
102016 <u>a</u>	lotice of Special Interest (NOSI): nd Vaping Drugs of Abuse in Ind	Medical Control of the second	onsequences of Smoking th HIV and COVID-19	National Institute on Drug Abuse/NIH/DHHS	NOT-DA- 21-017 07-1	May-2022	Not Specified
	Contact Name	Raul Man	dler, MD				
	Contact Telephone	301-480-2	2541				
	Contact Email	mandlerr	@nih.gov				
	Sponsor Website						
	Program URL	Link to pr	ogram URL				



SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Deadline Dates (ALL) Synopsis	07-May-2 2023 , 07- Feb-2024 NIDA is in cocaine a 19.	022 , 05-Jun-2022 , 16-Jun-2 May-2023 , 05-Jun-2023 , 16 , 07-May-2024 , 05-Jun-2024 terested in receiving researc nd/or methamphetamine to	022 , 07-Sep-2022 , 05-Oct-2022 , 16 5-Jun-2023 , 07-Sep-2023 , 05-Oct-20 4 , 16-Jun-2024 , 07-Sep-2024 th applications focusing on individuals determine the long-term effects of t	-Oct-2022 , 07-Jar 23 , 16-Oct-2023 , s with HIV who sm heir use among in	n-2023 , 05-Feb-20 07-Jan-2024 , 05- noke or vape marij dividuals with HIV	23 , 16-Feb- Feb-2024 , 16- uana, tobacco, and COVID-
103071	Notice of Special Interest (NOSI): Addicted Brain	Decipherir	ng the Mosaic of Glia in the	National Institute on Drug Abuse/NIH/DHHS	NOT-DA- 21-001 07-N	/lay-2022	Not Specified
	Contact Name	Shang-Yi	Anne Tsai, Ph.D				
	Contact Telephone	301-827-5	5842				
	Contact Email	<u>stsai@nih</u>	i.gov				
	Sponsor Website						
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	07-May-2 2023 , 05- Oct-2023 , 16-Jun-2	022 , 05-Jun-2022 , 16-Jun-2 Feb-2023 , 16-Feb-2023 , 25 , 16-Oct-2023 , 25-Oct-2023 024 , 25-Jun-2024 , 07-Sep-2	022 , 25-Jun-2022 , 07-Sep-2022 , 05 -Feb-2023 , 07-May-2023 , 05-Jun-20 , 07-Jan-2024 , 05-Feb-2024 , 16-Feb 2024	Oct-2022 , 16-Oc 23 , 16-Jun-2023 -2024 , 25-Feb-20	t-2022 , 25-Oct-20 , 25-Jun-2023 , 07 24 , 07-May-2024	22 , 07-Jan- -Sep-2023 , 05- , 05-Jun-2024
	Synopsis	National I interest ir and plasti disorders	nstitute on Drug Abuse (NID n research project grant subr city of glia and non-neurona (SUD). Glial and other non-n	A) is issuing this Notice of Special Intensions that examine the effects of on the system process in the terror out of the system process in the terror of ter	erest (NOSI) to inf Irug use on the stu he context of dru oglia, oligodendro	orm potential app ructural and funct g misuse and subs ocytes and epend	licants of its ional diversity tance use vmal cells.
100294	Notice of Special Interest (NOSI):	Neuroimm	nune Signaling and Function	National Institute on Drug	NOT-DA- 07-N	//av-2022	Not
	in Substance Use Disorders	1		Abuse/NIH/DHHS	20-046	, -	Specified
	Contact Name	Roger G S	orensen, Ph.D., MPA				
	Contact Telephone	301-443-3	3205				
	Contact Email	<u>rsorense@</u>	@nida.nih.gov				
	Sponsor Website						
	Program URL	Link to pr	ogram URL				

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Deadline Dates (ALL) Synopsis	07-May-2 2023 , 05- The purpo CNS in rel exposure	022 , 05-Jun-2022 , 16-Jun-202 Feb-2023 , 16-Feb-2023 , 25-F ose of this notice is to encoura ation to: the trajectory (i.e. ini to misused drugs: abstinence	22 , 25-Jun-2022 , 01-Sep-2022 , 05- eb-2023 , 07-May-2023 , 05-Jun-20 ge research project submissions exa tiation, escalation, and maintenanc and withdrawal from prolonged use	Oct-2022 , 16-Oc 23 , 16-Jun-2023 amining the role c e) of drug misuse e: and relapse or i	t-2022 , 25-Oct-20 , 25-Jun-2023 , 07- of neuroimmune si ; consequences of reinstatement of d	22 , 07-Jan- Sep-2023 gnaling in the chronic rug taking at
103874	Notice of Special Interest (NOSI): Connectome Resources in Model Neurobiology of Substance Abuse	molecular Leveraging Organisms Disorders	Transformative	Vational Institute on Drug Abuse/NIH/DHHS	NOT-DA- 21-006 07-N	Лау-2022	Not Specified
	Contact Name Contact Telephone Contact Email Sponsor Website	Olivier Be 301-827-7 <u>olivier.be</u> i	rton, Ph.D. 7771 r <u>ton@nih.gov</u>				
	Program URL Deadline Dates (ALL)	<u>Link to pro</u> 07-May-2 2023 , 07- Feb-2024	<mark>ogram URL</mark> 022 , 05-Jun-2022 , 16-Jun-202 May-2023 , 05-Jun-2023 , 16-J , 07-May-2024 , 05-Jun-2024 ,	22 , 07-Sep-2022 , 05-Oct-2022 , 16- un-2023 , 07-Sep-2023 , 05-Oct-202 16-Jun-2024 , 07-Sep-2024	Oct-2022 , 07-Jar 23 , 16-Oct-2023 ,	1-2023 , 05-Feb-20 07-Jan-2024 , 05-	23 , 16-Feb- Feb-2024 , 16-
	Synopsis	The purpo resources relevant t	ose of this notice is to encoura in genetically tractable model o substance use disorders (SU	ge research project submissionstha organisms to investigate the role o D).	t leverage whole- f distributed neu	brain or large con ronal circuits in be	nectome haviors
103870	Notice of Special Interest (NOSI): Animal Models to Identify Neural Resilience to Substance Use Disor	Leveraging Mechanis der	<u>t Longitudinal Studies in</u> ms of Vulnerability and	National Institute on Drug Abuse/NIH/DHHS	NOT-DA- 21-003 07-N	Лау-2022	Not Specified
	Contact Name Contact Telephone Contact Email Sponsor Website Program URL	Holly Mod 301-827-7 Holly.Mod	ore 7376 ore@nih.gov ogram URL				



SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount		
	Deadline Dates (ALL)	07-May-2 2023 , 05 Oct-2023 , 16-Jun-2	022 , 05-Jun-2022 , 16-Jun-20 -Feb-2023 , 16-Feb-2023 , 25- , 16-Oct-2023 , 25-Oct-2023 , 2024 , 25-Jun-2024 , 07-Sep-20	022 , 25-Jun-2022 , 07-Sep-2022 , 05 Feb-2023 , 07-May-2023 , 05-Jun-20 07-Jan-2024 , 05-Feb-2024 , 16-Feb 024	-Oct-2022 , 16-Oc 023 , 16-Jun-2023 0-2024 , 25-Feb-20	t-2022 , 25-Oct-20 , 25-Jun-2023 , 07- )24 , 07-May-2024	22 , 07-Jan- ·Sep-2023 , 05- , 05-Jun-2024		
	Synopsis Suppropriate paradigms are strongly encouraged.						k factors for effects of ntal-stage-		
105778	maging - Science Track Award fo Basic Experimental Studies with F	r Research Iumans Re	Transition (I/START) (RO3- equired)	National Institute on Drug Abuse/NIH/DHHS	PAR-21- 309 07-I	May-2022	150,000 USD		
	Contact Name	John Fede	ota, PhD						
	Contact Telephone	301-402-0	0812						
	Contact Email	john.fedo	ta@mail.nih.gov						
	Sponsor Website								
	Program URL	Link to pr	ogram URL						
	Deadline Dates (ALL)	07-May-2 2023 , 16	022 , 16-Jun-2022 , 07-Sep-20 -Oct-2023 , 07-Jan-2024 , 16-I	022 , 16-Oct-2022 , 07-Jan-2023 , 16 Feb-2024 , 07-May-2024 , 16-Jun-20	-Feb-2023 , 07-M 24 , 07-Sep-2024	ay-2023 , 16-Jun-2	023 , 07-Sep-		
	This Funding Opportunity Announcement (FOA) encourages Small Research Grant (RO3) applications to facilitate the entr investigators to the area of neuroimaging, including both newly independent investigators and established investigators Synopsis seeking to adopt neuroimaging methodologies in their research programs, to enable the conduct of small "proof of conce studies. The RO3 is intended to support research projects that can be carried out in a short period of time with limited resources.								
105780 <mark> </mark>	maging - Science Track Award fo Clinical Trial Optional)	r Research	Transition (I/START) (R03-	National Institute on Drug Abuse/NIH/DHHS	PAR-21- 310 07-I	May-2022	150,000 USD		
	Contact Name	John Fede	ota, PhD						
	Contact Telephone	301-402-0	0812						
	Contact Email	john.fedo	ta@mail.nih.gov						
	Sponsor Website								
	Program URL	Link to pr	ogram URL						

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Deadline Dates (ALL) Synopsis	07-May-2 2023 , 16- This Fund investigat investigat "proof of with limit	022 , 16-Jun-2022 , 07-Sep-20 Oct-2023 , 07-Jan-2024 , 16-F ing Opportunity Announceme ors to the area of neuroimagin ors seeking to adopt neuroima concept" studies. The R03 is in ed resources.	22 , 16-Oct-2022 , 07-Jan-2023 , 16 eb-2024 , 07-May-2024 , 16-Jun-20 nt (FOA) encourages Small Research ng, including both newly independe aging methodologies in their resear ntended to support research projec	-Feb-2023 , 07-Ma 24 , 07-Sep-2024 h Grant (R03) app ent investigators a ich programs, to e ts that can be carr	ay-2023 , 16-Jun-2 lications to facilita nd established nable the conduct ried out in a short	023 , 07-Sep- te the entry of of small period of time
104862	Notice of Special Interest (NOSI): A Computational Neuroscience	Advancing	HIV/AIDS Research through	National Institute on Drug Abuse/NIH/DHHS	NOT-DA- 21-030 07-N	/lay-2022	Not Specified
	Contact Name Contact Telephone	Yu (Wood 301-435-2	ly) Lin 1318				
	Contact Email	<u>ylin1@ma</u>	<u>ail.nih.gov</u>				
	Sponsor website	Link to pr	ogram LIPI				
	Deadline Dates (ALL)	07-May-2 2022 , 05- Feb-2023 , 25-Sep-2 2024 , 16- 07-Sep-20	022 , 25-May-2022 , 05-Jun-20 Oct-2022 , 12-Oct-2022 , 16-0 , 25-Feb-2023 , 07-May-2023 2023 , 05-Oct-2023 , 12-Oct-20 Feb-2024 , 25-Feb-2024 , 07-P 024 , 25-Sep-2024 , 12-Oct-202	022 , 12-Jun-2022 , 16-Jun-2022 , 25 Oct-2022 , 25-Oct-2022 , 07-Jan-202 , 25-May-2023 , 05-Jun-2023 , 12-Ju 023 , 16-Oct-2023 , 25-Oct-2023 , 07 May-2024 , 25-May-2024 , 05-Jun-20 24 , 25-Oct-2024 , 07-Jan-2025	5-Jun-2022 , 15-Au 3 , 25-Jan-2023 , ( un-2023 , 16-Jun-2 7-Jan-2024 , 25-Jar 024 , 12-Jun-2024	ng-2022 , 07-Sep-2 05-Feb-2023 , 12-F 2023 , 25-Jun-2023 n-2024 , 05-Feb-20 , 16-Jun-2024 , 25	022 , 25-Sep- eb-2023 , 16- 8 , 07-Sep-2023 024 , 12-Feb- 5-Jun-2024 ,
	Synopsis	This Notic collaborat proficienc support n methods) substance but an on	e of Special Interest [NOSI] is tive research between investig cy, including scientists from sta neritorious and innovative rese to investigate HIV-related new e use disorder (SUD). Investiga going collaboration or record	to support computational HIV/AIDS gators with experimental expertise atistics, physics, mathematics, engir earch built on well-established com urocognitive deficits and neuropath tors are expected to have complem of co-authorship is not required.	Fresearch as it related to HIV/AIE neering, and comp putational strateg ogenesis in the co nentary and integr	ates to NIDA's mis 25 and those with outer science. The gies (theory, mode ontext of substance ated expertise in t	sion through computational NOSI will Is, and e use or :heir field(s),
106007	Notice of Special Interest (NOSI): I on Drug Abuse and Addiction Rese	nternatio earch	nal Research Collaboration	National Institute on Drug Abuse/NIH/DHHS	NOT-DA- 21-064 07-N	/lay-2022	Not Specified

Contact Name Steve Gust, Ph.D.

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount		
	Contact Tolonhono	201 102	1110						
		501-402-							
	Sponsor Website	<u>sgust@m</u>							
	Sponsor website	Link to pr	ogram LIPI						
	Deadline Dates (ALL)	07-May-2 2023 , 07- Feb-2024	022 , 05-Jun-2022 , 16-Jun-202 -May-2023 , 05-Jun-2023 , 16- , 07-May-2024 , 05-Jun-2024 ,	22 , 07-Sep-2022 , 05-Oct-2022 , 16- Jun-2023 , 07-Sep-2023 , 05-Oct-20 . 16-Jun-2024 , 07-Sep-2024	-Oct-2022 , 07-Jan 23 , 16-Oct-2023 ,	-2023 , 05-Feb-20 07-Jan-2024 , 05-	23 , 16-Feb- Feb-2024 , 16-		
	Synopsis	The purpe of the Un treatmen newly for another c proposal health sci	if the United States. Applications examining all areas of NIDA-supported research addressing the causes, consequences, eatment, recovery, and prevention of drug use, misuse, and addiction are encouraged. Projects may be conducted through ewly formed or well-established partnerships between investigators in a U.Sbased institution and scientists working in nother country. All NIH grant applications for research to be conducted outside the United States must establish that the roposal takes advantage of unique research opportunities in other countries, speeds scientific discovery, and advances U.S ealth science.						
109268 📐	Notice of Special Interest (NOSI):	Epidemiol	ogy of Drug Abuse	National Institute on Drug Abuse/NIH/DHHS	NOT-DA- 22-004 05-Ju	un-2022	Not Specified		
	Contact Name	Marsha Lo	opez, PhD, MHS						
	Contact Telephone	301-443-6	6504						
	Contact Email	Marsha.L	<u>opez@nih.gov</u>						
	Sponsor Website								
	Program URL	Link to pr	ogram URL						
	Deadline Dates (ALL)	05-Jun-20 2023 , 05- May-2024 , 07-May-	05-Jun-2022 , 16-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 07-May- 2023 , 05-Jun-2023 , 16-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 16-Oct-2023 , 07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 07- May-2024 , 05-Jun-2024 , 16-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 16-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 16-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 16-Jun-2025 , 07-Sep-2025 The purpose of this Notice is to encourage the submission of research project applications that enhance our understanding of the nature, extent, distribution, etiology, comorbidities, and consequences of drug use, misuse, and addiction across individuals, families, communities, and diverse population groups. Of interest are applications that address multiple levels of risk, resilience, and causation across scientific disciplines, and that apply novel methods to advance knowledge of the interplay among genetic, environmental, neurobiological, and developmental factors and associated health and disease						
	Synopsis	The purpo of the nat individual risk, resili interplay							

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount	
		outcomes addition t agencies t treatmen disparities interactio	s. Priority will be given to rese to novel data collection, appro to harness existing data on th t programs. The research area s or inequities, familial/genet ns.	arch with a well described path towa baches are encouraged that build on e epidemiology and etiology of drug as noted below should be considered ic liability, and physical, psychiatric, a	ards translation the research in misuse to imp I in the contex and polysubsta	n and/or public health nvestments of NIH an rove public health pro t of topics such as hea ance comorbidities an	n impact. In d sister HHS evention and alth d	
109484	Notice of Special Interest (NOSI): Actionable Insights for Substance	Leveraging use Preve	g Data Science to Bring ntion and Treatment	National Institute on Drug Abuse/NIH/DHHS	NOT-DA- 23-006 0	5-Jun-2022	Not Specified	
	Contact Name	Janet Kur	amoto-Crawford, PhD					
	Contact Telephone	301-443-8	3856					
	Contact Email	janet.kura	amoto-crawford@nih.gov					
	Sponsor Website							
	Program URL	Link to pr	ogram URL					
	Deadline Dates (ALL)	adline Dates (ALL) 05-Jun-2022, 16-Jun-2022, 07-Sep-2022, 05-Oct-2022, 16-Oct-2022, 07-Jan-2023, 05-Feb-2023, 16-Feb-2023, 07-May- 2023, 05-Jun-2023, 16-Jun-2023, 07-Sep-2023, 05-Oct-2023, 16-Oct-2023, 07-Jan-2024, 05-Feb-2024, 16-Feb-2024, 07- May-2024, 05-Jun-2024, 16-Jun-2024, 07-Sep-2024, 05-Oct-2024, 16-Oct-2024, 07-Jan-2025, 05-Feb-2025, 16-Feb-2025 07-May-2025, 05-Jun-2025, 16-Jun-2025, 07-Sep-2025						
	Synopsis	This Notic preventio or near re treatmen health rec	e encourages research project in and treatment 2) shorten the eal-time, and 3) explore methor t and prevention. Priority will cords, syndromic surveillance,	ets that 1) leverage data science to provide time between data capture and data capture and data sand tools that may allow for faster be given to projects that emphasize claims data, registry data, pharmacy	rovide actiona ata availability er or better loo the use of exis y dispensing, s	ble insights for substa so that data are avai calized responses for sting data streams (e. ocial media, and mor	ance use lable real-time substance use g., electronic tality records).	
109316	<u>RFA-RM-22-010 Somatic Mosai</u> Program: Data Analysis Center (U	<u>cism acros</u> M1 Clinica	<u>s Human Tissues (SMaHT)</u> I Trial Not Allowed)	National Institute on Drug Abuse/NIH/DHHS	RFA-RM- 22-010 A	8-Jun-2022 Dptional][LOI/Pre- pp]	Not Specified	
	Contact Name	Amy C. Lo	ossie, Ph.D.					
	Contact Telephone	301-827-6	5092					
	Contact Email	SMaHT@	mail.nih.gov					
	Sponsor Website							



SPIN ID	Program Title	Sponsor Name		Sponsor Number		Deadline Date	Funding Amount		
	Program URL	Link to program URL							
	Deadline Dates (ALL)	)8-Jun-2022 [Optional][LOI/Pre-App], 08-Jul-2022							
	Synopsis	This Funding Opportunity Somatic Mosaicism across new biology and disease n responsible for the followi and standardized annotati deploying them as part of Variant Catalog and varian Announcement (FOA) is de NIH Director, Office of Stra Fund initiatives. The FOA v	Announcemen Human Tissue nechanisms me ing areas: 1. M ion, and archiv an accessible o at browser, and eveloped as a o ategic Coordina will be adminis	et (FOA) invites applications to estal es (SMaHT) Network. The purpose of ediated by genomic variation in som anaging all data on behalf of the Ne ing of data; 2. Developing new com data workbench; 3. Building a data d 4. Harmonizing SMaHT resources Common Fund initiative (http://com ation (https://dpcpsi.nih.gov/). All I tered by the National Institute of D	blish the Data An of the SMaHT Ne natic tissues. The etwork, including putational meth portal for the Ne with related prog nmonfund.nih.go NIH Institutes and rug Abuse (NIDA	alysis Center (DAC twork is to enable Data Analysis Cer ingestion, uniforr ods and bioinform twork, including th grams. This Fundin w/) through the N d Centers participa ) on behalf of the l	) for the discovery of iter will be n processing, atics tools and the SMaHT g Opportunity IH Office of the the in Common NIH.		
091370	NIMHD Exploratory/Developments Clinical Trial Optional)	al Research Grant Progran	n <u>(R21 -</u> N H D	lational Institute on Minority lealth and Health lisparities/NIH/DHHS	PAR-20- 150 07-N	Иау-2022	275,000 USD		
	Contact Name								
	Contact Telephone	301-402-1366							
	Contact Email	<u>GrantsInfo@nih.gov</u>							
	Sponsor Website								
	Program URL	Link to program URL							
	Deadline Dates (ALL)	07-May-2022 , 16-Jun-202	2,07-Sep-202	2 , 16-Oct-2022 , 07-Jan-2023 , 16-	Feb-2023 , 07-Ma	ay-2023			
	Synopsis	NIMHD invites application break new ground in the f directions or applications U.S.	s to support sh ields of minorit that can direct	nort-term exploratory or development ty health and/or health disparities of ly contribute to improving minority	ental research pr or extend previou health and/or re	ojects that have th us discoveries tow educing health disp	ie potential to ard new parities in the		
108660	Notice of Special Interest (NOSI): V Artificial Intelligence Tools for Imp Clinical, and Intervention Research	/alidation of Digital Health roved Assessment in Epide	<u>and</u> emiological, N	lational Institutes of Health/DHHS	NOT-CA- 22-037 05-4	Apr-2022	Not Specified		
	Contact Name	Dana Wolff-Hughes, PhD							

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount				
	Contact Telephone	240-620-0673								
	Contact Email	dana.wolff@nih.gov								
	Sponsor Website									
	Program URL	Link to program URL								
	Deadline Dates (ALL)	05-Apr-2022, 07-May-2022, 26-May-20 2022, 11-Jul-2022, 05-Sep-2022, 07-Se Nov-2022, 08-Nov-2022, 14-Nov-2022, , 07-Mar-2023, 10-Mar-2023, 10-Mar-2 Jun-2023, 10-Jul-2023, 26-Aug-2023, 0 01-Nov-2023, 05-Nov-2023, 13-Nov-20 2024, 07-Mar-2024	22, 11-Jul-2022, 05-Way-2022, 05-Way-2022, 05-Way-2022, 05-Jul-2022, 05-Jul-2022, 15-Jul-2022, 16-Jul-2022, 24-Jul- 22, 11-Jul-2022, 05-Sep-2022, 07-Sep-2022, 05-Oct-2022, 07-Oct-2022, 14-Oct-2022, 16-Oct-2022, 20-Oct-2022, 01- ov-2022, 08-Nov-2022, 14-Nov-2022, 28-Dec-2022, 05-Jan-2023, 07-Jan-2023, 05-Feb-2023, 15-Feb-2023, 16-Feb-2023 7-Mar-2023, 10-Mar-2023, 10-Mar-2023, 05-Apr-2023, 26-Apr-2023, 07-May-2023, 05-Jun-2023, 07-Jun-2023, 16- In-2023, 10-Jul-2023, 26-Aug-2023, 05-Sep-2023, 07-Sep-2023, 05-Oct-2023, 09-Oct-2023, 16-Oct-2023, 17-Oct-2023, 1-Nov-2023, 05-Nov-2023, 13-Nov-2023, 28-Dec-2023, 05-Jan-2024, 07-Jan-2024, 05-Feb-2024, 15-Feb-2024, 16-Feb- 024, 07-Mar-2024							
	Synopsis	The purpose of this Notice of Special Interest (NOSI) is to encourage grant applications to support the evaluation of the utility and validity of digital health and artificial intelligence (AI) tools and technologies in epidemiological, clinical, and intervention research. The intent is to support the addition of new measurement modalities to evaluate existing and recently developed but not yet validated digital health and AI tools such as sensor technologies, smartphone applications, software as a medical device (SaMD), and AI algorithms.								
108347	Notice of Special Interest (NOSI): dentified Factors Into Models of	Advancing NEI AGI Research on newly Visual System Regeneration	National Institutes of Health/DHHS	NOT-EY- 22-002 05-A	Apr-2022	Not Specified				
	Contact Name									
	Contact Telephone									
	Contact Email									
	Sponsor Website									
	Program URL	Link to program URL								
	Deadline Dates (ALL)	05-Apr-2022, 07-May-2022, 05-Jun-2022, 16-Jun-2022, 25-Jun-2022, 05-Sep-2022, 07-Sep-2022, 05-Oct-2022, 16-Oct- 2022, 25-Oct-2022, 05-Jan-2023, 07-Jan-2023, 05-Feb-2023, 09-Feb-2023, 16-Feb-2023, 25-Feb-2023, 05-Apr-2023, 07- May-2023, 05-Jun-2023, 16-Jun-2023, 25-Jun-2023, 05-Sep-2023, 07-Sep-2023, 05-Oct-2023, 16-Oct-2023, 25-Oct-2023, 05-Jan-2024, 07-Jan-2024, 05-Feb-2024, 16-Feb-2024, 25-Feb-2024, 05-Apr-2024, 07-May-2024, 05-Jun-2024, 16-Jun- 2024, 05-Sep-2024, 07-Sep-2024, 05-Oct-2024, 16-Oct-2024								
	Synopsis	The National Eye Institute (NEI) is issuing newly identified factors into new or exis	g this Notice of Special Interest (NOS ting models of visual system regene	SI) to encourage ration. These fac	novel research that tors were identifie	it incorporates ed by a				

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		consortiu communi	m of research teams as part of ty. Applicants beyond the origi	the Audacious Goal Initiative (AGI) nal consortium are strongly encour	and are being sh aged to apply.	ared broadly with	the research
104784	Notice of Special Interest (NOSI): Actionable Data Dissemination St	HIV Drug F rategies	Resistance Assays and N	National Institutes of Health/DHHS	NOT-AI- 21-056 05-A	Apr-2022	Not Specified
	Contact Name	Usha Sha	rma, PhD				
	Contact Telephone	240-292-4	4809				
	Contact Email	<u>usharma(</u>	<u>@niaid.nih.gov</u>				
	Sponsor Website						
	Program URL	<u>Link to pr</u>	ogram URL				
	Deadline Dates (ALL)	Deadline Dates (ALL) 05-Apr-2022 , 07-May-2022 , 05-Jun-2022 , 16-Jun-2022 , 01-Jul-2022 , 05-Sep-2022 , 07-Sep-2022 , 05-Oct-2022 , 16-Oct- 2022 , 05-Jan-2023 , 07-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 17-Feb-2023 , 05-Apr-2023 , 07-May-2023 , 05-Jun-2023 , 16- Jun-2023 , 06-Jul-2023 , 05-Sep-2023 , 07-Sep-2023 , 05-Oct-2023 , 16-Oct-2023 , 05-Jan-2024 , 07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 05-Apr-2024 , 07-May-2024 , 05-Jun-2024 , 05-Jun-2024 , 16-Jun-2024 , 07-Sep-2024					
	Synopsis	This Notic optimizat needed to Research can be int (ii) point o timely dis income co	ce of Special Interest (NOSI) is to ion of next generation method o improve the guidance availab responsive to this NOSI could in tegrated into multiplex assay sy of care (POC) DR assays, or (iii) assemination to healthcare provo countries as defined by the Wor	to inform potential applicants of NIA lologies for HIV-1 drug resistance (D ple to treatment and prevention pro- include the development of: (i) high systems capable of simultaneous ass strategies for rapid acquisition, cur- iders and public health decision ma- id Bank are especially encouraged.	AID's interest in t PR) mutation dete ograms for both ir Iy sensitive muta essment of large ation and analysi kers. Strategies a	he development a ection and reportin ndividuals and pop tion detection tec numbers of poter s of these HIV DR pplicable to low a	nd ng. This is bulations. hnologies that ntial mutations data and nd middle
105957	Time-Sensitive Obesity Policy and Not Allowed)	Program	Evaluation (R01 Clinical Trial N	National Institutes of Health/DHHS	PAR-21- 305 11-A	Apr-2022	Not Specified
	Contact Name	Mary Eva	ns, Ph.D.				
	Contact Telephone	301-594-4	4578				
	Contact Email	evansmar	ry@mail.nih.gov				
	Sponsor Website						
	Program URL	Link to pr	ogram URL				



SPIN ID	D Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount	
	Deadline Dates (ALL)	11-Apr-2( 2022 , 10 Sep-2023 2024 , 10	022 , 10-May-2022 , 09-Jun-202 -Jan-2023 , 09-Feb-2023 , 09-M , 09-Oct-2023 , 10-Oct-2023 , 1 -Jun-2024 , 09-Aug-2024 , 10-Se	2 , 11-Jul-2022 , 09-Aug-2022 , 09-5 ar-2023 , 11-Apr-2023 , 09-May-20 .1-Dec-2023 , 09-Jan-2024 , 09-Feb- ep-2024	Sep-2022 , 07-C 23 , 09-Jun-202 -2024 , 08-Mar	Oct-2022 , 09-Nov-20 23 , 11-Jul-2023 , 09- 2024 , 09-Apr-2024	)22 , 09-Dec- Aug-2023 , 08- , 08-May-	
	Synopsis	research to evaluate a new policy or program that is likely to influence obesity related behaviors (e.g., dietary intake, physical activity, sedentary behavior, and/or sleep) and/or weight outcomes in an effort to prevent or reduce obesity FOA is intended to support research where opportunities for empirical study are, by their very nature, only available expedited review and funding. All applications submitted to this FOA must demonstrate that the evaluation of an ober related policy or program offers an uncommon and scientifically-compelling research opportunity that will only be avif the research is initiated with minimum delay. For these reasons, applications submitted to this time-sensitive FOA eligible for re-submission. It is intended that eligible applications selected for funding will be awarded within 4 month application due date; however, administrative requirements and other unforeseen circumstances may delay issuance beyond that timeline.						
097189	Assay Development and Screenir Drugs or Immunomodulators (RO	ng for Disco 1)	overy of Chemical Probes, N	ational Institutes of Health/DHHS	PAR-20- [O 271 Ar	-May-2022 ptional][LOI/Pre- pp]	Not Specified	
	Contact Name	Suzanne	Forry, Ph.D.					
	Contact Telephone	240-276-	5922					
	Contact Emai	forryscs@	omail.nih.gov					
	Sponsor Website	h.						
	Program URL	Link to pr	ogram URL					
	Deadline Dates (ALL)	05-May-2 Jan-2023	022 [Optional][LOI/Pre-App], 0	7-May-2022 , 05-Jun-2022 , 05-Sep	-2022 [Optiona	ll][LOI/Pre-App], 05-	Oct-2022 , 07-	
	Synopsis	Through t novel, sm Institutes be validat primary s throughp set; and 4	this funding opportunity annou all molecules for their potentia (NIDCD, NIMH); and to generat ted as important drug targets. S creen implementation to identi ut screens); 3) hit validation usi ) hit-to-lead optimization.	ncement (FOA), NCI wishes to stimu I use in studying disease treatment te new insight into the biology of re stages of discovery research covere ify initial screening hits (high throug ng a series of assays and initial med	ulate research i relevant to the elevant disease d by this FOA ir ghput target-fo dicinal chemist	in discovery and dev e missions of the par s and processes that nclude: 1) assay deve cused screens, or m ry inspection to prio	elopment of ticipating NIH have yet to elopment; 2) oderate ritize the hit	

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
101814	Notice of Special Interest (NOSI): for Artificial Intelligence-based M Abdominal Cancers	Leveraging Real-World Imaging Data Iodeling and Early Detection of	National Institutes of Health/DHHS	NOT-CA- 21-028 07-N	Лау-2022	Not Specified
	Contact Name	Natalie Abrams, PhD				
	Contact Telephone	240-474-7336				
	Contact Email	natalie.abrams@nih.gov				
	Sponsor Website	2				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-May-2022 , 05-Jun-2022 , 07-Sep- 2023 , 05-Oct-2023 , 07-Jan-2024	2022 , 05-Oct-2022 , 07-Jan-2023 , 05-	Feb-2023 , 07-Ma	ay-2023 , 05-Jun-2	023 , 07-Sep-
	Synopsis	The purpose of this Notice of Special for Artificial Intelligence (AI)-based push assessment for abdominal cancers. The development approaches such as fed results without sharing the actual dat	Interest (NOSI) is to solicit applications redictive modeling with the ultimate go his Notice encourages applications pro lerated learning, which distributes the ta.	s to support the s bal of improving o posing multi-inst models to data-o	econdary use of r early detection an itutional collabora wners and aggreg	eal-world data d risk ative Al ates the
105617	Effectiveness of School-Based Hea (R01 Clinical Trial Optional)	alth Centers to Advance Health Equity	National Institutes of Health/DHHS	PAR-21- 287 07-N	May-2022	Not Specified
	Contact Name					
	Contact Telephone	2				
	Contact Email	<u>GrantsInfo@nih.gov</u>				
	Sponsor Website	2				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-May-2022 , 05-Jun-2022 , 07-Sep- 2023 , 07-Jan-2024 , 05-Feb-2024 , 07	2022 , 05-Oct-2022 , 07-Jan-2023 , 05- 7-May-2024 , 05-Jun-2024 , 07-Sep-202	Feb-2023 , 07-Ma 24 , 05-Oct-2024 ,	ay-2023 <i>,</i> 05-Jun-2 . 07-Jan-2025	023 , 07-Sep-
	Synopsis	The purpose of this Funding Opportu based health centers (SBHCs) as a hea populations with health disparities (h research that investigates the effectiv prevent chronic illnesses that disprop	nity Announcement is to support resea alth services care delivery model to ad ience, underserved youth). The goals o veness of SBHCs as a health services ca portionately burden underserved youth	arch that investig dress the needs o of this FOA are to re delivery mode n. The mechanism	ates the effective of school-aged chi support multidisc el to detect, manag ns of impact by wh	ness of school- Idren from Siplinary ge, and hich SBHCs

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		improve t in rural ar conceptu health ou initiative needs of intervent underser	the health of at-risk populations reas are also a relevant focus fo al model that describes hypoth tcomes and how SBHCs may co can help determine whether SE underserved youth and if so, wh ion to address disparities in chr ved communities who lack acce	s such as sexual and gender minorit r understanding effective models o esized causal pathways by which SE mplement (or reduce) the use of o BHCs can be adopted as a best pract hether SBHCs given their accessibili onic conditions, and behavioral, or ss to health care.	ty youth, immigra of SBHCs. Applicat BHCs engage und ther services. Les tice care model to ty to students ca al, and reproduct	int youth, and you ions are expected erserved youth to sons learned thro o address the hea n be an effective s ive health of yout	Ith who reside to provide a improve ugh this Ith services site of th from
094015 <u> </u>	Nentored Research Scientist Dev Independent Clinical Trial Require	<u>elopment</u> ed)	<u>Award (Parent K01 -</u> N	ational Institutes of Health/DHHS	PA-20- 176 07-N	/lay-2022	Not Specified
	Contact Name						
	Contact Telephone						
	Contact Email	grantsinfo	o@nih.gov				
	Sponsor Website						
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	07-May-2	022 , 12-Jun-2022 , 07-Sep-202	2, 12-Oct-2022, 07-Jan-2023, 12-	Feb-2023 , 07-Ma	iy-2023	
	Synopsis	The purper (three to sciences I mechanis individual illness or candidate separate trial, or p (PA-20-19 carefully requirem this anno strongly e	ose of the NIH Mentored Resea five years) for an intensive, sup eading to research independen in to support career developme ls who propose to train in a new pressing family circumstances es proposing to serve as the lead ancillary clinical trial, as part of roposing to gain research exper 20). Special Note: Not all NIH I note which ICs participate in th ents at the Table of IC-Specific I uncement will not consider app encouraged.	rch Scientist Development Award ( ervised career development experi- ce. Although all of the participating ent experiences that lead to researd v field or for individuals who have h This Funding Opportunity Annound d investigator of an independent cl their research and career developr rience in a clinical trial led by anoth nstitutes and Centers participate ir is announcement and view their re- Information, Requirements and Sta blications for funding. Consultation	K01) is to provide ence in the biom g NIH Institutes an ch independence had a hiatus in the cement (FOA) is c inical trial, a clinic ment. Those not p er investigator, m Parent Announc spective areas of ff Contacts websi with NIH staff be	e support and "pro edical, behavioral nd Centers (ICs) us , some ICs use the eir research caree lesigned specifica cal trial feasibility planning an indep nust apply to com rements. Applican research interest te. ICs that do no fore submitting an	otected time" , or clinical se this support e K01 award for r because of lly for study, or a endent clinical panion FOA its should and t participate in n application is

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
094020	Mentored Research Scientist Develo	opment Award (Parent K01 - ved)	National Institutes of Health/DHHS	PA-20- 190 07-N	Лау-2022	Not Specified
	Contact Name					
	Contact Telephone					
	Contact Email g	rantsinfo@nih.gov				
	Sponsor Website					
	Program URL LI	Ink to program URL			2022	
	Ti (t so m in ill Synopsis se m tr sh re tr sh re tr sh	he purpose of the NIH Mentored Re three to five years) for an intensive, ciences leading to research indeper nechanism to support career develor adividuals who propose to train in a lness or pressing family circumstant pplicants proposing research that de eparate ancillary clinical trial. Applic nentor or co-mentor. Applicants pro- ne companion FOA. Special Note: No hould carefully note which ICs parti- equirements at the Table of IC-Spec- nis announcement will not consider trongly encouraged.	esearch Scientist Development Award ( , supervised career development exper- ndence. Although all of the participating opment experiences that lead to resear a new field or for individuals who have h ces This Funding Opportunity Announ loes not involve leading an independen cants to this FOA are permitted to prop oposing a clinical trial or an ancillary clin lot all NIH Institutes and Centers partici cipate in this announcement and view cific Information, Requirements and Star r applications for funding. Consultation	K01) is to provide ience in the biom g NIH Institutes a ch independence nad a hiatus in the cement (FOA) is o t clinical trial, a cl ose research exp nical trial as lead pate in Parent Ar their respective a ff Contacts webs with NIH staff be	e support and "pro edical, behavioral nd Centers (ICs) us , some ICs use the eir research caree designed specifical linical trial feasibil erience in a clinica investigator, shou nouncements. Ap reas of research in ite. ICs that do not fore submitting ar	otected time" , or clinical Se this support KO1 award for r because of ly for ity study, or a al trial led by a ld apply to plicants nterest and c participate in application is
106062	Maximizing Opportunities for Scient Careers (MOSAIC) Postdoctoral Care Diversity (K99/R00 Independent Clin	tific and Academic Independent eer Transition Award to Promote nical Trial Not Allowed)	National Institutes of Health/DHHS	PAR-21- 271 07-N	Лау-2022	Not Specified
	Contact Name Ko Contact Telephone Contact Email <u>ka</u> Sponsor Website	enneth D. Gibbs, Jr., Ph.D. <u>enneth.gibbs@nih.gov</u>				

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount			
	Program URL <u>Link to p</u> 07-May- 2023 , 1	<u>rogram URL</u> 2022 , 12-Jun-2022 , 07-Sep-202 2-Oct-2023 , 07-Jan-2024 , 12-Fe	2 , 12-Oct-2022 , 07-Jan-2023 , 12-Feb-2023 , 07-Ma b-2024 , 07-May-2024 , 12-Jun-2024 , 07-Sep-2024	y-2023 , 12-Jun-2(	023 , 07-Sep-			
	The purp Career T investiga enhance transition from the position help awa organize activities This Fun involve I are pern trial or a	The purpose of the Maximizing Opportunities for Scientific and Academic Independent Careers (MOSAIC) Postdoctoral Career Transition Award to Promote Diversity (K99/R00) program is to support a cohort of early career, independent investigators from diverse backgrounds conducting research in NIH mission areas. The long-term goal of this program is to enhance diversity in the biomedical research workforce. The MOSAIC K99/R00 program is designed to facilitate a timely transition of promising postdoctoral researchers from diverse backgrounds (e.g., see Notice of NIH's Interest in Diversity) from their mentored, postdoctoral research positions to independent, tenure-track or equivalent research-intensive faculty positions. The MOSAIC K99/R00 program will provide independent NIH research support before and after this transition to help awardees launch successful, independent research careers. Additionally, MOSAIC K99/R00 scholars will be part of organized scientific cohorts and will be expected to participate in mentoring, networking, and professional development activities coordinated by MOSAIC Institutionally-Focused Research Education Award to Promote Diversity (UE5) grantees. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial. Applicants to this FO are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Applicants proposing a clinica trial or an ancillary clinical trial as lead investigator, should apply to the companion FOA PAR-21-272.						

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
108832	Notice of Special Interest (NOSI): Addressing Cancer-Related Financial Hardship to Improve Patient Outcomes	National Institutes of Health/DHHS	NOT-CA- 22-045	07-May- 2022	Not Specified

Contact Name Kathleen Castro, RN, MS, AOCN

Contact Telephone 240-276-6834

Contact Email kathleen.castro@mail.nih.gov

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL) 07-May-2022 , 25-May-2022 , 05-Jun-2022 , 07-Jun-2022 , 16-Jun-2022 , 24-Jun-2022 , 07-Sep-2022 , 25-Sep-2022 , 05-Oct-2022 , 07-Oct-2022 , 07-Oct-2022 , 20-Oct-2022 , 08-Nov-2022 , 07-Jan-2023 , 25-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 07-

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadl	ine Date	Funding Amount
	Synopsis	Mar-2023 , 16-Oct-2 The purp application patients in	3, 25-May-2023, 05-Jun-2023, 2023, 16-Oct-2023, 05-Nov-202 ose of this Notice of Special Inte ons that aim to study ways to m receiving cancer treatment, surv	07-Jun-2023 , 16-Jun-202 23 , 25-Jan-2024 , 05-Feb- erest (NOSI) is to promote itigate financial hardship t vivors, and caregivers.	23 , 25-Sep-2023 , 05-C 2024 , 16-Feb-2024 e intervention research for individuals impact	Oct-2023 , 0 n through in ed by a canc	7-Oct-2023 vestigator-i ser diagnosi	, 07-Oct-2023 nitiated s, including
097158	Notice of Special Interest (NOSI): Impacts of Particulate Matter in	Stimulatii Air Pollutio	ng Intervention Research to Reconstruction among High-Risk Populations	luce Cardiopulmonary	National Institutes of Health/DHHS	NOT-HL- 20-788	07-May- 2022	Not Specified
	Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) Synopsis	Lawrence 301-435-4 Lawrence Link to pr 07-May-2 2023 The purp Lung, and in applica air pollut	e J. Fine, MD, DrPH 0305 <u>e.Fine@NIH.gov</u> <u>rogram URL</u> 2022 , 05-Jun-2022 , 07-Sep-202 ose of this trans-NIH Notice of S d Blood Institute (NHLBI) and the stions aiming to investigate the ion on cardiovascular and pulme r clinical trials that examine the	2 , 05-Oct-2022 , 07-Jan-2 Special Interest (NOSI) is to e National Institute of Env impact of personal interve onary (cardiopulmonary) efficacy of personal air pe	2023 , 05-Feb-2023 , 0 o inform potential app vironmental Health Sci entions to reduce exp outcomes. This notice	7-May-2023 blicants that fences (NIEF osure to par specifically to reduce th	the Nation S) have speticulate ma encourages	023 , 07-Sep- al Heart, ecial interest tter (PM) in s intervention
102694	Notice of Special Interest (NOSI):	cardiopul	monary effects of Particulate M tems Science Methodologies to	latter (PM) <2.5 μm in dia Protect and Improve	National Institutes	NOT-HD-	07-May-	icipants. Not
	Contact Name Contact Telephone Contact Email Sponsor Website Program URI	Regina M 301-496- regina.bu	. Bures, Ph.D. 9485 I <u>res@nih.gov</u> rogram URI			20 032	LULL	Specified

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Dead	line Date	Funding Amount		
	Deadline Dates (ALL)	07-May-2 2023 , 05-	)7-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 07-Sep- 2023 , 05-Oct-2023 , 07-Jan-2024 , 05-Feb-2024 , 07-May-2024							
	Synopsis	The purpo proposing to multi-le for both b behaviora researche	purpose of this Notice of Special Interest (NOSI) is to solicit applications to support multi-dis osing research using systems science approaches to address persistent public health challe nulti-level methodologies addressing complex behavioral and social phenomena. This initiati ooth basic and applied research, including methodological and measurement development, avioral and/or social science. This initiative also seeks to promote interdisciplinary collabora archers and experts in mathematical modelling.					tific teams science refers applications human alth		
108369	RFA-AR-22-009 HEAL Initiative: (RE-JOIN) (UC2 Clinical Trial Not A	Restoring	Joint Health and Function to Re	educe Pain Consortium	National Institutes of Health/DHHS	RFA-AR- 22-009	07-May- 2022	8,000,000 USD		
	Contact Name	Leslie K. D	Derr, PhD							
	Contact Telephone	301-594-8	3174							
	Contact Email	leslie.derr	<u>@nih.gov</u>							
	Sponsor Website									
	Program URL	Link to pro	ogram URL							
	Deadline Dates (ALL)	07-May-2 2023 <i>,</i> 05- Feb-2025	022 , 05-Jun-2022 , 07-Sep-202 ·Oct-2023 , 07-Jan-2024 , 05-Fe , 07-May-2025	2 , 05-Oct-2022 , 07-Jan-2 b-2024 , 07-May-2024 , 09	2023 , 05-Feb-2023 , 07- 5-Jun-2024 , 07-Sep-202	May-2023 24 , 05-Oc	3 , 05-Jun-20 t-2024 , 07-	023 , 07-Sep- Jan-2025 , 05-		
	Synopsis	The purpo interdiscip JOIN). The collective sensory n will facilit mediators project to projects n descriptio This FOA a neurons in teams. Th	ose of this Funding Opportunity plinary teams that will cooperat e goal of RE-JOIN will be to defin ly form the joint (including bon- eurons that mediate the sensat ate the identification of key rec s and their receptors will provid map the sensory innervation of must focus on at least one of the on of specific plans to extend th also provides the opportunity to n joint tissues. Data harmonizat re goal will be to integrate data	Announcement is to solid tively form the Restoring J ne the innervation of the e, cartilage, synovium, joi tion of pain. Knowledge al teptors and mediators tha le novel targets for reduci of the joint tissues in anim e high priority joint types e project to other joints a to further adapt or develop tion, integration and visual from the different teams	cit cooperative agreeme Joint Health and Function different articular and p nt capsule, ligament, te bout the types and distr it induce pain by activat ing pain. Each Research al models, human tissu- listed in the FOA and ar nd, if the primary focus p technologies that wou alization will require ext to produce models of in	ent applica on to Redu peri-articu ndon, faso ibution of ing specif Team will es, or both e encoura is animal ild improve ensive coo nnervation	ations from uce Pain Cor lar tissues t cia and mus f neurites in ic sensory n l conduct a h. Research aged to inclu models, to ve the ability ordination k n in differer	nsortium (RE- hat cle), by joint tissues eurons. These research Teams ude a human tissue. y to map petween nt joints.		

SPIN ID	Program Title	Sponsor Name		Sponsor Number		Deadli	ne Date	Funding Amount
103908	Notice of Special Interest (NOSI): I from Diverse Backgrounds, Includi	NIH Research Project Gra	nt (R01) Applica <u>Ainorities</u>	tions from Individuals	National Institutes of Health/DHHS	NOT-NS- 21-049	07-May- 2022	Not Specified
	Contact Name Contact Telephone Contact Email Sponsor Website Program URL	Link to program URL						
	Deadline Dates (ALL) ( - i Synopsis ( i i	07-May-2022, 05-Jun-20 The National Institute of ncrease the participation diversity among the bion DD-20-031). NIH is comm backgrounds and "comm dismantling any policies a interest in receiving rese	22,07-Sep-202 Neurological Dis n of underrepres nedical research nitted to implem itted to institution and practices that arch project app	2,05-Oct-2022,07-Jan-2 orders and Stroke seeks ented groups. As the US workforce is vital to our enting approaches to ado ng new ways to support o at may harm our workfor lications submitted by in	2023, 05-Feb-2023, 07 to promote diversity in population becomes in science enterprise and dress the funding gap f liversity, equity, and in ce and our science". The vestigators from diversity	7-May-2023 n all of its res ncreasingly c I the NIH res for researche nclusion, anc his Notice is se backgrour	search prog liverse, refl earch miss ers from dir I identifying being issue nds.	grams and to lection of that ion (See NOT- verse g and ed to highlight
094038	Mentored Quantitative Research I Required)	Development Award (Par	ent K25 Indeper	ndent Clinical Trial	National Institutes of Health/DHHS	PA-20-197	07-May- 2022	Not Specified
	Contact Name Contact Telephone							
	Contact Email Sponsor Website	grantinfo@nih.gov						
	Program URL	Link to program URL 17-May-2022 , 12-lun-20	22 07-Sep-202	2 12-Oct-2022 07-lan-2	023 12-Feb-2023 0	7-Mav-2023		
	Synopsis	The purpose of the Ment those investigators whos questions of health and c and research for product maging science, informa research. This Funding O	ored Quantitative e quantitative so lisease. The K25 ive professionals tics, physics, che pportunity Anno	ve Research Career Devel cience and engineering re award will provide supp s with quantitative (e.g., r emistry) and engineering uncement (FOA) is design	opment Award (K25) i search has thus far no ort and "protected tim mathematics, statistics backgrounds to integr ned specifically for app	s to attract t ot been focus ne" for a per s, economics ate their exp plicants prop	o NIH-relev ed primari iod of supe , computer pertise with osing to se	vant research ly on rvised study r science, n NIH-relevant rve as the

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		lead inve their rese experient and Cent announce Requiren funding.	stigator of an independent clini- earch and career development. ce in a clinical trial led by anoth- ers participate in Parent Annou ement and view their respective nents and Staff Contacts website Consultation with NIH staff befo	cal trial, a clinical trial feas Applicants not planning ar er investigator, must apply ncements. Applicants sho e areas of research interes e. ICs that do not participa ore submitting an applicat	ibility study, or a separat independent clinical tria to companion FOA. Spec uld carefully note which it t and requirements at the te in this announcement on is strongly encouraged	e ancillary clinical I, or proposing to cial Note: Not all N Cs participate in th Table of IC-Speci will not consider a d.	trial, as part of gain research IIH Institutes iis fic Information, applications for
094234	Mentored Clinical Scientist Resea Trial Required)	arch Caree	r Development Award (Parent H	(08 Independent Clinical	National Institutes of Health/DHHS	-20-202 07-May- 2022	Not Specified
	Contact Name Contact Telephone Contact Email	301-496- grantinfo	8580 <u>@nih.gov</u>				
	Sponsor Website Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	07-May-2	2022 , 12-Jun-2022 , 07-Sep-202	2 , 12-Oct-2022 , 07-Jan-2	023 , 12-Feb-2023 , 07-M	ay-2023	
	Synopsis	The prim prepare of This prog individua of biome designed feasibility planning must app Applicant interest a participa applicatio	hary purpose of the NIH Mentor qualified individuals for careers fram represents the continuatio Is with a clinical doctoral degree dical and behavioral research, in specifically for applicants proper y study, or a separate ancillary of an independent clinical trial, or only to companion FOA. Special N its should carefully note which IC and requirements at the Table of te in this announcement will no on is strongly encouraged.	ed Clinical Scientist Resea that have a significant imp n of a long-standing NIH p e for an intensive, supervis ncluding translational rese osing to serve as the lead i linical trial, as part of thei proposing to gain researc ote: Not all NIH Institutes Cs participate in this annou f IC-Specific Information, I t consider applications for	rch Career Development , bact on the health-related rogram that provides sup sed research career devel arch. This Funding Oppor nvestigator of an indeper r research and career dev h experience in a clinical and Centers participate in uncement and view their Requirements and Staff C funding. Consultation wi	Awards (K08) prog research needs o port and "protect opment experience tunity Announcer indent clinical trial, elopment. Applica trial led by anothe in Parent Announc respective areas o ontacts website. I th NIH staff before	ram is to f the Nation. ed time" to the fields the fiel
094040	Mentored Quantitative Research Studies with Humans Required)	Developr	nent Award (Parent K25 Indepe	ndent Basic Experimental	National Institutes of Health/DHHS	-20-198 07-May <sup>.</sup> 2022	Not Specified

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Title         Contact Name         Contact Telephone         Contact Email         Sponsor Website         Program URL         Link to p         Deadline Dates (ALL)         The purp         those intervention	rogram URL 2022 , 12-Jun-2022 , 07-Sep-202 pose of the Mentored Quantitative s	2 , 12-Oct-2022 , 07-Jan-2 ve Research Career Develo cience and engineering re-	023 , 12-Feb-2023 , 07-Ma opment Award (K25) is to a search has thus far not bee	y-2023 attract to NIH-rele	Amount evant research ily on
	question and rese imaging research referred the NIH under th Synopsis indepen fundame planning a clinical Trial Not the part Centers and view and Staf Consulta	as of health and disease. The K2 parch for productive professional science, informatics, physics, ch to in NOT-OD-18-212 as "prospe- definition of a clinical trial and a is FOA include studies that prospe- dent variables) and that assess the ental aspects of phenomena with an independent clinical trial or trial or basic experimental stud clipating NIH Institutes and Cent participate in Parent Announcer of their respective areas of resear f Contacts website. ICs that do n ation with NIH staff before subm	5 award will provide support is with quantitative (e.g., r emistry) and engineering b ity Announcement is for ba- ective basic science studie lso meet the definition of pectively assign human pa- biomedical or behavioral of hout specific application to basic experimental study of y with humans led by another proposed project must be ers (ICs) based on their sci- nents. Applicants should co- rch interest and requiremen- ot participate in this anno- itting an application is stro-	ort and "protected time" for nathematics, statistics, ecc backgrounds to integrate the asic science experimental s is involving human particip basic research. Types of st rticipants to conditions (i.e utcomes in humans for the owards processes or produ with humans, or proposing ther investigator, must app related to the programmate entific missions. Special No arefully note which ICs part ents at the Table of IC-Spec- uncement will not conside ongly encouraged.	or a period of supe phomics, compute heir expertise with studies involving h ants." These stud sudies that should e., experimentally e purpose of unde cts in mind. Applie to gain research oly to the 'Indeper tic interests of one ote: Not all NIH In ticipate in this an ific Information, F r applications for	Prvised study r science, n NIH-relevant umans, ies fall within be submitted manipulate rstanding the cants not experience in ident Clinical e or more of stitutes and nouncement Requirements funding.
094235	Mentored Clinical Scientist Research Care Trial Not Allowed)	er Development Award (Parent I	KO8 Independent Clinical	National Institutes of Health/DHHS PA-:	20-203 07-May- 2022	Not Specified

Contact Name Contact Telephone 301-496-8580 Contact Email grantinfo@nih.gov

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount		
	Sponsor Website							
	Program URL	Link to program URL						
	Deadline Dates (ALL)	07-May-2022 , 12-Jun-2022 , 07-Sep-202	2 , 12-Oct-2022 , 07-Jan-2	023 , 12-Feb-2023 , 07-N	1ay-2023			
	Synopsis	The primary purpose of the NIH Mentored Clinical Scientist Research Career Development Awards (K08) program is prepare qualified individuals for careers that have a significant impact on the health-related research needs of the N This program represents the continuation of a long-standing NIH program that provides support and "protected tim individuals with a clinical doctoral degree for an intensive, supervised research career development experience in th of biomedical and behavioral research, including translational research. This Funding Opportunity Announcement (I designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a trial feasibility study, or an ancillary clinical trial. Applicants to this FOA are permitted to propose research experien clinical trial led by a mentor or co-mentor. Applicants proposing a clinical trial or an ancillary clinical trial as lead inv should apply to the companion FOA. Special Note: Not all NIH Institutes and Centers participate in Parent Announce Applicants should carefully note which ICs participate in this announcement and view their respective areas of rese interest and requirements at the website. ICs that do not participate in this announcement will not consider applica- funding. Consultation with NIH staff before submitting an application is strongly encouraged						
094233	Mentored Clinical Scientist Resea Experimental Studies with Human	arch Career Development Award (Parent K ns Required)	08 Independent Basic	National Institutes of Health/DHHS	A-20-201 07-May- 2022	Not Specified		
	Contact Name							
	Contact Telephone							
	Contact Email							
	Sponsor Website							
	Program URL	Link to program URL						
	Deadline Dates (ALL)	07-May-2022 , 12-Jun-2022 , 07-Sep-202	2 , 12-Oct-2022 , 07-Jan-2	023 , 12-Feb-2023 , 07-N	1ay-2023			
	Synopsis	The primary purpose of the NIH Mentor prepare qualified individuals for careers This program represents the continuation individuals with a clinical doctoral degree of biomedical and behavioral research, in for basic science experimental studies inv involving human participants." These stu	ed Clinical Scientist Reseau that have a significant imp n of a long-standing NIH p for an intensive, supervis including translational rese volving humans, referred t idies fall within the NIH de	ch Career Development act on the health-related rogram that provides sup ed research career deve arch. This Parent Fundin to in NOT-OD-18-212 as efinition of a clinical trial	Awards (K08) prog d research needs o pport and "protect lopment experience g Opportunity Ann 'prospective basic and also meet the	ram is to f the Nation. ed time" to ce in the fields ouncement is science studies definition of		

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadlin	ne Date	Funding Amount
		basic rese participar outcomes towards p with hum another in be related scientific carefully p requirem this anno strongly e	earch. Types of studies that sho outs to conditions (i.e., experime is in humans for the purpose of processes or products in mind. A nans, or proposing to gain resea investigator, must apply to the ' d to the programmatic interests missions. Special Note: Not all I note which ICs participate in thi ents at the Table of IC-Specific I uncement will not consider app encouraged.	build be submitted under t ntally manipulate indepen understanding the fundar Applicants not planning ar rch experience in a clinica Independent Clinical Trial s of one or more of the pa NIH Institutes and Centers is announcement and view Information, Requirement olications for funding. Con	his FOA include studies the ndent variables) and that nental aspects of phenom n independent clinical tria I trial or basic experimen Not Allowed' companior articipating NIH Institutes s participate in Parent An w their respective areas of ts and Staff Contacts web sultation with NIH staff b	nat prospe assess bio nena witho al or basic tal study w FOA. The and Cente nounceme f research site. ICs th efore subp	ectively ass omedical of out specific experimer with human proposed ers (ICs) ba ents. Applic n interest a nat do not mitting an	ign human r behavioral c application ntal study ns led by project must sed on their cants should nd participate in application is
094044	Mentored Quantitative Research Allowed)	1 Developn	nent Award (Parent K25 Indepe	ndent Clinical Trial Not	National Institutes of Health/DHHS	\-20-199	07-May- 2022	Not Specified
	Contact Name Contact Telephone Contact Email Sponsor Website	grantinfo	@nih.gov					
	Program URL Deadline Dates (ALL)	Link to pr 07-May-2	ogram URL 2022 , 12-Jun-2022 , 07-Sep-202	2 , 12-Oct-2022 , 07-Jan-2	2023 , 12-Feb-2023 , 07-N	1ay-2023		
	Synopsis	The purpo those invo questions and resea imaging s research. not involv FOA are p clinical tri Note: Not participat	ose of the Mentored Quantitati estigators whose quantitative s s of health and disease. The K2! arch for productive professional cience, informatics, physics, cho This Funding Opportunity Anno ve leading an independent clinic permitted to propose research e ial or an ancillary clinical trial as t all NIH Institutes and Centers p te in this announcement and vie	ve Research Career Devel cience and engineering re 5 award will provide supp s with quantitative (e.g., r emistry) and engineering buncement (FOA) is design cal trial, a clinical trial fease experience in a clinical triat lead investigator, should participate in Parent Anno- ew their respective areas	lopment Award (K25) is to esearch has thus far not b ort and "protected time" mathematics, statistics, e backgrounds to integrate ned specifically for applic sibility study, or an ancilla al led by a mentor or co-n apply to the companion buncements. Applicants s of research interest and r	o attract to een focuso for a perio conomics, their expo ants propo ry clinical nentor. Ap FOA (PA-2 hould care equireme	o NIH-releved od of supe computer ertise with osing resea trial. Appli oplicants pr co-197). Sp efully note nts at the	vant research ly on rvised study science, NIH-relevant arch that does icants to this roposing a ecial which ICs Table of IC-

SPIN ID	N ID Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		Specific Ir consider a	nformation, Requirements and a applications for funding. Consul	Staff Contacts website. IC Itation with NIH staff befo	Is that do not participate in ore submitting an applicatio	this announceme on is strongly enco	ent will not ouraged.
094026	Mentored Research Scientist Dev Studies with Humans Required)	<u>elopment</u>	Award (Parent K01 Independer	nt Basic Experimental	National Institutes of Health/DHHS	20-191 07-May- 2022	Not Specified
	Contact Name						
	Contact Telephone						
	Contact Email						
	Sponsor Website						
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	07-May-2	022 , 12-Jun-2022 , 07-Sep-202	2, 12-Oct-2022, 07-Jan-2	2023 , 12-Feb-2023 , 07-Ma	y-2023	atacted time"
	Synopsis	(three to sciences I mechanis individual illness or studies in participar research. participar outcomes towards p with hum another in be related scientific carefully p requirement this anno strongly e	five years) for an intensive, sup eading to research independen m to support career developme ls who propose to train in a new pressing family circumstances. volving humans, referred to in nts." These studies fall within th Types of studies that should be nts to conditions (i.e., experime is in humans for the purpose of processes or products in mind. A ans, or proposing to gain resea nvestigator, must apply to the ' d to the programmatic interests missions. Special Note: Not all I note which ICs participate in thi ents at the Table of IC-Specific I uncement will not consider app encouraged.	vervised career developm ice. Although all of the pa ent experiences that lead v field or for individuals w This Parent Funding Oppo NOT-OD-18-212 as "prosp he NIH definition of a clin e submitted under this FC ntally manipulate indepe understanding the fundant Applicants not planning a rch experience in a clinica Independent Clinical Trial s of one or more of the pa NIH Institutes and Center is announcement and vie Information, Requiremen plications for funding. Cor	ent experience in the biomul irticipating NIH Institutes ar to research independence, who have had a hiatus in the ortunity Announcement is f pective basic science studie lical trial and also meet the DA include studies that pro- endent variables) and that a mental aspects of phenome n independent clinical trial al trial or basic experimenta I Not Allowed' companion F articipating NIH Institutes a is participate in Parent Anno- w their respective areas of its and Staff Contacts websi- nsultation with NIH staff be	edical, behavioral ad Centers (ICs) us some ICs use the air research caree or basic science e s involving human definition of basic spectively assign h ssess biomedical ena without specif or basic experime al study with hum OA. The propose nd Centers (ICs) b buncements. App research interest te. ICs that do no fore submitting a	, or clinical se this support (K01 award for r because of experimental n c numan or behavioral fic application ental study ans led by (ed project must based on their licants should and t participate in n application is

SPIN ID	Program Title		Sponsor Name	Sponsor Number		De	eadline Date	Funding Amount
103220	Notice of Special Interest (NOSI):	COVID-19	Related School Disruptions Imp	<u>pact on Mental Health,</u>	National Institutes	NOT-N	ИН- 07-Мау-	Not
		Jevelopin				21-225	5 2022	Specified
	Contact Name	Susan Bo	rja, PhD					
	Contact Telephone	301-443-	1252					
	Contact Email	susan.boi	<u>'ja@nih.gov</u>					
	Sponsor Website							
	Program URL	Link to pr	ogram URL					
	Deadline Dates (ALL)	07-May-2	.022 , 05-Jun-2022 , 07-Sep-202	2				
	Synopsis	of the Co interested mental he for variou prepared	ronavirus Disease 2019 (COVID- d in the potential impact of prin ealth, cognitive, social, and emo is public health mitigation strate and respond to future public he	19) pandemic on school-a nary instruction settings d otional development of ch egies affecting children in ealth emergencies, includ	aged children, specific lisruptions (e.g., pre-so ildren. Empirical data the current pandemic ing pandemics and dis	ally ages chool, e would a c as well caster sc	s 3 - 12. Particu lementary scho aid in balancing l as inform how cenarios.	ilarly, we are ool) on the ; health risks / to both be
108001	Notice of Special Interest (NOSI): Pacific Islanders (Parent R01 Clini	<u>Epidemio</u> cal Trial N	logic studies in Asian Americans ot Allowed)	s, Native Hawaiians, and	National Institutes of Health/DHHS	NOT-H 23-001	lL- 07-May- 1 2022	Not Specified
	Contact Name	Robb Rov	vley, MD					
	Contact Telephone	301-827-9	9126					
	Contact Email	Robb.Rov	vley@nih.gov					
	Sponsor Website							
	Program URL	Link to pr	ogram URL					
	Deadline Dates (ALL)	07-May-2 2023 , 05	022 , 05-Jun-2022 , 07-Sep-202 -Oct-2023 , 07-Jan-2024 , 05-Fe	2 , 05-Oct-2022 , 07-Jan-2 b-2024 , 07-May-2024 , 0!	023 , 05-Feb-2023 , 0 5-Jun-2024 , 07-Sep-2	7-May-2 024 <i>,</i> 05	2023 , 05-Jun-2 -Oct-2024	023 , 07-Sep-
	Synopsis	The purpe gaps with frequentl ancestry, life, a crit	ose of this Notice of Special Inte in and between subpopulations y aggregated in research, poter culture, immigration patterns a ical need exists for epidemiolog	erest (NOSI) is to stimulate s of Asian Americans, Nati ntially masking important among Asian Americans, s gical research to enhance	e novel epidemiologica ve Hawaiians, and Pac social and health diffe ocioeconomic position our understanding of	al resea cific Islau rences. n, and a the inte	rch to address nders. These p Given clear he cculturation in rplay of enviro	key knowledge opulations are terogeneity in to American nmental

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadli	ne Date	Funding Amount
		exposures, lifestyle, behavioral, genomic American, Native Hawaiian, and Pacific Is	s, social, neighborhood, a slander subpopulations.	and biological factors t	hat impact t	he health c	of Asian
104359	Comprehensive Care for Adults v Disparities (R01 Clinical Trial Opt	vith Type 2 Diabetes Mellitus from Popula ional)	tions with Health	National Institutes of Health/DHHS	PA-21-232	07-May- 2022	2,500,000 USD
	Contact Name	Larissa Aviles-Santa, MD, MPH					
	Contact Telephone	301-827-6924					
	Contact Email	avilessantal@mail.nih.gov					
	Sponsor Website						
	Program URL	Link to program URL					
	Deadline Dates (ALL)	07-May-2022 , 05-Jun-2022 , 07-Sep-202 2023 , 07-Jan-2024 , 05-Feb-2024 , 07-M	2 , 05-Oct-2022 , 07-Jan-2 ay-2024 , 05-Jun-2024 , 0	2023 , 05-Feb-2023 , 0 7-Sep-2024	7-May-2023	, 05-Jun-2(	07-Sep-
	Synopsis	This initiative will support innovative res (including models of health care) to effec diabetes mellitus from populations with	earch to develop, test and ctively adapt and implement health disparities concord	d evaluate multi-level/ ent comprehensive clin dant with recommend	multi-componical care for ed and evide	onent strat individual ence-based	egies s with Type 2 guidelines.
104854	Notice of Special Interest (NOSI):	Harnessing Big Data to Halt HIV		National Institutes of Health/DHHS	NOT-AI- 21-054	07-May- 2022	Not Specified
	Contact Name	Rosemary McKaig, M.P.H, Ph.D.					
	Contact Telephone	240-627-3214					
	Contact Email	rm434n@nih.gov					
	Sponsor Website						
	Program URL	Link to program URL					
	Deadline Dates (ALL)	07-May-2022 , 05-Jun-2022 , 07-Sep-202 2023 , 05-Oct-2023 , 07-Jan-2024 , 05-Fe	2 , 05-Oct-2022 , 07-Jan-2 b-2024 , 07-May-2024	2023 , 05-Feb-2023 , 0	7-May-2023	, 05-Jun-2(	023 , 07-Sep-
	Synopsis	The purpose of this Notice of Special Inte to identify unappreciated biomedical, be acquisition, transmission, the developme BDS approaches can bring together data factors influencing the epidemiology of r	erest (NOSI) is to promote havioral, social patterns a ent of comorbidities, and to evaluate the complex isk and care. Further, bec	e and support innovation and other social deterr long-term viral contro interplay between ind ause this field can revo	ve methods ninants that l as in the HI ividual, cont eal unexpect	in Big Data shed light V treatmer extual, and ed associa	Science (BDS) on HIV nt continuum. I structural tions through

SPIN ID	D Program Title		Sponsor Name	Sponsor Number	or Number		ine Date	Funding Amount
		analysis o Discovery NOSI will modeling issues in t	f diverse data, BDS approaches of these events will considerat support the establishment of B , advanced epidemiology and st he use of public and personal c	may reveal events that a bly advance research on H DS standards, bioinforma ratistical analytic methods ata in the context of HIV	re unseen or transient IIV networks of transm tics data tools, machin s, and consideration ar research.	in traditior ission and t e-learning id application	al analysis of the care cor algorithms, on of privac	of datasets. atinuum. This mathematical y and ethical
104500	Notice of Special Interest (NOSI): Improve Use of Evidence-Based P	Behaviora Tractices fo	Il Economics for Implementatio or HLBS Conditions	n Research (BEIR) to	National Institutes of Health/DHHS	NOT-HL- 21-010	07-May- 2022	Not Specified
	Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) Synopsis	Rebecca A 301-496-2 <u>Rebecca.f</u> Link to pr 07-May-2 2023, 05- This Notic research ( address h cultural co (e.g., pati use of bel simplified clinical tri	A. Roper, MS, MPH 1051 Roper@nih.gov 022, 05-Jun-2022, 07-Sep-202 Oct-2023, 07-Jan-2024, 05-Fe ce of Special Interest (NOSI) is ir (BEIR) in order to develop more eart, lung, blood, and sleep (HL ontext, patterns of behavior cha ents, parents, clinicians, others havioral economics to develop i and minimally disruptive wher al design, as appropriate to the	2, 05-Oct-2022, 07-Jan-2 b-2024, 07-May-2024, 0 oftended to stimulate the of effective strategies for in BS) conditions. NHLBI end ange, and motivators for of b, groups, healthcare syste mplementation strategies possible are encouraged research objectives.	2023, 05-Feb-2023, 07 5-Jun-2024, 07-Sep-20 use of behavioral econ nplementaion of evide courages applications t change across decision ems and/or communiti s for user-driven, susta . Applications may pro	2-May-2023 024 omics strat nce-based hat recogn -making lev es. Applica inable inte pose either	egies for im practices (E ize the impo vels, includio tions that fo rventions th a clinical tr	23 , 07-Sep- plementation BP) to ortance of ng individuals ocus on the nat may be rial or non-
106925	Notice of Special Interest (NOSI): Cognitive Impairment and Demer	Promoting ntia (VCID)	g Research To Understand Vasc	ular Contributions to	National Institutes of Health/DHHS	NOT-HL- 23-002	07-May- 2022	Not Specified
	Contact Name Contact Telephone Contact Email Sponsor Website Program URL	Jue Chen, 301-435-( jue.chen@ Link to pr	Ph.D. 0550 @nih.gov ogram URL					

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Deadline Dates (ALL) Synopsis	D7-May-2022, 05-Jun-2022, 07-Sep-2022, 05-Oct-2022, 07-Jan-2023, 05-Feb-2023, 07-May-2023, 05-Jun-2023, 07- 2023, 05-Oct-2023, 07-Jan-2024, 05-Feb-2024, 07-May-2024, 05-Jun-2024, 07-Sep-2024, 05-Oct-2024, 07-Jan-20 Feb-2025, 07-May-2025 The purpose of this Notice is to inform potential applicants about an area of special interest to NHLBI, NINDS and NIA research to understand mechanisms of vascular contributions to cognitive impairment and dementia (VCID) and to do new approaches for the treatment of VCID.					023 , 07-Sep- Jan-2025 , 05- and NIA in nd to develop
093932	NIH Pathway to Independence Av	ward (Pare	nt K99/R00 Independent Clinic	al Trial Not Allowed)	National Institutes of Health/DHHS	-20-188 07-May- 2022	Not Specified
	Contact Name						
	Contact Telephone						
	Contact Email	grantinfo	<u>@nih.gov</u>				
	Sponsor Website						
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	07-May-2	022 , 12-Jun-2022 , 07-Sep-202	2 , 12-Oct-2022 , 07-Jan-2	023 , 12-Feb-2023 , 07-Ma	ay-2023	
	Synopsis	The purpose of the NIH Pathway to Independence Award (K99/R00) program is to facilitate a timely transition of outstanding postdoctoral researchers with a research and/or clinical doctorate degree from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. The program will provide independent NIH research support during this transition in order to help awardees to launch competitive, independent research careers. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Applicants proposing a clinical trial or an ancillary clinical trial as lead investigator, should apply to the companion FOA. Special Note: Not all NIH Institutes and Centers participate in Parent Announcements. Applicants should carefully note which ICs participate in this announcement and view their respective areas of research interest and requirements at the Table of IC-Specific Information, Requirements and Staff Contacts website. ICs that do not participate in this announcement will not consider applications for funding. Consultation with NIH staff before submitting an application is strongly encouraged.					
093935	NIH Pathway to Independence Av with Humans Required)	ward (Pare	nt K99/R00 Independent Basic	Experimental Studies	National Institutes of Health/DHHS	-20-189 07-May- 2022	Not Specified

Contact Name
SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) Synopsis	Link to program URL 07-May-2022 , 12-Jun-2022 , 07-Sej The purpose of the NIH Pathway to postdoctoral researchers with a res to independent, tenure-track or eq during this transition in order to he Opportunity Announcement is for k "prospective basic science studies i trial and also meet the definition of that prospectively assign human pa assess biomedical or behavioral out phenomena without specific applic clinical trial or basic experimental s experimental study with humans le companion FOA. The proposed proj participating NIH Institutes and Cer Centers participate in Parent Annou and view their respective areas of r and Staff Contacts website. ICs that Consultation with NIH staff before s	p-2022 , 12-Oct-2022 , 07-Jan Independence Award (K99/R earch and/or clinical doctorat uivalent faculty positions. The pawardees to launch compe- pasic science experimental stu- nvolving human participants.' basic research. Types of stud rticipants to conditions (i.e., e comes in humans for the pur ation towards processes or pr tudy with humans, or proposi d by another investigator, mu ect must be related to the pr ters (ICs) based on their scier incements. Applicants should esearch interest and requirent do not participate in this anr submitting an application is st	-2023 , 12-Feb-2023 , 07-N 00) program is to facilitate te degree from mentored, e program will provide inde titive, independent researd idies involving humans, ref "These studies fall within dies that should be submitt experimentally manipulate pose of understanding the roducts in mind. Applicants ing to gain research experie ist apply to the 'Independe ogrammatic interests of or ntific missions. Special Note I carefully note which ICs p nents at the Table of IC-Spe nouncement will not consic crongly encouraged.	lay-2023 a timely transition postdoctoral resea pendent NIH resea ch careers. This Par erred to in NOT-OE the NIH definition of red under this FOA independent varia fundamental aspect not planning an in ence in a clinical tria nt Clinical Trial Not e or more of the e: Not all NIH Institute articipate in this an ecific Information, I ler applications for	of outstanding rch positions rch support ent Funding 0-18-212 as of a clinical include studies bles) and that cts of dependent al or basic Allowed' utes and nouncement Requirements funding.
093931	NIH Pathway to Independence Aw	vard (Parent K99/R00 Independent	Clinical Trial Required)	National Institutes of Health/DHHS	A-20-187 07-May- 2022	Not Specified
	Contact Name Contact Telephone Contact Email Sponsor Website Program URL	grantinfo@nih.gov Link to program URL				

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline	Date	Funding Amount
	Deadline Dates (ALL) Synopsis	07-May-2 The purpe postdocto to indepe during thi Opportun independ career de clinical tri	2022, 12-Jun-2022, 07-Sep-202 ose of the NIH Pathway to Inde oral researchers with a research indent, tenure-track or equivale is transition in order to help aw hity Announcement (FOA) is des ent clinical trial, a clinical trial f velopment. Applicants not plan ial led by another investigator,	2 , 12-Oct-2022 , 07-Jan-2 pendence Award (K99/R00 n and/or clinical doctorate ent faculty positions. The p vardees to launch competi- signed specifically for appl easibility study, or a separ nning an independent clini must apply to companion	2023, 12-Feb-2023, 07-N D) program is to facilitate degree from mentored, program will provide inde tive, independent resear icants proposing to serve rate ancillary clinical trial cal trial, or proposing to FOA.	Nay-2023 e a timely tra postdoctora ependent NI ch careers. T e as the lead , as part of t gain researc	ansition o al researc H researc This Fund I investiga their resea ch experie	f outstanding h positions h support ing itor of an arch and ence in a
093955	Midcareer Investigator Award in Required)	Patient-Or	riented Research (Parent K24 In	dependent Clinical Trial	National Institutes of Health/DHHS	A-20-193 0 2	7-May- 022	Not Specified
	Contact Name							
	Contact Telephone							
	Contact Email	grantinfo	@nih.gov					
	Sponsor Website							
	Program URL	<u>Link to pr</u>	ogram URL					
	Deadline Dates (ALL)	07-May-2	022 , 12-Jun-2022 , 07-Sep-202	2 , 12-Oct-2022 , 07-Jan-2	023 , 12-Feb-2023 , 07-N	/lay-2023		
	Synopsis	The purp career he mentors f Announce clinical tri developm led by and Parent Ar respective Contacts with NIH	ose of the NIH Midcareer Invest alth-professional doctorates for for junior clinical investigators p ement (FOA) is designed specific ial, a clinical trial feasibility stuc- ment. Applicants not planning an other investigator, must apply to mouncements. Applicants shou e areas of research interest and website. ICs that do not particip staff before submitting an appl	tigator Award in Patient-C r protected time to devote oursuing POR research, suc cally for applicants propose by, or a separate ancillary of independent clinical trial to companion FOA. Specia and carefully note which ICs requirements at the Tabl pate in this announcement ication is strongly encoura	Driented Research (K24) e to patient-oriented res ch as clinical residents sing to serve as the lead clinical trial, as part of th l, or proposing to gain re l Note: Not all NIH Institu s participate in this anno e of IC-Specific Informat t will not consider applic aged.	is to provide earch (POR) This Funding investigator eir research search expe utes and Cer uncement a ion, Require ations for fu	e support and to ac Opportu of an ind and care rience in nters part nd view t ments an unding. Co	to mid- ct as research nity ependent er a clinical trial icipate in heir d Staff onsultation
093953	Midcareer Investigator Award in Not Allowed)	Patient-Or	riented Research (Parent K24 In	ndependent Clinical Trial	National Institutes of Health/DHHS	A-20-186 0 2	7-May- 022	Not Specified

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) Th he Fu lea Synopsis pe an Ce an an	antinfo@nih.gov hk to program URL -May-2022 , 12-Jun-2022 , 07-Sep-202 e purpose of the NIH Midcareer Invest alth-professional doctorates for prote entors for junior clinical investigators p nding Opportunity Announcement (FC ading an independent clinical trial, a cl rmitted to propose research experient ancillary clinical trial as lead investiga nters participate in Parent Announcer d view their respective areas of resear d Staff Contacts website. ICs that do n	22, 12-Oct-2022, 07-Jan-20 tigator Award in Patient-O cted time to devote to pat bursuing POR research, suc DA) is designed specifically inical trial feasibility study, ce in a clinical trial led by a tor, should apply to the co nents. Applicants should ca rch interest and requireme ot participate in this anno	023 , 12-Feb-2023 , 07-Ma riented Research (K24) is t ient-oriented research (PC ch as clinical residents and for applicants proposing r or an ancillary clinical tria mother investigator. Appli mpanion FOA. Special Not arefully note which ICs pa ents at the Table of IC-Spec uncement will not conside	ay-2023 to provide support OR) and to act as r /or junior clinical f research that does al. Applicants to th icants proposing a te: Not all NIH Inst rticipate in this an cific Information, F er applications for	to mid-career esearch faculty. This not involve is FOA are clinical trial or itutes and nouncement Requirements funding.
093954	Midcareer Investigator Award in Pat Experimental Studies with Humans R	ient-Oriented Research (Parent K24 Ir Required)	idependent Basic	National Institutes of Health/DHHS	-20-192 07-May- 2022	Not Specified
	Contact Name Contact Telephone Contact Email Sponsor Website					
	Program URL <u>Lir</u>	ik to program URL				
	Deadline Dates (ALL) 07	-May-2022 , 12-Jun-2022 , 07-Sep-202	2 , 12-Oct-2022 , 07-Jan-2	023 , 12-Feb-2023 , 07-Ma	ay-2023	
	Th Synopsis Pa	e purpose of the NIH Midcareer Invest alth-professional doctorates for prote entors for junior clinical investigators p rent Funding Opportunity Announcem	tigator Award in Patient-O cted time to devote to pat pursuing POR research, suc nent is for basic science exp	riented Research (K24) is t ient-oriented research (PC ch as clinical residents and perimental studies involvin	to provide support OR) and to act as r junior clinical fact ng humans, referre	t to mid-career esearch ulty. This ed to in NOT-

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		OD-18-21 of a clinic include st variables aspects o independ or basic e Allowed' the partic Centers p and view and Staff Consultat	12 as "prospective basic science cal trial and also meet the defini tudies that prospectively assign ) and that assess biomedical or of phenomena without specific a dent clinical trial or basic experin experimental study with human companion FOA. The proposed cipating NIH Institutes and Cent participate in Parent Announcen their respective areas of resear Contacts website. ICs that do n tion with NIH staff before subm	studies involving human tion of basic research. Ty human participants to co behavioral outcomes in h application towards proce mental study with human s led by another investiga project must be related t ers (ICs) based on their so nents. Applicants should o ch interest and requirem ot participate in this anno itting an application is str	participants." These studie ypes of studies that should onditions (i.e., experimenta numans for the purpose of the esses or products in mind. A so, or proposing to gain rese ator, must apply to the 'Ind to the programmatic intere cientific missions. Special N carefully note which ICs pa ents at the Table of IC-Spec puncement will not conside rongly encouraged.	es fall within the N be submitted und Illy manipulate inc understanding the Applicants not plan earch experience i ependent Clinical ests of one or more lote: Not all NIH In rticipate in this an cific Information, le er applications for	JIH definition ler this FOA lependent fundamental nning an n a clinical trial Trial Not of istitutes and inouncement Requirements funding.
093214	Independent Scientist Award (Pa Required)	rent KO2 l	ndependent Basic Experimental	Studies with Humans	National Institutes of Health/DHHS	-20-173 07-May- 2022	Not Specified
	Contact Name						
	Contact Telephone	grantinfo	Panih roy				
	Sponsor Website	grantino					
	Program URL	Link to pr	rogram URL				
	Deadline Dates (ALL)	07-May-2	2022 , 12-Jun-2022 , 07-Sep-202	2 , 12-Oct-2022 , 07-Jan-2	2023 , 12-Feb-2023 , 07-Ma	ay-2023	
	Synopsis	oster the development of o to their field of research. The endent scientists who can o research careers. Each inde didate. This Parent Funding to in NOT-OD-18-212 as "p definition of a clinical trial a this FOA include studies that ndent variables) and that a mental aspects of phenome	outstanding scient ne KO2 award prov demonstrate the r spendent scientist g Opportunity Anr prospective basic s and also meet the at prospectively as assess biomedical ena without speci	ists and enable vides three to need for a career award nouncement is science studies definition of ssign human or behavioral fic application			

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadli	ne Date	Funding Amount
		towards p with hum another i be related scientific	processes or products in mind. A ans, or proposing to gain resear nvestigator, must apply to the 'I d to the programmatic interests missions.	Applicants not planning an rch experience in a clinical Independent Clinical Trial s of one or more of the pai	independent clinical I trial or basic experim Not Allowed' compan rticipating NIH Institut	trial or basic ental study ion FOA. The res and Cent	e experimer with huma e proposed ers (ICs) ba	ntal study ns led by project must sed on their
093210	Independent Scientist Award (Pa	rent K02 -	Independent Clinical Trial Requ	ired)	National Institutes of Health/DHHS	PA-20-171	07-May- 2022	Not Specified
	Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) Synopsis	grantinfo Link to pr 07-May-2 The purpe them to e five years period of program designed feasibility planning must app	<u>@nih.gov</u> ogram URL 022 , 12-Jun-2022 , 07-Sep-202 ose of the NIH Independent Scie expand their potential to make s of salary support and "protecte intensive research focus as a m must be tailored to meet the in- specifically for applicants propor study, or a separate ancillary c an independent clinical trial, or ly to companion FOA.	2 , 12-Oct-2022 , 07-Jan-2 entist Award (K02) is to fos significant contributions to ed time" for newly indepe eans of enhancing their re dividual needs of the cand osing to serve as the lead i linical trial, as part of their proposing to gain researc	023 , 12-Feb-2023 , 07 ster the development o their field of research ndent scientists who c esearch careers. Each lidate. This Funding O nvestigator of an inde r research and career h experience in a clinic	7-May-2023 of outstand h. The K02 a can demonst independen portunity A pendent clin developmer cal trial led b	ing scientis ward provi trate the ne t scientist c Announcem nical trial, a nt. Applican by another	ts and enable des three to eed for a career award eent (FOA) is clinical trial ts not investigator,
093225	Independent Scientist Award (Pa	rent K02 -	Independent Clinical Trial Not A	Allowed)	National Institutes of Health/DHHS	PA-20-174	07-May- 2022	Not Specified
	Contact Name Contact Telephone Contact Email Sponsor Website Program URL	grantinfo Link to pr	<u>@nih.gov</u> ogram URL					

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadl	ine Date	Funding Amount
	Deadline Dates (ALL)	07-May-2 The purpo them to e five years period of program r designed trial feasil experienc investigat	022, 12-Jun-2022, 07-Sep-202 ose of the NIH Independent Scie expand their potential to make a of salary support and "protect intensive research focus as a m must be tailored to meet the in specifically for applicants prope bility study, or a separate ancill ce in a clinical trial led by anothe cor, should apply to the compar	2, 12-Oct-2022, 07-Jan-2 entist Award (K02) is to fo significant contributions to ed time" for newly independent neans of enhancing their ru dividual needs of the cand osing research that does n ary clinical trial. Applicants nion FOA.	2023, 12-Feb-2023, 07- ster the development of o their field of research endent scientists who ca esearch careers. Each in didate. This Funding Op not involve leading an ir as to this FOA are permi s proposing a clinical tri	May-2023 of outstand . The K02 a in demons independer portunity , depender tted to pro al or an an	ling scientis award provi trate the ne nt scientist o Announcem t clinical tri ppose resea cillary clinic	ts and enable des three to eed for a career award eent (FOA) is al, a clinical rch al trial as lead
100769	Addressing the Etiology of Health (R01 Clinical Trial Not Allowed)	Disparitie	es and Health Advantages Amor	ng Immigrant Populations	National Institutes of Health/DHHS	PAR-21- 080	07-May- 2022	Not Specified
	Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) Synopsis	Deborah I 301-402-2 deborah.I Link to pro 07-May-2 The purpo uniquely a immigran	Linares, Ph.D. 2516 <u>inares@nih.gov</u> 0gram URL 022 , 05-Jun-2022 , 07-Sep-202 ose of this Funding Opportunity associated with the immigration t populations.	2 , 05-Oct-2022 , 07-Jan-2 Announcement (FOA) is t n experience that contribu	2023 to support innovative route to health disparities	esearch to or health	understanc advantages	factors among U.S.
100780	Addressing Health Disparities amo Clinical Trial Optional)	ong Immig	grant Populations through Effec	ctive Interventions (R01	National Institutes of Health/DHHS	PAR-21- 081	07-May- 2022	Not Specified
	Contact Name Contact Telephone Contact Email Sponsor Website Program URL	Deborah I 301-402-2 <u>deborah.I</u> Link to pro	Linares, Ph.D. 2516 <u>inares@nih.gov</u> ogram URL					

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Dead	line Date	Funding Amount
	Deadline Dates (ALL) Synopsis	07-May-2022 , 05-Jun-2022 , 07-Sep-20 The purpose of this initiative is to support advantages and reduce the health dispa	22 , 05-Oct-2022 , 07-Jan- ort research to design and arities among US immigra	2023 I implement effective in nt populations.	ntervention	s to enhance	e health
100289	Discovery of in vivo Chemical Pro	bes for the Nervous System (R01 Clinica	l Trial Not Allowed)	National Institutes of Health/DHHS	PAR-21- 029	07-May- 2022	Not Specified
	Contact Name	Enrique L. Michelotti, Ph.D.					
	Contact Telephone	301-443 5415					
	Contact Email	michelottiel@mail.nih.gov					
	Sponsor Website						
	Program URL	Link to program URL					
	Deadline Dates (ALL)	07-May-2022 , 05-Jun-2022 , 07-Sep-20 2023 , 05-Oct-2023 , 07-Jan-2024	22 , 05-Oct-2022 , 07-Jan-	2023 , 05-Feb-2023 , 0	7-May-202	3 <i>,</i> 05-Jun-20	)23 , 07-Sep-
	Synopsis	The purpose of this Funding Opportunit to join efforts for the discovery of in viv hand, the starting compounds ("validat Through this FOA, NIH wishes to stimula potential use in understanding biological and/or validation of novel, biological ta on projects that provide new insight int emphasis of projects submitted under t developing cell-based chemical probes	ty Announcement (FOA) is to chemical probes for nov- ed hits") for chemical opti- ate research in 1) discover al processes relevant to the rgets that will inform stud to important disease-relat his FOA should be the dist may wish to apply using the	to support investigato vel brain targets. It is ex imization and bioassay ry and development of ne missions of NIMH, N lies of brain disease me ed biological targets ar covery of in vivo chemi he companion R21 me	ors who hav epected that s for testing novel, sma IDA, NEI, ar echanisms. nd biologica cal probes. chanism, (P.	e interest ar t applicants g new analog Il molecules nd/or NIA an Emphasis wi I processes. Applicants i AR-21-028).	nd capability will have, in g compounds for their id 2) discover ill be placed The main nterested in
105002	The Role of Work in Health Dispa	urities in the U.S. (R01 Clinical Trials Option	<u>onal)</u>	National Institutes of Health/DHHS	PAR-21- 275	07-May- 2022	Not Specified
	Contact Name	Rada K. Dagher, PhD, MPH					
	Contact Telephone	301-451-2187					
	Contact Email	rada.dagher@nih.gov					
	Sponsor Website						

Program URL Link to program URL



SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadli	ne Date	Funding Amount
	Deadline Dates (ALL)	07-May-2 2023 , 07	2022 , 05-Jun-2022 , 07-Sep-202 -Jan-2024 , 05-Feb-2024 , 07-M	2 , 05-Oct-2022 , 07-Jan-2 ay-2024 , 05-Jun-2024 , 07	023 , 05-Feb-2023 , 07 7-Sep-2024	7-May-2023	, 05-Jun-20	)23 , 07-Sep-
	Synopsis	The purp contribut outcomes social det	ose of this Funding Opportunity e to identifying and characteriz s and health status among popu erminant of health.	Announcement (FOA) is t ing pathways and mechan Ilations with health and/o	to support innovative isms through which w r health care disparitie	population-k ork or occup es, and how	based resea bation influ work funct	arch that can ences health ions as a
093908	NIH Research Project Grant (Pare	ent R01 Cli	nical Trial Not Allowed)		National Institutes of Health/DHHS	PA-20-185	07-May- 2022	Not Specified
	Contact Name							
	Contact Telephone							
	Contact Email	grantsinfo	<u>o@nih.gov</u>					
	Sponsor Website							
	Program URL	Link to pr	ogram URL					
	Deadline Dates (ALL)	07-May-2	2022 , 05-Jun-2022 , 07-Sep-202	2 , 05-Oct-2022 , 05-Feb-2	2023			
	Synopsis	The NIH F interests one or ma Announce participat their resp participat	Research Project Grant supports and competencies of the invest ore of the participating NIH Inst ement does not accept applicat the in Parent Announcements. Appective areas of research interes the in this announcement will no	a discrete, specified, circ igator(s). The proposed pr itutes and Centers (ICs) ba ions proposing clinical tria oplicants should carefully st at the R01 IC-Specific Sc t consider applications for	umscribed project in a roject must be related ased on their scientific al(s). Note: Not all NIH note which ICs particip ientific Interests and C	to the program to the program missions. The Institutes are pate in this a Contact web	enting the s rammatic i his Funding nd Centers innouncem site. ICs tha	specific nterests of g Opportunity (ICs) nent and view at do not
093638	Identifying Innovative Mechanism Consequences (R01 Clinical Trial	<u>ms or Inter</u> Optional)	ventions that Target Multimork	bidity and Its	National Institutes of Health/DHHS	PAR-20- 180	07-May- 2022	Not Specified
	Contact Name	David L. T	illev. MPH. MS. CPH					·
	Contact Telephone	301-827-	6014					
	Contact Email	david.tille	ey@nih.gov					
	Sponsor Website		· · · · · · · · · · · · · · · · · · ·					
	Program URL	Link to pr	ogram URL					

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadli	ine Date	Funding Amount
	Deadline Dates (ALL)	07-May-2 2023	022 , 05-Jun-2022 , 07-Sep-202	2 , 05-Oct-2022 , 07-Jan-2	2023 , 05-Feb-2023 , 07-I	√ay-2023	, 05-Jun-20	23,07-Sep-
<ul> <li>This Funding Opportunity Announcement (FOA) invites applications that seek to support the identification of share mechanisms and development of innovative interventions to address multimorbidity or multiple chronic conditions and its consequences. Intervention research supported by this initiative should be designed to study: (1) mechanism pathways that prevent MCCs, including the identification of early biomarkers, behavioral pathways, and individual contextual risk factors and interactions that contribute to the development of common MCCs; (2) targeted therapion management, including self-management, of MCCs to delay progression and prevent onset of new diseases; and (3) innovative health care partnership models for managing or treating MCCs. Studies may include shared mechanism: assessments of interactions between risk factors and interventions that address MCCs at different periods of the lir diverse populations. Use of innovative technologies to assess and intervene on risk factors and pathways are encored studies may also include those that make use of existing data and/or data linkages to explore new research question may be helpful in understanding the impact of mechanisms in isolation or in combination. Of particular interests relinterventions that target prevention and treatment of multiple chronic health conditions, including study designs t address therapeutic targets for preventing co-occurring MCCs. Prospective applicants whose research interests relideveloping improved measures and methods for understanding multimorbidity, including but not limited to measu to support developing improved measures and methods for understanding multimorbidity, including but not limited to measu to support basic mechanistic discovery of shared MCC pathways and identification and initial evaluation of MCC sh signatures, should see PAR-20-179.</li> </ul>							hared tions (MCCs) anisms or ual and rapies and d (3) isms, and he lifespan in necouraged. estions that t are ns that relate to easures/tools C shared	
093636	Advancing Research to Develop I	mproved N	Measures and Methods for Und	erstanding	National Institutes F	AR-20-	07-May-	Not
						79	2022	specified
	Contact Name	David L. 1	111ey, MPH, MS, CPH					
	Contact Fmail	david tille	w@nih.gov					
	Sponsor Website	<u>uuvu.tiit</u>	<u>yerni.gov</u>					
	Program URL	Link to pr	ogram URL					
Deadline Dates (ALL) 07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 07-May-2023 , 2023						, 05-Jun-20	23 , 07-Sep-	
Synopsis This Funding Opportunity Announcement (FOA) invites applications that seek to improve the availability, quality, and of data and measures that capture multimorbidity or multiple chronic conditions (MCCs) and the methods for analy multimorbidity data. Research supported by this initiative should be designed to discover, develop, and/or evaluated measures/tools that reflect the longitudinality and life course diversity of multimorbidity. This includes but is not limitative should be designed to multimorbidity.							y, and utility analyzing uate MCC ot limited to	

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadlin	e Date	Funding Amount
		measures identificat focused s approach harness th to explore studies th 180.	/tools to support basic mechan tion and initial biological, analy tudies that capture patient rep es best suited for use with mult he wealth of multimorbidity da e new research questions relate nat identify shared mechanisms	istic discovery of shared N tical, and clinical evaluatio orts and related constructs imorbidity data and match ta available in EHR systems ed to co-occurring MCCs. P or development of innova	ACC pathways using anir in of MCC shared signatu is such as functional limit hed to target population s. Studies may make use prospective applicants w ative interventions to add	nal models ires. Also s ations and s; and app of existing nose resea dress MCC	s of MCCs, ought are I quality o proaches t g data anc rch intere s should s	and patient- f life; analytic hat fully l data linkages ests relate to see PAR-20-
093907	Research Project Grant (Parent R	101 Basic Ex	xperimental Studies with Huma	<u>ns Required)</u>	National Institutes of Health/DHHS	4-20-184	07-May- 2022	Not Specified
	Contact Name							
	Contact Telephone	301-496-4	4000					
	Contact Email	grantsinfo	<u>o@od.nih.gov</u>					
	Sponsor Website							
	Program URL	Link to pr	ogram URL					
	Deadline Dates (ALL)	07-May-2	022 , 05-Jun-2022 , 07-Sep-202	2 , 05-Oct-2022 , 07-Jan-2	023 , 05-Feb-2023 , 07-N	1ay-2023		
	Synopsis	The NIH R interests a experime participar Types of s condition humans for processes submit ur to the pro missions. note whic Scientific funding.	Research Project Grant supports and competencies of the invest ntal studies involving humans, in ints." These studies fall within the studies that should submit under s (i.e., experimentally manipula or the purpose of understandin s or products in mind. Studies con or the appropriate 'Clinical Tr ogrammatic interests of one or Note: Not all NIH Institutes and the ICs participate in this announ Interests and Contact website.	a discrete, specified, circu igator(s). This Parent Func- referred to in NOT-OD-18- ie NIH definition of a clinic er this FOA include studies te independent variables) g the fundamental aspects onducted with specific app ials Required' or 'Clinical T more of the participating I d Centers (ICs) participate in cement and view their rest ICs that do not participate	umscribed project in are ling Opportunity Announ 212 as "prospective basis al trial and also meet the that prospectively assig and that assess biomed s of phenomena without plications toward process rial Optional' FOA. The NIH Institutes and Cente in Parent Announcement spective areas of researce in this announcement v	as represe acement is c science s e definition n human p ical or beh specific a ses or proc proposed p rs (ICs) bas ts. Applica h interest vill not cor	nting the for basic studies inv n of basic participant avioral ou pplication ducts in m project mu sed on the nts should at the RO2	specific science volving human research. :s to itcomes in towards ind should ust be related ir scientific d carefully 1 IC-Specific lications for

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadl	ine Date	Funding Amount
093035	Long-Term Effects of Disasters or Clinical Trial Optional)	n Health Ca	are Systems Serving Health Disp	parity Populations (R01-	National Institutes of Health/DHHS	PA-20-172	07-May- 2022	Not Specified
	Contact Name	Larissa Av	vilés-Santa, MD, MPH					
	Contact Telephone	301-827-0	6924					
	Contact Email	<u>avilessan</u> t	tal@nih.gov					
	Sponsor Website							
	Program URL	Link to pr	ogram URL					
	Deadline Dates (ALL)	07-May-2 2023	2022 , 05-Jun-2022 , 07-Sep-202	2 , 05-Oct-2022 , 07-Jan-2	023 , 05-Feb-2023 , 07	-May-2023	, 05-Jun-2	023 , 07-Sep-
	Synopsis	The purpe on under disparity include ra Native Ha and unde	ose of this Funding Opportunity standing the long-term effects of populations in communities in t acial and ethnic minorities (Blac awaiians and other Pacific Island rserved rural populations.	Announcement (FOA) is t of natural and/or human-r the U.S., including the U.S. ks/African Americans, His ders), sexual and gender m	o support investigative nade disasters on heal territories. NIH-desigr panics/Latinos, America ninorities, socioeconom	e and collal th care sys nated healt an Indians/ nically disad	oorative re tems servir h disparity 'Alaska Nat dvantaged	search focused ng health populations tives, Asians, populations,
099859	Notice of Special Interest (NOSI): Respiratory Distress Syndrome/A	The Influe	ence of Host Resilience on Hete Injury (ARDS/ALI)	rogeneity of Acute	National Institutes of Health/DHHS	NOT-HL- 20-814	07-May- 2022	Not Specified
	Contact Name	Guofei Zh	iou, PhD					
	Contact Telephone	301-827-	7825					
	Contact Email	guofei.zh	ou@nih.gov					
	Sponsor Website							
	Program URL	Link to pr	ogram URL					
	Deadline Dates (ALL)	07-May-2 2023 , 05	2022 , 05-Jun-2022 , 07-Sep-202 -Oct-2023 , 07-Jan-2024 , 05-Fe	2 , 05-Oct-2022 , 07-Jan-2 b-2024 , 07-May-2024 , 05	023 , 05-Feb-2023 , 07 5-Jun-2024	-May-2023	, 05-Jun-2	023 , 07-Sep-
	Synopsis	The purpo research /acute lui	ose of this Notice of Special Inte to understand host resilience as ng injury (ALI).	erest (NOSI) is to inform po s a critical determinant of	otential applicants of tl outcomes in acute resp	ne special i piratory dis	nterest of stress synd	NHLBI in rome (ARDS)
103050	Notice of Special Interest (NOSI): Understanding of Postural Ortho	Stimulate static Tach	Research on the Diagnosis, Tre	atment, and Mechanistic	National Institutes of Health/DHHS	NOT-HL- 21-008	07-May- 2022	Not Specified

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadli	ine Date	Funding Amount
	Contact Name	Denis Buy	ton PhD					
	Contact Telephone	301-435-0	0515					
	Contact Email	buxtond@	ົກhlbi.nih.gov					
	Sponsor Website							
	Program URL	Link to pr	ogram URL					
	Deadline Dates (ALL)	07-May-2 2023 , 05	022 , 05-Jun-2022 , 07-Sep-202 -Oct-2023 , 07-Jan-2024 , 05-Fe	2 , 05-Oct-2022 , 07-Jan-2 b-2024 , 07-May-2024	023 , 05-Feb-2023 , 07-	May-2023	, 05-Jun-20	023 , 07-Sep-
	Synopsis	Postural ( working c predomin there are compellin Improving major nee important address th	Orthostatic Tachycardia Syndroi or attending school. POTS prima hance. The peak incidence is at a no precise data on the prevale og need to stimulate research to g the diagnosis of POTS through ed. Translational studies and mo t goals. This NOSI signals interes hese critical needs.	me (POTS) can be a debilit willy affects women of chile age 14 years, but half of all nce of POTS, it is estimate b understand the causes of a the development of bion echanistic clinical trials to st in this important area w	ating condition that aff d-bearing age, with most ll individuals with POTS d to affect 0.2-1% of the f POTS in order to infor narkers or improved dia guide the development vith the goal of stimulat	ects routir st studies i develop it e U.S. pop m the deve gnostic to of better ing resear	ne activities reporting 8 in adulthou ulation. The elopment o ols represe treatments ch applicati	s such as 0-90% female od. While ere is thus a of treatments. nts another are also fons to
106732	Notice of Special Interest (NOSI): Assessment Methodologies Amo	<u>Dietary, P</u> ng Infants	hysical Activity, Sedentary Beha and Young Children (Birth to 5	avior and Sleep years) through Adults	National Institutes I of Health/DHHS	NOT-CA- 21-108	07-May- 2022	Not Specified
	Contact Name	Kirsten He	errick, PhD, MSc					
	Contact Telephone	240-276-5	5734					
	Contact Email	kirsten.he	errick@nih.gov					
	Sponsor Website							
	Program URL	Link to pr	ogram URL					
	Deadline Dates (ALL)	07-May-2	022 , 05-Jun-2022 , 07-Sep-202	2 , 05-Oct-2022 , 07-Jan-2	.023 , 05-Feb-2023 , 07-	May-2023		
	Synopsis	The purpo measurer developm on innova integratio	ose of this NOSI is to invite inve ment of diet, physical activity, so ment of improved methods (e.g. ative technologies (including ad on of measurements across mul	stigator-initiated applicati edentary behavior, and sle , device-based, self-report vanced statistical and com tiple behaviors (e.g., cons	ons addressing approace eep and their environm t, or other innovations). nputational and/or anal umption, sleep, sedenta	ches that in ental influ Such instr ytical appr ary and act	mprove the ences throu ruments she roaches), ar tive time). A	e ugh the ould be based nd/or Applications

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadli	ne Date	Funding Amount
		that explo develop o occur. Stu especially	ore and optimize innovative cor combined measures of perceive udies addressing infants and you y encouraged, although all popu	nbinations of instruments d and objective or physica ung children (birth to 5 ye ilations are eligible for stu	s across these behavio al features of the physe ears) and individuals fr udy under this notice.	ors are encou ical environr om underser	raged, as a nents in wł ved subgro	re efforts to hich they bups are
106715	Role of Astrocytes in Degeneration	on of the N	Neurovascular Unit in AD/ADRD	s (R01 Clinical Trial Not	National Institutes	PAR-22-	07-May-	2,500,000
	<u>Allowed)</u>	1			of Health/DHHS	037	2022	USD
	Contact Name							
	Contact Telephone							
	Contact Email							
	Sponsor Website							
	Program URL	Link to pr	ogram URL		_			
	Deadline Dates (ALL)	07-May-2 2023 , 07	2022 , 05-Jun-2022 , 07-Sep-202 -Jan-2024 , 05-Feb-2024 , 07-M	2 , 05-Oct-2022 , 07-Jan-2 ay-2024 , 05-Jun-2024 , 0	2023 , 05-Feb-2023 , 0 7-Sep-2024 , 05-Oct-2	7-May-2023 024 , 07-Jan-	, 05-Jun-20 2025	23 , 07-Sep-
	Synopsis	This fund on the m impairme Astrocyte cells, are	ing opportunity announcement echanisms of reactive astroglios ent and dementia. The neurovas es, due to their overlapping role uniquely positioned to be thera	(FOA) invites basic diseas sis in degeneration of the scular unit involves multip s regulating the blood bra speutic targets for the AD	se-related research to neurovascular unit th ole pathways that cont ain barrier, neuronal h /ADRDs.	address a ga at contribute ribute to neu ealth and res	p in the ba s to cognit ırodegeneı ponse to d	sic research ive ation. egenerating
093897	Research Project Grant (Parent R	01 Clinica	l Trial Required)		National Institutes of Health/DHHS	PA-20-183	07-May- 2022	Not Specified
	Contact Name							
	Contact Telephone							
	Contact Email	grantsinf	o@nih.gov					
	Sponsor Website							
	Program URL	Link to pr	ogram URL					
	Deadline Dates (ALL)	07-May-2	2022 , 05-Jun-2022 , 07-Sep-202	2 , 05-Oct-2022 , 07-Jan-2	2023 , 05-Feb-2023 , 0	7-May-2023		
	Synopsis	The NIH F interests	Research Project Grant supports and competencies of the invest	s a discrete, specified, circ igator(s). This Parent Fun	cumscribed project in ding Opportunity Ann	areas represe ouncement r	enting the s equires tha	specific at at least 1

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Dead	ine Date	Funding Amount
		clinical tri participat accept me National I and Strok (NIMH)	al be proposed. The proposed p ing NIH Institutes and Centers ( echanistic studies that meet NII nstitute of Arthritis and Muscu e (NINDS) National Center for C	project must be related to (ICs) based on their scient H's definition of a clinical to loskeletal and Skin Diseas Complementary and Integ	o the programmatic inte ific missions. NOTE: The trial. National Heart, Lu es (NIAMS) National Ins rative Health (NCCIH) N	rests of o following ng, and Bl titute of N ational Ins	ne or more o g Institutes/( ood Institute Neurological stitute of Me	of the Centers only e (NHLBI) Disorders ental Health
088091	Development and Application of F and for Pathophysiological Studie	PET and SI s of CNS D	PECT Imaging Ligands as Bioma Disorders (R01 Clinical Trial Opti	rkers for Drug Discovery ional)	National Institutes of Health/DHHS	PAR-20- 038	07-May- 2022	Not Specified
	Contact Name	Enrique N	1ichelotti, Ph.D.					
	Contact Telephone	301-443-5	5415					
	Contact Email	michelott	iel@mail.nih.gov					
	Sponsor Website							
	Program URL	Link to pro	ogram URL					
	Deadline Dates (ALL)	07-May-2	022 , 05-Jun-2022 , 07-Sep-202	2 , 05-Oct-2022 , 07-Jan-2	2023			
	Synopsis	This Fund evaluation (SPECT) in in pre-clin use in clin	ing Opportunity Announcemen n of novel radioligands for posit naging in human brain and the nical studies. These studies are nical research. Projects proposit	t (FOA) invites research g tron emission tomography incorporation of pilot or o expected to provide the re ng only preclinical animal	rant applications that p y (PET) or single photor clinical feasibility evalua equisite data needed to studies should consider	ropose the emission tion from advance the comp	e developme computed t previously c promising Pl anion FOA F	ent and omography collected data ET ligands for PAR-20-037 .
098640	Mentored Career Development P	<mark>rogram (K</mark>	01) for Early Stage Investigator	<u>s Using Nonhuman</u>	National Institutes	PAR-20-	07-May-	Not
	Primate Research Models (K01 Inc	dependen	t Clinical Trial Not Allowed)		of Health/DHHS	258	2022	Specified
	Contact Name	Deborah I	Philp, Ph.D.					
	Contact Telephone	301-761-7	7766					
	Contact Email	<u>deborah.</u> p	ohilp@nih.gov					
	Sponsor Website							
	Program URL	Link to pro	ogram URL					
	Deadline Dates (ALL)	07-May-2	022 , 12-Jun-2022 , 07-Sep-202	2 , 12-Oct-2022 , 07-Jan-2	2023			

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline D	ate	Funding Amount
	Synopsis	The purp "protecte guidance models a number o foster tra developm project g proposin study to a or co-me	ose of this Funding Opportunity ed time" (up to five years) for in of an experienced mentorship nd in translation of the results f of highly skilled scientists using l anslation of outcomes into the c nent and training, awardees will rant (e.g., R01) funding. This Fun g research that does not involve a clinical trial. Applicants to this ntor.	Announcement (FOA) is t tensive, research-focused team with expertise in bot from such studies to clinica NHP models to address co linic. The expectation is th I launch independent rese nding Opportunity Annour e leading an independent o FOA are permitted to pro	to provide early-stage inv career development prog th the preclinical applicat al application. The focus of mplex translational biom that through this sustained arch careers and become neement (FOA) is designe clinical trial, a clinical trial pose research experience	estigators wit gram activitie on of nonhur of this prograr edical researc period of res competitive d specifically feasibility stu in a clinical t	h supp s unde nan pr n is to ch desi earch o for nev for app udy, or rial led	ort and r the imate (NHP) increase the gned to career v research olicants an ancillary I by a mentor
094250	Mentored Patient-Oriented Rese Trial Required)	arch Care	er Development Award (Parent	K23 Independent Clinical	National Institutes of Health/DHHS	-20-206 07- 202	May- 2	Not Specified
	Contact Name							
	Contact Telephone							
	Contact Email	grantinfo	@nih.gov					
	Sponsor Website							
	Program URL	Link to pr	rogram URL					
	Deadline Dates (ALL)	07-May-2	2022 , 12-Jun-2022 , 07-Sep-202	2 , 12-Oct-2022 , 07-Jan-2	023 , 12-Feb-2023 , 07-M	ay-2023		
	Synopsis	The purp developm on patier proposin ancillary or proposin Note: No participa Specific li consider	pose of the NIH Mentored Patien nent of individuals with a clinica nt-oriented research. This Fundin g to serve as the lead investigat clinical trial, as part of their rese sing to gain research experience t all NIH Institutes and Centers te in this announcement and vie nformation, Requirements and applications for funding. Consul	nt-Oriented Research Care Il doctoral degree who hav ng Opportunity Announce or of an independent clini earch and career developn e in a clinical trial led by ar participate in Parent Anno ew their respective areas of Staff Contacts website. ICs Itation with NIH staff befo	eer Development Award ( ve made a commitment to ment (FOA) is designed s cal trial, a clinical trial fea nent. Applicants not plan nother investigator, must buncements. Applicants sh of research interest and re s that do not participate in re submitting an applicat	K23) is to sup o focus their r pecifically for sibility study, ning an indep apply to com nould carefull equirements an this announ on is strongly	port the researce application or a set endent panion y note at the T cement y encou	he career h endeavors ants eparate t clinical trial, FOA Special which ICs Fable of IC- it will not uraged.

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Dat	e Funding Amount
094248	Mentored Patient-Oriented Rese Trial Not Allowed)	arch Caree	er Development Award (Parent	K23 Independent Clinical	National Institutes of Health/DHHS	-20-205 07-M 2022	ay- Not Specified
	Contact Name						
	Contact Telephone						
	Contact Email	grantinfo	<u>@nih.gov</u>				
	Sponsor Website						
	Program URL	Link to pr	<u>ogram URL</u>				
	Synopsis	The purp developm on patien proposing ancillary of or co-me the comp carefully requirem this anno strongly of	ose of the NIH Mentored Patien nent of individuals with a clinica at-oriented research. This Fundin g research that does not involve clinical trial. Applicants to this F ntor. Applicants proposing a clir panion FOA Special Note: Not all note which ICs participate in thi ents at the Table of IC-Specific I uncement will not consider app encouraged.	nt-Oriented Research Care I doctoral degree who hav ng Opportunity Announce e leading an independent of OA are permitted to prop nical trial or an ancillary cl NIH Institutes and Center is announcement and view nformation, Requirement dications for funding. Cons	er Development Award (K ve made a commitment to ment (FOA) is designed sp clinical trial, a clinical trial ose research experience ir inical trial as lead investiga rs participate in Parent An v their respective areas of and Staff Contacts webs sultation with NIH staff be	23) is to suppo focus their res recifically for a feasibility stud a clinical trial ator, should ap nouncements. research inter- ite. ICs that do fore submittin	rt the career search endeavors oplicants y, or a separate led by a mentor ply to Applicants should est and not participate in g an application is
094244	Mentored Patient-Oriented Rese Experimental Studies with Human	arch Caree ns Require	er Development Award (Parent ed)	K23 Independent Basic	National Institutes of Health/DHHS	20-204 07-M 2022	ay- Not Specified
	Contact Name						
	Contact Telephone						
	Contact Email						
	Sponsor Website						
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	07-May-2	2022 , 12-Jun-2022 , 07-Sep-202	2 , 12-Oct-2022 , 07-Jan-2	023 , 12-Feb-2023 , 07-Ma	ay-2023	
	Synopsis	The purp developm	ose of the NIH Mentored Patien nent of individuals with a clinica	nt-Oriented Research Care I doctoral degree who hav	er Development Award (K ve made a commitment to	23) is to suppo focus their res	rt the career search endeavors

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		on patient-oriented research. This Paren involving humans, referred to in NOT-OD studies fall within the NIH definition of a should be submitted under this FOA inclu experimentally manipulate independent purpose of understanding the fundamen products in mind. Applicants not plannin proposing to gain research experience in must apply to the 'Independent Clinical T programmatic interests of one or more of Special Note: Not all NIH Institutes and C ICs participate in this announcement and IC-Specific Information, Requirements ar consider applications for funding. Consul	t Funding Opportunity And D-18-212 as "prospective b clinical trial and also meet ude studies that prospective variables) and that assess tal aspects of phenomena g an independent clinical to a clinical trial or basic exp frial Not Allowed' compani of the participating NIH Ins centers participate in Paren d view their respective are and Staff Contacts website.	nouncement is for basic asic science studies invo t the definition of basic vely assign human partic biomedical or behavior without specific applica trial or basic experiment erimental study with hu ion FOA. The proposed p titutes and Centers (ICs) of Announcements. App as of research interest a ICs that do not participa re submitting an applica	science experime olving human part research. Types of cipants to condition al outcomes in hu ation towards pro- cal study with hum umans led by anon- project must be re- based on their so licants should can nd requirements ate in this announ tion is strongly en	ental studies cicipants." These of studies that ons (i.e., mans for the cesses or nans, or ther investigator, elated to the cientific missions. refully note which at the Table of cement will not ncouraged.
099392	Notice of Special Interest (NOSI): Obstetrical Outcomes in Adolesc (Clinical Trial Optional)	Optimizing Precision Treatment of Gyneo ents and Adults with PCOS and Associated	cologic, Reproductive and d Comorbid Conditions	National Institutes N of Health/DHHS 2	IOT-HD- 07-Ma 0-026 2022	y- Not Specified
	Contact Name	Esther Eisenberg, MD MPH				
	Contact Telephone	301-496-6516				
	Contact Email	esther.eisenberg@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-May-2022 , 05-Jun-2022 , 16-Jun-202 2023 , 07-May-2023 , 05-Jun-2023 , 16-Ju	2 , 07-Sep-2022 , 05-Oct-2 un-2023 , 07-Sep-2023	022 , 16-Oct-2022 , 07-J	an-2023 , 05-Feb	·2023 , 16-Feb-
	Synopsis	The National Institute of Child Health and announce the opportunity for investigate adolescents and reproductive age wome are to stimulate interdisciplinary scientifi and subspecialists in diverse medical field mental health professionals, pulmonolog gynecologic, reproductive and obstetrica	d Human Development (No ors to apply for funding to n with a diagnosis of Polyc ic collaboration between g ds, including cardiologists, gists, among others, to: 1) Il needs and desires; 2) pro	ICHD) is issuing this Noti optimize treatments of cystic Ovary Syndrome (I synecologists/reproduct endocrinologists, gastro advance individualized t omote translational and	ice of Special Inte comorbid conditi PCOS). The goals ive endocrinologi penterologists, ps creatments consis clinical research	rest (NOSI) to ons in of this initiative sts/obstetricians ychiatrists, tent with to

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadl	ine Date	Funding Amount
		increase l outcomes with unde adults wit	knowledge and understanding c s; and 3) discover and develop r erlying comorbid conditions. Ult th PCOS who have concomitant	of interaction of various th novel safe and more effect timately, this research wor medical conditions.	erapies on gynecologic ive therapies for adole uld advance precision t	, reproduc scents and herapeuti	ctive and ob d women wi cs for adole	ostetric th PCOS scents and
104245	Academic Research Enhancemen Not Allowed)	t Award fo	or Undergraduate-Focused Insti	tutions (R15 Clinical Trial	National Institutes of Health/DHHS	PAR-21- 155	07-May- 2022	300,000 USD
	Contact Name Contact Telephone Contact Email Sponsor Website	Alexandra alexandra	a M. Ainsztein, Ph.D. a.ainsztein@nih.gov					
	Program URL Deadline Dates (ALL)	<u>Link to pr</u> 07-May-2 2023 , 25-	<mark>ogram URL</mark> 022 , 25-Jun-2022 , 07-Sep-202 -Oct-2023 , 07-Jan-2024 , 25-Fe	2 , 25-Oct-2022 , 07-Jan-2 b-2024 , 07-May-2024	023 , 25-Feb-2023 , 07	May-2023	3 , 25-Jun-20	023 , 07-Sep-
	Synopsis	The purpe small scal providing at applica million do composed all the no Funding L	ose of this Academic Research E e research grants at institutions biomedical research experienc int institutions. Eligible institution ollars per year of NIH support (in d of multiple schools and colleg n-health professional schools an evel can be found here.	Enhancement Award (ARE, s that do not receive subst es primarily for undergrac ons must award baccalaur n both direct and F&A/ind es, the \$6 million funding nd colleges within the inst	A) for Undergraduate-I tantial funding from th luate students, and en eate science degrees a irect costs) in 4 of the limit is based on the au itution as a whole. Hel	ocused In NIH, with nancing th nd have re ast 7 fisca nount of N o determin	stitutions is n an emphase research e eceived no r l years. For NH funding ning the Org	to support sis on environment nore than \$6 institutions received by ganization
104244	Academic Research Enhancemen Required)	t Award fo	or Undergraduate-Focused Insti	tutions (R15 Clinical Trial	National Institutes of Health/DHHS	PAR-21- 154	07-May- 2022	300,000 USD
	Contact Name Contact Telephone Contact Email Sponsor Website Program URL	Minna Lia 301-827- <u></u> <u>liangm@r</u> <u>Link to pr</u>	ing, Ph.D. 5708 <u>hida.nih.gov</u> ogram URL					



SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Deadline Dates (ALL)	07-May-2 2023 , 25	2022 , 25-Jun-2022 , 07-Sep-202 -Oct-2023 , 07-Jan-2024 , 25-Fe	2 , 25-Oct-2022 , 07-Jan-2 b-2024 , 07-May-2024	023 , 25-Feb-2023 , 07-Ma	y-2023 , 25-Jun-2	023 , 07-Sep-
	Synopsis	The purpe small scal providing at applica million pe compose all the no Funding L	ose of this Academic Research E le research grants at institutions biomedical research experienc ant institutions. Eligible institution er year of NIH support (in both o d of multiple schools and colleg n-health professional schools an evel can be found here.	Inhancement Award (ARE/ s that do not receive subst es primarily for undergrad ons must award baccalaur direct and F&A/indirect co es, the \$6 million funding nd colleges within the inst	A) for Undergraduate-Focu antial funding from the NI luate students, and enhan- eate science degrees and I sts) in 4 of the last 7 fiscal limit is based on the amou itution as a whole. Help de	used Institutions is H, with an empha cing the research have received no u years. For institut int of NIH funding etermining the Org	s to support sis on environment more than \$6 ions received by ganization
104076	Pilot Health Services and Econom Disorders (R34 - Clinical Trial Opt	nic Researd ional)	ch on the Treatment of Drug, Al	cohol, and Tobacco Use	National Institutes of Health/DHHS	21-180 07-May- 2022	450,000 USD
	Contact Name	Keisher H	lighsmith, DrPH				
	Contact Telephone						
	Contact Email	<u>duffys@n</u>	<u>iida.nih.gov</u>				
	Sponsor Website						
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	07-May-2 2023 , 16	2022 , 16-Jun-2022 , 07-Sep-202 -Oct-2023 , 07-Jan-2024 , 16-Fe	2 , 16-Oct-2022 , 07-Jan-2 b-2024 , 07-May-2024	023 , 16-Feb-2023 , 07-Ma	y-2023 , 16-Jun-2	023 , 07-Sep-
	Synopsis	This Fund services r and polici alcohol us condition lack an ev approach	ling Opportunity Announcemen research effectiveness trials. Rel ies designed to optimize access se disorder treatments and rela is. Relevant approaches may inc vidence base. This FOA provides ies, in addition to usual trial pre	t (FOA) encourages pilot a evant trials may test a wic to, and the quality, effect ted services, as well as ser lude both those that are r resources for assessing th paration activities.	nd preliminary research in le range of approaches, in iveness, affordability and u vices for comorbid medica novel, and those that are c ne feasibility, acceptability	n preparation for la cluding intervention utilization of drug, al and mental diso ommonly used in , and utility of the	arger-scale ons, practices, tobacco, or order practice but se
107542	Nation of Special Interact (NOSI):	Accolorat	ing Progress in Colias Disease P	acoarch	National Institutes NO	T-Al- 07-May-	Not

107543	Notice of Special Interest (NOSI): Accelerating Progress in Cellac Disease Research	of Health/DHHS	22-004	2022	Specified	
407542	Number of Constant (NOCI), An all write Descent to Calles Discourses	National Institutes	NOT-AI-	07-May-	Not	

Contact Name Annette L. Rothermel, Ph.D.



SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadli	ine Date	Funding Amount
	Contrat Talanhana	240 627						
	Contact Telephone	240-627-:	34//					
	Contact Emain	arotherm	el@maid.mn.gov					
	Sponsor website	Link to pr	ogram LIPI					
07-May-2022, 13-May-2022, 25-May-2022, 01-Jun-2022, 05-Jun-2022, 16-Jun-2022, 24-Jun 2022, 14-Sep-2022, 25-Sep-2022, 05-Oct-2022, 16-Oct-2022, 20-Oct-2022, 07-Jan-2023, 13- Deadline Dates (ALL) Feb-2023, 05-Feb-2023, 16-Feb-2023, 07-May-2023, 12-May-2023, 13-May-2023, 25-May- 2023, 07-Sep-2023, 14-Sep-2023, 25-Sep-2023, 05-Oct-2023, 16-Oct-2023, 07-Jan-2024, 12- Feb-2024, 16-Feb-2024, 07-May-2024, 25-May-2024, 05-Jun-2024, 16-Jun-2024, 07-Sep-202							2,07-Sep-2 2023,25-Ja 05-Jun-20 2024,25-Ja 5-Sep-2024	022 , 13-Sep- an-2023 , 01- 23 , 16-Jun- an-2024 , 05-
The purpose of this Notice of Special Interest (NOSI) is to inform potential applicants to the Synopsis (NIH) of special interest in research on the etiology and pathogenesis of celiac disease, ide and development of preventative or disease ameliorating therapies/strategies.						he Nationa lentificatior	n of therape	of Health Eutic targets,
107545	Notice of Special Interest (NOSI): Stage Investigators	Expanding	g the Otitis Media Research Wo	rkforce: Focus on Early	National Institutes of Health/DHHS	NOT-DC- 22-001	07-May- 2022	Not Specified
	Contact Name	Bracie Wa	atson, Jr., Ph.D.					
	Contact Telephone	301-402-3	3458					
	Contact Email	watsonb@	@nidcd.nih.gov					
	Sponsor Website							
	Program URL	Link to pr	ogram URL					
Deadline Dates (ALL)SynopsisSynopsisNormal SupervisionSynopsisSynops							2, 11-Oct- eb-2023, 07- 16-Oct-2023, 24, 20-Jun- Jun-2025, 16-	
							e cadre of terest (NOSI) at focus on	

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadli	ne Date	Funding Amount
		OM—com approach	nmonly known as ear infections es that accelerate the developr	. There is a critical need f nent of effective ways to	or focused, novel, crea prevent and treat OM	ative and inr	iovative res	search
100050	Notice of Special Interest (NOSI)	: Research	on Rehabilitation Needs Associ	ated with the COVID-19	National Institutes of Health/DHHS	NOT-HD- 20-031	07-May- 2022	Not Specified
	Contact Name	Theresa C	ruz, PhD.					
	Contact Telephone	301-496-9	9233					
	Contact Email	<u>cruzth@n</u>	nail.nih.gov					
	Sponsor Website							
	Program URL	Link to pr	ogram URL					
	Deadline Dates (ALL)	07-May-2 2023 , 07-	022 , 05-Jun-2022 , 16-Jun-202 May-2023	2 , 07-Sep-2022 , 05-Oct-2	2022 , 16-Oct-2022 , 0	7-Jan-2023 ,	05-Feb-20	23 , 16-Feb-
	Synopsis	COVID-19 survivors associated and the as considere Center for	ose of this Notice of Special Inte , the associated mitigation action of COVID-19 Understand the im d mitigation actions Understand ssociated mitigation actions on d responsive; not all topics are r Medical Rehabilitation Resear	erest is to encourage appl ons, and rehabilitation: En ppact of disruptions to rel d the social, behavioral, e people with physical disa expected within the same rch (NCMRR) at NICHD.	ications in three areas ncourage research to a habilitation services ca conomic, and health in ibilities Research appli e application. Applicat	a related to t address the bused by the mpact of the cations addu ions will be	he intersec rehabilitatio COVID-19 COVID-19 ressing the directed to	ition of on needs of pandemic ar pandemic se topics are the Nationa
094033	NIH Exploratory/Developmental	Research (	Grant Program (Parent R21 Clin	ical Trial Not Allowed)	National Institutes of Health/DHHS	PA-20-195	07-May- 2022	275,000 USD
	Contact Name							
	Contact Telephone							
	Contact Email	grantsinfo	o@nih.gov					
	Sponsor Website							
	Program URL	Link to pr	ogram URL					
	Deadline Dates (ALL)	07-May-2	022 , 16-Jun-2022 , 07-Sep-202	2 , 16-Oct-2022 , 07-Jan-2	2023 , 16-Feb-2023 , 0	7-May-2023		
	Synopsis	The NIH E for the ea	xploratory/Developmental Gra rly and conceptual stages of the	nt supports exploratory a ese projects. These studie	nd developmental res es may involve conside	earch projeo erable risk bu	cts by provi ut may lead	ding support I to a

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		breakthro applicatio Institutes this anno Contact v	bugh in a particular area, or to t ons that could have a major imp and Centers (ICs) participate in uncement and view their respe vebsite. ICs that do not participa	he development of novel act on a field of biomedic Parent Announcements. ctive areas of research int ate in this announcement	techniques, agents, metho cal, behavioral, or clinical re Applicants should carefully terest at the R21 IC-Specific will not consider application	dologies, models, esearch. Note: Not v note which ICs p c Scientific Interes ons for funding.	or t all NIH articipate in ts and
094032	NIH Exploratory/Developmental	Research (	Grant Program (Parent R21 Clin	ical Trial Required)	National Institutes of Health/DHHS	20-194 07-May- 2022	275,000 USD
	Contact Name						
	Contact Telephone						
	Contact Emai	grantsinfo	<u>o@nih.gov</u>				
	Sponsor Website						
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	07-May-2	2022 , 16-Jun-2022 , 07-Sep-202	2 , 16-Oct-2022 , 07-Jan-2	2023 , 16-Feb-2023 , 07-Ma	y-2023	
	Synopsis	The NIH E for the ea breakthro applicatic Opportur program Applicant NIH's def accept m of Arthrit Institutes this anno Required consider	Exploratory/Developmental Gra arly and conceptual stages of the bugh in a particular area, or to t ons that could have a major imp nity Announcement requires that matic interests of one or more of is should note that some ICs (se inition of a clinical trial through echanistic studies that meet NII is and Musculoskeletal and Skin and Centers (ICs) participate in uncement and view their respe- IC-Specific Scientific Interests a applications for funding.	nt supports exploratory a ese projects. These studie he development of novel act on a field of biomedic at at least 1 clinical trial be of the participating NIH In- eRelated Notices) only ac this funding opportunity H's definition of a clinical Diseases (NIAMS) Nation Parent Announcements. ctive areas of research int nd Contact website. ICs th	nd developmental research es may involve considerable techniques, agents, metho cal, behavioral, or clinical re- e proposed. The proposed stitutes and Centers (ICs) b cept applications proposin announcement. The follow trial. See Related Notices so hal Institute of Mental Heal Applicants should carefully terest at the R21 Basic Expen- hat do not participate in th	n projects by prov e risk but may lead dologies, models, esearch. This Paren project must be re ased on their scie g mechanistic stud ing Institutes/Cer ection below. Nat th (NIMH) Note: N v note which ICs p erimental Studies is announcement	iding support d to a or nt Funding elated to the ntific missions. dies that meet aters only ional Institute Not all NIH articipate in with Humans will not
094034	NIH Exploratory/Developmental with Humans Required)	Research (	Grant Program (Parent R21 Basi	<u>c Experimental Studies</u>	National Institutes of Health/DHHS PA-	20-196 07-May-	275,000 USD
	<u>man namans negarica</u>					2022	000

Contact Name

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) Synopsis	301-496-4000 grantsinfo@od.nih.gov Link to program URL 07-May-2022 , 16-Jun-2022 , 07-Sep-202 The NIH Exploratory/Developmental Gra for the early and conceptual stages of th breakthrough in a particular area, or to t applications that could have a major imp Opportunity Announcement is for basic "prospective basic science studies involv and also meet the definition of basic res prospectively assign human participants assess biomedical or behavioral outcom phenomena without specific application toward processes or products in mind sh Optional' FOA. The proposed project mu Institutes and Centers (ICs) based on the Parent Announcements. Applicants shou respective areas of research interest at t	22 , 16-Oct-2022 , 07-Jan-2 ant supports exploratory a bese projects. These studie the development of novel bact on a field of biomedic science experimental stud ving human participants." earch. Types of studies that to conditions (i.e., experin es in humans for the purp- towards processes or pro hould submit under the ap list be related to the progra- eir scientific missions. Note ald carefully note which IC the R21 Basic Experimenta	2023 , 16-Feb-2023 , 07-Ma nd developmental researc es may involve considerabl techniques, agents, metho al, behavioral, or clinical re lies involving humans, refe These studies fall within th at should submit under thi mentally manipulate indep ose of understanding the f ducts in mind. Studies con propriate 'Clinical Trials Re ammatic interests of one co e: Not all NIH Institutes and s participate in this annou al Studies with Humans Rec	ay-2023 h projects by prov e risk but may lead odologies, models, esearch. This Pareu rred to inNOT-OD ie NIH definition o s FOA include stud bendent variables) undamental aspect ducted with specific equired' or 'Clinica or more of the part d Centers (ICs) par ncement and view quired IC-Specific S	iding support I to a or nt Funding 18-212as f a clinical trial lies that and that tis of fic applications I Trial cicipating NIH ticipate in their scientific
	Nation of Consideration (NOCI):	Interests and Contact website. ICs that c	lo not participate in this a	nnouncement will not com	sider applications	for funding.
101780	and Disease	Promoting Research on Interoception an	id its impact on Health	of Health/DHHS 21-	002 2022	Not Specified
	Contact Name	Wen G. Chen, M.MSc, Ph.D.				
	Contact Telephone	301-451-3989				
	Contact Email	<u>chenw@mail.nih.gov</u>				
	Sponsor Website					
	Program URL	Link to program URL				



SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadli	ne Date	Funding Amount
	07 Deadline Dates (ALL) 20 Fe	7-May-2 023 , 07- eb-2024	022 , 05-Jun-2022 , 16-Jun-202 May-2023 , 05-Jun-2023 , 16-Ju , 07-May-2024	2 , 07-Sep-2022 , 05-Oct-2 In-2023 , 07-Sep-2023 , 0	2022 , 16-Oct-2022 , 07 5-Oct-2023 , 16-Oct-202	an-2023 , 3 , 07-Jan-	05-Feb-202 2024 , 05-Fe	3 , 16-Feb- eb-2024 , 16-
	disease. This initiative is broadly supported by many participating NIH institutes, centers, and offices (ICOs). For this NOS interoception includes the processes by which an organism senses, interprets, integrates, and regulates signals originati from within itself and represents its internal states. This NOSI encourages basic and clinical research projects that 1) Synopsis combine diverse expertise; 2) develop and use innovative technologies and approaches to delineate interoceptive mechanisms at the molecular, cellular, circuit, functional, and/or behavioral levels; 3) assess pathophysiological process interoception in the context of diseases and disorders; 4) determine the impact of interventions and therapies to manip interoceptive processes on health and/or disease; and 5) develop and validate predictive biomarkers, computational mo or artificial intelligence models relevant to interoception and its impact on health and disease.							Ith and this NOSI, originating at 1) ve processes of co manipulate ional models,
105478	Notice of Special Interest (NOSI): Ac Neurodevelopmental Disorders	dvancing	<u>g Research in Gastrointestinal D</u>	ysfunction in People with	National Institutes N of Health/DHHS 2	IOT-NS- 2-003	07-May- 2022	Not Specified
	Contact Name Ad	dam L. H	lartman, MD					
	Contact Telephone 30	01-496-9	9135					
	Contact Email ac	dam.har	tman@nih.gov					
	Sponsor Website							
	Program URL <u>Li</u>	ink to pro	ogram URL					
	07 Deadline Dates (ALL) 20 Fe	7-May-2 023 , 07- eb-2024	022 , 05-Jun-2022 , 16-Jun-202 May-2023 , 05-Jun-2023 , 16-Ju , 07-May-2024 , 05-Jun-2024 ,	2 , 07-Sep-2022 , 05-Oct-2 Jn-2023 , 07-Sep-2023 , 09 16-Jun-2024	2022 , 16-Oct-2022 , 07 5-Oct-2023 , 16-Oct-202	an-2023 , 3 , 07-Jan-	05-Feb-202 2024 , 05-Fe	3 , 16-Feb- eb-2024 , 16-
	Tr Synopsis ap pr	he Natio pplicatio reventio	nal Institute of Neurological Dis ns focused in the following are n, or treatment of gastrointest	sorders and Stroke is issui a(s) to support basic, tran inal dysfunction in people	ng this Notice to highlig slational, and/or clinical with neurodevelopmen	ht interest research tal disorde	in receiving on the cause ers.	र grant es, diagnosis,
107483	Notice of Special Interest (NOSI): M Gender Differences in HIV-Associate	lechanis ed Neur	tic Studies on the Impact of Sub ocognitive Disorders	ostance Use in Sex and	National Institutes N of Health/DHHS 2	IOT-DA- 2-047	07-May- 2022	Not Specified
	Contact Name Contact Telephone							



SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadl	ine Date	Funding Amount
	Contact Email							
	Snonsor Website							
	Program LIRI	Link to pr	ogram LIRI					
	Deadline Dates (ALL)	07-May-2 2023 , 07- Feb-2024	022 , 05-Jun-2022 , 16-Jun-202 -May-2023 , 05-Jun-2023 , 16-Ju , 07-May-2024 , 05-Jun-2024 ,	2 , 07-Sep-2022 , 05-Oct-2 Jn-2023 , 07-Sep-2023 , 05 16-Jun-2024 , 07-Sep-2024	022 , 16-Oct-2022 , 07 5-Oct-2023 , 16-Oct-20 4 , 05-Oct-2024 , 16-Oc	, Jan-2023, 23 , 07-Jan t-2024 , 07	05-Feb-202 -2024 , 05-F '-Jan-2025	23 , 16-Feb- eb-2024 , 16-
	Synopsis	Compared notice is t gender-sp therapeut	d to men, women are often mo to inform potential applicants o pecific differences in HIV-associa tics and optimization of treatmo	re likely to develop HIV-as f NIDA's special interest ir ated neurocognitive disor ent options in HIV positive	ssociated neurocognition or understanding the ne ders. This information e individuals with subst	ve impairm urobiologio can be use ance use d	ents. The pr cal bases for d for targeto isorders.	urpose of this r sex or ed
107484	Notice of Special Interest (NOSI):	The Funct	ional Oral Microbiome		National Institutes of Health/DHHS	NOT-DE- 21-015	07-May- 2022	Not Specified
	Contact Name	Tamara N	IcNealy, PhD.					
	Contact Telephone	202-430-2	1474					
	Contact Email	tamara.m	icnealy@nih.gov					
	Sponsor Website							
	Program URL	Link to pr	ogram URL					
	Deadline Dates (ALL)	07-May-2 2023 , 07- Feb-2024 , 16-Feb-2	022 , 05-Jun-2022 , 16-Jun-202 -May-2023 , 05-Jun-2023 , 16-Ju , 07-May-2024 , 05-Jun-2024 , 2025 , 07-May-2025 , 05-Jun-20	2 , 07-Sep-2022 , 05-Oct-2 Jn-2023 , 07-Sep-2023 , 09 16-Jun-2024 , 07-Sep-2024 25 , 16-Jun-2025 , 07-Sep-	022 , 16-Oct-2022 , 07 5-Oct-2023 , 16-Oct-20 4 , 05-Oct-2024 , 16-Oc -2025	, Jan-2023, 23 , 07-Jan t-2024 , 07	05-Feb-202 -2024 , 05-F '-Jan-2025 ,	23 , 16-Feb- eb-2024 , 16- 05-Feb-2025
	Synopsis	The Natio encourag	onal Institute of Dental and Crar e research studies that focus be	niofacial Research (NIDCR) eyond the bacteria to the i	is issuing this Notice o multispecies communit	f Special In ies making	terest (NOS gup the ora	l) to microbiome.
099801	Notice of Special Interest (NOSI): and/or Uninfected Individuals to	Mechanis Inform Inr	ms of Mycobacterial-Induced Ir novative Tuberculosis Vaccine D	mmunity in HIV-Infected Design Notice Number:	National Institutes of Health/DHHS	NOT-AI- 20-071	07-May- 2022	Not Specified
	Contact Name Contact Telephone	Que Dang 240-292-6	g, PhD 6181					
	Contact Email	<u>que.dang</u>	<u>@nih.gov</u>					



SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadli	ne Date	Funding Amount		
	Sponsor Website								
	Program ORL Link to p	<u>2022_05_lun_2022_16_lun_202</u>	2 07-Son-2022 05-Oct-2	022 16-0ct-2022 07	lan_2022				
	SynopsisThe purpose of this Notice of Special Interest (NOSI) is to stimulate innovative studies to identify and understand the immune responses that mediate protection fromMycobacterium tuberculosis(Mtb) infection or progression to active tuberculosis (TB) disease. Studies may focus on any stage of mycobacterial infection or following vaccination with Bacillus Calmette-Guérin (BCG) or investigational TB vaccines and may include HIV-infected or uninfected individuals. Research supported under this NOSI should go beyond descriptive information currently known about Mtb infection, immune responses to TB vaccines, or immune modulation by non-tuberculous mycobacterial (NTM) infection, or by HIV/AIDS. Applications that include characterization of the timing, anatomical location, and contribution to disease outcome, of 								
108065	Notice of Special Interest (NOSI): Pediatri	c COVID-19 and Respiratory Vira	<u>Co-infection</u>	National Institutes of Health/DHHS	NOT-HL- 22-004	07-May- 2022	Not Specified		
	Contact Name								
	Contact Telephone								
	Contact Email								
	Sponsor Website								
	Program URL <u>Link to p</u>	orogram URL							
	07-May 2023, 0 Feb-202 , 07-Jan	-2022 , 05-Jun-2022 , 16-Jun-202 7-May-2023 , 05-Jun-2023 , 16-J 24 , 16-Feb-2024 , 07-May-2024 , -2025 , 05-Feb-2025 , 07-May-20	2 , 07-Sep-2022 , 05-Oct-2 un-2023 , 07-Sep-2023 , 05 05-Jun-2024 , 16-Jun-2024 25 , 05-Jun-2025 , 07-Sep-	022 , 16-Oct-2022 , 07 5-Oct-2023 , 16-Oct-20 4 , 16-Jun-2024 , 07-Se 2025	-Jan-2023 , 23 , 07-Jan p-2024 , 05	05-Feb-20 2024 , 05-I -Oct-2024	23 , 16-Feb- <sup>-</sup> eb-2024 , 16 , 16-Oct-2024		
	This NO Synopsis screen f investig	SI is intended to support project or co-infection, phenotype and c ator-initiated applications for ba	s that will employ existing collect biospecimens to an sic, translational and huma	and new clinical trial c swer some of these qu an subject research (no	ohorts/obs estions and ot clinical tr	ervational I to encour ials) in this	cohorts to age space.		
104057	Joint NINDS/NIMH Exploratory Neuroscie	nce Research Grant (R21 Clinical	Trial Optional)	National Institutes of Health/DHHS	PA-21-219	07-May- 2022	275,000 USD		



SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount		
	Contact Name	Karrah Benson						
	Contact Telephone	301-496-0838						
	Contact Email	Karrah.benson@nih.gov						
	Sponsor Website	2						
	Program URL	Link to program URL						
	Deadline Dates (ALL)	07-May-2022 , 16-Jun-2022 , 07-Sep- 2023 , 16-Oct-2023 , 07-Jan-2024 , 16	2022 , 16-Oct-2022 , 07-Jan- -Feb-2024 , 07-May-2024	2023 , 16-Feb-2023 , 07-N	lay-2023 , 16-Jun-2	023 , 07-Sep-		
	Synopsis	The Joint NINDS/NIMH Exploratory N projects, which fall within the mission stages of projects. These studies ofte but have the potential to bring about development of novel techniques, ag this funding opportunity also accepts (studying pathophysiology or mechan studies with humans (BESH) will be su that are within scope of this funding of the Funding Opportunity Description,	euroscience Research Grant is of the NINDS and NIMH. A n assess the feasibility of a r breakthroughs in the under ents, methodologies, or mo- clinical trials, only application ism of action of an interven upported. For information o opportunity announcement below, respectively.	program supports explora wards will provide suppor lovel avenue of investigation standing of important are dels, of high value to the n ons proposing "mechanisti tion, but not safety or effic n NIH clinical trial definition refer to the NIH Definition	atory and innovative t for the early and on and involve con as of neuroscience euroscience comm c clinical trials or st cacy) or basic expe ns and the types o of a Clinical Trial p	e research conceptual siderable risk, , or to the unity. While tudies" rimental f clinical trials page and		
104053	Notice of Special Interest (NOSI):	: Biology of Lung and Head and Neck P	reneoplasia	National Institutes No of Health/DHHS 21	DT-CA- 07-May- -057 2022	Not Specified		
	Contact Name	Ron Johnson, Ph.D.						
	Contact Telephone	240-276-6250						
	Contact Email	rjohnso2@mail.nih.gov						
	Sponsor Website	2						
	Program URL	Link to program URL						
	Deadline Dates (ALL) O7-May-2022, 05-Jun-2022, 16-Jun-2022, 07-Sep-2022, 05-Oct-2022, 16-Oct-2022, 07-Jan-2023, 05-Feb-2023, 16-Feb 2023, 07-May-2023 This Notice of Special Interest (NOSI) seeks applications investigating mechanistic and biological aspects of preneoplasia Synopsis Synopsis Reading to invasive lung and head and neck (HN) cancers. Despite having better molecular understanding of lung and HN cancers and improved therapies for affected patients, these tumors remain a major health problem in the United States (							

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadl	ine Date	Funding Amount
		and globa known ab addition, developm standard regulation cellular ch oncogenio	Illy. While molecular markers of bout the molecular mechanisms growing evidence highlights the nent. In recent years, immune-b therapies for many malignancie n of premalignancy, including lu nanges involved in the formatio c progression and accelerate de	f early injury of the aerodi that initiate these prener e importance of the intera pased therapies (especially es including lung and HN c ing and HN preneoplasias in and advancement of lur evelopment of effective, ra	gestive epithelial field oplasias and drive the action between the im , checkpoint inhibitor ancers. However, little . A functional understang and HN preneoplas	I have been ir progressio mune syste s) have com e is known a anding of th ias will enha	found, relat on to invasiv m and cance to the for about the im the key molec ance our kno d therapeuti	tively little is re cancer. In er refront of nmune cular and owledge of ic strategies.
103983	Notice of Special Interest (NOSI): Drug-Related Behaviors and Outo	Public Pol comes	icy Effects on Alcohol-, Cannab	is-, Tobacco-, and Other	National Institutes of Health/DHHS	NOT-AA- 21-028	07-May- 2022	Not Specified
	Contact Name Contact Telephone Contact Email Sponsor Website Program URL	Gregory B <u>Gregory.E</u> <u>Link to pr</u> 07-May-2	Bloss, M.A., M.P.P. Bloss@nih.gov ogram URL 022 , 05-Jun-2022 , 16-Jun-202	2 , 07-Sep-2022 , 05-Oct-2	2022 , 16-Oct-2022 , 0	7-Jan-2023 ;	, 05-Feb-202	23 , 16-Feb-
<ul> <li>O7-May-2022, 05-Jun-2022, 16-Jun-2022, 07-Sep-2022, 05-Oct-2022, 16-Oct-2022, 07-Jan-2023, 0</li> <li>Deadline Dates (ALL)</li> <li>2023, 07-May-2023, 05-Jun-2023, 16-Jun-2023, 07-Sep-2023, 05-Oct-2023, 16-Oct-2023, 07-Jan-2</li> <li>Feb-2024, 07-May-2024, 05-Jun-2024, 16-Jun-2024, 07-Sep-2024</li> <li>This announcement encourages applications to conduct research on the effects of public policies on behaviors and outcomes associated with alcohol, cannabis, tobacco, prescription drugs, and other su of the Notice is to advance understanding of how public policy may serve as a tool for improving pub through its effects on behaviors and outcomes pertaining to alcohol and other drugs. This Notice is ir innovative research to examine policy effects that have the potential to lead to meaningful changes i multiple public policies; evaluations of the effectiveness of specific public policies as tools for improving through their effects on alcohol-, cannabis-, tobacco-, and other substance-related behaviors and ou disparities in policy effects and the role of policy in exacerbating or potentially reducing health dispa advance methods and measurement used in studying relationships between public policies and alcol advance methods and measurement used outcomes</li> </ul>								eb-2024 , 16- ited The purpose and welfare support ealth. cts of one or health udies of research to ibis-, tobacco-

SPIN ID	Program Title		Sponsor Name	Sponsor Number		[	Deadlir	ne Date	Funding Amount
103986	Notice of Special Interest (NOSI):	: Early-life F	actors and Cancer Developme	nt Later in Life	National Institutes of Health/DHHS	NOT- 21-07	-CA- 74	07-May- 2022	Not Specified
	Contact Name								
	Contact Telephone								
	Contact Email								
	Sponsor Website								
	Program URL	Link to pro	ogram URL						
	Deadline Dates (ALL)	07-May-20 2022 , 07- 05-Oct-20	022 , 05-Jun-2022 , 16-Jun-202 Jan-2023 , 05-Feb-2023 , 16-Fe 23 , 16-Oct-2023 , 05-Nov-2023	2 , 24-Jun-2022 , 07-Sep-2 b-2023 , 07-Mar-2023 , 07 3 , 07-Jan-2024 , 05-Feb-2	022 , 05-Oct-2022 , 1 7-May-2023 , 05-Jun-2 024 , 16-Feb-2024 , 0	6-Oct-2 2023 , 2 7-Mar-	2022 , 2 16-Jun •2024	20-Oct-202 -2023 , 07-	22 , 08-Nov- Sep-2023 ,
	Synopsis	The purpo (maternal- life.	ose of this Notice of Special Inte -paternal, in utero, birth and in	erest (NOSI) is to stimulate Ifancy, puberty, adolescer	e research focused on nce, and young adult y	the ro vears) i	oles of e in canc	early-life fa er develop	actors ment later in
108483	Notice of Special Interest (NOSI):	COVID-19	Pandemic Mental Health Resea	arch	National Institutes of Health/DHHS	NOT- 22-10	-MH- 00	07-May- 2022	Not Specified
	Contact Name	Pim Brouv	vers, Ph.D.						
	Contact Telephone	240-627-3	863						
	Contact Email	<u>ebrouwer</u>	@mail.nih.gov						
	Sponsor Website	h -							
	Program URL	Link to pro	ogram URL						
	Deadline Dates (ALL)	07-May-20 2023 , 05- Oct-2023 , , 16-Jun-20	022 , 05-Jun-2022 , 15-Jun-202 Feb-2023 , 15-Feb-2023 , 16-Fe , 16-Oct-2023 , 17-Oct-2023 , 0 024 , 07-Sep-2024 , 05-Oct-202	2 , 16-Jun-2022 , 07-Sep-2 2b-2023 , 07-May-2023 , 0 17-Jan-2024 , 05-Feb-2024 24 , 16-Oct-2024 , 07-Jan-2	022 , 05-Oct-2022 , 1 5-Jun-2023 , 15-Jun-2 , 15-Feb-2024 , 16-Fe 2025	4-Oct-2 023 , 1 b-2024	2022 , : L6-Jun- 4 <i>,</i> 07-N	16-Oct-202 2023 , 07- May-2024 ,	22 , 07-Jan- Sep-2023 , 05- 05-Jun-2024
	Synopsis	NIMH is is services re to underst COVID-19, the pande	suing this Notice of Special Inte esearch relevant to the COVID- tand how mental illness contrik , and the development of scala emic both specifically related to	erest (NOSI) to highlight in 19 pandemic. NIMH is esp outes to COVID-19 risk and ble interventions to meet o the virus but also at a bro	terest in basic, transle becially interested in r d mortality, how incid the public mental hea bader population leve	ational esearc ent me alth ne I that i	l, interv h to pr ental ill eeds du is impa	vention an rovide an e Iness deve Iring and ro cted by sti	d vidence base ops with esulting from ress,

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Dead	line Date	Funding Amount
		disruptior treatmen populatio health dis	ns, and loss of lives in the pande t and prevention are also of inte ns based on existing evidence of parities.	emic. Research addressing erest to NIMH. Research i of increased mental health	g the intersection of Co s anticipated to focus n symptoms and illness	OVID-19, m on particul s and pree>	ental health arly vulnera isting and w	, and HIV ble vorsening
099505	Notice of Special Interest (NOSI):	Advancing	g the Science of Geriatric Palliat	ive Care	National Institutes of Health/DHHS	NOT-AG- 20-041	07-May- 2022	Not Specified
	Contact Name	Basil Elda	dah, M.D., Ph.D.					
	Contact Telephone	301-496-6	5761					
	Contact Email	<u>eldadahb</u>	<u>@nia.nih.gov</u>					
	Sponsor Website							
	Program URL	Link to pr	ogram URL					
	Deadline Dates (ALL)	Deadline Dates (ALL) 07-May-2022 , 05-Jun-2022 , 16-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 07-Ja 2023 , 07-May-2023 , 05-Jun-2023 , 16-Jun-2023 , 07-Sep-2023						
	Synopsis	This Notic populatio specialty a clinics and healthcar and media specimen observatio	e of Special Interest (NOSI) end ns. This NOSI covers studies in a medical or surgical wards, inter d doctors' offices, patients' hom e or community settings. This N cal records, claims data, or othe repositories, and other existing onal approaches, quasi-experim	ourages research grant a a variety of settings includ sive care units, and emer les and other residential s IOSI encourages both pro er sources. Leveraging ong g research resources and hental designs, and interv	pplications focused on ding hospitals (and spe gency departments), p settings, long-term car spective studies and a going cohorts, interver infrastructure is encou entional studies.	palliative of cific sites v post-acute e facilities, nalyses of of ntion studie traged. Stud	care in geria vithin hospit care setting hospices, an existing data es, networks dy designs n	tric sals including s, outpatient nd other sets, health , data and nay include
105890	Notice of Special Interest (NOSI):	Precision	Imaging of Oral Lesions		National Institutes of Health/DHHS	NOT-DE- 21-010	07-May- 2022	Not Specified
	Contact Name	Zhong Ch	en, MD, PhD					
	Contact Telephone	301-529-7	7083					
	Contact Email	zhong.che	en@nih.gov					
	Sponsor Website							
	Program URL	Link to pr	ogram URL					



SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadli	ne Date	Funding Amount
	Deadline Dates (ALL)	07-May-2 2023 , 07 Feb-2024	2022 , 05-Jun-2022 , 16-Jun-202 -May-2023 , 05-Jun-2023 , 16-Ju - , 07-May-2024 , 05-Jun-2024 ,	2 , 07-Sep-2022 , 05-Oct-2 un-2023 , 07-Sep-2023 , 0 16-Jun-2024 , 07-Sep-202	2022 , 16-Oct-2022 , 07 5-Oct-2023 , 16-Oct-20 4	7-Jan-2023 , )23 , 07-Jan-	05-Feb-202 2024 , 05-F	23 , 16-Feb- <sup>-</sup> eb-2024 , 16-
	Diagnosing and treating lesions of the oral cavity and oropharynx are challenging due to reliance on subjective a clinical features and histopathological diagnostic criteria. High resolution and quantitative tools are needed to e precision of diagnostic approaches for oral pathologies to guide options for treatment. This Notice of Special Interest is to encourage research projects that develop, adapt, optimize, and validate imaging-based applications and da tools to enhance oral disease detection, diagnosis, and treatment. The long-term goal is to facilitate translation findings into clinical practice, paving the way for personalized health care through objective measures that pronaccurate and timely diagnosis, targeted therapies, and improved patient survival and quality of life.							analyses of enhance the terest (NOSI) ata analysis of research mote
106848	Notice of Special Interest (NOSI): Disparities	Biologic F	actors Underlying Dental, Oral,	and Craniofacial Health	National Institutes of Health/DHHS	NOT-DE- 21-013	07-May- 2022	Not Specified
	Contact Name	Hiroko lio	da, DDS, MPH					
	Contact Telephone	301-594-	7404					
	Contact Email	hiroko.iic	la@nih.gov					
	Sponsor Website							
	Program URL	Link to pr	rogram URL					
	Deadline Dates (ALL)	07-May-2 2023 , 07 Feb-2024	2022 , 05-Jun-2022 , 16-Jun-202 -May-2023 , 05-Jun-2023 , 16-Ju - , 07-May-2024 , 05-Jun-2024 ,	2 , 07-Sep-2022 , 05-Oct-2 un-2023 , 07-Sep-2023 , 0 16-Jun-2024 , 07-Sep-202	2022 , 16-Oct-2022 , 07 5-Oct-2023 , 16-Oct-20 4 , 05-Oct-2024 , 16-O	/-Jan-2023 , )23 , 07-Jan- ct-2024 , 07	05-Feb-202 2024 , 05-F -Jan-2025	23 , 16-Feb- <sup>-</sup> eb-2024 , 16-
	Synopsis	The Natio encourag immune,	onal Institute of Dental and Crar research studies designed to genetic) contribute to disparition	niofacial Research (NIDCR) identify and understand t es in dental, oral, and crar	) is issuing this Notice ( he mechanisms by whi niofacial disease onset,	of Special In ch biologic progressio	terest (NOS factors (mion n, and pers	31) to crobial, istence.
094050	NIH Small Research Grant Progra	m (Parent	RO3 Clinical Trial Not Allowed)		National Institutes of Health/DHHS	PA-20-200	07-May- 2022	100,000 USD
	Contact Name							
	Contact Telephone							
	Contact Email	grantsinf	<u>o@nih.gov</u>					
	Sponsor Website							

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline	Date	Funding Amount
	Program URL L	ink to program URL					
	Deadline Dates (ALL) 0	07-May-2022 , 16-Jun-2022 , 07-Sep-202	2 , 16-Oct-2022 , 07-Jan-2	023 , 16-Feb-2023 , 07-	May-2023		
	T w a Synopsis ti w S fi	The NIH Small Research Grant Program s with limited resources. This program sup analysis of existing data; small, self-conta of new research technology. This Funding rial(s). Note: Not all NIH Institutes and C which ICs participate in this announceme scientific Interests and Contact website. unding.	upports small research proports different types of prained research projects; de g Opportunity Announcen enters (ICs) participate in ent and view their respection ICs that do not participate	ojects that can be carri rojects including pilot a evelopment of research nent does not accept a Parent Announcement ive areas of research in e in this announcement	ed out in a sh nd feasibility n methodolog oplications pr s. Applicants terest at the will not cons	ort perio studies; s gy; and de oposing o should ca R01 IC-Sp ider appl	d of time secondary evelopment clinical arefully note becific ications for
103541	Notice of Special Interest (NOSI): R and Services within Employment a	esearch on Strategies to Enhance Menta nd Job Training Settings	al Health Interventions	National Institutes of Health/DHHS	NOT-MH- 0 21-230 2	07-May- 2022	Not Specified
	Contact Name S	tephen O'Connor, Ph.D.					
	Contact Telephone 3	801-480-8366					
	Contact Email <u>s</u>	tephen.o'connor2@nih.gov					
	Sponsor Website						
	Program URL <u>L</u>	ink to program URL					
	Deadline Dates (ALL) 2	07-May-2022 , 05-Jun-2022 , 15-Jun-202 2023 , 05-Feb-2023 , 15-Feb-2023 , 16-Fe	2 , 16-Jun-2022 , 07-Sep-2 b-2023 , 07-May-2023 , 0	022 , 05-Oct-2022 , 14- 5-Jun-2023 , 15-Jun-20	Oct-2022 , 16 23 , 16-Jun-20	5-Oct-202 023 <i>,</i> 07-9	2,07-Jan- Sep-2023
	T p u Synopsis u b s	The purpose of this Notice of Special Interpretent or treat mental health concerns, underemployed people participating in e ervice customers" or "customers"). Con unemployment raises concerns about the pehaviors, and suicide risk and necessitation trategies in this area.	erest (NOSI) is to encourag symptoms or disorders in mployment programs and sidering the COVID-19 par e development and worse tes further research to cor	ge research focused on acluding drug-related co d job training settings (r ademic, the sharp rise a aning of mental health s anfirm the efficacy or de	detection and onditions amo eferred to he ind potential ymptoms and monstrate ef	d interver ong unem ere as "en ly long du d disorde fectivene	ntion to poloyed and nployment iration of rs, drug use ess of
103732	Notice of Special Interest (NOSI): V Abuse/Dependence	Vomen and Sex/Gender Differences in D	rug and Alcohol	National Institutes of Health/DHHS	NOT-DA- 0 21-012 2	07-May-	Not Specified

Contact Name Keisher Highsmith, DrPH

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline I	Date	Funding Amount
	Contact Telephone							
	Contact Email	highsmith	nks@nih.gov					
	Sponsor Website	_	-					
	Program URL	Link to pr	ogram URL					
	Deadline Dates (ALL)	07-May-2 2023 , 07 Feb-2024	2022 , 05-Jun-2022 , 16-Jun-202 -May-2023 , 05-Jun-2023 , 16-Ju - , 07-May-2024 , 05-Jun-2024 ,	2 , 07-Sep-2022 , 05-Oct-2 un-2023 , 07-Sep-2023 , 09 16-Jun-2024 , 07-Sep-2024	022 , 16-Oct-2022 , 07-Ja 5-Oct-2023 , 16-Oct-2023 4	an-2023 , 05- 8 , 07-Jan-202	Feb-202 24 , 05-F	23 , 16-Feb- <sup>:</sup> eb-2024 , 16-
	Synopsis	The purpe grant app gender di misuse to advance r areas of c	ose of this Notice is to inform p plications to conduct rigorous ba ifferences in risk for substance o o uncover the mechanisms of th research specific to women or h drug and alcohol research.	otential applicants of the asic, translational and/or o use disorders or the respo ose differences, and to co highly relevant to women.	National Institute on Dru Ilinical research to: (1) ac nse or medical conseque nduct translational resea Both preclinical and clin	g Abuse (NID lvance identi inces of alcoh arch on those ical studies a	DA) spec fication nol or su e differe are soug	ial interest in of sex and/or Ibstance nces, and (2) tht across all
105365	Notice of Special Interest (NOSI): Outcomes at the Individual Patie	<u>Research</u> nt Level fo	to Improve the Interpretation on the Interpretation of the Interpr	of Patient-Reported	National Institutes N of Health/DHHS 2	OT-OD- 07 D-079 20	7-May- )22	Not Specified
	Contact Name	Ashley W	ilder-Smith, Ph.D., MPH					
	Contact Telephone	240-276-6	6714					
	Contact Email	<u>smithas@</u>	omail.nih.gov					
	Sponsor Website							
	Program URL	Link to pr	ogram URL					
	Deadline Dates (ALL)	07-May-2 2023 , 07-	2022 , 05-Jun-2022 , 16-Jun-202 -May-2023	2 , 07-Sep-2022 , 05-Oct-2	022 , 16-Oct-2022 , 07-Ja	an-2023 , 05-	Feb-202	23 , 16-Feb-
	Synopsis	A patient well-bein else. PRO and offer increasing individual importan	-reported outcome (PRO) is def g, that is gathered directly from s are critical for the support of important information to impr gly being used by clinical staken I patients' symptoms and function t piece of information for clinical	ined as any report of a pe a patient, without interp patient-centered care, as ove patient-clinician comr olders (e.g., providers, ca ional status and the chang al decision-making, includ	rson's health status inclu retation of that report by they provide information nunication, decision-mal re delivery systems, paye te in outcomes over time ing shared decision-mak	ding sympton a clinician, control from the pacting, and care ers and regula . Thus, PROs ng. The purp	ms, fun observe tient's j e delive ators) to are beo ose of t	ction and r, or anyone perspective, ry. PROs are o characterize coming an this Notice of

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Dead	line Date	Funding Amount			
		Special Interest (NOSI) is to stimulate re interpretation at the individual patient l	esearch that contributes to level for use in clinical prac	o the evidence base for ctice.	r precise and	d accurate P	RO score			
105363	Notice of Special Interest (NOSI)	: Integration of Individual Residential Hist	tories in Cancer Research	National Institutes of Health/DHHS	NOT-CA- 21-092	07-May- 2022	Not Specified			
	Contact Name	Zaria Tatalovich, Ph.D.								
	Contact Telephone	240-276-6976								
	Contact Email	tatalovichzp@mail.nih.gov								
	Sponsor Website									
	Program URL	Link to program URL								
	Deadline Dates (ALL)	07-May-2022 , 05-Jun-2022 , 16-Jun-202 2023 , 07-May-2023 , 05-Jun-2023 , 16-J Feb-2024 , 07-May-2024	22 , 07-Sep-2022 , 05-Oct- Jun-2023 , 07-Sep-2023 , 0	2022 , 16-Oct-2022 , 0 5-Oct-2023 , 16-Oct-2	7-Jan-2023 023 , 07-Jar	, 05-Feb-202 n-2024 , 05-F	23 , 16-Feb- eb-2024 , 10			
	Synopsis	This Notice of Special Interest (NOSI) se Sciences to support investigation of the residence over the life course - relative	his Notice of Special Interest (NOSI) seeks to highlight the interest of NCI's Division of Cancer Control and Population ciences to support investigation of the role of individual Residential Histories - a record of an individual's places of cience over the life course - relative to cancer risk, etiology, prevention, treatment, and outcomes.							
088092	NIBIB Trailblazer Award for New	and Early Stage Investigators (R21 Clinica	al Trial Optional)	National Institutes of Health/DHHS	PAR-20- 084	07-May- 2022	400,000 USD			
	Contact Name	Randy King, Ph.D.								
	Contact Telephone	301-451-0707								
	Contact Email	Randy.King@nih.gov								
	Sponsor Website									
	Program URL	Link to program URL								
	Deadline Dates (ALL)	07-May-2022 , 16-Jun-2022 , 07-Sep-20	22 , 16-Oct-2022 , 07-Jan-2	2023						
		This Trailblazer Award is an opportunity (https://grants.nih.gov/policy/early-invo	<pre> for NIH-defined New and estigators/index.htm) to p </pre>	Early Stage Investigat ursue research progra	ors ms of high i	nterest to th				

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadl	ine Date	Funding Amount
		prelimina if availabl independ limited to one figure	ry data. A distinct feature for th e, minimal preliminary data are ently produced and not yet pub one-half page, which may inclu e will be considered noncomplia	is FOA is that no prelimin allowed. Preliminary data lished in a peer-reviewed ide one figure. Application ant with the FOA instruction	ary data are required, o a are defined as materi I journal.All preliminary ns including data more ons and will not go fory	expected, al which th data shou than one- vard to rev	or encourag ne applicant Ild be clearl half page or view.	ged. However, t has y marked and r more than
103419	Notice of Special Interest (NOSI): Regimens to Promote Health	Improving	Patient Adherence to Treatme	nt and Prevention	National Institutes of Health/DHHS	NOT-OD- 21-100	07-May- 2022	Not Specified
	Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) Synopsis	Wendy Na 240-276-6 nelsonw@ Link to pr 07-May-2 2022, 14- Jun-2023 16-Feb-20 This Notic Social Scie research p outcomes Descriptiv including participat	elson, PhD, MPH 5971 <u>Omail.nih.gov</u> 022 , 05-Jun-2022 , 15-Jun-2022 Dec-2022 , 07-Jan-2023 , 05-Fe , 10-Aug-2023 , 07-Sep-2023 , 0 024 , 07-May-2024 , 05-Jun-202 ce of Special Interest (NOSI) is b ences Research (OBSSR) with pa grant applications that address s. Applications may address hea re and intervention research ma the patient, caregiver/family, p ing NIH Institutes and Centers a	2 , 16-Jun-2022 , 10-Aug-2 b-2023 , 15-Feb-2023 , 16 95-Oct-2023 , 16-Oct-2023 4 eing issued by the NIH Ad articipation from multiple patient adherence to trea lthcare regimen initiation ay address adherence det rovider, healthcare syster are detailed within.	2022 , 07-Sep-2022 , 05 5-Feb-2023 , 07-May-20 3 , 17-Oct-2023 , 07-Jan herence Network throu NIH Institutes, Centers atment and prevention , implementation, and/ erminants at one or mo n, and community leve	Oct-2022 23 , 05-Jun 2024 , 05 and Offic regimens or persisto re levels c s. The spe	, 14-Oct-20 n-2023 , 15- -Feb-2024 , fice of Beha es. This NO to promote ence by pat of ecologic i ecific resear	22 , 16-Oct- Jun-2023 , 16- 15-Feb-2024 , vioral and SI calls for health ients. nfluence, ch interests of
103312	Notice of Special Interest (NOSI): to Improve Health and Well-Being	Developir g	g and Testing Multilevel Physic	al Activity Interventions	National Institutes of Health/DHHS	NOT-OD- 21-087	07-May- 2022	Not Specified
	Contact Name Contact Telephone Contact Email Sponsor Website	Bramaran 301-435-8 bramaran	nba Kowtha MS, RDN, LDN 3052 <u>nba.kowtha@nih.gov</u>					

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadli	ne Date	Funding Amount
	Program URL Link to program URL							
	Deadline Dates (ALL)	07-May-2022 , 05-Jun-2022 , 16-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 LL) 2023 , 07-May-2023 , 05-Jun-2023 , 16-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 16-Oct-2023 , 07-Jan-2024 , 05-Fek Feb-2024						23 , 16-Feb- <sup>:</sup> eb-2024 , 16-
	- i Synopsis f f	The Office of Disease Prevention and participating ICOs are issuing this Notice to highlight our interest in encouraging highly nnovative and promising translational research to improve our understanding of how to increase and maintain health- enhancing physical activity using multi-level interventions in a wide range of population groups across the lifespan (e.g., ncluding racial and ethnic minorities, children, older adults, persons with medical/behavioral health conditions, and persons with disabilities). This includes efficacy, effectiveness and dissemination and implementation studies. It also includes support for pilot, exploratory, or developmental work in preparation for full-scale, fully powered efficacy studies, preliminary feasibility studies, as well as expanded feasibility work for a discrete, specified, circumscribed project that is based on well-established theory, existing data and evidence-based interventions.						
103244	Notice of Special Interest (NOSI): F Multiple Organ Dysfunction Syndr	Research ome in Cl	to Advance the Understanding hildren (R01, R21)	and Management of the	National Institutes N of Health/DHHS 2	OT-HD- 1-024	07-May- 2022	Not Specified
	Contact Name Robert Tamburro, MD, MSc							
	Contact Telephone	301-451-4	1295					
	Contact Email	robert.tar	<u>mburro@nih.gov</u>					
	Sponsor Website							
	Program URL	<u>Link to pr</u>	ogram URL					
	Deadline Dates (ALL)	07-May-2 2023 , 07·	022 , 05-Jun-2022 , 16-Jun-202 May-2023	2 , 07-Sep-2022 , 05-Oct-2	022 , 16-Oct-2022 , 07-J	an-2023 ,	05-Feb-202	23 , 06-Feb-
	- F Synopsis F Synopsis F Synopsis F Synopsis F Synopsis F Synopsis F Synopsis F Synopsis F Synopsis F Synopsis F Synopsis	The purpe preventio encounte by the fai processes Despite it years ago entity wit longitudir	ose of this Notice of Scientific Ir in and treatment of pediatric m red in the pediatric intensive ca lure or dysfunction of a consiste s and clinical insults, most notat s high prevalence and unfavora , it still can only be described as h a distinguishable cause. The c nal research. Applications may i	terest (NOSI) is to continu ultiple organ dysfunction are unit that is associated ent group of body organs of oly sepsis and trauma, and ble outcomes, this clinical is a "syndrome," a constell current lack of understand nclude any appropriate st	ue a program of research syndrome (MODS). MOI with significant morbidit or organ systems. It is tr I is frequently associated I entity remains poorly u ation of symptoms, rath ling underscores the nee udy design ranging from	to advan S is a clin y and mor ggered by with unconderstood er than as d for more basic scie	ce the und ical conditi rtality. It is a wide rar ontrolled ir d. First desc a specific p e basic, exp ence and an	erstanding, on commonly characterized nge of disease nflammation. cribed over 40 pathologic oloratory and nimal models
SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadl	ine Date	Funding Amount
--	-----------------------------------	---	--	---	---	--	---	--
		through p outcomes applicatic on this No	prospective randomized control s will improve both in terms of on in response to this NOSI are s OSI in advance of the application	lled trials. It is hoped that the prevention and treatm strongly encouraged to co n due date.	as a result of research nent of MODS in childr ntact the NICHD scien	solicited th en. Applica :ific/progra	rrough this nts plannin mmatic cor	NOSI, g to submit an ntact(s) listed
100292	Discovery of Cell-based Chemica	l Probes fo	r Novel Brain Targets (R21 Clini	cal Trial Not Allowed)	National Institutes of Health/DHHS	PAR-21- 028	07-May- 2022	275,000 USD
	Contact Name	Enrique L	. Michelotti, Ph.D.					
	Contact Telephone	301-443 5	5415					
	Contact Emai	michelott	iel@mail.nih.gov					
	Sponsor Website	N.						
	Program URL	Link to pr	ogram URL					
Deadline Dates (ALL) 07-May-2022 , 16-Jun-2022 , 07-Sep-2022 , 16-Oct-2022 , 07-Jan-2023 , 16-Feb-2023 , 07-May-2023 , 16-Jun-2023 , 07- 2023 , 16-Oct-2023 , 07-Jan-2024							023 , 07-Sep-	
	Synopsis	The purper to join eff in hand, t compoun for their p discovery be placed main emp interested	ose of this Funding Opportunity forts for the discovery of cell-back he starting compounds ("valida ds. Through this FOA, NIH wish potential use in understanding and/or validation of novel, bio on projects that provide new i phasis of projects submitted un d in developing in vivo chemica	Announcement (FOA) is t ased chemical probes for r ated hits") for chemical op es to stimulate research ir biological processes releva logical targets that will inf nsight into important dise der this FOA should be the I probes may wish to apply	to support investigator novel brain targets. It is timization and bioassa n: 1) discovery and dev ant to the missions of I form studies of brain d base-related biological e discovery of cell-base y using the companion	s who have s expected ys for testi elopment o NIMH, NIDA isease mec targets and ed chemical R01 mech	e interest ar that applica ng new ana of novel, sm A, NEI and/c hanisms. Er I biological I probes. Ap anism, (PAR	nd capability ants will have, log nall molecules or NIA; and 2) mphasis will processes. The oplicants R-21-029).
105732	Notice of Special Interest (NOSI)	: Immune F	Responses to Arthropod Feedin	<u>g on Vertebrate Hosts</u>	National Institutes of Health/DHHS	NOT-AI- 21-059	07-May- 2022	Not Specified
	Contact Name	Qian "Joy	" Liu, M.D., MSc.					
	Contact Telephone	301-761-6	5621					
	Contact Emai	<u>liujoy@ni</u>	aid.nih.gov					
	Sponsor Website							
	Program URL	Link to pr	ogram URL					

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadli	ne Date	Funding Amount
	0 Deadline Dates (ALL) 2 Fi	7-May-2 023 , 07- eb-2024	022 , 05-Jun-2022 , 16-Jun-202 -May-2023 , 05-Jun-2023 , 16-Ju , 07-May-2024 , 05-Jun-2024 ,	2 , 07-Sep-2022 , 05-Oct-2 In-2023 , 07-Sep-2023 , 05 16-Jun-2024 , 07-Sep-2024	022 , 16-Oct-2022 , 07 5-Oct-2023 , 16-Oct-202 4	Jan-2023 , 3 , 07-Jan	05-Feb-202 -2024 , 05-F	23 , 16-Feb- eb-2024 , 16-
	This Notice of Special Interest (NOSI) solicits transdisciplinary research projects to understan vertebrate host that occur at the bite site (skin) and systemically during and after feeding by ectoparasitic arthropods. Exploratory research on arthropod blood feeding was formerly sup expired FOA, PAR-18-860, "Immune Response to Arthropod Blood Feeding (R21 Clinical Trial NOSI is to indicate continued NIAID support for research in this area as described below thro R01 and R21 FOAs.Research Enhancement Award Program (REAP) for Health Professional Schools and GraduateNational Institutes						nmunologic ophagous a by NIAID th owed). The plications to	events in the nd irough the intent of this o the parent
108327	Research Enhancement Award Prop Schools (R15 Clinical Trial Required	gram (RE )	EAP) for Health Professional Sch	ools and Graduate	National Institutes I of Health/DHHS	PAR-21- 357	07-May- 2022	300,000 USD
	Contact Name N	lahua M	lukhopadhyay, Ph.D.					
	Contact Telephone 3	01-435-6	5886					
	Contact Email <mark>n</mark>	<u>ukhopa</u>	m@mail.nih.gov					
	Sponsor Website							
	Program URL L	<u>nk to pr</u>	ogram URL					
	Deadline Dates (ALL) 2	7-May-2 023 , 25	022 , 25-Jun-2022 , 07-Sep-202 -Oct-2023 , 07-Jan-2024 , 25-Fe	2 , 25-Oct-2022 , 07-Jan-2 b-2024 , 07-May-2024 , 25	023 , 25-Feb-2023 , 07- 5-Jun-2024 , 07-Sep-202	May-2023 4 , 25-Oct	, 25-Jun-20 -2024 , 07-J	23 , 07-Sep- an-2025
	T o e Synopsis d f t a c c l c l c l c l c l c l c l c l c l	he purpo o suppor n provid nhancing cience do osts) in 4 ased on etermin unding o ddressin inical tri ow risks	ose of the Research Enhancement of small scale research grants at ing biomedical research experie g the research environment at a egrees and have received no me of the last 7 fiscal years. For in the amount of NIH funding rece ing the Organization Funding Le pportunity announcement (FO/ g the mission and research inter fals are defined as those that do to potentially cause physical or	ent Award Program (REAP) institutions that do not re ences primarily for health applicant institutions. Eligi ore than \$6 million dollars stitutions composed of m evel can be found here or l A) supports investigator-in rests of the participating o not require FDA oversigh psychological harm.	for Health Professiona eceive substantial fundin professional, undergrad ble institutions must av s per year of NIH suppor ultiple schools and colle d colleges within the in https://grants.nih.gov/g nitiated mechanistic and NIH institutes. For purp at, do not intend to form	I Schools a ng from th duate and vard bacca t (in both eges, the \$ stitution a grants/fun l/or minim oses of thi nally estab	Ind Graduat e NIH, with graduate st alaureate or direct and F 6 million fu s a whole. F ding/r15.ht al risk clinic s FOA, mini lish efficacy	e Schools is an emphasis udents and advanced &A/indirect nding limit is Help m. This REAP cal trials mal risk <i>y</i> , and have

SPIN ID	Program Title		Sponsor Name	Sponsor Number		D	eadline	e Date	Funding Amount
102638	New Directions in Hematology Re	esearch (SI	HINE-II) (R01 Clinical Trial Optio	nal)	National Institutes of Health/DHHS	PAS-2 150	1- ( 2	07-May- 2022	600,000 USD
	Contact Name	Shilpa Hat	ttangadi, M.D.						
	Contact Telephone	301-594-7	7726						
	Contact Email	shilpam.h	pam.hattangadi@nih.gov						
	Sponsor Website								
	Program URL	Link to pr	ogram URL						
	Deadline Dates (ALL)	07-May-2 2023 , 05-	.022 , 05-Jun-2022 , 07-Sep-202 -Oct-2023 , 07-Jan-2024 , 05-Fe	2 , 05-Oct-2022 , 07-Jan-2 b-2024 , 07-May-2024	023 , 05-Feb-2023 , 07	7-May-2	2023,(	05-Jun-20	23 , 07-Sep-
	Synopsis	This Fund that will s focused ir concepts	Funding Opportunity Announcement (FOA) seeks innovative grant applications in nonmalignant hematology research will steer the field in new directions. Applications to this FOA should propose proof of principle research that is tightly sed into one specific aim, which can be accomplished within a 1-3 year project period, and is directed at validating nov epts and approaches that promise to open new pathways for discovery.						
105050	Notice of Special Interest (NOSI): Diagnosis, Assessments, Interven Syndrome Across the Lifespan (R2	Use of Dig tions, Mar 21 Clinical	gital Technology and Mobile He nagement and Outcomes for Ind Trial Not Allowed)	alth (mHealth) to Improve dividuals with Down	National Institutes of Health/DHHS	NOT-0 21-092	DD- 0 2 2	07-May- 2022	Not Specified
	Contact Name	Sujata Ba	rdhan, Ph.D.						
	Contact Telephone	301-435-0	0471						
	Contact Email	sujata.bar	rdhan@nih.gov						
	Sponsor Website								
	Program URL	Link to pr	ogram URL						
	Deadline Dates (ALL)	07-May-2 2023 , 16-	022 , 16-Jun-2022 , 07-Sep-202 -Oct-2023	2 , 16-Oct-2022 , 07-Jan-2	023 , 16-Feb-2023 , 07	7-May-2	2023,1	16-Jun-20	23 , 07-Sep-
	Synopsis	This Notice invites applications specifically aimed at developing or building upon existing technological tools to improve Synopsis diagnosis, assessments, interventions, management, and outcomes for infants, children, adolescents and adults with Down Syndrome.							improve s with Down
106126	Notice of Special Interest (NOSI): Underserved and Vulnerable Pop	Social, Bel ulations	havioral, and Economic Impact	of COVID-19 in	National Institutes of Health/DHHS	NOT-N 21-33	ИН- ( 0 2	07-May- 2022	Not Specified

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Contact Name Contact Telephone Contact Email Sponsor Website Program URL	Adam Ha <u>haima@r</u> <u>Link to pr</u> 07-May-2 2022 , 16	im, Ph.D. <u>nail.nih.gov</u> rogram URL 2022 , 05-Jun-2022 , 07-Jun-202 -Oct-2022 , 07-Jan-2023 , 05-Fe	2 , 15-Jun-2022 , 16-Jun-2 b-2023 , 07-Feb-2023 , 15	2022 , 07-Sep-2022 , 04-Oc 5-Feb-2023 , 16-Feb-2023	ct-2022 , 05-Oct-20 , 07-May-2023 , 05	22 , 14-Oct- JJun-2023 , 06-
		Jun-2023 05-Feb-20 NIH Instit	, 15-Jun-2023 , 16-Jun-2023 , 0 024 , 06-Feb-2024 , 15-Feb-2024 cutes, Centers, and Offices parti	7-Sep-2023 , 03-Oct-2023 4 , 16-Feb-2024 , 07-May- cipating in the Social, Beh	, 05-Oct-2023 , 16-Oct-20 2024 , 05-Jun-2024 , 16-Ju avioral, and Economic Im	)23 , 17-Oct-2023 , un-2024 , 07-Sep-2 pacts of COVID-19	07-Jan-2024 , 024 in Vulnerable
	Synopsis	and Healt strengthe more effe supporte experienc impacts o level inte sustainab large-scal vaccinatio and econ and vulne pandemic mitigatio	th Disparity Populations initiative en the understanding and respo- ectively for future public health d by other funding opportunities ce health disparities and in vuln of interventions, particularly the rventions in healthcare settings bility of services that are utilized le data sources with broad popu- ons, masking, and physical dista- omic impacts, and assess the de- erable populations. Additionally c and subsequent social and eco- n strategies.	ve are issuing this Notice of inse to the Coronavirus Di emergencies. While resea es, there are additional un erable populations. The p base under the umbrella of to address access, reach, I during and following the ulation coverage to impro- uncing to inform the public pownstream health and he to the use of large-scale da phomic changes is needed	of Special Interest (NOSI) to sease 2019 (COVID-19) para arch related to the direct of gent public health needs, purpose of this Notice is to digital health, as well as of delivery, engagement, eff pandemic, and 2) encour ve prediction of various m c health response) on tran althcare access effects, wi ta sources to study the in d to understand the costs a	o highlight interes indemic and help u clinical effects of C particularly in pop 1) emphasize the ommunity-engage fectiveness, scalab age the leveraging nitigation efforts (in smission reduction ith an emphasis on direct health impa and benefits of var	: in research to s prepare OVID-19 are Jlations who roles and d and multi- ility, and of existing ncluding n and on social underserved cts of the ious COVID-19
106119	Small Grants for New Investigato Trial Optional)	<u>rs to Prom</u>	note Diversity in Health-Related	Research (R21 Clinical	National Institutes PA of Health/DHHS 31	R-21- 07-May- 3 2022	375,000 USD
	Contact Name	Katrina J.	Serrano, Ph.D.				
	Contact Telephone	301-480-	7855				
	Contact Email	katrina.se	errano@nih.gov				

Sponsor Website

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadli	ne Date	Funding Amount
	Program LIPI	Link to pr	ogram LIPI					
	Program OKL	1111111000000000000000000000000000000	$\frac{\text{Ogrann OKL}}{1022} = 16 - 100 - 2022 = 07 - 560 - 202$	2 16-Oct-2022 07-lan-2	022 16-Eab-2022 07-	May_2022	16-lun-20	122 07-Son-
	Deadline Dates (ALL)	2023, 16·	-Oct-2023 , 07-Jan-2024 , 16-Fe	b-2024 , 07-May-2024 , 16	6-Jun-2024 , 07-Sep-202	4 4	, 10-Jun-20	J25,07-Sep-
	Synopsis	backgrounds, including from groups nationally underrepresented in biomedical, clinical, behavioral and social research, to conduct small research projects in the scientific mission areas of the National Institute of Diabet and Kidney Diseases (NIDDK), the National Human Genome Research Institute (NHGRI) or the National Instit Biomedical Imaging and Bioengineering (NIBIB). New investigators at the time of award under this FOA will h than \$125,000 direct costs of combined research funding (excluding NIH training and NIH career awards). Th support small research projects that can be carried out in a short period of time with limited resources and s transition to research independence. The R21 grant mechanism supports different types of projects includin feasibility studies; secondary analysis of existing data; small, self-contained research projects; development methodology; and development of new research technology.						n diverse sciences and Digestive e of ve had less R21 will eks to facilitate bilot and research
106131	Notice of Special Interest (NOSI): Cohorts and Datasets in Order to Aging Research	<u>Maximizir</u> Address R	ng the Scientific Value of Second Research Gaps and Foster Additi	dary Analyses of Existing ional Opportunities in	National Institutes N of Health/DHHS 2	NOT-AG- 1-020	07-May- 2022	Not Specified
	Contact Name	Rosalv Co	prrea-de-Arauio. MD. MSc. Ph.D					
	Contact Telephone	, 301-496-6	6762					
	Contact Email	rosaly.cor	rrea-de-Araujo@nih.gov					
	Sponsor Website							
	Program URL	Link to pr	ogram URL					
	Deadline Dates (ALL)	07-May-2 2023 , 07·	.022 , 05-Jun-2022 , 16-Jun-202 -May-2023	2 , 07-Sep-2022 , 05-Oct-2	022 , 16-Oct-2022 , 07	an-2023 ,	05-Feb-202	23 , 16-Feb-
	Synopsis	The goal of secondary changes in (AD/ADRI impacts of biological design an	of this Notice of Special Interest y analyses to investigate novel s nfluencing health across the life D)), (2) diseases and disabilities on health (the hallmarks of aging research, clinical aging researc d implementation of future epi	(NOSI) is to encourage the scientific ideas and/or add espan (e.g., Alzheimer's di in older persons, and/or ( g). Activities of high priorit h, behavioral or social res demiologic or human inte	te use of existing cohort lress clinically related is: sease and Alzheimer's d 3) the changes in basic ty include those address earch, and/or translatio rvention studies; interv	s and data sues on: (1 isease-rela biology of sing specifi nal gerosc entions in	esets for we added demen aging that ic hypothes ience to in animal mo	ell-focused ntias underlie these ses in basic form: the dels of aging;

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline	e Date	Funding Amount
		research practice i relationsh also be us gender di gender m for Medic are stron approach developm very stron	on behavioral and social factors n maintenance of health, diseas hips between rates of aging and sed to develop and test new ma fferences across health disparit inorities) are of high relevance. care and Medicaid Services (CM gly encouraged to describe plan es (see Goal 3, NIH Strategic Plan nental projects should consider ng and well-developed scientific	s over the life course that se management, and prev findings extracted by sec athematical modeling and y groups (e.g., racial and e Use of cohorts that are lin S) administrative data are as for rapid sharing of data an For Data Science). Pleas using PA-20-195, whereas premise should use PA-2	influence health (e.g., ea ention of disability; or re ondary analysis of the ex statistical analytical app ethnic groups, socioecon nked to electronic health especially welcome. App and results as well as in se note that applications s projects that already ha 0-185.	rly life adve search test isting data coaches. Ar omic status record sys olicants res novative da proposing ve sufficier	ersity); cu ing of pos . Existing halyses of s, and sex stems and ponding t ata analyt explorato nt prelimi	rrent geriatric ssible causal datasets may sex and/or ual and l/or Centers to this NOSI tics ory or nary data or a
106966	Notice of Special Interest (NOSI): Outcomes	Somatic C	Cell Gene Editing Therapies To Ir	mprove Transplantation	National Institutes N of Health/DHHS 2	OT-AI- ( L-080 2	07-May- 2022	Not Specified
	Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) Synopsis	Nasrin Na 240-627-3 nnabavi@ Link to pr 07-May-2 2023 , 07 Feb-2024 The Natic gene edit islet, or va clinical us	abavi, Ph.D. 3538 2000 2002 , 05-Jun-2022 , 16-Jun-2023 -May-2023 , 05-Jun-2023 , 16-Ju - 07-May-2024 , 05-Jun-2024 , 10 2000 2010 2010 2010 2010 2010 2010 2	2 , 07-Sep-2022 , 05-Oct-2 Jn-2023 , 07-Sep-2023 , 05 16-Jun-2024 , 07-Sep-2024 ctious Diseases (NIAID) is ove graft survival and outc (VCA) transplants in anim	022 , 16-Oct-2022 , 07-J 5-Oct-2023 , 16-Oct-2023 4 , 05-Oct-2024 , 16-Oct- interested in supporting omes for recipients of al al models or human tissu	an-2023 , 0 5 , 07-Jan-2 2024 , 07-J research th logenic soli les or organ	5-Feb-202 024 , 05-F an-2025 nat applie d organ, j ns exclude	23 , 16-Feb- <sup>-</sup> eb-2024 , 16- s somatic cell pancreatic ed from
107787	Notice of Special Interest (NOSI): Nicotine and Tobacco Delivery Sy	Electronic stems: Ba	Nicotine Delivery Systems (EN sic Mechanisms of Health Effec	DS) and Alternative ts	National Institutes N of Health/DHHS 2	OT-OD- ( 2-022 2	07-May- 2022	Not Specified
	Contact Name Contact Telephone	Ron John 240-276-0	son, Ph.D. 6250					

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount	
	Contact Email	rjohnso2	@mail.nih.gov					
	Sponsor Website							
	Program URL	Link to pr	ogram URL					
	Deadline Dates (ALL)	07-May-2 2022 , 07	2022 , 05-Jun-2022 , 16-Jun-202 -Jan-2023 , 05-Feb-2023 , 16-Fe	2 , 24-Jun-2022 , 11-Jul-20 b-2023 , 10-Mar-2023 , 07	22 , 07-Sep-2022 , 05-O '-May-2023	ct-2022 , 16-Oct-2	022 , 20-Oct-	
	Synopsis	The Office of Disease Prevention and participating ICOs are issuing this Notice to communicate our interest in research examining how electronic nicotine delivery systems (ENDS) affect normal and disease states relevant to human cells, tissue organs, and behaviors. Research on alternative nicotine and tobacco delivery systems [e.g., heated tobacco products (also called heat-not-burn)] will also be considered. Studies exclusively examining smokeless tobacco or combustible tobacco products (e.g., cigarettes, cigars) will be considered non-responsive.						
108008	Notice of Special Interest (NOSI):	Research	to Address Vaccine Hesitancy,	Uptake, and	National Institutes N	OT-MD- 07-Ma	y- Not	
100000	Implementation among Populatio	ons that Ex	xperience Health Disparities		of Health/DHHS 2	2-006 2022	Specified	
	Contact Name	Deborah	E. Linares, Ph.D., M.A.					
	Contact Telephone	301-402-2	2516					
	Contact Email	<u>deborah.</u>	linares@nih.gov					
	Sponsor Website							
	Program URL	Link to pr	ogram URL					
	Deadline Dates (ALL)	07-May-2	2022 , 05-Jun-2022 , 08-Jun-202	2 , 07-Sep-2022 , 05-Oct-2	022 , 08-Nov-2022 , 07	lan-2023		
This Notice of Special Interest (NOSI) highlights the need for research on strategies, and interventions to address vaccine hesitancy, uptake, and implementation among populations who experience health disparities in the US and its territories. Research is needed to understand and address misinformation, distrust, and hesitancy regarding uptake of vaccines (e.g. SARS-CoV-2, pneumococcal, influenza, hepatitis B, human papilloma virus (HPV)) among adults in the United States and territories, especially in populations at increased risk for morbidity and mortality due to long-standing systemic health and social inequities and chronic medical conditions. This NOSI is focused on adults 18 years and older except for SARS-CoV-2, and HPV-related vaccine topics, which may include eligible children and adolescents. The purpose of this NOSI is to solici research to: 1) evaluate community-engaged interventions (e.g., expand reach, increase access, address psychosocial barriers) to facilitate vaccination uptake in clinical and community contexts; 2) evaluate organizational, local, state, and federal policies and initiatives that mitigate or exacerbate disparities in vaccine access, uptake, and series completion, and understand and address barriers to increasing reach, access, and uptake of vaccinations among populations who experies health disparities.								

SPIN ID	Program Title		Sponsor Name	Sponsor Number		D	eadlin	e Date	Funding Amount
101367	Notice of Special Interest (NOSI):	<u>Use of Hu</u>	man Connectome Data for Seco	ondary Analysis	National Institutes of Health/DHHS	NOT-N 21-17	МН- 5	07-May- 2022	Not Specified
	Contact Name	Yvonne B	ennett, Ph.D.						
	Contact Telephone	301-222-7	7094						
	Contact Email	<u>yvonne.b</u>	ennett@nih.gov						
	Sponsor Website								
	Program URL	Link to pr	ogram URL						
	Deadline Dates (ALL)	07-May-2 2023 , 07- Feb-2024	022 , 05-Jun-2022 , 16-Jun-202 May-2023 , 05-Jun-2023 , 16-Ju , 07-May-2024	2 , 07-Sep-2022 , 05-Oct-2 un-2023 , 07-Sep-2023 , 05	022 , 16-Oct-2022 , 07 5-Oct-2023 , 16-Oct-20	'-Jan-2( )23 , 07	023 , C 7-Jan-2	95-Feb-202 2024 , 05-F	23 , 16-Feb- Feb-2024 , 16-
	Synopsis	NIMH and secondary Human Co originally complex i processes developm and clinic website: I	d participating institutes/center y analyses of data from the Hun onnectome projects and the Hu collected the data are encourag nterrelationships among: brain s; environmental factors; life ev tent, aging, or disease. Details a al and behavioral assessments, nttps://www.humanconnectom	is (ICs) listed above are issuman Connectome Project ( iman Connectomes Relate ged to apply. The analyses structure, function and content, social and psychosocial about the "Lifespan" and " can be found at the Connection he.org/ and at the NIMH D	uing this Notice of Spe HCP) including the mu d to Human Disease. / will serve to generate onnectivity; cognitive, al factors; genomic da Disease" Connectome ectome Coordinating I ata Archive (NDA) ww	cial Int Itiple c Applica and e affectiv ta, and s, inclu Facility w.nda.	terest datase ants be evaluat ve, ser d clinic uding r .nih.gc	(NOSI) to o ts in the Li eyond the e hypothe nsory and al sympto neuroimag	encourage ifespan groups that eses about the motor ms during ing protocols
101300	Notice of Special Interest (NOSI):	Use of Hu	man Connectome Data for Seco	ondary Analysis	National Institutes of Health/DHHS	NOT-N 21-075	МН- 5	07-May- 2022	Not Specified
	Contact Name	Yvonne B	ennett, Ph.D.						
	Contact Telephone	301-222-7	7094						
	Contact Email	<u>yvonne.b</u>	ennett@nih.gov						
	Sponsor Website								
	Program URL	Link to pr	ogram URL						
	Deadline Dates (ALL)	07-May-2 2023 , 07- Feb-2024	022 , 05-Jun-2022 , 16-Jun-202 May-2023 , 05-Jun-2023 , 16-Ju , 07-May-2024	2 , 07-Sep-2022 , 05-Oct-2 In-2023 , 07-Sep-2023 , 05	022 , 16-Oct-2022 , 07 5-Oct-2023 , 16-Oct-20	'-Jan-2( )23 , 07	023 , C 7-Jan-2	95-Feb-202 2024 , 05-F	23 , 16-Feb- eb-2024 , 16-

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadl	ine Date	Funding Amount
	Synopsis	NIMH an secondary Human Co originally complex i processes developm and clinic website: l	d participating institutes/cente y analyses of data from the Hur onnectome projects and the Hu collected the data are encoura interrelationships among: brain s; environmental factors; life ev nent, aging, or disease. Details a al and behavioral assessments, https://www.humanconnector	rs (ICs) listed above are iss nan Connectome Project ( iman Connectomes Relate ged to apply. The analyses structure, function and co ent, social and psychosoci bout the "Lifespan" and " can be found at the Conn- ne.org/ and at the NIMH D	suing this Notice of Sp HCP) including the ma od to Human Disease. will serve to generat onnectivity; cognitive, al factors; genomic da Disease" Connectome ectome Coordinating ata Archive (NDA) wa	ecial Intere ultiple datas Applicants I e and evalu affective, s ata, and clin es, including Facility ww.nda.nih.	st (NOSI) to sets in the Li beyond the ate hypothe ensory and ical sympton g neuroimag gov.	encourage fespan groups that ses about the motor ms during ing protocols
104865	Notice of Special Interest (NOSI):	Navigatin	g Pediatric to Adult Health Care	:: Lost in Transition	National Institutes of Health/DHHS	NOT-HD- 21-027	07-May- 2022	Not Specified
	Contact Name	Sonia Lee	, PhD					
	Contact Telephone	301-594-4	4783					
	Contact Email	leesonia@	omail.nih.gov					
	Sponsor Website							
	Program URL	Link to pr	ogram URL					
	Deadline Dates (ALL)	07-May-2 2023 , 16- 05-Nov-20	022 , 05-Jun-2022 , 16-Jun-202 -Feb-2023 , 07-Mar-2023 , 07-N 023 , 07-Jan-2024	2 , 07-Sep-2022 , 05-Oct-2 1ay-2023 , 05-Jun-2023 , 1	022 , 16-Oct-2022 , 08 6-Jun-2023 , 07-Sep-2	3-Nov-2022 023 , 05-Oo	, 07-Jan-202 t-2023 , 16-	23 , 05-Feb- Oct-2023 <i>,</i>
	Synopsis	The purpo pediatric Research care trans encourag	ose of this Notice of Special Intention health care transition for youth applications that will advance of sitions (HCT) from pediatric to a ed. The ultimate goal is to impression of the section of the	erest (NOSI) is to encourag with chronic physical/me our understanding of prom idult care settings as well a ove care quality and patie	ge applications in high dical conditions or int hising practices desigr as barriers and facilita nt and family outcom	-priority res ellectual/de ed to facilit tors to such es during a	search areas evelopment ate success n transition a nd after HCT	related to al disabilities. ful health are
107763	Notice of Special Interest (NOSI): Nicotine and Tobacco Delivery Sy Health Effects	Electronic stems: Po	Nicotine Delivery Systems (EN pulation, Clinical and Applied P	DS) and Alternative revention Mechanisms of	National Institutes of Health/DHHS	NOT-OD- 22-023	07-May- 2022	Not Specified
	Contact Name	Rachel Gr	ana Mayne, PhD, MPH					
	Contact Telephone	240-276-5	5899					



SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline	e Date	Funding Amount
	Contact Email	rachel.ma	ayne@nih.gov					
	Sponsor Website							
	Program URL	Link to pr	ogram URL					
	Deadline Dates (ALL)	07-May-2 2022 , 08 16-Jun-20 2024	2022 , 05-Jun-2022 , 16-Jun-202 -Nov-2022 , 07-Jan-2023 , 05-Fe 023 , 05-Oct-2023 , 16-Oct-2023	2 , 24-Jun-2022 , 11-Jul-2 eb-2023 , 16-Feb-2023 , 0 3 , 05-Nov-2023 , 07-Jan-2	022 , 07-Sep-2022 , 05-Oc 7-Mar-2023 , 10-Mar-202 024 , 05-Feb-2024 , 16-Fe	t-2022 , 16- 3 , 07-May- b-2024 , 07	-Oct-202 2023 , 05 7-Mar-20	2 , 20-Oct- 5-Jun-2023 , 24 , 07-May-
	Synopsis	The Office of Disease Prevention and participating ICOs are issuing this Notice to communicate our interest in re electronic nicotine delivery systems (ENDS). Research on alternative nicotine and tobacco delivery systems [e.g., tobacco products (also called heat-not-burn)] will also be considered. Research with a focus on other non-combutes nicotine and tobacco products will be considered on a case-by-case basis. Studies should examine population-bat and applied prevention of disease, including etiology and epidemiology of use, potential risks, benefits and impartobacco use behavior among different populations. Studies exclusively examining smokeless tobacco or combus products (e.g., cigarettes, cigars) will be considered non-responsive.						
107449	Notice of Special Interest (NOSI):	Reducing	Stigma Related to Drug Use in I	Human Service Settings	National Institutes No of Health/DHHS 21	DT-DA- 0 060 2	)7-May- 2022	Not Specified
	Contact Name	Richard A	. Jenkins PhD					
	Contact Telephone	301-443-:	1923					
	Contact Email	jenkinsri (	@mail.nih.gov					
	Sponsor Website							
	Program URL	Link to pr	ogram URL					
	Deadline Dates (ALL)	07-May-2 2022 , 07 05-Oct-20 2024 , 05	2022 , 05-Jun-2022 , 16-Jun-202 -Jan-2023 , 05-Feb-2023 , 16-Fe 023 , 16-Oct-2023 , 07-Jan-2024 -Oct-2024 , 16-Oct-2024 , 07-Ja	2 , 11-Aug-2022 , 15-Aug- b-2023 , 07-May-2023 , 0 , 05-Feb-2024 , 16-Feb-2 n-2025	2022 , 07-Sep-2022 , 05-0 5-Jun-2023 , 16-Jun-2023 024 , 07-May-2024 , 05-Ju	Oct-2022 , 1 , 11-Aug-20 in-2024 , 16	.6-Oct-20 023 , 07-: 6-Jun-202	022 , 18-Nov- Sep-2023 , 24 , 07-Sep-
	Synopsis	The Natic related to people w conseque associate	onal Institute on Drug Abuse (NI o HIV prevention and care. Stign ho use drugs (PWUD) and insuf ences of drug use) among PWUI d with providing services to PW	DA) recognizes that stigm na contributes to a lack o ficient uptake of services D. Stigmas of interest inclu /UD, and stigma toward P	na is pervasive in clinic, so f attention to drug use sci to prevent, treat, or mitig ude: internalized stigma a WUD by providers or serv	cial service eening, ina ate HIV infe mong drug ice settings	and othe dequate ection (a users, st s. Policies	er settings outreach to nd related igma and

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadl	ine Date	Funding Amount
		practices otherwise and, in so however, other con developm	that create or augment stigma broaden their services to PWL me cases, implemented on a w knowledge from this work can aditions (e.g., cancer, mental illr ment of new interventions addre	also are of interest here, a JD. Stigma reduction inter ride scale, but generally ta inform stigma among PW ness) which also can provid essing PWUD.	as well as stigma expe ventions for HIV servi rget sexual transmissi UD. Large literatures de conceptual and pro	erienced by ice settings ion as the pr on stigma a ogrammatic	providers wi have been d rimary beha lso exist in a bases to spe	ho might eveloped vioral risk; variety of eed the
107248	Notice of Special Interest (NOSI):	Improving	g Outcomes in Cancer Treatmer	nt-Related Cardiotoxicity	National Institutes of Health/DHHS	NOT-CA- 22-001	07-May- 2022	Not Specified
	Contact Name	Crystal W	'olfrey					
	Contact Telephone	240-276-0	6277					
	Contact Email	wolfreyc(	@mail.nih.gov					
	Sponsor Website							
	Program URL	Link to pr	ogram URL					
	Deadline Dates (ALL)	07-May-2 2022 , 25 Feb-2023 , 09-Oct-2 2024 , 07	2022 , 25-May-2022 , 05-Jun-202 -Sep-2022 , 05-Oct-2022 , 07-O , 16-Feb-2023 , 07-Mar-2023 , 2023 , 16-Oct-2023 , 05-Nov-202 -Jun-2024 , 16-Jun-2024 , 07-Se	22 , 07-Jun-2022 , 16-Jun-2 ct-2022 , 16-Oct-2022 , 24 07-May-2023 , 05-Jun-202 23 , 07-Jan-2024 , 05-Feb- p-2024 , 08-Oct-2024	2022 , 21-Jun-2022 , 2 -Oct-2022 , 08-Nov-20 23 , 07-Jun-2023 , 16-J 2024 , 16-Feb-2024 , (	24-Jun-2022 022 , 07-Jan Jun-2023 , 0 07-Mar-202	, 20-Jul-202 -2023 , 25-Ja 7-Sep-2023 4 , 07-May-2	2 , 07-Sep- an-2023 , 05- , 05-Oct-2023 2024 , 05-Jun-
	Synopsis	The purpo cardiovas cardiotox	ose of this Notice of Special Inte cular dysfunction while optimiz icity and translating the finding	erest (NOSI) is to encourag zing cancer outcomes by u s to improve risk stratifica	ge collaborative and in nderstanding the mean th	nnovative ap chanisms of prevention,	oproaches to cancer trea and manag	o mitigate tment-related ement.
106064	Maximizing Opportunities for Sci Career Transition Award to Prom with Humans Required (BESH))	entific and ote Divers	Academic Independent Career ity (K99/R00 - Independent Bas	rs (MOSAIC) Postdoctoral sic Experimental Studies	National Institutes of Health/DHHS	PAR-21- 273	07-May- 2022	Not Specified
	Contact Name	Lanay M.	Mudd, Ph.D., FACSM					
	Contact Telephone	301-594-9	9346					
	Contact Email	lanay.mu	dd@nih.gov					
	Sponsor Website							
	Program URL	Link to pr	ogram URL					

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadl	ine Date	Funding Amount
	Deadline Dates (ALL)	07-May-2 2023 , 12	2022 , 12-Jun-2022 , 07-Sep-202 -Oct-2023 , 07-Jan-2024 , 12-Fe	2 , 12-Oct-2022 , 07-Jan-2 b-2024 , 07-May-2024 , 1	2023 , 12-Feb-2023 , 07 .2-Jun-2024 , 07-Sep-20	-May-2023 24	8 , 12-Jun-20	023 , 07-Sep-
The purpose of the Maximizing Opportunities for Scientific and Academic Independent Careers (MOSAIC) Postdocto Career Transition Award to Promote Diversity (K99/R00) program is to support a cohort of early career, independent investigators from diverse backgrounds conducting research in NIH mission areas. The long-term goal of this program enhance diversity in the biomedical research workforce. The MOSAIC K99/R00 program is designed to facilitate a tim transition of promising postdoctoral research positions to independent, tenure-track or equivalent research-intensive positions. The MOSAIC K99/R00 program will provide independent NIH research support before and after this transit help awardees launch successful, independent research careers. Additionally, MOSAIC K99/R00 scholars will be part organized scientific cohorts and will be expected to participate in mentoring, networking, and professional developm activities coordinated by MOSAIC Institutionally-Focused Research Education Award to Promote Diversity (UE5) gran This Funding Opportunity Announcement is for basic science experimental studies involving humans, referred to in 18-212 as "prospective basic science studies involving human participants." These studies fall within the NIH definitic clinical trial and also meet the definition of basic research. Types of studies that should be submitted under this FOA studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent vari and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental as phenomena without specific application towards processes or products in mind. Applicants not planning an indepen clinical trial or basic experimental study with humans, or proposing to gain research experience in a clinical trial or b experimental study with humans led by another investigator, must apply to the 'Independent Clinical Trial Not Allow companion FOA. The proposed project must be related to the programmatic interes							doctoral ndent ogram is to a timely Diversity) nsive faculty transition to part of elopment ) grantees. to in NOT-OD- efinition of a s FOA include to variables) tal aspects of lependent I or basic Allowed' rticipating	
108357	Research Enhancement Award Pr Schools (R15 Clinical Trial Not All	rogram (R owed)	EAP) for Health Professional Sch	nools and Graduate	National Institutes of Health/DHHS	PAR-22- 060	07-May- 2022	300,000 USD
	Contact Name	Lisa Chad	wick					
	Contact Telephone	301-435-	7275					
	Contact Email	lisa.chady	wick@nih.gov					
	Sponsor Website							
	Program URL	Link to pr	ogram URL					
	Deadline Dates (ALL)	07-May-2 2023 , 25	2022 , 25-Jun-2022 , 07-Sep-202 -Oct-2023 , 07-Jan-2024 , 25-Fe	2 , 25-Oct-2022 , 07-Jan-2 b-2024 , 07-May-2024 , 2	2023 , 25-Feb-2023 , 07 5-Jun-2024 , 07-Sep-20	-May-2023 24 , 25-Oc	8 , 25-Jun-20 t-2024 , 07-J	)23 , 07-Sep- lan-2025

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadl	ine Date	Funding Amount
	Synopsis	The purpor to suppor on provid enhancing science de costs) in 4 based on determini	ose of the Research Enhanceme t small scale research grants at ing biomedical research experie g the research environment at a egrees and have received no me of the last 7 fiscal years. For in the amount of NIH funding rece ing the Organization Funding Le	ent Award Program (REAP) institutions that do not re ences primarily for health applicant institutions. Eligi ore than \$6 million dollars istitutions composed of m eived by all the schools an evel can be found here or l	for Health Profession eceive substantial fund professional, undergra ble institutions must a per year of NIH suppo ultiple schools and col d colleges within the i nttps://grants.nih.gov,	al Schools a ing from th aduate and ward bacca ort (in both leges, the \$ nstitution a /grants/fun	and Gradua ne NIH, with graduate st alaureate or direct and G million fu s a whole. I ding/r15.ht	te Schools is an emphasis tudents and r advanced F&A/indirect unding limit is Help rm.
106063	Maximizing Opportunities for Scie	entific and ote Divers	Academic Independent Career ity (K99/R00 - Independent Clir	s (MOSAIC) Postdoctoral nical Trial Required)	National Institutes of Health/DHHS	PAR-21- 272	07-May- 2022	Not Specified
	Contact Name	Lanay M.	Mudd, Ph.D., FACSM					
	Contact Telephone	301-594-9	9346					
	Contact Email	lanay.mu	dd@nih.gov					
	Sponsor Website							
	Program URL	Link to pr	ogram URL					
	Deadline Dates (ALL)	07-May-2 2023 , 12-	022 , 12-Jun-2022 , 07-Sep-202 -Oct-2023 , 07-Jan-2024 , 12-Fe	2 , 12-Oct-2022 , 07-Jan-2 b-2024 , 07-May-2024 , 12	023 , 12-Feb-2023 , 07 2-Jun-2024 , 07-Sep-20	'-May-2023 24	, 12-Jun-2(	)23 , 07-Sep-
	Synopsis	The purper Career Tra- investigat enhance of transition from their positions. help awar organized activities This Fund investigat research a experience	ose of the Maximizing Opportur ansition Award to Promote Dive cors from diverse backgrounds of diversity in the biomedical resea of promising postdoctoral resea r mentored, postdoctoral resea The MOSAIC K99/R00 program rdees launch successful, indepe I scientific cohorts and will be e coordinated by MOSAIC Institution ing Opportunity Announcement for of an independent clinical tr and career development. Applic ce in a clinical trial led by anothe	nities for Scientific and Aca ersity (K99/R00) program i conducting research in NIH arch workforce. The MOS/ earchers from diverse back rch positions to independent will provide independent ndent research careers. A xpected to participate in r tionally-Focused Research t (FOA) is designed specifi ial, a clinical trial feasibility cants not planning an inde er investigator, must apply	ademic Independent C s to support a cohort of a mission areas. The lo AIC K99/R00 program is grounds (e.g., see Not ent, tenure-track or eo the tenure-track or eo tentoring, networking the tenure-track or eo tenutoring, networking the tenure-track or eo tenutoring the tenutoring the tenutoring the tenutoring the tenutoring tenutoring the tenutoring tenutoring the tenutoring tenutoring tenutoring tenut	areers (MC of early car ng-term go s designed tice of NIH's quivalent re before and 99/R00 sch s, and profe romote Div oposing to s ancillary cli or proposin AR-21-271.	DSAIC) Posto eer, indepe al of this pr to facilitate s Interest in esearch-inte d after this to olars will be ssional dev versity (UE5 serve as the nical trial, a g to gain re	doctoral ndent rogram is to a timely Diversity) ensive faculty transition to a part of elopment ) grantees. e lead as part of their esearch

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadlin	ne Date	Funding Amount
108364	Health Care Models for Persons v Health Disparities: Advancing Health	vith Multi alth Care 1	ple Chronic Conditions from Po cowards Health Equity (R01 - Cli	pulations that Experience nical Trials Optional)	National Institutes PA of Health/DHHS 09	AR-22- )2	07-May- 2022	Not Specified
	Contact Name Contact Telephone Contact Email	Larissa Av 301-827- <u>avilessan</u>	vilés-Santa, MD, MPH 6924 <u>tal@nih.gov</u>					
	Program URL Deadline Dates (ALL)	<u>Link to pr</u> 07-May-2 2024 , 05	<del>. 2022 , 05-Jun-2022 , 07-Sep-202 -Jun-2024 , 07-Sep-2024</del>	2 , 05-Feb-2023 , 07-May-	2023 , 05-Jun-2023 , 07-	Sep-2023 ,	, 05-Feb-2	024 , 07-May-
	Synopsis	This initia adaptatic (MCCs) fr compone initiative	ative will support innovative, co on, integration, and implementation om populations that experience ant and/or more than one level is attainment of optimal treatment	llaborative, and multi-disc ation of recommended gui e health disparities. Projec of influence within existing nent and health outcomes	iplinary research designe delines of care of person its would be expected to g or newly proposed hea goals to advance health	d to study s with mu involve m Ith care m care towa	y the effect ltiple chro ore than o odels. The rds health	tive nic conditions one goal of this equity.

SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Amount
106928	RFA-AT-22-001 NIH Health Care Implementation Trials of Embedd Optional)	e Systems Research Collaboratory - Pragmatic and led Interventions (UG3/UH3, Clinical Trials	National Institutes of Health/DHHS	RFA-AT- 22-001	07-May-2022	4,500,000 USD
	Contact Name	Wendy Weber, ND, PhD, MPH				
	Contact Telephone	301-402-1272				
	Contact Email	weberwj@mail.nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-Maγ-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oα 2023 , 05-Oct-2023 , 07-Jan-2024 , 05-Feb-2024 ,	ct-2022 , 07-Jan-2023 , 05-F 07-May-2024 , 05-Jun-202	eb-2023 , 0 4 , 07-Sep-2	7-May-2023 , 05-Jun-2023 024 , 05-Oct-2024	3,07-Sep-
	Synopsis	This Funding Opportunity Announcement (FOA) e efficient, large-scale pragmatic or implementation	encourages UG3/UH3 phase n trials to improve health a	ed cooperat nd care deli	ive research applications ivery, with a particular foc	to conduct us on

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	health c patient with pos requirer followin health c populati pragmat care set world" s HCS; or three or NIH HCS Center ( applican the prop	are systems (HCS) with less histo populations. Awards made unde ssible transition to a trial conduc nents may transition to the UH3 g the instructions described in the are strategies and clinical practic ons in a variety of healthcare co cic studies supported by this FOA tings. This FOA requires that the ettings. Studies can propose to i implement HCS changes to impre- more health care systems (HCS) Research Collaboratory. The NII CCC) that is providing national le- ts will work with the HCS CCC (hosed study.	prical involvement in research stud r this FOA will initially support a or t phase (UH3). UG3 projects that h phase. The UG3/UH3 application in this FOA. The overall goal of this initi- ces and procedures in health care s intexts, with a strong focus on pop a should inform policy makers, pay intervention under study be ember integrate multi-modal or multiple i ove adherence to evidence-based that provide care to patient popu H HCS Research Collaboratory Prog eadership and technical expertise i ittps://rethinkingclinicaltrials.org/)	ies focused on imp ne-year milestone- nave met the scien must be submitted tiative is to suppor systems (HCS) that ulations with healt ers, doctors and p edded into health of interventions that guidelines. Trials s lations and will be gram has establish n all aspects of res to facilitate furtho	broving health out driven planning p tific milestone and d as a single applic t the "real world" lead to improved th disparities. Resu atients across dive care delivery syste have demonstrate hould be conduct come part of and ed a Collaboratory search with HCS. A er planning and re	comes for US hase (UG3), d feasibility ation, assessment of care for ults from the erse patient en, "real ed efficacy into ed across work with the y Coordinating warded finement of
088011	Engineering Next-Generation Human Nerv (R01 Clinical Trials Not Allowed)	ous System Microphysiological S	Systems National Institutes of Health/DHHS	PAR-20- 055 07-1	May-2022	Not Specified

Contact Name David M. Panchision, Ph.D.

Contact Telephone 301-443-5288

Contact Email panchisiond@mail.nih.gov

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL) 07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023

Synopsis Synopsis This Funding Opportunity Announcement (FOA) encourages research grant applications directed toward developing nextgeneration human cell-derived microphysiological systems (MPS) and related assays that replicate complex nervous system architectures and physiology with improved fidelity over current capabilities. Supported projects will be expected to enable future studies of complex nervous system development, function and aging in healthy and disease states. This FOA is intended to provide support for the further development of projects where preliminary data supports the feasibility of the line of investigation. Applicants without preliminary data may wish to apply to the companion R21 FOA(PAR-20-082).

SPIN ID	Program Title		Sponsor Name	Sponso	or Number			Deadline Date	Funding Amount
088012	Engineering Next-Generation Hur (R21 Clinical Trials Not Allowed)	man Nervo	us System Microphysiological S	Systems	National Institutes of Health/DHHS	PAR-20- 082	07-1	May-2022	275,000 USD
	Contact Name	David M.	Panchision, Ph.D.						
	Contact Telephone	301-443-5	5288						
	Contact Email	panchisio	nd@mail.nih.gov						
	Sponsor Website								
	Program URL	Link to pr	ogram URL						
	Deadline Dates (ALL)	07-May-2	022 , 16-Jun-2022 , 07-Sep-202	22,16-C	ct-2022 , 07-Jan-2023				
	Synopsis	This Fund generatio architectu future stu mechanis stages of FOA. App	ing Opportunity Announcemer in human cell-derived microphy ures and physiology with impro idies of complex nervous syster m is intended to encourage exp project development. High risk licants with preliminary data m	nt (FOA) ysiologic ved fide m develo plorator /high re ay wish	encourages research grant al systems (MPS) and relate lity over current capabilitie opment, function and aging y/developmental research I ward projects that lack pre- to apply to the companion	applications ed assays this s. Supported in healthy a by providing liminary dat R01 mechar	dired at rep d proj and di supp a may nism (	cted toward deve plicate complex ne ects will be expec isease states. The port for the early a y be most approp (PAR-20-NNN).	loping next- ervous system ited to enable R21 grant and conceptual riate for this
	Development and Application of	PET and SP	PECT Imaging Ligands as Biomai	r <mark>kers for</mark>	National Institutes of	PAR-20-			825,000
088090	Drug Discovery and for Pathophys	siological S	Studies of CNS Disorders (R01 C	linical	Health/DHHS	037	07-1	May-2022	USD
	<u>Indi Not Allowed</u>								
	Contact Name	Enrique N	lichelotti, Ph.D.						
	Contact Telephone	301-443-5	5415						
	Contact Email	michelott	iel@mail.nih.gov						
	Sponsor Website								
	Program URL	Link to pr	ogram URL						
	Deadline Dates (ALL)	07-May-2	022,05-Jun-2022,07-Sep-202	22,05-C	ct-2022 , 07-Jan-2023				1.1
	Synopsis	of novel r imaging ir studies ar to FOA PA	ing Opportunity Announcemer adioligands for positron emissi n rodent and nonhuman primat nd appropriate model developn AR-20-038 .	on tomo te brain nent. Pr	invites research grant appli graphy (PET) or single phot and incorporation of pilot c ojects proposing clinical ass	cations that con emissior or clinical fea essments of	prop com asibili f nove	ose the preclinica puted tomograph ty evaluation in p el radioligands sho	ii development by (SPECT) re-clinical buld respond

SPIN ID	Program Title		Sponsor Name	Sponso	r Number		Deadline Date	Funding Amount
108950	RFA-AI-22-015 Biomarker Signa Without HIV (R01 Clinical Trial No	tures of T t Allowed	B Infection in Young Children W	ith and	National Institutes of Health/DHHS	RFA-AI- 22-015	09-May-2022 [Optional][LOI/Pre-App	3,500,000 )] USD
	Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) Synopsis	Tania B. L 301-761- tania.lom Link to pr 09-May-2 The purp biomarke without H	ombo, Ph.D. 7612 <u>bo@nih.gov</u> 022 [Optional][LOI/Pre-App], 03 ose of this Funding Opportunity rs of Tuberculosis (TB) infection IIV.	8-Jun-20 Annour and sul	122 Incement (FOA) is to advance Disequent risk of progression	e research to n to TB diseas	discover and validate i se in young children wi	novel th and
102735	RFA-NS-21-015 HEAL Initiative: Non-addictive Analgesic Theraper Allowed)	Team Res utics Deve	earch for Initial Translational Ef lopment (U19 Clinical Trial Not	<u>forts in</u>	National Institutes of Health/DHHS	RFA-NS- 21-015	10-May-2022 [Optional][LOI/Pre-App	7,500,000 )] USD
	Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL)	Michael L 301-496- <u>michael.c</u> Link to pr 10-May-2	Oshinsky, PhD 9964 <u>oshinsky@nih.gov</u> ogram URL 022 [Optional][LOI/Pre-App], 09	9-Jun-20	122 , 11-Sep-2022 [Optional	][LOI/Pre-Ap	p], 11-Oct-2022 , 10-M	ay-2023
	Synopsis	[Optional This fund non-addio screening pharmaco of the pro Initiative: Clinical Tr propose a	][LOI/Pre-App], 09-Jun-2023, 1 ing opportunity announcement ctive therapeutics to treat pain. g and early optimization work to odynamic markers efficacy and oject should be to advance a hit Non-addictive Analgesic Therap rial Optional) within the 5 years a plan that will lead to the devel	0-Sep-20 (FOA) is The goa develop pharmad or lead of lead of the a lopment	D23 [Optional][LOI/Pre-App part of a suite of FOAs to s of this FOA is to support t o a non-addictive therapeut cokinetic/pharmacodynami to the point where they car Development [Small Molecu ward, there is no opportun of analgesics with a rigoro	], 10-Oct-202 upport the d eam-based re- cic to treat pa- c (PK/PD) sturn meet the er ules and Biolo ity for renew us biological	23 evelopment of safe, eff esearch projects to dev in. Discovery and valid dies are also responsiv ntry criteria for RFA-NS ogics] to Treat Pain (UG al of this award. Applic rationale and scientific	fective, and relop assays, ation of e. The result -21-010 HEAL i3/UH3 ations should ally sound

SPIN ID	Program Title		Sponsor Name	Sponsor N	lumber		Deadline Date	Funding Amount
		assays. If putative t will produ develop t osteoarth pain, visce considere pathologi such as w patients a should be	the data does not currently exis herapeutic target(s) to the pro- uce desirable outcomes for the herapeutics for acute pain, chro pritis, diabetic neuropathy, chen eral pain, post stroke pain, myo ed. Projects to develop analgesic cal conditions will also be consi omen, children, older adults, an and caregivers on the therapeut e to identify candidate therapeut	st, the appl posed pain disease. Th onic pain, p motherapy- ofascial pair ics for a con idered. Proj nd other ur tic goals of utic(s) that v	ication must include a st indication and supportir is FOA is not specific for ainful neuropathy, musc induced neuropathy, eye n, painful disorders of the nbination of chronic over jects that seek to identify nderrepresented groups the project is encourage will be ready to be subm	rong plan for deing the hypothesis any one or group suloskeletal pain, e pain, sickle-cell e orofacial region rlapping pain con y pain treatment will also be respond. The goal of ea itted to RFA-NS-	veloping data linking s that altering the p of pain condition headache disorde pain, post-surgica n and other conditi nditions or for specific targets in specific ponsive to this FOA. ch 5-year U19 app 21-010 for further	ng the carget activity s. Projects to rs, I pain, cancer ons will be cific disease or populations Input from lication optimization.
104595 E	FA-NS-21-029 HEAL Initiative: Development [Small Molecules a	Planning S nd Biologic	Studies for Initial Analgesic [s] (R61 Clinical Trial Not Allowe	N ed) H	ational Institutes of ealth/DHHS	RFA-NS- 10- 21-029 [Op	May-2022 tional][LOI/Pre-Ap	1,000,000 p] USD
	Contact Name	Michael L	. Oshinsky, PhD					
	Contact Telephone	301-496-9	9964					
	Contact Email	michael.o	<u>shinsky@nih.gov</u>					
	Sponsor Website							
	Program URL	Link to pr	ogram URL					
	Deadline Dates (ALL)	10-May-2 [Optional]	022 [Optional][LOI/Pre-App], 0 ][LOI/Pre-App], 09-Jun-2023 , 1	9-Jun-2022 0-Sep-2023	, 11-Sep-2022 [Optional 3 [Optional][LOI/Pre-App	][LOI/Pre-App], : ], 10-Oct-2023	11-Oct-2022 , 10-N	1ay-2023
	Synopsis	The goal of propose 2 Initiative: Biologics] establish the groun team to c research t indication	of this funding opportunity anno 2-year exploratory/planning awa Team Research - for Initial Trar (U19 Clinical Trial Not Allowed a strong research team, feasibil adwork for a subsequent Team I ollect initial data and recruit ad team, as well as a strategy to co and supporting the hypothesis	ouncement vards that a nslational E I).Thus, the Iity, validity Research U dditional co ollect prelin s that alteri	t (FOA) is to solicit Initial re expected to enable a f fforts in Non-addictive A limited scope of aims an y, or other technically qua 19 application. These R6 llaborators. The applicat ninary data linking putat ng target activity will pro	Analgesic Develo future applicatio nalgesic Develop d approach of th alifying results th 1 awards will su ion must include ive therapeutic t oduce desirable o	opment R61 applic n for RFA-NS-21-02 oment [Small Mole nese applications a nat support, enable pport the building a plan for develop argets to the prop- putcomes for the d	ations that L5 HEAL cules and re expected to e, and/or lay of a research sing a strong osed pain isease.

SPIN ID	Program Title		Sponsor Name	Sponso	r Number		Deadline Date	Funding Amount
109543	RFA-NS-22-028 BRAIN Initiative: Programs - eTeamBCP (1101 Clinic	<u>Explorato</u> Al Trials O	ory Team-Research BRAIN Circu	<u>it</u>	National Institutes of Health/DHHS	RFA-NS- 22-028	15-May-2022	Not nnl Specified
	Contact Name	Karen K D	avid Ph D			22 020		pp] opeomed
	Contact Telephone	301-496-9	9964					
	Contact Email	BRAINCire	cuits@nih.gov					
	Sponsor Website							
	Program URL	Link to pr	ogram URL					
	Deadline Dates (ALL)	15-May-2 [Optional	022 [Optional][LOI/Pre-App], 1 ][LOI/Pre-App], 14-Jun-2024	4-Jun-20	22 , 16-May-2023 [Optiona	al][LOI/Pre-A	App], 15-Jun-2023 , 15	-May-2024
	Synopsis	cross bou behaviora tackled by advances theoretica Targeted enable a an etholo expertise fields by i sophistica expected methods CNS.	ndaries of interdisciplinary colla al or neural system. Application y a synergistic team-based appr These studies at the explorato al frameworks in preparation for 3CP (R01) or the multi-compone arge-scale analysis of neural sy gically relevant behavior. Towa and to integrate experimental ncorporating rich information of the danalyses of an ethologically to aim for a mechanistic under such as those for large-scale rec	ry stage oach an ry stage r a futur ent, Tear stems ar rd this e with cor on cell-ty relevar standing cording,	n to elucidate the contribu- couraged to propose adver d have the potential to be to are intended for the devel re competition for larger-so m-Research BRAIN Circuit F ad circuits within the conte nd, teams are expected to mputational and theoretica pes, on circuit functionality at behavior of an organism of the circuits of the centr manipulation, and analysis	tions of dyna turous and o transformati opment of e ale or exten rograms (U2 xt and durin assemble an al approache y and conne or a well-de al nervous s of neural ci	amic circuit activity to challenging goals that ive and/or to enable s experimental capabiliti nded efforts, including 19). The overall goal o og the simultaneous m nd leverage multi-disci es. Teams are expected ctivity, in conjunction fined neural system. T system (CNS) by applyi ircuits across multiple	a specific can only be gnificant es and/or the BRAIN f this FOA is to easurement of plinary I to bridge with eams are also ng cutting-edge regions of the
108564	RFA-MH-22-145 BRAIN Initiative he BRAIN Initiative (R01 Clinical T	<u>: Standar</u> rial Not A	ds to Define Experiments Relate llowed)	<u>ed to</u>	National Institutes of Health/DHHS	RFA-MH- 22-145	15-May-2022 [Optional][] OJ/Pre-A	Not ppl Specified
	Contact Name Contact Telephone Contact Email Sponsor Website	Ming Zha 301-827-3 ming.zhai	n, Ph.D. 3678 n <u>@nih.gov</u>					<u></u>

SPIN ID	Program Title		Sponsor Name	Sponso	or Number		Deadline Date	Funding Amount	
	Program URL	Link to pr	ogram URL						
	Deadline Dates (ALL)	15-May-2 [Optional	2022 [Optional][LOI/Pre-App], 14 ][LOI/Pre-App], 14-Jun-2024	4-Jun-20	022 , 15-May-2023 [Optior	nal][LOI/Pre-Ap	op], 14-Jun-2023 , 15-N	May-2024	
This Funding Opportunity Announcement (FOA) aims to develop standards that describe experimental protoco as part of the BRAIN Initiative. It is expected that applications will solicit community input at all stages of the pro- Synopsis recommended that the first step of standard development will involve sharing data between different key grou experimental community in order to ensure that the developing standard will encompass the data collection en- groups. The developed standard is expected to be broadly disseminated for use and widely available.									
105360	RFA-HG-21-001 Technology Dev Sequencing and Single-Cell Protect	velopment	t for Single-Molecule Protein wis (P01 Clinical Trial pot allowe	d)	National Institutes of	RFA-HG-	16-May-2022	275,000 D211 [0	
	Contact Nama			<u>u)</u>		21-001		p] 05D	
		301-480-	111, P11.D. 2280						
	Contact Fmail	gatlincl@	nih gov						
	Sponsor Website	gutificie	<u>IIII.gov</u>						
	Program URI	Link to pr	ogram URI						
	Deadline Dates (ALL)	16-May-2	022 [Optional][LOI/Pre-App], 1	5-Jun-2	022 , 16-May-2023 [Optior	nal][LOI/Pre-Ag	op], 15-Jun-2023		
	Synopsis	This Func protein so next five routinely methods achieve t	ling Opportunity Announcemen equencing through technology of years that enable generation of in studies of genome biology ar other than those currently in us he goals of this FOA.	t (FOA) develop proteir nd funct se is hig	solicits R21 grant applicati ment. The goal of this initi sequencing data at suffici tion, and in biomedical and hly encouraged. High-risk/	ons to catalyze ative is to achi ent scale, spee I clinical reseau high-payoff ap	e major advances in sin eve technological adva ed, cost and accuracy to rch in general. Explora oplications are appropr	ngle-molecule ances over the to use tion of riate to	
105362 <u>R</u> S	RFA-HG-21-002 Technology Dev Sequencing (R21 Clinical Trial not	velopment allowed)	t for Single-Molecule Protein		National Institutes of Health/DHHS	RFA-HG- 21-002	16-May-2022 [Optional][LOI/Pre-Ap	1,500,000 p] USD	
	Contact Name	Tina Gatli	in, Ph.D.						
	Contact Telephone	301-480-	2280						
	Contact Email	gatlincl@	<u>nih.gov</u>						
	Sponsor Website								

SPIN ID	Program Title		Sponsor Name	Sponsor Nu	umber		Deadline Date	Funding Amount
	Program URL Deadline Dates (ALL) Synopsis	Link to pr 16-May-2 This Fund protein se achieve to speed, co in genera	ogram URL 022 [Optional][LOI/Pre-App], 1 ing Opportunity Announcemen equencing and single cell protec echnological advances over the st and accuracy to use routinely I.	5-Jun-2022 , at (FOA) solic ome analysis next five yea y in studies c	. 16-May-2023 [Optiona its grant applications to s through technology de ars that enable generat of genome biology and f	I][LOI/Pre-App], catalyze major evelopment. The ion of protein se function, and in	15-Jun-2023 advances in single- goal of this initiativ quencing data at su piomedical and clin	molecule ve is to ufficient scale, ical research
099865	RFA-NS-21-010 HEAL Initiative: Development [Small Molecules an Optional)	Non-addio nd Biologio	<u>ctive Analgesic Therapeutics</u> cs] to Treat Pain (UG3/UH3 Clini	i <u>cal Trial</u> He	tional Institutes of alth/DHHS	RFA-NS- 16- 21-010 [Op	May-2022 tional][LOI/Pre-Apj	Not o] Specified
	Contact Name Contact Telephone Contact Email Sponsor Website	Michael ( 301-496- <u>michael.c</u>	Oshinsky 9964 J <u>shinsky@nih.gov</u>					
	Program URL Deadline Dates (ALL)	Link to pr 16-May-2 [Optional [Optional	ogram URL 022 [Optional][LOI/Pre-App], 1 ][LOI/Pre-App], 14-Feb-2023 , 1 ][LOI/Pre-App], 17-Oct-2023	5-Jun-2022 , l6-May-2023	. 14-Sep-2022 [Optional 3 [Optional][LOI/Pre-Ap	][LOI/Pre-App], : p], 15-Jun-2023 ,	14-Oct-2022 , 14-Ja 17-Sep-2023	n-2023
	Synopsis	The purperson of the purperson of the purperson of the purperson of the program of the purperson	ose of this funding opportunity ctive, and non-addictive small n e the optimization and develop for the Early Phase Pain Investi oppic-net or other Phase II clini plogical rationale for the intend includes optimization and early odynamic/target engagement b inical testing. This is a milestone staff in the development of the	announcement molecule and ment of pror igation Clinic ical studies. A led approach development iomarker, as e-driven pha project plan	ent (FOA) is to support d biologic therapeutics t mising small molecule a cal Network (EPPIC-Net) Applicants must have a n, and identified assays nt activities, IND-enablin ssembly and filing of an used cooperative agreer n and monitoring of rese	preclinical optim to treat pain. The and biologic hits/ ) https://heal.nih promising biolog for optimization ng studies, devel Investigational N ment program in earch progress.	ization and develo goal of the progra leads to Phase I clin gic or small molecu of the agent. The s opment of a New Drug (IND) app volving participatio	pment of m is to nical trials and ical- le hit/lead, cope of this llication and n of NIH
109978	RFA-MH-22-220 BRAIN Initiative Data (R01 Clinical Trial Not Allowe	<u>e: Integrat</u> ed)	ion and Analysis of BRAIN Initia	n <u>tive</u> Na He	tional Institutes of alth/DHHS	RFA-MH- 16- 22-220 [Op	May-2022 tional][LOI/Pre-App	Not ] Specified

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Contact Name N Contact Telephone 3	Лing Zhan, Ph.D. 801-827-3678				
	Contact Email <u>n</u>	ning.zhan@nih.gov				
	Sponsor Website					
	Program URL <u>L</u>	ink to program URL				
	1 Deadline Dates (ALL) [۱ [۱]	.6-May-2022 [Optional][LOI/Pre-App], 10 Optional][LOI/Pre-App], 09-Jun-2023 , 13 Optional][LOI/Pre-App], 07-Jun-2024	)-Jun-2022 , 14-Sep-2022 [Option 3-Sep-2023 [Optional][LOI/Pre-Ap	al][LOI/Pre-App], 1 p], 13-Oct-2023 , (	L4-Oct-2022 , 10-M D8-May-2024	May-2023
	synopsis p ir ir a a a	Inis Funding Opportunity Announcement and integrating data related to the BRAIN building the informatics infrastructure for These include modifying existing analysis ypes of BRAIN Initiative datasets. Propos permitted. The tools supported under thi integrated into the data repositories, both informatics program. The tools must be u hould analyze/visualize data without req analysis/visualization from multiple location	The BRAIN Initiative, the FOA sup and visualization tools to deal wi- ing the development of new tool s FOA will make use of relevant d h of which are created in awards ser-friendly in accessing and anal juiring users to download data. The ons.	relop informatics to erstanding of the b oports several diffe th BRAIN Initiative s to deal with BRA ata standards and under the other FC yzing data from ap ne tools should als	oois for analyzing prain. As part of pi erent, but related data and integrat IN Initiative data i will be built so th DAs of the BRAIN ppropriate data ar o allow data to be	, visualizing, rograms of activities. ting different is also at they can be initiative rchives, and e combined for
108562	RFA-HL-23-001 ARDS, Pneumonia Centers (U01 Clinical Trial Not Allov	a, and Sepsis Phenotyping Consortium Cl wed)	inical National Institutes of Health/DHHS	RFA-HL- 17-N 23-001 [Opt	Vlay-2022 tional][LOI/Pre-Ap	2,075,000 pp] USD
	Contact Name L	ora Reineck, MD, MS				
	Contact Telephone 3	801-827-7845				
	Contact Email <mark>Ic</mark>	ora.reineck@nih.gov				
	Sponsor Website					
	Program URL <u>L</u>	ink to program URL				
	Deadline Dates (ALL) 1	.7-May-2022 [Optional][LOI/Pre-App], 17	'-Jun-2022			
	T Synopsis C	This funding opportunity announcement Respiratory Distress Syndrome (ARDS), Pr Consortium will seek to understand the h	(FOA) seeks applications for Clinic neumonia, and Sepsis Phenotypin eterogeneity and underlying mec	cal Centers to form g Consortium (APS hanisms of critical	n a cooperative m 5 Consortium). The illness syndrome	ulti-site Acute e APS s and

SPIN ID	Program Title		Sponsor Name	Sponso	or Number		Deadline Date	Funding Amount
		recovery, among th data and diagnoses hospital v and phys Consortiu a Clinical biospecin possible. pneumor scientific (see RFA-	specifically in adults with ARDS bese syndromes. This will be acc biospecimen collection of 5,000 s: ARDS, pneumonia, or sepsis. will have follow-up at 3, 6, and 2 iological resolution of ARDS, pn um-wide longitudinal cohort, as Center-specific scientific projec nens collected will be made ava The Clinical Centers will be exp hia, and sepsis, such as emerger expertise for their specific projec HL-23-002).	5, pneun complish 0 adults It is expo 12 mont eumoni well as ct. Throu ailable as ected to ncy med ects. Thi	nonia, and/or sepsis, as we red through a prospective, hospitalized in the United ected that approximately h hs to facilitate understand a, and sepsis. Each of the C utilize the data, imaging, a ghout the program's fund is a resource to the broader have expertise in enrollin icine, hospital medicine, an s FOA runs in parallel with	ell as the relation longitudinal ob States with one half of the partic ing of long-term Clinical Centers w nd/or biospecin ing period, data r research comm g participants in nd critical care of the APS Consor	nship and biological servational study wi or more of the follo cipants discharged fr n outcomes, includir will enroll participan nens collected Conse (including imaging on nunity as rapidly and clinical studies of A clinical researchers, a rtium Coordinating O	overlap th common wing om the ng biological ts in a ortium-wide in data) and d simply as .RDS, as well as Center
108563 <mark>6</mark>	RFA-HL-23-002 ARDS, Pneumor Coordinating Center (U01 Clinical	nia, and Se I Trial Not	epsis Phenotyping Consortium Allowed)		National Institutes of Health/DHHS	RFA-HL- 1 23-002 [0	7-May-2022 Optional][LOI/Pre-Ap	Not p] Specified
	Contact Name	Lora Rein	eck, MD, MS					
	Contact Telephone	301-827-	7845					
	Contact Email	lora.reine	<u>eck@nih.gov</u>					
	Sponsor Website	2						
	Program URL	Link to pr	rogram URL					
	Synopsis	This fund cooperat Consortiu syndrome biologica study wit diagnose hospital v and phys imaging c	ing opportunity annoucement ( ive multi-site Acute Respiratory um). The APS Consortium will se es and recovery, specifically in a l overlap among these syndrom th common data and biospecime s: ARDS, pneumonia, or sepsis. will have follow-up at 3, 6, and 2 iological resolution of ARDS, pn data) and biospecimens collecte	(FOA) se v Distress eek to ur adults w hes. This en colled It is expo 12 mont eumoni ed will bo	eks applications for a Coor s Syndrome (ARDS), Pneun aderstand the heterogenei ith ARDS, pneumonia, and, will be accomplished throu ction of 5,000 hospitalized ected that approximately h hs to facilitate understand a, and sepsis. Throughout e made available as a resou	rdinating Center nonia, and Sepsi ty and underlyin /or sepsis, as we ugh a prospectiv adults with one half of the partic ing of long-term the program's fu	that will support the is Phenotyping Cons ng mechanisms of cr ell as the relationshi ve, longitudinal obse or more of the follo cipants discharged fr n outcomes, includir unding period, data der research comm	e activities of a ortium (APS itical illness p and ervational owing fom the ng biological (including unity as rapidly

SPIN ID	Program Title		Sponsor Name	Sponso	r Number		Deadline Date	Funding Amount
		and simpl information in develop 23-001).	y as possible. The Coordinating cs, data management (including ping proactive policies for shari	Center g imagin ng. This	will be expected to have ex g data), and biospecimen r FOA runs in parallel with th	opertise in statist nanagement, and ne APS Consortiu	ics, longitudinal cc I to have demonst m Clinical Centers	hort studies, rable interest (see RFA-HL-
104041 <u>a</u> 0	FA-NS-21-023 BRAIN Initiative nd Modulation in the Human Ce Optional)	: Next-Ger ntral Nerv	neration Invasive Devices for Re ous System (UG3/UH3 Clinical 1	<u>cording</u> T <u>rial</u>	National Institutes of Health/DHHS	RFA-NS- 21- 21-023 [Op	May-2022 tional][LOI/Pre-Ap	Not pp] Specified
	Contact Name	Brooks Gr	ross, PhD					
	Contact Telephone	301-496-1	L447					
	Contact Email	NINDS-De	evices@nih.gov					
	Sponsor Website							
	Program URL	Link to pr	ogram URL					
	Deadline Dates (ALL) [Optional][LOI/Pre-App], 21-Feb-2023, 20-May-2023 [Optional][LOI/Pre-App], 18-Oct-2022, 22-Jan-2 [Optional][LOI/Pre-App], 21-Feb-2023, 20-May-2023 [Optional][LOI/Pre-App], 19-Jun-2023, 18-Sep-2023 [Optional][LOI/Pre-App], 18-Oct-2023, 21-Jan-2024 [Optional][LOI/Pre-App], 20-Feb-2024							an-2023
	Synopsis	The purpe activities better und devices, m Device Ex clinical stu supported cannot be novelty of participat Individual device ma a number approved be sufficie informatio	ose of this Funding Opportunity and small clinical studies for rec derstand the human brain. Acti- ion-clinical safety and efficacy t emption (IDE) for a Significant F udies that will require an Invest d by this FOA. The clinical study e practically obtained through a f the device or its intended use. ion of NIH program staff in neg s, institutions, or businesses de anufacturers are welcome to ap of device manufacturers willing but appropriate for clinical res- ent to enable new FDA IDE and on on the BRAIN PPP, see https	Annour cording vities su esting, c Risk (SR) igationa is expec dditiona . This FC otiating velopin oply dire g to mal earch. In IRB app ://brain	ncement (FOA) is to encour and/or stimulating devices pported in this program in design verification and valid study, as well as a subsequ I Device Exemption (IDE) fr cted to provide information al non-clinical assessments A is a milestone-driven coor the final project plan befor g their own devices or that ctly to RFA-NS-21-024 or the ce such devices available, in a general, it is expected that rovals without need for sig initiative.nih.gov/brain-pro	age investigators to treat central r clude implement dation activities, o uent small clinica rom the FDA, suc about the device (e.g., bench top o operative agreem re award and mo already have est his FOA. The BRA including devices t the devices' exi nificant additiona grams/public-pri	s to pursue transla nervous system dis ation of clinical pr obtaining an Inves I study. Only Signit h as chronic impla e function or final or animal studies) nent program and nitoring of researc ablished collabora N PPP includes ag and capabilities no sting safety and ur al non-clinical data vate-partnerships	tional orders and ototype tigational ficant Risk (SR) nts, will be design that due to the will involve th progress. tions with reements with of yet market tility data will . For more



SPIN ID	Program Title	Sponsor Name	Sponso	r Number		Deadline Date	Funding Amount		
104043	RFA-NS-21-024 BRAIN Initiative: Clinical Invasive Devices for Recording and Modula System (UH3 Clinical Trial Optional)	Studies to Advance Next-Genera ation in the Human Central Nerv	ition ous	National Institutes of Health/DHHS	RFA-NS- 21-024	21-May-2022 [Optional][LOI/Pre-Ap	Not pp] Specified		
	Contact Name Brooks (	Gross, PhD							
	Contact Telephone 301-496	-1447							
	Contact Email <u>NINDS-E</u>	evices@nih.gov							
	Sponsor Website								
	Program URL Link to p	rogram URL							
21-May-2022 [Optional][LOI/Pre-App], 20-Jun-2022, 18-Sep-2022 [Optional][LOI/Pre-App], 18-Oct-2022, 22-Jan-2023 Deadline Dates (ALL) [Optional][LOI/Pre-App], 21-Feb-2023, 20-May-2023 [Optional][LOI/Pre-App], 19-Jun-2023, 18-Sep-2023 [Optional][LOI/Pre-App], 18-Oct-2023, 21-Jan-2024 [Optional][LOI/Pre-App], 20-Feb-2024									
	Synopsis general, approva see http develop apply dir	age investiga central nerve an Investigat al study is exp provide inform cal assessme t of a mileste ne final proje lic-Private Pa of device ma d but approp e sufficient t e information ips Individua	ators to pursue first-in- ous system disorders a tional Device Exemptic pected to provide data mation about the devic ents (e.g., bench top or one-driven cooperative ect plan before award a artnership Program (Bf anufacturers willing to priate for clinical resea o enable new FDA IDE n on the BRAIN PPP, ils, institutions, or busi e manufacturers are w	numan or ind better in (IDE) from to answer ke ce function or animal e agreement and monitorir RAIN PPP) tha make such rch. In and IRB nesses relcome to					
108952	RFA-MH-22-130 Integrating Mental Hea	th Care into Health Care System	<u>s in</u>	National Institutes of	RFA-MH-	23-May-2022	Not		

Low- and Middle-Income Countries (R01 Clinical Trial Optional)

Health/DHHS [Optional][LOI/Pre-App] Specified 22-130

Contact Name Andrea Horvath Marques, M.D., MPH, Ph.D.



SPIN ID	Program Title		Sponsor Name	Sponsor	Number		Deadline Date	Funding Amount
	Contact Tolophono	201 646 -	7220					
	Contact Telephone	androa ho	rszu					
	Sponsor Website	anurea.ne	<u>orvacimarques@mm.gov</u>					
	Program LIRI	Link to pr	ogram LIRI					
	Deadline Dates (ALL)	23-May-2	022 [Optional][LOI/Pre-App], 22	2-Jun-20	22			
	Synopsis	This Fund innovative middle-in sustaining availabilit sustainab research a	ing Opportunity Announcement e theory-based strategies to inte come countries (LMICs). This FC g integrated mental health care y of mental health care. This FC le research capacity in LMICs ar advancements. NIMH encourag	t (FOA) ii egrate m DA aims t models i DA is also nd enhan es partno	nvites implementation res ental and physical health to support innovative rese to ultimately increase dem expected to contribute to cing the potential for mul- erships between institutio	earch applicatior care within healt arch for impleme and and utilizati the long-term g tidirectional knowns in LMICs and h	is to develop, optin h care systems in lo enting, scaling up, a on, quality, access, oals of strengthenin wledge and the exc nigh-income-countr	nize, and test ow-and nd financially and ng the hange of ries (HICs).
108901	RFA-NS-22-050 HEAL Initiative: Signatures to Facilitate Clinical Tri Optional)	Discovery ials for Pai	of Biomarkers and Biomarker n Therapeutics (UG3/UH3 Clinic	al Trial	National Institutes of Health/DHHS	RFA-NS- 24- 22-050 [Op	May-2022 tional][LOI/Pre-Ap <sub>l</sub>	Not p] Specified
	Contact Name	Ram Arud	lchandran, PhD					
	Contact Telephone	301-402-5	5257					
	Contact Email	<u>ramachar</u>	ndran.arudchandran@nih.gov					
	Sponsor Website							
	Program URL	Link to pr	ogram URL					
	Deadline Dates (ALL)	24-May-2 [Optional]	022 [Optional][LOI/Pre-App], 23 ][LOI/Pre-App], 23-Feb-2023	3-Jun-202	22 , 13-Sep-2022 [Optiona	l][LOI/Pre-App],	13-Oct-2022 , 24-Ja	n-2023
	Synopsis	The purpe biomarke trials. The identificat biomarke underlyin therapeut that repre	ose of this Funding Opportunity r signatures for pain that can be biomarkers or biomarker signa tion of pain biomarkers or biosi rs or biomarker signatures may g pathophysiology. Applications tic response across several relat esent each of the related pain co	Announ e used to ture will gnatures be focus to ident ed pain o ponditions	cement (FOA) is to promo facilitate the testing of no be developed through clin that predict and/or monit red on a single pain condit cify biomarkers or biomark conditions should feature and associated clinical ne	te the discovery on-opioid pain th nical research spo cor response to p ion or on several ter signatures tha Multiple Principa etworks. The MPI	of candidate bioma erapeutics in Phase ecifically focused or ain therapeutics. T pain conditions wi at predict or monito I Investigator (MPI -led teams are exp	rkers or I I clinical I the he resulting th common or a )-led teams ected to

SPIN ID	Program Title		Sponsor Name	Sponso	r Number		Deadline Date	Funding Amount
		decide up Quantitat biosignatu that will of analysis a biomarke condition signature standardi this FOA n biomarke signature models m deliver th ready for practice.	oon a single set of measures or l tive Sensory Testing (QST), actig ure for all pain conditions repre- coordinate clinical trials and sta and algorithm development acro- ers or biomarker signatures that may also feature MPI-led team development, along with the s ize sample or data collection me may include those necessary for ers or biomarker signatures, and s identification and developme nust be verified in human sample perapeutic response prediction a definitive analytical and clinica	biomarke graphy, E esented i indardize oss the p t will be u ns that re same typ ethods, t or the ide d must in ent if poss les at the and/or n il validati	er modalities including, be lectroencephalography (for n the application. Applicate all sample or data collecter ain conditions under invest used to predict and/or mode epresent the cross function es of centralized resources echnology development a ntification and initial biological clude human samples and sible. If not, biomarkers of e end of the UG3 phase of nonitoring candidate pain on appropriate for use in	ut not limited to a EEG), digital measu itions should featu tion methods, tech estigation. Applicat onitor a therapeuti onal expertise nece e groups that coorc and statistical anal ogical, analytical, a d data as the sourc r signatures resulti r during the UH3 p biomarkers or bio clinical trial design	combination of on res, etc.as compo- re centralized resc anology developme ions seeking to de c response for a si ssary for biomarke dinate clinical trials ysis. Studies to be and clinical validati the for candidate bio ing from identifica hase. This initiative marker signatures o or decision-makin	nics, nents of the purce groups ent, statistical velop ngle pain er and/or and supported by on of pain omarkers or tion in animal e aims to that are ng in clinical
109009	Notice of Special Interest (NOSI): Equity/Health Disparities	Research /	Addressing Eye and Vision Heal	<u>th</u>	National Institutes of Health/DHHS	NOT-EY- 22-004 25-1	May-2022	Not Specified
	Contact Name	Jimmy Le	, Sc.D.					
	Contact Email	limmy le	@nih.gov					
	Sponsor Website	<u>,.</u>	<u>C</u>					
	Program URL	Link to pr	ogram URL					
	Deadline Dates (ALL)	25-May-2 2022 , 17 Apr-2023 2023 , 25 Feb-2024 2024 , 07	2022 , 05-Jun-2022 , 16-Jun-202 -Nov-2022 , 08-Dec-2022 , 05-Ja , 08-Apr-2023 , 07-May-2023 , -Sep-2023 , 05-Oct-2023 , 16-O , 05-Apr-2024 , 08-Apr-2024 , 0 -Sep-2024 , 25-Sep-2024 , 08-D	2 , 08-Au an-2023 25-May- ct-2023 , 07-May-2 vec-2024	ıg-2022 , 05-Sep-2022 , 0 , 07-Jan-2023 , 25-Jan-20 2023 , 05-Jun-2023 , 16-J . 08-Dec-2023 , 05-Jan-20 2024 , 25-May-2024 , 05-J , 05-Jan-2025 , 07-Jan-20	7-Sep-2022 , 25-Se 23 , 05-Feb-2023 , un-2023 , 08-Aug-2 24 , 07-Jan-2024 , lun-2024 , 16-Jun-2 25 , 25-Jan-2025	p-2022 , 05-Oct-2( 16-Feb-2023 , 17- 2023 , 05-Sep-2023 25-Jan-2024 , 05-F 2024 , 08-Aug-2024	)22 , 16-Oct- Feb-2023 , 05- 3 , 07-Sep- eb-2024 , 16- 4 , 05-Sep-
	Synopsis	The purpo promote	ose of this Notice of Special Intention health equity in the prevention	DSI) is to highlight interest ent, and management of	t in supporting rese eye and vision con	earch that aims to ditions. Applicatio	ns that target	

SPIN ID	Program Title		Sponsor Name	Sponso	or Number			Deadline Date A	unding mount
		reduction application health ine	of health disparities experience ns that investigate the impact o equities.	ed by pe of bias, s	eople who are visually imp structural racism, and disc	aired or blin rimination in	d are er causin	ncouraged, as well g or sustaining eye	as or vision
108959	RFA-NS-22-027 BRAIN Initiative TargetedBCPP (R34 Clinical Trials	: Targeted Not Allow	BRAIN Circuits Planning Projected)	<u>ts –</u>	National Institutes of Health/DHHS	RFA-NS- 22-027	01-Jui [Optic	n-2022 onal][LOI/Pre-App]	Not Specified
	Contact Name	Karen K D	avid, PhD						
	Contact Telephone	301-496-9	9964						
	Contact Email	BRAINCire	cuits@NIH.GOV						
	Sponsor Website								
	Program URL	Link to pr	ogram URL						
	01-Jun-2022 [Optional][LOI/Pre-App], 01-Jul-2022 , 06-Sep-2022 [Optional][LOI/Pre-App], 06-Oct-2022 , 31-May-2023 Deadline Dates (ALL) [Optional][LOI/Pre-App], 30-Jun-2023 , 04-Sep-2023 [Optional][LOI/Pre-App], 04-Oct-2023 , 29-May-2024 [Optional][LOI/Pre-App], 28-Jun-2024 , 02-Sep-2024 [Optional][LOI/Pre-App], 02-Oct-2024								
	Synopsis	This R34 I other tecl subseque Applicatic approach	OA solicits applications that of nnically qualifying results that, i nt Targeted BRAIN Circuits Proj ons should be adventurous, exp es to understand how circuit ac	fer a lim f succes ects - Ta loratory tivity gi	ited scope of aims and an sful, would support, enab argetedBCP R01, as describ research projects that use ves rise to mental experier	approach th e, and/or lay bed in the co e innovative, nce and beha	at will e the gro mpanio metho wior.	establish feasibility oundwork for a po on FOA (RFA-NS-22- dologically-integra	, validity, or tential, -026). ted
094931	NCCIH Natural Product Early Phas	e Clinical	Frial Award (R33 Clinical Trial Re	equired)	National Institutes of Health/DHHS	PAR-20- 217	01-Jui	n-2022	1,050,000 USD
	Contact Name	Wendy W	eber, N.D., Ph.D, M.P.H.						
	Contact Telephone	301-402-2	1272						
	Contact Email	weberwj(	@mail.nih.gov						
	Sponsor Website								
	Program URL	Link to pr	ogram URL						
	Deadline Dates (ALL)	22 , 07-Sep-2022 , 01-Feb-2023	в,07-М	ay-2023					
	Synopsis	This Fund of natura	ing Opportunity Announcemen products (i.e., botanicals, dieta	t (FOA) ary supp	encourages applications for lements, and probiotics),	or investigate which have a	or-initia strong	ted, early phase, cl scientific premise	linical trials to justify

SPIN ID	Program Title		Sponsor Name	Sponso	or Number		Deadline Date	Funding Amount
		further cl informati This FOA signature biologica studies to delivery of combine study the FOA are of NCCIH. The natural p not support	linical testing. Under this FOA, t ion of high scientific utility and v will provide up to 3 years support e(s) when used by humans and a l signature and functional or clir o determine how to optimize th of the natural product by exami- the natural product with another empact of the natural product is expected to be hypothesis based his R33 funding mechanism is in roducts into early stage clinical ort efficacy or effectiveness tria	rials mu will supp ort for s assess w nical out e impac ning diff er treat in a targ d, miles itended testing ls, nor v	st be designed so that rest port decisions about furthe tudies to replicate the imp hether there is an associat comes in a patient popula t of the natural product or ferent doses or formulation ment approach that is know et population that is more tone-driven, and directly re to accelerate the translati to determine whether con vill it support trials to test	ults, whether er developme act of the na- tion between tion. Applica- n the biologic ns. In additio wn to impact responsive. elated to the on of emergi tinued clinica natural produ	positive or negative, we ent or testing of the na- tural product on the b the degree of the imp tions are encouraged al signature by optimi n, applications can be the same biological s Clinical trials submitte research priorities an ng basic science findir al research is warrante ucts for the treatment	will provide tural product. iological pact on the to design zing the designed to gnature; or d under this d mission of gs about d. This FOA will or prevention
108298 <mark> </mark>	imited Competition: Basic Instru Not Allowed)	imentation	n Grant (BIG) Program (S10 Clini	cal Trial	National Institutes of Health/DHHS	PAR-22- 081	01-Jun-2022	250,000 USD
	Contact Name	C. Ashley	Barnes, PhD					
	Contact Telephone	301-435-	0783					
	Contact Emai	ashley.ba	arnes@nih.gov					
	Sponsor Website	2						
	Program URL	Link to pr	rogram URL					
	Deadline Dates (ALL)	01-Jun-20	022 , 01-Jun-2023 , 03-Jun-2024					
	Synopsis	The Basic purchase BIG Progr the prece of June 1 2020-202 There is r include, b	c Instrumentation Grant (BIG) Pro- e a single high-priced, specialized ram is limited to institutions that eding 3 Federal fiscal years (FY). , 2022, consider S10 funding in 22; for application due date of Ju- no maximum price limit for the in- pout are not limited to, basic cell	rogram d, comm It have r Use the FYs 2019 une 3, 2 instrum sorters,	encourages applications fro hercially available instrument not received S10 instrument following to determine ap 9-2021; for application due 024, consider S10 funding ent; however, the maximut confocal microscopes, ult	om groups of ent or an inte- ntation fundin oplicable funde e date of June in FYs 2021-2 m award is \$ ramicrotome	NIH-supported invest grated instrumentation of \$250,001 or great ding periods: for appli- e 1, 2023, consider S10 2023. The minimum av 250,000. Instruments s, gel imagers, or com	igators to n system. The ater in any of cation due date o funding in FYs vard is \$25,000. supported puter systems.

SPIN ID	Program Title		Sponsor Name	Sponso	or Number		Dea	eadline Date	Funding Amount
108955	<u>RFA-NS-22-026 BRAIN Initiative</u> (R01 Clinical Trial Not Allowed)	: Targeted	BRAIN Circuits Projects- Target	edBCP	National Institutes of Health/DHHS	RFA-NS- 22-026	01-Jun-2 [Option	2022 nal][LOI/Pre-Ap	Not p] Specified
	Contact Name Contact Telephone	Karen K D 301-496-	David, PhD 9964						
	Contact Email Sponsor Website	BRAINCir	cuits@NIH.GOV						
Program URL Link to program URL 01-Jun-2022 [Optional][LOI/Pre-App], 01-Jul-2022 , 06-Sep-2022 [Optional][LOI/Pre-App], 06-Oct-202 Deadline Dates (ALL) [Optional][LOI/Pre-App], 30-Jun-2023 , 04-Sep-2023 [Optional][LOI/Pre-App], 04-Oct-2023 , 29-May-2 [Optional][LOI/Pre-App], 28-Jun-2024 , 02-Sep-2024 [Optional][LOI/Pre-App], 02-Oct-2024							rt-2022 , 31-Ma May-2024	y-2023	
Synopsis Synopsis							ntal enturous ress circuit ling, data analysis, r stematically tivity. Diverse n based on e principles.		
108296	High-End Instrumentation (HEI) G	irant Prog	ram (S10 Clinical Trial Not Allow	ed)	National Institutes of Health/DHHS	PAR-22- 079	01-Jun-2	2022	2,000,000 USD
		I .							

Contact Name Guanghu (Jeff) Wang, PhD

Contact Telephone 301-435-0772

Contact Email <u>HEI@mail.nih.gov</u>

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL) 01-Jun-2022 , 01-Jun-2023 , 03-Jun-2024



SPIN ID	Program Title		Sponsor Name	Sponso	or Number		Deadline Date	Funding Amount	
	Synopsis	The High- purchase minimum \$2,000,00 systems, electron a	End Instrumentation (HEI) Gran or upgrade a single item of hig award is \$600,001. There is no 00. Instruments supported inclu mass spectrometers, nuclear m and light microscopes, flow cyto	nt Progr n-end, s maxim de, but agnetic ometers	am encourages application pecialized, commercially a um price limit for the instru are not limited to, X-ray di resonance spectrometers, , and biomedical imagers.	is from group vailable instr ument; howe ffractomete DNA and pr	os of NIH-supported ruments or integrate ever, the maximum a rs, high throughput r otein sequencers, bi	investigators to d systems. The ward is obotic screening osensors,	
108297 <u>S</u>	hared Instrumentation Grant (SI	<u>G) Prograr</u>	n (S10 Clinical Trial Not Allowed	<u>I)</u>	National Institutes of Health/DHHS	PAR-22- 080	01-Jun-2022	600,000 USD	
	Contact Name	Guanghu	(Jeff) Wang, PhD						
	Contact Telephone	301-435-0	0772						
	Contact Email	<u>SIG@mai</u>	l.nih.gov						
	Sponsor Website								
	Program URL	Link to pr	ogram URL						
	Deadline Dates (ALL)	01-Jun-20	)22 , 01-Jun-2022 , 03-Jun-2024						
	Synopsis	The Share purchase instrumen maximum spectrom microsco	ed Instrument Grant (SIG) Progr or upgrade a single item of higl ntation system. The minimum a n award is \$600,000. Instrumen eters, nuclear magnetic resona pes, flow cytometers, and biom	am enc n-pricec ward is ts suppo nce spe edical ir	ourages applications from , specialized, commercially \$50,000. There is no maxin prted include, but are not li ctrometers, DNA and prote magers.	groups of NI / available in mum price li imited to: X- ein sequence	H-supported investig struments or integra mit for the instrume ray diffractometers, ers, biosensors, elect	gators to Ited nt; however, the mass ron and light	
094932 <mark>N</mark>	CCIH Natural Product Early Phas R61/R33 Clinical Trial Required)	<u>e Clinical <sup>-</sup></u>	Trial Phased Innovation Award		National Institutes of Health/DHHS	PAR-20- 218	01-Jun-2022	1,750,000 USD	
	Contact Name	Wendy W	/eber, N.D., Ph.D, M.P.H.						
	Contact Telephone	1272							
	Contact Email	@mail.nih.gov							
	Sponsor Website								
	Program URL	Link to pr	ogram URL						
	Deadline Dates (ALL) 01-Jun-2022 , 07-Sep-2022 , 01-Feb-2023 , 07-May-2023								

SPIN ID Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount				
	This Funct of natura further cl informati This FOA bioavaila on a biolo be award whether outcome Synopsis impact of different treatmen target po milestone intended testing to trials, not be suppo Scientific to this FO	ling Opportunity Announcemen I products (i.e., botanicals, dieta inical testing. Under this FOA, to on of high scientific utility and w will provide up to three years (F bility, and assessment of the na ogical signature(s). If milestones led to replicate the impact of th there is an association between s in a patient population. Applic f the natural product on the biol doses or formulation. In addition t approach that is known to imp pulation that is more responsive e-driven, and directly related to to accelerate the translation of o determine whether continued r will it support trials to test nat rted by the two phases of the R /Research contact for the area of OA.	It (FOA) encourages applications f ary supplements, and probiotics), rials must be designed so that res will support decisions about furthe R61 phase) of support for mileston tural product's effect (i.e., measu is in the R61 phase are achieved, u e natural product on the biological the degree of the impact on the rations are encouraged to design f logical signature by optimizing the on, applications can be designed to pact the same biological signature e. Clinical trials submitted under to the research priorities and mission emerging basic science findings a clinical research is warranted. Th ural products for the treatment o 61/R33 award. Applicants are encour- port science for which they are plan	or investigator-ini which have a stro ults, whether posi er development o ne-driven testing o re of mechanism o p to 3 years of ado al signature(s) whe biological signatur R33 studies to det e delivery of the n o combine the nat e; or study the imp shis FOA are expect on of NCCIH. This F about natural proc is FOA will not sup r prevention of ca couraged to conta ning to develop ar	tiated, early phase ng scientific prem itive or negative, v r testing of the na- of pharmacokineti of action) when us ditional support (R en used by human re and functional of ermine how to op atural product by cural product by cural product with bact of the natural cted to be hypothe R61/R33 funding n ducts into early-sta oport efficacy or	e, clinical trials ise to justify vill provide tural product. cs, ed by humans 33 phase) may s and assess or clinical timize the examining another product in a esis based, nechanism is age clinical ffectiveness of 5 years will NCCIH to submitting				
097095 Promoting Research o Interventions (R61/R3	n Music and Health: I 3 Clinical Trial Option	Phased Innovation Award for M al)	usic National Institutes of Health/DHHS	PAR-20- 266 02-	Jun-2022	1,750,000 USD				
Сог	ntact Name Wen G. C	hen, Ph.D.								
Contact	Telephone 301-451-	3989								
Со	ntact Email <u>chenw@</u>	mail.nih.gov								
Spons	or Website									
Pr	ogram URL Link to pr	L Link to program URL								
Deadline	Dates (ALL) 02-Jun-20	02-Jun-2022 , 17-Jun-2022 , 03-Oct-2022 , 19-Oct-2022 , 02-Jun-2023 , 19-Jun-2023								
	Synopsis an emph	ose of this Funding Opportunity asis on developing music interve	Announcement (FOA) is to prom entions aimed at understanding the state of the st	ote innovative res neir mechanisms o	earch on music ar of action and clinic	nd health with al applications				

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		for the tr data are researche professio mechanis provide fi relevant a technolog mechanis clinical st appropria depend o	eatment of many diseases, diso needed to apply under this FOA ers, translational science resear nals, and technology developm on to support mechanistic resear unding to either investigate the animal models, healthy human gy or approaches to enhance m stic investigations in human sub udies may focus on intervention ate outcome measures to inforr on successful completion of pre-	orders, and conditions. Given the e a. Because of the need for a multid chers, music intervention experts, ent researchers are encouraged. T arch and to evaluate the clinical re biological mechanisms or behavio subjects, and/or clinical populatio usic intervention research. The se jects or animal models, intervention n optimization/refinement, feasibin future clinical research. Transitio specified milestones established i	Imphasis on ini lisciplinary app other clinical in The FOA utilize elevance of mu oral processes ns, or can be u cond R33 phas on developme ility, adherence on from the R6 n the R61.	novation, little or no roach, collaborations researchers, music he s a phased R61/R33 f sic interventions. The underlying music inte sed to develop innov e will provide suppor nt, or pilot clinical stu e, and/or identificatio 1 to the R33 phase o	preliminary among basic ealth unding R61 phase will erventions in ative of for further udies. The pilot on of f the award will
087955	Surgical Disparities Research (RO	1 Clinical T	rial Optional)	National Institutes of Health/DHHS	PAR-20- 079	05-Jun-2022	Not Specified
	Contact Name	Benyam I	Hailu, MD, MPH				
	Contact Telephone	301-594-	8696				
	Contact Emai	Benyam.	Hailu@nih.gov				
	Sponsor Website	į					
	Program URI	Link to pr	ogram URL				
	Deadline Dates (ALL)	05-Jun-20	022				
	Synopsis	The purp on under While the disparitie	ose of this Funding Opportunity standing and addressing dispari goal is to better understand an s, this initiative will also seek to	Announcement (FOA) is to support ities in surgical care and outcomes and explore effectiveness of clinical oridentify multi-level strategies at to	ort investigative s, in minority a intervention a the institutiona	e and collaborative re nd health disparity po approaches for addre al and systems level.	esearch focusec opulations. ssing surgical
090374	In-Depth Phenotyping and Resea Strains Exhibiting Embryonic or P Not Allowed)	rch Using I erinatal Le	MPC-Generated Knockout Mou thality or Subviability (R01 Clini	ise National Institutes of Health/DHHS	PAR-20- 137	05-Jun-2022	2,499,995 USD
	Contact Name	Mahua M	lukhopadhyay, PhD				

Contact Telephone 301-435-6886



SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Contact Email Sponsor Website Program URL Deadline Dates (ALL) Synopsis	mukhopam@mail.nih.gov Link to program URL 05-Jun-2022 , 05-Oct-2022 The purpose of this Funding Opportunity research on embryonic lethal knockout (k Consortium (IMPC) of which the NIH Knoc to generate a comprehensive catalogue of human genetic variation. As of Novem 9,051 mouse genes, completed phenotyp genes. Overall, the IMPC hopes to achieve strains either are expected to be embryou are expected to have viable heterozygous these mouse strains while they are being additional in-depth phenotyping and rese	Announcement (FOA) is to encou (O) mouse strains being generate ckout Mouse Phenotyping Progra of mammalian gene function that ber 2019, the IMPC-KOMP2 KO m bes of 7153 lines, and released da e broad-based phenotyping of ro nic or perinatal lethal, or subviab s phenotypes. The scientific comm created and bred as part of the l earch.	urage applications ed through the Inte em (KOMP2) is a m will provide the for nouse phenotyping ta for 6255 lines of ughly 20,000 KO s le. A large portion nunity has the uni MPC adult mouse	to phenotype and ernational Mouse I nember. The missic pundation for func g effort has genera corresponding to 5 trains. About 30% of homozygous le que opportunity to phenotyping effor	/or perform Phenotyping on of IMPC is tional analyses ted mutants in 361 mutant of these thal mutations o leverage t to perform
105618	Molecular Imaging of Inflammation	on in Cancer (R01 Clinical Trial Not Allowed	d) National Institutes of Health/DHHS	PAR-21- 05- 294	Jun-2022	Not Specified
	Contact Name					
	Contact Telephone	301-945-7573				
	Contact Email	<u>GrantsInfo@nih.gov</u>				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	05-Jun-2022 , 05-Oct-2022 , 05-Feb-2023	, 05-Jun-2023 , 05-Feb-2024 , 05	-Jun-2024		
		The purpose of this Funding Opportunity development and use of current and eme	Announcement (FOA) is to invite erging molecular imaging method	research grant ap s to gain fundame	pplications (R01) fo ental insights into c	r the ancer

inflammation in vivo. The motivation for this initiative is that much of current imaging research into the role of inflammation Synopsis in cancer is largely based on in vitro and ex vivo methods with limited utilization of imaging approaches that could lead to significant new insights relevant to dynamic cancer and inflammation interactions. Utilization of molecular imaging probes in pre-clinical and clinical investigations for precise temporal resolution at the molecular and cellular level are valuable approaches for identification and characterization of in vivo inflammatory cellular physiology in cancers and of molecular

SPIN ID	Program Title		Sponsor Name	Sponsor	Number			Deadline Date	Funding Amount
		changes i approach science re cancer in	n response to treatment. This F les to interrogate the role of inf esearchers and imaging scientis flammation interactions.	FOA enco flammatic sts. These	urages applications that f on in cancer through stro collaborations are expec	focus on dev ng cross-field ted to advan	eloping I collab Ice scie	integrated imagoration betweer nce and underst	ing a cancer basic anding of
109181	Notice of Special Interest (NOSI):	Public Hea	alth Research on Cannabis		National Institutes of Health/DHHS	NOT-DA- 22-003	05-Ju	n-2022	Not Specified
	Contact Name	Marsha L	opez, PhD						
	Contact Telephone	(301) 402	2-1846						
	Contact Emai	( <u>301) 402</u>	<u>-1846</u>						
	Sponsor Website	2							
	Program URI	Link to pr	ogram URL						
	Deadline Dates (ALL)	05-Jun-20 2023 , 05 May-2024	022 , 16-Jun-2022 , 07-Sep-2022 -Jun-2023 , 16-Jun-2023 , 07-Se 4 , 05-Jun-2024 , 16-Jun-2024 ,	2 , 05-Oct ep-2023 , 07-Sep-2(	-2022 , 16-Oct-2022 , 07- 05-Oct-2023 , 16-Oct-202 024 , 05-Oct-2024 , 16-Oc	Jan-2023 , 0 23 , 07-Jan-20 ct-2024 , 07-J	5-Feb-2 024 <i>,</i> 05 lan-202	2023 , 16-Feb-20 5-Feb-2024 , 16- 25 , 05-Feb-2025	23 , 07-May- Feb-2024 , 07- , 16-Feb-2025
	Synopsis	The Natio	onal Institute on Drug Abuse (NI laws and policies in the US and	IDA) is iss I globally (	uing this notice to encou on public health.	rage grant a	oplicati	ons on the effec	ts of changing
109066	Notice of Special Interest (NOSI):	Research	on Drowning Prevention		National Institutes of Health/DHHS	NOT-HD- 21-048	05-Ju	n-2022	Not Specified
	Contact Name	Cinnamo	n A. Dixon, DO, MPH						
	Contact Telephone	301-827-	6189						
	Contact Emai	cinnamor	n.dixon@nih.gov						
	Sponsor Website	2							
	Program URI	Link to pr	ogram URL						
	Deadline Dates (ALL)	05-Jun-2022, 12-Jun-2022, 16-Jun-2022, 07-Sep-2022, 05-Oct-2022, 12-Oct-2022, 16-Oct-2022, 07-Jan-2023, 05-Feb- L) 2023, 12-Feb-2023, 16-Feb-2023, 07-May-2023, 05-Jun-2023, 12-Jun-2023, 16-Jun-2023, 07-Sep-2023, 05-Oct-2023, 12- Oct-2023, 16-Oct-2023, 07-Jan-2024, 05-Feb-2024, 12-Feb-2024, 16-Feb-2024, 07-May-2024							
	Synopsis	Though e have the	pidemiologic research has help greatest efficacy to prevent dro	oed identii owning ar	fy drowning risk factors, l nd/or improve outcomes	little is know after a drow	n abou ning ev	t what intervent ent. Thus, the go	ion strategies bal of this NOSI

SPIN ID	Program	Sponsor Name	Sponsor Number	Deadline Date	Funding
	Title	•	•		Amount

is to encourage and facilitate scientific discovery for drowning prevention, specifically aimed at reducing drowning risk and improving outcomes in three primary domains. Domain 1: Understanding drowning disparities and developing drowning interventions to address these disparities. Rates of drowning vary significantly. Reasons contributing to drowning risks among certain populations are multifaceted and likely related to access and exposure to water, knowledge and skills around water, and behaviors and beliefs. Research evaluating both structural and/or systemic forces which contribute to disparities in drowning risk among children, parents and communities is needed. Development of effective interventions aimed at addressing these factors as they pertain to drowning prevention is critical. Domain 2: Studying the effects of swim instruction on swim skills to prevent drowning. Swim skills, which are often obtained through swim instruction, can decrease drowning risk; however tremendous variability among types and techniques of swim instruction exists. Validated measures which consistently assess swim skill efficacy to prevent drowning at differing ages and developmental abilities are lacking. Metrics which help to identify effective, quality swim instruction to prevent drowning are needed. The development of evidence-based best practices as to when and how to instruct populations most at risk for drowning (such as children of young age, of certain races/ethnicities, with intellectual or developmental disabilities, or those with linguistic or cultural differences), is essential. Domain 3: The adoption, integration and sustainable scale-up of the drowning chain of survival. The five steps of drowning chain of survival can reduce drowning mortality. These steps include: (1) preventing drowning, (2) recognizing distress, (3) providing flotation, (4) removal from water and (5) providing care as needed. Depending on the water source, interventions which constitute these layers of drowning protection exist. Research to advance the adoption, integration and sustainable scale-up of evidence-based drowning prevention interventions and the drowning chain of survival across families and communities is needed.

109172 <u>Microbial-based Cancer Imaging a</u> Not Allowed)	and Therapy - Bugs as Drugs (R01 Clinical Trial	National Institutes of Health/DHHS	PAR-22- 085	05-Jun-2022	Not Specified			
Contact Name	Avi Rasooly, PhD							
Contact Telephone	240-276-6196							
Contact Email	rasoolya@mail.nih.gov							
Sponsor Website								
Program URL Link to program URL								
Deadline Dates (ALL)	Deadline Dates (ALL) 05-Jun-2022 , 05-Oct-2022 , 05-Feb-2023 , 05-Jun-2023 , 05-Oct-2023 , 05-Feb-2024 , 05-Jun-2024 , 05-Oct-20 2025							
Synopsis	This Funding Opportunity Announcement (FOA) bacteriophages, or other non-oncolytic viruses a complex interactions between microorganisms,	DA) solicits grant applications proposing to utilize bacteria, archaebacteria, es and their natural products to study the underlying mechanisms of the ns, tumors, and the immune system, and to explore their clinical potential for						
SPIN ID	Program Title		Sponsor Name	Sponso	r Number		Deadline Da	te Funding Amount
---------	--	--	--	---	--	--	--	---
		cancer im of anti-tu existing to models. A relevant t diagnosis	aging, therapeutics or diagnost mor immunity, or as delivery ve ools and approaches. This FOA applicants are encouraged to ad to microbial-based cancer thera . This funding opportunity is par	ics. Proj ehicles fo will supp ldress bo py (inclu rt of a b	ects can focus on using mic or treatment, diagnosis, or port basic mechanistic and p oth the microbial and tumo uding therapies for oral can roader NCI-sponsored resea	roorganisms imaging, cor preclinical st r aspects of cer), tumor arch on micr	s as anti-tumor age nplementing or syr udies in cell cultur microbial tumor in imaging, tumor de obial based cancer	nts, as activators nergizing with e and animal teractions tection, or therapy.
107841	Risk and Protective Factors of Far Clinical Trial Optional)	nily Health	and Family Level Interventions	<u>s (R01 -</u>	National Institutes of Health/DHHS	PAR-21- 358	05-Jun-2022	Not Specified
	Contact Name	Deborah	E. Linares, PhD, MA					
	Contact Telephone	301-402-2	2516					
	Contact Email	Deborah.	Linares@nih.gov					
	Sponsor Website							
	Program URL	Link to pr	ogram URL					
	Deadline Dates (ALL)	05-Jun-20 2024 , 05-	022 , 07-Sep-2022 , 05-Oct-2022 -Feb-2024 , 07-May-2024 , 05-Ju	2 , 07-Jai un-2024	ו-2023 , 05-Feb-2023 , 07-N , 07-Sep-2024 , 05-Oct-202	/lay-2023 , 0 24 , 07-Jan-2	5-Jun-2023 , 07-Se 025 , 05-Feb-2025	p-2023 , 07-Jan- , 07-May-2025
	Synopsis	The purpo family he and famil	ose of this initiative is to advance alth and well-being and resilien y resilience as critically importa	ce the so ce. The nt areas	ience of minority health an NIMHD Research Framewor of research to decrease di	d health dis rk recognize sparities and	parities by support s family health, far I promote equity.	ing research on nily well-being,
098071	Notice of Special Interest (NOSI):	Simulation	n Modeling and Systems Science	<u>e to</u>	National Institutes of	NOT-MD-	05-lun-2022	Not
	Address Health Disparities				Health/DHHS	20-025	05 501 2022	Specified
	Contact Name	Rada Dag	her, Ph.D., M.P.H.					
	Contact Telephone	301-451-2	2187					
	Contact Email	rada.dagh	ner@nih.gov					
	Sponsor Website							
	Program URL	Link to pr	ogram URL					
	Deadline Dates (ALL)	05-Jun-20	022 , 05-Oct-2022 , 05-Feb-2023	}				
	Synopsis	The purpo and evalu	ose of this Notice of Special Inte nating simulation modeling and	erest is t systems	o support investigative and science to understand and	collaborativ address mi	ve research focused nority health and h	d on developing ealth disparities.

SPIN ID	Program Title	Sponsor Name	Sponso	r Number		Deadline Date	Funding Amount			
105755	Investigator Initiated Research in Clinical Trial Not Allowed)	Computational Genomics and Data Scienc	ce (R01	National Institutes of Health/DHHS	PAR-21- 254	05-Jun-2022	2,500,000 USD			
	Contact Name Contact Telephone	Daniel Gilchrist, Ph.D.								
	Contact Email Sponsor Website	<u>daniel.gilchrist@nih.gov</u>								
	Program URL									
	Deadline Dates (ALL)	Jun-2024								
The purpose of this funding opportunity announcement (FOA) is to invite applications for a broad range of resea in computational genomics, data science, statistics, and bioinformatics relevant to one or both of basic or clinical science, and broadly applicable to human health and disease. This FOA supports fundamental genomics research develops innovative analytical methodologies and approaches, early-stage development of tools and software, a refinement or hardening of software and tools of high value to the biomedical genomics community. Work supp this FOA should be enabling for genomics and be generalizable or broadly applicable across diseases and biologic										
107429	Patient-Clinician Relationship: Imp Experience Health Care Disparitie	proving Health Outcomes in Populations t s (R01 Clinical Trial Optional)	<u>hat</u>	National Institutes of Health/DHHS	PAR-22- 064	05-Jun-2022	Not Specified			
	Contact Name	Larissa Aviles-Santa, MD, MPH								
	Contact Telephone	301-827-6924								
	Contact Email	avilessantal@nih.gov								
	Sponsor Website									
	Program URL	Link to program URL								
	Deadline Dates (ALL)	05-Jun-2022 , 05-Oct-2022 , 05-Feb-2023	, 05-Ju	n-2023 , 05-Feb-2024 , 05-J	un-2024 , 05	-Oct-2024				
The purpose of this Funding Opportunity Announcement (FOA) is to support innovative multi-disciplinary and multi-le (e.g., patient, clinician, interpersonal, health care system, community) research designed to understand how optimizin patient-clinician communication and relationship affects health care outcomes in patients from populations with heal Synopsis disparities. In addition, this initiative will support research to (1) gain an understanding of how the Patient-Clinician Relationship (PCR) in the primary care and chronic disease care settings affects clinical and non-clinical health outcom populations that experience health disparities, and (2) identify best practices and interventions that build and improv- leading to better health outcomes and increased health equity.										

SPIN ID	Program Title		Sponsor Name	Sponso	or Number			Deadline Date	Funding Amount
103967	Screening and Functional Validati (R01 Clinical Trial Not Allowed)	on of Huma	an Birth Defects Genomic Varia	ants	National Institutes of Health/DHHS	PAR-21- 229	05-J	un-2022	2,499,995 USD
	Contact Name Contact Telephone	Mahua Mu 301-435-6	ukhopadhyay, Ph.D. 886						
	Contact Email Sponsor Website	mukhopan	n@mail.nih.gov						
	Program URL	Link to pro	ogram URL						
	Deadline Dates (ALL)	05-Jun-202	22 , 05-Feb-2023 , 05-Jun-2023	8,05-Fe	b-2024 , 05-Jun-2024 , 05-I	eb-2025			
	Synopsis	generation f congent born error ble to the Gabriel ClinGen) lefects-a propriat tween ic con the p	on sequencing technologie nital defects including struct ors of metabolism (IEMs). L ne research community thr la Miller Kids First Data Res . The purpose of this initiat associated genetic variants e animal models, in vitro sy lentifying sequence variati henotype of interest.	s have led to ctural birth d arge quantit ough several source Porta ive is to pror identified th ystems or mu	the i efects ies of data l, the note rough ulti-pr tial in	dentification of g s (SBDs), intellect genomic data co bases such as the European Genom the screening, fun n public facing dat onged approache terest and recogn	enetic variants ual llected from Database of ne-Phenome nctional tabases and es. This nizing which of		
108898	Notice of Special Interest (NOSI): Response Services	Priority Res	search Opportunities in Crisis		National Institutes of Health/DHHS	NOT-MH- 22-110	05-J	un-2022	Not Specified
	Contact Name	Stephen O	'Connor, Ph.D.						
	Contact Telephone	301-480-8	366						
	Contact Email	stephen.o	<u>'connor2@nih.gov</u>						
	Sponsor Website								
	Program URL	Link to pro	ogram URL						
	Deadline Dates (ALL)	05-Jun-202 2023 , 15-l Oct-2023 , , 07-Sep-20	22 , 15-Jun-2022 , 16-Jun-2022 Feb-2023 , 16-Feb-2023 , 07-W 17-Oct-2023 , 07-Jan-2024 , 0 024 , 05-Oct-2024 , 16-Oct-202	:, 07-Se lay-2023 5-Feb-2 24 , 07-J	o-2022 , 05-Oct-2022 , 14-0 8 , 05-Jun-2023 , 15-Jun-20 024 , 15-Feb-2024 , 16-Feb an-2025 , 05-Feb-2025 , 16	Oct-2022 , 16 23 , 16-Jun-2 -2024 , 07-M -Feb-2025 , 0	-Oct- 023 , ay-2( )7-Ma	2022 , 07-Jan-202 07-Sep-2023 , 05 )24 , 05-Jun-2024 ay-2025	23 , 05-Feb- -Oct-2023 , 16- , 16-Jun-2024

SPIN ID	Program Title		Sponsor Name	Sponso	r Number		Deadline Date	Funding Amount
The National Institutes of Health seeks research conducted in real-world settings, where a wide range of presentations, psychosocial factors, age-related (e.g., youth; adult; older adult), geographic (rural/remo- considerations, and health disparities influence the types of care that are provided. Examples of NIMH are encouraged through this Notice address the continuum of crisis service systems. Applications that in for children and under-resourced populations are encouraged. Topics of research interest span the crisi including the effectiveness of these components: call center capabilities to address distress and coordin mobile crisis outreach and support, and crisis services that can diagnose and provide short term stabiliz								
107608	Drug Discovery For Nervous Syste	m Disorde	ers (R01 Clinical Trials Not Allow	<u>ved)</u>	National Institutes of Health/DHHS	PAR-22- 031	05-Jun-2022	Not Specified
	Contact Name	Enrique N	/ichelotti, PhD					
	Contact Telephone	301-443-	5415					
	Contact Email	michelott	<u>iel@mail.nih.gov</u>					
	Sponsor Website							
	Program URL	Link to pr	ogram URL					
	Deadline Dates (ALL)	05-Jun-20	022 , 05-Oct-2022 , 05-Feb-2023	3,05-Ju	n-2023 , 05-Oct-2023 , 05-I	Feb-2024 , 05	-Jun-2024 , 05-Oct-20	024
	Synopsis	This Fund treatmen Identifica Initial hit- to improv will be pla	ing Opportunity Announcemen t of nervous system disorders. tion, design, synthesis, and pre- to-lead chemistry to improve a ve efficacy and pharmacokinetic aced on projects that provide ne	t (FOA) Through clinical t ctivity o cs; and 4 ovel app	supports the discovery of r this FOA, NIMH, NIAAA, N esting of small molecules f f compounds against the ta ) Initial drug metabolism a proaches for identifying pot	novel compou IDA and NIA for their poter arget of inter nd pharmaco tential therap	inds for the prevention wish to stimulate resonation ntial as candidate the est; 3) Later stage lea kinetic properties (D eutic agents.	on and earch in: 1) erapeutics ; 2) d optimization MPK). Emphasis
096053	Behavioral Tasks Targeting Brain S Experimental Studies with Humar	Systems R Is Require	elevant to Anhedonia (R01 Basi d)	<u>c</u>	National Institutes of Health/DHHS	PAR-20- 235	05-Jun-2022	Not Specified
	Contact Name	Andrew F	Rossi					
	Contact Telephone	301-443-	1576					
	Contact Email	<u>rossia@n</u>	nail.nih.gov					
	Sponsor Website							
	Program URL	Link to pr	ogram URL					
	Deadline Dates (ALL)	05-Jun-2(	022 , 05-Oct-2022 , 05-Feb-2023	8 , 05-Ju	า-2023			

SPIN ID	Program Title		Sponsor Name	Sponso	or Number		Deadline Date	Funding Amount		
	Synopsis	This Fund shown to resolution construct involving research. condition humans for disorders. FOAs http improvem of action	ing Opportunity Announcement engage brain systems relevant n. The goal is to identify behavior s associated with anhedonia and human participants that fall wir Types of studies that should su s (i.e., experimentally manipulat or the purpose of understandin . These mechanistic studies are ps://grants.nih.gov/grants/guid nent of the health status of the of an intervention or a measura	nt (FOA) to anhe oral task ind in trea ibmit ur ate inde ibmit ur ate inde g the fu e expecte individu able imp	encourages research to de edonia using neuroimaging as that can be used as quar atment development. This NIH definition of a clinical oder this FOA include studio pendent variables) and that indamental aspects of braited to be appropriate for the e-files/NOT-MH-19-006.htr ual or a group of individual provement in health.	evelop task-based or other brain me ntitative tools in fu FOA is for basic so trial and also mee es that prospective at assess biomedic n function in healt e Basic Experimen ml since they are n s either by better	behavioral measu easures with simila iture studies of th cience experiment et the definition or ely assign human al or behavioral o thy individuals or ital StudiesWith H ot intended to inf understanding the	ares that are ar spatial e functional tal studies f basic participants to utcomes in those with lumans (BESH) form on the e mechanism		
103168 [	Research on Autism Spectrum Dis	sorders (RC	01 Clinical Trial Optional)		National Institutes of Health/DHHS	PA-21-201 05-J	un-2022	Not Specified		
	Contact Name	Lisa Gilott	ty, Ph.D.							
	Contact Telephone	301-443-3825								
	Contact Email	gilottyl@r	mail.nih.gov							
	Sponsor Website									
	Program URL	Link to pr	ogram URL							
	Deadline Dates (ALL)	05-Jun-20	022 , 05-Oct-2022 , 05-Feb-2023	3,05-Ju	n-2023 , 05-Oct-2023 , 05-	Feb-2024				
	Synopsis	The purpor research of Autism Sp based in s mission of interests of prelimina conceptus secondary consider t	ose of this Funding Opportunity designed to elucidate the etiolo bectrum Disorders (ASD). The R scientific areas that represent to f the participating NIH Institute of one or more of the participa ry data are generally expected. al stages of project development y analysis of existing data, and p the companion R03 FOA, PA-21	y Annou ogy, epic esearch he inves es and Co ting NIH Applica nt shoul pilot or -199.	ncement (FOA) is to encou demiology, diagnosis, and o Project Grant (R01) mecha tigators' specific interests enters (ICs). The proposed Institutes and Centers (IC ints pursuing exploratory/o d consider the companion feasibility studies that can	rage research gran optimal means of s anism supports dis and competencies project must be re s) based on their s developmental res R21 FOA, PA-21-2 be completed with	nt applications to service delivery in screte, specified p s, and that fall wit elated to the prog cientific missions, earch to support 00. Applicants pu h limited budgets	support relation to rojects hin the grammatic , and early and rsuing should		

SPIN ID	Program Title	Sp	ponsor Name	Sponso	r Number			Deadline Date	Funding Amount
103023	Academic-Industrial Partnerships fo Treatment (R01 - Clinical Trial Not A	r Translatio llowed)	ion of Technologies for Diagno	osis and	National Institutes of Health/DHHS	PAR-21- 166	05-Ju	ın-2022	2,495,000 USD
	Contact Name N	iguel Ossa	andon MS						
	Contact Telephone 24	10-276-571	14						
	Contact Email og	<u>sandom@</u>	omail.nih.gov						
	Sponsor Website								
	Program URL <u>Li</u>	<u>nk to prog</u> i	ram URL						
	Deadline Dates (ALL) 0	5-Jun-2022	2 , 05-Oct-2022 , 05-Feb-2023	, 05-Ju	n-2023 , 05-Oct-2023 , 05-F	eb-2024			
	Synopsis tr or ca ca ca ca ca ca ca ca ca ca ca ca ca	ne purpose ngineering oplied rese pabilities t are in pre-c articipating sperience k nould estak rategy to c e solution ganization ganization emonstrati ilidate, and eatment, a nd users.	e of this Funding Opportunity developments into methods earch to assess risk, detect, pr to meet evolving requiremen clinical, clinical and non-clinic g institutes. This FOA specifie by engaging the strengths of blish an inter-disciplinary, mu develop and translate a solution will be suitable for end users h. Each partnership should pla- tion of possibility to a status u d otherwise translate technol and/or monitoring of disease	or tools revent, o ts for te al settir s a parti academ Iti-instit ion to th s. Each p an to tra seful in logies th status.	that address problems in b diagnose, treat, and/or mar chnologies and methods re gs, domestic or foreign, for hership structure that is exp ic, industrial, and other inve- utional research team to w heir chosen problem. They a hartnership should include a nsition a technology, meth the chosen setting. Funding at address problems in bio This FOA defines "innovatio	te efforts to h pasic research age disease. elevant to the conditions a pected to help estigators. Th ork in strateg are expected at least one a od, assay, de g may be required logy, patholo on" as likeliho	rrans n to L The adva nd di o brid e pa gic all to pl. cade vice, ueste gy, ri od to	anderstand diseas rationale is to del ance of research iseases within the dge gaps in know rtners on each ap liance to impleme an, design, and va mic and one indu and/or system fr ed to enhance, ad isk assessment, di o deliver a new ca	coveries and se, or in liver new and delivery of e missions of ledge and oplication ent a coherent alidate that listrial om a lapt, optimize, iagnosis, apability to
092568	Research on Myalgic Encephalomye Clinical Trials Not Allowed)	litis/Chron	nic Fatigue Syndrome (ME/CF	<u>S) (R01</u>	National Institutes of Health/DHHS	PAR-20- 165	05-Ju	ın-2022	Not Specified
	Contact Name V	cky Whitte	emore, PhD						
	Contact Telephone 30	)1-496-191	17						
	Contact Email <u>vi</u>	<u>cky.whitte</u>	emore@nih.gov						
	Sponsor Website								
	Program URL <u>Li</u>	<u>nk to prog</u> i	ram URL						

SPIN ID	Program Title		Sponsor Name	Sponso	r Number		Deadline Date	Funding Amount	
	Deadline Dates (ALL) Synopsis	05-Jun-20 This Fund the etiolo (ME/CFS) environm common interested based solution research in pathophy innovative	22, 05-Oct-2022, 05-Feb-2023 ing Opportunity Announcement gy, diagnosis, pathophysiology in diverse groups and across th ental and biological risk factors, mechanisms influencing the mu d in funding interdisciplinary res utions to improve the diagnosis may include the building of scie siological response of organ sys e research that will break new g	t (FOA) of and mar e lifespa the det ltiple af earch th treatm ntific tea tems in rround c	encourages investigator(s)- nifestations of myalgic ence on. Applications that address rerminants of heterogeneit fected body systems in ME nat will enhance our knowle ent, and quality of life of al ams to study and develop b individuals with ME/CFS. A r extend previous discover	initiated applic phalomyelitis/ s gaps in the u y among indivis /CFS are encou edge of disease I persons with piomarkers and pplicants are e	ations that propose chronic fatigue synd nderstanding of the duals with ME/CFS, a raged. The NIH is pa processes and prov ME/CFS. This interdi /or characterize the ncouraged to propose	to examine rome and the rticularly ide evidence- isciplinary se novel and	
091413	Academic-Industrial Partnerships Systems (R01 Clinical Trial Optiona	(AIP) to Tr al)	anslate and Validate In Vivo Im-	aging	National Institutes of Health/DHHS	PAR-20- 155 05	-Jun-2022	Not Specified	
	Contact Name Contact Telephone Contact Email	Christoph 240-781-3 <u>christoph</u>	er M. Hartshorn, Ph.D. 3315 <u>er.hartshorn@nih.gov</u>						
	Program URL Deadline Dates (ALL)	2 - <u>Link to program URL</u>							
	Synopsis	The purpo engineeri contempo and/or dis of an acao partners t this sense scientific would dri likelihood performa clinical tri	bese of this Funding Opportunity ng developments in imaging, da orary problems in understanding sease status for cancer or other demic-industrial partnership: a s to identify and translate a techn e, the FOA acts more as funding or clinical research area. These we the field of imaging, as a who to deliver a new capability to e nce in the chosen setting. This F als that lack translation as the p	Annour ta scien g the fui disease strategic ological mechan partners ole, furtl nd user OA is no	acement (FOA) is to stimula ce and/or spectroscopic te ndamental biology, potenti . A distinguishing feature o alliance of academic and i solution for mitigation of a ism for driving translationa ships are expected to solidi ner than if they had not be s. This FOA will support clir ot intended to support com motivation.	te translation of chnologies into al risk of develo f each applicat ndustrial invest a cancer (or oth al research in in fy pre-existing en formed. This incal trials that imercial produc	of scientific discovering methods or tools the opment, diagnosis, the on to this FOA will be igators who work to er disease-related) p maging more than for collaborations or new FOA defines innova- test functionality, or stion, basic research	es and nat address reatment, re formation ogether as problem. In r a specific w ones that ntion as validate projects, or	

SPIN ID	Program Title		Sponsor Name	Sponso	r Number			Deadline Date	Funding Amount
091506	Novel Mechanism Research on Ne Dementia (R01 Clinical Trial Optio	europsych nal)	iatric Symptoms (NPS) in Alzhei	mer's	National Institutes of Health/DHHS	PAR-20- 157	05-J	un-2022	Not Specified
	Contact Name	Jovier D.	Evans, PhD						
	Contact Telephone	301-443-	1369						
	Contact Email	jevans1@	omail.nih.gov						
	Sponsor Website								
	Program URL	Link to pr	ogram URL						
	Deadline Dates (ALL)	05-Jun-20	022 , 05-Oct-2022 , 05-Feb-2023	3					
	tudies that will er Alzheimer's diser histic understandi t into novel thera and/or ADRD. This High risk/high par anism.	Thance ase (AD) or ing of both peutic targets s FOA uses the yoff projects							
100571	Notice of Special Interest (NOSI):	Enhancing	g Research on Deciphering Mecl	hanisms	National Institutes of	NOT-HL-		un 2022	Not
108371	of COVID-19-Associated Coagulop	<u>athy</u>			Health/DHHS	23-003	02-1	u11-2022	Specified
	Contact Name	Anthony	Agresti						
	Contact Telephone	301-827-	8014						
	Contact Email	agrestia@	<u>Inhlbi.nih.gov</u>						
	Sponsor Website								
	Program URL	Link to pr	ogram URL						
	Deadline Dates (ALL)	05-Jun-20 2023 , 07	022 , 07-Sep-2022 , 05-Oct-2022 -Jan-2024 , 05-Feb-2024 , 07-M	2 , 07-Ja ay-2024	n-2023 , 05-Feb-2023 , 07-N , 05-Jun-2024 , 07-Sep-202	/lay-2023 <i>,</i> 0 4 , 05-Oct-2	5-Jun 024,	-2023 , 07-Sep-20 05-Feb-2025 , 05	)23 , 05-Oct- -Jun-2025
	Synopsis	This Notic Associate hypercoa future de applied to	ce of Special Interest (NOSI) aim ed Coagulopathy (CAC) which ar gulability at genomic, molecula sign of early diagnostics and eff o on-going COVID-19 clinical tria	ns to acc e provo r, and co fective t als.	elerate a comprehensive u ked by vascular endothelial ellular levels. Knowledge ob reatment for high-risk patie	nderstandin, cell injury, f otained from ents as well a	g of tl nyperi i such as ena	he mechanisms o immune response studies may be a able CAC research	f COVID-19- es, and pplied to the findings to be

SPIN ID	Program Title		Sponsor Name	Sponso	or Number		Deadline Date	Funding Amount
109791	Accelerating the Pace of Child He Adolescent Brain Cognitive Devel Allowed)	alth Resea opment (A	arch Using Existing Data from th ABCD) Study (R01-Clinical Trial N	<u>e</u> lot	National Institutes of Health/DHHS	PAR-22- 137	05-Jun-2022	1,250,000 USD
	Contact Name	Julia Zehr	, Ph.D.					
	Contact Telephone	301-443-	1617					
	Contact Email	<u>Zehrj@m</u>	ail.nih.gov					
	Sponsor Website							
	Program URL	Link to pr	ogram URL					
	Deadline Dates (ALL)	05-Jun-20 2023 , 07 May-202	022 , 07-Sep-2022 , 05-Oct-2022 -Jan-2024 , 05-Feb-2024 , 07-M 5	2 , 07-Ja ay-2024	n-2023 , 05-Feb-2023 , 07-I - , 05-Jun-2024 , 07-Sep-202	May-2023 , 0 24 , 05-Oct-2	05-Jun-2023 , 07-Sep-2 2024 , 07-Jan-2025 , 09	2023 , 05-Oct- 5-Feb-2025 , 07-
	Synopsis	The Adole function, are 9-10 communi applicatio More info the R01 g	escent Brain Cognitive Developr substance use, cultural and env years-old and following them lo ity through the NIMH Data Arch ons proposing the analysis of thi prmation about the ABCD Study grant mechanism, whereas its co	ment (A vironme ongitudin nive. The is public v may be ompanic	BCD) Study is collecting dat ntal factors, and brain stru- nally to early adulthood. The purpose of this Funding O use dataset to increase kn found on the ABCD Study on FOA, PAR-22-138, seeks	a on health cture and fu nese data wi pportunity A owledge of web page (v shorter, hig	and mental health, co nction from youth sta Il be made available to Announcement (FOA) i adolescent health and vww.abcdstudy.org). her-risk R21 grant app	gnitive rting when they o the scientific s to encourage development. This FOA uses lications.
102069	Natural History of Disorders Scree Optional)	<u>enable in t</u>	he Newborn Period (R01 Clinica	<u>al Trial</u>	National Institutes of Health/DHHS	PAR-21- 115	05-Jun-2022	Not Specified
	Contact Name	Melissa P	arisi, MD, PhD					
	Contact Telephone	301-435-	6880					
	Contact Email	parisima(	@mail.nih.gov					
	Sponsor Website							
	Program URL	Link to pr	ogram URL					
	Deadline Dates (ALL)	05-Jun-20	022 , 05-Oct-2022 , 05-Feb-2023	3,05-Ju	n-2023 , 05-Oct-2023			
	Synopsis	This fund broad un by newbo	ing opportunity announcement derstanding of the natural histo orn screening. A comprehensive	: (FOA) e ory of di e unders	encourages applications that sorders that already do or o tanding of the natural histo	it propose to could potent ory of a diso	o develop studies that ially benefit from earl rder has been identifie	will lead to a y identification ed as a

SPIN ID Program Title	Sponsor Nam	e Spo	onsor Number		Deadline Date	Funding Amount
	necessary element to fa sequence and timing of the field. In addition, for course, and for other dis understanding of the clii facilitate the field's abili phenotypic expression c manage, and treat symp support and predictive i	cilitate appropriate in the onset of symptor some disorders, spe corders, identification nical outcomes for ar ty to: 1) accurately di f the disorder; 3) ide toms and complication	nterventions for infants identions ms and complications of a disc cific genotype-phenotype com n of modifying genetic, epigen n individual with such a condit iagnose the disorder; 2) under entify underlying mechanisms ons of the disorder; and 5) pro- e disorder.	fied by newborr order, a valuable relations may al etic, or environr ion. Comprehen stand the genet related to basic ovide children ar	screening. By definit resource will be dev ow prediction of the nental factors will en sive data on natural ic and clinical hetero defects; 4) potential and their families with	ing the veloped for e clinical nhance an history will ogeneity and ly prevent, n needed
Notice of Special Interest (NOSI): I110057Disease 2019 (COVID-19) Research Women, Children and Individuals	Emerging and Existing Iss n Related to the Health a with Physical and/or Inte	ues of Coronavirus nd Well-Being of ellectual Disabilities	National Institutes of Health/DHHS	NOT-HD- 22-002	-Jun-2022	Not Specified
Contact Name	Robert Tamburro, MD, N	ЛSc				
Contact Telephone	301-480-2619					
Contact Email	robert.tamburro@nih.g	<u>vc</u>				
Sponsor Website						
Program URL	Link to program URL					
Deadline Dates (ALL)	05-Jun-2022 , 16-Jun-20 2023 , 05-Jun-2023 , 16- May-2024 , 05-Jun-2024	22 , 07-Sep-2022 , 05 Jun-2023 , 07-Sep-20	5-Oct-2022 , 16-Oct-2022 , 07 023 , 05-Oct-2023 , 16-Oct-202	Jan-2023 , 05-Fe 3 , 07-Jan-2024	b-2023 , 16-Feb-202 , 05-Feb-2024 , 16-F	23 , 07-May- eb-2024 , 07-
Synopsis	The purpose of this func addressing these and ot children and adolescent	ling opportunity is to her emerging and exi s, and individuals wit	provide an avenue for resear isting COVID-related issues am h physical and/or intellectual	chers to pursue nong pregnant a disabilities.	funding to conduct in nd lactating people,	research infants,
110112 Leveraging Health Information Technology Health Care Disparities (R01 Clinic	chnology (Health IT) to A al Trial Optional)	ddress and Reduce	National Institutes of Health/DHHS	PAR-22- 145	-Jun-2022	Not Specified
Contact Name	Yewande A. Oladeinde,	Ph.D.				
Contact Telephone	301-402-4307					
Contact Email	<u>beda.jean-francois@nih</u>	.gov				
Sponsor Website						

SPIN ID	Program Title	Sponsor Name	Sponso	or Number		Deadline Date	Funding Amount
	Program URL Lin	k to program URL					
	Deadline Dates (ALL) 20 Ma	Jun-2022 , 07-Sep-2022 , 05-Oct-202 23 , 07-Jan-2024 , 05-Feb-2024 , 07-N y-2025	2 <i>,</i> 07-Jai lay-2024	n-2023 , 05-Feb-2023 , 07-N · , 05-Jun-2024 , 07-Sep-202	1ay-2023 , 05-Jun 4 , 05-Oct-2024 ,	-2023 , 07-Sep-20 07-Jan-2025 , 05-I	23 , 05-Oct- <sup>-</sup> eb-2025 , 07-
_	Th Synopsis inf col	s funding opportunity announcement ormation technology (health IT) to re- nmunication, and health outcomes for	t (FOA) s duce dis or popula	eeks to support research th parities in access to and util ations that experience healt	at examines the i ization of health h disparities in th	mpact of leveragin care services, pation le U.S.	ng health ent-clinician
110034	Notice of Special Interest (NOSI): Res Support the Delivery of Evidence-Bas General Medical Healthcare Settings	earch Using Implementation Science ed Practices in Community-Based Me	<u>To</u> ental or	National Institutes of Health/DHHS	NOT-MH- 22-170 05-J	un-2022	Not Specified
	Contact Name						
	Contact Telephone						
	Contact Email						
	Sponsor Website						
	Program URL <u>Lin</u>	<u>k to program URL</u>					
	05 20 Deadline Dates (ALL) Au 07 20	Jun-2022 , 15-Jun-2022 , 16-Jun-2022 22 , 07-Jan-2023 , 05-Feb-2023 , 15-Fe g-2023 , 07-Sep-2023 , 05-Oct-2023 , May-2024 , 05-Jun-2024 , 16-Jun-202 25 , 07-May-2025	2 , 11-Au 2b-2023 16-Oct-2 4 , 07-Se	g-2022 , 07-Sep-2022 , 05-C , 16-Feb-2023 , 07-May-202 2023 , 17-Oct-2023 , 07-Jan- ep-2024 , 05-Oct-2024 , 16-0	Oct-2022 , 14-Oct <sup>.</sup> 23 , 05-Jun-2023 , 2024 , 05-Feb-20 Oct-2024 , 07-Jan	2022 , 16-Oct-202 15-Jun-2023 , 16- 24 , 15-Feb-2024 , -2025 , 05-Feb-202	2 , 18-Nov- Jun-2023 , 11- 16-Feb-2024 , 25 , 16-Feb-
	Th su Synopsis pe Cli Co	s Notice of Special Interest (NOSI) hig oport the adoption and sustainability ople with mental illness. These setting nics (CCBHCs) funded through the Sub mmunity Behavioral Health Clinic-Exp	hlights i of evide ss could ostance A ansion (	nterest in mental health ser nce-based practices (EBPs) i include, but are not limited Abuse and Mental Health Se CCBHC-E) grant program.	vices and implem n community-bas to, Certified Com ervices Administra	nentation science sed settings that d imunity Behaviora ation (SAMHSA) Ce	research to eliver care to I Health ertified
110102	Notice of Special Interest (NOSI): Dis Advance Mental, Emotional, and Beh	emination and Implementation Rese avioral Health Preventive Interventio	arch to ns in	National Institutes of Health/DHHS	NOT-AT- 22-004 05-J	un-2022	Not Specified

School Settings

Contact Name Beda Jean-Francois, Ph.D.

SPIN ID	Program Title	Sponsor Name	Sponso	r Number		Deadline Date	Funding Amount				
	Contact Telephone	202-313-2144									
	Contact Email	Beda.Jean-Francois@nih.gov									
	Sponsor Website										
	Program URL	Link to program URL									
	Deadline Dates (ALL)	D5-Jun-2022 , 15-Jun-2022 , 16-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 14-Oct-2022 , 16-Oct-2022 , 17-Nov-2022 , 07-Jan-2023 , 05-Feb-2023 , 15-Feb-2023 , 16-Feb-2023 , 17-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 15-Jun-2023 , 16-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 16-Oct-2023 , 17-Oct-2023 , 07-Jan-2024 , 05-Feb-2024 , 15-Feb-2024 , 16-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 05-Jun-2024 , 15-Feb-2024 , 16-Feb-2024 , 07-May-2024 , 05-Jun-2023 , 16-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 15-Feb-2024 , 16-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 05-Feb-2024 , 15-Feb-2024 , 16-Feb-2024 , 07-May-2024 , 05-Jun-2024									
The purpose of this Notice of Special Interest (NOSI) is to stimulate dissemination and implementation research to support innovative approaches to identifying, understanding, and developing strategies for overcoming barriers to the adoption, adaptation, integration, scale-up and sustainability of evidence-based preventive interventions to support children's mer emotional, and behavioral (MEB) health in school settings. This NOSI encourages applications which focus on disseminati and implementation research to deliver interventions in the school setting that will promote healthy MEB development and/or prevent MEB disorders. Applications should include a focus on one of the following: (1) primary/universal preven MEB programs designed to promote healthy MEB development by decreasing risk factors and increasing protective factor to prevent onset of an MEB disorder; or (2) secondary/selective prevention programs designed to support screening and early identification of MEB disorders to slow progression with early intervention. Applications focused on tertiary/indicar treatment of MEB disorders will be considered non-responsive to this Notice.											
109941	Focused Technology Research and	d Development (R01 Clinical Trial Not Allo	owed)	National Institutes of Health/DHHS	PAR-22- 127 05-	Jun-2022	Not Specified				
	Contact Name	Fei Wang, Ph.D.									
	Contact Telephone										
	Contact Email	wangf@mail.nih.gov									
	Sponsor Website										
	Program URL	Link to program URL									
	Deadline Dates (ALL)	05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 2023 , 07-Jan-2024 , 05-Feb-2024 , 07-M May-2025	5-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 07-Sep-2023 , 05-Oct- 023 , 07-Jan-2024 , 05-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 07- /ay-2025								
	Synopsis	This Funding Opportunity Announcemer institutes or Centers (ICs) participating ir	nt (FOA) In the FO	supports projects relevant A that focus solely on the o	to the NIGMS mi development of to	ssion or those of c echnologies with t	ther NIH he potential to				

SPIN ID	Program Title		Sponsor Name	Sponso	r Number		Deadline Date	Funding Amount
		enable ac technical significant of biomed devices, a by human demonstr As such, a biological a focus or	quisition of biomedical knowled innovation for impacting future tly advance the current state of dical research questions. These Igorithms and software, chemic intervention to become resear rated proof-of-concept that hav upplications should not propose questions are not responsive to n optimization, hardening, or ob	dge. Pro biomeo the art outcom cal reage rch tools re remain to test o this FC povious es	ojects should be justified in dical research. Outcomes of and be sufficiently charact es may include, but are no ents and processes, biolog s. The goal of this FOA is to ning significant technical c specific biological question OA and will be administrati strapolations of establishe	a terms of tech or products of terized for app t limited to: la ical molecules o support the of hallenges to f ns. Application vely withdraw d technology	nnical innovation and the proposed projec plication in addressin aboratory instrument or systems that have development of tech ull implementation a ns proposing to test s yn without review. Ap will be a lower priori	l utility of such t should g a broad range s and other e been modified nologies with nd broad utility. pecific oplications with ty for funding.
109721	International Research Ethics Edu Clinical Trial Not Allowed)	ication and	l Curriculum Development Awa	<u>rd (R25</u>	National Institutes of Health/DHHS	PAR-22- 118	07-Jun-2022	1,150,000 USD
	Contact Name	Barbara S	ina, Ph.D.					
	Contact Telephone	301-402-9	9467					
	Contact Email	<u>sinab@m</u>	ail.nih.gov					
	Sponsor Website							
	Program URL	Link to pr	ogram URL					
	Deadline Dates (ALL)	07-Jun-20	22 , 06-Jun-2023 , 06-Jun-2024					
The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this R25 program is to support "the ethics of" educational activities that foster a better understandin biomedical, behavioral and clinical research and its implications. (The overarching goal of this R25 program is to support educational activities that foster a better understanding of "the ethics of" biomedical, behavioral and clinical research are its implications.) To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on: Courses for Skills Development Mentoring Activities Curriculum or Methods Development Research Experiences The Fogarty International Bioethics Training Program aims to increase the number of research intensive institutions in low- and middle-income countries (LMICs) that can provide advanced education in international research ethics. This FOA will support innovative LMIC master's level research ethics ducation programs proposing integrated activities to develop culturally appropriate foundational research ethics curriculum, research ethics career skills development courses, ethics research or practicum experiences, and effective mentoring approaches. Education program supported by this initiative should equip scientists, health professionals and academics in these countries with in-depth knowledge of the ethical principles, processes and policies related to international research. Programs should be designed to activities related to international research.								NIH. The nderstanding of to support research and ties with a Research tensive al research tegrated ills ion programs h in-depth t be designed to

SPIN ID	Program Title		Sponsor Name	Sponso	r Number		De	eadline Date	Funding Amount
		strengthen the critical competencies needed to provide research ethics education, ethical revie consultation to LMIC researchers, their academic or research institutions, governments and int organizations to enhance the application of research ethics principles.							
108601	RFA-MH-22-115 BRAIN Initiativ Specific and Circuit-Specific Proce (UG3/UH3 Clinical Trial Optional)	e: Develop esses in Hu	ment of Novel Tools to Probe C man and Non-Human Primate F	<u>Cell-</u> Brain	National Institutes of Health/DHHS	RFA-MH- 22-115	07-Jun	-2022	Not Specified
	Contact Name	Douglas S	. Kim, Ph.D.						
	Contact Telephone	301-827-6	5463						
	Contact Email	douglas.k	im@nih.gov						
	Sponsor Website								
	Program URL	Link to pr	<u>ogram URL</u>						
	Synopsis	The purpe Announce manipulat are hinde with nove circuit ma additiona especially monitorin cutting-ee human th more dire studies ai species (e	bese of this Brain Research throu ement is to encourage application tion of complex circuits in large red by our lack of ability to mor el cell- and circuit-specific tools inipulation. In addition to ident I challenges. Neuroscience has since the launch of the BRAIN ag, and manipulating tools has b dge tools are increasingly adapt erapeutic strategies for brain d ectly relevant to the human brai med at demonstrating the feasi e.g., non-human primate [NHP]/	igh Adva ons that brains. hitor and will requisification experien lnitiative been dev able to isorders n is the bility of sheep/p	incing Innovative Neuroted will develop and validate Critical advances in the tree d manipulate circuitry in sa uire extensive focused rese and removal of barriers, the need an impressive influx of e. However, the majority of veloped for use in model of arger mammalian brains a . A pressing need to develop focus of this initiative. The using the cutting-edge app ogs).	chnologies (B novel tools to atment of br fe, minimally earch designed he need to de f exciting new f these cell- a rganisms, pri nd, more imp op tools for u initiative will proaches in h	RAIN) Ir o facilita ain diso -invasiv d to rer elineate w reseau nd circu marily r portantl se in lar l suppor umans	nitiative Funding offer the detailed orders in human we ways. Clinical nove barriers fo dysfunctional c rch tools in the uit-specific map odents, fish and y, are emerging orge brains or the rt initial proof o and other mam	; Opportunity analysis and populations intervention or targeted circuitry poses past decade, ping, I flies. These as potential ose that are f principle malian
108852	RFA-NS-22-018 HEAL Initiative: Pain-associated Genes & Cells (U	Discovery 19 Clinical	and Functional Evaluation of Hu Trial Not Allowed)	<u>uman</u>	National Institutes of Health/DHHS	RFA-NS- 22-018	07-Jun [Option	-2022 nal][LOI/Pre-Apj	7,500,000 p] USD
	Contact Name Contact Telephone	D.P. Moha 301-496-9	apatra, PhD 9964						

SPIN ID	Program Title		Sponsor Name	Sponso	r Number		Deadline Date	Funding Amount
	Contact Email	dp.moha	patra@ni.gov					
	Sponsor Website							
	Program URL	Link to pr	ogram URL					
	Deadline Dates (ALL)	07-Jun-20 [Optional	)22 [Optional][LOI/Pre-App], 07 ][LOI/Pre-App], 09-Mar-2023	-Jul-202	2 , 11-Sep-2022 [Optional	l][LOI/Pre-App]	, 11-Oct-2022 , 07-Feb	o-2023
	Synopsis	The purpo comprehe molecular concerted human pa Specify In cooperati the U24 F harmoniz	ose of this funding opportunity ensive datasets for the discover r/cellular pathways that underli d multidisciplinary team science ain processing as part of the NIH tricacies, Origins, and the Natur ve network to promote collabo IEAL Initiative: Human Pain-asso e, and integrate datasets gener	announ y and ch e huma efforts HEAL I re of Hu ration a pociated ated by	cement is to support rese aracterization of function n pain transduction, trans that apply large-scale hig nitiative's Program to Rev man Pain (PRECISION Hur nd coordination of resear Genes & Cells Data Coord this U19 research program	arch that uses nal genetic elen mission, and p h-throughput a real and Evalua nan Pain). U19 ch activities. U2 ination and Inte m.	human tissue or cells t nents, epigenetic signa rocessing. This FOA wi pproaches on tissues te Cells-to-gene Inforr Centers will operate a 19 Centers will also co egration Center that v	o generate atures, and Il support involved in nation that is a ordinate with vill curate,
108853	RFA-NS-22-021 HEAL Initiative: Coordination and Integration Cen	<u>Human Pa</u> iter (U24 C	iin-associated Genes & Cells Da Clinical Trial Not Allowed)	<u>ta</u>	National Institutes of Health/DHHS	RFA-NS- 22-021	07-Jun-2022 [Optional][LOI/Pre-Ap	5,000,000 p] USD
	Contact Name	D.P. Moh	apatra, PhD					
	Contact Telephone	301-496-9	9964					
	Contact Email	dp.moha	oatra@ni.gov					
	Sponsor Website							
	Program URL	Link to pr	ogram URL					
	Deadline Dates (ALL)	07-Jun-20	022 [Optional][LOI/Pre-App], 07	-Jul-202	2 , 11-Sep-2022 [Optional	l][LOI/Pre-App]	, 11-Oct-2022	
	Synopsis	The goal of and Integ Specify In Center wi U19 Center character pain signa Integratio	of this funding opportunity anno- ration Center as part of the NIH tricacies, Origins, and the Natur II curate, harmonize, and integr ers for Discovery and Functiona ization of functional genetic ele al transduction, transmission an on Center will lead efforts to est	ouncem I HEAL II re of Hu rate com I Evalua ments, d proce ablish s	ent is to support a Humar nitiative's Program to Rev man Pain (PRECISION Hur prehensive -omics and ce tion of Human Pain-assoc epigenetic signatures, and ssing. The Human Pain-as patial and semantic stand	n Pain-associate eal and Evaluat nan Pain).The I ellular function iated Genes & d molecular/cel sociated Genes ards for manag	ed Genes & Cells Data e Cells-to-gene Inform Data Coordination and datasets generated by Cells, which include th Iular pathways that un & Cells Data Coordina ing heterogeneous hu	Coordination nation that Integration companion ne nderlie human ation and man pain-

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline	Date	Funding Amount	
		associated tissue coc research d datasets, pathogen	d data types and information, c ordinate systems, and establish community. A central goal of th maps, and other resources on h esis and susceptibility to specifi	ollect ar a web-a e PRECI numan g c pain c	nd register multimodal hun accessible information syste SION Human Pain network genes and cellular function onditions.	nan pain-asso em that can b is to generat phenotypes	ociated data to be widely used t e comprehensi underlying the	commo through ve, inte heterog	n neural out the grated geneity,
087107	RFA-NS-19-044 BRAIN Initiative to Promote Diversity (K99/R00 In	Advanced dependent	l Postdoctoral Career Transition t Clinical Trial Required)	Award	National Institutes of Health/DHHS	RFA-NS- 19-044	08-Jun-2022		Not Specified
	Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL)	Edmund ( 301-496-2 BRAINDIV	Ned) Talley, PhD 1917 <u>/ERSITYK99R00@nih.gov</u> ogram URL 122 11-Oct-2022						
	Synopsis	The purp program i NIH-supp designed degree fro program competiti applicants separate independ to the cor	ose of the NIH BRAIN Initiative is to enhance workforce diversi- orted, independent investigato to facilitate a timely transition om mentored, postdoctoral res will provide independent NIH re- ve, independent research caree s proposing to serve as the lead ancillary study to an existing tri ent clinical trial, or proposing to mpanion FOA (RFA-NS-19-043)	Advance ty in the of outsta earch po esearch ers. This investig al, as pa o gain re	ed Postdoctoral Career Tra neuroscience workforce a diverse backgrounds in BR/ anding postdoctoral resear ositions to independent, te support during this transiti Funding Opportunity Anno gator of an independent cli rt of their research and car search experience in a clin	nsition Award nd maintain AIN Initiative chers with a nure-track or on in order to ouncement (F nical trial, a c reer developr ical trial led b	d to Promote D a strong cohort research areas research and/o equivalent fac o help awardee OA) is designed linical trial feas nent. Applicant by another inve	iversity of new This pro- r clinica ulty pos s to lau d specif sibility s ts not p stigator	(K99/R00) and talented, rogram is al doctorate sitions. The nch ically for tudy, or a lanning an r, must apply
087104	<u>RFA-NS-19-043 BRAIN Initiative</u> to Promote Diversity (K99/R00 In	Advanced dependent	l Postdoctoral Career Transition t Clinical Trial Not Allowed)	Award	National Institutes of Health/DHHS	RFA-NS- 19-043	08-Jun-2022		Not Specified
	Contact Name Contact Telephone Contact Email	Edmund ( 301-496-2 BRAINDIV	Ned) Talley, PhD 1917 <u>/ERSITYK99R00@nih.gov</u>						

SPIN ID	Program Title		Sponsor Name	Sponso	r Number		Deadline Date	Funding Amount	
	Spansor Wabsita								
	Program LIBI	Link to pr	ogram LIRI						
	Deadline Dates (ALL)	08-1un-20	122 11-Oct-2022						
	Synopsis	The purpose of the NIH BRAIN Initiative Advanced Postdoctoral Career Transition Award to Promote Diversity (K99/R00) program is to enhance workforce diversity in the neuroscience workforce and maintain a strong cohort of new and talented, NIH-supported, independent investigators from diverse backgrounds in BRAIN Initiative research areas. This program is designed to facilitate a timely transition of outstanding postdoctoral researchers with a research and/or clinical doctorate degree from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. The program will provide independent NIH research support during this transition in order to help awardees to launch competitive, independent research careers. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Applicants proposing a clinical trial or an ancillary study to an ongoing clinical trial as lead investigator, should apply to the companion FOA REA-NS-19-044							
102690 <u>R</u>	FA-OD-21-004 Maximizing the ollections (R21 Clinical Trial Not	Scientific Allowed)	Value of Existing Biospecimen		National Institutes of Health/DHHS	RFA-OD- 21-004	09-Jun-2022 [Optional][LOI/Pre-Apj	275,000 ] USD	
	Contact Name	Rachel Gr	ana Mayne, PhD						
	Contact Telephone	240-276-5	5899						
	Contact Email	granar@r	<u>nih.gov</u>						
	Sponsor Website								
	Program URL	Link to pr	ogram URL						
	Deadline Dates (ALL)	09-Jun-20	022 [Optional][LOI/Pre-App], 08	-Aug-20	22 , 07-Jan-2023 [Optiona	l][LOI/Pre-App	), 08-Mar-2023		
	Synopsis	The purper relevant t (publicly a collection Nutrition Repositor Screening researche	ose of this Funding Opportunity to the mission of the Food and I available) biospecimens current as associated with the Populatio Examination Survey (NHANES), ry Information Coordinating Cer g Trial. Proposed research shoul ers with an opportunity to gene	Annour Drug Adı Iy store In Assess the Nat Iter (Bio d seek t rate pre	ncement (FOA) is to invite ministration (FDA) - Cente d in repositories in the Un sment of Tobacco and Hea ional Heart, Lung and Bloc LINCC), and the Prostate, o maximize the scientific v liminary data for subseque	R21 application r for Tobacco I ited States. The olth (PATH) Study od Institute's ( Lung, Colorect value of these sent research p	ons to stimulate explora Products (CTP) using ex- is will include, but not idy, the National Healt NHLBI) Biologic Specim cal and Ovarian (PLCO) stored collections and roposals. Other publicl	atory research kisting be limited to, h and een and Data Cancer to provide y available	

SPIN ID	Program Title		Sponsor Name	Sponso	or Number		Deadline Date	Funding Amount
		datasets of the data set. data set. CTP and t to genera and mark to the reg	would be considered, dependin set is unique, and the research The awards under this FOA will he Family Smoking Prevention te findings and data that are di eting of tobacco products to pr gulatory authority of the Food a	g on and question be adm and Tob rectly re otect pu nd Drug	alyses to be conducted. The ns cannot be answered fro inistered by NIH using fun acco Control Act (P.L. 111 elevant in informing the FI ublic health. Research Proj Administration (FDA) - Ce	nese applications r om a publicly availands that have been -31). Research res DA's regulation of jects must address enter for Tobacco	need to provide ju able, nationally re made available th sults from this FOA the manufacture, s the research prio Products (CTP).	stification why presentative, prough FDA- are expected distribution, rities related
102689 <mark>R</mark>	FA-OD-21-003 Secondary Ana lealth (R21 Clinical Trial Not Allo	<u>lyses of Ex</u> wed)	isting Datasets of Tobacco Use	and	National Institutes of Health/DHHS	RFA-OD- 09- 21-003 [Op	Jun-2022 ptional][LOI/Pre-Ap	275,000 op] USD
	Contact Name Contact Telephone Contact Email	Rachel Gr 240-276-5 granar@r	ana Mayne, PhD 5899 <u>hih.gov</u>					
	Sponsor Website							
	Program URL	Link to pr	ogram URL					
	Deadline Dates (ALL)	09-Jun-20	022 [Optional][LOI/Pre-App], 08	-Aug-20	22 , 07-Jan-2023 [Optiona	al][LOI/Pre-App], C	)8-Mar-2023	
	Synopsis	The purpo of existing scientific significan Center fo conducted data sets from a (purposed) may infor using fund (P.L. 111- informing Research Administr	ose of this Funding Opportunity g (publicly available) nationally ideas and/or to generate new r t impact on biomedical or biobe r Tobacco Products (CTP). Othe d; however, nationally represer will need to provide justificatio ublicly available) nationally rep m tobacco regulatory actions in ds that have been made availab 31). Research results from this g the FDA's regulation of the ma Projects must address the rese ration (FDA) - Center for Tobacco	represe nodels, ehaviora r public ntative a n why t resentat of the Un of th	ncement (FOA) is to invite ntative U.S. cross-sectiona systems, tools, methods, al research in areas releva by available data sets woul inalyses will receive priori he data set is unique, and tive data set. This FOA end ited States (U.S.). The awa ugh FDA-CTP and the Famile expected to generate find re, distribution, and mark porities related to the regu- nets (CTP).	R21 applications al and longitudinal or technologies th nt to the Food and ld be considered d ty. Applications no why the research courages the analy ards under this FO ily Smoking Prever dings and data that seting of tobacco p latory authority of	proposing the inner data, to investiga at have the poten d Drug Administrat depending on the a bt using nationally questions cannot vses of public use o A will be administ ntion and Tobacco at are directly releve products to protect f the Food and Dru	ovative analysis te novel tial for ion (FDA) - inalyses to be representative be answered latasets that ered by NIH Control Act vant in t public health.

SPIN ID	Program Title		Sponsor Name	Sponso	or Number		Deadline Date	Funding Amount
103396	RFA-MH-21-180BRAIN Initiative: Access and Manipulation to Broade Neuroscience (U24 Clinical Trial No	Reagent n Distril : Allowe	Resources for Brain Cell Type-S oution of Enabling Technologies d)	<u>pecific</u> for	National Institutes of Health/DHHS	RFA-MH- 1 21-180 [	.2-Jun-2022 Optional][LOI/Pre-Apj	Not o] Specified
	Contact Name D Contact Telephone 3 Contact Email <u>d</u> Sponsor Website	ouglas S 01-827- ouglas.k	5. Kim, Ph.D. 6463 <u>sim@nih.gov</u>					
	Program URL <u>L</u> Deadline Dates (ALL) 1	<u>nk to pr</u> 2-Jun-2(	r <mark>ogram URL</mark> D22 [Optional][LOI/Pre-App], 12	-Jul-202	2			
	T N (I tv Synopsis f c p d d c c u u	his Func eurotec MSIs) an ype-spec wardee or use th ommuni roducec esigned rcuit fun ontribut sers.	ling Opportunity Announcemen chnologies <sup>®</sup> (BRAIN) Initiative is d Institutional Development Aw cific access and manipulation re cific access and manipulation ac s under this FOA will work with aroughout the neuroscience con- ity as well as with the neuroscie I and distributed could include k for selective access to and man- nction with high precision in exp e to the production and distributed	t (FOA) intende vard (ID agents. ross ver the othe nmunity nce reso but are r ipulatio perimen ition of	from the NIH Brain Researc d to support the establishm eA)-eligible institutions for s Reagents will be initially de tebrate species from the BF er Armamentarium awarded r. It is envisioned that the ave earch community to optimize not limited to viral vectors, n of brain cell types. Such re tal animals and ex vivo hum BRAIN Initiative Armament	h through Adv nent of facilities scaled product veloped in pile RAIN Initiative es to manufact wardees will v ze the new rea nucleic acid co eagents will e nan tissue and arium project	vancing Innovative es at minority-serving tion and distribution of ot resource projects for Armamentarium proj ture and distribute th vork both with the Arr agents. The types of re onstructs, and nanopa nable neuroscientists cells. Facilities are ne reagents broadly to n	institutions of brain cell or brain cell ect. e resources mamentarium eagents to be rticles to probe eded to euroscience
109251	RFA-NS-22-048 BRAIN Initiative C Comprehensive Centers for Mouse	<u>onnectiv</u> Brain (L	vity across Scales (BRAIN CONN IM1 Clinical Trial Not Allowed)	<u>ECTS):</u>	National Institutes of Health/DHHS	RFA-NS- 1 22-048 [	.3-Jun-2022 Optional][LOI/Pre-Apj	Not o] Specified
	Contact Name E Contact Telephone 3 Contact Email <u>B</u> Sponsor Website Program URL <u>L</u>	dmund <sup>-</sup> 01-496- RAIN-CC nk to pr	Talley 1917 <u>DNNECTS-Inquiries@nih.gov</u> rogram URL					



SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount				
	Deadline Dates (ALL) Synopsis	13-Jun-2022 [Optional][LOI/Pre-App], 13 This Funding Opportunity Announcement capacity and technical capabilities to man mapping of local and long-range cell-to-or volume of the central nervous system (C reconstructing, analyzing, integrating, dis resulting feasibility data from these awar subsequent five-year funding period for and optimization using additional specie justification is provided. Applications multiple Processing and Data Acquisition, (2) Data Discovery, and (5) Feasibility Metrics and sample collection through data integration streamline processes for sample collection with other datasets of the same and differ collaborative annotation and analyses. T understanding the relationship between CONNECTS Network, consisting of project at developing wiring diagrams that can s	-Jul-2022 , 13-Jun-2023 [O t (FOA) solicits application p mouse brain connectivity cell connectivity at the leve NS), provided the volume sseminating, and interpret rds are expected to inform production of brain-wide v s beyond mouse for testbe st address the following fir a Processing and Managem I Milestones. Successful Ce on and dissemination, usin on and data acquisition, op netruction. They will incorp erent modalities, and for e hey will apply their data to structure and function of rts from this FOA and its co pan entire brains across m	Optional][LOI/Pre-App], 13 as for Comprehensive Cen y, with goals of brain-wide el of synaptic connections is sufficiently large to den ting synapse-level connect on NIH decisions on program wiring diagrams. Applicati ed technology developme ve required research active nent, (3) Integration and D enters will establish and se as state-of-art methods. T otimize protocols for data porate toolsets and infras- easy-access dissemination of address research question brain circuits. Centers will ompanion announcement oultiple scales.	B-Jul-2023 ters to develop the e coverage and co . Proposals may for nonstrate feasibilit tivity maps of enti m continuation in ons may propose nt, if strong scient vity elements: (1) S Dissemination, (4) cale complete pipe hey will automate management, and tructure for seaml to the research co ons of high signific l be integrated int s, as a coordinated	e research mprehensive ocus on a sub- ty of collecting, re brains. The a potential limited testing ific and cost Sample Research elines from and d develop ess integration ommunity for ance for o the BRAIN d effort aimed				
109253 <mark>5</mark>	RFA-NS-22-049 BRAIN Initiative Specialized Projects for Scalable T	Connectivity across Scales (BRAIN CONN Fechnologies (U01 Clinical Trial Not Allowe	ECTS): National Institute ed) Health/DHHS	es of RFA-NS- 13- 22-049 [Op	Jun-2022 tional][LOI/Pre-Ap	Not pp] Specified				
	Contact Name Contact Telephone	Edmund Talley 301-496-1917								
	Sponsor Website	BRAIN-CONNECTS-Inquines@fill.gov								
	Program URL	Link to program URL								
	Deadline Dates (ALL)	LL) 13-Jun-2022 [Optional][LOI/Pre-App], 13-Jul-2022 , 13-Jun-2023 [Optional][LOI/Pre-App], 13-Jul-2023 , 13-Jun-2024 [Optional][LOI/Pre-App], 13-Jul-2024								
	Synopsis	This Funding Opportunity Announcements of generate comprehensive atlases of br	t (FOA) supports Specialize ain connectivity, with an e	ed Projects to develop cu mphasis on human, non-l	rrent or emerging numan primate (N	technologies HP), and				

SPIN ID	Program Title		Sponsor Name	Sponso	or Number		Deadline Date	Funding Amount
		mouse. Pr approach reconstru to enable Proposals Comprehe technolog the BRAIN companic can span	rojects using other species are a es that can be generalized acros iction, analysis, integration, diss faster, more precise, and more are encouraged to develop dist ensive Centers solicited by the o gies, or proposing entirely new, N CONNECTS Network, consistin on announcements, as a coordir entire brains across multiple sca	also per ss speci eminat cost-ef tinct ca compan disrupt g of oth nated ef ales.	mitted, if their use is well ju es. Applications may addre- ion, and interpretation of b fective generation and inte pabilities and competencies ion FOAs, with aims of furth ive, and potentially risky ap her Specialized Projects from fort aimed at developing th	ustified and the g ss any aspect(s) rain connectivity rpretation of brass that may be ex her developing a proaches. Funde n this FOA, and ( ne capabilities to	goal is test and valid of data collection, and associated dat ain-wide wiring diag pected to complemend optimizing curre ad projects will be in Comprehensive Cen generate wiring dia	ate a pipelines, rams. ent nt itegrated into ters from its igrams that
109249	RFA-NS-22-047 BRAIN Initiative Comprehensive Centers for Huma Trial Not Allowed)	<u>Connectiv</u> an and Nor	vity across Scales (BRAIN CONNE n-Human Primate Brain (UM1 C	<u>ECTS):</u> linical	National Institutes of Health/DHHS	RFA-NS- 13- 22-047 [Op	Jun-2022 otional][LOI/Pre-App	Not o] Specified
	Contact Name	Edmund 1	Гalley					
	Contact Telephone	301-496-2	1917					
	Contact Email	BRAIN-CC	NNECTS-Inquiries@nih.gov					
	Sponsor Website							
	Program URL	Link to pr	ogram URL					
	Deadline Dates (ALL)	13-Jun-20	022 [Optional][LOI/Pre-App], 13	-Jul-202	2 , 13-Jun-2023 [Optional][	LOI/Pre-App], 1	3-Jul-2023	
	Synopsis	This Fund capacity a coverage focus on a feasibility maps of e continuat may prop developm research a and Disse scale com	ing Opportunity Announcement and technical capabilities to map and comprehensive mapping of a sub-volume of the central ner- of collecting, reconstructing, and entire brains. The resulting feasi- tion in a potential subsequent fir- ose limited testing and optimiza- nent, if strong scientific and cost activity elements: (1) Sample Pri- mination, (4) Research Discover uplete pipelines from sample col-	t (FOA) o huma f region vous sys halyzing bility da ve-year ation us justific ocessin ry, and llection	solicits applications for Cor n and non-human primate ( -to-region connectivity at the stem (CNS), provided the vo g, integrating, disseminating ata from these awards are ef- funding period for product ing additional species beyo ration is provided. Application g and Data Acquisition, (2) (5) Feasibility Metrics and N through data integration a	nprehensive Cer (NHP) brain conr he level of axona olume is sufficier g, and interpretir expected to infor tion of brain-wid ond human and N ons must addres Data Processing Ailestones. Succe nd dissemination	ters to develop the lectivity, with goals il projections. Propo- atly large to demons og projection-level of m NIH decisions on e wiring diagrams. A IHPs for testbed teo s the following five and Management, ( essful Centers will es n, using state-of-art	research of brain-wide osals may strate connectivity program Applications hnology required (3) Integration stablish and methods.

SPIN ID	Program Title		Sponsor Name	Sponso	r Number		Deadline Date	Funding Amount			
		They will managem infrastruc dissemina research Centers w announce scales.	automate and streamline proce nent, and develop solutions for sture for seamless integration w ation to the research communit questions of high significance for vill be integrated into the BRAIN ements, as a coordinated effort	esses for highly a ith othe y for col or under I CONNE aimed a	sample collection and dat ccurate circuit reconstruct r datasets of the same and laborative annotation and standing the relationship ECTS Network, consisting o t developing wiring diagra	ta acquisition ion. They wil d different m l analyses. Th between stru of projects fro ams that can	a, optimize protocols fo I incorporate toolsets a odalities, and for easy- ney will apply their data acture and function of b om this FOA and its con span entire brains acro	r data nd access to address orain circuits. opanion ss multiple			
097805 <mark>R</mark> <u>C</u>	FA-MH-20-600 BRAIN Initiativ linical Trial Optional)	<u>e: Data Ar</u>	chives for the BRAIN Initiative (I	<u>824</u>	National Institutes of Health/DHHS	RFA-MH- 20-600	14-Jun-2022 [Optional][LOI/Pre-Ap	Not pp] Specified			
	Contact Name	Ming Zha	n, Ph.D.								
	Contact Telephone	301-827-3	3678								
	Contact Email	ming.zha	<u>ıg.zhan@nih.gov</u>								
	Sponsor Website										
	Program URL	Link to pr	ogram URL								
	Deadline Dates (ALL)	14-Jun-2022 [Optional][LOI/Pre-App], 14-Jul-2022 , 14-Jun-2023 [Optional][LOI/Pre-App], 14-Jul-2023									
	Synopsis	This Fund store, and to incorp The data FOA. A go standards research.	ling Opportunity Announcemen d curate data related to BRAIN I porate tools that allow users to a archives will use appropriate sta pal of this program is to advance s and summary information that	t (FOA) nitiative nalyze a andards e researd t is broa	solicits applications to dev e activities. The data archiv and visualize the data, but to describe the data, but ch by creating a communit dly available and accessib	relop web-actives teams will the creation the creation the creation ty resource d le to the rese	cessible data archives to l work with the researc of such tools is not par of such standards is no ata archive with approp arch community for fur	o capture, h community t of this FOA. t part of this priate thering			
105415 <mark>T</mark>	echnology Development for Sins linical Trial Not Allowed)	<u>gle-Molecu</u>	Ile Protein Sequencing (R43/R44	<u>1</u>	National Institutes of Health/DHHS	PAR-21- 247	15-Jun-2022	Not Specified			
	Contact Name	Tina Gatli	n, Ph.D.								
	Contact Telephone	301-480-2	2280								
	Contact Email	gatlincl@	nih.gov								
	Sponsor Website										

SPIN ID	Program Title		Sponsor Name	Sponso	r Number		Deadline Date	Funding Amount					
	Program URL	Link to pr	ogram URL										
	Deadline Dates (ALL)	15-Jun-20	)22 , 15-Jun-2023										
This Funding Opportunity Announcement (FOA) solicits R43/R44 grant applications to catalyze major advance molecule protein sequencing through technology development. The goal of this initiative is to achieve techno Synopsis advances over the next five years that enable generation of protein sequencing data at sufficient scale, speed accuracy to use routinely in studies of genome biology and function, and in biomedical and clinical research i Exploration of methods other than those currently being commercialized is highly encouraged.													
109173	Microbial-based Cancer Imaging a Not Allowed)	and Therap	oy - Bugs as Drugs (R21 Clinical <sup>-</sup>	<u>Frial</u>	National Institutes of Health/DHHS	PAR-22- 086	.6-Jun-2022	275,000 USD					
	Contact Name	Avi Rasoc	ly, PhD										
	Contact Telephone	240-276-0	5196										
	Contact Email	rasoolya@	oolya@mail.nih.gov										
	Sponsor Website												
	Program URL	Link to pr	<u>ink to program URL</u>										
	Deadline Dates (ALL)	16-Jun-20 2025	022 , 16-Oct-2022 , 16-Feb-2023	, 16-Jur	n-2023 , 16-Oct-2023 , 16-	Feb-2024 , 16	un-2024 , 16-Oct-20	)24 , 16-Feb-					
	Synopsis	This Fund bacteriop complex i cancer im of anti-tu existing to models. A relevant t diagnosis	ing Opportunity Announcemen hages, or other non-oncolytic v interactions between microorga aging, therapeutics or diagnost mor immunity, or as delivery ve cools and approaches. This FOA v Applicants are encouraged to ad to microbial-based cancer thera This funding opportunity is par	t (FOA) s iruses a anisms, t ics. Proj chicles fo will supp dress bo py (inclu t of a br	solicits grant applications and their natural products to sumors, and the immune s ects can focus on using mi for treatment, diagnosis, or port basic mechanistic and oth the microbial and tume uding therapies for oral can oader NCI-sponsored rese	proposing to un to study the un ystem, and to croorganisms a imaging, comp preclinical stu- or aspects of m ncer), tumor in arch on microb	ilize bacteria, archa derlying mechanism explore their clinical as anti-tumor agents plementing or syner dies in cell culture an icrobial tumor inter haging, tumor detect ial based cancer the	ebacteria, s of the potential for s, as activators gizing with nd animal actions tion, or erapy.					
104714 <mark>(</mark>	imited Competition: Promoting a R34 Clinical Trial Not Allowed)	a Basic Un	derstanding of Chemical Threat	s to Skin	National Institutes of Health/DHHS	PAS-21- 245	.6-Jun-2022	450,000 USD					
	Contact Name Contact Telephone	Hung Tse 301-496-0	ng PhD 0810										

SPIN ID	Program Title		Sponsor Name	Sponso	r Number		Deadline D	ate	Funding Amount
	Contact Email	tsengh@	mail.nih.gov						
	Sponsor Website								
	Program URL	Link to pr	rogram URL						
	Deadline Dates (ALL)	16-Jun-20	022 , 16-Oct-2022 , 16-Feb-2023	s , 05-Ju	n-2023 , 16-Oct-2023 , 16-	Feb-2024 , 16	6-Jun-2024		
	Synopsis	This Func research populatic pathways	ling Opportunity Announcemen community to contribute to bas on, with an emphasis on investig s and therapeutic targets for cou	t (FOA) sic unde gating th unterme	is to support applications t rstanding of skin injuries ca e commonalities of such in easure development.	to a new NIA aused by che njuries and ic	MS initiative to er mical threats to t lentifying potenti	ncoura he civ al sha	ige the skin ilian red signaling
108897	Notice of Special Interest (NOSI): among Children and Preteens	<u>Assessme</u>	nt of Suicide Thoughts and Beha	aviors	National Institutes of Health/DHHS	NOT-MH- 22-086	16-Jun-2022		Not Specified
	Contact Name	Eric R. M	urphy, PhD						
	Contact Telephone	301-443-	9230						
	Contact Email	eric.mur	ohy@nih.gov						
	Sponsor Website								
	Program URL	Link to pr	rogram URL						
	Deadline Dates (ALL)	16-Jun-20 2023 <i>,</i> 07	022 , 07-Sep-2022 , 16-Oct-2022 -Jan-2024 , 16-Feb-2024 , 07-Ma	2 , 07-Jai ay-2024	ו-2023 , 16-Feb-2023 , 07-ו	May-2023 , 1	.6-Jun-2023 , 07-S	Sep-20	23 , 16-Oct-
	Synopsis	The purp related to purposes consider strategies	ose of this Notice of Special Inte o the developmentally and cultu of this NOSI, children/preteens issues relevant to the assessment s for assessment among youth f	erest (No irally ap are def nt of div rom mir	DSI) is to encourage advan propriate characterization ined as youth 12 years old rerse youth, including the a noritized backgrounds and,	ce research t and assessm and younger acceptability /or sexual an	hat addresses ou bent of STB in chil r. NIMH encourag and cultural relev d gender minorit	tstanc dren/  ;es ap  /ance y yout	ing questions preteens. For plications that of the h.
092569	Research on Myalgic Encephalom Clinical Trials Not Allowed)	nyelitis/Ch	ronic Fatigue Syndrome (ME/CF	<u>S) (R21</u>	National Institutes of Health/DHHS	PAR-20- 168	16-Jun-2022		275,000 USD
	Contact Name	Vicky Wh	ittemore, PhD						
	Contact Telephone	301-496-	1917						
	Contact Email	<u>vicky.whi</u>	ttemore@nih.gov						
	Sponsor Website								

SPIN ID	Program Title		Sponsor Name	Sponse	or Number		Deadline Date	Funding Amount		
	Program URL	Link to pr	ogram URL							
	Deadline Dates (ALL)	16-Jun-20		3						
	This Funding Opportunity Announcement (FOA) encourages investigator(s)-initiated applications that propose to examine the etiology, diagnosis, pathophysiology and manifestations of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) in diverse groups and across the lifespan. Applications that address gaps in the understanding of the environmental and biological risk factors, the determinants of heterogeneity among individuals with ME/CFS, and the common mechanisms influencing the multiple affected body systems in ME/CFS are encouraged. The NIH is particularly interested in funding interdisciplinary research that will enhance our knowledge of disease processes and provide evider subscriptions to improve the diagnosis, treatment, and quality of life of all persons with ME/CFS. This interdisciplinary research may include the building of scientific teams to study and develop biomarkers and/or characterize the pathophysiological response of organ systems in individuals with ME/CFS. The R21 Grant mechanism is intended to supprint involution, high impact research projects. Such projects would either 1) generate pilot data to assess the feasibility of a novel avenue of investigation; 2) involve high risk experiments that could lead to a breakthrough in ME/CFS; 3) demonst the feasibility of new technologies that could have a major impact on ME/CFS research. Applications submitted under th mechanism should be limited to those with the potential for truly ground-breaking impact.									
087474	Research Infrastructure Developm - Clinical Trial Optional)	nent for In	nterdisciplinary Aging Studies (R	21/R33	National Institutes of Health/DHHS	PAR-20- 070	5-Jun-2022	1,775,000 USD		
	Contact Name	Winifred	K. Rossi							
	Contact Telephone	301-496-3	3836							
	Contact Email	<u>rossiw@r</u>	<u>mail.nih.gov</u>							
	Sponsor Website									
	Program URL	Link to pr	ogram URL							
	Deadline Dates (ALL)	16-Jun-20	022 , 16-Oct-2022							
	This FOA invites applications that propose to develop novel research infrastructure that will advance the science of aging in specific areas requiring interdisciplinary partnerships or collaborations. This FOA will use the NIH Phased Innovation Award (R21/R33) mechanism to provide up to 2 years of R21 support for initial developmental activities and up to 3 years of R33 support for expanded activities. Through this award, investigators will develop a sustainable research infrastructure to support projects that address key interdisciplinary aging research questions.									
091508	Novel Mechanism Research on Ne Dementia (R21 Clinical Trial Optio	europsych mal)	iatric Symptoms (NPS) in Alzhei	imer's	National Institutes of Health/DHHS	PAR-20- 159	5-Jun-2022	275,000 USD		
			NIH Eunding Opportu	nitios D	uo: luno 2022					

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount					
	Contact Nama	Louior D. Evans, PhD									
	Contact Name										
	Contact Telephone	501-445-1509									
		Jevansi@mail.inii.gov									
	Sponsor website										
	Program URL	LINK to program ORL	22								
	Deadline Dates (ALL)	The goal of this Funding Opportunity (									
	Synopsis	cnowledge of mechanisms associated with neuropsychiatric symptoms (NPS) in persons with Alzheimer's disease (AD Alzheimer's disease-related dementia (ADRD). The findings are expected to advance mechanistic understanding of bo biobehavioral and neurobiological pathways leading to NPS. Findings may also provide insight into novel therapeutic t that can be advanced into interventions to treat and prevent the development of NPS in AD and/or ADRD. PAR-20-15 the R01 grant mechanism, while PAR-20-159 uses the R21 mechanism. High risk/high payoff projects that lack prelimi data or utilize existing data may be most appropriate for the R21 mechanism.									
100734	Exploring the Scientific Value of E Collections (R21/R33 - Clinical Tria	xisting or New Sepsis Human Biospecim al Not Allowed)	en National Institutes of Health/DHHS	PAR-21- 16 077	Jun-2022	Not Specified					
	Contact Name	Xiaoli Zhao, Ph.D.									
	Contact Telephone										
	Contact Email	<u>xiaoli.zhao@nih.gov</u>									
	Sponsor Website										
	Program URL	Link to program URL									
	Deadline Dates (ALL)	16-Jun-2022 , 16-Oct-2022									
	Synopsis	The purpose of this funding opportunity biospecimens and associated clinical da goals of this FOA are to determine the s testbeds for studies on human sepsis an human biospecimens, thus maximizing submit proof of concept and scale-up st	y announcement (FOA) is to suppo ata from critically ill patients, ultima scientific value of existing or newly nd to provide guidance on the best their value for the entire sepsis res tudies to determine the scientific v	rt efficient collection ately for use in mean collected sepsis ha practices for colle search community. alue of existing or	on, banking, and s chanistic research uman biospecimer cting, utilizing, and This FOA invites a new collections of	haring of on sepsis. The n sets as d analyzing applicants to f human sepsis					

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	------------------	--------------	----------------	---------------	-------------------

cutting-edge technologies in the analysis of these biospecimens is highly encouraged. Studies should focus on: 1) assessment of the utility of existing biospecimen repositories from critically ill and septic patients for future mechanistic research; or 2) development of improved methods for de novo collection and analysis of biospecimens from critically ill patients, ultimately for mechanistic studies of sepsis. The proposed studies should be information-gathering and useful for hypothesis generation; the final results should be data and approaches that can ultimately form the basis for future mechanistic studies and biospecimen collection efforts. Mechanistic studies based on testable hypotheses already formed should be submitted to other opportunities for research grants (e.g., R01 or R35 applications). Applications to solely support novel technology development should be submitted for the Technology Development program. Interventional studies that meet the NIH definition for a clinical trial, or studies including animal models of sepsis, will not be accepted. The FOA will provide support for up to two years (R21 phase) for research planning activities and feasibility studies, followed by the possible transition to up to an two additional years of scaled-up, expanded, or confirmatory research support (R33 phase). Ideally, in the R21 phase, applicants should test new methods for biospecimen acquisition and/or verify the quality of those or existing biospecimens, and identify assays useful for future mechanistic research. The R33 phase should focus on scale-up activities to generate data useable to formulate testable hypotheses of the prediction, development, complexity, and resolution of sepsis in humans. The total project period for an application may not exceed four years. This FOA requires applicantidentified measurable R21 phase milestones, which will be used to determine whether an award transitions to the R33 phase. Transition to the R33 phase is not automatic, and NIGMS anticipates that about half of the funded R21 phase awards may progress to the R33 phase award.

107609 Drug Discovery For Nervous Syste	em Disorders (R21 Clinical Trials Not Allowed)	National Institutes of Health/DHHS	PAR-22- 032	16-Jun-2022	275,000 USD
Contact Name	Enrique Michelotti, PhD				
Contact Telephone	301-443-5415				
Contact Email	michelottiel@mail.nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	16-Jun-2022 , 16-Oct-2022 , 16-Feb-2023 , 16-Ju	n-2023 , 16-Oct-2023 , 16-	Feb-2024 , 1	.6-Jun-2024 , 16-Oct-	2024
Synopsis	This Funding Opportunity Announcement (FOA) treatment of nervous system disorders. Through Identification, design, synthesis, and preclinical Initial hit-to-lead chemistry to improve activity of to improve efficacy and pharmacokinetics; and	supports the discovery of a this FOA NIMH, NIA, NIA, testing of small molecules of compounds against the t 4) Initial drug metabolism a	novel compo AA and NIDA for their pot arget of inte and pharmac	ounds for the preven wish to stimulate re- ential as candidate the crest; 3) Later stage le cokinetic properties (	tion and search in: 1) terapeutics; 2) ad optimization DMPK). Emphasis

SPIN ID	IN ID Program Title		Sponsor Name	Sponso	or Number		Deadline Date	Funding Amount		
		will be placed on projects that provide novel approaches for identifying potential therapeutic agents. This FOA will als support applications proposing preclinical discovery of biotechnology products and biologics with potential as candida therapeutics including, but not limited to, large biologic macromolecules, (e.g., proteins, antibodies, and peptides), ge based therapies (i.e., oligonucleotide- and viral-based), cell therapies, and novel emerging therapies (e.g., microbial a microbiome therapies).								
103180	Research on Autism Spectrum Dis	sorders (R2	21 Clinical Trial Optional)		National Institutes of Health/DHHS	PA-21-200 16-J	un-2022	275,000 USD		
	Contact Name	Lisa Gilot	ty, Ph.D.							
	Contact Telephone	301-443-3	3825							
	Contact Email	gilottyl@	mail.nih.gov							
	Sponsor Website									
Program URL Link to program URL										
	Deadline Dates (ALL)	16-Jun-20	022 , 16-Oct-2022 , 16-Feb-2023	, 16-Ju	n-2023 , 16-Oct-2023 , 16-	Feb-2024				
	Synopsis	The purpor research Autism Sp by provid ground ou required studies th pursuing R01 FOA,	ose of this Funding Opportunity designed to elucidate the etiolo pectrum Disorders (ASD). The Ri- ing support for the early and co r extend previous discoveries to but may be included if available hat can be completed with limited arger studies in established scie PA-21-201.	Annoui 21 grant nceptua ward ne Applic ed budg entific a	ncement (FOA) is to encou lemiology, diagnosis, and mechanism is intended to al stages of project develo ew directions are appropri ants pursuing secondary a ets should consider the co reas where preliminary da	arage research gran optimal means of so o encourage exploi pment. Explorator ate for this mecha nalysis of existing ompanion R03 FOA ata are expected sh	nt applications to service delivery in ratory/developme y, novel studies th nism. No prelimin data, and pilot or ,PA-21-199. Appl nould consider the	support relation to ental research at break new ary data are feasibility icants companion		
103183	Research on Autism Spectrum Dis	sorders (R(	)3 Clinical Trial Optional)		National Institutes of Health/DHHS	PA-21-199 16-J	un-2022	100,000 USD		
	Contact Name	Lisa Gilot	ty, Ph.D.							
	Contact Telephone	301-443-3	3825							
	Contact Email	gilottyl@	mail.nih.gov							
	Sponsor Website									
	Program URL	<u>Link to pr</u>	ogram URL							

SPIN ID	Program Title		Sponsor Name	Sponso	r Number		Deadline Date	Funding Amount
	Deadline Dates (ALL) Synopsis	16-Jun-20 The purp research Autism Sp years and technolog in applica early and pursuing R01 FOA,	022 , 16-Oct-2022 , 16-Feb-2023 ose of this Funding Opportunity designed to elucidate the etiolo pectrum Disorders (ASD). An RO d that require limited resources. gy, secondary analysis of existin ations proposing pilot or feasibil conceptual stages of project de larger studies in established scie PA-21-201.	3, 16-Jur Annour gy, epid 3 grant s R03 app g data, a ity studi evelopm entific an	n-2023 , 16-Oct-2023 , 16-F acement (FOA) is to encour emiology, diagnosis, and o supports small, discrete, we plications may include deve and pilot or feasibility studi es. Applicants pursuing exp ent should consider the con reas where preliminary dat	eb-2024 age research ptimal means ell-defined pro elopment of n es. Preliminar oloratory/deve mpanion R21 a are expecte	grant applications to of service delivery in bjects that can be cor ew research method y data are not requir elopmental research FOA, PA-21-200. App d should consider the	support relation to npleted in two ologies or ed, particularly to support licants e companion
109792	Accelerating the Pace of Child Hea Adolescent Brain Cognitive Develo Allowed)	alth Resea opment (A	rch Using Existing Data from the ABCD) Study (R21-Clinical Trial N	<u>e</u> lot	National Institutes of Health/DHHS	PAR-22-	l6-Jun-2022	275,000 USD
	Contact Name	Julia Zehr	r, Ph.D.					
	Contact Telephone	301-443-	1617					
	Contact Email	<u>Zehrj@m</u>	ail.nih.gov					
	Sponsor Website							
	Program URL	Link to pr	ogram URL					
	Deadline Dates (ALL)	16-Jun-20 2023 , 07 May-202	022 , 07-Sep-2022 , 16-Oct-2022 -Jan-2024 , 16-Feb-2024 , 07-Ma 5	2 , 07-Jar ay-2024	n-2023 , 16-Feb-2023 , 07-N , 16-Jun-2024 , 07-Sep-202	/lay-2023 , 16 24 , 16-Oct-20	Jun-2023 , 07-Sep-20 24 , 07-Jan-2025 , 16	023 , 16-Oct- -Feb-2025 , 07-
	Synopsis	The Adole function, are 9-10 communi applicatio More info shorter, h	escent Brain Cognitive Developr substance use, cultural and env years-old and following them lo ity through the NIMH Data Arch ons proposing the analysis of thi ormation about the ABCD Study higher-risk	nent (AE vironmen ngitudin ive. The s public may be	BCD) Study is collecting data ntal factors, and brain struct ally to early adulthood. Th purpose of this Funding Op use dataset to increase kno found on the ABCD Study	a on health ar cture and func- lese data will oportunity An owledge of ad web page (ww	id mental health, cog tion from youth star be made available to nouncement (FOA) is olescent health and vw.abcdstudy.org). T	nitive ting when they the scientific to encourage development. his FOA seeks
105756	Investigator Initiated Research in Clinical Trial Not Allowed)	Computat	tional Genomics and Data Scient	<u>ce (R21</u>	National Institutes of Health/DHHS	PAR-21-	16-Jun-2022	275,000 USD

SPIN ID	Program Title		Sponsor Name	Sponso	r Number		Deadline Date	Funding Amount
	Contact Name	Daniel Gil	lchrist, Ph.D.					
	Contact Telephone							
	Contact Email	daniel.gil	<u>christ@nih.gov</u>					
	Sponsor Website							
	Program URL	Link to pr	ogram URL					
	Deadline Dates (ALL)	16-Jun-20	022 , 16-Oct-2022 , 16-Feb-2023	, 16-Ju	n-2023 , 16-Oct-2023 , 16-	Feb-2024 , 16-J	lun-2024	
Synopsis Synopsis FOA should be enabling for genomics and tools of high value to the biomedical genomics community. Work supported this FOA should be enabling for genomics and be generalizable or broadly applicable across diseases and biological sy								
108358	Exploratory/Developmental Bioer Trial Not Allowed)	ngineering	Research Grants(EBRG) (R21 Cl	<u>inical</u>	National Institutes of Health/DHHS	PAR-22- 090	16-Jun-2022	275,000 USD
	Contact Name	Miguel R.	Ossandon, Ph.D.					
	Contact Telephone	240-276-	5714					
	Contact Email	<u>ossandon</u>	n@mail.nih.gov					
	Sponsor Website							
	Program URL	<u>Link to pr</u>	ogram URL					
	Deadline Dates (ALL)	16-Jun-20	)22 , 16-Oct-2022 , 16-Feb-2023	, 16-Ju	n-2023 , 16-Oct-2023 , 16-	Feb-2024 , 16-J	un-2024 , 16-Oct-20	24
Synopsis The purpose of this engineering-oriented funding opportunity announcement (FOA) is to encourage submissions of exploratory/developmental Bioengineering Research Grant (EBRG) applications to demonstrate feasibility and potentia utility of new capabilities or improvements in quality, speed, efficacy, operability, costs, and/or accessibility of solution problems in basic biomedical, pre-clinical, or clinical research, clinical care delivery, or accessibility								
101555	Early Stage Investigator Research Clinical Trial Not Allowed)	Using Nor	human Primate (NHP) Models	( <u>R21</u>	National Institutes of Health/DHHS	PAR-21- 109	L6-Jun-2022	400,000 USD
	Contact Name	Manuel N	/loro, DVM, Ph.D.					

Contact Telephone 301-480-1796

SPIN ID	Program Title		Sponsor Name	Sponso	or Number			Deadline Date	Funding Amount			
	Contact Email	manuel.n	noro@nih.gov									
	Sponsor Website											
	Program URL	Link to pr	<u>c to program URL</u>									
	Deadline Dates (ALL)	16-Jun-20	022 , 16-Oct-2022 , 16-Feb-2023	8,16-Ju	n-2023 , 16-Oct-2023 , 16-	Feb-2024						
Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to support research using not models performed by early-stage investigators who are within 10 years of their terminal degree have at least two years of postdoctoral experience. This FOA is designed specifically for applic research directions using NHP models in basic science or translational research.							onhuman primat ee or residency t ants proposing t	e (NHP) raining and o develop new				
100042	Fechnology Development Resear	ch for Esta	blishing Feasibility and Proof of		National Institutes of	PAR-22-	10 10	- 2022	275,000			
109942	<u> Concept (R21 - Clinical Trial Not A</u>	llowed)			Health/DHHS	126	10-JU	in-2022	USD			
	Contact Name	Fei Wang	, Ph.D.									
	Contact Telephone											
	Contact Email	wangf@n	nail.nih.gov									
	Sponsor Website											
	Program URL	Link to pr	ogram URL									
	Deadline Dates (ALL)	16-Jun-20 2023 , 07 May-202!	L6-Jun-2022, 07-Sep-2022, 16-Oct-2022, 07-Jan-2023, 16-Feb-2023, 07-May-2023, 16-Jun-2023, 07-Sep-2023, 16-Oct- 2023, 07-Jan-2024, 16-Feb-2024, 07-May-2024, 16-Jun-2024, 07-Sep-2024, 16-Oct-2024, 07-Jan-2025, 16-Feb-2025, 07- May-2025									
	Synopsis	This Fund technolog participat potential the curre software, to becom for feasib FOA does applicatic research. prelimina	ling Opportunity Announcemen gies for biomedical research that ing in this FOA. Projects should impact in biomedical research. Int state of the art, may include, chemical reagents and process re research tools. The goal of th ility and exploratory technology not support technology develop ons should propose developmen Moreover, feasibility of the pro- ry data. Applications that are for	t (FOA) at is rele entail a Outcom but are ses, biolo is FOA is y develo opment t of inn oposed t ocused o	supports exploratory resea vant to the NIGMS mission high degree of risk and/on thes or products of the prop a not limited to: laboratory ogical molecules or system to support proof of conce opment. Due to the constra- that is narrowly focused on ovative tools that can pote ecchnology must not have on technology development	arch leading or that of o r novelty, wh posed projec instruments is that have l ept, high-risk aints that wo n addressing entially bene already beer it to address	to the ther Ni hich wil t, whic s and of been m a and po build be specifi fit a br n estab specifi	development of IH Institutes or C I be offset by a h h should significa ther devices, algo nodified by huma otentially high-re imposed on broa ic biological ques oad spectrum of lished in the liter ic biological ques	innovative enters (ICs) ligh future antly advance orithms and in intervention ward studies ad utility, this stions. Rather, biomedical rature or with stions and/or			

SPIN ID	Program Title		Sponsor Name	Sponso	or Number		Deadline	e Date	Funding Amount
		include u administr	npublished or published data th atively withdrawn without revio	iat prov ew.	ide proof of concept are no	ot responsive	e to this FOA ar	nd will be	2
097436	Ethical, Legal and Social Implicati	ons (ELSI) I	Research (R01 Clinical Trial Opti	onal)	National Institutes of Health/DHHS	PAR-20- 254	17-Jun-2022		Not Specified
	Contact Name	Joy Boyer							
	Contact Telephone	301-402-4	1997						
	Contact Email	boyerj@r	nail.nih.gov						
	Sponsor Website								
	Program URL	Link to pr	ogram URL						
	Deadline Dates (ALL)	17-Jun-20	22 , 19-Oct-2022 , 17-Feb-2023	8,19-Ju	n-2023				
	Synopsis	or mixed approach such as th	methods. Proposed approache es, legal, economic and normat lose involving the direct engage	s may in ive ana ement o	nclude but are not limited to yses, and other types of ar f stakeholders.	to data-gene nalytical and	rating qualitati conceptual res	ive and q search m	uantitative ethodologies,
097437	Ethical, Legal and Social Implicati Grant (R21 Clinical Trial Optional	ons (ELSI) I )	Exploratory/Developmental Res	earch	National Institutes of Health/DHHS	PAR-20- 255	17-Jun-2022		275,000 USD
	Contact Name	Joy Boyer							
	Contact Telephone	301-402-4	1997						
	Contact Email	<u>boyerj@r</u>	nail.nih.gov						
	Sponsor Website								
	Program URL	Link to pr	ogram URL						
	Deadline Dates (ALL)	17-Jun-20	022 , 19-Oct-2022 , 17-Feb-2023	8,19-Ju	n-2023				
	Synopsis	This Fund propose t propose s prelimina emerging	ing Opportunity Announcemen o study the ethical, legal and so ingle or mixed methods studies ry data in preparation for large genomic technologies or novel	t (FOA) ocial important s that be r studie uses of	invites Exploratory/Develo blications (ELSI) of human g reak new ground, extend p s. Of particular interest are genomic information.	pmental Res genome rese revious disco studies that	earch Grant (R arch. These ap overies in new o explore the im	821) appli oplicatior direction nplicatior	ications that is should s or develop ns of new or

SPIN ID	Program Title	Sponsor Name	Sponso	r Number		Deadline Date	Funding Amount
097475	Ethical, Legal and Social Implications Optional)	i (ELSI) Small Research Grant (RO3 Clini	cal Trial	National Institutes of Health/DHHS	PAR-20- 257	17-Jun-2022	100,000 USD
	Contact Name Jo Contact Telephone 30 Contact Email <u>bo</u> Sponsor Website Program URL <u>Lir</u> Deadline Dates (ALL) 17	y Boyer 01-402-4997 0yerj@mail.nih.gov 0 <u>k to program URL</u> 2-Jun-2022 , 19-Oct-2022 , 17-Feb-2023	s , 19-Ju	1-2023			
	Th an Synopsis co en ex	is Funding Opportunity Announcemen of social implications (ELSI) of human g ojects, such as those that involve single nceptual analyses, including focused le nerging issues. This mechanism can als isting data.	t (FOA) enome e investi egal, ecc o be use	invites Small Research Gran research. These application gators. Of particular intere nomic, philosophical, anth ed for the collection of prel	nt (RO3) appli ns should be st are projec ropological, o iminary data	ications to study the of for small, self-contain ts that propose norm or historical analyses and the secondary and	ethical, legal ned research ative or of new or nalysis of
108288	Notice of Special Interest (NOSI): BR Technologies from Early-stage Devel Blueprint MedTech	AIN Initiative: Translation of Groundbrook Opment through Early Clinical Study vi	<u>eaking</u> a	National Institutes of Health/DHHS	NOT-NS- 22-052	20-Jun-2022	Not Specified
	Contact Name Ni Contact Telephone 30 Contact Email NI Sponsor Website Program URL Lir Deadline Dates (ALL) 20 Th Re Synopsis pri cli	ck Langhals, PhD 11-496-1779 <u>NDS-Devices@nih.gov</u> hk to program URL -Jun-2022 , 18-Oct-2022 , 21-Feb-2023 his Notice of Special Interest (NOSI) end esearch through Advancing Innovative I ogram. Academic and Small Business C nical validation for subsequent clinical oundbreaking neurotechnologies that	, 19-Ju ourages Neurote oncerns feasibili fit withi	n-2023 , 18-Oct-2023 , 20-F the translation of the nove chnologies® (BRAIN) Initiat (SBCs) are encouraged to ty studies. Applications sup n the mission of the BRAIN	eb-2024 , 20 el neurotech ive and over submit grant porting the Initiative are	I-Jun-2024 nologies, funded thro seen by the NIH Blue applications that pro development and tra encouraged.	ugh the Brain print MedTech pose non- nslation of

SPIN ID	Program Title		Sponsor Name	Sponso	or Number		Deadline Date	Funding Amount
106107	Blueprint Medtech: Small Busine	ss Translat	or (U44 - Clinical Trial Optional)	1	National Institutes of Health/DHHS	PAR-21- 282 20	)-Jun-2022	Not Specified
	Contact Name	Leonardo	Angelone, Ph.D					
	Contact Telephone							
	Contact Email	Blueprint	MedTech@nih.gov					
	Sponsor Website							
	Program URL	Link to pr	ogram URL					
	Deadline Dates (ALL) 20-Jun-2022 , 18-Oct-2022 , 21-Feb-2023 , 20-Jun-2023 , 18-Oct-2023 , 20-Feb-2024 , 20-Jun-2							
	Synopsis	(SBCs) to diagnostic include in validation Administri is expecte additiona This FOA negotiatin receive fu funded co commerc organizat and medi manufact BP MedTe	pursue translational activities a c devices for disorders that affe plementation of clinical proto- activities leading to submissio ation (FDA) or Institutional Rev ed to provide information about I non-clinical assessments (e.g., is a milestone-driven cooperati- ng the final project plan before inding for all activities to be con- onsultants to receive assistance ialization, and strategic partner ions (CROs) that specialize in la cal monitoring. SBCs developing urers are welcome to apply dire- ech website: https://neuroscier	ind limit act the n type dev n of an l riew Boa t the de bench ve agree award a mducted with sp rships. P rge anin g their c ectly to nceblue	ed-size clinical studies to a ervous or neuromuscular s vices, non-clinical safety and nvestigational Device Exem rd (IRB) application for a N vice function or final design top or animal studies) due t ement program and will inv and monitoring of research in their own laboratories. I ecialty areas including regu articipants can also augmen hal testing, sterilization test won devices or that already this FOA or any of the comporint.nih.gov/neurotherape	dvance the dev ystems.Activitie d efficacy testir on-Significant F on that cannot be to the novelty of olve participati progress. Partie n addition, app ilatory, reimbur nt their project ting, biocompati have establishe panion opportu- utics/blueprint	elopment of therap es supported in this ag, design verificatio the U.S. Food and Di Risk (NSR) study. The practically obtaine of the device or its in on of NIH program s cipants in Blueprint licants will collabora rsement, intellectua with NIH contract re- tibility assessment, r ed collaborations wi inities. For more info- medtech	eutic and program in and rug e clinical study d through ntended use. staff in MedTech ate with NIH- l property, esearch manufacturing, ith device ormation see

106116 Blueprint MedTech Translator (UG3/UH3 - Clinical Trial Optional)	National Institutes of	PAR-21-	20-lun-2022	Not
	Health/DHHS	315		Specified

Contact Name Nick Langhals, PhD Contact Telephone 301-496-1779 Contact Email <u>NINDS-Devices@nih.gov</u>



SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount		
	Sponsor Website   Program URL   Link to program URL   Deadline Dates (ALL)   20-Jun-2022, 18-Oct-2022, 21-Feb-2023, 19-Jun-2023, 18-Oct-2023, 20-Feb-2024, 20-Jun-2024   The purpose of this Funding Opportunity Announcement (FOA) is to encourage investigators to pursue translational activities and clinical feasibility studies to advance the development of therapeutic, and diagnostic devices for disorders i affect the nervous or neuromuscular systems. Activities supported in this program include implementation of clinical prototype devices, non-clinical safety and efficacy testing, design verification and validation activities, obtaining an Investigational Device Exemption (IDE) for a Significant Risk (SR) study or Institutional Review Board (IRB) approval for a I Significant Risk (SR) study, as well as a subsequent clinical feasibility study. The clinical study is expected to provide information about the device function or final design that cannot be practically obtained through additional non-clinical assessments (e.g., bench top or animal studies) due to the novelty of the device or its intended use. This FOA is a milestor sub aborte receive agreement program and will involve participation of NIH program staff in negotiating the final projec plan before award and monitoring of research progress. Participants will collaborate with NIH-funded consultants to receive assistance with specialty areas including regulatory, reimbursement, intellectual property, commercialization, and strate partnerships. Participants can also augment their project with NIH contract research organizations that specialize in largi animal testing, sterilization testing, biocompatibility assessment, manufacturing, and medical monitoring. Individuals,								
		manufacturers are welcome to apply directly to this FOA or any of the companion opportunities. For more information see BP MedTech website: https://neuroscienceblueprint.nih.gov/neurotherapeutics/blueprint-medtech							
106783 H	Research on Biopsychosocial Factoria Research on Biopsychosocial Factoria Realth, Wellbeing, Illness, and Realth Research Required)	ors of Soci covery (RC	ial Connectedness and Isolation 11 Basic Experimental Studies w	on National Institutes of <u>ith</u> Health/DHHS	PAR-21- 349 21-J	lun-2022	Not Specified		
	Contact Name	William E	lwood, PhD						
	Contact Telephone	301-402-0	0116						
	Contact Email	<u>william.el</u>	wood@nih.gov						
	Sponsor Website								
	Program URL	<u>Link to pr</u>	ogram URL						
	Deadline Dates (ALL)	21-Jun-20	)22 , 21-Jun-2023 , 21-Jun-2024						

SPIN ID	Program Title		Sponsor Name	Sponso	or Number		Deadline Date	Funding Amount
	Synopsis	This fund processes and overa participar behaviora isolation. studies in clinical tri Applicatio under the Health, W	ing opportunity announcement s, and trajectories of social relat all wellbeing. Types of projects s nts to conditions (i.e., experime al outcomes in humans to under NIH considers such studies as B ivolving human participants tha ials (see, e.g., NOT-OD-19-024). ons that propose studies includi e companion FOA, PAR-21-350 " Vellbeing, Illness, and Recovery	(FOA) i ionship submitti ntally m rstand f asic Exp t meet f Applica ng mod 'Researd (R01 Cli	nvites research projects that s and how these factors aff ed under this FOA include s nanipulate independent var undamental aspects of phe perimental Studies with Hu the NIH definition of basic r tions should not propose a el animal research or obser ch on Biopsychosocial Facto nical Trials Not Allowed).	at seek to exp ect outcomes studies that pr iables) and th enomena relat mans (BESH) t research and f goal of clinica rvational studions of Social Co	ain the underlying m in human health, illn ospectively assign hu at assess biomedical ed to social connecte hat are prospective b all within the NIH def al outcomes or produ es involving humans onnectedness and Iso	echanisms, ess, recovery, man and/or dness and basic science inition of cts. should submit blation on
106784	Research on Biopsychosocial Factor Health, Wellbeing, Illness, and Rec	ors of Soc covery (RC	ial Connectedness and Isolation 01 Clinical Trials Not Allowed)	on	National Institutes of Health/DHHS	PAR-21- 350	21-Jun-2022	Not Specified
	Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) Synopsis	William E 301-402-0 william.el Link to pr 21-Jun-20 This fund processes overall we allowed. 21-349, " Recovery	Iwood, PhD 0116 Iwood@nih.gov rogram URL 022 , 21-Jun-2023 , 21-Jun-2024 ing opportunity announcement s, and trajectories of social relat ellbeing. Both animal model and Researchers proposing Basic Ex Research on Biopsychosocial Fa (R01 Basic Experimental Studie	(FOA) i ionship d huma perimer ctors of s with H	nvites research projects that s and how these factors aff n subjects research project ntal Studies with Humans (F Social Connectedness and fumans Required)".	at seek to mod ect outcomes s are welcome 3ESH) should d Isolation on H	del the underlying me in health, illness, rec ; however, clinical tri consider the compani lealth, Wellbeing, Illn	chanisms, overy, and ials are not on FOA, PAR- ess, and
106790	Research on Biopsychosocial Factor Health, Wellbeing, Illness, and Rec	ors of Soc covery (RC	ial Connectedness and Isolation 01 Clinical Trial Required)	on	National Institutes of Health/DHHS	PAR-21- 352	21-Jun-2022	Not Specified
	Contact Name Contact Telephone	William E 301-402-(	lwood, PhD 0116					


SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Contact Email Sponsor Website Program URL Deadline Dates (ALL) Th pr ar tr in Synopsis th pu pr th Re in 21 Re	nk to program URL 1-Jun-2022 , 21-Jun-2023 , 21-Jun-2024 his funding opportunity announcement ( rocesses, and trajectories of social relation nd overall wellbeing. Types of projects su ials. Mechanistic studies are defined as a tervention, a biological or behavioral pro- 1H-19-006 for examples of clinical trials to fluence a clinical outcome, test safety of n intervention, or analyze the effect size hat should submit under this FOA include urpose of understanding the fundament roducts in mind. Researchers proposing his FOA's companion for basic experiment ecovery (R01 Basic Experimental Studies mited to, model animal research or obse 1-350, "Research on Biopsychosocial Fac ecovery (R01 Clinical Trials Not Allowed)	(FOA) invites research projects the onships and how these factors aff ubmitted under this FOA include in studies with the objective to under ocess, or the pathophysiology of that are/are not considered mech r feasibility of an intervention, de of an intervention on clinical out e clinical trials that assess biomed al aspects of phenomena without basic science experimental studies that studies with humans, PAR-21 with Humans Required)." Applica ervational studies involving human tors of Social Connectedness and	at seek to explain fect outcomes in h mechanistic studie erstand the mecha a disease/conditic anistic studies. Cli monstrate the clin comes are ineligib ical or behavioral t specific application s involving human -349, "Research o ations proposing s ns should submit to Isolation on Heal	the underlying mo- numan health, illn es that are classifi- anism(s) of action on. See NOT-AT-20 inical trials that pr nical efficacy or efficient of the ole for this FOA. Ty outcomes in hum on towards proce n participants sho n Health, Wellbein studies that includ under the compar- th, Wellbeing, Illn	echanisms, ess, recovery, ed as clinical of an )-001 and NOT- opose to fectiveness of rpes of studies ans for the sses or uld consider ng, Illness, and e, but are not ion FOA, PAR- ess, and
102740	Innovation Grants to Nurture Initial Development and Neurotherapeutic Not Allowed)	Translational Efforts (IGNITE): Assay c Agent Identification (R61/R33 Clinical T	Trial National Institutes of Health/DHHS	PAR-21- 21-J 124	lun-2022	750,000 USD
	Contact Name Be	ecky Roof, PhD				
	Contact Telephone 30	01-496-1779				
	Contact Email <u>re</u> Sponsor Website	epecca.roor@nin.gov				
	Program URL Li	nk to program URL				
	Deadline Dates (ALL) 21	1-Jun-2022 , 18-Oct-2022 , 21-Feb-2023 ,	, 20-Jun-2023 , 20-Oct-2023 , 20-	Feb-2024		



SPIN ID	Program Title		Sponsor Name	Sponso	r Number		C	Deadline Date	Funding Amount
	Synopsis	This fundi assays an neuromus advance p other trar	ng opportunity announcement d conduct iterative screening ef scular disorders. This FOA is par projects to the point where they nslational programs.	(FOA) e forts to t of a su r can me	ncourages research grant identify and characterize ite of Innovation Grants to eet the entry criteria for th	applications potential the o Nurture Ini e Blueprint	to deve erapeuti itial Trai Neuroth	elop in vitro and ic agents for neu nslational Effort nerapeutics Net	/or ex vivo urological or s (IGNITE) to work (BPN) or
105249	Identification and Characterizatio Advancing Research on Microbe- Allowed)	on of Bioac Diet-Host I	tive Microbial Metabolites for nteractions (R01 Clinical Trial N	<u>ot</u>	National Institutes of Health/DHHS	PAR-21- 253	22-Jur	า-2022	Not Specified
	Contact Name	Padma M	aruvada						
	Contact Telephone	301-594-8	3884						
	Contact Email	maruvadp	o@mail.nih.gov						
	Sponsor Website								
	Program URL	Link to pr	ogram URL						
	Deadline Dates (ALL)	22-Jun-20	22 , 20-Oct-2022 , 22-Jun-2023	, 19-Oc	t-2023				
Synopsis The purpose of the Funding Opportunity Announcement is to invite applications to identify and characterize microbial metabolites that will establish causal associations between microbial metabolism and host health and disease. Data acque through this initiative will be used to create a knowledgebase of microbial metabolites and associated functions that will provided to the research community. Development of the database and knowledge portal for these awards will be supported under a separate initiative: RFA-DK-21-014, Identification and Characterization of Bioactive Microbial Metabol for Advancing Research on Microbe-Diet-Host Interactions Knowledgebase Management Center (Clinical Trial Not Allowe									nicrobial . Data acquired ns that will be ill be al Metabolites Not Allowed).
109667	Centers of Excellence in Genomic	: Science (R	M1 Clinical Trial Optional)		National Institutes of Health/DHHS	PAR-22- 107	22-Jur	n-2022	7,500,000 USD
	Contact Name	Adam Fel	senfeld, Ph.D.						
	Contact Telephone	301-480-2	2269						
	Contact Email	adam_fel	<u>senfeld@nih.gov</u>						
	Sponsor Website	A.							
	Program URL	Link to pr	ogram URL						
	Deadline Dates (ALL)	22-Jun-20	22 , 22-Jun-2023 , 21-Jun-2024						

SPIN ID	Program Title		Sponsor Name	Sponso	or Number		Deadline Date	Funding Amount
	Synopsis	The Cente Each CEG approach medicine, will entail will focus comprehe for under clinical ap Along wit novel met scientists	ers of Excellence in Genomic Sci S award supports a multi-invest es to address a biomedical prob or computational genomics, pr substantial risk, balanced by ou on the development of novel to ensive data sets, on a genome-s standing biological systems or f oplications. Each CEGS will nurtu h its scientific goals, CEGS will a thods, concepts, and knowledge at all career levels	ence (C igator, i olem. A oposing utstandi echnolo cale bio cale bio urtherir ire geno lso expa e develo	EGS) program establishes a interdisciplinary team to de CEGS project will address a g a highly innovative solution ing scientific and managem gical or computational met medical problem, or on oth medical problem, or on oth omics by facilitating the inter and the pool of genomic sci oped by the CEGS by provid	academic Cente evelop integrate critical issue in on that would b ent plans and w hods for the pr her ways to dew nic knowledge, eraction of inve ientists and eng ing education a	rs for advanced gen ed, transformative g genomic science, g e a major advance. rery high potential p oduction or analysis relop and use genor data, and methods stigators from seven gineers that can use and outreach experio	iome research. enomic The research bayoff. A CEGS s of nic approaches towards ral disciplines. and apply the ences to
095409	Enhancing Science, Technology, E (ESTEEMED) Research Education I	nginEering Experience	g, and Math Educational Diversi es (R25)	<u>ty</u>	National Institutes of Health/DHHS	PAR-20- 223 24	1-Jun-2022	Not Specified
	Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL)	Zeynep Er 301-451-4 erimz@m Link to pr 24-Jun-20	rim, Ph.D. 1797 I <u>ail.nih.gov</u> Ogram URL 122					
	Synopsis	The NIH R overarchi backgrout studies or activities sophomo relevant t technolog their colle prepare s that prom	Research Education Program (R2 ng goal of this R25 program is to nds, including those from group careers in research To accomp with a primary focus on: Course res from diverse backgrounds, i to bioengineering, such as enging gies and innovation. The ESTEEN age careers and interest them in tudents to join, in their junior a notes STEM and entrance into a	25) supp o suppo os under olish the es for Sk ncludin eering AED pro potent nd senie Ph.D. p	oorts research education ac rt educational activities that represented in the biomed e stated over-arching goal, t ills Development Research g those from groups under or the physical/computatio ogram is intended to expose ially pursuing advanced stu or years, an honors program rogram. The ultimate goal	tivities in the m at encourage in lical and behavi- this FOA will su Experiences fo represented in nal sciences, w e students to bi udies in bioengi m, supported by is for the partic	hission areas of the dividuals from diver oral sciences, to pu pport creative educ r undergraduate fre bioengineering or S hich play key roles i oengineering resear neering or a related r federal or instituti ipants to pursue a F	NIH. The rse rsue further ational shmen and TEM fields n biomedical rch early in I field. It will onal funds, Ph.D. or

SPIN ID	Program Title		Sponsor Name	Spons	or Number			Deadline Date	Funding Amount
		M.D./Ph. biology ir	D. degree and a subsequent res academia or industry.	earch c	areer integrating engineer	ing and the p	ohysica	Il sciences with m	nedicine and
108628 <u> </u>	asker Clinical Research Scholars	Program (	Si2/R00 Clinical Trial Optional)		National Institutes of Health/DHHS	PAR-22- 078	24-Ju	un-2022	Not Specified
	Contact Name	Charles R	. Dearolf, Ph.D.						
	Contact Telephone	301-402-	1225						
	Contact Email	LaskerSch	nolar@nih.gov						
	Sponsor Website								
	Program URL	Link to pr	ogram URL						
	Deadline Dates (ALL)	24-Jun-20	)22						
	Synopsis	research a unique phase, La Research NIH supp investigat	activities during the early stage bridge between the NIH intram sker Scholars will receive appoi Program with independent res ort for their research at an extra tor within the intramural progra	career: ural an ntment earch b amural am.	s of independent clinical re d extramural research com s for up to 5-7 years as ten udgets. In the second phas research facility; or, the Sc	searchers. T munities and ure-track inv e, successfu holar can be	he pro d conta /estiga l schola consic	gram offers the c ains two phases. tors within the N ars will receive u dered to remain a	opportunity for In the first IH Intramural o to 3 years of as an
076848	NLM Research Grants in Biomedi Frial Optional)	<u>cal Inform</u>	atics and Data Science (R01 Clin	<u>ical</u>	National Library of Medicine/NIH/DHHS	PAR-18- 896	07-N	1ay-2022	1,000,000 USD
	Contact Name	Dr. Hua-C	Chuan Sim						
	Contact Telephone	301-594-	4882						
	Contact Email	simh@ma	ail.nih.gov						
	Sponsor Website								
	Program URL	Link to pr	ogram URL						
	Deadline Dates (ALL)	07-May-2	2022 , 05-Jun-2022 , 07-Sep-202	2					
	Synopsis	National data scier approach	Library of Medicine (NLM) offer nce. The scope of NLM's interes es to foster data driven discove	s suppo t in the ery in th	ort for innovative research se research domains is bro e biomedical and clinical h	and develop ad, with em ealth science	ment i phasis es as w	n biomedical info on new methods rell as domain-inc	ormatics and and dependent,

SPIN ID	Program Title		Sponsor Name	Sponso	or Number		Dead	lline Date	Funding Amount
	r E C t i r t S	reusable a Biomedica computer biomedica informatio represent biology. N processes sets of da	approaches to discovery, curati al informatics and data science science and engineering, and s al research, clinical and translat on management in disasters, ar ration, organization, manageme IIH defines data science as the i s, and systems are developed ar ta. This FOA will use the NIH Re	on, anal draw up ocial/be ional re id simila nt, inte nterdiso nd used search	ysis, organization and man oon many fields, including r ehavioral sciences. Applicat search, precision medicine ar areas. NLM defines biom gration and presentation o ciplinary field of inquiry in v to extract knowledge and i Project (R01) award mecha	agement o mathematio tion domain , public hea redical info f informatio which quan insights fro	f health-rela cs, statistics, ns include he alth, biosurve rmatics as th on relevant t titative and m increasing	ted digital ob information ealth care del eillance, heal e science of co human hea analytical ap ly large and/	ojects. science, livery, basic th optimal alth and proaches, or complex
099844	Computational Approaches to Cura (R01 Clinical Trial Not Allowed)	<u>ation at S</u>	cale for Biomedical Research As	<u>ssets</u>	National Library of Medicine/NIH/DHHS	PAR-20- 304	07-May-2	022	1,000,000 USD
	Contact Name A	Alan VanE	Biervliet, PhD						
Contact Telephone 301-594-4882									
	Contact Email 🛓	vanbiervli	etaq@mail.nih.gov						
	Sponsor Website								
	Program URL <u>I</u>	<u>Link to pr</u>	ogram URL						
	Deadline Dates (ALL) (	07-May-2	022 , 05-Jun-2022 , 07-Sep-202	2 , 05-0	ct-2022 , 07-Jan-2023 , 05-	Feb-2023,	07-May-202	3	
National Library of Medicine (NLM) wishes to accelerate the availability of and access to secure, complete data sets and Synopsis computational models that can serve as the basis of transformative biomedical discoveries by improving the speed and scope of the curation processes.								a sets and eed and	
SPIN ID	Program Title				Sponsor Name		Sponsor Number	Deadline Date	Funding Amount
102835	Development of Animal Models an (R21 Clinical Trial Not Allowed)	<u>nd Relate</u>	d Biological Materials for Resea	<u>irch</u>	Office of Research Infrast Programs/NIH/DHHS	ructure	PAR-21-167	07-May- 2022	275,000 USD

Contact Name Sige Zou, Ph.D.

Contact Telephone 301-435-0749

Contact Email zous@mail.nih.gov

Sponsor Website

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Dea	adline Date	Funding Amount
	Program URL L Deadline Dates (ALL) T Synopsis R e o w	ink to program URL 07-May-2022 , 16-Jun-2022 , 07-Sep-2022 2023 , 16-Oct-2023 , 07-Jan-2024 , 16-Fek This funding opportunity announcement nodels, biological materials, and novel te projects aimed at improving the diagnosis The proposed project must have broad ap Research Infrastructure Programs' (ORIP) evaluate diseases that impact multiple bo of research, or only propose studies prima vill be withdrawn.	2, 16-Oct-2022, 07-Jan-2023, 16-Feb-2023, p-2024, 07-May-2024 (FOA) encourages innovative research to dev echnologies to better understand human hea s and control of diseases that interfere with a oplication to multiple NIH Institutes or Cente trans-NIH mission. The proposed studies mu ody systems. Applications that develop mode arily relevant to a single NIH IC, will be consid	07-May-20 velop, chara Ith and dise animal use f rs (ICs) to a ust explore i ls focused o dered not a	23 , 16-Jun-20 acterize, and in ease. This FOA for biomedica lign with the ( multiple body on a specific d cceptable to t	D23 , 07-Sep- mprove animal also seeks I research. Dffice of systems or isease or area his FOA and
107732	Notice of Special Interest (NOSI): D for Enhancing Rigor, Reproducibilit Biomedical Research	Development of Resources and Technolog ty, and Translatability of Animal Models i	gies Office of Research Infrastructure Programs/NIH/DHHS	NOT-OD- 22-039	07-May- 2022	Not Specified
	Contact Name S Contact Telephone 3 Contact Email Sponsor Website Program URL <u>L</u> Deadline Dates (ALL) V P Synopsis R ir	ige Zou, PhD 201-435-0749 ous@mail.nih.gov ink to program URL 27-May-2022, 16-Jun-2022, 07-Sep-2022 2023, 16-Oct-2023, 07-Jan-2024, 16-Feb With this Notice of Special Interest (NOSI) projects aimed at developing broadly app enhancing the rigor, reproducibility, and t rey animal resource- and technology-rela Research" workshop organized by ORIP, N nclude, but are not limited to, invertebra	2, 16-Oct-2022, 07-Jan-2023, 16-Feb-2023, p-2024, 07-May-2024 ), ORIP intends to support exploratory/develo licable technologies, tools, and resources for translatability of animal research. This NOSI i ted gaps identified in the "Validation of Anim NHLBI, NIA, NIDDK, NIGMS, and NINDS. Anim te and vertebrate organisms ranging from C.	07-May-20 opmental a r validating s for two-ye nal Models al models c . elegans an	023 , 16-Jun-20 nd highly inno animal model ear projects th and Tools for of interest for ad Drosophila	023 , 07-Sep- ovative ls and nat address Biomedical this NOSI to zebrafish,

SPIN ID	Program Title		Sponsor Name		Sponsor Number	Deadline Date	Funding Amount
105980	Dear Colleague Letter: Special Gu National Science Foundation and Opportunities	idelines for Submitting Collaborative Pr Czech Science Foundation Collaborativ	roposals under the e Research	National Science Foundation	NSF 21- 111	01-Jun-2022 [LOI/Pre-App]	Not Specified
	Contact Name						
	Contact Telephone						
	Contact Email	nsf-gacr@nsf.gov					
	Sponsor Website						
	Program URL	Link to program URL					
	Deadline Dates (ALL)	01-Jun-2022 [LOI/Pre-App]					
	Synopsis	The U.S. National Science Foundation ( Understanding (MOU) on Research Cou and Czech research communities and s MOU provides for an international coll Czech researchers may receive funding both countries to collaborate to write collaborative research opportunity foc nanotechnology, and plasma science. F of GACR's Call for Proposals and partic of International Research and Engineer https://www.nsf.gov/od/oise/IntlColla	NSF) and the Czech Sc operation. The MOU p sets out the principles I aboration arrangemen g from GACR. Through a single proposal that v uses on discoveries an Proposals will be accep ipating NSF programs. ring (OISE) website at borations/CzechReput	ience Foundation rovides a framewo by which jointly su a "lead agency mo will undergo a sing d innovations in th ted for collaborat Specific participat	(GACR) have s prk to encoura pported activi searchers may del," NSF and le review proc he areas of art ive research in ing NSF progra	igned a Memorar ge collaboration ities might be dev receive funding GACR will allow p cess at NSF. This ificial intelligence these areas at th ams are listed on	ndum of between U.S. reloped. The from NSF and proposers from NSF-GACR , ne intersection the NSF Office
107542	Dear Colleague Letter: Cryogenic	s below 1 K - Systems, Cycle, and Mater	ials	National Science Foundation	NSF 22- 018	30-Apr-2022 [LOI/Pre-App]	Not Specified
	Contact Name	Thomas F. Kuech					
	Contact Telephone						
	Contact Email	tkuech@nsf.gov					
	Sponsor Website	Link to sponsor website					
	Program URL						

Deadline Dates (ALL) 30-Apr-2022 [LOI/Pre-App], 30-Jun-2022



SPIN ID	Program Title		Sponsor Name		Sponsor Number	Deadline Date	Funding Amount
	Synopsis	With this Dear Colleague Letter (DCL), Directorate for Mathematical & Physic Research (EAGER) proposals to focus o temperature refrigeration, and new pr	the National Science Fo al Sciences (MPS) invite on new approaches to re ocessing techniques ne	oundation's (NSF) the submission c efrigeration at <1 eded to fabricate	Directorate f of Early-conce <, materials n these new ty	or Engineering (El ept Grants for Exp eeded to enable pes of refrigeration	NG) and loratory ultra-low on systems.
108663	Expanding Capacity in Quantum I	Information Science and Engineering		National Science Foundation	22-561	06-May-2022	Not Specified
	Contact Name	Tomasz Durakiewicz					
	Contact Telephone	703-292-4892					
	Contact Email	tdurakie@nsf.gov					
	Sponsor Website	Link to sponsor website					
	Program URL	Link to program URL					
	Deadline Dates (ALL)	06-May-2022 , 03-Jun-2022 , 03-Feb-2	023 [LOI/Pre-App], 03-N	Mar-2023 , 07-Apı	-2023		
	Synopsis	The NSF Expanding Capacity in Quantum research capacity and broaden particip through the creation of a diversified in engineering breakthroughs, while secu- academia continue to outgrow the availate between new efforts and existing impa- while creating and nurturing necessary of increasing the participation of all me enrolled students come from groups th (MSIs), are especially encouraged to ap	In Information Science bation in Quantum Infor vestment portfolio in re uring a talent pipeline in additional talent. The Expan actful work done at the v critical mass at Institut embers of society in the nat are currently under- oply.	and Engineering rmation Science a esearch and educ a field where wo adQISE program h existing QISE Cen tions not yet fully escientific enterp -represented in th	ExpandQISE) nd Engineerin ation that wil rkforce need elps build and ters or leadir involved in C rise, institution ne sciences, e	program aims to ng (QISE) and rela I lead to scientific s of industry, gove d maintain a close ng QISE research In QISE. In keeping w ons at which more .g. minority-servir	Increase ted disciplines and ernment and connection hstitutions, th the NSF goal than 50% of ng institutions
105122	Tribal Colleges and Universities P	rogram (TCUP)		National Science Foundation	21-595	01-Jun-2022	Not Specified
	Contact Name	Jody Chase					
	Contact Telephone	703-292-8640					
	Contact Email	Ichase@nsf.gov					
	Sponsor Website	Link to sponsor website					



SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Program URL Deadline Dates (ALL)	Link to program URL 01-Jun-2022 , 01-Sep-2022				
	Synopsis	The Tribal Colleges and Universities Pro Universities, Alaska Native-serving inst (including sociology, psychology, anthr behavioral sciences; natural sciences; o information science, and cybersecurity outreach. Support is available to TCUP projects through Instructional Capacity for Secondary and Elementary Teacher Cyberinfrastructure Health, Assistance Collaborations led by TCUP institutions Partnerships, with the participation of studies that further the scholarly activi (SGR). Through the opportunities highl divisions and directorates, and other o improve the quality of STEM programs enterprise in TCUP institutions' service	ogram (TCUP) provides awards to federa itutions, and Native Hawaiian-serving in opology, linguistics, economics and bio computer science, including, but not lime ), technology, engineering and mathem -eligible institutions for transformative of Excellence in TCUP Institutions (ICE-TI) is in STEM (TSETS), TCU Enterprise Adva , and Improvements (CHAI), and Prepar is that involve non-TCUP institutions of h other NSF programs to support the wor ty of individual faculty members are sup ighted above, as well as collaborations of rganizations, TCUP aims to increase Nat at TCUP-eligible institutions, and facilit areas.	ally recognized[1 astitutions to pro economics, statis ited to, artificial atics (STEM), STI capacity-building , Targeted STEM ncement Center ing for TCUP Imp igher education k of non-TCUP ir poported through with other Natio ive individuals' p ate the developr	] Tribal Colleges mote high quali stics, and other s intelligence, qua EM education, ro or community of or community of Infusion Project s (TEA Centers), lementation (Pr are supported the stitutions. Final Small Grants for nal Science Four participation in S nent of a strong	and ty science social and antum esearch, and engagement ts (TSIP),TCUP e-TI). hrough TCUP ly, research r Research ndation (NSF) TEM careers, STEM
109414	Industry-University Cooperative I	Research Centers Program	National Science Foundation	e 20-570 C	8-Jun-2022	Not Specified
	Contact Name	Prakash G. Balan				
	Contact Telephone	703-292-5341				
	Contact Email	pbalan@nsf.gov				
	Sponsor Website	Link to sponsor website				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	08-Jun-2022 , 14-Sep-2022 [LOI/Pre-Ap	pp], 14-Dec-2022			
		The IUCRC program catalyzes breakthr	ough pre-competitive research by enab	ling close and su	stained engager	nent between

Synopsis industry innovators, world-class academic teams, and government agencies. IUCRCs help industry partners and government agencies connect directly and efficiently with university researchers to achieve three primary objectives: 1) Conduct high-impact research to meet shared and critical industrial needs in companies of all sizes; 2) Enhance U.S. global leadership in

SPIN ID	Program Title		Sponsor Name		Sponsor Number	Deadline Date	Funding Amount
		driving innovative technology develop engineering workforce.	ment, and 3) Identify, mentor a	nd develo	p a diverse, l	nighly skilled scie	nce and
101564	Cyber-Physical Systems (CPS)		Nationa Founda	al Science tion	21-551	15-Jun-2022	Not Specified
	Contact Name	David Corman					
	Contact Telephone	703-292-8754					
	Contact Email	dcorman@nsf.gov					
	Sponsor Website	Link to sponsor website					
	Program URL	Link to program URL					
	Deadline Dates (ALL)	15-Jun-2022 , 30-Dec-2022					
	Synopsis	dependable, high-confidence, or prova machine learning including real-time learning including real-time learning including real-time learning from the particulars of spectrudamental scientific and engineering application domains. The program add components based upon these cross-controls program also fosters a research control accelerating the transition of CPS research	ble behaviors. Core research ar earning for control, autonomy, o loop, networking, privacy, real- cific systems and application do g principles that underpin the in itionally supports the developm utting principles, along with val ommunity that is committed to arch into the real world.	reas of the design, Int time syste omains, th tegration nent of me idation of advancing	e program inc ernet of Thir ems, safety, s e CPS progra of cyber and ethods, tools the principle g education a	clude control, dat ngs (IoT), mixed in security, and verif m seeks to revea physical elemen , and hardware a es via prototypes nd outreach in Cl	a analytics, and nitiatives fication. By I cross-cutting, ts across all nd software and testbeds. PS and
110003	Spectrum Innovation Initiative: N	lational Radio Dynamic Zones	Nationa Founda	al Science tion	22-579	20-Jun-2022	Not Specified
	Contact Name	John M. Chapin					
	Contact Telephone	703-292-8222					
	Contact Email	<u>Sll@nsf.gov</u>					
	Sponsor Website	Link to sponsor website					
	Program URL	Link to program URL					
	Deadline Dates (ALL)	20-Jun-2022					



	SPIN ID Program Title Sponsor Name Sponsor Deadline Funding   SPIN ID Program Title Date Amount
--	---

The electromagnetic spectrum is an essential resource for many sectors of society and the economy. Commercial applications (e.g., wireless communication, navigation, and telemetry) compete for spectrum access with scientific activities (e.g., radio astronomy, earth observation, geospace sciences, and polar research) and other vital spectrum-dependent services (e.g., air traffic control). Ongoing technological progress has created a situation where each application, activity, and service seeks additional spectrum access. Potential benefits from additional spectrum access include faster communications, new astronomical and scientific discoveries, more energy-efficient cities, increased highway capacity and safety, and more accurate weather predictions. Achieving these benefits calls for increased use of dynamic spectrum sharing – ways to enable diverse spectrum users to safely operate closer together in space or frequency or to trade spectrum access more rapidly than is possible with traditional spectrum management approaches. The goal of this Spectrum Innovation Initiative: National Radio Dynamic Zones (SII-NRDZ) program is to advance the use of dynamic spectrum sharing. The unifying concept investigated in SII-NRDZ is the radio dynamic zone: an area or volume with automatic spectrum management mechanisms that control electromagnetic energy entering, escaping, or occupying the zone. SII-NRDZ seeks to perform extended (6- to 12-month) field trials of various types of radio dynamic zone spectrum sharing at sites where the field trials will enhance spectrum access for Synopsis facilities or applications. The field trials will mature understanding and capability towards wider use of spectrum sharing, and towards eventual establishment of a permanent highly capable National Radio Dynamic Zone somewhere in the USA. The National Radio Dynamic Zone is envisioned to support a facility for at-scale research and experimentation on systems that use or manage spectrum in innovative ways. SII-NRDZ is an interdisciplinary program that seeks to foster collaboration among spectrum sharing researchers; domain experts with knowledge of specific applications, scientific activities, or instruments; site or mission experts who understand the operations of specific facilities or systems; spectrum regulatory specialists; and others. The SII-NRDZ program includes two types of projects. SII-NRDZ research studies are traditional NSF grants for investigation of spectrum sharing solutions and risk analysis techniques, or for investigation of applications and sites for radio dynamic zone field trials. SII-NRDZ Engineering and Execution Lead awards are cooperative agreements for work to mature results of the research studies into robust implementations and to lead the planned extended field trials. The SII-NRDZ goal to advance the use of dynamic spectrum sharing requires the evolution of spectrum management practice. The key to spectrum management evolution is ensuring trust by stakeholders who rely on current interference prevention mechanisms and seek to protect future options. SII-NRDZ program activities are designed to help build the trust that is critical for progress.

100200	NSF Small Business Innovation Research Phase II (SBIR)/ Small Business Technology Transfer	National Science	NSF 22- 20 Jun 2022	1,000,000
100209	(STTR) Programs Phase II (SBIR/STTR Phase II)	Foundation	552	USD

Contact Name

Contact Telephone 703-292-8050



SPIN ID	Program Title		Sponsor Name		Sponsor Number	Deadline Date	Funding Amount
	Contact Email	chir@net.gov					
	Contact Email						
	Sponsor website	Link to program LIDI					
	Program ORL	20 Jun 2022 26 Oct 2022					
	Synopsis	The NSF SBIR/STTR programs support r By investing federal research and devel economy and stimulate the creation of small business in meeting federal resea supported research results; and develo by socially and economically disadvanta proposals based on groundbreaking sci consistent with NSF's mission to promo and to secure the national defense.	moving scientific excelled lopment funds into start novel products, service arch and development n op and increase the US w aged and women-owned ientific discoveries or sig ote the progress of scien	nce and technolo tups and small bu s, and solutions i eeds; increase th vorkforce, especi d small businesse gnificant enginee hce; to advance th	ogical innovatio usinesses, NSF h in the private se ne commercial a fally by fostering es. The SBIR/ST ring breakthrou he national hea	n from the lab to opes to build a ctor; strengther pplication of feo g and encouragir TR programs at ghs from the sm th, prosperity, a	o the market. strong national o the role of derally ng participation NSF solicit nall businesses and welfare;
108391	NSF Small Business Innovation Re Programs Phase I (SBIR/STTR Pha	search (SBIR)/ Small Business Technolog se I)	gy Transfer (STTR)	National Science Foundation	NSF 22- 551	0-Jun-2022	275,000 USD
	Contact Name	Henry Ahn					
	Contact Telephone	703-292-7069					
	Contact Email	<u>hahn@nsf.gov</u>					
	Sponsor Website						
	Program URL	Link to program URL					
	Deadline Dates (ALL)	30-Jun-2022 , 26-Oct-2022					
	Synopsis	The NSF SBIR/STTR programs support r By investing federal research and devel economy and stimulate the creation of small business in meeting federal resea supported research results; and develo by socially and economically disadvanta proposals from small businesses based consistent with NSF's mission to promo	noving scientific excelled lopment funds into start novel products, service arch and development n op and increase the US w aged and women-owned on groundbreaking scie ote the progress of scien	nce and technolo tups and small bu s, and solutions i eeds; increase th vorkforce, especi d small businesse entific discoveries ace; to advance t	ogical innovatio usinesses, NSF h in the private se ne commercial a fally by fostering es. The NSF SBIF s or significant e he national hea	n from the lab to iopes to build a ctor; strengther ipplication of feo g and encouragir X/STTR programs engineering brea lth, prosperity, a	o the market. strong national the role of derally ng participation s solicit kthroughs and welfare;



	Program Title	Sponsor Namo	Sponsor	Deadline	Funding
SPINID	Program Title	sponsor Name	Number	Date	Amount

and to secure the national defense.



SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
104738	Lawrence and Isabel Barnett Dru	g Development Pr	ogram ALS Associ	ation	01-Jun-2022	500,000 USD
	Contact Name	· · · · · · · · · · · · · · · · · · ·				,
	Contact Telephone	1-800-782-4747				
	Contact Email	researchgrants@	alsa-national.org			
	Sponsor Website	Link to sponsor w	/ebsite			
	Program URL	Link to program l	JRL			
	Deadline Dates (ALL)	01-Jun-2022				
	Synopsis	The ALS Associati assessment of the to industry and a limited \$500,000	on offers the Lawrence a erapeutics for ALS that ha cademic investigators pro total costs for the entire	nd Isabel Barnett Drug Development Pro we a high probability of reaching the clin posing to develop novel or repositioning 2-year period of performance.	gram provides support ic within three years. Th approaches for ALS. Av	for preclinical nis program is open wards will be
	Applicant Types					
	Funding Limit	250,000.00 per y	ear			
	Limited Submission	No				
042399	Research Grants		American Foundatio	Academy of Otolaryngic Allergy n	01-Jun-2022	10,000 USD
	Contact Name	Elisabeth Herzfel	d-Rice			
	Contact Telephone	202-955-5010 x 6	600			
	Contact Email	foundation@aao	allergy.org			
	Sponsor Website	Link to sponsor w	<u>vebsite</u>			
	Program URL	Link to program l	JRL			
	Deadline Dates (ALL)	01-Jun-2022				
	Synopsis	The AAOA Found inviting application of otolaryngic allo \$10,000.	ation seeks to advance al ons for grants to conduct ergy. Funds are available	lergy research and knowledge for the tre research in the pathogenesis, pathophys to support multiple projects each year; e	atment of otolaryngic c iology, diagnosis, preve each project may have t	onditions by ntion, or treatment otal direct costs of
	Applicant Types					
	Funding Limit	10,000.00 maxim	um			



SPIN ID	Program Title	Sponsor Nar	ne	Sponsor Number	Deadline Date	Funding Amount
	Limited Submission	No				
045882	Outstanding Investigator Award	for Breast Cancer Research	American Association for (	Cancer Research	30-Jun-2022	Not Specified
	Contact Name	Michael J. Powell, PhD, Deputy	/ Director of Scientific Progr	ams		
	Contact Telephone	215-440-9373				
	Contact Email	michael.powell@aacr.org				
	Sponsor Website	Link to sponsor website				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	30-Jun-2022				
	Synopsis	The AACR established this Awa reaching impact on the etiolog discipline across the continuur	ard to recognize an investiga y, detection, diagnosis, trea n of biomedical research, in	tor whose novel and signific tment, or prevention of bre cluding basic, translational,	cant work has had or ast cancer. Such wor clinical, and epidemi	may have a far- k may involve any ological studies.
	Applicant Types					
	Funding Limit	0.00 see detail				
	Limited Submission	No				
032751	Eva King Killiam Research Award	·	American College of Neuro	opsychopharmacology	23-Jun-2022	Not Specified
	Contact Name					
	Contact Telephone	615-324-2360				
	Contact Email	acnp@acnp.org				
	Sponsor Website	Link to sponsor website				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	23-Jun-2022				
	Synopsis	The American College of Neuro researcher on the basis of outs	opsychopharmacology (ACN standing translational resea	P) presents the Eva King Kill rch contributions to neurop	am Research Award sychopharmacology.	to an early career

Applicant Types

Funding Limit 0.00 see detail



SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Limited Submission	No			
103871	Barbara Fish Memorial Award	American (	College of Neuropsychopharmacology	23-Jun-2022	Not Specified
	Contact Name				
	Contact Telephone	615-324-2360			
	Contact Email	acnp@acnp.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	23-Jun-2022			
	Synopsis	The American College of Neuropsychophar who has made an outstanding contributior monetary award and a plaque to be given a	macology (ACNP) presents the Barbara Fish to basic, translational or clinical neuroscie at the ACNP Annual Meeting.	Memorial Award to nce. Award recipient	an ACNP member s will receive a
	Applicant Types				
	Funding Limit	0.00 see detail			
	Limited Submission	No			
072617	Joel Elkes Research Award	American (	College of Neuropsychopharmacology	23-Jun-2022	Not Specified
	Contact Name				
	Contact Telephone	615-324-2360			
	Contact Email	ancp@acnp.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	23-Jun-2022			
	Synopsis	The American College of Neuropsychophar recognition of an outstanding clinical contr	macology (ACNP) presents the Joel Elkes Re ibution to neuropsychopharmacology.	esearch Award to a ye	oung scientist in
	Applicant Types				
	Funding Limit	0.00 see detail			



SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Limited Submission	No			
095617	Media Award	American College	of Neuropsychopharmacology	23-Jun-2022	Not Specified
	Contact Name				
	Contact Telephone	615-324-2360			
	Contact Email	acnp@acnp.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	23-Jun-2022			
	Synopsis	The ACNP Media Award was established to recogn and substance abuse research and the positive imp paid trip to the ACNP Annual Meeting and a plaque	ize major contributions to the edu pact of research on treatment. The e to be presented at the Annual M	cation of the public ab Media Award consists eeting.	oout mental illness s of an expense
	Applicant Types				
	Funding Limit	0.00 see detail			
	Limited Submission	No			
092353	Stephanie Watts Career Develop	ment Award American Heart As	sociation	25-May-2022	Not Specified
	Contact Name				
	Contact Telephone	214-706-1240			
	Contact Email	council.awards@heart.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	25-May-2022 , 01-Jun-2022 , 03-Jun-2022			
	Synopsis	This award supports early career investigators wor promise but may be currently unfunded or have lin	king in hypertension and cardiova nited access to extramural funding	scular research who sh ȝ.	now exceptional
	Applicant Types				
	Funding Limit	0.00 see detail			



SPIN ID	Program Title	Sponsor Nan	ne	Sponsor Number	Deadline Date	Funding Amount
	Limited Submission	No				
079306	Lifestyle and Cardiometabolic He Award	alth Early Career Investigator	American Heart Associatio	on	09-Jun-2022	Not Specified
	Contact Name					
	Contact Telephone	214-706-1181				
	Contact Email	council.awards@heart.org				
	Sponsor Website	Link to sponsor website				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	09-Jun-2022				
	Synopsis	The Council on Lifestyle and Ca investigator and trainee counc young scientists to become inv productive careers.	ardiometabolic Health Youn il members for their achieve volved in the Council on Life	g Investigator Award recogn ements and their continuing style and Cardiometabolic H	izes and awards early research. The award ealth and to develop	y career also encourages and maintain
	Applicant Types					
	Funding Limit	0.00 see detail				
	Limited Submission	Yes				
092352	Harry Goldblatt New Investigator	r Award	American Heart Associatio	n	01-Jun-2022	Not Specified
	Contact Name					
	Contact Telephone	214-706-1181				
	Contact Email	council.awards@heart.org				
	Sponsor Website	Link to sponsor website				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	01-Jun-2022 , 03-Jun-2022				
	Synopsis	The Harry Goldblatt Award for cardiovascular research who ha cardiovascular disease. The aw submitted abstracts accepted	New Investigators recognize as significantly contributed vardee will be selected by th for presentation at the Hype	es a new independent invest to our understanding of the le Council's Awards Committ ertension Scientific Sessions,	tigator working in hy causes of hypertensi see from applicants v along with other ma	pertension or ion and related vho have aterials.

				_
Applicant Types Funding Limit Limited Submission	0.00 see detail No			
Marvin Moser Clinical Hypertens	ion Award Ame	rican Heart Association	03-Jun-2022	2,000 USD
Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) Synopsis Applicant Types Funding Limit Limited Submission	212-696-9099 <u>council.awards@heart.org</u> <u>Link to sponsor website</u> <u>Link to program URL</u> 03-Jun-2022 The Marvin Moser Clinical Hypertens dedication to the treatment and card 2,000.00 see detail No	sion Award recognizes a qualified mid-career or e of hypertensive patients.	senior Hypertension C	linician for their
Award for Outstanding Doctoral	Thesis Research in Biological Ame	rican Physical Society	01-Jun-2022	Not Specified
Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) Synopsis Applicant Types	301-209-3200 honors@aps.org Link to sponsor website Link to program URL 01-Jun-2022 The Award for Outstanding Doctoral quality and achievement in any area construed, and to encourage effective	Thesis Research in Biological Physics recognizes of experimental, computational, engineering, o ve written and oral presentation of research res	doctoral thesis resear r theoretical Biological ults.	rch of outstanding I Physics, broadly
	Funding Limit Limited Submission Marvin Moser Clinical Hypertens Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) Synopsis Applicant Types Funding Limit Limited Submission Award for Outstanding Doctoral Physics Contact Name Contact Telephone Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) Synopsis	Funding Limit0.00 see detailLimited SubmissionNoMarvin Moser Clinical Hypertension AwardAmeContact Name212-696-9099Contact Telephone212-696-9099Contact Emailcouncil.awards@heart.orgSponsor WebsiteLink to sponsor websiteProgram URLLink to program URLDeadline Dates (ALL)03-Jun-2022SynopsisThe Marvin Moser Clinical Hypertensi dedication to the treatment and card dedication to the treatment and card dedication to the treatment and card bedication to the treatment and card addication to the treatment and card dedication to the treatment and card bedication to the treatment and card dedication to the treatment and card bedication to the treatment and card addication to the treatment and card bedication to	Funding Limit   0.00 see detail     Limited Submission   No     Marvin Moser Clinical Hypertension Award   American Heart Association     Contact Name   212-696-9099     Contact Telephone   212-696-9099     Contact Telephone   Council.awards@heart.org     Sponsor Website   Link to sponsor website     Program URL   Link to sponsor website     Deadline Dates (ALL)   03-Jun-2022     Synopsis   The Marvin Moser Clinical Hypertension Award recognizes a qualified mid-career or deciation to the treatment and care of hypertensive patients.     Applicant Types   2,000.00 see detail     Funding Doctoral Thesis Research in Biological   American Physical Society     Physics   301-209-3200     Contact Telephone   201-209-3200     Contact Telephone   201-209-3200<	Funding Limit 0.00 see detail     Limited Submission   No     Marvin Moser Clinical Hypertension Award   American Heart Association   03-Jun-2022     Contact Name   212-696-9099   212-696-9099     Contact Telephone   212-696-9099   200-2012     Sponsor Website   Link to sponsor website   200-2012     Program URL   Deadline Dates (ALL)   03-Jun-2022     Synopsis   The Marvin Moser Clinical Hypertension Award recognizes a qualified mid-career or senior Hypertension C decication to the treatment and care of hypertensive patients.   Applicant Types     Funding Limit   2,000.00 see detail   2000-00 see detail     Limited Submission   No   American Physical Society   01-Jun-2022     Award for Outstanding Doctoral Thesis Research In Biological   American Physical Society   01-Jun-2022     Contact Name   Signosor website   201-209-3200   201-Jun-2022     Contact Telephone   301-209-3200   201-209-3200   201-209-3200     Contact Telephone   10-100-2022   The Award for Outstanding Doctoral Thesis Research in Biological Physics recognizes doctoral thesis research quality and achievement in any area of experimental, computational, engineering, or theoretical Biological anoticular and achievement in any area of experimental, computational, engineering, o

SPIN ID	Program Title	Sponsor Nar	ne	Sponsor Number	Deadline Date	Funding Amount
	Funding Limit Limited Submission	0.00 see detail Yes				
083145	APA Distinguished Scientific Awa Contribution to Psychology	rds for an Early Career	American Psychological A	ssociation	01-Jun-2022	Not Specified
	Contact Name	Suzanne Wandersman				
	Contact Telephone	202-336-6000				
	Contact Email	swandersman@apa.org				
	Sponsor Website	Link to sponsor website				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	01-Jun-2022				
	Synopsis	The American Psychological As of their research careers.	ssociation (APA) provides ar	n award to recognize exceller	nt psychologists who	are at early stages
	Applicant Types					
	Funding Limit	0.00 not provided				
	Limited Submission	No				
102829	Mitchell A. Baran Achievement A	ward for Clinical Excellence in	American Respiratory Car	e Foundation	01-Jun-2022	2,500 USD
	Aerosol and Airway Clearance Th					
	Contact Name					
	Contact Telephone	972-243-2272				
	Contact Email					
	Sponsor Website	Link to sponsor website				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	01-Jun-2022				
	Synopsis	This award is given to recogniz and promoting the use of evid application of non-pharmacolo	e and honor those individua ence-based, clinically sound ogic airway clearance therag	als demonstrating clinical exo I practices for the delivery of pies.	cellence and leaders aerosolized medica	hip in advocating tions and/or the
	Applicant Types					

SPIN ID	Program Title	Sponsor Nai	me	Sponsor Number	Deadline Date	Funding Amount
	Funding Limit Limited Submission	2,500.00 see detail No				
068798	Thomas L. Petty, MD Invacare Aw Respiratory Care	vard for Excellence in Home	American Respiratory Care	e Foundation	01-Jun-2022	Not Specified
	Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) Synopsis Applicant Types Funding Limit Limited Submission	Crystal Maldonado 972-243-2272 <u>Link to sponsor website</u> <u>Link to program URL</u> 01-Jun-2022 This award recognizes outstan 0.00 see detail No	nding individual achievement	: in home respiratory care.		
068800	NBRC Frederic Helmholz, Jr., MD	Educational Research Fund	American Respiratory Care	e Foundation	01-Jun-2022	5,000 USD
	Contact Name Contact Telephone Contact Email	972-243-2272				
	Sponsor Website Program URL Deadline Dates (ALL)	Link to sponsor website Link to program URL 01-Jun-2022 The National Board for Boarier	atom Care (Applied Measure	mont Drofossionals Inc. has	provided on order	mont to the
	Synopsis	American Respiratory Care Fo or Doctoral Dissertation with p	undation to support up to \$5 practical value to the respira	5,000 for educational or cred tory care profession are acce	lentialing research. <i>i</i>	A Master's Thesis, by a candidate.
	Applicant Types					
	Funding Limit	5,000.00 see detail				
	Limited Submission	No				



SPIN ID	Program Title	Sponsor Nar	ne	Sponsor Number	Deadline Date	Funding Amount
068786	Forrest M. Bird, MD, PhD, ScD Lif	etime Scientific Achievement	American Respiratory Care	e Foundation	01-Jun-2022	Not Specified
	Contact Name	Crystal Maldonado				
	Contact Telephone	972-243-2272				
	Contact Email					
	Sponsor Website	Link to sponsor website				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	01-Jun-2022				
	Synopsis	This award acknowledges outs disorders.	tanding individual scientific	contributions in the area of	respiratory care of c	ardiopulmonary
	Applicant Types					
	Funding Limit	0.00 see detail				
	Limited Submission	No				
035693	ASRM/NIH/Duke Clinical Researc Training (CREST) Program	h/Reproductive Scientist	American Society for Repro	oductive Medicine	01-Jun-2022	Not Specified
	Contact Name					
	Contact Telephone	202-863-4985				
	Contact Email	nicole.goetz@cuanschutz.edu				
	Sponsor Website	Link to sponsor website				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	01-Jun-2022				
	Synopsis	The CREST training program is ASRM. This 2-year program me academic training in the quant	offered by the NICHD, the C eets an existing need for phy itative and methodological p	linical Research Training Pro vsicians in private or academ orinciples of clinical research	gram (CRTP) at Duk ic clinical practice to i in reproductive me	e University, and o obtain formalized dicine.
	Applicant Types					
	Funding Limit	0.00 not provided				
	Limited Submission	No				



SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
104547	Career Transition Grants		American Society of Tr	ansplantation	01-Jun-2022	50,000 USD
	Contact Name					
	Contact Telephone	856-439-9986				
	Contact Email	research@myast	.org			
	Sponsor Website	Link to sponsor w	<u>vebsite</u>			
	Program URL	Link to program	JRL			
	Deadline Dates (ALL)	01-Jun-2022				
	Synopsis	The purpose of the field of solid orgation of the field of solid orgation of the field of the fi	hese grants is to promote the careers in transplantation (and/or immunolog nsition to an R-series or equivalent gra	of mid-career independent inve y relating to solid organ transpl int.	estigators whose rese ant). The grants sup	earch relates to the port the
	Applicant Types					
	Funding Limit	50,000.00 see de	tail			
	Limited Submission	No				
019022	Department of Urology - Endour Northwestern	ology Fellowship a	American Urological As	sociation	02-Jun-2022	Not Specified
	Contact Name	Debra Caridi, Fell	owship Coordinator			
	Contact Telephone	516-520-1226				
	Contact Email	debra@endouro	logysociety.com			
	Sponsor Website	Link to sponsor w	<u>vebsite</u>			
	Program URL	Link to program	JRL			
	Deadline Dates (ALL)	02-Jun-2022 , 20-	-Jun-2022			
	Synopsis	The Endourologic developing advar surgery. Fellows and potential nat	cal Society facilitates one and two yea nced knowledge, experience, and tech also receive training in translational re cional and international leaders in thei	clinical fellowships around the nical skills in endourologic and search, as an underlying goal is r specialty.	e world. The training laparoscopic and/or the training of futur	is focused on robotic assisted re academicians
	Applicant Types					
	Funding Limit	0.00 not provide	d			



SPIN ID	Program Title	Sponsor Nam	ne	Sponsor Number	Deadline Date	Funding Amount
	Limited Submission	No				
104556	Request for Proposals (RFP) Div Cultivating a New Generation of	versity, Equity and Inclusion in Rheumatologists	Arthritis Foundation		06-Jun-2022	Not Specified
	Contact Name Contact Telephone Contact Email	1-800-283-7800 <u>AFScience@arthritis.org</u>				
	Sponsor Website	Link to sponsor website				
	Program URL	LINK to program UKL				
	Synopsis	The Arthritis Foundation (AF) is diverse generation of rheumate those living with arthritis. Two aspirations. The first program a outcomes across different racia program has a goal to increase physician/scientists. The ability with potential for their findings success. Focus on arthritis rese	s committed to Diversity, Eq ologists and to improve heal complementary AF initiative aims to provide seed funding al and ethnic groups, as well diversity in the next generary of proposed projects to have s to lead directly to advocacy earch and curriculum develop	uity, and Inclusion (DEI) in o Ith outcomes for all patients as were launched in 2021 an g to support impactful and in as among various categorie tion of rheumatologists, for ve a lasting impact and to be y and to reduce structural ba pment is preferred.	rder to support the with rheumatic disc d will continue in 20 novative research t s of socioeconomic those who are phys e sustained beyond t arriers, are considere	training of a eases, especially 022 to support AF's o improve health status. The second icians or he award period, ed important for
	Applicant Types					
	Limited Submission	No				
018455	Sir Harcourt Caughey Award		Auckland Medical Research	n Foundation	29-Jun-2022	17,250 USD
	Contact Name	Research Programme Manager	•			
	Contact Telephone	+64 9 923 1701				
	Contact Email	amrf@medicalresearch.org.nz				
	Sponsor Website	Link to sponsor website				
	Program URL	LINK to program URL				
	Deadline Dates (ALL)	29-JUN-2022				



SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	The Sir Harcourt Caughey Award provides funds up to \$25, having trained in research overseas, is returning to New Ze sufficient experience in research to deserve part-time supp research; or (ii) be a New Zealand medical graduate in Auc overseas and to undertake research in that area, especially be sufficiently prestigious in a particular field of medical kr to foster interest and research in that specialty. SPECIAL IN Foundation will only accept applications for this grant type the destination(s) identified in the application. For informa applicants must provide evidence from their host institutio application. The AMRF will not be responsible for any cost quarantine in any situation, whether or not it was an appro-	,000 for recipients who may ealand to a part-time appoin port (or similar to a part-time kland who is deserving of as y where there is a local defic nowledge and/or research to ISTRUCTIONS FOR 2022 ROL e if the NZ government cond ation, please refer to https:// on that they allow travel to t s associated with the recipie oved destination when the a	: (i) be a graduate of tment in Auckland a e Senior Research Fe sistance to train in a iency in expertise in o visit Auckland, norr JND 1: The Auckland itions are met for sa /covid19.govt.nz/tra he destination reque nt being stranded or opplication was subm	New Zealand who, nd who has Ilowship) in such specific field that field; or (iii) nally for 3-4 weeks, d Medical Research fe travel to or from vel/ For category 2, ested in their r having to nitted.
Applicant Types					
	Funding Limit	25,000.00 maximum			
	Limited Submission	No			
096334	Frontiers of Knowledge Awards	BBVA Foundation		30-Jun-2022	440,000 USD
	Contact Name				
	Contact Telephone	94 487 52 52			
	Contact Email	<u>awards-info@fbbva.es</u>			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	30-Jun-2022			
	Synopsis	The BBVA Foundation Frontiers of Knowledge Awards records scientific knowledge, technology, humanities and artistic of the second secon	ognize fundamental contribu reation.	tions in a broad arra	y of areas of
	Applicant Types				
	Funding Limit	400,000.00 see detail			
	Limited Submission	No			
089931	PhD Fellowships	Boehringer Ingelheim Fon	ds	01-Jun-2022	Not Specified

SPIN ID	Program Title	Sponsor N	lame	Sponsor Number	Deadline Date	Funding Amount
	Contact Name					
	Contact Telephone	+49 (0)6131 2750 80				
	Contact Email	secretariat@bifonds.de				
	Sponsor Website	Link to sponsor website				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	01-Jun-2022 , 01-Oct-2022				
	Synopsis	The Boehringer Ingelheim Forwho wish to pursue an amb	onds (BIF) awards PhD fellows itious PhD project in basic bior	hips of 2 to 3.5 years to outs medical research in an intern	tanding junior scient ationally leading lab	tists worldwide ooratory.
	Applicant Types					
	Funding Limit	0.00 see detail				
	Limited Submission	No				
045367	Partnering Opportunity for Late S (CLIN1)	Stage Preclinical Projects	California Institute for Reg	generative Medicine	29-Apr-2022	6,000,000 USD
	Contact Name					
	Contact Telephone	510-340-9101				
	Contact Email	clinical@cirm.ca.gov				
	Sponsor Website	Link to sponsor website				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	29-Apr-2022 , 31-May-2022	, 30-Jun-2022 , 31-Jul-2022			
	Synopsis	The mission of California Institute for Regenerative Medicine (CIRM) is to accelerate stem cell treatments to patients with unmet medical needs. The objective of this program announcement is to create a highly competitive partnering opportunity to accelerate the completion of an IND or IDE filing with the Food and Drug Administration (FDA) and initiate clinical trial start-up with a promising stem or progenitor cell-based or gene therapy treatment that addresses an unmet medical need. CIRM expects projects under this program to advance rapidly into the clinic and to achieve the proposed IND filing within 24 months.				
	Applicant Types					
	Funding Limit	6,000,000.00 maximum				
	Limited Submission	No				



SPIN ID	Program Title	Sponsor Nar	me	Sponsor Number	Deadline Date	Funding Amount	
045538	Partnering Opportunity For Clinic	cal Trial Stage Projects (CLIN2)	California Institute for Reg	generative Medicine	29-Apr-2022	Not Specified	
	Contact Name						
	Contact Telephone	510-340-9101					
	Contact Email	Clinical@cirm.ca.gov					
	Sponsor Website	Link to sponsor website					
	Program URL	Link to program URL					
	Deadline Dates (ALL)	29-Apr-2022 , 31-May-2022 , 3	30-Jun-2022 , 31-Jul-2022				
	Synopsis	The mission of California Institute for Regenerative Medicine (CIRM) is to accelerate stem cell treatments to patients with unmet medical needs. The objective of this program announcement is to create a highly competitive partnering opportunity to accelerate the completion of a clinical trial for a promising stem or progenitor cell-based or gene therapy treatment that addresses an unmet medical need. Under this program, CIRM will act not only as a funding agency, but will also devote significant internal resources and leverage its external team of world-class subject matter experts to actively advance the project. The result of a successful application will be the formation of a true partnership that both accelerates the program and gives it the greatest opportunity for success.					
	Applicant Types						
	Funding Limit	0.00 see detail					
	Limited Submission	No					
074890	Team Grant: E-Rare-6 Joint Trans	snational Call (2022)	Canadian Institutes of Hea	alth Research	15-Jun-2022	355,500 USD	
	Contact Name						
	Contact Telephone	613-954-1968					
	Contact Email	support@cihr-irsc.gc.ca					
	Sponsor Website						
	Program URL	Link to program URL					
	Deadline Dates (ALL)	15-Jun-2022					
	Synopsis	CIHR-IG is pleased to be partn Joint Programme on Rare Dise Research to improve health ca	ering with approximately 18 eases (EJP RD) call for propos are implementation and eve	international funding organ sals 2021. The topic of the ca ryday life of people living wit	izations in the conte all is Social Sciences h a rare disease.	xt of this European and Humanities	



SPIN ID	Program Title	Sponsor Na	ime	Sponsor Number	Deadline Date	Funding Amount
	Applicant Types Funding Limit Limited Submission	150,000.00 per year No				
109754	Request for Applications: Essenti Science (Cycle 5)	al Open Source Software for	Chan Zuckerberg Initiative		19-Apr-2022	400,000 USD
	Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) Synopsis	sciencegrants@chanzuckerbe Link to sponsor website Link to program URL 19-Apr-2022 , 02-Jun-2022 The Chan Zuckerberg Initiativ biomedical research. The goa engagement for these critical year for two years (inclusive of USD and \$400,000 USD total	erg.com re invites applications in supp I of the program is to suppor I tools. Applications can reque of up to 15% for indirect/over costs for the two-year duration	ort of open source software t software maintenance, gro est funding between \$50,000 head costs) for an overall ar on of the grant.	projects that are es wth, development, a 0 USD and \$200,000 nount requested be	sential to and community USD total costs per tween \$100,000
	Applicant Types	200 000 00 perveer				
	Limited Submission	No				



SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Contact Email	grapts@off org				
	Contact Emain	link to sponsor v	vohsito			
	Sponsor website	Link to sponsor v	vebsile			
		LINK to program	URL			
	Deadline Dates (ALL)	01-Jun-2022				
	Synopsis	The Cystic Fibros scientists to enha capabilities to be	is Clinical Research Scholars Pr ance their clinical research pro ecome independent investigate	ogram (CRSP) Award is designed to e ficiency and support their developme ors who formulate and lead multi-cer	nable promising early ent of the necessary cli iter, clinical research s	-career physician inical research tudies.
	Applicant Types					
	Funding Limit	0.00 see detail				
	Limited Submission	No				
070774	Research Grants	<u> </u>	Diabetes Resea (U.S.)	rch and Wellness Foundation	30-Jun-2022	100,000 USD
	Contact Name	Valerie Jeremiah	I			
	Contact Telephone	202-298-9211				
	Contact Email	<u>diabeteswellness</u>	s@diabeteswellness.net			
	Sponsor Website	Link to sponsor w	<u>vebsite</u>			
	Program URL	Link to program	<u>URL</u>			
	Deadline Dates (ALL)	30-Jun-2022 , 30	-Dec-2022			
	Synopsis	The Diabetes Research and Wellness Foundation (DRWF) accepts research applications related to finding the cause, Synopsis prevention, treatment, and cure of diabetes and its complications. The maximum support of these grants is up to \$50,000 per year for up to two years.				
	Applicant Types					
	Funding Limit	50,000.00 per ye	ar			
	Limited Submission	No				
057992	Simulation Research Grant	·	Emergency Me	dicine Residents' Association	03-Jun-2022	500 USD
	Contact Name					

Contact Telephone 972-550-0920



SPIN ID	Program Title	Spo	onsor Name	Sponsor Number	Deadline Date	Funding Amount
	Contact Email	<u>awards@emra.org</u>				
	Sponsor Website	Link to sponsor websi	<u>ite</u>			
	Program URL	Link to program URL				
	Deadline Dates (ALL)	03-Jun-2022				
	Synopsis	The purpose of the EI in-training interested	MRA Simulation Research G I in completing simulation-b	rant is to provide research funding to ased projects during residency/medic	Emergency Medicin al school.	e (EM) physician-
	Applicant Types					
	Funding Limit	500.00 see detail				
	Limited Submission	No				
030970	Eppendorf & Science Prize for Ne	eurobiology	Eppendorf AG		15-Jun-2022	25,000 USD
	Contact Name	Selection Committee	for the Eppendorf & Science	e Prize for Neurobiology Science		
	Contact Telephone	+1 202326 6513				
	Contact Email	eppendorfsciencepriz	ze@aaas.org			
	Sponsor Website	Link to sponsor websi	<u>ite</u>			
	Program URL	Link to program URL				
	Deadline Dates (ALL)	15-Jun-2022				
	Synopsis	The international Epp than 35 years for the by him/her during the	pendorf & Science Prize for I most outstanding neurobio e past three years. The prize	Neurobiology is awarded annually to c logical research based on methods of consists of \$25,000.	ne young scientist v molecular and cell b	vho is not older viology conducted
	Applicant Types					
	Funding Limit	25,000.00 see detail				
	Limited Submission	No				
006022	<u>Module I – Observational Trainin</u> <u>Grant</u>	g with Experts Fellows	ship European Society	of Gastrointestinal Endoscopy	01-Jun-2022	1,430 USD
	Contact Name					
	Contact Telephone	+ 49-89-907 7936-00				
	Contact Email	secretariat@esge.con	<u>m</u>			



SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Sponsor Website	Link to sponsor w	vehsite			
	Program LIRI	Link to program I				
	Deadline Dates (ALL)	The European Se	ciaty of Costraintactinal Endos	conv (FECE) offers followship grapts to	fully trained and ac	opicto wiching to
	Synopsis	undertake furthe through a mutua per year in an exc	er training in highly specialised I cooperation, ESGE and the Ja change programme. The select	endoscopic techniques at officially reco pan Gastroenterological Endoscopy Soc ed ESGE grantee is assigned to one of t	gnised ESGE training iety (JGES) offer one he leading Japanese	g centres. Also, e grant, Module I, institutions.
	Applicant Types					
	Funding Limit	1,300.00 see deta	ail			
	Limited Submission	No				
057307	Research Grants		Fibrolamellar Ca	ancer Foundation	01-Jun-2022	Not Specified
	Contact Name					
	Contact Telephone	203-340-7800				
	Contact Email	grants@fibrofou	ndation.org			
	Sponsor Website	Link to sponsor w	<u>vebsite</u>			
	Program URL	Link to program l	URL			
	Deadline Dates (ALL)	01-Jun-2022 , 01-	-Oct-2022			
	Synopsis	The Fibrolamellar Cancer Foundation (FCF) is accepting proposals to support innovative research leading to improved understanding and curative treatments for fibrolamellar carcinoma (FLC). FLC, also known as fibrolamellar hepatocellular carcinoma (FL-HCC), is an aggressive liver cancer that tends to strike teens and young adults. The research must focus specifically on FLC. Studies should be intended to advance knowledge relevant to the understanding, diagnosis, epidemiolog or treatment of FLC. Of particular interest are applications showing a clear path towards a novel therapy or clinical trials with the ultimate goal of achieving a cure for FLC. The Foundation will accept grant applications to support innovative and promising research projects towards the listed goals. The FCF believes that collaboration engaging the best talent across institutions, together with early sharing of data and resources, often accelerates the path to a cure for rare cancers.				
	Applicant Types					
	Funding Limit	0.00 see detail				
	Limited Submission	No				



SPIN ID	Program Title	Sponsor Nan	ne	Sponsor Number	Deadline Date	Funding Amount
001781	William T. Grant Scholars Program	<u>n</u>	Grant (William T.) Found	ation	15-Jun-2022 [LOI/Pre-App	350,000 USD
	Contact Name					
	Contact Telephone	212-752-0071				
	Contact Email	info@wtgrantfdn.org				
	Sponsor Website	Link to sponsor website				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	15-Jun-2022 [LOI/Pre-App], 06	5-Jul-2022			
	Synopsis	The William T. Grant Scholars I funds five-year research and m and content areas.	Program supports career d nentoring plans that signific	evelopment for promising eau cantly expand researchers' ex	rly-career researcher pertise in new discip	rs. The program blines, methods,
	Applicant Types					
	Funding Limit	350,000.00 maximum				
	Limited Submission	Yes				
058073	University of Toronto Integrated Training Program	Neonatal-Perinatal Fellowship	Hospital for Sick Children Foundation	Foundation/Sick Kids	30-Jun-2022	Not Specified
	Contact Name	Sonia Dos Santos, Interim Educ	cation Administrative Coor	dinator		
	Contact Telephone	416-813-7654 x 228902				
	Contact Email	neonatal.fellowship@sickkids.	<u>ca</u>			
	Sponsor Website	Link to sponsor website				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	30-Jun-2022				
	Synopsis	The University of Toronto Trai to paediatricians.	ining Program in Neonatal-	Perinatal Medicine provides t	wo years of neonata	al-perinatal training
	Applicant Types					
	Funding Limit	0.00 not provided				
	Limited Submission	No				



SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
012624	International Travel and Subsiste	nce Grants	Houghton Trus	t	15-Jun-2022	Not Specified
	Contact Name	Dr. S. J. Baigent				
	Contact Telephone					
	Contact Email	sue.baigent@out	<u>tlook.com</u>			
	Sponsor Website	Link to sponsor v	<u>vebsite</u>			
	Program URL	Link to program	<u>URL</u>			
	Deadline Dates (ALL)	15-Jun-2022				
	Synopsis	Grants are award meetings, visiting scope of Avian Pa oral/poster prese	ded for the furtherance of stud g appropriate laboratories for athology journal defines the re entation will be considered mo	y or research in avian diseases by atter discussions and learning specific technic search areas for appropriate applicatio ore favourably.	nding/participating ir ques, or attending tr ns. Applicants who v	n relevant scientific raining courses. The will give an
	Applicant Types					
	Funding Limit	0.00 see detail				
	Limited Submission	No				
109019	Incyte Ingenuity Awards		Incyte		24-Jun-2022	100,000 USD
	Contact Name					
	Contact Telephone					
	Contact Email	IncyteIngenuity@	VOZAdvisors.com			
	Sponsor Website	Link to sponsor v	<u>vebsite</u>			
	Program URL	Link to program	<u>URL</u>			
	Deadline Dates (ALL)	24-Jun-2022				
	Synopsis	The Incyte Ingen that address cha	uity Awards aim to support the llenges faced by GVHD patient	e graft-versus-host disease (GVHD) com s, caregivers, and healthcare providers.	imunity by funding t	wo novel initiatives
	Applicant Types					
	Funding Limit	100,000.00 maxi	mum			
	Limited Submission	Yes				



SPIN ID	Program Title	Sponsor I	Name	Sponsor Number	Deadline Date	Funding Amount
058306	Operating Grants		International Organizatio Inflammatory Bowel Dise	n For the Study of ase	30-Jun-2022	275,000 USD
	Contact Name	Marischka Konings				
	Contact Telephone	+31 35 5426745				
	Contact Email	ioibd@mkproducties.nl				
	Sponsor Website	Link to sponsor website				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	30-Jun-2022				
	Synopsis	The International Organizat to €250,000 for one year, p grants less than or equal to	tion For the Study of Inflamma preferably equally divided betw o €50,000.	tory Bowel Disease (IOIBD) o veen Clinical and Basic Science	ffers Operating Grar e Projects. Preferend	nts of up ce will be given to
	Applicant Types					
	Funding Limit	250,000.00 maximum				
	Limited Submission	Yes				
009045	Ernst H. Bárány Prize		International Society for I	Eye Research	01-Jun-2022	Not Specified
	Contact Name					
	Contact Telephone	415-561-8569				
	Contact Email	mail@iser.org				
	Sponsor Website	Link to sponsor website				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	01-Jun-2022				
	Synopsis	The Ernst H. Bárány Prize is increases our understandin macular degeneration, or r	awarded to a distinguished so ng of ocular pharmacology dire elated retinal diseases.	ientist who has made outstan ctly related to or applicable to	nding contributions o glaucoma, diabetio	in research that c retinopathy,
	Applicant Types					
	Funding Limit	0.00 not provided				



SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Limited Submission	No			
061954	Asia Pacific Chapter Scholarship	International	Society for Peritoneal Dialysis	30-Jun-2022	3,000 USD
	Contact Name	Professor CC Szeto			
	Contact Telephone				
	Contact Email	<u>ccszeto@cuhk.edu.hk</u>			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	30-Jun-2022 , 31-Dec-2022			
	Synopsis	Asia Pacific Chapter Scholarships promote PD months. It is intended primarily for nephrolog countries. The ISPD APC aims to offer up to tw exceed US\$3,000.	awareness, knowledge and expertise by gists and renal nurses in the Asia Pacific rework of fellowship grants per semester. The to	visiting a centre of e egion, especially in th stal maximum per inc	xcellence for 2-3 ne developing dividual cannot
	Applicant Types				
	Funding Limit	3,000.00 maximum			
	Limited Submission	No			
024383	Scholarship Program	International	Team for Implantology (ITI)	30-Jun-2022	21,600 USD
	Contact Name	Anna Häuptli			
	Contact Telephone	+41 (0) 61 270 83 83			
	Contact Email	scholarship@iti.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	30-Jun-2022			
	Synopsis	The International Team for Implantology (ITI) experience in implant dentistry. The program prosthetic restorations and, in most ITI Schol	offers a post-graduate program for youn a allows ITI Scholars to gain insight into ca arship Centers, also into research and tea	g clinicians to gain ir se planning, implant ching.	iternational surgery and
	Applicant Types				
	Funding Limit	20,000.00 see detail			



SPIN ID	Program Title	Sponsor Nan	ne	Sponsor Number	Deadline Date	Funding Amount
	Limited Submission	No				
110041	DOROTHY COFUND Develop In Health Crises Collaboratively	terdisciplinary Approaches to	Irish Research Council		23-May-2022	Not Specified
	Contact Name					
	Contact Telephone					
	Contact Email	dorothy@research.ie				
	Sponsor Website	Nebsite Link to sponsor website				
	Program URL	Im URL Link to program URL				
	Deadline Dates (ALL) 23-May-2022 , 07-Jun-2022					
	Synopsis	DOROTHY is a postdoctoral research programme open to researchers from all disciplines who wish to focus on research in public health crises. DOROTHY is open to applicants from all nationalities and disciplines, provided that their research topic relates to public health crises. Research areas will include, but will not be limited to, epidemiology, engineering of materia health psychology, health economics, social history, medical and health humanities, and philosophy.				
	Applicant Types					
	Funding Limit	0.00 see detail				
	Limited Submission	No				
024717	Strategic Research Agreements: I	Multi Project	Juvenile Diabetes Research International	h Foundation	03-May-2022 [LOI/Pre-App	Not ] Specified
	Contact Name					
	Contact Telephone	800-533-2873				
	Contact Email	preawardsupport@jdrf.org				
	Sponsor Website	Link to sponsor website				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	03-May-2022 [LOI/Pre-App], 17-Jun-2022 [LOI/Pre-App]				
	Synopsis	JDRF's Strategic Research Agreements provide research funding for single or multiple investigators to address critical gaps and challenges and potential breakthroughs in Type 1 diabetes research. The JDRF Strategic Research Agreement for multiple projects provides a mechanism to stimulate new collaborations between clinical and basic scientists and/or between scientists from diverse backgrounds as a means to conceive and develop new approaches to major challenges, potential				


SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Applicant Types Funding Limit	breakthroughs, or persistent obstacles to progress complications. 0.00 not provided	along the various paths to prevent	, treat or cure Type 1	diabetes and its
061435	Research Grants	LEO Foundation	<u> </u>	21-Jun-2022	Not Specified
	Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) Synopsis Applicant Types Funding Limit Limited Submission	+ 45 32 72 51 10 <u>applications@leo-foundation.org</u> <u>Link to sponsor website</u> <u>Link to program URL</u> 21-Jun-2022 , 04-Sep-2022 LEO Foundation open competition grants are given 0.00 not provided No	ו to support the best dermatology ו	esearch projects wor	ldwide.
036282	LEO Foundation Awards	LEO Foundation		21-Jun-2022	100,000 USD
	Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) Synopsis	+ 45 32 72 51 10 <u>applications@leo-foundation.org</u> <u>Link to sponsor website</u> <u>Link to program URL</u> 21-Jun-2022, 04-Sep-2022 The LEO Foundation Awards constitute a global rec work represent extraordinary contributions to derr of the Americas EMEA (Europe/Middle Eact/Africa	cognition and are given annually to matology research. There will be th	outstanding young so ree awards of 100.00	cientists whose 0 USD, one in each



SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Applicant Types Funding Limit Limited Submission	100,000.00 maximum No			
002595	Distinguished Innovator Award (I	DIA) Lupus Research Alliance		15-Jun-2022	1,000,000 USD
	Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) Synopsis Applicant Types Funding Limit	Dr. Hoang Nguyen, Senior Scientific Program Manager -646-884-6000 hnguyen@lupusresearch.org Link to sponsor website Link to program URL 15-Jun-2022 The Distinguished Innovator Award provides outstanding s research into the fundamental causes of systemic lupus er cure. Applications from investigators from diverse discipli years.	scientists with substantial su Tythematosus and so provide nes are encouraged. The aw	pport to conduct hig e new directions tow ard provides \$1.0 m	shly innovative vards a illion over four
108503	New Program	Mathers (G.Harold and Le	ila Y.) Foundation	15-Apr-2022 [LOI/Pre-App	Not Specified
	Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL)	support@mathersfoundation.org Link to sponsor website 15-Apr-2022 [LOI/Pre-App], 30-Jun-2022			
	Synopsis	The mission of The G. Harold and Leila Y. Mathers Founda	tion is to advance knowledge	e in the life sciences	by sponsoring



SPIN ID	Program Title	Sponsor Nar	ne	Sponsor Number	Deadline Date	Funding Amount
		scientific research that will ber goal, and fundamental to the F	nefit mankind. Basic scientif Foundation's operating princ	ic research, with potential tr ciples.	anslational applicat	on, is central to this
	Applicant Types					
	Funding Limit	0.00 not provided				
	Limited Submission	Yes				
022414	Fellowship Program		Matsumae International F	oundation	20-Jun-2022	Not Specified
	Contact Name					
	Contact Telephone					
	Contact Email	contact@mif-japan.org				
	Sponsor Website	Link to sponsor website				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	20-Jun-2022				
	Synopsis	The Matsumae International F who have never been to Japan	oundation offers fellowship	s of three to six months in d	uration to doctorate	e degree holders
	Applicant Types					
	Funding Limit	0.00 see detail				
	Limited Submission	No				
067186	Pediatric Dermatology Fellowshi	p (Minnesota)	Mayo Clinic College of Me	dicine and Science	30-Jun-2022	Not Specified
	Contact Name	Kelly J. Ihrke				
	Contact Telephone	507-284-3736				
	Contact Email	mayodermfellows@mayo.edu				
	Sponsor Website	Link to sponsor website				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	30-Jun-2022				
	Synopsis	Mayo Clinic in Rochester, Minr	nesota, offers a one-year Pe	diatric Dermatology Fellows	hip that focuses on a	advanced care of



SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Applicant Types	infants and child residents in clinic ophthalmology a	ren with severe skin disease. cal, laboratory and procedura and other departments.	During this fellowship, fellows will work I dermatology, as well as colleagues in p	with Mayo Clinic sta lastic surgery, rheum	ff members and natology,
	Applicant Types	0.00 cas datail				
		0.00 see detail				
		NO				
061247	Merck MISP Clostridium Difficile	<u>Grant</u>	Merck		11-Jun-2022	Not Specified
	Contact Name	Boski Patel				
	Contact Telephone	267-305-3173				
	Contact Email	boski_patel@ms	d.com			
	Sponsor Website	Link to sponsor v	<u>vebsite</u>			
	Program URL	Link to program	<u>URL</u>			
	Deadline Dates (ALL)	11-Jun-2022				
	Synopsis	The Investigator drug/vaccine and external investig	Studies Program aims to adva d/or total/partial funding, hig ators. Results will be generate	ance science and improve patient care by h-quality research that is initiated, design ed and properly disseminated in peer-rev	y supporting, throug ned, implemented an viewed publications.	h the provision of nd sponsored by
	Applicant Types					
	Funding Limit	0.00 not provide	d			
	Limited Submission	No				
058805	Investigator Studies Program (M	ISP) Surgery A	Anesthesia Merck		01-May-2022 [LOI/Pre-App	2 Not b] Specified
	Contact Name	Lisa Mount				
	Contact Telephone	267-305-1258				
	Contact Email	lisa_mount@me	<u>rck.com</u>			
	Sponsor Website	Link to sponsor v	<u>vebsite</u>			
	Program URL	Link to program	<u>URL</u>			



SPIN ID	Program Title	Sponsor Na	me	Sponsor Number	Deadline Date	Funding Amount
	Deadline Dates (ALL) Synopsis	01-May-2022 [LOI/Pre-App], 2 The Investigator Studies Prog drug/vaccine and/or total/par external investigators. Results	18-Jun-2022 , 01-Sep-2022 [Lo ram aims to advance science rtial funding, high-quality reso s will be generated and prope	OI/Pre-App], 19-Oct-2022 and improve patient care by earch that is initiated, design erly disseminated in peer-rev	y supporting, through ned, implemented ar viewed publications.	n the provision of nd sponsored by
	Applicant Types Funding Limit Limited Submission	0.00 not provided No				
109786	Request for ProposalsStudy of Solution (SAS) in the Newfoundland Dog B	Subvalvular Aortic Stenosis Breed	Morris Animal Foundation		03-Jun-2022	50,000 USD
	Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) Synopsis Applicant Types Funding Limit	800-243-2345 grantapplications@morrisanin Link to program URL 03-Jun-2022 The sponsor is accepting prop more of the following areas m other breeds that have high o studies of Newfoundlands dia Necropsy investigations of Ne echocardiography.	malfoundation.org posals for the study of subvalv nust be addressed: Genetic st r low prevalence of this disea gnosed in secondary (rather t wfoundlands with or without	vular aortic stenosis (SAS) in udies - these may include co ase. Functional studies are p than tertiary) referral center SAS lesions, that were prev	the Newfoundland c omparison of Newfou articularly welcome. rs by board-certified viously examined usir	log breed. One or undlands with Epidemiological cardiologists.
	Limited Submission	No				
097011	Research Fellow Award		Multiple Myeloma Researc	ch Foundation	24-Jun-2022	75,000 USD
	Contact Name Contact Telephone Contact Email	Mark Hamilton, PhD 203-652-0233 <u>hamiltonm@themmrf.org</u>				



SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount	
	Sponsor Website	Link to sponsor website				
	Program URL	Link to program URI				
	Deadline Dates (ALL)	24-Jun-2022				
	Synopsis	The Multiple Myeloma Research Foundation (MMRF) seek initiative supporting early career researchers at the post-c interested in research in multiple myeloma. Investigators costs, per year for a two (2) year period (total award is \$1	ks proposals for the MMRF 20 loctorate, medical fellow, or may request up to \$75,000 to 50,000).	D22 Research Fellow junior faculty levels otal costs, including	ship Program, an currently active or up to 10% indirect	
	Applicant Types					
Funding Limit 75,000.00 maximum						
Limited Submission No						
067593	Pilot Project Grants	Myositis Association		16-May-2022 [LOI/Pre-App	2 [	
	Contact Name	Chrissy Thornton				
	Contact Telephone	703-553-2631				
	Contact Email	chrissy@myositis.org				
	Sponsor Website	Link to sponsor website				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	16-May-2022 [LOI/Pre-App], 30-Jun-2022				
	Synopsis	Pilot Grants are designed to fund new and innovative research projects in the hope that they will attract funding from other sources (such as NIH). A competitive application will clearly delineate how this pilot funding will lead to future grant support. In addition, a competitive application will clearly distinguish itself from the investigator's existing research program. Any industry partnership must be clearly disclosed and a letter of support from the industry partner must be included. Pilot grant will be awarded for one or two years and up to a maximum of \$100,000 annually, subject to satisfactory progress.				
	Applicant Types					
	Funding Limit	100,000.00 maximum				
	Limited Submission	No				
067591	Research Fellowships	Myositis Association		16-May-2022 [LOI/Pre-App	2 100,000 USD	

SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount		
	Contact Name Contact Telephone	Chrissy Thornton 703-553-2631						
	Contact Email	Chrissy@myositi	S.Org					
	Sponsor Website	Link to sponsor v	vebsite					
	Program URL	Link to program	URL					
	Deadline Dates (ALL)	16-May-2022 [LC	0I/Pre-App], 30-Jun-2022					
	Synopsis	Mentored Resea subject to satisfa of \$50,000. Cand prior to commen must devote at le should be limited	entored Research Fellowships are designed to help promising junior investigators (MDs and PhDs) for a period of two years, bject to satisfactory progress, at the salary level approved by the participating institution, to a maximum received annually \$50,000. Candidates should have completed residency or fellowship training or have received a PhD within the three years or to commencing the Fellowship and be performing research under the supervision of an established mentor. Recipients ust devote at least 50% of their time to research, but may include some study and clinical experience in allied fields. There ould be limited supplementation of salary from outside sources.					
	Applicant Types							
	Funding Limit	50,000.00 per ye	ar					
	Limited Submission	No						
004820	Research Grants (Temporarily Su	<u>spended)</u>	National Headache Found	ation	30-Jun-2022	Not Specified		
	Contact Name	Dr. Timothy R. Sr	nith, Research Committee Chair					
	Contact Telephone	312-274-2650						
	Contact Email	tsmith@studyme	etrix.com					
	Sponsor Website	Link to sponsor v	vebsite					
	Program URL							
	Deadline Dates (ALL)	30-Jun-2022 , 30	-Sep-2022 , 31-Dec-2022					
	Synopsis	Synopsis The National Headache Foundation supports research in the field of headache and pain as part of its mission, which also includes offering education and information to people living with migraine disease and headache disorders.						
	Applicant Types							
	Funding Limit	0.00 see detail						
	Limited Submission	No						



SPIN ID	Program Title	Sponsor Nai	me	Sponsor Number	Deadline Date	Funding Amount
075992	Peter G. Pentchev Niemann-Pick	Type C Research Fellowship	National Niemann-Pick Dis	ease Foundation, Inc.	01-Jun-2022	Not Specified
	Contact Name	Joslyn Crowe, NNPDF Executiv	ve Director			
	Contact Telephone	877-287-3672				
	Contact Email	nnpdf@nnpdf.org				
	Sponsor Website	Link to sponsor website				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	01-Jun-2022				
	Synopsis	The National Niemann-Pick Di of Niemann-Pick Type C (NPC)	sease Foundation (NNPDF) ir , a lethal neuro-degenerative	nvites applications for resea e disease for which there are	rch fellowships exam e no effective therap	ining the biology ies.
	Applicant Types					
	Funding Limit	0.00 see detail				
	Limited Submission	No				
078566	Research Grants Program		National Rosacea Society		17-Jun-2022	15,000 USD
	Contact Name					
	Contact Telephone	847-382-8971				
	Contact Email	info@rosacea.org				
	Sponsor Website	Link to sponsor website				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	17-Jun-2022				
	Synopsis	The National Rosacea Society	awards grants of up to \$15,0	00, or higher in special case	s, for research on ros	sacea.
	Applicant Types					
	Funding Limit	15,000.00 see detail				
	Limited Submission	No				
045773	Predoctoral and Postdoctoral Fel Research	lowships in Spinal Cord Injury	New York State Departme	nt of Health RFA	A # 01-Jun-2022	Not Specified



SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount		
	Contact Name	David Googins						
	Contact Telephone	518-474-7002						
	Contact Fmail	scirb@health.nv	POV					
	Sponsor Website	Link to sponsor w	vebsite					
	Program URL	Link to program	URL					
	Deadline Dates (ALL)	01-Jun-2022						
	Synopsis	The New York Stanot-for-profit org postdoctoral fell approximately si predoctoral fello of up to \$80,000	e New York State Department of Health and the Spinal Cord Injury Research Board (SCIRB) are accepting applications from t-for-profit organizations and governmental organization in New York State. They will provide funding for predoctoral and stdoctoral fellowships. Approximately \$1.5 million will be available for this request for applications (RFA) to fund proximately six to ten training (pre- or post- doctoral) awards. Eligible organizations are invited to submit applications for edoctoral fellowships with total annual costs of up to \$51,000 per year or postdoctoral fellowships with total annual costs up to \$80,000 per year. Each will be a two year awards.					
	Applicant Types							
	Funding Limit	0.00 see detail						
	Limited Submission	No						
021106	Research Grants		Oncology Nursing Socie	ty Foundation	08-May-202 [LOI/Pre-Apj	2 50,000 USD		
	Contact Name							
	Contact Telephone	866-257-4667						
	Contact Email	info@onfgivesba	ack.org					
	Sponsor Website	Link to sponsor w	<u>vebsite</u>					
	Program URL	Link to program	URL					
	Deadline Dates (ALL)	08-May-2022 [LC	DI/Pre-App], 30-Jun-2022					
	Synopsis	Oncology Nursin who have not pr	g Society Foundation offers General Re eviously received and completed at lea	search grants for emerging to store study with a fu	mid-career oncology nding level of \$50,0	nurse researchers 00 as the study PI.		
	Applicant Types							
	Funding Limit	50,000.00 maxim	num					

Limited Submission No



SPIN ID	Program Title		Sponsor Name		Sponsor Number	Deadline Date	Funding Amount
083547	Collaborative Research Developn	nent Grant	Ovari	an Cancer Research A	Alliance	07-Apr-2022 [LOI/Pre-App	900,000 USD
	Contact Name	Sarah DeFeo					
	Contact Telephone	212-268-1002					
	Contact Email	grants@ocrf.org					
	Sponsor Website	Link to sponsor w	<u>vebsite</u>				
	Program URL	Link to program l	<u>JRL</u>				
	Deadline Dates (ALL)	07-Apr-2022 [LOI	/Pre-App], 22-Jun-20	)22			
	Synopsis	Ovarian Cancer R purpose of this g investigators with are encouraged.	esearch Alliance is re rantmaking program hin one institution or	equesting Letters of I is to provide funds for collaborations betw	ntent for the 2022 Collabor or ovarian cancer research r een groups in multiple insti	ative Research Devel projects that may inv tutions. Interdisciplin	opment Grant. The olve several ary collaborations
	Applicant Types						
	Funding Limit	300,000.00 per y	ear				
	Limited Submission	No					
078435	Early Career Investigator Grant		Ovari	an Cancer Research A	Alliance	07-Apr-2022 [LOI/Pre-App	450,000 USD
	Contact Name	Kristin McGowan	l				
	Contact Telephone	212-268-1002					
	Contact Email	grants@ocrahop	e.org				
	Sponsor Website	Link to sponsor w	<u>vebsite</u>				
	Program URL	Link to program l	<u>JRL</u>				
	Deadline Dates (ALL)	07-Apr-2022 [LOI	/Pre-App], 22-Jun-20	)22			
	Synopsis	Ovarian Cancer R the Liz Tilberis Ea investigative care commitment to r	esearch Alliance is ro rly Career Award). T eer in the field of ova research and academ	equesting Letters of I he Early Career Inves rian cancer research ic endeavors in ovari	ntent for the 2023 Early Car tigator Grant is for junior fa . The intent of these grants ian cancer.	eer Investigator Gran culty with a strong co is to support a substa	nt (formerly called ommitment to an antial time
	Applicant Types						

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Funding Limit Limited Submission	150,000.00 per year No			
089503	Designated Grant Program	Pediatric Ca	ncer Research Foundation	01-Jun-2022	Not Specified
	Contact Name				
	Contact Telephone	949-859-6312			
	Contact Email	info@pcrf-kids.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
Deadline Dates (ALL) 01-Jun-2022					
	Synopsis	Donor Designated Grant Programs fund proj activity. Grants can be for any specific amou	ects in communities or regions local to t nt as designated by the donor or contrik	he specific donor or fu outing organization.	Indraising
	Applicant Types				
	Funding Limit	0.00 see detail			
	Limited Submission	No			
089498	Emerging Investigator Fellowship	o Grant Pediatric Ca	ncer Research Foundation	01-Jun-2022	50,000 USD
	Contact Name				
	Contact Telephone	949-859-6312			
	Contact Email	info@pcrf-kids.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	01-Jun-2022			
	Synopsis	Emerging Investigator Fellowship Grants are for emerging pediatric cancer researchers to	designed to support Post-Doctoral Fello pursue exciting research ideas.	wships and Clinical Inv	vestigator training
	Applicant Types				
	Funding Limit	50,000.00 per year			
	Limited Submission	No			

SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
089495	Basic Research Science Grant		Pediatric Cancer Research	Foundation	01-Jun-2022	750,000 USD
	Contact Name					
	Contact Telephone	949-859-6312				
	Contact Email	info@pcrf-kids.or	rg			
	Sponsor Website	Link to sponsor w	vebsite			
	Program URL	Link to program l	URL_			
	Deadline Dates (ALL)	01-Jun-2022				
	Synopsis	Basic Science Res initiatives. Fundir	search Grants fund basic science, translat ng is up to \$250,000 per year, for up to 3	ional and/or clinical state of years.	the art pediatric can	cer research
	Applicant Types					
	Funding Limit	250,000.00 per y	ear			
	Limited Submission	No				
089497	Translational Research Grant		Pediatric Cancer Research	Foundation	01-Jun-2022	200,000 USD
	Contact Name					
	Contact Telephone	949-859-6312				
	Contact Email	info@pcrf-kids.o	rg			
	Sponsor Website	Link to sponsor w	<u>vebsite</u>			
	Program URL	Link to program l	<u>URL</u>			
	Deadline Dates (ALL)	01-Jun-2022				
	Synopsis	Translational Res accelerates cures \$100,00 per year	search Grants fund new research protoco s from the laboratory bench to the bedsic r, for up to 2 years.	ls and therapies that hold pro- le of children and teens with	omise for improved highrisk cancers. Fu	outcomes and nding is up to
	Applicant Types					
	Funding Limit	100,000.00 per y	ear			
	Limited Submission	No				
109506	Competitive Grant Program: Tran Fellowship - United States	nsthyretin Cardiac	<u>Amyloidosis</u> Pfizer Pharmaceuticals		15-Jun-2022	80,000 USD

SPIN ID	Program Title	Sponsor Nam	ne	Sponsor Number	Deadline Date	Funding Amount
	Contact Nama	Amanda Stoin Crant Officer				
		Amanua Stein, Grant Onicer				
	Contact Telephone					
	Contact Email	amanda.j.stein@pfizer.com				
	Sponsor Website	Link to sponsor website				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	15-Jun-2022				
	Synopsis	Pfizer is issuing this Request for strong focus on clinical practice amyloidosis. Grant funding is av	r Proposals (RFP) to support e, research, and education to vailable to support one fello	: institutions with fellowship o further the understanding ow for up to a year at \$80,00	programs for Cardic of transthyretin carc 0.	logists that have a Jiac
	Applicant Types					
	Funding Limit	80,000.00 maximum				
	Limited Submission	No				
110048	Competitive Grant Program: Acro States	omegaly Research- United	Pfizer Pharmaceuticals		30-Jun-2022	100,000 USD
	Contact Name	Amanda Stein, Grant Officer				
	Contact Telephone					
	Contact Email	amanda.j.stein@pfizer.com				
	Sponsor Website	Link to sponsor website				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	30-Jun-2022				
	Synopsis	Pfizer is issuing this Request for projects requesting up to \$100,	r Proposals (RFP) for project ,000 will be considered.	s involving acromegaly research	arch in the United St	ates. Individual
	Applicant Types					
	Funding Limit	100,000.00 maximum				
	Limited Submission	No				
070888	RPB Stein Innovation Awards		Research to Prevent Blindr	ness	15-Jun-2022 [LOI/Pre-App	300,000 USD



SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount			
		1							
	Contact Name	Pattie Moran							
	Contact Telephone	646-892-9566							
	Contact Email	pmoran@rpbusa	a.org						
	Sponsor Website	Link to sponsor v	<u>vebsite</u>						
	Program URL	Link to program	URL						
	Deadline Dates (ALL)	15-Jun-2022 [LO	I/Pre-App], 01-Jul-2022						
	Synopsis	The RPB Stein In the visual system proposed high-ri thinking.	risual system and the diseases that compromise its function. These SI Awards are intended to provide seed money to osed high-risk/high-gain vision science research which is innovative, cutting-edge, and demonstrates out-of-the-box ing.						
	Applicant Types								
	Funding Limit	t 300,000.00 maximum							
	Limited Submission	No							
006942	Career Development Awards		Research to Prevent Blindr	ness	15-Jun-2022 [LOI/Pre-App	350,000 USD			
	Contact Name	Pattie Moran, Di	rector of Grants Administration						
	Contact Telephone	646-892-9566							
	Contact Email	pmoran@rpbusa	a.org						
	Sponsor Website	Link to sponsor v	<u>vebsite</u>						
	Program URL	Link to program	URL						
	Deadline Dates (ALL)	15-Jun-2022 [LO	I/Pre-App], 01-Jul-2022						
	Synopsis	The RPB Career Development Award helps RPB-supported ophthalmology chairs support promising junior ophthalmology Synopsis faculty who have demonstrated their potential for independent research. The \$350,000 grant is payable for up to four year upon approval of a 20-month substantive progress report.							
	Applicant Types								
	Funding Limit	350,000.00 maxi	mum						
	Limited Submission	No							



SPIN ID	Program Title		Sponsor Name	Sponsor Number	De	adline Date	Funding An	nount
001730	Physician and Public Awareness F	Proposals	ResMed Fou	ndation		15-Jun-2022	Not Speci	fied
	Contact Name	Kristi Burlingame	, Executive Director					
	Contact Telephone	858-361-0755						
	Contact Email	kristib@resmedf	oundation.org					
	Sponsor Website	Link to sponsor w	<u>vebsite</u>					
	Program URL	Link to program l	URL					
	Deadline Dates (ALL)	15-Jun-2022 , 15-	-Dec-2022					
	Synopsis	The Foundation's untreated sleep of educators and th	s goal in this funding categor disordered breathing, its syn e general public.	y is to further the awareness and kn nptoms, diagnosis and treatment wi	owledge th sleep s	of the inherent of the inherent of the inherent of the specialists, prima	langers of ry care physi	icians,
	Applicant Types							
	Funding Limit	0.00 not provideo	d					
	Limited Submission	No						
002115	Investigator Award		Rheumatolo	gy Research Foundation		01-Jun-2022 [LOI/Pre-App	.] 375,0	00 USD
	Contact Name							
	Contact Telephone	404-365-1373						
	Contact Email	foundation@rhe	umatology.org					
	Sponsor Website	Link to sponsor w	<u>vebsite</u>					
	Program URL	Link to program l	URL					
	Deadline Dates (ALL)	01-Jun-2022 [LOI	/Pre-App], 01-Jul-2022					
	Synopsis	This award is inter a project that wil fellowship. The p relevant to the rh establishment as	ended to support junior inve Il be competitive for NIH and purpose is to provide suppor neumatic diseases for the pe an independent investigato	stigators with a faculty appointment I/or equivalent funding. It is not inte t for basic science, translational, and riod between the completion of pos r.	during t nded to l clinical i t-doctora	he period that th be a second poste nvestigators enga ate fellowship tra	ey are devel doctoral aged in resea ining and	loping arch
	Applicant Types							



SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Funding Limit	375,000.00 maximum			
	Limited Submission	No			
000622	Scientist Development Award	Rheumatology Re	esearch Foundation	01-Jun-2022 [LOI/Pre-App]	Not ] Specified
	Contact Name				
	Contact Telephone	404-365-1373			
	Contact Email	foundation@rheumatology.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	01-Jun-2022 [LOI/Pre-App], 01-Jul-2022			
	Synopsis	This award is designed for individuals in the early research experience who plan to embark on care for a structured research training program for rhe	stages of their career (typically Fe ers in rheumatic diseases. The pur eumatologists or health profession	llows) or those without pose of this award is to p als in the field of rheum	significant prior provide support atology.
	Applicant Types				
	Funding Limit	0.00 see detail			
	Limited Submission	No			
095001	Innovative Research Award	Rheumatology Re	esearch Foundation	01-Jun-2022 [LOI/Pre-App]	400,000 USD
	Contact Name				
	Contact Telephone	404-365-1373			
	Contact Email	foundation@rheumatology.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	01-Jun-2022 [LOI/Pre-App], 01-Jul-2022			
	Synopsis	The Innovative Research Award provides essentia cause, progression, treatment, and outcomes of r \$400,000 for two years (maximum \$200,000 per y	Il support for innovative studies fo heumatic and musculoskeletal dis year).	cused on generating nev eases. The award amou	w insights into the nt is up to



SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Applicant Types Funding Limit Limited Submission	400,000.00 maxii No	num			
039276	Research Professorship		Royal Society		09-Jun-2022	Not Specified
	Contact Name					
	Contact Telephone	+44 (0) 20 7451 2	263			
	Contact Email	<u>seniorfellowships</u>	@royalsociety.org			
	Sponsor Website	<u>Link to sponsor w</u>	<u>vebsite</u>			
	Program URL	Link to program l	JRL			
Deadline Dates (ALL) 09-Jun-2022						
	Synopsis	Royal Society Res promise. The aim focus on research	earch Professorships provide long term s of this scheme is to release the best lead n.	support for world-class resea ding researchers from teachi	rchers of outstandir ng and administratio	ng achievement and on allowing them to
	Applicant Types					
	Funding Limit	0.00 see detail				
	Limited Submission	No				
027718	International Exchanges Scheme		Royal Society		15-Jun-2022	15,720 USD
	Contact Name					
	Contact Telephone	+44(0) 20 7451 2	557			
	Contact Email	international.exc	hanges@royalsociety.org			
	Sponsor Website	Link to sponsor w	<u>vebsite</u>			
	Program URL	Link to program l	JRL			
	Deadline Dates (ALL)	15-Jun-2022 , 28-	Sep-2022			
	Synopsis	These schemes a through either a	re for scientists based in the UK who wan one-off visit or bilateral travel.	t to stimulate collaborations	with leading scient	ists overseas
	Applicant Types					



SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Funding Limit Limited Submission	12,000.00 maximum No			
071837	Research Grants	SENS Research Foundatio	)n	25-Jun-2022	Not Specified
	Contact Name				
	Contact Telephone	650-336-1780			
	Contact Email	foundation@sens.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	25-Jun-2022 , 23-Sep-2022 , 01-Nov-2022			
	Synopsis	SRF is uniquely focused on a damage repair approach to t to positively affect the human condition by giving people productive life.	reating the diseases of aging interventions and treatment	;. This approach has a :s that yield more yea	amazing potential ars of healthy,
	Applicant Types				
	Funding Limit	0.00 not provided			
	Limited Submission	Νο			
095262	Humanitarian Award	Society for Industrial & O	rganizational Psychology	01-Jun-2022	1,500 USD
	Contact Name				
	Contact Telephone	419-353-0032			
	Contact Email	SIOP@siop.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	01-Jun-2022			
	Synopsis	The SIOP Humanitarian Award is given for sustained, sign psychology. The recipient of the award is given a plaque a donated to the charity/foundation of the recipient's choi	ificant, and outstanding hum and a cash prize of \$1,500 (or ce).	anitarian contributio	ins related to I-O ame amount
	Applicant Types	I			

SPIN ID	Program Title	Sponsor Nan	ne	Sponsor Number	Deadline Date	Funding Amount
	Funding Limit Limited Submission	1,500.00 see detail No				
016255	SOPHE/CDC Student Fellowship i	n Injury Prevention	Society for Public Health E	ducation	01-Jun-2022	2,000 USD
	Contact Name Contact Telephone Contact Email	202-408-9804 info@sophe.org				
	Sponsor Website	Link to sponsor website				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	01-Jun-2022				
	Synopsis	The SOPHE/CDC Student Fellow practice-based projects in eithe education or the behavioral sci	vship in Injury Prevention re er unintentional injury preve ences.	ecognizes, assists and trains ention or violence preventio	students working on n from the perspect	research or ive of health
	Applicant Types					
	Funding Limit	2,000.00 see detail				
	Limited Submission	No				
040849	Research Grant		Society for the Advanceme Management	ent of Blood	01-Jun-2022	25,000 USD
	Contact Name	Steven Frank				
	Contact Telephone	928-551-6400				
	Contact Email	<u>sfrank3@jhmi.edu</u>				
	Sponsor Website	Link to sponsor website				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	01-Jun-2022				
	Synopsis	The SABM Research Grant, sup field of patient blood managen conservation. This one-year gra patient blood management. Pr	ported by SABM and an edu nent by supporting a young ant provides starter funding eference will be given to jur	ucation grant from HemoSor investigator who intends to to further scientific inquiry nior faculty who will be advis	nics LLC, is intended study methods of pr and clinical knowled sed by an experience	to advance the romoting blood ge in the field of ed mentor. It is



SPIN ID	Program Title	:	Sponsor Name	Sponsor Number	Deadline	Date	Funding Amount
	Applicant Types Funding Limit Limited Submission	anticipated that th grant applications that all applicants 25,000.00 maximu No	ne funded study will gener focused on methods to in will be members of SABM um	ate results that can be used as pilot c nprove blood management and to pro , or will become members of SABM fo	lata or prelimina omote blood cor or at least one y	ary finding nservation ear.	s to support future . It is expected
066849	Mentored Clinical Scientist Resea Award (K08)	arch Career Develo	pment Society for \	/ascular Surgery	12-	-Jun-2022	Not Specified
	Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) Synopsis Applicant Types Funding Limit Limited Submission	Jane D. Scott 301-435-0535 <u>scottj2@nhlbi.nih</u> <u>Link to sponsor we</u> <u>Link to program U</u> 12-Jun-2022 , 12-J The SVS Foundatic of individuals purs NHLBI K08 mechai 0.00 see detail No	.gov ebsite RL Jul-2022 , 12-Oct-2022 , 12 on offers this award in par suing a career in vascular r nism.	-Nov-2022 tnership with the NHLBI as a means to esearch. This award provides financia	o facilitate the n I support over a	esearch ca and above	areer development that offered by the
096603	Vilcek Prize for Creative Promise	in Biomedical Scier	nce Vilcek Found	dation	10-	-Jun-2022	50,000 USD
	Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL)	212-472-2500 <u>info@vilcek.org</u> <u>Link to sponsor we</u> <u>Link to program U</u> 10-Jun-2022	<u>ebsite</u> <u>RL</u>				



SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount	
	Synopsis	The Vilcek Found who demonstrate and/or translatio	ation will award three Creative Pror e outstanding early achievement. Eli nal biomedical science.	nise Prizes of \$50,000 each to gible work may be creative, in	young foreign-born bic dependent research in	medical scientists basic, applied,	
	Applicant Types						
	Funding Limit	50,000.00 see de	tail				
	Limited Submission	No					
001134	Requests for Proposals in Leuker	nia Research	When Everyone Surv	ives Foundation, Inc.	01-Jun-2022	2 50,000 USD	
	Contact Name						
	Contact Telephone	770-595-3573					
	Contact Email	grants@wesfoun	dation.org				
	Sponsor Website	Link to sponsor w	<u>vebsite</u>				
	Program URL	Link to program l	JRL				
	Deadline Dates (ALL)	01-Jun-2022					
	Synopsis	This request for proposals (RFP) is offered by the When Everyone Survives Foundation (WES Leukemia Research Foundation) is to solicit innovative research in leukemia. Grants of \$50,000 for one year are offered to new and established investigators who are requesting support for laboratory, translational, or clinical research related to acute leukemia.					
	Applicant Types						
	Funding Limit	50,000.00 maxim	um				
	Limited Submission	No					



SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
083145	APA Distinguished Scientific Av to Psychology	vards for an Early Career Contribution	American Psychological Association	01-Jun-202	22 Not Specified
	Contact Name	Suzanne Wandersman			
	Contact Telephone	202-336-6000			
	Contact Email	swandersman@apa.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	01-Jun-2022			
	Synopsis	The American Psychological Associatio early stages of their research careers.	n (APA) provides an award to recognize ex	cellent psychologis	ts who are at
	Applicant Types				
	Funding Limit	0.00 not provided			
	Limited Submission	No			
061954	Asia Pacific Chapter Scholarshi	<u>p</u>	International Society for Peritoneal Dialysis	30-Jun-202	22 3,000 USD
	Contact Name	Professor CC Szeto			
	Contact Telephone				
	Contact Email	<u>ccszeto@cuhk.edu.hk</u>			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	30-Jun-2022 , 31-Dec-2022			
	Synopsis	Asia Pacific Chapter Scholarships prom for 2-3 months. It is intended primarily	ote PD awareness, knowledge and expert of or nephrologists and renal nurses in the	ise by visiting a cen Asia Pacific region,	tre of excellence especially in the



SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date Fu	nding Amount			
		developing countries. The ISPD APC air	ns to offer up to two fellowship grants per	r semester. The total n	naximum per			
		individual cannot exceed US\$3,000.						
	Applicant Types							
	Funding Limit	3,000.00 maximum						
	Limited Submission	No						
035693	ASRM/NIH/Duke Clinical Resea (CREST) Program	arch/Reproductive Scientist Training	American Society for Reproductive Medicine	01-Jun-2022	Not Specified			
	Contact Name							
	Contact Telephone	202-863-4985						
	Contact Email	nicole.goetz@cuanschutz.edu						
	Sponsor Website	Link to sponsor website						
	Program URL	Link to program URL						
	Deadline Dates (ALL)	01-Jun-2022						
	Synopsis	Synopsis Synopsis The CREST training program is offered by the NICHD, the Clinical Research Training Program (CRTP) at Duke University, and ASRM. This 2-year program meets an existing need for physicians in private or academic clinic practice to obtain formalized academic training in the quantitative and methodological principles of clinical re in reproductive medicine.						
	Applicant Types							
	Funding Limit	0.00 not provided						
	Limited Submission	No						
041313	Australian Aboriginal and Torro	es Strait Islander Awards	National Heart Foundation of Australia	17-Jun-2022	Not Specified			
	Contact Name							



SPIN ID	Program Title		Sponsor Name		Sponsor Number	Deadline Date	Funding Amount
	Contact Telephone	(03) 9321 1581					
	Contact Email	research@hear	tfoundation.org.au				
	Sponsor Website	Link to sponsor	website				
	Program URL	Link to program	<u>ı URL</u>				
	Deadline Dates (ALL)	17-Jun-2022					
	Synopsis	The Aboriginal creating high-ir	and Torres Strait Islander Award npact change in the Aboriginal a	d is exp and Tor	ected to produce tangible res Strait Islander cardiova	outcomes with the scular health resea	potential of rch community.
	Applicant Types						
	Funding Limit	0.00 see detail					
	Limited Submission	No					
080457	Award for Outstanding Doctor	al Thesis Resear	ch in Biological Physics Americ	an Phys	sical Society	01-Jun-202	22 Not Specified
	Contact Name						
	Contact Telephone	301-209-3200					
	Contact Email	honors@aps.or	g				
	Sponsor Website	Link to sponsor	website				
	Program URL	Link to program	<u>n URL</u>				
	Deadline Dates (ALL)	01-Jun-2022					
	Synopsis	The Award for Outstanding Doctoral Thesis Research in Biological Physics recognizes doctoral thesis research of outstanding quality and achievement in any area of experimental, computational, engineering, or theoretical Biological Physics, broadly construed, and to encourage effective written and oral presentation of research results.					
	Applicant Types						
	Funding Limit	0.00 see detail					



SPIN ID	Program Title	Sponsor Name		Sponsor Number	Deadline Date	Funding Amount
	Limited Submission	Yes				
103871	Barbara Fish Memorial Award		American Colle Neuropsychop	ege of harmacology	23-Jun-202	22 Not Specified
	Contact Name					
	Contact Telephone	615-324-2360				
	Contact Email	acnp@acnp.org				
	Sponsor Website	Link to sponsor website				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	23-Jun-2022				
	Synopsis	The American College of Neurop member who has made an outst will receive a monetary award a	osychopharmacology ( tanding contribution t nd a plaque to be give	ACNP) presents the Barba o basic, translational or c en at the ACNP Annual Me	ara Fish Memorial Av linical neuroscience. eeting.	vard to an ACNP Award recipients
	Applicant Types					
	Funding Limit	0.00 see detail				
	Limited Submission	No				
089495	Basic Research Science Grant		Pediatric Canc	er Research Foundation	01-Jun-202	22 750,000 USD
	Contact Name					
	Contact Telephone	949-859-6312				
	Contact Email	info@pcrf-kids.org				
	Sponsor Website	Link to sponsor website				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	01-Jun-2022				



SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount			
		1							
	Synopsis	Basic Science Re research initiativ	esearch Grants fund basic so ves. Funding is up to \$250,0	cience, translational and/or clinical sta DOO per year, for up to 3 years.	te of the art pediat	ric cancer			
	Applicant Types								
	Funding Limit	250,000.00 per y	year						
	Limited Submission	No							
109073	Better Methods, Better Resear	<u>·ch</u>	Me	dical Research Council (MRC)	15-Jun-202	2 818,750 USD			
	Contact Name	Dr Rosalind Rob	erts, Programme Manager						
	Contact Telephone								
	Contact Email	rosalind.roberts	rosalind.roberts@mrc.ukri.org						
	Sponsor Website	Link to sponsor	Link to sponsor website						
	Program URL	Link to program	URL						
	Deadline Dates (ALL)	15-Jun-2022							
	Synopsis	Researchers bas others in biome	ed at an organisation eligit dical and health research. F	ble for UKRI funding can apply for fund Projects must focus on an area within I	ing to improve the MRC or NIHR's rem	methods used by it.			
	Applicant Types								
	Funding Limit	625,000.00 max	imum						
	Limited Submission	No							
079625	Call for Proposals for Transnat Cerebrovascular Diseases	ional Research Pr	rojects on ERA	A-NET NEURON	28-Jun-202	2 Not Specified			
	Contact Name	Dr. Waed Khalek	k						
	Contact Telephone	+49 228 3821-11	191						
	Contact Email	NeuronCalls@ag	<u>gencerecherche.fr</u>						



SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount		
	Sponsor Website	Link to sponsor	website					
	Program URL	Link to program	<u>I URL</u>					
	Deadline Dates (ALL)	28-Jun-2022						
	Synopsis	The aim of this translational qu (CSVD) and the	year's call is to facilitate multinational estions in the areas of stroke and oth dysfunction of brain barriers.	, collaborative research pro er cerebrovascular diseases	ojects that will addr s including small ve	ess important ssels disease		
	Applicant Types							
	Funding Limit	0.00 see detail						
	Limited Submission	No						
006942	Career Development Awards		Research to P	revent Blindness	15-Jun-202 [LOI/Pre-A	22 350,000 App] USD		
	Contact Name	Pattie Moran, D	Pirector of Grants Administration					
	Contact Telephone	646-892-9566						
	Contact Email	pmoran@rpbus	a.org					
	Sponsor Website	Link to sponsor	website					
	Program URL	Link to program	URL					
	Deadline Dates (ALL)	15-Jun-2022 [L0	DI/Pre-App], 01-Jul-2022					
	Synopsis	The RPB Career Development Award helps RPB-supported ophthalmology chairs support promising junior south ophthalmology faculty who have demonstrated their potential for independent research. The \$350,000 grant is payable for up to four years upon approval of a 20-month substantive progress report.						
	Applicant Types							
	Funding Limit	350,000.00 max	kimum					
	Limited Submission	No						



SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date F	unding Amount							
104547	Career Transition Grants		American Society of Transplantation	01-Jun-2022	50,000 USD							
	Contact Name											
	Contact Telephone	856-439-9986										
	Contact Email	research@myast.org										
	Sponsor Website	Link to sponsor website										
	Program URL	Link to program URL										
	Deadline Dates (ALL)	01-Jun-2022										
	Synopsis	The purpose of these grants is to prom relates to the field of solid organ transp support the investigator's transition to	e purpose of these grants is to promote the careers of mid-career independent investigators whose research lates to the field of solid organ transplantation (and/or immunology relating to solid organ transplant). The grants pport the investigator's transition to an R-series or equivalent grant.									
	Applicant Types											
	Funding Limit	50,000.00 see detail										
	Limited Submission	No										
074665	Clinical Research Scholars Prog	gram Award	Cystic Fibrosis Foundation	01-Jun-2022	Not Specified							
	Contact Name											
	Contact Telephone	301-841-2614										
	Contact Email	grants@cff.org										
	Sponsor Website	Link to sponsor website										
	Program URL	Link to program URL										
	Deadline Dates (ALL)	01-Jun-2022										
	Synopsis	The Cystic Fibrosis Clinical Research Scl physician scientists to enhance their cli	nolars Program (CRSP) Award is designed inical research proficiency and support the	to enable promising e eir development of th	arly-career e necessary							



SPIN ID	Program Title		Sponsor Name		Sponsor Number	Deadline Date	Funding Amou	unt
		clinical research	n capabilities to become in	ndependent in	vestigators who formulat	e and lead multi-ce	nter, clinical	
	Applicant Types	research studies	5.					
	Eunding Limit	licteb ees 0.00						
	Limited Submission	No						
	Elimed Submission						<b>.</b>	
014129	Clinical Trial Award		C	ancer Researc	h UK	09-Jun-202 [LOI/Pre-A	2 Not pp] Specified	d
	Contact Name							
	Contact Telephone	0203 469 8498						
	Contact Email	<u>clinicalresearch</u>	@cancer.org.uk					
	Sponsor Website	Link to sponsor	website					
	Program URL	Link to program	URL					
	Deadline Dates (ALL)	09-Jun-2022 [LC	DI/Pre-App]					
	Synopsis	Clinical Trial Aw radiotherapy an	ards support intervention nd surgery) with the aim c	nal clinical tria of improving o	ls of cancer treatment (ind utcome.	cluding systemic tre	atment,	
	Applicant Types							
	Funding Limit	0.00 see detail						
	Limited Submission	No						
083547	33547 <u>Collaborative Research Development Grant</u>		C	varian Cancer	Research Alliance	07-Apr-202 [LOI/Pre-A	2 900,000 pp] USD	1
	Contact Name	Sarah DeFeo						
	Contact Telephone	212-268-1002						
	Contact Email	grants@ocrf.org	g					



SPIN ID	Program Title		Sponsor Name		Sponsor Number	Deadline Date	Funding Amount
	Sponsor Website	Link to sponsor	website				
	Program URL	Link to program	URL				
	Deadline Dates (ALL)	07-Apr-2022 [L0	DI/Pre-App], 22-Jun-2022				
	Synopsis	Ovarian Cancer Grant. The purp involve several Interdisciplinary	Research Alliance is reques ose of this grantmaking pro investigators within one ins collaborations are encour	sting Letters ogram is to p stitution or c aged.	of Intent for the 2022 Col provide funds for ovarian o collaborations between gro	laborative Research cancer research pro oups in multiple ins	<ul> <li>Development</li> <li>jects that may</li> <li>titutions.</li> </ul>
	Applicant Types						
	Funding Limit	300,000.00 per	year				
	Limited Submission	No					
110048	Competitive Grant Program: A	cromegaly Resea	nrch- United States Pfiz	zer Pharmac	euticals	30-Jun-202	22 100,000 USD
	Contact Name	Amanda Stein,	Grant Officer				
	Contact Telephone						
	Contact Email	amanda.j.stein(	<u>@pfizer.com</u>				
	Sponsor Website	Link to sponsor	<u>website</u>				
	Program URL	Link to program	URL				
	Deadline Dates (ALL)	30-Jun-2022					
	Pfizer is issuing this Request for Proposals (RFP) for projects involving acromegaly research in the United Synopsis States. Individual projects requesting up to \$100,000 will be considered.						
	Applicant Types						
	Funding Limit	100,000.00 max	timum				
	Limited Submission	No					



SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
110047	Competitive Grant Program: Tr (ATTR-CM) Research in Canada	ransthyretin Amyloid Cardiomyopathy a	Pfizer Pharmaceuticals	07-Jun-20	22 100,000 USD
	Contact Name	Amanda Stein, Grant Officer			
	Contact Telephone				
	Contact Email	amanda.j.stein@pfizer.com			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	07-Jun-2022			
	Synopsis	Pfizer Global Medical Grants (GMG) is Amyloid Cardiomyopathy (ATTR-CM) in	issuing this Request for Proposals n Canada. Individual projects reque	(RFP) for research involving esting up to \$100,000 will b	g Transthyretin De considered.
	Applicant Types				
	Funding Limit	100,000.00 maximum			
	Limited Submission	No			
109506	Competitive Grant Program: Tr Fellowship - United States	ransthyretin Cardiac Amyloidosis	Pfizer Pharmaceuticals	15-Jun-20	22 80,000 USD
	Contact Name	Amanda Stein, Grant Officer			
	Contact Telephone				
	Contact Email	amanda.j.stein@pfizer.com			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	15-Jun-2022			



SPIN ID	Program Title		Sponsor Name		Sponsor Number	Deadline Date	Funding Amount
		Pfizer is issuing	this Request for Propo	osals (RFP) to su	pport institutions with fello	wship programs for	r Cardiologists that
	Synopsis	have a strong fo amyloidosis. Gr	ocus on clinical practic ant funding is available	e, research, and e to support one	education to further the use fellow for up to a year at \$	nderstanding of tra \$80,000.	nsthyretin cardiac
	Applicant Types						
	Funding Limit	80,000.00 maxi	mum				
	Limited Submission	No					
019022	Department of Urology - Endo	urology Fellowsł	nip at Northwestern	American Uro	logical Association	02-Jun-202	22 Not Specified
	Contact Name	Debra Caridi, Fe	ellowship Coordinator				
	Contact Telephone	516-520-1226					
	Contact Email	debra@endour	ologysociety.com				
	Sponsor Website	Link to sponsor	<u>website</u>				
	Program URL	Link to program	<u>I URL</u>				
	Deadline Dates (ALL)	02-Jun-2022 , 2	0-Jun-2022				
	Synopsis	The Endourolog on developing a assisted surgery academicians a	gical Society facilitates advanced knowledge, o y. Fellows also receive nd potential national a	one and two ye experience, and training in trans and internationa	ar clinical fellowships arour technical skills in endourol lational research, as an uno l leaders in their specialty.	nd the world. The t ogic and laparoscop derlying goal is the t	raining is focused bic and/or robotic training of future
	Applicant Types						
	Funding Limit	0.00 not provid	ed				
	Limited Submission	No					
089503	Designated Grant Program			Pediatric Cano	er Research Foundation	01-Jun-202	22 Not Specified



SPIN ID	Program Title		Sponsor Name		Sponsor Number	Deadline Date	Funding Amount	
	Contact Name							
	Contact Telephone	949-859-6312						
	Contact Email	info@pcrf-kids.	org					
	Sponsor Website	Link to sponsor	website					
	Program URL	Link to program	<u>ı URL</u>					
	Deadline Dates (ALL)	01-Jun-2022						
	Synopsis	Donor Designat activity. Grants	ed Grant Programs fund projec can be for any specific amount	ts in con as desig	nmunities or regions local nated by the donor or cor	to the specific dom tributing organizat	or or fundraising ion.	
	Applicant Types							
	Funding Limit	0.00 see detail						
	Limited Submission	No						
002595	Distinguished Innovator Awarc	<u>i (DIA)</u>	Lupus F	Research	Alliance	15-Jun-202	1,000,000 USD	
	Contact Name	Dr. Hoang Nguy	ven, Senior Scientific Program N	lanager				
	Contact Telephone	-646-884-6000						
	Contact Email	hnguyen@lupu	sresearch.org					
	Sponsor Website	Link to sponsor	website					
	Program URL	Link to program	<u>n URL</u>					
	Deadline Dates (ALL)	15-Jun-2022						
	Synopsis Synopsis							



SPIN ID	Program Title		Sponsor Name		Sponsor Number	Deadline Date	Fund	ling Amount
	Applicant Types							
	Funding Limit	250,000.00 per	year					
	Limited Submission	No						
110041	DOROTHY COFUND Develop Crises Collaboratively	Interdisciplinary	Approaches to Healt	<sup>1</sup> Irish Research	Council	23-May-20	)22	Not Specified
	Contact Name							
	Contact Telephone							
	Contact Email	dorothy@resea	rch.ie					
	Sponsor Website	Link to sponsor	<u>website</u>					
	Program URL	Link to program	<u>URL</u>					
	Deadline Dates (ALL)	23-May-2022,	07-Jun-2022					
	Synopsis	DOROTHY is a postdoctoral research programme open to researchers from all disciplines who wish to focus on research into public health crises. DOROTHY is open to applicants from all nationalities and disciplines, provided their research topic relates to public health crises. Research areas will include, but will not be limited to, epidemiology, engineering of materials, health psychology, health economics, social history, medical and health humanities, and philosophy.						
	Applicant Types							
	Funding Limit	0.00 see detail						
	Limited Submission	No						
110085	Early Career Fellowships			Multiple Sclerc N. Ireland	osis Society of G.B. and	07-Jun-202	22	327,500 USD
	Contact Name							
	Contact Telephone	020-8438-0822						

Icahn School of Medicine at Mount Sinai

SPIN ID	Program Title		Sponsor Name		Sponsor Number	Deadline Date	Funding Amount		
	Contact Email	researchnetworl	k@mssociety.org.uk						
	Sponsor Website	Link to sponsor v	<u>website</u>						
	Program URL	Link to program	<u>URL</u>						
	Deadline Dates (ALL)	07-Jun-2022							
	Synopsis	Early Career Fell career in Multipl towards higher l	owships aim to attract ar le Sclerosis research. The evel appointments. Fund	nd retain tale se grants pro ing is up to £	nted postdoctoral research vide a staged career struct 250,000.	ners who want to bu ture and the opport	uild a successful unity to progress		
	Applicant Types								
	Funding Limit	250,000.00 maxi	imum						
	Limited Submission	No							
078435	Early Career Investigator Grant	<u>-</u>	0	varian Cance	r Research Alliance	07-Apr-202 [LOI/Pre-A	22 450,000 pp] USD		
	Contact Name	Kristin McGowar	า						
	Contact Telephone	212-268-1002							
	Contact Email	grants@ocrahop	<u>be.org</u>						
	Sponsor Website	Link to sponsor v	<u>website</u>						
	Program URL	Link to program	URL						
	Deadline Dates (ALL)	07-Apr-2022 [LO	I/Pre-App], 22-Jun-2022						
	Synopsis	Ovarian Cancer Research Alliance is requesting Letters of Intent for the 2023 Early Career Investigator Grant (formerly called the Liz Tilberis Early Career Award). The Early Career Investigator Grant is for junior faculty with a strong commitment to an investigative career in the field of ovarian cancer research. The intent of these grants is to support a substantial time commitment to research and academic endeavors in ovarian cancer.							
	Applicant Types								
	Funding Limit	150,000.00 per y	/ear						



SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date F	unding Amount
		1				
	Limited Submission	No				
029516	Early Career Researcher Partne	ership Award	Diabetes	Canada	17-Jun-2022	Not Specified
	Contact Name					
	Contact Telephone	416-363-3373				
	Contact Email	research@diabe	tes.ca			
	Sponsor Website	Link to sponsor v	<u>website</u>			
	Program URL	Link to program	URL			
	Deadline Dates (ALL)	17-Jun-2022				
	Synopsis	Diabetes Canada purpose of enco the field of diabe CIHR-INMD. The	a established the Early Career Re uraging, by appropriate recognit etes. This award continues today significance of the award and th	searcher Award (previously Yo ion, outstanding research cond with the support of research f e distinguished recipient is rec	ung Scientist Award) in Jucted in Canada by yo Junding from Diabetes Cognized by a special le	1987 for the ung scientists in Canada and cture.
	Applicant Types					
	Funding Limit	0.00 not provide	ed			
	Limited Submission	No				
089498	Emerging Investigator Fellows	hip Grant	Pediatric	Cancer Research Foundation	01-Jun-2022	50,000 USD
	Contact Name					
	Contact Telephone	949-859-6312				
	Contact Email	info@pcrf-kids.c	org			
	Sponsor Website	Link to sponsor v	<u>website</u>			
	Program URL	Link to program	URL			
	Deadline Dates (ALL)	01-Jun-2022				


SPIN ID	Program Title	Sponsor Name		Sponsor Number	Deadline Date	Funding Amount
	Synopsis	Emerging Investigator Fellowship G training for emerging pediatric can	rants are designed er researchers to	to support Post-Doctoral F pursue exciting research id	Fellowships and Clir eas.	nical Investigator
	Applicant Types					
	Funding Limit	50,000.00 per year				
	Limited Submission	No				
063826	Endometriosis Millennium Fun	<u>ıd</u>	Royal College Gynaecologist	of Obstetricians and s	17-Jun-202	22 6,550 USD
	Contact Name					
	Contact Telephone	+44 20 7772 6200				
	Contact Email	awards@rcog.org.uk				
	Sponsor Website	Link to sponsor website				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	17-Jun-2022				
	Synopsis	Available to RCOG Members and Tr to stimulate and encourage researc	ainees working in h (clinical or labor	the British Isles, the RCOG i atory based) in the field of	is able to offer up to endometriosis.	o £5,000 in order
	Applicant Types					
	Funding Limit	5,000.00 maximum				
	Limited Submission	No				
108209	Environmental Sustainability in	n Life Sciences and Medical Practice	Medical Resea	arch Council (MRC)	28-Jun-202	22 131,000 USD
	Contact Name					
	Contact Telephone					
	Contact Email					



SPIN ID	Program Title		Sponsor Name		Sponsor Number	Deadline Date	Funding Amount	
	Sponsor Website	Link to sponsor	website					
	Program URL	Link to program	URL					
	Deadline Dates (ALL)	28-Jun-2022						
	Synopsis	Researchers car practice. Applic understanding o will be funded f	a apply for funding to research ations should: show how net or provide practical solutions. or up to 12 months.	i environi zero carb MRC will	mental sustainability in lif on aspirations will be sup fund 80% of the full econ	e science and medio ported seek to impr omic cost up to £10	cal ove MRC's 0,000. Projects	
	Applicant Types							
	Funding Limit	100,000.00 max	timum					
	Limited Submission	No						
030970	Eppendorf & Science Prize for	Neurobiology	Epper	dorf AG		15-Jun-202	22 25,000 USD	
	Contact Name	Selection Comm	nittee for the Eppendorf & Sci	ence Prize	e for Neurobiology Science	e		
	Contact Telephone	+1 202326 6513	1					
	Contact Email	eppendorfscien	ceprize@aaas.org					
	Sponsor Website	Link to sponsor	<u>website</u>					
	Program URL	Link to program	URL					
	Deadline Dates (ALL)	15-Jun-2022						
	Synopsis	The international Eppendorf & Science Prize for Neurobiology is awarded annually to one young scientist who is not older than 35 years for the most outstanding neurobiological research based on methods of molecular and cell biology conducted by him/her during the past three years. The prize consists of \$25,000.						
	Applicant Types							
	Funding Limit	25,000.00 see d	etail					
	Limited Submission	No						



SPIN ID	Program Title	Spons	or Name	Sponsor Number	Deadline Date	Funding Amount
009045	Ernst H. Bárány Prize		Interna	tional Society for Eye Research	01-Jun-202	2 Not Specified
	Contact Name					
	Contact Telephone	415-561-8569				
	Contact Email	mail@iser.org				
	Sponsor Website	Link to sponsor websit	<u>e</u>			
	Program URL	Link to program URL				
	Deadline Dates (ALL)					
	Synopsis	The Ernst H. Bárány Pr that increases our und retinopathy, macular c	ize is awarded to a distir lerstanding of ocular pha degeneration, or related	nguished scientist who has made o rmacology directly related to or a retinal diseases.	outstanding contribution policable to glaucor	utions in research na, diabetic
	Applicant Types					
	Funding Limit	0.00 not provided				
	Limited Submission	No				
032751	Eva King Killiam Research Awa	r <u>d</u>	Americ Neurop	an College of osychopharmacology	23-Jun-202	2 Not Specified
	Contact Name					
	Contact Telephone	615-324-2360				
	Contact Email	acnp@acnp.org				
	Sponsor Website	Link to sponsor websit	<u>e</u>			
	Program URL	Link to program URL				
	Deadline Dates (ALL)	23-Jun-2022				



SPIN ID	Program Title		Sponsor Name		Sponsor Number	Deadline Date	Funding Amount
	Synopsis Applicant Types Funding Limit Limited Submission	The American C career research 0.00 see detail No	College of Neuropsycho er on the basis of outst	pharmacology ( anding translat	ACNP) presents the Eva Kir ional research contributior	ng Killam Research / ns to neuropsychop	Award to an early harmacology.
068786	Forrest M. Bird, MD, PhD, ScD	Lifetime Scientif	ic Achievement Award	American Resp Foundation	piratory Care	01-Jun-202	22 Not Specified
	Contact Name	Crystal Maldon	ado				
	Contact Telephone	972-243-2272					
	Contact Email						
	Sponsor Website	Link to sponsor	<u>website</u>				
	Program URL	Link to program	<u>URL</u>				
	Deadline Dates (ALL)	01-Jun-2022					
	Synopsis	This award ackr cardiopulmona	nowledges outstanding ry disorders.	individual scien	tific contributions in the ar	rea of respiratory ca	are of
	Applicant Types						
	Funding Limit	0.00 see detail					
	Limited Submission	No					
096334	Frontiers of Knowledge Award	<u>s</u>		BBVA Foundat	ion	30-Jun-202	22 440,000 USD
	Contact Name						
	Contact Telephone	94 487 52 52					
	Contact Email	awards-info@fb	<u>obva.es</u>				



SPIN ID	Program Title		Sponsor Name		Sponsor Number	Deadline Date	Funding Amount
	Sponsor Website	Link to sponsor	website_				
	Program URL	Link to program	URL				
	Deadline Dates (ALL)	30-Jun-2022					
	Synopsis	The BBVA Found of scientific kno	dation Frontiers of Kno wledge, technology, hu	wledge Awards umanities and a	recognize fundamental co rtistic creation.	ontributions in a bro	ad array of areas
	Applicant Types						
	Funding Limit	400,000.00 see	detail				
	Limited Submission	No					
020223	Gavin and Ann Kellaway Medic	cal Research Fello	owship	Auckland Med Foundation	lical Research	29-Jun-20	22 41,400 USD
	Contact Name						
	Contact Telephone	+64 9 923 1701					
	Contact Email	amrf@medicalr	<u>esearch.org.nz</u>				
	Sponsor Website	Link to sponsor	<u>website</u>				
	Program URL	Link to program	URL				
	Deadline Dates (ALL)	29-Jun-2022					
The Gavin and Ann Kellaway Medical Research Fellowship supports senior medically qualified, or established research persons, who would gain value from further study abroad, or in furthering their research expertise knowledge at an approved overseas research institution. SPECIAL INSTRUCTIONS FOR 2022 ROUND 1: The Synopsis Medical Research Foundation will only accept applications for this grant type if the NZ government condition met for safe travel to or from the destination(s) identified in the application. For information, please refer to https://covid19.govt.nz/travel/ For category 2, applicants must provide evidence from their host institution allow travel to the destination requested in their application. The AMRF will not be responsible for any costs							itablished medical expertise and 1: The Auckland conditions are refer to stitution that they any costs



SPIN ID	Program Title	Sponsor Name		Sponsor Number	Deadline Date	Funding Amount
		associated with the recipient being str approved destination when the applica	anded or having ation was submi	g to quarantine in any situ itted.	ation, whether or n	ot it was an
	Applicant Types					
	Funding Limit	20,000.00 per month				
	Limited Submission	No				
109124	Global Alliance for Chronic Dis to Common Non- Communical Reduction Funding	eases (GACD): A Life Course Approach ble Disease Risk Factor Prevention and	National Healt Council	h and Medical Research	GO5443 02-Jun-20	22 Not Specified
	Contact Name					
	Contact Telephone					
	Contact Email	help@nhmrc.gov.au				
	Sponsor Website	Link to sponsor website				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	02-Jun-2022				
	Synopsis	NHMRC invites applications from Aust opportunity will support implementati non-communicable diseases (NCDs) in populations in high-income countries (	ralian researche on research pro low- and middle HICs).	rs under the GACD Comn posals that take a life cou e-income countries (LMIC	non Risk Factors Call Irse approach to red s) and/or in disadva	2022. This grant lucing the risks for ntaged
	Applicant Types					
	Funding Limit	0.00 see detail				
	Limited Submission	No				



SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount		
082337	Grants Program			Pacific Power Foundation	15-Jun-202	22 Not Specified		
	Contact Name	Tarie Hansen, Fo	oundation Grants Admir	nistrator				
	Contact Telephone	503-813-7257						
	Contact Email	pacificorpfound	ation@pacificorp.com					
	Sponsor Website	Link to sponsor	website					
	Program URL	Link to program	URL					
Deadline Dates (ALL) 15-Jun-2022 , 15-Sep-2022 , 15-Dec-2022								
Synopsis The Pacific Power Foundation awards grants to nonprofit organizations in the categories of education/STEM community enhancement; culture and arts; and safety and wellness.								
	Applicant Types							
	Funding Limit	0.00 see detail						
	Limited Submission	No						
056842	Grants Program			Sonora Area Foundation	01-Jun-20	22 Not Specified		
	Contact Name	Allie Lincoln, Gra	ants Administrator					
	Contact Telephone	209-533-2596						
	Contact Email	allie@sonora-ar	ea.org					
	Sponsor Website	Link to sponsor	website					
	Program URL	Link to program	<u>URL</u>					

Deadline Dates (ALL) 01-Jun-2022 , 01-Aug-2022 , 01-Oct-2022 , 01-Dec-2022



SPIN ID	Program Title		Sponsor Name		Sponsor Number	Deadline Date	Funding Amount
	Synonsis	The Foundation	n provides funding in the	se primary inte	erest areas: human service	s; education;	ports pilot or
	59110[533	demonstration	projects, new or expand	ed programs, a	and capacity building.	13. The sponsor sup	
	Applicant Types						
	Funding Limit	0.00 not provid	ed				
	Limited Submission	No					
068718	Grants Program			Washington Sq Foundation	uare Health	01-Jun-202	22 Not Specified
	Contact Name	Catherine Kape	lla				
	Contact Telephone	312-664-6488					
	Contact Email	washington@w	<u>vshf.org</u>				
	Sponsor Website	Link to sponsor	<u>website</u>				
	Program URL	Link to program	<u>n URL</u>				
	Deadline Dates (ALL)	01-Jun-2022 , 0	1-Dec-2022				
	Synopsis	The Washington healthcare for a meets this goal services.	n Square Health Foundat all people in the Chicago through its grants for m	tion, Inc. grants land area regar edical and nurs	s funds in order to promot dless of race, sex, creed or sing education, medical res	e and maintain acce r financial need. The search and direct he	ess to adequate e Foundation ealthcare
	Applicant Types						
	Funding Limit	0.00 not provid	ed				
	Limited Submission	No					



SPIN ID Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount	
092352 Harry Goldblatt New I	Investigator Award	Amer	ican Heart Association	01-Jun-202	22 Not Specified	
Conta	ict Name					
Contact Te	elephone 214-706-1181					
Conta	act Email <u>council.awards</u>	<u>@heart.org</u>				
Sponsor	Website Link to sponsor	website				
Prog	ram URL <u>Link to program</u>	<u>n URL</u>				
Deadline Da	tes (ALL) 01-Jun-2022 , 0	3-Jun-2022				
	The Harry Gold or cardiovascul Synopsis related cardiov have submitted materials.	blatt Award for New Investiga ar research who has significar ascular disease. The awardee I abstracts accepted for prese	tors recognizes a new independent tly contributed to our understandir will be selected by the Council's Aw ntation at the Hypertension Scientif	investigator workir ng of the causes of h vards Committee fro fic Sessions, along w	ig in hypertension hypertension and om applicants who with other	
Applica	nt Types					
Fund	ing Limit 0.00 see detail					
Limited Sul	bmission No					
095262 <u>Humanitarian Award</u>		Socie Psych	ty for Industrial & Organizational ology	01-Jun-202	2 1,500 USD	
Conta	ict Name					
Contact Te	elephone 419-353-0032					
Conta	act Email <u>SIOP@siop.org</u>					
Sponsor	Website Link to sponsor	website				
Prog	ram URL Link to program	<u>n URL</u>				



SPIN ID	Program Title		Sponsor Name		Sponsor Number	Deadline Date	Fund	ing Amount
	Deadline Dates (ALL)	01-Jun-2022						
	Synopsis	The SIOP Huma to I-O psycholog amount donate	nitarian Award is given for su gy. The recipient of the award ed to the charity/foundation c	istained, si d is given a of the recip	ignificant, and outstanding a plaque and a cash prize c pient's choice).	g humanitarian con of \$1,500 (or a dona	tributi ation o	ons related f the same
	Applicant Types							
	Funding Limit	1,500.00 see de	etail					
	Limited Submission	No						
109198	Ignite Innovation Grants		Arthr	ritis Societ	у	16-May-20 [LOI/Pre-A	)22 .pp]	79,000 USD
	Contact Name							
	Contact Telephone							
	Contact Email	research@arth	ritis.ca					
	Sponsor Website	Link to sponsor	website					
	Program URL	Link to program	<u>n URL</u>					
	Deadline Dates (ALL)	16-May-2022 [l	LOI/Pre-App], 29-Jun-2022					
	Synopsis	The Innovation Grants program provides funding to support research proposals aligned with the Arthritis Society's priority focus areas. The Arthritis Society's Strategic Plan 2020-2025: Accelerating Impact - Research Strategy aims to identify research avenues that focus on areas of highest priority to patients and achieve the highest levels of scientifi excellence and rigour. Projects must be based on "high risk" ideas that have a strong potential for "high reward". Applications must focus on innovative research efforts in the following priority areas: arthritis pain, OA, IA, childhood and work.						Society's tegy aims to s of scientific ain, OA, IA,
	Applicant Types							
	Funding Limit	50,000.00 per y	/ear					
	Limited Submission	No						



SPIN ID	Program Title	Sponsor Name		Sponsor Number	Deadline Date	Funding Amount
109019	Incyte Ingenuity Awards		Incyte		24-Jun-202	22 100,000 USD
	Contact Name					
	Contact Telephone					
	Contact Email	IncyteIngenuity@VOZAdvisors.com	<u>l</u>			
	Sponsor Website	Link to sponsor website				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	24-Jun-2022				
	Synopsis	The Incyte Ingenuity Awards aim to initiatives that address challenges fa	support the graft-v aced by GVHD patie	versus-host disease (GVHD ents, caregivers, and healt	) community by fur hcare providers.	nding two novel
	Applicant Types					
	Funding Limit	100,000.00 maximum				
	Limited Submission	Yes				
059508	Individual Investigator Researc	<u>ch Awards</u>	Cancer Prevent Institute of Tex	tion and Research as	08-Jun-202	22 1,050,000 USD
	Contact Name					
	Contact Telephone	512-463-3190				
	Contact Email	cprit@cprit.state.tx.us				
	Sponsor Website	Link to sponsor website				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	08-Jun-2022				
	Synopsis	Individual Investigator Research Aw important questions that will signifi	vards support applic icantly advance knc	cations for innovative rese wledge of the causes, pre	arch projects addre vention, and/or tre	essing critically atment of cancer.



SPIN ID	Program Title	Sponsor Name		Sponsor Number	Deadline Date	Funding Amount	
		Areas of interest include laboratory re request a maximum of \$350,000 in to	esearch, translat tal costs per yea	ional studies, and/or clinica Ir for up to 3 years for rese	al investigations. Ap arch.	plicants may	
	Applicant Types						
	Funding Limit	350,000.00 per year					
	Limited Submission	No					
088485	Individual Investigator Researce Biology of Cancer	ch Awards for Computational Systems	Cancer Preven Institute of Te	ition and Research xas	08-Jun-202	2 1,200,000 USD	
	Contact Name						
	Contact Telephone	512-463-3190					
	Contact Email	cprit@cprit.state.tx.us					
	Sponsor Website	Link to sponsor website					
	Program URL	Link to program URL					
	Deadline Dates (ALL)	08-Jun-2022					
	Synopsis	The Cancer Prevention and Research Institute of Texas supports applications for innovative mathematical and/or computational research projects addressing questions that will advance current knowledge in the (a) mechanisms that tie altered gene expression and downstream molecular mechanisms to functional cancer phenotypes and/or (b) mechanisms that tie tumor morphology to functional cancer phenotypes and/or mechanisms that tie tumor morphology to functional cancer phenotypes and/or mechanisms that tie treatment sequence and combination to evolving functional cancer phenotypes (that emerge as a result of treatment selection).					
	Applicant Types						
	Funding Limit	400,000.00 per year					
	Limited Submission	No					
109814	Innovation in Time Resilience, Demonstrator	Dissemination and Application –	Innovate UK		01-Jun-202	2 1,310,000 USD	



SPIN ID	Program Title		Sponsor Name		Sponsor Number	Deadline Date	Funding Amount		
	Contact Name								
	Contact Telephone	0300 321 4357							
	Contact Email	support@innov	iteuk.gov.uk						
	Sponsor Website	Link to sponsor	<u>website</u>						
	Program URL	Link to program	<u>n URL</u>						
	Deadline Dates (ALL)	01-Jun-2022							
	Synopsis	Innovate UK, part of UK Research and Innovation, is working with the National Physical Laboratory (NPL) to invest to £4.7 million in innovation projects that contribute to resilient time, frequency and synchronisation (TFS) and i dissemination and application. The key areas for development are: resilience distribution trust, assurance and security integration and processing of signals The aims of this competition are to: support and enable business le innovation across the UK supply chain in resilient TFS for the development of products, services and end user applications develop a TFS ecosystem and capability for relevant industries and critical national infrastructure di and create new markets, both in the UK and globally, to improve the provision of TFS The innovation in time resilience, dissemination and application competition has two strands: Strand 1: demonstrator (this strand) - fo projects undertaking late stage industrial research or experimental developmental projects. Strand 2: feasibility							
	Applicant Types								
	Funding Limit	1,000,000.00 m	laximum						
	Limited Submission	No							
109812	Innovation in Time Resilience, Feasibility	Dissemination a	nd Application –	Innovate UK		01-Jun-202	22 327,500 USD		
	Contact Name								
	Contact Telephone	0300 321 4357							
	Contact Email	support@innov	<u>ateuk.gov.uk</u>						



SPIN ID	Program Title	Sponsor N	lame	Sponsor Number	Deadline Date	Funding Amount			
	Sponsor Website	Link to sponsor website							
	Program URL	Link to program URL							
	Deadline Dates (ALL)	01-Jun-2022							
	Synopsis	Innovate UK, part of UK Research and Innovation, is working with the National Physical Laboratory (NPL) to invest to £4.7 million in innovation projects that contribute to resilient time, frequency and synchronisation (TFS) and i dissemination and application. The key areas for development are: resilience distribution trust, assurance and security integration and processing of signals The aims of this competition are to: support and enable business le innovation across the UK supply chain in resilient TFS for the development of products, services and end user applications develop a TFS ecosystem and capability for relevant industries and critical national infrastructure di and create new markets, both in the UK and globally, to improve the provision of TFS The innovation in time resilience, dissemination and application competition has two strands: Strand 1: demonstrator - for projects undertaking late stage industrial research or experimental developmental projects. Strand 2: feasibility (this stra for projects undertaking early stage feasibility studies.							
	Applicant Types								
	Funding Limit	250,000.00 maximum							
	Limited Submission	No							
095001	Innovative Research Award		Rheumatology	Research Foundation	01-Jun-202 [LOI/Pre-Aj	2 400,000 op] USD			
	Contact Name								
	Contact Telephone	404-365-1373							
	Contact Email	foundation@rheumatolog	<u>y.org</u>						
	Sponsor Website	Link to sponsor website	Link to sponsor website						
Program URL Link to program URL									
	Deadline Dates (ALL)	01-Jun-2022 [LOI/Pre-App]	, 01-Jul-2022						



SPIN ID	Program Title		Sponsor Name	Sponsor	Number	Deadline Date	Funding Amount
		The Innovative	Possarch Award provides o	contial support for i	nnovativo studior	focused on genera	ting now incidents
	Synopsis	into the cause, is up to \$400,00	progression, treatment, and 00 for two years (maximum	outcomes of rheum \$200,000 per year).	natic and muscule	oskeletal diseases. T	he award amount
	Applicant Types						
	Funding Limit	400,000.00 max	kimum				
	Limited Submission	No					
027718	International Exchanges Schen	<u>ne</u>	Roy	al Society		15-Jun-202	2 15,720 USD
	Contact Name						
	Contact Telephone	+44(0) 20 7451	2557				
	Contact Email	international.ex	changes@royalsociety.org				
	Sponsor Website	Link to sponsor	<u>website</u>				
	Program URL	Link to program	<u>I URL</u>				
	Deadline Dates (ALL)	15-Jun-2022 , 2	8-Sep-2022				
	Synopsis	These schemes overseas throug	are for scientists based in t gh either a one-off visit or b	ne UK who want to s lateral travel.	timulate collabor	ations with leading	scientists
	Applicant Types						
	Funding Limit	12,000.00 maxi	mum				
	Limited Submission	No					
012624	International Travel and Subsis	tence Grants	Ηοι	ghton Trust		15-Jun-202	2 Not Specified
	Contact Name	Dr. S. J. Baigent					
	Contact Telephone						
	Contact Email	sue.baigent@o	utlook.com				



SPIN ID	Program Title	Sponsor Nan	ne	Sponsor Number	Deadline Date	Funding Amount		
	Sponsor Website	Link to sponsor website						
	Program URL	Link to program URL						
	Deadline Dates (ALL)	15-Jun-2022						
	Synopsis	Grants are awarded for the for scientific meetings, visiting a training courses. The scope o Applicants who will give an o	urtherance of study or re opropriate laboratories fo f Avian Pathology journa ral/poster presentation v	search in avian diseases by or discussions and learning I defines the research area vill be considered more fav	vattending/participa specific techniques s for appropriate ap vourably.	ating in relevant , or attending oplications.		
	Applicant Types							
	Funding Limit 0.00 see detail							
	Limited Submission	No						
002115	Investigator Award		Rheumatology	Research Foundation	01-Jun-202 [LOI/Pre-A	2 375,000 pp] USD		
	Contact Name							
	Contact Telephone	404-365-1373						
	Contact Email	foundation@rheumatology.c	org					
	Sponsor Website	Link to sponsor website						
	Program URL	Link to program URL						
	Deadline Dates (ALL)	01-Jun-2022 [LOI/Pre-App], 0	1-Jul-2022					
	Synopsis	This award is intended to sup developing a project that will postdoctoral fellowship. The engaged in research relevant fellowship training and estab	port junior investigators be competitive for NIH a purpose is to provide sup to the rheumatic disease lishment as an independe	with a faculty appointmen and/or equivalent funding. oport for basic science, tran es for the period between t ent investigator.	It during the period It is not intended to nslational, and clinic the completion of p	that they are be a second cal investigators ost-doctorate		
	Applicant Types							



SPIN ID	Program Title	Sponsor Name	2	Sponsor Number	Deadline Date	Funding Amount			
	Funding Limit	375,000.00 maximum							
	Limited Submission	No							
058805	Investigator Studies Program (	MISP) Surgery Anesthesia	Merck		01-May-20 [LOI/Pre-A	22 Not op] Specified			
	Contact Name	Lisa Mount							
	Contact Telephone	267-305-1258							
	Contact Email	Contact Email <u>lisa_mount@merck.com</u>							
	Sponsor Website <u>Link to sponsor website</u> Program URL <u>Link to program URL</u>								
	Deadline Dates (ALL)	01-May-2022 [LOI/Pre-App], 18	3-Jun-2022 , 01-Sep-202	2 [LOI/Pre-App], 19-Oct-2	022				
	Synopsis	The Investigator Studies Progra provision of drug/vaccine and/ and sponsored by external inve publications.	am aims to advance scie or total/partial funding, estigators. Results will b	nce and improve patient on high-quality research that e generated and properly	care by supporting, t t is initiated, designe disseminated in pee	hrough the ed, implemented er-reviewed			
	Applicant Types								
	Funding Limit	0.00 not provided							
	Limited Submission	No							
017267	James Cook Research Fellowsh	<u>iips</u>	Royal Society c	of New Zealand	12-May-20	22 151,800 USD			
	Contact Name								
	Contact Telephone	+64 4 470 5764							
	Contact Email	james.cook@royalsociety.org.r	<u>1Z</u>						

Sponsor Website Link to sponsor website



SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount	
	Program URL	Link to program	URL				
	Deadline Dates (ALL)	12-May-2022 , 1	16-Jun-2022				
	Synopsis	The James Cook Government, ar demonstrate th fellowships allor administrative a relevant expens	Research Fellowships, administered e awarded to researchers who have t at they have achieved national and in w them to concentrate on their chose and teaching duties. The funding pack ses.	by the Royal Society Te Apa he requisite qualifications a ternational recognition in t en research for two years w age annually is \$100,000 pl	arangi on behalf of t and experience and heir area of scientifi ithout the additiona us GST and up to \$1	he New Zealand are able to c research. The Il burden of .0,000 plus GST in	
	Applicant Types						
	Funding Limit	110,000.00 per	year				
	Limited Submission	No					
072617	Joel Elkes Research Award		American Col Neuropsycho	lege of pharmacology	23-Jun-202	2 Not Specified	
	Contact Name						
	Contact Telephone	615-324-2360					
	Contact Email	ancp@acnp.org					
	Sponsor Website	Link to sponsor	website				
	Program URL	Link to program	URL				
	Deadline Dates (ALL)	23-Jun-2022					
	Synopsis	The American College of Neuropsychopharmacology (ACNP) presents the Joel Elkes Research Award to a young scientist in recognition of an outstanding clinical contribution to neuropsychopharmacology.					
	Applicant Types						
	Funding Limit	0.00 see detail					
	Limited Submission	No					



SPIN ID	Program Title	Sponsor Name		Sponsor Number	Deadline Date	Funding Amount
107875	Joint Translational Call (JTC) 20	)22	European Joint Diseases (EJP-F	: Programme on Rare RD)	15-Jun-202	2 Not Specified
	Contact Name	Maria Druet, Joint Call Secretariat				
	Contact Telephone	+34 91 822 2530				
	Contact Email	mdruet@isciii.es				
	Sponsor Website	Link to sponsor website				
	Program URL	Link to program URL				
Deadline Dates (ALL) 15-Jun-2022 , 28-Jul-2022						
The aim of this call is to enable scientists in diff interdisciplinary research project based on com Synopsis the results in the future for benefit of patients. Project (JTC 2022) focuses on the "Developmen facilitate diagnostic monitoring of rare diseases				ountries to build an effecti ntarities and sharing of exp P RD Joint Transnational Ca w analytic tools and pathw	ive collaboration on pertise, with expect all 2022 for Rare Dis vays to accelerate d	a common ed impact to use eases Research iagnosis and
	Applicant Types					
	Funding Limit	0.00 see detail				
	Limited Submission	No				
107672	Joint Transnational Call 2022: I	Prevention in Personalised Medicine	ERA PerMed		14-Jun-202	2 Not Specified
	Contact Name	Monika Frenzel and Michael Joulie				
	Contact Telephone	+33 1 73 54 83 32				
	Contact Email	ERAPerMed@agencerecherche.fr				
	Sponsor Website	Link to sponsor website				
	Program URL	Link to program URL				



SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Deadline Dates (ALL)	14-Jun-2022				
	Synopsis	Through its fifth personalised m susceptibility to perceived value	n transnational call (non-cofu edicine. Personalised prevent o the risk of disease (e.g. depe e and benefit (cultural and soc	nded by the EC), ERA PerMed aims ion or targeted/tailored preventior inding on the genomic, environmen ial factors).	to foster research o I considers both ind Ital background or li	n prevention in ividual ifestyle) and its
	Applicant Types					
	Funding Limit	0.00 see detail				
	Limited Submission	No				
097748	<u>KTEs – Knowledge Transfer Ex</u>	<u>periments</u>	SMA	RT4ALL	15-Jun-202	22 Not Specified
	Contact Name	Prof. Nikolaos V	/oros, Project Coordinator			
	Contact Telephone	+30 2610 36915	51			
	Contact Email	<u>voros@uop.gr</u>				
	Sponsor Website	Link to sponsor	website			
	Program URL	Link to program	<u>ו URL</u>			
	Deadline Dates (ALL)	15-Jun-2022				
	Synopsis	SMART4ALL is a self-sustained, o targets Custom and combines a policies, differe revealing "hidd funding – and h strategy, the pr for supporting a	A H2020 funded project that b cross-border experiments that ised Low-Energy Computing ( a set of unique characteristics int geographical areas and dif- en innovation treasures" – ma- helping them to find the path roject will develop and mainta academics, SMEs and Slightly	uilds capacity amongst European st t transfer knowledge and technolog CLEC) for Cyber-Physical Systems (C that join together under a commor ferent application domains. SMART ainly from geographical areas that a to market via new, innovative comr in an active network of DIHs across Bigger Companies entering the digi	akeholders via the gy between academ PS) and the Interne vision different cul 4ALL brings a new p are underrepresente nercial products. As Central, South and tisation era. In orde	development of ia and industry. It it of Things (IoT) Itures, different baradigm for ed in European is part of its Eastern Europe er to achieve this,



SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date F	unding Amount
	Applicant Types Funding Limit	SMART4ALL will Knowledge Tran Technology Tran Transfer Experin mature ideas to potentials. 0.00 see detail No	l design and implement 3 insfer Experiments (KTE) 2) nsfer Experiments (KTE) 2) ments (KTE), which compr be presented, tested and	types of cross-border Pathfinder Applic Focused Technology Transfer Experime These guidelines describe the SMART4 ise a novel type of internship experime thus potentially find the fertile ground	ation Experiments (P/ ents (FTTEs) 3) Cross-o ALL first Open Call for nts allowing smaller p to grow and reveal it	AEs): 1) Jomain <sup>r</sup> Knowledge rojects, or less s product
019937	Large Project Grants (Tempora	arily Suspended)	Ba	arts and The London Charity	10-May-2022 [LOI/Pre-App	2 655,000 )] USD
	Contact Name Contact Telephone	020 7618 1717				
	Contact Email	grants@bartsch	narity.org.uk			
	Sponsor Website	Link to sponsor	website			
	Program URL	Link to program	<u>I URL</u>			
	Deadline Dates (ALL)	10-May-2022 [L	.OI/Pre-App], 30-Jun-2022	[LOI/Pre-App], 07-Jul-2022 , 20-Oct-20	22	
	Synopsis	The sponsor wa significance and	ints to help advance resea I which supports the delive	rch focused on health-related problems ery of safe and compassionate care to p	s of local and internat atients.	ional
	Applicant Types					
	Funding Limit	500,000.00 max	kimum			
	Limited Submission	No				
104738	Lawrence and Isabel Barnett D	rug Developmer	n <u>t Program</u> AL	_S Association	01-Jun-2022	500,000 USD



SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount		
	Contact Name							
	Contact Telephone	1-800-782-4747	,					
	Contact Email	researchgrants(	@alsa-national.org					
	Sponsor Website	Link to sponsor	website					
	Program URL	Link to program	URL					
	Deadline Dates (ALL)	01-Jun-2022						
	Synopsis	The ALS Association offers the Lawrence and Isabel Barnett Drug Development Program provides support for preclinical assessment of therapeutics for ALS that have a high probability of reaching the clinic within three years. This program is open to industry and academic investigators proposing to develop novel or repositioning approache for ALS. Awards will be limited \$500,000 total costs for the entire 2-year period of performance.						
	Applicant Types							
	Funding Limit	250,000.00 per	year					
	Limited Submission	No						
036282	LEO Foundation Awards		LEO Found	ation	21-Jun-202	100,000 22 USD		
	Contact Name							
	Contact Telephone	+ 45 32 72 51 10	)					
	Contact Email	applications@le	eo-foundation.org					
	Sponsor Website	Link to sponsor	<u>website</u>					
	Program URL	Link to program	URL					

Deadline Dates (ALL) 21-Jun-2022 , 04-Sep-2022



SPIN ID	Program Title		Sponsor Name		Sponsor Number	Deadline Date	Funding Amount
	Synoncic	The LEO Founda	ation Awards constitute a glo	bal recogr	nition and are given annual	lly to outstanding y	oung scientists
	Synopsis	USD, one in eac	h of the Americas. EMFA (Fu	ope/Mido	dle East/Africa) and Asia-Pa	acific regions.	
	Applicant Types			000/11100			
	Funding Limit	100 000 00 max	zimum				
	Limited Submission	No					
079306	Lifestyle and Cardiometabolic	Health Early Care	eer Investigator Award Amer	ican Hear	t Association	09-Jun-202	22 Not Specified
	Contact Name						
	Contact Telephone	214-706-1181					
	Contact Email	council.awards(	@heart.org				
	Sponsor Website	Link to sponsor	<u>website</u>				
	Program URL	Link to program	<u>I URL</u>				
	Deadline Dates (ALL)	09-Jun-2022					
	Synopsis	The Council on Lifestyle and Cardiometabolic Health Young Investigator Award recognizes and awards early ca investigator and trainee council members for their achievements and their continuing research. The award als encourages young scientists to become involved in the Council on Lifestyle and Cardiometabolic Health and to develop and maintain productive careers.					
	Applicant Types						
	Funding Limit	0.00 see detail					
	Limited Submission	Yes					
005950	Marvin Moser Clinical Hyperte	nsion Award	Amer	ican Hear	t Association	03-Jun-202	22 2,000 USD
	Contact Name						



SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Contact Telephone	212-696-9099				
	Contact Email	<u>council.awards</u>	<pre>@heart.org</pre>			
	Sponsor Website	Link to sponsor	<u>website</u>			
	Program URL	Link to program	<u>u URL</u>			
	Deadline Dates (ALL)	03-Jun-2022				
	Synopsis	The Marvin Mo their dedicatior	ser Clinical Hypertension Award n to the treatment and care of h	recognizes a qualified mid-ca ypertensive patients.	reer or senior Hyperter	nsion Clinician for
	Applicant Types					
	Funding Limit	2,000.00 see de	etail			
	Limited Submission	No				
006412	McDonald Fellowship		Multiple Federat	e Sclerosis International ion	30-Jun-202	22 78,600 USD
	Contact Name					
	Contact Telephone	+44 (0)20 7620	1911			
	Contact Email	research@msif.	.org			
	Sponsor Website	Link to sponsor	<u>website</u>			
	Program URL	Link to program	<u>1 URL</u>			
	Deadline Dates (ALL)	30-Jun-2022				
	Synopsis	The McDonald to work in a res or local projects participants eitl	Fellowship enables early career earch institution outside of thei s to overcome the travel restrict her gain expertise or carry out p	multiple sclerosis researchers r own country. For 2022 the s ions imposed by COVID-19. D arts of joint research projects	from low- and middle- ponsor is open to appli uring the visit or virtua <sup>l</sup>	income countries cations for virtual l project,
	Applicant Types					



SPIN ID	Program Title	Sponsor Nam	e	Sponsor Number	Deadli	ne Date	Funding Amount
	Funding Limit	60,000.00 see detail					
	Limited Submission	No					
095617	Media Award		American Colle Neuropsychop	ege of harmacology		23-Jun-2022	2 Not Specified
	Contact Name						
	Contact Telephone	615-324-2360					
	Contact Email	acnp@acnp.org					
	Sponsor Website	Link to sponsor website					
	Program URL	Link to program URL					
	Deadline Dates (ALL)	23-Jun-2022					
	Synopsis	The ACNP Media Award was e illness and substance abuse re an expense paid trip to the AC	established to recognize a search and the positive CNP Annual Meeting and	major contributions to th impact of research on tre a plaque to be presented	e educati atment. I at the A	ion of the pu The Media A Innual Meeti	blic about mental ward consists of ng.
	Applicant Types						
	Funding Limit	0.00 see detail					
	Limited Submission	No					
108036	Medical Research Future Fund Opportunity	<ul> <li>– Clinical Trials Activity Grant</li> </ul>	National Healt Council	h and Medical Research	GO5344	22-Jun-2022 [LOI/Pre-Ap	2 Not pp] Specified
	Contact Name						
	Contact Telephone	1800 500 983					
	Contact Email	help@nhmrc.gov.au					
	Sponsor Website	Link to sponsor website					
	Program URL	Link to program URL					



SPIN ID	Program Title		Sponsor Name		Sponsor Number	Deadli	ne Date	Fund	ling Amount	
	Deadline Dates (ALL) Synopsis	22-Jun-2022 [LC The Clinical Tria which treatmen international co efficient and eff	Iun-2022 [LOI/Pre-App], 06-Jul-2022 Clinical Trials Activity (the Initiative) aims to: give patients across Australia more access to clinical trials sho ch treatments and medicines work best for patients provide researchers with more opportunities to work w ernational colleagues to bring international trials to Australian patients promote new approaches that suppo cient and effective research The grant opportunity aims to fund research in two priority areas: • Rare cance							
	Applicant Types	diseases and un	nmet need • Effective h	ealth interventi	ons.					
	Funding Limit	0.00 see detail								
	Limited Submission	No								
108041	Medical Research Future Fund Research Initiative2021 Chro Opportunity	– Preventive an nic Respiratory (	d Public Health Conditions Grant	National Healt Council	h and Medical Research	GO5338	29-Jun-202 [LOI/Pre-A	22 2	Not Specified	
	Contact Name									
	Contact Telephone	1800 500 983								
	Contact Email	Help@nhmrc.go	ov.au							
	Sponsor Website	Link to sponsor	website							
	Program URL	Link to program	<u>I URL</u>							
	Deadline Dates (ALL)	29-Jun-2022 [LC	OI/Pre-App], 13-Jul-202	2						
	Synopsis	The Preventive public health ap prevalence and innovative appr translation of ne improve the qua (MRFF) – Preven	and Public Health Rese oproaches, such as thro persistence of chronic roaches to treat and ma ew preventive and publ ality and cost-effectiver ntive and Public Health	arch Initiative (t ugh exercise an and complex dis nage chronic ar lic health measu ness of preventi Research Initiat	the Initiative) aims to ena d nutrition, to address th seases in Australia fundir nd complex diseases gene ures into practice implem we healthcare intervention tive – 2021 Chronic Resp	ble or su e risk fac g health erating ev enting in ons The I ratory Co	pport: testir stors associa system rese vidence to su novative ap Medical Rese onditions Gra	ig inn ted w arch t uppor proac earch ant O	ovative vith the to identify t the thes to Future Fund pportunity	



SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadl	ine Date	Funding Amount		
	Applicant Types Funding Limit	will support research that: Stream 1: or respiratory disease Stream 2: clinically therapeutic adherence and self-manage 0.00 not provided	develop treatable trait-based precisic validate feasible technology enablec gement of chronic respiratory disease	n medicine approaches s.	approaches f s to medicati	or chronic on and		
107982	Medical Research Future Fund Research Initiative2021 Cons	<u>–Preventive and Public Health</u> umer-Led Research Grant	National Health and Medical Resear Council	<sup>ch</sup> GO5353	29-Jun-202 [LOI/Pre-A	2 Not pp] Specified		
	Contact Name Contact Telephone Contact Email	1800 500 983 <u>help@nhmrc.gov.au</u>						
	Sponsor website Program URL	Link to program URL						
	Deadline Dates (ALL)	29-Jun-2022 [LOI/Pre-App], 13-Jul-202	2					
	Synopsis	The Preventive and Public Health Research Initiative (the Initiative) aims to enable or support research to: test novative public health approaches, such as through exercise and nutrition, to address the risk factors associated with the prevalence and persistence of chronic and complex diseases in Australia fund health system research to dentify innovative approaches to treat and manage chronic and complex diseases generate evidence to support the ranslation of new preventive and public health measures into practice implement innovative approaches to improve he quality and cost-effectiveness of preventive healthcare interventions Applicants to this grant opportunity are expected to describe how their proposed project aligns with the objectives and outcomes of the Preventive and Public Health Research Initiative and the Measures of Success as described in the Evaluation Strategy.						
	Applicant Types							
	Funding Limit	0.00 see detail						



SPIN ID	Program Title		Sponsor Name		Sponsor Number	Deadli	ne Date	Funding Amour	nt
	Limited Submission	No							
108040	Medical Research Future Fund Researchers Grant Opportunity	2021 Early to N Y	<u> Aid-Career</u>	National Health Council	n and Medical Research	GO5339	29-Jun-202 [LOI/Pre-A	2 Not pp] Specified	
	Contact Name								
	Contact Telephone	1800 500 983							
	Contact Email	help@nhmrc.go	ov.au						
	Sponsor Website	Link to sponsor	<u>website</u>						
	Program URL	Link to program	URL						
	Deadline Dates (ALL)	29-Jun-2022 [LC	DI/Pre-App], 13-Jul-202	2					
	Synopsis	The MRFF, established under the Medical Research Future Fund Act 2015 (MRFF Act), provides gr assistance to support health and medical research and innovation to improve the health and well It operates as an endowment fund with the capital preserved in perpetuity. The objectives and in this grant opportunity are aligned with the following Australian Medical Research and Innovation 2022: Consumer-Driven Research Translational Research Infrastructure The intended outcomes of funded by this grant opportunity is to improve the health and wellbeing of Australians by: Stream supporting early-career researchers to develop innovative solutions for addressing significant hea Stream 2 (Accelerator): supporting mid-career researchers to transform health practice and/or per (Targeted Call for Research): supporting early to mid-career researchers to translate new therapid into practice						ts of financial ing of Australian nded outcomes o iorities 2020- he research (Incubator): n challenges. and/or products	ıs. of
	Applicant Types								
	Funding Limit	0.00 see detail							
	Limited Submission	No							
042680	Medical/Dental Postgraduate S	Scholarship		National Health Council	n and Medical Research	GO3917	11-May-20 [LOI/Pre-A	22 Not pp] Specified	



SPIN ID	Program Title	Sponsor Name		Sponsor Number	Deadline Date	Funding Amount
	Contact Name					
	Contact Telephone	61 2 6217 9000				
	Contact Email	nhmrc@nhmrc.gov.au				
	Sponsor Website	Link to sponsor website				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	11-May-2022 [LOI/Pre-App], 08-Jun-2	2022			
	Synopsis	Medical/Dental Postgraduate Scholar medical or dental graduates undertal	ships are awarde	ed to provide support to co earch degree involving full-1	mbined MBBS/PhD time research.	students, and
	Applicant Types					
	Funding Limit	0.00 see detail				
	Limited Submission	No				
066849	Mentored Clinical Scientist Res (K08)	search Career Development Award	Society for Va	scular Surgery	12-Jun-202	.2 Not Specified
	Contact Name	Jane D. Scott				i
	Contact Telephone	301-435-0535				
	Contact Email	scottj2@nhlbi.nih.gov				
	Sponsor Website	Link to sponsor website				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	12-Jun-2022 , 12-Jul-2022 , 12-Oct-20	22 , 12-Nov-202	2		
	Synopsis	The SVS Foundation offers this award development of individuals pursuing above that offered by the NHLBI K08	in partnership w a career in vascu mechanism.	vith the NHLBI as a means t lar research. This award pro	o facilitate the rese ovides financial sup	arch career port over and
	Applicant Types					



SPIN ID	Program Title	:	Sponsor Name		Sponsor Number	Deadline Date	Fund	ling Amount
	Funding Limit	0.00 see detail						
	Limited Submission	No						
061247	Merck MISP Clostridium Diffici	<u>le Grant</u>		Merck		11-Jun-202	22	Not Specified
	Contact Name	Boski Patel						
	Contact Telephone	267-305-3173						
	Contact Email	boski_patel@ms	<u>d.com</u>					
	Sponsor Website	Link to sponsor v	<u>vebsite</u>					
	Program URL	Link to program	<u>URL</u>					
	Deadline Dates (ALL)	11-Jun-2022						
	Synopsis	The Investigator provision of drug and sponsored b publications.	Studies Program aims g/vaccine and/or total/ y external investigators	to advance scie partial funding, s. Results will b	nce and improve patient c high-quality research that e generated and properly	are by supporting, is initiated, design disseminated in pe	throu; ed, im er-rev	gh the plemented iewed
	Applicant Types							
	Funding Limit	0.00 not provide	d					
	Limited Submission	No						
102829	Mitchell A. Baran Achievemen Aerosol and Airway Clearance	t Award for Clinic Therapies	al Excellence in	American Resp Foundation	iratory Care	01-Jun-202	22	2,500 USD
	Contact Name Contact Telephone Contact Email Sponsor Website	972-243-2272 Link to sponsor v	<u>vebsite</u>					



SPIN ID	Program Title		Sponsor Name		Sponsor Number	Deadline Date	Funding Amount
	Program URL	Link to program	URL				
	Deadline Dates (ALL)	01-Jun-2022					
	Synopsis	This award is gi advocating and medications an	ven to recognize and h promoting the use of e d/or the application of	onor those indiv evidence-based, non-pharmacol	iduals demonstrating clini clinically sound practices f ogic airway clearance ther	cal excellence and I for the delivery of a apies.	eadership in erosolized
	Applicant Types						
	Funding Limit	2,500.00 see de	etail				
	Limited Submission	No					
006022	Module I – Observational Trair	ning with Experts	s Fellowship Grant	European Socie Endoscopy	ety of Gastrointestinal	01-Jun-202	22 1,430 USD
	Contact Name						
	Contact Telephone	+ 49-89-907 793	36-00				
	Contact Email	secretariat@es	<u>ge.com</u>				
	Sponsor Website	Link to sponsor	<u>website</u>				
	Program URL	Link to program	<u>I URL</u>				
	Deadline Dates (ALL)	01-Jun-2022					
	The European Society of Gastrointestinal Endoscopy (ESGE) offers fellowship grants to fully-trained endoscopist wishing to undertake further training in highly specialised endoscopic techniques at officially recognised ESGE t Synopsis centres. Also, through a mutual cooperation, ESGE and the Japan Gastroenterological Endoscopy Society (JGES) one grant, Module I, per year in an exchange programme. The selected ESGE grantee is assigned to one of the la Japanese institutions.						endoscopists hised ESGE training hciety (JGES) offer one of the leading
	Applicant Types						
	Funding Limit	1,300.00 see de	etail				
	Limited Submission	No					



SPIN ID	Program Title	Spons	or Name	Sponsor Number	Deadline Date	Funding Amount
106496	Momentum – Funding for Reco	ently Tenured Professo	<u>rs</u> Volk	swagenStiftung Foundation	01-Jun-202	22 Not Specified
	Contact Name	Dr. Selahattin Danisma	an			
	Contact Telephone	+49 511 8381-256				
	Contact Email	danisman@volkswage	enstiftung.de			
	Sponsor Website	Link to sponsor websit	<u>:e</u>			
	Program URL	Link to program URL				
	Deadline Dates (ALL)	01-Jun-2022				
This initiative addresses academi Synopsis The goal is to open up opportuni of their professorship.				ly stage following the appointment bhase of their career to advance the	to their first tenured content and strateg	d professorship. gic development
	Applicant Types					
	Funding Limit	0.00 see detail				
	Limited Submission	No				
068800	NBRC Frederic Helmholz, Jr., N	D Educational Researc	<u>h Fund</u> Ame Four	rican Respiratory Care Idation	01-Jun-202	2 5,000 USD
	Contact Name					
	Contact Telephone	972-243-2272				
	Contact Email					
	Sponsor Website	Link to sponsor websit	<u>:e</u>			
	Program URL	Link to program URL				
	Deadline Dates (ALL)	01-Jun-2022				



SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	The National Bo American Respi Thesis, or Docto a candidate.	ard for Respiratory Care/Ap ratory Care Foundation to su ral Dissertation with practic	plied Measurement Professionals, I ipport up to \$5,000 for educational al value to the respiratory care prof	nc. has provided an e or credentialing rese ession are acceptabl	endowment to the earch. A Master's e submissions by
	Applicant Types					
	Funding Limit	5,000.00 see de	tail			
	Limited Submission	No				
108503	New Program		Mat Four	hers (G.Harold and Leila Y.) ndation	15-Apr-202 [LOI/Pre-A	22 Not pp] Specified
	Contact Name					
	Contact Telephone					
	Contact Email	support@mathe	ersfoundation.org			
	Sponsor Website	Link to sponsor	<u>website</u>			
	Program URL					
	Deadline Dates (ALL)	15-Apr-2022 [L0	0I/Pre-App], 30-Jun-2022			
	Synopsis	The mission of 1 sponsoring scien application, is co	The G. Harold and Leila Y. Mantific research that will bene entral to this goal, and funda	athers Foundation is to advance kno fit mankind. Basic scientific researc amental to the Foundation's operat	wledge in the life sci h, with potential trar ng principles.	iences by Islational
	Applicant Types					
	Funding Limit	0.00 not provide	ed			
	Limited Submission	Yes				
100431	Non-Drug Approaches Grants		Park	inson's UK	22-Jun-202	262,000 USD



SPIN ID	Program Title	S	ponsor Name		Sponsor Number	Deadline Date	Funding Amount
	Contact Name						
	Contact Telephone						
	Contact Email	researchapplication	ons@parkinsons.org.uk				
	Sponsor Website	Link to sponsor w	<u>vebsite</u>				
	Program URL	Link to program U	JRL				
	Deadline Dates (ALL)	22-Jun-2022 , 14-	Sep-2022				
	Synopsis	Parkinson's UK is non-drug approac	accepting applications for a chest for a chest for Parkinson's. There	a grant sch is no mini	neme that aims to support mum value and the maxim	and accelerate resenum award amount	arch to develop is £200,000.
	Applicant Types						
	Funding Limit	200,000.00 maxin	num				
	Limited Submission	No					
071378	Norman Borlaug Award for Fie	Id Research and A	pplication Wor	ld Food Pr	ize Foundation	15-Jun-202	2 10,000 USD
	Contact Name	Ms.Ellen Franzent	burg, Director of Secretaria	nt Operatio	ons		
	Contact Telephone	+1-515-245-3783					
	Contact Email	efranzenburg@w	orldfoodprize.org				
	Sponsor Website	Link to sponsor w	<u>vebsite</u>				
	Program URL	Link to program U	<u>JRL</u>				
	Deadline Dates (ALL)	15-Jun-2022					
	Synopsis	The Norman Borla recognize excepti under 40 who has global hunger and	aug Award for Field Resear ional, science-based achiev s clearly demonstrated inte d poverty.	ch and Ap ement in i ellectual co	plication is presented annun nternational agriculture ar purage, stamina, and deter	ually in the amount nd food production mination in the figh	of \$10,000 to by an individual It to eliminate
	Applicant Types						



SPIN ID	Program Title	Sponsor Name		Sponsor Number	Deadline Date	Funding Amount
	Funding Limit	10,000.00 maximum				
	Limited Submission	No				
090392	Open Scheme		Pathological So and Ireland	ociety of Great Britain	01-Jun-202	22 13,100 USD
	Contact Name					
	Contact Telephone	020 7 484 8046				
	Contact Email	admin@pathsoc.org				
	Sponsor Website	Link to sponsor website				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	01-Jun-2022 , 01-Sep-2022 , 01-Dec-	2022			
	Synopsis	The Open Scheme provides support the Society's mission, which is to pro £10,000.	for activities not o mote the unders	covered by another Society tanding of disease. The sur	v scheme, all of whit n requested should	ch should support not exceed
	Applicant Types					
	Funding Limit	10,000.00 maximum				
	Limited Submission	No				
058306	Operating Grants		International C Study of Inflan	Drganization For the nmatory Bowel Disease	30-Jun-202	275,000 USD
	Contact Name	Marischka Konings				
	Contact Telephone	+31 35 5426745				
	Contact Email	ioibd@mkproducties.nl				
	Sponsor Website	Link to sponsor website				
	Program URL	Link to program URL				



SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount		
	Deadline Dates (ALL)	30-Jun-2022						
	Synopsis	The Internation to €250,000 for given to grants	nternational Organization For the Study of Inflammatory Bowel Disease (IOIBD) offers Operating Grants of up 50,000 for one year, preferably equally divided between Clinical and Basic Science Projects. Preference will be to grants less than or equal to €50,000.					
	Applicant Types							
	Funding Limit	250,000.00 max	kimum					
	Limited Submission	Yes						
104632	Orange Knowledge Programm	<u>e (OKP)</u>	Nuffic		28-Jun-202	Not Specified		
	Contact Name							
	Contact Telephone	+31 (0)70 - 426	0 260					
	Contact Email							
	Sponsor Website	Link to sponsor	website					
	Program URL	Link to program	<u>n URL</u>					
	Deadline Dates (ALL)	28-Jun-2022 , 1	1-Oct-2022					
	Synopsis	The Orange Kno institutions in t months) or mas	owledge Programme scholarships are o he Netherlands. Scholarships are availa ster's programmes (duration 12 to 24 n	open to mid-career profess able for a selection of short nonths).	ionals in specific cou courses (duration 2	untries to study at 2 weeks to 12		
	Applicant Types							
	Funding Limit	0.00 see detail						
	Limited Submission	No						


SPIN ID	Program Title	Spo	onsor Name	Sponsor Number	C	Deadline Date	Funding Amount
SPIN ID	Program Title		Sponsor Name		Sponsor Number	r Deadline Da	te Funding Amount
045882	Outstanding Investigator Awar Research	rd for Breast Cancer	American Associat	ion for Cancer Research		30-Jun-2022	Not Specified
	Contact Name	Michael J. Powell, P	hD, Deputy Director of	Scientific Programs			
	Contact Telephone	215-440-9373					
	Contact Email	michael.powell@aa	acr.org				
	Sponsor Website	Link to sponsor web	<u>bsite</u>				
	Program URL	Link to program UR	<u> </u>				
	Deadline Dates (ALL)	30-Jun-2022					
	Synopsis	The AACR establish a far-reaching impa involve any disciplir epidemiological stu	ed this Award to recogn act on the etiology, deter ne across the continuum udies.	ize an investigator whose nov ction, diagnosis, treatment, on of biomedical research, inclu	vel and sig r preventi Iding basio	nificant work has on of breast canco c, translational, cl	had or may have er. Such work may inical, and
	Applicant Types						
	Funding Limit	0.00 see detail					
	Limited Submission	No					
045538	Partnering Opportunity For Cli (CLIN2)	nical Trial Stage Proj	jects California Institute	for Regenerative Medicine		29-Apr-2022	Not Specified
	Contact Name						
	Contact Telephone	510-340-9101					
	Contact Email	Clinical@cirm.ca.go	<u>ov</u>				



SPIN ID	Program Title	Spons	sor Name	Sponsor Number	Deadline Date	Funding Amount
	Program URL	Link to program URL				
	Deadline Dates (ALL)	29-Apr-2022 , 31-May	-2022 , 30-Jun-2022 , 31-Jul-202	2		
	Synopsis	The mission of Californ with unmet medical more opportunity to acceler therapy treatment that agency, but will also d experts to actively adv partnership that both	nia Institute for Regenerative Me eeds. The objective of this progr rate the completion of a clinical t at addresses an unmet medical n evote significant internal resour ance the project. The result of a accelerates the program and giv	edicine (CIRM) is to acceler ram announcement is to cr trial for a promising stem c need. Under this program, o ces and leverage its extern a successful application will yes it the greatest opportu	rate stem cell treatr eate a highly compe or progenitor cell-ba CIRM will act not or al team of world-cla I be the formation c nity for success.	nents to patients etitive partnering used or gene uly as a funding ass subject matter of a true
	Applicant Types					
	Funding Limit	0.00 see detail				
	Limited Submission	No				
045367	Partnering Opportunity for Lat Projects (CLIN1)	e Stage Preclinical	California Institute for Regene	erative Medicine	29-Apr-2022	6,000,000 USD
	Contact Name					
	Contact Telephone	510-340-9101				
	Contact Email	clinical@cirm.ca.gov				
	Sponsor Website	Link to sponsor websit	t <u>e</u>			
	Program URL	Link to program URL				
	Deadline Dates (ALL)	29-Apr-2022 , 31-May	-2022 , 30-Jun-2022 , 31-Jul-202	2		
	Synopsis	The mission of Californ with unmet medical no opportunity to acceler initiate clinical trial sta	nia Institute for Regenerative Me eeds. The objective of this progr rate the completion of an IND or art-up with a promising stem or p	edicine (CIRM) is to acceler am announcement is to cr IDE filing with the Food ar progenitor cell-based or ge	rate stem cell treatr eate a highly compe nd Drug Administrat ene therapy treatme	nents to patients atitive partnering tion (FDA) and ant that addresses



SPIN ID	Program Title	2	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		an unmet medica	al need. CIRM expects pro	pjects under this program to advance ra	apidly into the clinic	and to achieve
	Applicant Types					
	Funding Limit	6,000,000.00 ma	iximum			
	Limited Submission	No				
067186	Pediatric Dermatology Fellows	hip (Minnesota)	Mayo Clinic Colle	ge of Medicine and Science	30-Jun-2022	Not Specified
	Contact Name	Kelly J. Ihrke				
	Contact Telephone	507-284-3736				
	Contact Email	<u>mayodermfellow</u>	<u>vs@mayo.edu</u>			
	Sponsor Website	Link to sponsor v	<u>vebsite</u>			
	Program URL	Link to program	<u>URL</u>			
	Deadline Dates (ALL)	30-Jun-2022				
	Synopsis	Mayo Clinic in Ro care of infants ar members and re rheumatology, o	ochester, Minnesota, offe nd children with severe sk sidents in clinical, laborat phthalmology and other o	rs a one-year Pediatric Dermatology Fe in disease. During this fellowship, fello ory and procedural dermatology, as we departments.	llowship that focus ws will work with M all as colleagues in p	es on advanced 1ayo Clinic staff plastic surgery,
	Applicant Types					
	Funding Limit	0.00 see detail				
	Limited Submission	No				
075992	Peter G. Pentchev Niemann-Pi Fellowship	ck Type C Researc	h National Nieman	n-Pick Disease Foundation, Inc.	01-Jun-2022	Not Specified
	Contact Name	Joslyn Crowe, NN	NPDF Executive Director			



SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Contact Telephone	877-287-3672				
	Contact Email	nnpdf@nnpdf.c	rg			
	Sponsor Website	Link to sponsor	website			
	Program URL	Link to program	URL			
	Deadline Dates (ALL)	01-Jun-2022				
	Synopsis	The National Ni biology of Niem	emann-Pick Disease Foundation (NNPE ann-Pick Type C (NPC), a lethal neuro-	OF) invites applications for degenerative disease for w	research fellowship hich there are no e	s examining the ffective therapies.
	Applicant Types					
	Funding Limit	0.00 see detail				
	Limited Submission	No				
089931	PhD Fellowships		Boehringer Ingelheim Fonds		01-Jun-2022	Not Specified
	Contact Name					
	Contact Telephone	+49 (0)6131 27	50 80			
	Contact Email	secretariat@bif	onds.de			
	Sponsor Website	Link to sponsor	website			
	Program URL	Link to program	URL			
	Deadline Dates (ALL)	01-Jun-2022 . 0	1-0ct-2022			
		, -	1 000 2022			
	Synopsis	The Boehringer worldwide who laboratory.	I gelheim Fonds (BIF) awards PhD fello wish to pursue an ambitious PhD projo	owships of 2 to 3.5 years to ect in basic biomedical rese	o outstanding junior earch in an internat	r scientists ionally leading
	Synopsis Applicant Types	The Boehringer worldwide who laboratory.	Ingelheim Fonds (BIF) awards PhD fello wish to pursue an ambitious PhD projo	owships of 2 to 3.5 years to ect in basic biomedical rese	o outstanding junior earch in an internat	r scientists ionally leading



SPIN ID	Program Title	Sponsor	<sup>r</sup> Name	Sponsor Number	Deadline Date	Funding Amount
	Limited Submission	No				
046432	PhD Fellowships		Multiple Sclerosis Society of	G.B. and N. Ireland	07-Jun-2022	Not Specified
	Contact Name					
	Contact Telephone	020-8438-0822				
	Contact Email	researchnetwork@msso	<u>ciety.org.uk</u>			
	Sponsor Website	Link to sponsor website				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-Jun-2022				
	Synopsis	PhD Fellowships are desi Sclerosis.	igned to encourage the best	science graduates to embar	k on a research car	eer in Multiple
	Applicant Types					
	Funding Limit	0.00 see detail				
	Limited Submission	No				
061875	PhD Studentships		International Spinal Research	n Trust	06-Jun-2022	Not Specified
	Contact Name					
	Contact Telephone	+44 (0)207 653 8937				
	Contact Email	research@spinal-researc	ch.org			
	Sponsor Website	Link to sponsor website				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	06-Jun-2022				



SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		International Spinal Research Trust offers PhD Stude	ntships aimed at encouragir	ng the development	of talented,
	Synopsis	highly-motivated young scientists in the field of spin- environments.	al cord repair, in both clinica	al and basic science r	esearch
	Applicant Types				
	Funding Limit	0.00 see detail			
	Limited Submission	No			
001730	Physician and Public Awarenes	ss Proposals ResMed Foundation		15-Jun-2022	Not Specified
	Contact Telephone	858-361-0755			
	Contact Email	kristib@resmedfoundation.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	15-Jun-2022 , 15-Dec-2022			
	Synopsis	The Foundation's goal in this funding category is to f untreated sleep disordered breathing, its symptoms, physicians, educators and the general public.	urther the awareness and ki , diagnosis and treatment w	nowledge of the inhe ith sleep specialists,	erent dangers of primary care
	Applicant Types				
	Funding Limit	0.00 not provided			
	Limited Submission	No			
067593	Pilot Project Grants	Myositis Association		16-May-2022 [LOI/Pre-App	2 ] 100,000 USD
	Contact Name	Chrissy Thornton			



SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount		
	Contact Telephone	703-553-2631						
	Contact Email	chrissy@myosit	<u>tis.org</u>					
	Sponsor Website	Link to sponsor	website					
	Program URL	Link to program	<u>1 URL</u>					
	Deadline Dates (ALL)	16-May-2022 [L	-OI/Pre-App], 30-Jun-2022					
	Synopsis	Pilot Grants are other sources (s grant support. I research progra partner must be annually, subjee	ther sources (such as NIH). A competitive application will clearly delineate how this pilot funding will lead to future and support. In addition, a competitive application will clearly distinguish itself from the investigator's existing earch program. Any industry partnership must be clearly disclosed and a letter of support from the industry rtner must be included. Pilot grants will be awarded for one or two years and up to a maximum of \$100,000 nually, subject to satisfactory progress.					
	Applicant Types	bes						
	Funding Limit	100,000.00 max	ximum					
	Limited Submission	No						
020216	Postdoctoral Fellowship		Auckland Medical Research F	oundation	01-Jun-2022 [LOI/Pre-Apj	PNot p]Specified		
	Contact Name							
	Contact Telephone	+64 9 923 1701						
	Contact Email	admin@medica	alresearch.org.nz					
	Sponsor Website	Link to sponsor	website					
	Program URL	Link to program	<u>1 URL</u>					
	Deadline Dates (ALL)	01-Jun-2022 [L0	OI/Pre-App], 17-Aug-2022					
	Synopsis	The Postdoctor recently comple	al Fellowship provides two years supported a degree at doctorate level and w	ort for outstanding science ho propose to pursue a car	or medical graduat eer in medical rese	es who have arch.		



SPIN ID	Program Title	Sponse	or Name	Sponsor Number	Deadline Date	Funding Amount
	Applicant Types					
	Funding Limit	0.00 see detail				
	Limited Submission	No				
	Predoctoral and Postdoctoral	Fellowshins in Spinal		PE	∧ <i>#</i>	Not
045773	Cord Injury Research		New York State Department of	of Health 18	591 01-Jun-2022	Specified
	Contact Name	David Googins				
	Contact Telephone	518-474-7002				
	Contact Email	<u>scirb@health.ny.gov</u>				
	Sponsor Website	Link to sponsor website	<u>e</u>			
	Program URL	Link to program URL				
	Deadline Dates (ALL)	01-Jun-2022				
	The New York State Department of Health and the Spinal Cord Injury Research Board (SCIRB) are accepting applications from not-for-profit organizations and governmental organization in New York State. They will prov funding for predoctoral and postdoctoral fellowships. Approximately \$1.5 million will be available for this requ applications (RFA) to fund approximately six to ten training (pre- or post- doctoral) awards. Eligible organization invited to submit applications for predoctoral fellowships with total annual costs of up to \$51,000 per year or postdoctoral fellowships with total annual costs of up to \$80,000 per year. Each will be a two year awards.					
	Applicant Types					
	Funding Limit	0.00 see detail				
	Limited Submission	No				
095968	Prevention and Population Res	search Project Awards	Cancer Research UK		23-Jun-2022	Not Specified

Contact Name Dr. Anbalakan Paramasivam



SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount	
	Contact Telephone	+44 (0) 20 3469	8824				
	Contact Email	pprc@cancer.or	<u>g.uk</u>				
	Sponsor Website	Link to sponsor	website				
	Program URL	Link to program	URL				
	Deadline Dates (ALL)	23-Jun-2022					
	Synopsis	Prevention and questions in pre	Population Research Awards provide vention and population research.	support for focused resear	ch proposals centre	d on key	
	Applicant Types						
	Funding Limit	0.00 see detail					
	Limited Submission	No					
071885	Regional Grant Program		Idaho Community Foundation	วท	15-Jun-2022	25,000 USD	
	Contact Name						
	Contact Telephone	208-342-3535					
	Contact Email	grants@idahocf	.org				
	Sponsor Website	Link to sponsor	<u>website</u>				
	Program URL	Link to program	URL				
	Deadline Dates (ALL)	15-Jun-2022 , 15	5-Aug-2022				
	Synopsis	The Forever Idaho Regional Grant Program distributes general operating grants with special consideration given to organizations working in one of ICF's Areas of Impact (Family Homelessness and Basic Needs, Mental and Physical Health, Educational Opportunities, and/or Access to Services). If awarded, funds may be used for any direct or indirect costs related to the organization's activities, including payroll, rent, utilities, supplies and equipment, project costs, capital improvements, and/or programmatic needs.					
	Applicant Types						



SPIN ID	Program Title	Sponse	or Name	Sponsor Number	Deadline Date	Funding Amount		
	Funding Limit Limited Submission	25,000.00 maximum No						
109754	Request for Applications: Esse Software for Science (Cycle 5)	ntial Open Source	Chan Zuckerberg Initiative		19-Apr-2022	400,000 USD		
	Contact Name Contact Telephone							
	Contact Email	sciencegrants@chanzu	<u>ckerberg.com</u>					
	Sponsor Website	Link to sponsor website	<u>e</u>					
	Program URL	Link to program URL						
	Deadline Dates (ALL) 19-Apr-2022 , 02-Jun-2022							
	The Chan Zuckerberg Initiative invites applications in support of open source software projects that are essent biomedical research. The goal of the program is to support software maintenance, growth, development, and Synopsis community engagement for these critical tools. Applications can request funding between \$50,000 USD and \$ USD total costs per year for two years (inclusive of up to 15% for indirect/overhead costs) for an overall amou							
	Applicant Types							
	Funding Limit	200,000.00 per year						
	Limited Submission	No						
104556	Request for Proposals (RFP) Inclusion in Cultivating a New Rheumatologists	<u>Diversity, Equity and</u> <u>Generation of</u>	Arthritis Foundation		06-Jun-2022	Not Specified		
	Contact Name							
	Contact Telephone	1-800-283-7800						



SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Contact Email	AFScience@art	hritis.org			
	Sponsor Website	Link to sponsor	website			
	Program URL	Link to program	<u>I URL</u>			
	Deadline Dates (ALL)	06-Jun-2022				
	The Arthritis Foundation (AF) is committed to Diversity, Equity, and Inclusion (DEI) in order to support the training a diverse generation of rheumatologists and to improve health outcomes for all patients with rheumatic diseases, especially those living with arthritis. Two complementary AF initiatives were launched in 2021 and will continue in 2022 to support AF's aspirations. The first program aims to provide seed funding to support impactful and innovat research to improve health outcomes across different racial and ethnic groups, as well as among various categorie socioeconomic status. The second program has a goal to increase diversity in the next generation of rheumatologi for those who are physicians or physician/scientists. The ability of proposed projects to have a lasting impact and be sustained beyond the award period, with potential for their findings to lead directly to advocacy and to reduce structural barriers, are considered important for success. Focus on arthritis research and curriculum development preferred.					
	Applicant Types					
	Funding Limit	0.00 see detail				
	Limited Submission	No				
109786	Request for ProposalsStudy of Stenosis (SAS) in the Newfound	of Subvalvular Ad dland Dog Breec	<u>ortic</u> Morris Animal Found	ndation	03-Jun-2022	2 50,000 USD
	Contact Name					
	Contact Telephone	800-243-2345				
	Contact Email	grantapplication	ns@morrisanimalfoundatior	i.org		
	Sponsor Website					
	Program URL	Link to program	<u>I URL</u>			



SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Doodling Dates (ALL)	02 100 2022				
	Deadline Dates (ALL)	03-Jun-2022				
	Synopsis	The sponsor is a One or more of Newfoundlands welcome. Epide board-certified previously exam	ccepting proposals for the s the following areas must be with other breeds that have miological studies of Newfo cardiologists. Necropsy inve ined using echocardiograph	e addressed: Genetic studies - these e high or low prevalence of this dis undlands diagnosed in secondary stigations of Newfoundlands with Ny.	(SAS) in the Newfour e may include compa- ease. Functional stud rather than tertiary) or without SAS lesion	idiand dog breed. rison of ies are particularly referral centers by s, that were
	Applicant Types					
	Funding Limit	50,000.00 maxii	num			
	Limited Submission	No				
001134	Requests for Proposals in Leuk	emia Research	When Everyone Su	rvives Foundation, Inc.	01-Jun-2022	2 50,000 USD
	Contact Name					
	Contact Telephone	770-595-3573				
	Contact Email	grants@wesfou	ndation.org			
	Sponsor Website	Link to sponsor	<u>website</u>			
	Program URL	Link to program	URL			
	Deadline Dates (ALL)	01-Jun-2022				
This request for proposals (RFP) is offered by the When Everyone Survives Foundation (WES Leukemia Research Foundation) to solicit innovative research in leukemia. Grants of \$50,000 for one year are offered to new and established investigators who are requesting support for laboratory, translational, or clinical research related to a leukemia.						
	Applicant Types					
	Funding Limit	50,000.00 maxii	num			
	Limited Submission	No				



SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount		
109608	Research and Innovation for G Transformation - Call 5	<u>lobal Health</u>	National Institute	for Health Research (NIHR)	29-Jun-2022	3,930,000 USD		
	Contact Name	NIHR RIGHT Glo	bal Health team					
	Contact Telephone	+44 (0)20 8843	8843					
	Contact Email	ccf-globalhealth	n@nihr.ac.uk					
	Sponsor Website	Link to sponsor	website					
	Program URL	Link to program	<u>n URL</u>					
	Deadline Dates (ALL)	29-Jun-2022						
	The NIHR fifth Research and Innovation for Global Health Transformation (RIGHT) call will support targeted resea to strengthen health service delivery and resilience in low and middle income countries (LMICs) in the context of extreme weather events. The NIHR is seeking programmes of applied health research that can strengthen health service delivery and resilience in LMICs in the context of extreme weather events caused by the changing climate. This funding opportunity is open to lead applicants from UK or LMIC institutions. RIGHT typically awards funding of £1-3 million (maximum of £3 million) for research projects with a duration of 3-5 years.							
	Applicant Types							
	Funding Limit	3,000,000.00 m	naximum					
	Limited Submission	No						
097011	Research Fellow Award		Multiple Myelom	a Research Foundation	24-Jun-2022	75,000 USD		
	Contact Name	Mark Hamilton,	, PhD					
	Contact Telephone	203-652-0233						
	Contact Email	hamiltonm@th	emmrf.org					
	Sponsor Website	Link to sponsor	website					
	Due energy LIDI							

Program URL Link to program URL



SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Deadline Dates (ALL)	24-Jun-2022				
	Synopsis	The Multiple M Program, an ini levels currently costs, including	yeloma Research Foundation tiative supporting early caree active or interested in resear up to 10% indirect costs, per	(MMRF) seeks proposals for the M r researchers at the post-doctorat rch in multiple myeloma. Investiga r year for a two (2) year period (tot	MMRF 2022 Research e, medical fellow, or tors may request up al award is \$150,000	i Fellowship junior faculty to \$75,000 total ).
	Applicant Types					
	Funding Limit	75,000.00 maxi	mum			
	Limited Submission	No				
067591	Research Fellowships		Myositis Association	1	16-May-202 [LOI/Pre-Ap	22 p] 100,000 USD
	Contact Name	Chrissy Thornto	on			
	Contact Telephone	703-553-2631				
	Contact Email	<u>Chrissy@myosi</u>	tis.org			
	Sponsor Website	Link to sponsor	website			
	Program URL	Link to program	<u>n URL</u>			
	Deadline Dates (ALL)	16-May-2022 [l	LOI/Pre-App], 30-Jun-2022			
Synopsis Synopsis Synopsis						
	Applicant Types					
	Funding Limit	50,000.00 per y	/ear			



SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount			
	Limited Submission	No							
040849	Research Grant		Society for the Adva Management	ncement of Blood	01-Jun-2022	2 25,000 USD			
	Contact Name	Steven Frank							
	Contact Telephone	928-551-6400							
	Contact Email <u>sfrank3@jhmi.edu</u> Sponsor Website <u>Link to sponsor website</u>								
Program URL <u>Link to program URL</u> Deadline Dates (ALL) 01-Jun-2022									
									Synopsis
	Applicant Types								
	Funding Limit	25,000.00 maxi	mum						
	Limited Submission	No							
071837	Research Grants		SENS Research Foun	dation	25-Jun-2022	Not Specified			
	Contact Name								

Contact Telephone 650-336-1780



SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount	
	Contact Email	foundation@se	ns.org				
	Sponsor Website	Link to sponsor	website				
	Program URL	Link to program	<u>I URL</u>				
	Deadline Dates (ALL)	25-Jun-2022 , 2	3-Sep-2022 , 01-Nov-2022				
	Synopsis	SRF is uniquely potential to posylected years of healthy	focused on a damage repair approach sitively affect the human condition by § /, productive life.	to treating the diseases of giving people interventions	aging. This approac and treatments the	ch has amazing at yield more	
	Applicant Types						
	Funding Limit	0.00 not provid	ed				
	Limited Submission No						
061435	Research Grants		LEO Foundation		21-Jun-2022	Not Specified	
	Contact Name						
	Contact Telephone	+ 45 32 72 51 1	0				
	Contact Email	applications@le	eo-foundation.org				
	Sponsor Website	Link to sponsor	website				
	Program URL	Link to program	<u>I URL</u>				
	Deadline Dates (ALL)	21-Jun-2022 , 0	4-Sep-2022				
	Synopsis	LEO Foundatior	open competition grants are given to	support the best dermatol	ogy research proje	cts worldwide.	
	Applicant Types						
	Funding Limit	0.00 not provid	ed				
	Limited Submission	No					



SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount				
021106	Research Grants	Oncology Nursing	g Society Foundation	08-May-202 [LOI/Pre-App	2 50,000 USD				
	Contact Name								
	Contact Telephone	866-257-4667							
	Contact Email	info@onfgivesback.org							
	Sponsor Website	Link to sponsor website							
	Program URL	Link to program URL							
	Deadline Dates (ALL)	08-May-2022 [LOI/Pre-App], 30-Jun-2022							
	Synopsis	Oncology Nursing Society Foundation offers General Research grants for emerging to mid-career oncology nurs psis researchers who have not previously received and completed at least one research study with a funding level o \$50,000 as the study PI.							
	Applicant Types								
	Funding Limit	50,000.00 maximum							
	Limited Submission	No							
057307	Research Grants	Fibrolamellar Ca	ncer Foundation	01-Jun-2022	Not Specified				
	Contact Name								
	Contact Telephone	203-340-7800							
	Contact Email	grants@fibrofoundation.org							
	Sponsor Website	Link to sponsor website							
	Program URL	Link to program URL							
	Deadline Dates (ALL)	01-Jun-2022 , 01-Oct-2022							



SPIN ID	Program Title		Sponsor Name		Sponsor Number	Deadline Date	Funding Amount
	Synopsis	The Fibrolamell understanding a hepatocellular o research must f understanding, path towards a accept grant ap believes that co resources, ofter	ar Cancer Foundation (FCF) is a and curative treatments for fib carcinoma (FL-HCC), is an aggre ocus specifically on FLC. Studie diagnosis, epidemiology, or tre novel therapy or clinical trials y plications to support innovative llaboration engaging the best to accelerates the path to a cure	ccepting rolamella ssive live s should atment o vith the e and pro alent acr	g proposals to support inne ar carcinoma (FLC). FLC, al er cancer that tends to stri be intended to advance k of FLC. Of particular intere ultimate goal of achieving omising research projects ross institutions, together	ovative research lea so known as fibrola ike teens and young nowledge relevant est are applications a cure for FLC. The towards the listed g with early sharing o	Iding to improved mellar g adults. The to the showing a clear Foundation will goals. The FCF of data and
	Applicant Types						
	Funding Limit	0.00 see detail					
	Limited Submission	No					
070774	Research Grants		Diabetes Research an (U.S.)	d Wellne	ess Foundation	30-Jun-2022	100,000 USD
	Contact Name	Valerie Jeremia	h				
	Contact Telephone	202-298-9211					
	Contact Email	diabeteswellnes	ss@diabeteswellness.net				
	Sponsor Website	Link to sponsor	<u>website</u>				
	Program URL	Link to program	URL				
	Deadline Dates (ALL)	30-Jun-2022 , 30	0-Dec-2022				
The Diabetes Research and Wellness Foundation (DRWF) accepts research applications related to finding the ca Synopsis prevention, treatment, and cure of diabetes and its complications. The maximum support of these grants is up \$50,000 per year for up to two years.							
	Applicant Types						



SPIN ID	Program Title	Spons	or Name	Sponsor Number	Deadline Date	Funding Amount
	Funding Limit	50,000.00 per year				
	Limited Submission	No				
042399	Research Grants		American Academy of Otola Foundation	aryngic Allergy	01-Jun-2022	2 10,000 USD
	Contact Name	Elisabeth Herzfeld-Rice	e			
	Contact Telephone	202-955-5010 x 600				
	Contact Email	foundation@aaoallerg	<u>ty.org</u>			
	Sponsor Website	Link to sponsor websit	<u>.e</u>			
	Program URL	Link to program URL				
	Deadline Dates (ALL)	01-Jun-2022				
	Synopsis	The AAOA Foundation by inviting applications treatment of otolaryns total direct costs of \$1	seeks to advance allergy resea s for grants to conduct researc gic allergy. Funds are available 0,000.	arch and knowledge for the ch in the pathogenesis, path e to support multiple project	treatment of otolar ophysiology, diagno ts each year; each p	yngic conditions osis, prevention, or oroject may have
	Applicant Types					
	Funding Limit	10,000.00 maximum				
	Limited Submission	No				
004820	Research Grants (Temporarily	Suspended)	National Headache Foundat	ion	30-Jun-2022	Not Specified
	Contact Name	Dr. Timothy R. Smith, I	Research Committee Chair			
	Contact Telephone	312-274-2650				
	Contact Email	tsmith@studymetrix.c	om			
	Sponsor Website	Link to sponsor websit	<u>e</u>			



SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Program URL					
	Deadline Dates (ALL)	30-Jun-2022 , 30	)-Sep-2022 , 31-Dec-2022			
	Synopsis	The National He also includes off	adache Foundation supports research Fering education and information to pe	in the field of headache a eople living with migraine o	nd pain as part of its disease and headach	s mission, which ne disorders.
	Applicant Types					
	Funding Limit	0.00 see detail				
	Limited Submission	No				
078566	Research Grants Program		National Rosacea Society		17-Jun-2022	15,000 USD
	Contact Name					
	Contact Telephone	847-382-8971				
	Contact Email	info@rosacea.o	rg			
	Sponsor Website	Link to sponsor	website			
	Program URL	Link to program	URL			
	Deadline Dates (ALL)	17-Jun-2022				
	Synopsis	The National Ro	sacea Society awards grants of up to $\$$	515,000, or higher in specia	al cases, for research	n on rosacea.
	Applicant Types					
	Funding Limit	15,000.00 see d	etail			
	Limited Submission	No				
039276	Research Professorship		Royal Society		09-Jun-2022	Not Specified
	Contact Name					
	Contact Telephone	+44 (0) 20 7451	2263			



SPIN ID	Program Title	Sp	oonsor Name	Sponsor Number	Deadline Date	Funding Amount
	Contact Email	seniorfellowships@	@royalsociety.org			
	Sponsor Website	Link to sponsor we	ebsite			
	Program URL	Link to program UI	<u>RL</u>			
	Deadline Dates (ALL)	09-Jun-2022				
	Synopsis	Royal Society Rese achievement and p administration allo	earch Professorships prov promise. The aim of this s pwing them to focus on re	ide long term support for world-cla cheme is to release the best leading esearch.	ss researchers of out g researchers from te	standing eaching and
	Applicant Types					
	Funding Limit	0.00 see detail				
	Limited Submission	No				
053972	Response Mode Funding Sche Improvement, Protection and Committee Grants	<u>me - Health</u> Services Research	Chief Scientist Offi	ce - Scotland	24-Jun-2022	2 393,000 USD
	Contact Name	Dr. Tom Barlow				
	Contact Telephone	0131 244 8350				
	Contact Email	tom.barlow@gov.s	<u>scot</u>			
	Sponsor Website	Link to sponsor we	ebsite			
	Program URL	Link to program UI	<u>RL</u>			
	Deadline Dates (ALL)	24-Jun-2022				
	Synopsis	The Health Improv improving or prote Scotland.	erement, Protection and Secting population health o	ervices Research Committee consid or improving the quality, safety and	ers applications for re /or effectiveness of h	esearch aimed at nealthcare in
	Applicant Types					
	Funding Limit	300,000.00 maxim	um			



SPIN ID	Program Title	Sponso	r Name	Sponsor Number	Deadline Date	Funding Amount
	Limited Submission	No				
053968	Response Mode Funding Scher Clinical Studies Research Com	<u>me - Translational</u> nittee Grants	Chief Scientist Office - Scotlan	nd	24-Jun-2022	393,000 USD
	Contact Name	Dr. Alan McNair				
	Contact Telephone	0131 244 8494				
	Contact Email	alan.mcnair@gov.scot				
	Sponsor Website	Link to sponsor website				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	24-Jun-2022				
	Synopsis	The Translational Clinicative treatments and / or diag	al Studies Research Committee gnostic approaches for condition	considers applications for ons of clinical importance	research aimed at to the population o	improving f Scotland.
	Applicant Types					
	Funding Limit	300,000.00 maximum				
	Limited Submission	No				
070888	RPB Stein Innovation Awards		Research to Prevent Blindness	S	15-Jun-2022 [LOI/Pre-Ap	300,000 USD
	Contact Name	Pattie Moran				
	Contact Telephone	646-892-9566				
	Contact Email	pmoran@rpbusa.org				
	Sponsor Website	Link to sponsor website				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	15-Jun-2022 [LOI/Pre-A	pp], 01-Jul-2022			



SPIN ID	Program Title		Sponse	or Name	S	ponsor Number	Deadline Date	Fun	ding Amount
	Synopsis	The RPB Stein Ir understanding f provide seed m demonstrates o	nnovation the visu oney to out-of-th	on (SI) Awards provide funds t al system and the diseases the proposed high-risk/high-gain ne-box thinking.	to tw nat c n visi	wo groups of researchers compromise its function. ion science research whi	s, both with a com These SI Awards an ch is innovative, cu	mon g re inte ıtting-	goal of ended to -edge, and
	Applicant Types								
	Funding Limit	300,000.00 max	kimum						
	Limited Submission	No							
024383	Scholarship Program			International Team for Impl	lant	ology (ITI)	30-Jun-202	2	21,600 USD
	Contact Name	Anna Häuptli							
	Contact Telephone	+41 (0) 61 270 8	33 83						
	Contact Email	<u>scholarship@iti</u>	.org						
	Sponsor Website	Link to sponsor	website	<u>e</u>					
	Program URL	Link to program	URL						
	Deadline Dates (ALL)	30-Jun-2022							
	Synopsis	The Internation experience in in and prosthetic	al Team nplant o restorat	n for Implantology (ITI) offers a dentistry. The program allows ions and, in most ITI Scholars	a po s ITI : ship	ost-graduate program foi Scholars to gain insight i Centers, also into resear	r young clinicians t nto case planning, ch and teaching.	o gain impla	n international Int surgery
	Applicant Types								
	Funding Limit	20,000.00 see d	letail						
	Limited Submission	No							
061426	Scholarships for the Next Gene	eration of Scient	ists	Cancer Research Society, Inc	IC.		28-Apr-202	2	94,800 USD
	Contact Name	Dajan O'Donnel							
	Contact Telephone	514 861-9227 x	234						



SPIN ID	Program Title	Sponsor Na	me	Sponsor Number	Deadline Date	Funding Amount	
	Contact Email	grants@src-crs.ca					
	Sponsor Website	Link to sponsor website					
	Program URL	Link to program URL					
	Deadline Dates (ALL)	28-Apr-2022 , 29-Jun-2022					
	Synopsis	The Scholarships for the Ne supporting upcoming young three years, with no possibi	xt Generation of Scientists cohorts of Canadian resea lity for renewal.	is a Cancer Research Socie archers. The award consists	ty funding program s of two parts cover	n with the goal of ring a period of	
	Applicant Types						
	Funding Limit	120,000.00 maximum					
Limited Submission No							
000622	Scientist Development Award	Rh	eumatology Research Four	ndation	01-Jun-2022 [LOI/Pre-Ap	Not p] Specified	
	Contact Name						
	Contact Telephone	404-365-1373					
	Contact Email	foundation@rheumatology	org				
	Sponsor Website	Link to sponsor website					
	Program URL	Link to program URL					
	Deadline Dates (ALL)	01-Jun-2022 [LOI/Pre-App],	01-Jul-2022				
	Synopsis This award is designed for individuals in the early stages of their career (typically Fellows) or those without signi prior research experience who plan to embark on careers in rheumatic diseases. The purpose of this award is to provide support for a structured research training program for rheumatologists or health professionals in the fie rheumatology.						
	Applicant Types						
	Funding Limit	0.00 see detail					



SPIN ID	Program Title	Sponso	or Name	Sponsor Number	Deadline Date	Funding Amount
_	Limited Submission	No				
089247	Second International Call: One Zoonoses Research and Innova	Health Approach to ation	ERA-NET Cofund on I of Research on Infect (ICRAD)	nternational Coordination ious Animal Diseases	30-Jun-2022	Not Specified
	Contact Name					
	Contact Telephone					
	Contact Email	ptj-icrad-calls@fz-juelic	<u>ch.de</u>			
	Sponsor Website	Link to sponsor website	2			
	Program URL	Link to program URL				
	Deadline Dates (ALL)	30-Jun-2022				
	Synopsis	The overall goal of this focussing on the animal platforms to improve a	ICRAD call is to suppor I-human-environment nimal health and by co	t cross-cutting research and innova interface and by developing novel nsequence animal welfare.	ation to better unde vaccine and diagno	erstand zoonoses stics technology
	Applicant Types					
	Funding Limit	0.00 see detail				
	Limited Submission	No				
073896	Short Industry Fellowship		Royal Society		02-Jun-2022	1,310 USD
	Contact Name					
	Contact Telephone	+44 20 7451 2666				
	Contact Email	innovationgrants@roya	alsociety.org			
	Sponsor Website	Link to sponsor website	2			
	Program URL	Link to program URL				
	Deadline Dates (ALL)	02-Jun-2022 , 03-Nov-2	.022			



SPIN ID	Program Title	Sponso	or Name	Sponsor Number	Deadline Date	Funding Amount
		This scheme, part of th	e Royal Society's Indu	stry programme, enables scientists o	employed in industr	y or academia
	Synopsis	and/or their postdocto working on a mutually	ral researcher to have beneficial and collabo	shorter more dynamic engagement rative project.	ts between academi	a and industry,
	Applicant Types					
	Funding Limit	1,000.00 see detail				
	Limited Submission	No				
057992	Simulation Research Grant		Emergency Medicine	e Residents' Association	03-Jun-2022	500 USD
	Contact Name					
	Contact Telephone	972-550-0920				
	Contact Email	<u>awards@emra.org</u>				
	Sponsor Website	Link to sponsor website	<u>e</u>			
	Program URL	Link to program URL				
	Deadline Dates (ALL)	03-Jun-2022				
	Synopsis	The purpose of the EM physician-in-training in	RA Simulation Researd terested in completing	h Grant is to provide research fund s simulation-based projects during r	ing to Emergency M esidency/medical so	ledicine (EM) chool.
	Applicant Types					
	Funding Limit	500.00 see detail				
	Limited Submission	No				
098360	Singapore International Gradu	ate Award	Agency for Science,	Technology & Research	01-Jun-2022	Not Specified
	Contact Name					
	Contact Telephone	65 6826 6111				
	Contact Email	singa_enquiries@hq.a-	star.edu.sg			



SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount	
	Sponsor Website	Link to sponsor	<u>website</u>				
	Program URL	Link to program	<u>I URL</u>				
	Deadline Dates (ALL)	01-Jun-2022					
	Synopsis	SINGA is an awa and strong inter University. SING Technology, and	ard offered to international students w rest in doing research leading to a doct GA supports PhD studies in Biomedical d Physical Sciences.	vith excellent academic und torate (PhD) in Science and Sciences, Computing and I	dergraduate and/or I Engineering at a Si nformation Science	master's results, ingapore s, Engineering and	
	Applicant Types						
	Funding Limit	0.00 see detail					
	Limited Submission	No					
020227	Sir Douglas Robb Memorial Fu	<u>nd</u>	Auckland Medical Research F	oundation	29-Jun-2022	2 1,380 USD	
	Contact Name						
	Contact Telephone	+64 9 923 1701					
	Contact Email	amrf@medicalr	esearch.org.nz				
	Sponsor Website	Link to sponsor	website				
	Program URL	Link to program	URL				
	Deadline Dates (ALL)	29-Jun-2022					
	Synopsis	The Sir Douglas Robb Memorial Fund is for the support of small projects which would normally have a medical background, but which need not be strictly "medical research". For example, the fund has been used to enhance medical libraries, to fund overseas speakers at medical conferences, and to assist in publication of papers relating to medical research.					
	Applicant Types						
	Funding Limit	2,000.00 maxim	num				



SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount			
	Limited Submission	No							
018455	Sir Harcourt Caughey Award		Auckland Medical Research I	oundation	29-Jun-2022	2 17,250 USD			
	Contact Name	Research Progr	amme Manager						
	Contact Telephone	+64 9 923 1701							
	Contact Email	amrf@medicalr	esearch.org.nz						
	Sponsor Website	Link to sponsor	website						
	Program URL	Link to program	to program URL						
	Deadline Dates (ALL)	29-Jun-2022							
	Synopsis	The Sir Harcour Zealand who, h Auckland and w Research Fellow assistance to tra deficiency in ex research to visit INSTRUCTIONS grant type if the application. For evidence from t will not be resp situation, whet	t Caughey Award provides funds up to aving trained in research overseas, is r who has sufficient experience in resear vship) in such research; or (ii) be a New ain in a specific field overseas and to u pertise in that field; or (iii) be sufficien a Auckland, normally for 3-4 weeks, to FOR 2022 ROUND 1: The Auckland M e NZ government conditions are met for information, please refer to https://c wheir host institution that they allow tr onsible for any costs associated with the her or not it was an approved destinat	\$25,000 for recipients who returning to New Zealand to ch to deserve part-time sup w Zealand medical graduate indertake research in that a stly prestigious in a particular foster interest and research edical Research Foundation or safe travel to or from the ovid19.govt.nz/travel/ For or ravel to the destination require the recipient being stranded cion when the application we	o may: (i) be a grad o a part-time appoin oport (or similar to a e in Auckland who is area, especially whe ar field of medical k h in that specialty. S will only accept ap e destination(s) iden category 2, applican uested in their appl d or having to quara yas submitted.	uate of New ntment in a part-time Senior s deserving of ere there is a local cnowledge and/or SPECIAL oplications for this ntified in the nts must provide ication. The AMRF antine in any			
	Applicant Types								
	Funding Limit	25,000.00 maxi	mum						
	Limited Submission	No							



SPIN ID	Program Title	Sponse	or Name	Sponsor Number	Deadline Date	Funding Amount		
014087	Small Research Grant		Fisheries Society of the Britis	h Isles	01-Jun-2022	6,550 USD		
	Contact Name							
	Contact Telephone	+44 (0)151 600 3362						
	Contact Email	admin@fsbi.org.uk						
	Sponsor Website	Link to sponsor website	<u>e</u>					
	Program URL	Link to program URL						
	Deadline Dates (ALL)	01-Jun-2022 , 01-Oct-2	022					
	Synopsis	The FSBI funds a numb research into any aspe Research Grant scheme	he FSBI funds a number of small research projects each year to support members of the Society to undertake novel esearch into any aspect of fish biology and fisheries science that is relevant to the Society's objectives. The Small esearch Grant scheme is open to bids for up to £5000 per project.					
	Applicant Types							
	Funding Limit	5,000.00 maximum						
	Limited Submission	No						
016255	SOPHE/CDC Student Fellowshi	<u>p in Injury Prevention</u>	Society for Public Health Edu	cation	01-Jun-2022	2,000 USD		
	Contact Name							
	Contact Telephone	202-408-9804						
	Contact Email	info@sophe.org						
	Sponsor Website	Link to sponsor website	<u>e</u>					
	Program URL	Link to program URL						
	Deadline Dates (ALL)	01-Jun-2022						
	Synopsis	The SOPHE/CDC Studen or practice-based projection health education or the	nt Fellowship in Injury Preventi ects in either unintentional inju e behavioral sciences.	on recognizes, assists and t ry prevention or violence p	rains students work revention from the	king on research perspective of		



SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Applicant Types					
	Funding Limit	2,000.00 see d	etail			
	Limited Submission	No				
067126	Sowers Club of Nebraska Foun	dation Grant	Sowers Club of Lincoln, Inc.		15-Jun-2022	Not Specified
	Contact Name					
	Contact Telephone	402-438-2244				
	Contact Email	info@thesowe	ersclub.com			
	Sponsor Website	Link to sponso	<u>r website</u>			
	Program URL	Link to program	<u>n URL</u>			
	Deadline Dates (ALL)	15-Jun-2022 , 2	15-Sep-2022			
	Synopsis	The Sowers Clu	ub accepts grant applications to help se	rve the community and the	ose in need.	
	Applicant Types					
	Funding Limit	0.00 not provid	ded			
	Limited Submission	No				
073623	Stars Career Development Awa	ard	Arthritis Society		18-May-202	2 Not Specified
	Contact Name					
	Contact Telephone	416-979-7228	x3320			
	Contact Email	research@arth	nritis.ca			
	Sponsor Website	Link to sponso	<u>r website</u>			
	Program URL	Link to program	<u>n URL</u>			



SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Deadline Dates (ALL)	18-May-2022 , 2	9-Jun-2022			
	Synopsis	The Stars Career investigators. Th CIHR-IMHA, togr provides funding Arthritis Society and work.	r Development award was created t his salary and research funding repr ether with an additional three (3) y g to support research programs alig will be accepting applications relev	to help firmly establish the ca esents a three (3) year comm ear commitment by the appli ned with the Arthritis Society rant to five research priority a	reer of early and mi itment by the Arthr cant's Host Institutio y's 2020-2025 Resea areas: arthritis pain,	d-career itis Society and on. The program rch Strategy. The OA, IA, childhood
	Applicant Types					
	Funding Limit	0.00 see detail				
	Limited Submission	No				
092353	Stephanie Watts Career Devel	opment Award	American Heart Associatio	n	25-May-2022	2 Not Specified
	Contact Name					
	Contact Telephone	214-706-1240				
	Contact Email	<u>council.awards@</u>	Pheart.org			
	Sponsor Website	Link to sponsor	website			
	Program URL	Link to program	URL			
	Deadline Dates (ALL)	25-May-2022 , C	1-Jun-2022 , 03-Jun-2022			
	Synopsis	This award supp exceptional pro	orts early career investigators worl mise but may be currently unfunde	king in hypertension and card d or have limited access to ex	iovascular research tramural funding.	who show
	Applicant Types					
	Funding Limit	0.00 see detail				
	Limited Submission	No				



SPIN ID	Program Title	Sp	onsor Name	S	ponsor Number	Deadline Date	Funding Amount
024717	Strategic Research Agreement	<u>s: Multi Project</u>	Juvenile Diabe International	etes Research Fou	ndation	03-May-202 [LOI/Pre-App	2 Not 5] Specified
	Contact Name						
	Contact Telephone	800-533-2873					
	Contact Email	preawardsupport@	ojdrf.org				
	Sponsor Website	Link to sponsor we	<u>bsite</u>				
	Program URL	Link to program UR	<u> </u>				
Deadline Dates (ALL) 03-May-2022 [LOI/Pre-App], 17-Jun-2022 [LOI/Pre-App]							
	Synopsis	JDRF's Strategic Re gaps and challenge Agreement for mul scientists and/or be to major challenges treat or cure Type 3	search Agreements s and potential brea ltiple projects provic etween scientists fro s, potential breakthu 1 diabetes and its co	provide research akthroughs in Type des a mechanism t om diverse backgr roughs, or persiste omplications.	funding for single of mile e 1 diabetes research. T to stimulate new collabe ounds as a means to co ent obstacles to progres	Itiple investigators t he JDRF Strategic Re prations between cli nceive and develop is along the various p	o address critical search nical and basic new approaches baths to prevent,
	Applicant Types						
	Funding Limit	0.00 not provided					
	Limited Submission	No					
074890	Team Grant: E-Rare-6 Joint Tra	ansnational Call (202	22) Canadian Insti	itutes of Health Re	esearch	15-Jun-2022	355,500 USD
	Contact Name						
	Contact Telephone	613-954-1968					
	Contact Email	support@cihr-irsc.	gc.ca				
	Sponsor Website						
	Program URL	Link to program UR	<u>RL</u>				



SPIN ID	Program Title	S	ponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Deadline Dates (ALL)	15-Jun-2022				
	Synopsis	CIHR-IG is pleased European Joint Pr and Humanities R disease.	d to be partnering with app ogramme on Rare Disease esearch to improve health	proximately 18 international funding on s (EJP RD) call for proposals 2021. The care implementation and everyday lited in the second se	organizations in the e topic of the call is fe of people living	e context of this s Social Sciences with a rare
	Applicant Types					
	Funding Limit	150,000.00 per ye	ear			
	Limited Submission	No				
068798	Thomas L. Petty, MD Invacare Home Respiratory Care	Award for Exceller	American Respirato	ory Care Foundation	01-Jun-2022	Not Specified
	Contact Name	Crystal Maldonad	0			
	Contact Telephone	972-243-2272				
	Contact Email					
	Sponsor Website	Link to sponsor w	<u>ebsite</u>			
	Program URL	Link to program U	<u>IRL</u>			
	Deadline Dates (ALL)	01-Jun-2022				
	Synopsis	This award recogr	nizes outstanding individua	al achievement in home respiratory ca	re.	
	Applicant Types					
	Funding Limit	0.00 see detail				
	Limited Submission	No				
089497	Translational Research Grant		Pediatric Cancer Re	esearch Foundation	01-Jun-2022	200,000 USD
	Contact Name					
	Contact Telephone	949-859-6312				



SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Contact Email	info@pcrf-kids.c	org			
	Sponsor Website	Link to sponsor	website			
	Program URL	Link to program	URL			
	Deadline Dates (ALL)	01-Jun-2022				
	Synopsis	Translational Re and accelerates is up to \$100,00	search Grants fund new research pro cures from the laboratory bench to th per year, for up to 2 years.	tocols and therapies that here bedside of children and t	old promise for imp teens with highrisk	roved outcomes cancers. Funding
	Applicant Types					
	Funding Limit	100,000.00 per y	year			
	Limited Submission	No				
046658	Translational Research Project	<u>Grants</u>	Heart Research UK		01-Jun-2022	262,000 USD
	Contact Name					
	Contact Telephone	0113 234 7474				
	Contact Email	grants@heartre	search.org.uk			
	Sponsor Website	Link to sponsor	website			
	Program URL	Link to program	URL			
	Deadline Dates (ALL)	01-Jun-2022				
	Synopsis	Translational Re care.	search Project Grants aim to bridge th	ne gap between laboratory	-based scientific res	earch and patient
	Applicant Types					
	Funding Limit	200,000.00 see	detail			
	Limited Submission	No				



SPIN ID	Program Title	Sponso	or Name	Sponsor Number	Deadline Date	Funding Amount
012008	TWAS-SN Bose Postgraduate F	ellowship Programme	TWAS, the Academy of Scienc Developing World	es for the	30-Jun-2022	Not Specified
	Contact Name					
	Contact Telephone	+39 040 2240687				
	Contact Email	fellowships@twas.org				
	Sponsor Website	Link to sponsor website	1			
	Program URL	Link to program URL				
	Deadline Dates (ALL)	30-Jun-2022				
	Synopsis	TWAS and the S.N. Bose foreign scientists from a	e National Centre for Basic Scie developing countries who wish	nces in Kolkata, India have to pursue research toward	e agreed to offer fel ds a PhD in physical	lowships to young sciences.
	Applicant Types					
	Funding Limit	0.00 see detail				
	Limited Submission	No				
109784	Two-stage Call for Proposals for Women RISE	or Research Teams for	International Development Re (IDRC)	esearch Centre	15-Apr-2022	Not Specified
	Contact Name					
	Contact Telephone					
	Contact Email	women-RISE-femmes@	<u>iidrc.ca</u>			
	Sponsor Website	Link to sponsor website				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	15-Apr-2022 , 24-Jun-20	022			
	Synopsis	The Women RISE initiat unpaid) intersect and in	ive will support action-oriented iteract in the context of prepar	d research on how women ing, responding to and rec	's health and their overing from COVII	work (paid or D-19. Specifically,



SPIN ID	Program Title	Spon	sor Name	Sponsor Number	Deadline Date	Funding Amount
	Applicant Types Funding Limit Limited Submission	it will support popula Recovery Priority 3.5: and how can recovery 0.00 see detail No	tion and public health research : "How have recent economic ch y strategies be inclusive, gender	that addresses UN Research hanges disproportionately af transformative and health	n Roadmap for the O ffect women and wo promoting for wom	COVID-19 omen's health, en?"
058073	University of Toronto Integrate Fellowship Training Program	ed Neonatal-Perinatal	Hospital for Sick Children Fo Foundation	undation/Sick Kids	30-Jun-2022	Not Specified
	Contact Name	Sonia Dos Santos, Inte	erim Education Administrative C	Coordinator		
	Contact Telephone	416-813-7654 x 2289	02			
	Contact Email	neonatal.fellowship@	<u>esickkids.ca</u>			
	Sponsor Website	Link to sponsor websi	<u>ite</u>			
	Program URL	Link to program URL				
	Deadline Dates (ALL)	30-Jun-2022				
	Synopsis	The University of Tor training to paediatrici	ronto Training Program in Neona ians.	atal-Perinatal Medicine prov	vides two years of n	eonatal-perinatal
	Applicant Types					
	Funding Limit	0.00 not provided				
	Limited Submission	No				
022157	Victor Cohn Prize for Excellence Reporting	ce in Medical Science	Council for the Advancemen	t of Science Writing	30-Jun-2022	3,000 USD
	Contact Name	Sylvia Kantor				
	Contact Telephone	206-880-0177				


SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount		
	Contact Email	il sylviakantor@casw.org						
	Sponsor Website	Link to sponsor	Link to program URL 30-Jun-2022					
	Program URL	Link to program						
	Deadline Dates (ALL)	30-Jun-2022						
	Synopsis	The Victor Cohn Prize for Excellence in Medical Science Reporting is given annually, and seeks to honor a writ body of work published or broadcast within the last five years which, for reasons of uncommon clarity, accura breadth of coverage, enterprise, originality, insight and narrative power, has made a profound and lasting contribution to public awareness and understanding of critical advances in medical science and their impact of human health and well-being.						
	Applicant Types							
	Funding Limit	3,000.00 see de	etail					
	Limited Submission	No						
093521	Vienna Research Groups for Yo	oung Investigato	ors (VRG) Vienna Science and Techno	ology Fund (WWTF)	15-Jun-2022	1,760,000 USD		
	Contact Name Dr. Donia Lasir		ger					
	Contact Telephone	+43 1 402 31 4	3 - 16					
	Contact Email	donia.lasinger@	@wwtf.at					
	Sponsor Website	Link to sponsor	<u>website</u>					
	Program URL	Link to program	n URL					
Deadline Dates (ALL) 15-Jun-2022								
The current Vienna Research Groups for Young Investigators call 2022 is issued for up to two group leader as part of the WWTF's Environmental Systems Research programme. It addresses Vienna-based universitie research institutions that intend to hire an excellent young researcher from abroad for setting up and man independent research group. Active recruitment procedures are mandatory.					leader positions versities and 1d managing an			



SPIN ID	Program Title	Spo	onsor Name	Sponsor Number	Deadline Date	Funding Amount
	Applicant Types					
	Funding Limit	1,600,000.00 maxir	num			
	Limited Submission	No				
096603	Vilcek Prize for Creative Promi	se in Biomedical Sci	ence Vilcek Foundation		10-Jun-2022	50,000 USD
	Contact Name					
	Contact Telephone	212-472-2500				
	Contact Email	info@vilcek.org				
	Sponsor Website	Link to sponsor wel	<u>bsite</u>			
	Program URL	Link to program UR	<u>IL</u>			
	Deadline Dates (ALL)	10-Jun-2022				
	Synopsis	The Vilcek Foundat scientists who dem basic, applied, and/	ion will award three Creative onstrate outstanding early ac or translational biomedical so	Promise Prizes of \$50,000 ea hievement. Eligible work may sience.	ch to young foreign-bo v be creative, independ	orn biomedical dent research in
	Applicant Types					
	Funding Limit	50,000.00 see deta	il			
	Limited Submission	No				
001781	William T. Grant Scholars Prog	ram	Grant (William T.) Foun	dation	15-Jun-2022 [LOI/Pre-Ap	
	Contact Name					
	Contact Telephone	212-752-0071				
	Contact Email	info@wtgrantfdn.o	rg			
	Sponsor Website	Link to sponsor wel	<u>bsite</u>			



SPIN ID	Program Title		Sponsor Name	Sp	oonsor Number	Deadline Date	Funding Amount		
	Program URL	ogram URL Link to program URL							
	Deadline Dates (ALL)	Deadline Dates (ALL) 15-Jun-2022 [LOI/Pre-App], 06-Jul-2022							
	Synopsis	The William T. G program funds f disciplines, met	he William T. Grant Scholars Program supports career development for promising early-career researchers. The program funds five-year research and mentoring plans that significantly expand researchers' expertise in new lisciplines, methods, and content areas.						
	Applicant Types								
	Funding Limit	350,000.00 max	imum						
	Limited Submission	Yes							
015485	Wynn Kent Public Communica	tion Award	Actuarial Foundati	on		01-Jun-2022	1,000 USD		
	Contact Name								
	Contact Telephone	847-706-3535							
	Contact Email	conference@cc	actuaries.org						
	Sponsor Website	nsor Website Link to sponsor website							
	Program URL	Program URL Link to program URL							
	Deadline Dates (ALL)	tes (ALL) 01-Jun-2022							
	Synopsis	The Wynn Kent Public Communication Award recognizes an actuary who has contributed to the public awareness of financial risk and the work product of the actuarial profession to the public in the fields of life, health, casualty, pension, and/or in other related areas.							
	Applicant Types								
	Funding Limit	1,000.00 see de	tail						
	Limited Submission	No							
019729	Young Investigator Prize		Lundbeck Foundat	on		28-Jun-2022	140,000 USD		
	Contact Name								



SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount	
	Contact Telephone	+4539128001					
	Contact Email	application@lu	ndbeckfonden.com				
	Sponsor Website	Link to sponsor					
	Program URL	am URL Link to program URL					
	Deadline Dates (ALL) 28-Jun-2022						
	The LF Young Investigator prize is awarded to a particularly promising scientist under the age of 40, who l Synopsis conducted outstanding research within biomedical sciences.						
	Applicant Types						
	Funding Limit	Funding Limit 1,000,000.00 see detail					
	Limited Submission	No					
103440	Young Talents in Clinical Resea	arch	Swiss Academy of Medical Sc	iences	30-Jun-2022	Not Specified	
	Contact Name Dr. Myriam Tap Contact Telephone +41 31 306 92		ernoux				
			70				
	Contact Email	m.tapernoux@	samw.ch				
	Sponsor Website	Link to sponsor	website				
	Program URL Link to program URL						
	Deadline Dates (ALL)	30-Jun-2022					
	Synopsis	Medical doctor during medical support in Swit and practical sk Clinical Researc	s engaged in clinical research are faced training, and the scarcity of funding fo zerland for young doctors starting out ills mostly on their own. By funding pro h contributes to improving the quality	with many challenges, inc r research projects. There i in clinical research: they m otected time for research a of clinical research in Swit:	luding the lack of tin is currently no syste ust acquire the nece and project grants, Y zerland and to imple	me, particularly m-inherent essary theoretical 'oung Talents in ementing the	



SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
Roadmap for developing the next generation of clinical researchers of the Federal Office of Public H research supported must take place in Switzerland.				ealth. The		
	Applicant Types					

Funding Limit 0.00 see detail Limited Submission No

